[
    "This trial is testing the effectiveness of trastuzumab, paclitaxel, and myocet in treating HER2 overexpressing metastatic or locally advanced breast cancer in women aged 18-70 with measurable lesions, while excluding those with prior treatment for advanced breast cancer or Herceptin, bone or central nervous system metastasis as the only site of disease, and history of another malignancy within 5 years of study.",
    "This trial is a phase 1/phase 2 study for breast cancer patients with tumors overexpressing HER2neu, testing the efficacy of myocet, taxotere, and herceptin, with eligibility criteria including age, performance status, and adequate organ function.",
    "The sample is a phase 1/2 trial for patients with pancreatic cancer, testing the efficacy of vismodegib and gemcitabine hydrochloride, with eligibility criteria including histologically confirmed adenocarcinoma of the pancreas, measurable disease, and Karnofsky performance status >= 80%.",
    "This trial is for diabetic macular edema and involves the drug ranibizumab, with eligibility criteria including a diagnosis of diabetes mellitus and evidence of retinal thickening due to macular edema.",
    "This sample is a phase 1/phase 2 trial for type 1 diabetes using etanercept and placebo drugs, with inclusion criteria such as positive GAD 65 and/or islet cell antibody, HbA1c at diagnosis above 6%, and insulin regimen with 3 injections of insulin daily, and exclusion criteria such as infection requiring IV antibiotics at diagnosis or within past 14 days from study entry, BMI over 85th percentile for age and gender, and evidence of psychiatric disease in the potential study subject and/or primary care taker.",
    "This clinical trial is for patients with refractory or relapsed multiple myeloma and will test the drug hll1-dox, which is the doxorubicin conjugate of milatuzumab, with eligibility criteria including measurable disease and adequate hematologic, renal, and hepatic function.",
    "This trial is testing the drug tandutinib on patients with recurrent adult brain tumors, who meet specific eligibility criteria, including having measurable disease and a Karnofsky performance status of 60-100%.",
    "The sample is a phase 1/2 trial for non small cell lung cancer and lung cancer patients, testing the efficacy of abt-751 and carboplatin, with eligibility criteria including advanced stage of disease, adequate hematologic, renal and hepatic function, and adequate performance status.",
    "The sample is a phase 1/phase 2 trial for metastatic colorectal cancer, testing the efficacy of azd2171, folfox, and placebo cediranib, with specific inclusion and exclusion criteria listed.",
    "The sample is a phase 1/phase 2 trial for non-small-cell lung cancer using pemetrexed, cisplatin, and carboplatin as drugs, with eligibility criteria including inoperable cancer, no significant weight loss, and adequate organ function.",
    "The sample is a phase 1/phase 2 trial for patients with recurring or metastatic pancreatic adenocarcinoma, testing the efficacy of gemcitabine and etanercept, with specific inclusion and exclusion criteria listed.",
    "The sample is a phase 1/phase 2 trial for patients with Type 1 Diabetes Mellitus, testing the efficacy of Viaject\u00ae25, Viaject\u00ae7, and insulin lispro, with inclusion criteria including age, BMI, and insulin antibody levels, and exclusion criteria including Type 2 Diabetes Mellitus, C-peptide and HbA1c values, and history of severe allergies or drug/alcohol abuse.",
    "This trial is testing the efficacy of capecitabine and PHY906 in treating locally advanced or metastatic pancreatic adenocarcinoma, with specific eligibility criteria including prior gemcitabine therapy and adequate hepatic and renal function.",
    "This is a phase 1/phase 2 clinical trial for patients with recurrent epithelial ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer, testing the drug decitabine, with eligibility criteria including platinum-resistant or platinum refractory disease, measurable or detectable disease, and acceptable organ function.",
    "This is a phase 1/phase 2 trial for kidney transplant patients with anti-HLA antibody, testing the efficacy of IVIG and rituximab in inhibiting cytotoxic anti-HLA antibody activity, with inclusion and exclusion criteria listed.",
    "The sample is a phase 1/phase 2 trial for patients with HER2+ ve metastatic breast cancer, testing the efficacy of panobinostat and trastuzumab, with eligibility criteria including prior treatment and progression on trastuzumab, adequate laboratory values, and an ECOG performance status of <2.",
    "This clinical trial is testing the effectiveness of everolimus, cetuximab, irinotecan, and capecitabine, oxaliplatine in treating non-resectable or metastatic pancreatic cancer patients who have previously been treated with gemcitabine.",
    "The sample is a phase 1/2 trial for patients with androgen-independent prostate cancer, testing the efficacy of taxotere and doxil chemotherapy drugs, with eligibility criteria including adequate bone marrow, liver, and renal function, and a life expectancy of greater than 12 weeks.",
    "This trial is testing the efficacy of doxorubicin-eluting beads and everolimus in treating hepatocellular carcinoma in patients who meet specific eligibility criteria, including having a Child-Pugh score < 8 and no tumor involvement > 50% of the whole liver.",
    "The sample is a phase 1/phase 2 trial testing the drug docetaxel on patients with various types of cancer, including recurrent non-small cell lung cancer and recurrent prostate cancer, who meet specific eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for patients with refractory metastatic melanoma, testing the efficacy of dmf5 melanoma reactive til, cyclophosphamide, fludarabine, and aldesleukin, with specific eligibility criteria including measurable metastatic melanoma, HLA-A 0201 positivity, and normal serology and chemistry levels.",
    "The sample is a phase 1/phase 2 trial for patients with metastatic breast cancer, testing the drug amrubicin, with eligibility criteria including confirmation of HER2-negative breast cancer, prior chemotherapy regimens, and adequate organ function.",
    "This trial is testing the use of cetuximab, a drug, in patients with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, and the eligibility criteria includes age, histological proof of cancer, and no distant metastases.",
    "This trial is for patients with chronic myeloid leukemia who have resistance or suboptimal response to imatinib, dasatinib, or nilotinib and no known T315I/A Abl-kinase mutation, and will test the efficacy of dasatinib and bms-833923.",
    "This trial is for patients with recurrent glioblastoma multiforme, glioma, astrocytoma, or brain tumor who have failed initial surgical resection followed by standard adjuvant therapy, and will test the efficacy of itv depocyt + temozolomide as a treatment option.",
    "The sample is a phase 1/phase 2 trial for the treatment of malignant melanoma using the drug pivanex, with eligibility criteria including confirmed melanoma, measurable disease, and adequate organ function, while exclusion criteria include receipt of more than three systemic treatment regimens for malignant melanoma and untreated brain metastases.",
    "The sample is a phase 1/phase 2 trial for pulmonary disease, chronic obstructive, with the drug uk-369,003, and eligibility criteria including GOLD criteria 2 to 4 and a 10 pack year history of smoking.",
    "The sample is a phase 1/2 trial testing the use of the drug amd3100 in patients with various types of leukemia, lymphoma, myelodysplastic syndromes, and multiple myeloma, with specific eligibility criteria for both donors and recipients.",
    "The sample is a phase 1/phase 2 trial for glioblastoma multiforme, testing the efficacy of bcnu wafer, irinotecan, and bevacizumab, with specific inclusion and exclusion criteria for patient eligibility.",
    "The sample is a phase 1/phase 2 trial for previously untreated diffuse large B-cell lymphoma patients, testing the efficacy of bortezomib, cyclophosphamide, doxorubicin, vincristine, prednisolone, and lenograstim, with specific eligibility criteria and exclusion criteria.",
    "This trial is testing the efficacy of cabazitaxel plus bavituximab in treating castration-resistant prostate cancer patients who have only received one prior chemotherapy regimen containing docetaxel, and meet specific eligibility criteria.",
    "This trial is a phase 1/phase 2 study testing the drug ly2886721 and placebo on participants with Alzheimer's disease or mild cognitive impairment due to Alzheimer's disease, with specific inclusion and exclusion criteria, and requiring a positive scan for the presence of amyloid beta.",
    "The sample is a phase 1/phase 2 clinical trial for the treatment of multiple myeloma using bortezomib, lenalidomide, and dexamethasone, with eligibility criteria including a diagnosis of multiple myeloma, no prior systemic therapy, and a Karnofsky performance status of greater or equal to 60.",
    "The sample is a phase 1/phase 2 trial for patients with leukemia or lymphoma, testing the drug laromustine, with eligibility criteria including ECOG performance status, renal and liver function, and no uncontrolled illness or psychiatric illness.",
    "This sample is a phase 1/phase 2 trial for the treatment of diffuse and systemic scleroderma using abatacept and placebo, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 1/phase 2 trial for postmenopausal women with estrogen and/or progesterone receptor positive adenocarcinoma of the breast, testing the efficacy of exemestane and sunitinib malate, with inclusion and exclusion criteria listed.",
    "This clinical trial is testing the drug cep-18770 for patients with relapsed multiple myeloma that has progressed following therapies that included bortezomib and an IMiD, either alone or in any combination, and is refractory to the most recent therapy or the patient did not tolerate and discontinued the most recent therapy for multiple myeloma but has recovered from its toxic effects.",
    "This trial is testing the efficacy of bez235, prednisone, and abiraterone acetate in treating castrate-resistant prostate cancer patients who meet specific eligibility criteria.",
    "This trial is testing the combination of hydroxychloroquine and gemcitabine for patients with biopsy-proven adenocarcinoma of the pancreas, with specific inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for advanced breast cancer patients with HER2 positive breast cancer, testing the efficacy of hki-272 and trastuzumab, with eligibility criteria including progression following at least one Herceptin-containing cytotoxic chemotherapy regimen and adequate performance status.",
    "This clinical trial is testing the efficacy of PB1023, a GLP-1 receptor agonist, in treating type 2 diabetes mellitus in patients who meet specific inclusion and exclusion criteria. The trial involves both single and multiple subcutaneous injections of PB1023 or placebo.",
    "This is a phase 1/phase 2 clinical trial for ulcerative colitis, testing the efficacy of he3286 compared to placebo, with specific inclusion and exclusion criteria for participants.",
    "This trial is testing the combination of azd0530 and gemcitabine hydrochloride for patients with unresectable pancreatic adenocarcinoma, with eligibility criteria including ECOG 0-2 performance status, normal hematopoietic, hepatic, renal, and pulmonary function, and no other serious medical conditions or illnesses that would preclude study participation.",
    "This sample is a phase 1/phase 2 trial testing the drug imatinib on healthy male non-smokers with seasonal allergic rhinitis caused by Timothy grass pollen allergy, with specific inclusion and exclusion criteria.",
    "This trial is testing the effectiveness of carfilzomib, lenalidomide plus dexamethasone in treating newly diagnosed, previously untreated Stage I, II, or III multiple myeloma patients with measurable disease, and who meet certain eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for patients with progressive hormone-refractory prostate cancer, testing the efficacy of docetaxel, prednisone, and su011248, with inclusion criteria including confirmed adenocarcinoma of the prostate and measurable or non-measurable disease with elevated PSA, and exclusion criteria including prior chemotherapy and uncontrolled pain or urinary obstruction.",
    "The sample is a phase 1/phase 2 trial for patients with myelodysplastic syndromes and leukemia, testing the efficacy of azacitidine and lenalidomide as treatment, with specific eligibility criteria and prior concurrent therapy restrictions.",
    "This sample is a phase 1/2 trial for newly diagnosed acute myeloid leukemia patients who meet specific eligibility criteria, and will test the efficacy of clofarabine, cytarabine, and idarubicin as treatment options.",
    "This trial is testing the effectiveness of BNP and placebo in treating left ventricular diastolic dysfunction in patients with certain eligibility criteria and exclusion criteria.",
    "This sample is a phase 1/phase 2 trial for HIV infected patients with genotypic or phenotypic resistance to protease inhibitors, testing the efficacy of lopinavir/ritonavir and saquinavir as drugs, with inclusion and exclusion criteria listed.",
    "The sample is a phase 1/phase 2 trial for patients with various hematologic malignancies, testing the efficacy of busulfan, cyclophosphamide, methotrexate, and tacrolimus as a conditioning regimen for allogeneic hematopoietic stem cell transplantation, with eligibility criteria including specific disease characteristics and HLA matching requirements for donors.",
    "This sample is a phase 1/phase 2 trial for the drug tki258 in patients with locally advanced or metastatic melanoma that is refractory to standard therapy, with inclusion criteria including measurable disease and ECOG performance status 0 or 1, and exclusion criteria including concurrent therapy with any other investigational agent and uncontrolled central nervous system metastases.",
    "The sample is a phase 1/phase 2 trial testing the drug gs-9219 on patients with relapsed or refractory non-hodgkin's lymphoma, chronic lymphocytic leukemia, or multiple myeloma, with specific inclusion and exclusion criteria.",
    "This clinical trial is testing the effectiveness of cyclophosphamide and fludarabine phosphate in treating non-Hodgkin Lymphoma or chronic lymphocytic leukemia patients who have failed at least 2 prior chemotherapy regimens, and have an available related HLA-haploidentical natural killer cell adult donor.",
    "This trial is testing the effectiveness of sodium nitrite injection in treating vaso-occlusive crisis in sickle cell disease patients who meet specific eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for patients with recurrent malignant glioma, testing the efficacy of ixabepilone and anticonvulsant drugs, with eligibility criteria including prior therapy recovery, performance status, blood counts, and stable corticosteroid regimen.",
    "The sample is a phase 1/phase 2 trial for follicular lymphoma using rituximab, bortezomib, and ibritumomab tiuxetan, with eligibility criteria including confirmed diagnosis, CD20+ status, and exclusion criteria including prior stem cell transplantation and known hypersensitivity to the drugs.",
    "This sample is a phase 1/phase 2 trial for HIV infected children weighing between 6 and 30 kilograms, testing the efficacy of gpo-vir z30 tablet, lamivudine, nevirapine, and zidovudine, with eligibility criteria including HAART regimen of NVP and 2 NRTIs, ability to swallow study drugs, and willingness to be hospitalized for 12-hour intensive PK study.",
    "The sample is a phase 1/phase 2 trial for metastatic bladder cancer using pemetrexed, gemcitabine, and platinol, with eligibility criteria including biopsy-proven cancer and exclusion criteria including brain metastases and clinically relevant fluid collection.",
    "This trial is for patients with graft failure and will test the effectiveness of fludarabine, campath 1h, and fk506 in combination with a healthy donor for engraftment, with specific inclusion and exclusion criteria.",
    "This sample is a phase 1/phase 2 trial for previously treated, relapsed or refractory acute lymphoblastic leukemia using vincristine sulfate liposomes injection and dexamethasone, with eligibility criteria including measurable disease, adequate liver and renal function, and negative pregnancy test.",
    "The sample is a phase 1/phase 2 trial for rheumatoid arthritis using rituximab as a drug, with inclusion criteria including a diagnosis of RA and positive RF and/or CCP, and exclusion criteria including allergy to MTX and previous exposure to anti-CD20 monoclonal antibody therapy.",
    "This sample is a phase 1/phase 2 trial testing the drug mifepristone on HIV-1 infected patients with specific eligibility criteria, including a CD4 count of 350 cells/mm3 or more and a willingness to use acceptable forms of contraception during the study and for 30 days after stopping study medication.",
    "The sample is a phase 1/phase 2 clinical trial for patients with multiple myeloma, testing the drug simvastatine, with inclusion criteria including stable or progressive disease, age \u226518, and performance status <3, and exclusion criteria including pregnancy and medication with drugs known to interact with simvastatine.",
    "The sample is a phase 1/phase 2 trial for Parkinson's disease, testing the efficacy of levodopa and carbidopa solution for sc administration and placebo, with specific inclusion and exclusion criteria for subjects.",
    "The sample is a phase 1/phase 2 trial for small cell lung cancer, testing the efficacy of topotecan and vorinostat in patients who have relapsed after first-line chemotherapy, with specific inclusion and exclusion criteria.",
    "This sample is a phase 1/phase 2 trial for patients with chronic systolic heart failure, testing the efficacy of the drug CXL-1020 and its various doses, with strict inclusion and exclusion criteria.",
    "The clinical trial is testing the efficacy of HKI-272 and paclitaxel in treating advanced breast cancer and malignant solid tumors with specific eligibility criteria, including HER2 positive tumor and prior treatment with Herceptin, while excluding subjects with bone or skin as the only site of disease and those with significant cardiac or gastrointestinal disorders.",
    "The sample is a phase 1/phase 2 trial for kidney transplantation with primary cadaveric or non-HLA-identical living donor kidney, using drugs such as alemtuzumab, sirolimus, and tacrolimus, and with eligibility criteria including no previous kidney transplant, no concomitant systemic corticosteroid therapy, and no known hypersensitivity to the drugs used.",
    "The sample is a phase 1/2 trial for patients with metastatic or chest wall recurrent breast cancer who overexpress HER-2 gene, and will test the combination of vorinostat and trastuzumab, with eligibility criteria including no active infection, no history of allergic reaction to compounds of similar chemical or biologic composition to vorinostat or other agents used in study, and normal cardiac function.",
    "This trial is for patients with metastatic solid tumor malignancy, including prostate cancer, and will test the drug 2-deoxyglucose, with eligibility criteria including age, performance status, and previous treatment, and exclusion criteria including infection, diabetes, and cardiovascular disease.",
    "The sample is a phase 1/phase 2 trial testing the efficacy of vildagliptin in patients with type 2 diabetes, with inclusion criteria including non-smoking Caucasian and African American males and females between 30 and 65 years of age, and exclusion criteria including history of type 1 diabetes or insulin use, coagulation abnormalities, abnormal heart conditions, pregnancy or breastfeeding.",
    "This trial is testing the drug combretastatin a-4 phosphate on patients with age-related macular degeneration and choroidal neovascularization, with strict eligibility criteria including age, visual acuity, lesion size, and medical history.",
    "The sample is a phase 1/phase 2 trial for metastatic renal cell carcinoma, testing the efficacy of gefitinib and sunitinib, with specific inclusion and exclusion criteria.",
    "This sample is a phase 1/phase 2 trial for the drug nilotinib in patients with chronic myelogenous leukemia or acute lymphoblastic leukemia (philadelphia chromosome positive) who are either relapsed after or refractory to standard therapy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for type 1 diabetes, testing the efficacy and safety of sitagliptin and insulin in patients who meet specific inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for type II diabetes, testing the drugs placebo, sitagliptin, and lez763, with eligibility criteria including age, weight, BMI, and HbA1c levels, and exclusion criteria including smoking and history of drug or alcohol abuse.",
    "This trial is testing the combination of belinostat and erlotinib for patients with non-small cell lung cancer, with specific eligibility criteria including acceptable liver, kidney, and bone marrow function, and exclusion criteria such as active infection or significant cardiovascular disease.",
    "The sample is a phase 1/2 trial for the treatment of castrate-resistant prostate cancer using temsirolimus and casodex, with eligibility criteria including rising PSA levels, failure of previous therapies, and performance status requirements.",
    "The sample is a phase 1/2 trial for patients with gastrointestinal cancer, testing the efficacy of everolimus and tivozanib, with eligibility criteria including age, disease confirmation, ECOG performance status, and adequate organ function, and exclusion criteria including prior therapy with inhibitors of mTOR or VEGFR, clinically significant cardiovascular disease, and active bleeding diathesis.",
    "This trial is for newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplantation and will test the effectiveness of carfilzomib, cyclophosphamide, and dexamethasone as treatment options.",
    "The sample is a phase 1/phase 2 trial for the drug pirfenidone in patients with diabetes mellitus and diabetic nephropathy, with inclusion criteria including abnormal kidney function and history of proteinuria, and exclusion criteria including cancer, heart disease, and pregnancy.",
    "The sample is a phase 1/phase 2 trial for heart failure, testing the drugs trv120027 and placebo, with inclusion criteria including a diagnosis of congestive heart failure and NYHA Class III or IV heart failure.",
    "This is a phase 1/phase 2 trial for patients with previously treated lymphoma, testing the drug pci-24781, with inclusion and exclusion criteria listed.",
    "This trial is testing the efficacy of voraxaze and placebo in patients with solid tumors and hematologic malignancies who have delayed methotrexate clearance, with inclusion criteria including ECOG performance status 0-2 and exclusion criteria including medications that may interfere with MTX excretion or enhance MTX toxicity.",
    "The sample is a phase 1/phase 2 trial testing the drug Exjade on patients with non-alcoholic steatohepatitis and increased iron storage/disturbed distribution, with specific inclusion and exclusion criteria listed.",
    "This clinical trial is testing the efficacy of docetaxel and everolimus in treating patients with locally advanced or metastatic squamous cell carcinoma of the head and neck who have received one line of prior chemotherapy, and meet specific eligibility criteria.",
    "This trial is testing the effectiveness of azacytidine and vorinostat, two drugs, in treating relapsed or resistant diffuse large B cell lymphoma, with specific eligibility criteria for patients.",
    "The sample is a phase 1/phase 2 trial testing the efficacy of lapatinib, carboplatin, and paclitaxel in treating relapsed ovarian and metastatic breast cancer patients who have failed previous chemotherapies, with specific inclusion and exclusion criteria. The trial includes patients with ovarian epithelial cancer stage III, stage IV ovarian cancer, and stage IV breast cancer, and the icd-10 codes for the diseases are provided.",
    "The sample is a phase 1/phase 2 trial for gk1-399 and placebo in patients with type 2 diabetes mellitus, with inclusion criteria including stable background medication and BMI between 20-40 kg/m2, and exclusion criteria including type 1 diabetes, recent heart attack or stroke, uncontrolled blood pressure, and significant kidney disease.",
    "The sample is a phase 1/phase 2 clinical trial for atopic dermatitis, testing the efficacy of DPK-060 1% ointment and placebo, with eligibility criteria including a clinical diagnosis of atopic dermatitis and exclusion criteria including previous local or systemic antimicrobial therapy within the last four weeks prior to the first application of the investigational product.",
    "This trial is testing the drug talaporfin sodium on patients with primary hepatocellular carcinoma, with specific eligibility criteria including liver lesions of a certain size and no extrahepatic metastases.",
    "The sample is a phase 1/phase 2 trial for patients with glioblastoma multiforme, testing the efficacy of mpc-6827 + carboplatin, with specific inclusion and exclusion criteria.",
    "This trial is testing the efficacy of temsirolimus and sorafenib in patients with advanced hepatocellular carcinoma who have received sorafenib at 400 mg bid with consecutive dose reduction to 200 mg bid due to intolerance, toxicity or adverse events or patients who are not eligible for full-dose first-line therapy with sorafenib, and meet a range of eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for patients with myelofibrosis, polycythemia vera, or thrombocytosis, testing the drug ruxolitinib, with inclusion criteria including diagnosis of PMF or Post-PV/ET MF and adequate bone marrow reserve, and exclusion criteria including receiving anti-cancer medications or investigational therapy in the past 14 days.",
    "This clinical trial is testing the safety and efficacy of safinamide and levodopa in treating idiopathic Parkinson's disease, with specific inclusion and exclusion criteria for eligible participants.",
    "This trial is testing the efficacy of abiraterone acetate and prednisone/prednisolone or dexamethasone in treating prostate neoplasms in patients who meet specific inclusion criteria for phase 1 and phase 2, with additional criteria for phase 2 including the presence of target or non-target abnormalities and no prior treatment with ketoconazole for the management of androgen independent prostate cancer.",
    "The sample is a phase 1/phase 2 trial testing the use of fludarabine in patients with severe combined immunodeficiency disease, severe primary immunodeficiency disorder, undefined T cell deficiency disorder, or Wiskott-Aldrich syndrome, who have an HLA mismatched family member or an HLA matched/mismatched unrelated donor, and meet certain eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for non-small cell lung cancer patients with stage IIIA or IIIB, testing the drug S-3304, with eligibility criteria including ECOG performance status 0-1 and ability to receive conventional chemoradiation therapy.",
    "This trial is testing the drug nkt-01 for the treatment of lupus nephritis in patients who meet specific inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for patients with recurrent ovarian or primary peritoneal cancer, testing the efficacy of pemetrexed and carboplatin, with inclusion and exclusion criteria specified.",
    "This trial is testing the drug vandetanib on patients with platinum-refractory ovarian cancer who have received at least one previous platinum- and taxane-based chemotherapy regimen, and are planned to receive pegylated liposomal doxorubicin, with specific inclusion and exclusion criteria.",
    "This is a phase 1/phase 2 trial for a vaccine for influenza, using placebo as the drug, with eligibility criteria including age, health status, and absence of allergies or other medical conditions.",
    "The sample is a phase 1/phase 2 trial for non-small cell lung cancer patients, testing the efficacy of carboplatin, erlotinib hydrochloride, and paclitaxel, with eligibility criteria including specific disease characteristics and patient characteristics, and restrictions on prior concurrent therapy.",
    "This trial is testing the efficacy of chr-2797 (tosedostat), an aminopeptidase inhibitor, in treating acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma patients who have relapsed or are refractory to front line and/or salvage therapy, and who are not candidates for chemotherapy.",
    "This trial is testing the drug odm-201 on patients with progressive metastatic prostate cancer who are undergoing androgen deprivation therapy, and have adequate bone marrow, hepatic, and renal function, while excluding those with brain metastases, history of other malignancy within the previous 5 years, known gastrointestinal disease or procedure that affects the absorption, and those who are not able to swallow the study drug.",
    "This trial is for phase 1/phase 2 and focuses on ovarian cancer, using drugs such as carboplatin, cyclophosphamide, etoposide, paclitaxel, and topotecan hydrochloride, with eligibility criteria including histologically proven stage IIIC ovarian epithelial cancer and achieved at least partial response (PR) following six courses of standard dose chemotherapy.",
    "The sample is a phase 1/2 trial for metastatic malignant melanoma using karenitecin and valproic acid as drugs, with inclusion criteria including age, performance status, and hematological function, and exclusion criteria including active infection and uncontrolled CNS metastasis.",
    "This is a phase 1/phase 2 clinical trial for ovarian cancer patients who have relapsed after platinum-based chemotherapy, testing the efficacy of lenvatinib, carboplatin, and gemcitabine, with strict eligibility criteria including age, disease stage, performance status, and various laboratory values.",
    "This sample is a phase 1/phase 2 trial for patients with hepatocellular carcinoma, testing the efficacy of mapatumumab and sorafenib as compared to placebo, with eligibility criteria including measurable disease and adequate bone marrow, renal and liver function.",
    "The sample is a phase 1/phase 2 trial for patients with locally advanced or metastatic colorectal cancer, testing the efficacy of bevacizumab and ag-013736 (axitinib) in combination with chemotherapy, with specific inclusion and exclusion criteria.",
    "This trial is testing the effectiveness of sorafenib and topotecan in treating patients with histologically-confirmed epithelial ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer who have failed at least one prior platinum based chemotherapeutic regimen.",
    "The sample is a phase 1/phase 2 trial testing the use of smoked cannabis for patients with multiple sclerosis who have moderate or severe spasticity, with inclusion criteria including diagnosis of clinically definite multiple sclerosis and exclusion criteria including preexisting pulmonary and cardiac conditions, recent cannabis use of more than twice per week one month prior to study entry, and inability to provide informed consent.",
    "This trial is testing the drug lenalidomide on patients with urinary bladder neoplasms, with specific inclusion and exclusion criteria for eligibility.",
    "The sample is a phase 1/2 trial for advanced non-small cell lung cancer, testing the efficacy of carboplatin, hydroxychloroquine, and paclitaxel, with eligibility criteria including measurable disease, ECOG performance status 0-1, and no other active malignancy within the past 3 years.",
    "The sample is a phase 1/phase 2 trial for acute ischemic stroke, testing the efficacy of mrx-801 and placebo drugs, with inclusion criteria including occlusion demonstrated by transcranial Doppler ultrasound and eligibility for tPA, and exclusion criteria including right to left cardiac shunt, moderate to severe COPD, and uncontrolled hypertension.",
    "This trial is testing the drug lisofylline on adults with type 1 diabetes mellitus who have been on a stable dose of insulin for at least 3 months, with the goal of improving blood glucose control.",
    "The sample is a phase 1/phase 2 trial for recurrent childhood acute lymphoblastic leukemia, testing a combination of drugs including l-asparaginase, doxorubicin hydrochloride, and methotrexate, with eligibility criteria including diagnosis of B lymphoblastic leukemia and certain performance status and laboratory values.",
    "The sample is a phase 1/phase 2 trial for patients with mild bronchial asthma, testing the sensitivity to methacholine with a provocation concentration of methacholine resulting in a 20% fall in FEV1 (PC20 methacholine) of \u2264 8 mg/ml at screening, using active and placebo drugs, and with inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 clinical trial testing the drug mln8237 (alisertib) on patients with various advanced solid tumors, including non-small cell lung cancer, small cell lung cancer, metastatic breast cancer, head and neck squamous cell carcinoma, and gastroesophageal adenocarcinoma, with specific inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for the treatment of intermittent claudication using trans sodium crocetinate (TSC) and 0.9% normal saline, with eligibility criteria including a diagnosis of PAD secondary to atherosclerosis and stable claudication severity, and exclusion criteria including previous treatment with TSC and poorly controlled type 1 or type 2 diabetes.",
    "This trial is testing the efficacy of obatoclax mesylate and topotecan hydrochloride in treating recurrent small cell lung cancer and unspecified adult solid tumors, with eligibility criteria including no progressive brain metastases and normal blood counts.",
    "The sample is a phase 1/phase 2 trial for metastatic melanoma using mpc-6827 + temozolomide as drugs, with inclusion criteria such as histologically proven melanoma and unresectable melanoma with measurable metastases, and exclusion criteria such as hypersensitivity to Cremophor EL and cardiovascular disease.",
    "The sample is a phase 1/phase 2 trial for chronic myeloid leukemia patients with primary or acquired resistance to imatinib mesylate, testing the efficacy of dasatinib, with inclusion and exclusion criteria specified.",
    "The sample is a phase 1/phase 2 trial for recipients of liver transplantation with hepatitis B core antibody positive grafts, testing the efficacy of adefovir dipivoxil and hepatitis B vaccination in preventing hepatitis B infection, with inclusion and exclusion criteria listed, and diseases including hepatitis B and liver transplantation, and drugs including adefovir dipivoxil and hepatitis B vaccination.",
    "The sample is a phase 1/phase 2 trial testing the drug Torisel on patients with advanced adenocarcinoma or neoplasms, with specific inclusion and exclusion criteria.",
    "The sample is a phase 1/2 trial for patients with advanced non-hematologic malignancy, including brain and central nervous system tumors, melanoma, and solid tumors, testing the efficacy of ps-341 (velcade) and temozolomide, with eligibility criteria including adequate organ system function and completion of prior chemotherapy, and exclusion criteria including peripheral neuropathy and uncontrolled infection.",
    "This sample is a phase 1/phase 2 trial for patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, or acute leukemia of ambiguous lineage, testing the efficacy of clofarabine, cytarabine, and methotrexate, with specific eligibility criteria for patients' disease and health status.",
    "This trial is testing the efficacy of bevacizumab and bortezomib in treating patients with Stage IIIB or Stage IV non-small cell lung cancer who have received one or two prior systemic therapies containing a platinum compound, and have no history of brain metastases, with a set of eligibility criteria that includes having an ECOG Performance Status of 0-2, adequate hepatic function, and no other concurrent anticancer treatment.",
    "The sample is a phase 1/2 trial for HIV infections testing the efficacy of raltegravir poloxamer film coated tablet, raltegravir chewable tablet, and raltegravir oral granules for suspension (20 mg/ml) with inclusion criteria including HIV-1 infection, unchanged therapeutic regimen for at least 12 weeks, and HIV RNA of 1,000 copies/mL or greater at screening.",
    "This trial is for patients with malignant pleural mesothelioma and will test the effectiveness of chemotherapy, with specific eligibility criteria including no previous chemotherapy and adequate organ function.",
    "This trial is testing the drug ecopipam on subjects with Tourette's Syndrome who meet specific inclusion criteria, while excluding those with certain medical conditions or who have taken certain medications in the past.",
    "The sample is a phase 1/phase 2 trial for advanced non-small cell lung cancer patients who have progressed after treatment with at least one chemotherapy regimen, testing the efficacy of docetaxel and npi-2358 + docetaxel, with eligibility criteria including ECOG performance status \u2264 1 and exclusion criteria including brain metastases and concurrent, active second malignancy.",
    "The sample is a phase 1/phase 2 trial for patients with non-small cell lung cancer, testing the efficacy of everolimus and gefitinib, with eligibility criteria including prior chemotherapy, performance status, and various medical conditions.",
    "The sample is a phase 1/phase 2 trial for patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma, testing the efficacy of pegylated liposomal doxorubicin hydrochloride, with eligibility criteria including measurable disease, prior chemotherapy regimens, and various patient characteristics such as hematopoietic and cardiovascular health.",
    "The sample is a phase 1/phase 2 trial for patients with ovarian cancer, peritoneal cancer, fallopian tube cancer, and bowel obstruction, testing the efficacy of cisplatin and paclitaxel, with eligibility criteria including CT findings suggestive of complete bowel obstruction and non-surgical candidacy.",
    "The sample is a phase 1/phase 2 trial for HIV infections testing the safety and efficacy of tipranavir and ritonavir capsules in patients with a documented HIV-1 RNA load and stable ZDV or ABC regimen for at least 6 months.",
    "The sample is a phase 1/phase 2 trial testing the drug td-1211 and placebo on healthy subjects and those with opioid-induced constipation, with inclusion and exclusion criteria listed, and diseases identified as \"healthy\" and \"opioid-induced constipation\" with corresponding ICD-10 codes.",
    "This trial is for patients with metastatic prostate cancer who have received prior therapy with docetaxel and will test the efficacy of abt-751, with eligibility criteria including evidence of radiographic progression and adequate hematologic, renal and hepatic function.",
    "The sample is a phase 1/phase 2 trial for primary open-angle glaucoma and ocular hypertension, testing the efficacy of opa-6566, placebo, and latanoprost, with specific inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for patients with acute myocardial infarction, testing the efficacy of Lovaza\u00ae and a placebo containing corn oil, with eligibility criteria including post-PCI TIMI flow grade = 3 and exclusion criteria including known allergy to fish, fish oil, or aspirin.",
    "This trial is testing the efficacy of docetaxel, cisplatin, and sti571 in treating non-small cell lung cancer patients who meet specific eligibility criteria.",
    "This trial is testing the effectiveness of lo-ovral oral contraceptive pills and placebo in treating aplastic anemia, menorrhagia, and amenorrhea in women aged 12-55 years with a uterus and at least one functioning ovary, who have bone marrow failure and require treatment with chemotherapy or stem cell transplantation.",
    "The sample is a phase 1/phase 2 trial testing the drugs zalutumumab and cisplatin on patients with locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, with specific inclusion and exclusion criteria, and icd-10 codes for the diseases.",
    "This trial is testing the use of aliskiren, a drug, in patients with type 2 diabetes and nephropathy, with specific inclusion and exclusion criteria.",
    "This trial is testing the effectiveness of mitomycin c and chemophase in treating bladder cancer patients who meet specific eligibility criteria, including having a Karnofsky Performance Status greater than or equal to 80% and acceptable liver and renal function, while excluding those with a history of bladder fibrosis or urinary incontinence that would compromise the ability to retain the study drug.",
    "This trial is testing the efficacy of belinostat, paclitaxel, and carboplatin in treating various types of cancer, including ovarian and bladder cancer, with specific eligibility criteria for patients, such as having no known curative therapy and acceptable liver, renal, and bone marrow function.",
    "The sample is a phase 1/2 trial for pediatric patients with relapsed or refractory acute lymphoblastic leukemia, testing a combination of drugs including abt-751, dexamethasone, and peg-asparaginase, with eligibility criteria including age, prior therapy, and reproductive function.",
    "The sample is a phase 1/2 trial for patients with various hematologic malignancies, including leukemia, lymphoma, and myeloma, who have failed or are ineligible for autologous transplant, and will receive a transplant of two umbilical cord blood units after conditioning with cyclophosphamide and fludarabine phosphate.",
    "This clinical trial is testing the use of fludarabine and treosulfan in combination with allogeneic bone marrow or peripheral blood stem cell transplantation for patients with leukemia or myelodysplastic syndromes, with specific eligibility criteria including donor availability and certain patient characteristics.",
    "The sample is a phase 1/phase 2 trial for graft versus host disease, testing the use of rapamycin and tacrolimus as GVHD prophylaxis in patients who received an allogeneic MSD or MUD PBSCT, with specific inclusion and exclusion criteria.",
    "This clinical trial is testing the efficacy of bortezomib and sorafenib in treating relapsed or refractory multiple myeloma patients who have received no more than 2 prior regimens, with specific eligibility criteria including ECOG performance status, blood counts, liver and kidney function, and exclusion criteria such as peripheral neuropathy, thrombolic or embolic events, and other medical conditions that may interfere with participation.",
    "This clinical trial is testing the efficacy of dasatinib and docetaxel in treating metastatic prostate cancer patients who have shown evidence of progressive disease, with specific eligibility criteria including a serum testosterone level of \u226450 ng/dL and no prior radioisotope therapy with Strontium-89, Samarium, or similar agents.",
    "This trial is testing the drug tesofensine on overweight to obese subjects with BMI 28-35 kg/m\u00b2 and the eligibility criteria includes exclusion of subjects with specific diseases interfering with their metabolism, mental or psychiatric disorder, and history of cancer within the past 5 years.",
    "This trial is testing the drug temsirolimus on patients with chemotherapy-refractory metastatic castration-resistant prostate cancer who meet specific eligibility criteria.",
    "This trial is testing the drug tbr-652, a CCR5 antagonist, on antiretroviral treatment-experienced individuals with HIV-1 infection, with specific inclusion and exclusion criteria.",
    "This trial is testing the drug RAD001 on patients with unresectable or metastatic hepatocellular carcinoma, with eligibility criteria including prior chemotherapy and biologic regimens, measurable disease, and adequate bone marrow, liver, and renal function.",
    "The sample is a phase 1/phase 2 trial for myeloma patients, testing the efficacy of trisenox, velcade, melphalan, and vitamin C, with specific eligibility criteria including refractory disease, age up to 75, and Zubrod performance status of <2.",
    "The sample is a phase 1/phase 2 trial for patients with advanced malignant solid tumors or ErbB-2-positive breast cancer, testing the efficacy of HKI-272 and vinorelbine as a treatment option, with specific inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for breast cancer patients, testing the efficacy of docetaxel and epirubicin hydrochloride, with eligibility criteria including specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions.",
    "The sample is a phase 1/phase 2 trial for kidney transplantation using the drug aeb071, with inclusion criteria for adult recipients of a functioning kidney within 24 hours post transplant and exclusion criteria for patients with a history of cancer within the last 5 years or significant cardiac disorder.",
    "This sample is a phase 1/phase 2 trial for an experimental vaginal gel containing dapivirine to prevent HIV infections in HIV-negative women who are willing to use two forms of contraception and undergo pelvic examinations, and meet certain inclusion criteria while excluding those who are pregnant or have certain genital abnormalities or infections.",
    "This trial is testing the combination of vorinostat, carboplatin, and etoposide in chemotherapy-naive patients with small cell lung cancer who meet specific eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for lung cancer patients with inoperable stage IIB or unresectable stage IIIA or IIIB, testing the effectiveness of celecoxib, with eligibility criteria including age, performance status, and medical history.",
    "This trial is for patients with active rheumatoid arthritis and a stable dose of methotrexate, testing the efficacy of a placebo drug, with specific inclusion and exclusion criteria.",
    "This trial is testing the efficacy of eptifibatide and placebo in treating sickle cell disease, with eligibility criteria including confirmed diagnosis of sickle cell anemia or sickle beta zero thalassemia, age between 18 and 55 years, and normal baseline coagulation profile.",
    "This trial is for patients aged 0-18 with relapsed or residual juvenile myelomonocytic leukemia (JMML) who have undergone allogeneic hematopoietic cell transplant (HCT), and will test the efficacy of cyclosporine, cytarabine, filgrastim, methotrexate, methylprednisolone, mitoxantrone hydrochloride, and cis-retinoic acid as treatment options.",
    "The sample is a phase 1/phase 2 clinical trial for patients with multiple myeloma, testing the efficacy of kw-2478 and bortezomib drugs, with eligibility criteria including confirmed diagnosis of multiple myeloma, prior failed or relapsed regimens, and adequate hematologic status, liver and renal function.",
    "This trial is testing the efficacy of (folpi) picoplatin with 5-fu and leucovorin, folpi, and folfox in treating metastatic colorectal cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for primary and inherited erythromelalgia, testing the efficacy of xpf-002 and placebo, with eligibility criteria including BMI, pain flares, and willingness to comply with study procedures and restrictions.",
    "The sample is a phase 1/phase 2 trial for metastatic colorectal cancer testing the efficacy of capecitabine, gefitinib, and oxaliplatin, with eligibility criteria including confirmed colorectal cancer, measurable disease, and specific patient characteristics.",
    "This sample is a phase 1/phase 2 trial for the treatment of irritable bowel syndrome constipation predominant, using the drugs rose-010 and placebo, with eligibility criteria including a previous diagnosis of IBS and constipation predominant type IBS.",
    "This trial is testing the use of human secretin in patients with chronic pancreatitis who are using opioid analgesics for pain management, and includes inclusion and exclusion criteria related to age, medical history, and contraceptive use.",
    "This sample is a phase 1/2 trial for patients with recurrent or refractory malignant CNS tumors, testing the drug lapatinib ditosylate, and includes eligibility criteria such as histological diagnosis, measurable disease, and adequate general condition.",
    "The sample is a phase 1/phase 2 trial for patients with proliferative diabetic retinopathy, using ranibizumab as the drug, with eligibility criteria including previous treatment with full panretinal photocoagulation and no known sensitivity to ranibizumab, and exclusion criteria including pregnancy and uncontrolled glaucoma.",
    "The sample is a phase 1/phase 2 trial for patients with Stage IV or unresectable Stage III melanoma, testing the efficacy of sunitinib and dacarbazine, with eligibility criteria including adequate organ function and measurable disease by RECIST criteria.",
    "This trial is testing the effectiveness of pentostatin, tacrolimus, and methotrexate in treating leukemia and lymphoma patients who are receiving allogeneic hematopoietic transplants from an unrelated donor or one antigen mismatched related donors, and meet specific eligibility criteria.",
    "This sample is a phase 1/phase 2 trial for metastatic melanoma using the drug temozolomide, with eligibility criteria including prior systemic therapy and measurable disease, and exclusion criteria including prior temozolomide or dacarbazine and concurrent use of certain medications.",
    "The sample is a phase 1/phase 2 trial for locally advanced squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx, testing the efficacy of carboplatin, rad001, and paclitaxel, with eligibility criteria including various patient characteristics and prior concurrent therapy restrictions.",
    "This trial is for patients with adult glioblastoma or gliosarcoma who have evidence of tumor progression and have received no more than two prior systemic chemotherapy regimens. The trial will test the effectiveness of sorafenib tosylate and temsirolimus as treatment options.",
    "The sample is a phase 1/phase 2 trial for head and neck cancer patients, testing the efficacy of carboplatin, cisplatin, docetaxel, fluorouracil, and lapatinib ditosylate, with eligibility criteria including specific disease characteristics and patient characteristics, and restrictions on prior concurrent therapy.",
    "The sample is a phase 1/phase 2 trial for CCX 354-C in patients with stable rheumatoid arthritis who have been on a stable dose of methotrexate, with inclusion and exclusion criteria listed.",
    "The sample is a phase 1/phase 2 trial for non-small cell lung cancer using etoposide and cisplatin as drugs, with eligibility criteria including confirmed stage II or III NSCLC, inoperable status, measurable disease, and normal organ and marrow function.",
    "This sample is a phase 1/phase 2 trial for multiple sclerosis patients in the Sacramento area, testing the effects of inhaled cannabis, oral THC, and placebos on spasticity, with specific inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for metastatic pancreatic cancer, testing the efficacy of ipi-926 plus gemcitabine and placebo plus gemcitabine, with eligibility criteria including confirmed diagnosis, radiologically evaluable metastatic lesion, ECOG 0 or 1, and adequate birth control methods.",
    "The sample is a phase 1/phase 2 trial for inoperable stage III or IV malignant melanoma using imexon and dtic drugs, with eligibility criteria including normal blood cell counts and chemistries, and exclusion criteria including prior chemotherapy for stage III or IV disease and brain metastases.",
    "This trial is for patients with leukemia or myelodysplastic syndromes who are unsuitable for intensive chemotherapy and will be treated with cytarabine, and eligibility criteria include ECOG performance status, absence of serious illnesses, and no history of other malignancies.",
    "The sample is a phase 1/phase 2 trial for metastatic pancreatic cancer, testing the efficacy of gemcitabine and albumin-bound paclitaxel as a treatment option, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for rheumatoid arthritis, testing the efficacy of ocrelizumab and placebo in patients who have failed one DMARD or biologic, and have been on stable methotrexate treatment for at least 12 weeks, with inclusion and exclusion criteria listed.",
    "The sample is a phase 1/2 trial for patients with persistent or recurrent ovarian epithelial, primary peritoneal, or fallopian tube cancer, testing the efficacy of docetaxel as a treatment option, with specific eligibility criteria and exclusion criteria.",
    "This is a phase 1/phase 2 trial testing the drug patupilone on patients with unresectable locally advanced or metastatic non-small-cell lung carcinoma who have had prior treatment with a platinum-containing regimen, and meet various eligibility criteria.",
    "This trial is testing the effectiveness of carvedilol phosphate, lisinopril, and their combination, as well as placebo, in treating pre-hypertension in patients with additional cardiovascular risk factors, while excluding those with recent cardiac or vascular events, beta blocker or ACE inhibitor therapy, angiotensin receptor blocker therapy, or diabetes.",
    "The sample is a phase 1/phase 2 trial for allergic asthma, testing the efficacy of qge031 and omalizumab compared to placebo, with specific inclusion and exclusion criteria for patients.",
    "This clinical trial is testing the efficacy of sorafenib tosylate, erlotinib hydrochloride, tipifarnib, and temsirolimus in treating patients with recurrent adult brain tumors, specifically glioblastoma multiforme or gliosarcoma, who meet specific eligibility criteria.",
    "This trial is testing the efficacy of docetaxel, epirubicin, and bevacizumab in treating metastatic breast adenocarcinoma with specific eligibility criteria, including no previous therapy for metastatic breast cancer and adequate liver, renal, and bone marrow function.",
    "This trial is for patients with extensive or recurrent small cell lung carcinoma and will test the efficacy of carboplatin, cisplatin, etoposide, and sunitinib malate as well as eligibility criteria including measurable disease, no prior chemotherapy for SCLC, and performance status.",
    "This clinical trial is testing the effectiveness of RAD001 and docetaxel in treating non-small cell lung cancer patients who meet specific eligibility criteria.",
    "This trial is for patients with Richter's transformation, leukemia, or relapsed/refractory B-cell chronic lymphocytic leukemia, and will test the efficacy of oxaliplatin, fludarabine, cytarabine, rituximab, and pegfilgrastim in treating the diseases. The eligibility criteria include age, performance status, renal and hepatic function, and platelet counts, while exclusion criteria include untreated or uncontrolled life-threatening infection, intolerance to the drugs, pregnancy or lactation, and recent chemotherapy or radiation therapy.",
    "The sample is a phase 1/phase 2 trial for esophagus cancer using oxaliplatin, docetaxel, and capecitabine, with eligibility criteria including adenocarcinoma or squamous cell carcinoma of the esophagus or G/E junction, surgical candidacy, and no previous treatment for esophageal cancer.",
    "The sample is a phase 1/phase 2 trial for patients with relapsed or refractory B- or T-cell non-Hodgkin's lymphoma, testing the efficacy of bortezomib and gemcitabine hydrochloride as a therapeutic regimen, with eligibility criteria including prior therapeutic regimens, ECOG performance status, and various medical and psychiatric conditions.",
    "This trial is for patients with chronic lymphocytic leukemia and will test the efficacy of bendamustine, rituximab, and lenalidomide as a treatment option, with specific eligibility criteria including prior treatment regimens and liver function.",
    "The sample is a phase 1/2 trial for kidney transplant recipients, testing the efficacy of daclizumab, mycophenolate mofetil, prednisone, tacrolimus, ganciclovir, valganciclovir, and trimethoprim and sulfamethoxazole, with eligibility criteria including PRA of 20% or less and exclusion criteria including previous steroid treatment within 6 months prior to transplantation and HIV infection.",
    "This trial is testing the efficacy of chr-2797 and erlotinib in treating non-small-cell lung carcinoma patients who have failed platinum-based chemotherapy, with eligibility criteria including specific disease stage, performance status, and laboratory values.",
    "This clinical trial is testing the combination of ixazomib, lenalidomide, and dexamethasone for previously untreated multiple myeloma patients who meet specific eligibility criteria.",
    "This trial is a phase 1/phase 2 study testing the drug ro5024048 on patients diagnosed with chronic hepatitis C infection, genotype-1, for at least 6 months, who are HCV treatment-naive, with no history of exposure to interferon, ribavirin, or direct antivirals, and have at least one measurement of serum HCV RNA of \u2265 100,000 IU/mL measured during Screening by the COBAS AmpliPrep/COBAS TaqMan HCV.",
    "This trial is a phase 1/2 study testing the combination of vorinostat and paclitaxel in patients with male or stage IIIB/IIIC/IV breast cancer, with specific eligibility criteria including disease accessibility to biopsy and consent to serial biopsy, and exclusion criteria including recent chemotherapy or radiotherapy and ongoing or active infection.",
    "The sample is a phase 1/phase 2 trial for Friedreich ataxia, testing the drug resveratrol, with inclusion criteria of homozygosity for the GAA repeat expansion in intron 1 of the FXN gene and functional stage on the Ataxia subscale of the FARS of 1 or higher, and exclusion criteria including pregnancy or lactation, active arrhythmias or significant cardiac insufficiency, and use of idebenone, Coenzyme Q or vitamin E within 30 days prior to enrollment or use of amiodarone or other medications which may have clinically significant drug interactions that cannot be safely monitored.",
    "This trial is for patients with untreated childhood brain stem glioma and will test the drug tipifarnib, with eligibility criteria including no prior chemo or radiation therapy, certain blood counts, and negative pregnancy test.",
    "This trial is testing the efficacy of docetaxel and imatinib mesylate in treating hormone-refractory prostate cancer patients who have progressed after at least two prior hormonal manipulations, with specific eligibility criteria outlined.",
    "This sample is a phase 1/phase 2 trial for hypertension and renal transplant patients, testing the effectiveness of allopurinol and placebo drugs, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for rectal and colorectal cancer using cetuximab, oxaliplatin, capecitabine, and diphenhydramine hydrochloride (hcl) as drugs, with eligibility criteria including histologically-confirmed adenocarcinoma of the rectum, age \u2265 18, and ability to swallow pills without difficulty.",
    "This sample is a phase 1/phase 2 trial for patients with anaplastic or poorly differentiated variant thyroid carcinoma, testing the efficacy of cisplatin, doxorubicin hydrochloride, and fosbretabulin disodium, with eligibility criteria including specific disease characteristics and patient characteristics.",
    "The sample is a phase 1/phase 2 trial for breakthrough nausea and vomiting and unspecified adult solid tumor patients receiving inpatient chemotherapy containing at least moderately emetogenic agents, with eligibility criteria including self-report of at least mild nausea, scheduled 5-HT3 receptor antagonist antiemetic, and no history of chronic nausea and/or vomiting, with study drugs fosaprepitant dimeglumine and systemic chemotherapy.",
    "This trial is for patients with stage IV pancreatic cancer and will test the effectiveness of erlotinib hydrochloride and gemcitabine hydrochloride as drugs, with eligibility criteria including measurable and/or nonmeasurable disease, Zubrod performance status 0-1, and no prior chemotherapy, hormonal therapy, immunotherapy, or chemoradiotherapy for advanced or locally advanced pancreatic cancer.",
    "This is a phase 1/phase 2 trial for ovarian cancer patients who have progressed following chemotherapy with platinum and paclitaxel, and will test the efficacy of cc-5013 and topotecan as treatment options. The eligibility criteria includes measurable metastatic advanced ovarian or primary peritoneal carcinoma, ECOG performance status of 0 or 1, and exclusion criteria includes prior use of lenalidomide and any standard or experimental anti-cancer drug therapy within 28 days of the initiation of study drug therapy.",
    "This trial is testing the effectiveness of various drugs, including ciclosporin and betamethasone, on chronic plaque type psoriasis, with specific inclusion and exclusion criteria.",
    "This trial is testing the drug erlotinib hydrochloride on patients with various types of brain tumors, who meet specific eligibility criteria, including having measurable or evaluable disease and a performance status of Karnofsky 60-100%.",
    "This clinical trial is testing the drugs cci-779 and bortezomib on patients with relapsed and/or refractory multiple myeloma, with specific eligibility criteria outlined in the inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for non-Hodgkin's lymphoma, testing the efficacy of bortezomib, chop, and rituximab, with eligibility criteria including confirmed diagnosis, no prior anti-cancer therapy, measurable disease, and certain blood counts, while exclusion criteria include CNS involvement, HIV, pregnancy or nursing, major surgery within the last 3 weeks, and known peripheral neuropathy > Grade 2.",
    "The sample is a phase 1/2 trial for patients with recurrent or advanced melanoma, testing the efficacy of imatinib mesylate as a treatment option, with a list of eligibility criteria including disease history, performance status, and various medical parameters.",
    "This trial is testing the efficacy of Arikayce and its placebos in treating cystic fibrosis patients with chronic P.aeruginosa infection, with eligibility criteria including confirmed diagnosis of CF and FEV1 \u226540% of predicted at Screening.",
    "This trial is testing the effectiveness of obatoclax mesylate and bortezomib in treating refractory multiple myeloma, with specific eligibility criteria including prior treatment with bortezomib and absence of certain medical conditions.",
    "The sample is a phase 1/phase 2 trial for the treatment of Fanconi anemia and severe aplastic anemia using fludarabine, with eligibility criteria including diagnosis confirmation, HLA matching, and certain health conditions, while exclusion criteria include cardiac disease, severe infection, and mental illness.",
    "This trial is for patients with end-stage renal disease who are highly-HLA sensitized and a candidate for transplantation after desensitization, and will test the efficacy of Immune Globulin Intravenous 10%/Rituximab or C1 INH, and placebos as drugs, with inclusion and exclusion criteria.",
    "This clinical trial is testing the drugs pci-32765 and ofatumumab on patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, prolymphocytic leukemia, or Richter's transformation, who have failed prior therapies and meet certain eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for rheumatoid arthritis testing the drug he3286 in combination with methotrexate, with eligibility criteria including stable disease and normal thyroid levels, and exclusion criteria including previous use of certain immunosuppressive drugs and clinically significant abnormalities in laboratory results.",
    "The sample is a phase 1/phase 2 trial for chronic hepatitis C, testing the efficacy of daclatasvir and placebo drugs, with specific eligibility criteria including genotype 1 infection, treatment-naive or non-responders/intolerant, and BMI 18 to 35 kg/m\u00b2.",
    "The sample is a phase 1/phase 2 trial for Crohn's disease, testing delayed release 6mp or calcitriol vs. purinethol, with inclusion criteria including moderate Crohn's Disease and exclusion criteria including previous bowel resection and evidence of other serious diseases.",
    "The sample is a phase 1/phase 2 trial for AUY922 in postmenopausal women with metastatic or resistant locally advanced HER2+ and ER+ breast cancer, with eligibility criteria including laboratory values, disease stage, prior treatment, and measurable lesions, and exclusion criteria including cardiac function and HIV status.",
    "The sample is a phase 1/phase 2 trial for rheumatoid arthritis, testing the efficacy of ask8007 and placebo drugs in patients who meet specific inclusion criteria, including having active poly-arthritis and being treated with MTX, leflunomide, or sulfasalazine for at least 4 months prior to baseline.",
    "This trial is testing the use of rituximab in patients with hematological malignancies who have undergone allogeneic stem cell transplantation, with specific inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for kidney diseases, testing the efficacy of yspsl and placebo drugs for primary cadaver renal transplants, with specific inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for non-small-cell lung carcinoma using the drugs entinostat, sndx-275, and erlotinib, with eligibility criteria including confirmed NSCLC of stage IIIb or IV, prior chemotherapy or chemoradiotherapy regimens, and measurable lesions.",
    "The sample is a phase 1/2 trial for breast cancer patients with primary tumors over 2 cm, testing the efficacy of bibf + paclitaxel and paclitaxel, with eligibility criteria including HER2 negativity, adequate hematologic, renal and hepatic function, and premenopausal women under effective birth control.",
    "This trial is testing the use of aliskiren, a drug, in patients with type 2 diabetes and incipient or overt diabetic nephropathy, with specific eligibility criteria including stable hypoglycemic medications and discontinuation of certain medications, and exclusion criteria such as severe hypertension and history of malignancy.",
    "This sample is a phase 1/phase 2 trial for pancreatic cancer patients who have undergone surgery, with gemcitabine hydrochloride as the drug being tested, and includes eligibility criteria related to patient characteristics and prior concurrent therapy.",
    "The sample is a phase 1/phase 2 trial for metastatic breast cancer patients with HER2-positive tumors, testing the combination of lapatinib and docetaxel, with eligibility criteria including age, ECOG performance status, prior treatment history, and cardiac and organ function.",
    "This trial is testing the drug Velcade on patients with peripheral T-cell lymphomas and non-Hodgkin lymphoma, with specific eligibility criteria including age, performance status, and laboratory values.",
    "The sample is a phase 1/phase 2 trial for multiple myeloma, testing the effectiveness of lenalidomide, bortezomib, dexamethasone, and doxil, with eligibility criteria including age, measurable disease, and LVEF, and exclusion criteria including peripheral neuropathy, renal insufficiency, and other medical conditions.",
    "The sample is a phase 1/phase 2 trial for patients with non-small-cell lung cancer, testing the efficacy of abt-751 and pemetrexed compared to placebo, with eligibility criteria including prior treatment and measurable disease, and exclusion criteria including allergy to study drugs and significant systemic disease.",
    "This clinical trial is testing the effectiveness of hydroxychloroquine and ixabepilone in treating metastatic breast cancer that is resistant to anthracycline and taxane, and patients must meet specific eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for non-Hodgkin's lymphoma using rituximab, dhap, tec, and autologous stem cell transplantation as drugs, with eligibility criteria including first relapse or primary refractory disease of aggressive Non-Hodgkin's lymphoma stage I-IV, pretreatment with systemic therapy, and age between 18-65 years.",
    "This clinical trial is testing the effectiveness of paclitaxel, carboplatin, and vorinostat in treating stage IIIA, IIIB, and IV non-small cell lung cancer patients who have not received prior chemotherapy, and meet specific eligibility criteria.",
    "This sample is a phase 1/phase 2 trial for heart failure and asymptomatic systolic dysfunction, testing the effectiveness of nesiritide and placebo, with specific inclusion and exclusion criteria for subjects.",
    "This is a phase 1/phase 2 trial for patients with clinical stage T4 or recurrent adenocarcinoma of the rectum, using capecitabine as the drug, and the eligibility criteria includes confirmation of histology, no distant metastatic disease, and certain medical conditions.",
    "The sample is a phase 1/phase 2 trial for locally advanced or metastatic, unresectable soft tissue sarcoma, testing the drugs amg 655 and doxorubicin, with inclusion criteria including confirmed soft tissue sarcoma, measurable disease, and adequate organ function, and exclusion criteria including prior treatment with anthracyclines and uncontrolled cardiovascular disease.",
    "The sample is a phase 1/phase 2 trial for patients with relapsed or refractory acute lymphoblastic leukemia, testing the efficacy of clofarabine, with eligibility criteria including CD52 expression on at least 10% of lymphoblasts and adequate renal and hepatic functions.",
    "This trial is testing the efficacy of tivantinib, placebo, cetuximab, and irinotecan in treating metastatic colorectal cancer patients who have received one prior line of chemotherapy and express the wild-type form of the gene KRAS.",
    "This trial is testing the combination of gefitinib and gemcitabine for patients with pancreatic cancer, with specific eligibility criteria and exclusion criteria listed.",
    "The sample is a phase 1/2 trial for patients with non-small-cell lung carcinoma who have failed standard chemotherapy and will test the drug pt-523 for injection, with eligibility criteria including age \u2265 18 years, ECOG performance status 0-2, and adequate organ function and bone marrow reserve.",
    "The sample is a phase 1/phase 2 trial for patients with chronic lymphocytic leukemia, testing the efficacy of gleevec and chlorambucil as a treatment option, with specific inclusion and exclusion criteria.",
    "The sample is a phase 1/2 trial testing the drug mgcd0103 on patients with high-risk myelodysplastic syndrome or acute myelogenous leukemia, with specific eligibility criteria and exclusion criteria listed.",
    "The sample is a phase 1/phase 2 trial for metastatic and/or locally advanced colorectal cancer using bevacizumab, oxaliplatin, and capecitabine as drugs, with eligibility criteria including age, histologically confirmed colorectal cancer, and measurable lesion according to RECIST.",
    "This trial is testing the effectiveness of samarium sm-153 lexidronam + docetaxel in treating castrate metastatic prostate cancer patients with at least 3 bone metastases, who have shown progression of disease following withdrawal of anti-androgen therapy, and meet other eligibility criteria.",
    "The sample is a phase 1/2 trial testing the drug gefitinib on Asian patients with non-small cell lung cancer, with specific eligibility criteria including EGFR mutational status and never/light smoking history.",
    "The sample is a phase 1/phase 2 trial for essential tremor, testing the efficacy of levetiracetam and placebo drugs, with inclusion and exclusion criteria related to neurological and renal diseases, and pregnancy.",
    "This is a phase 1/2 trial for patients with metastatic colorectal cancer who have received prior cetuximab-containing regimens, and will test the efficacy of irinotecan hydrochloride as a treatment option. The eligibility criteria includes specific disease and medical history requirements, as well as laboratory values and performance status.",
    "The sample is a phase 1/phase 2 trial for patients with rheumatoid arthritis, testing the efficacy of cdp 6038 sc and methotrexate, with specific inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for relapsing multiple sclerosis, testing the drugs cdp323 and placebo, with inclusion criteria including age, disease type, and EDSS score, and exclusion criteria including concomitant treatment with MS disease modifying drugs.",
    "The sample is a phase 1/phase 2 trial for ta-7284 and placebo in clinically stable type 2 diabetes mellitus patients with specific inclusion and exclusion criteria, including BMI, hemoglobin A1c levels, fasting blood glucose levels, blood pressure, and medication history.",
    "This sample is a phase 1/phase 2 trial for patients with multiple myeloma, testing the efficacy of depsipeptide, bortezomib, and dexamethasone as treatment options, with specific inclusion and exclusion criteria outlined.",
    "The sample is a phase 1/phase 2 trial for patients with advanced non-small cell lung cancer, testing the drug irinotecan, with eligibility criteria including prior chemotherapy, high ISG15 levels, and adequate bone marrow, hepatic, and renal function.",
    "The sample is a phase 1/phase 2 trial for metastatic melanoma using the drug raf265, with eligibility criteria including confirmed diagnosis of melanoma, measurable disease, and ECOG performance status of 0 or 1.",
    "The sample is a phase 1/phase 2 trial for HIV infections, testing the efficacy of tenofovir df and tenofovir alafenamide, with inclusion and exclusion criteria listed.",
    "The sample is a phase 1/phase 2 trial for patients with clinically refractory or resistant prostate cancer, testing the efficacy of abiraterone acetate, abiraterone acetate mtd, and dexamethasone, with eligibility criteria including histologically documented adenocarcinoma of the prostate and PSA evidence for progressive prostate cancer.",
    "The sample is a phase 1/phase 2 trial for locally advanced or metastatic pancreatic cancer, testing the efficacy of gemcitabine, capecitabine, erlotinib, and bevacizumab, with eligibility criteria including confirmed adenocarcinoma of the pancreas, measurable disease, and no invasion of adjacent organs, among other requirements.",
    "The sample is a phase 1/2 clinical trial for small cell lung cancer, testing the efficacy of at-101 and topotecan as second-line treatment, with specific eligibility criteria including prior chemotherapy regimen and ECOG performance status.",
    "The sample is a phase 1/phase 2 trial for non-small-cell lung cancer patients who have failed prior treatment, using the drugs vorinostat and erlotinib, with inclusion and exclusion criteria listed.",
    "The sample is a phase 1/phase 2 trial for patients with stage IV non-small cell lung cancer, testing the efficacy of paclitaxel albumin-stabilized nanoparticle formulation, with eligibility criteria including measurable disease, specific performance status, and no prior chemotherapy for metastatic disease.",
    "This trial is testing the effectiveness of docetaxel and pemetrexed in treating non-small cell lung cancer in patients who have not previously been treated with these drugs, and have met certain eligibility criteria.",
    "This trial is for patients with primary refractory or relapsed acute myeloid leukemia, who have not received high-dose cytarabine within 3 months prior to registration, and are not pregnant or nursing. The treatment includes cytarabine and lovastatin.",
    "The sample is a phase 1/phase 2 clinical trial for the drug abt-263 in patients with small cell lung cancer or small cell lung carcinoma who have experienced disease progression or are refractory to prior chemotherapy treatment regimens, with eligibility criteria including age, disease diagnosis, prior treatment history, ECOG performance score, and adequate bone marrow, renal, and hepatic function.",
    "This trial is testing the efficacy of Alks 5461 and placebo in treating major depressive disorder in patients who have had an inadequate response to SSRI or SNRI treatment, with specific inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for patients with various hematologic diseases, testing the efficacy of a combination of drugs including campath, busulfan, fludarabine, and fk-506, with eligibility criteria including age, performance status, and availability of a healthy donor.",
    "This trial is for phase 1/phase 2 of oligog cf-5/20 and saline in treating cystic fibrosis patients with Pseudomonas aeruginosa, with specific inclusion and exclusion criteria.",
    "This trial is for patients with relapsed or refractory acute myeloid leukemia and acute promyelocytic leukemia, and will test the efficacy of clofarabine and cytarabine as treatment options.",
    "This trial is testing the efficacy of bilb 1941 zw and placebo in treating chronic hepatitis C in adult males with specific inclusion and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for small cell lung cancer using pemetrexed and cisplatin as drugs, with inclusion criteria including measurable disease and a performance status of 0 to 1, and exclusion criteria including prior chemotherapy and/or thoracic radiotherapy and concurrent administration of any other antitumor therapy.",
    "This is a phase 1/phase 2 trial for non-small-cell lung carcinoma using cisplatinum and docetaxel as drugs, with eligibility criteria including confirmed NSCLC, stage III unresectable LA-NSCLC, and adequate cardiac function.",
    "This trial is testing the efficacy of lenalidomide, pioglitazone, dexamethasone, and treosulfan in treating multiple myeloma patients who have relapsed after at least two different anti-myeloma treatments, and have been previously treated with lenalidomide for the phase II part.",
    "The sample is a phase 1/phase 2 trial for patients with hepatocellular carcinoma, testing the drug denspm, with eligibility criteria including measurable disease, renal and hepatic function, and exclusion criteria including prior therapy within certain time frames and unstable medical conditions.",
    "This sample is a phase 1/phase 2 trial testing the drug Proellex on healthy adult females with excessive menstrual bleeding, menstrual pain, uterine fibroids, or endometriosis, who meet certain eligibility criteria and do not have any exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for patients with vision-threatening autoimmune uveitis, using the drug apremilast, with inclusion criteria of failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects, and exclusion criteria of serious concomitant illness, previous or current use of an alkylating agent, use of CYP3A4 inhibitors during the trial, and TNF blocker use within the 8 weeks prior to enrollment.",
    "The sample is a phase 1/phase 2 trial for the drug arn-509 in patients with non-metastatic or metastatic castration-resistant prostate cancer, with specific eligibility criteria and exclusion criteria.",
    "This clinical trial is for patients with Malignant Pleural Mesothelioma and will test the effectiveness of carboplatin, bevacizumab, and pemetrexed as a treatment, with specific eligibility criteria and exclusion criteria.",
    "This trial is a phase 1/2 study testing erlotinib hcl, a drug used to inhibit epidermal growth factor receptor (EGFR), in patients with non-small cell lung cancer who have received at least one chemotherapy regimen for advanced or metastatic NSCLC, and have measurable disease on computed tomography (CT) and at least one detectable lesion on FDG-PET scan and/or FLT-PET scan that is measurable on CT.",
    "The sample is a phase 1/phase 2 trial for prostate cancer using the drugs tak-700, docetaxel, and prednisone, with eligibility criteria including confirmed diagnosis of prostate adenocarcinoma, radiograph-documented metastatic disease, and prior surgical castration or concurrent use of an agent for medical castration.",
    "The sample is a phase 1/phase 2 trial for metastatic or relapsed locally advanced breast cancer with HER2-positive by FISH, using bevacizumab and herceptin as drugs, and with specific eligibility and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for glioblastoma multiforme using the drug aee788, with inclusion criteria including confirmed GBM in first or second recurrence or relapse, adequate hematologic, hepatic and renal function, age \u2265 18 years, Karnofsky performance status score \u2265 70%, and life expectancy \u2265 12 weeks, and exclusion criteria including peripheral neuropathy > grade 1, diarrhea > grade 1, gastrointestinal dysfunction, compromised cardiac function, and concurrent severe and/or uncontrolled medical conditions.",
    "This trial is for patients with symptomatic multiple myeloma requiring treatment, who have been approved for single or tandem autologous transplant, and will test the efficacy of busulfan in combination with DT-PACE.",
    "The sample is a phase 1/phase 2 trial for osteoarthritis, testing the efficacy of normal saline as a treatment, with specific inclusion and exclusion criteria listed.",
    "The sample is a phase 1/2 trial for the drug tmc278la in HIV-infected individuals, with inclusion and exclusion criteria listed, and the value is the potential efficacy of the drug in treating HIV.",
    "This sample is a phase 1/phase 2 clinical trial for patients with mantle cell lymphoma, testing the efficacy of temsirolimus and bendamustine in patients who have relapsed or progressed during therapy, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for glaucoma and ocular hypertension, testing the drugs ino-8875 and placebo, with inclusion criteria based on age and mean intraocular pressure, and exclusion criteria based on visual field loss, cup-to-disc ratio, central corneal thickness, and medical history.",
    "The sample is a phase 1/phase 2 clinical trial for the treatment of anterior cruciate ligament injury and osteoarthritis using hyaluronan, with eligibility criteria including ACL reconstruction surgery within six months, autograft use, and willingness to participate in follow-up for 24 months.",
    "This clinical trial is testing the drug radotinib on patients with Ph+ CML who are resistant or intolerant to imatinib or other targeted anticancer agents, with specific inclusion and exclusion criteria based on disease phase, performance status, laboratory values, and medical history.",
    "The sample is a phase 1/phase 2 trial for relapsed or refractory multiple myeloma patients using the drug Revlimid, with eligibility criteria including measurable levels of myeloma paraprotein, ECOG performance status score of 0, 1 or 2, and no more than 3 prior anti-myeloma regimens.",
    "The sample is a phase 1/phase 2 trial testing the safety and efficacy of ibi-20089/Lucentis in treating active, subfoveal choroidal neovascular membranes due to age-related macular degeneration, with specific inclusion and exclusion criteria for subjects.",
    "This trial is testing the drug panobinostat on HIV patients who meet specific eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for patients with hermansky-pudlak syndrome, pulmonary fibrosis, oculocutaneous albinism, platelet storage pool deficiency, and metabolic disease, testing the efficacy of losartan, zileuton, n-acetylcysteine, pravastatin, and erythromycin, with specific eligibility and exclusion criteria.",
    "This trial is testing the efficacy of capecitabine, epirubicin, amg 102, cisplatin, and placebo in treating unresectable locally advanced or metastatic gastric or esophagogastric junction adenocarcinoma, with specific inclusion and exclusion criteria.",
    "This is a phase 1/phase 2 trial for patients with progressive, metastatic prostate cancer, testing the efficacy of docetaxel, prednisone, and vatalanib, with eligibility criteria including castrate levels of testosterone, Karnofsky performance status \u2265 60%, and no pre-existing grade 3 or 4 clinical peripheral neuropathy.",
    "The sample is a phase 1/phase 2 trial for kidney transplantation, testing the drugs aeb071 and mycophenolic acid, with inclusion criteria including adult recipients of a functioning kidney transplant and exclusion criteria including patients with a history of cancer or severe systemic infections.",
    "The sample is a phase 1/phase 2 trial for metastatic colorectal cancer, colon cancer, colorectal cancer, and rectal cancer, testing the efficacy of placebo, amg 655, modified folfox6, and bevacizumab, with eligibility criteria including confirmed diagnosis, ECOG score of 0 or 1, and adequate organ function.",
    "This trial is testing the efficacy of idarubicin, sorafenib, and ara-c in treating AML and high risk MDS in patients aged 15 to 60 years who meet specific eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for locally advanced pancreatic ductal adenocarcinoma, testing the efficacy of bevacizumab, 5-fluorouracil, oxaliplatin, and gemcitabine, with specific eligibility criteria and exclusion criteria.",
    "This trial is testing the drug camptothecin (cpt) conjugated to a linear, cyclodextrin-based polymer on patients with advanced, histologically-confirmed solid tumors refractory to standard therapy or for which no standard therapy exists, with measurable or evaluable disease, and who have not received prior chemotherapy or radiation for >/= 4 weeks prior to first dose of study drug, among other eligibility criteria.",
    "This trial is for patients with relapsed or primary refractory lymphoid malignancy, and the treatment includes chemotherapy with drugs such as vorinostat, ifosfamide, carboplatin, and etoposide, with specific eligibility criteria including measurable disease and a SWOG performance status of 0, 1, or 2.",
    "The sample is a phase 1/phase 2 trial for non-small cell lung cancer using tlk286, carboplatin, and paclitaxel as drugs, with eligibility criteria including confirmed NSCLC, measurable disease, and adequate liver and renal function.",
    "This clinical trial is testing the efficacy of AVE1642, sorafenib, and erlotinib in treating liver carcinoma patients who are not eligible for surgical resection, liver transplantation, local ablation techniques or chemoembolisation, and have histologically proven liver carcinoma or a combination of radiologically documented hypervascular liver tumour and \u03b1 foeto protein level \u2265 400 ng/ml.",
    "This trial is testing the combination of pemetrexed, cisplatin, and LY2603618 for the treatment of non-small cell lung cancer and malignant mesothelioma in Phase 1 and NSCLC in Phase 2, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for metastatic colorectal cancer testing the efficacy of pimasertib, placebo, and folfiri as treatment options for patients who have progressed during or after a first-line treatment with oxaliplatin and fluoropyrimidines based chemotherapy with or without bevacizumab, with eligibility criteria including K-Ras mutated colon/rectum cancer and evidence of metastatic measurable disease at trial entry.",
    "The sample is a phase 1/phase 2 trial for psoriasis vulgaris using hat1 topical solution and calcipotriol as drugs, with inclusion criteria including a PASI score >3 and <12, and exclusion criteria including systemic treatment with immunosuppressive drugs or corticosteroids within 4 weeks prior to enrollment.",
    "The sample is a phase 1/phase 2 trial for patients with locally advanced non-small cell lung cancer, testing the efficacy of bortezomib, paclitaxel, and carboplatin in combination with radiotherapy, with strict eligibility criteria including performance status, blood counts, liver and kidney function, and exclusion of prior chemotherapy or radiation therapy to the chest.",
    "This trial is testing the efficacy of entinostat and imatinib mesylate in treating Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia patients who have failed primary induction therapy or relapsed after achieving complete remission, and meet specific eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for systemic sclerosis, testing the efficacy of rapamycin and methotrexate as treatment options, with specific inclusion and exclusion criteria.",
    "This trial is testing the efficacy of pemetrexed, cisplatin and cbp501, and pemetrexed and cisplatin in treating malignant pleural mesothelioma and solid tumors in patients who meet specific eligibility criteria.",
    "This trial is testing a combination therapy of bortezomib, dexamethasone, peg-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine for patients with relapsed or refractory acute lymphoblastic leukemia who meet specific eligibility criteria.",
    "This clinical trial is testing the efficacy of placebo, palifermin, and cisplatin in treating mucositis and head and neck cancer patients who meet specific eligibility criteria, including having newly diagnosed squamous cell carcinoma and receiving adjuvant concurrent chemoradiation treatment within 12 weeks of surgery. The trial is in phase 1/phase 2 and includes patients with various ICD-10 codes.",
    "This trial is testing the efficacy of paclitaxel, nanoparticle albumin-bound in treating patients with recurrent bladder cancer refractory to standard intravesical therapy, with specific eligibility criteria including confirmed diagnosis of transitional cell carcinoma, high-grade histology, and exclusion of muscle invasion.",
    "This sample is a phase 1/phase 2 trial for patients with unresectable pancreatic cancer, testing the efficacy of oxaliplatin, 5fu, and folfox 6, with eligibility criteria including no prior chemotherapy or radiation therapy, ECOG performance status 0-1, and adequate organ function.",
    "The sample is a phase 1/phase 2 trial for squamous cell cancer, testing the efficacy of cilengitide, cetuximab, 5-fluorouracil, and cisplatin, with specific inclusion and exclusion criteria.",
    "This trial is testing the drug pd-0325901 on patients with metastatic or inoperable breast cancer, colon cancer, or melanoma, with eligibility criteria including age, prior treatment, and adequate organ function.",
    "This clinical trial is testing the efficacy of carboplatin, paclitaxel, and medi-575 in treating inoperable Stage IIIB or Stage IV non-small cell lung cancer patients with squamous cell carcinoma, who meet specific eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for metastatic breast cancer, testing the drugs ct-p6, herceptin, and paclitaxel, with eligibility criteria including Her 2 over-expression and ECOG 0 or 1.",
    "This trial is testing the efficacy of carboplatin, cetuximab, and rad001 in treating patients with recurrent, refractory or metastatic squamous cell carcinoma of the head and neck who failed to respond to prior chemoradiotherapy, and the eligibility criteria includes various medical conditions and laboratory values.",
    "This clinical trial is testing the combination of bay86-9766 and gemcitabine for patients with locally advanced, inoperable or metastatic pancreatic adenocarcinoma, with specific inclusion and exclusion criteria.",
    "This sample is a phase 1/phase 2 trial for Friedreich's ataxia, testing the efficacy of deferiprone and placebo drugs, with inclusion and exclusion criteria for eligibility.",
    "The sample is a phase 1/phase 2 trial for lung cancer using the drug ipi-504, with inclusion criteria of Stage IIIb or Stage IV NSCLC and measurable disease by RECIST criteria, and exclusion criteria of previous treatment with 17-AAG, DMAG or other known Hsp90 inhibitor.",
    "This trial is testing the efficacy of trastuzumab and rad001 in patients with HER-2-overexpressing breast cancer and metastatic disease who have previously received trastuzumab-based therapy, and have met specific eligibility criteria.",
    "The sample is a phase 1/phase 2 trial for patients with advanced metastatic or recurrent gastric cancer, testing the effectiveness of paclitaxel, with specific eligibility criteria including proper bone marrow, kidney, and liver function, and exclusion criteria such as blood tumors or uncontrolled infectious disease.",
    "The sample is a phase 1/phase 2 trial for patients with idiopathic cardiomyopathy, testing the use of allopurinol and dobutamine, with inclusion and exclusion criteria listed.",
    "The sample is a phase 1/phase 2 trial for hormone refractory prostate cancer using docetaxel and gemcitabine as drugs, with eligibility criteria including PSA > 10 microgram/l and stage IV disease.",
    "This trial is testing the effectiveness of rituximab in treating Sjogren's syndrome, with inclusion criteria including positive autoantibodies and a parotid gland biopsy, and exclusion criteria including previous treatment with anti-TNF or other monoclonal antibodies and underlying medical conditions that place the patient at an unacceptable risk for participation in the study.",
    "This trial is testing the effectiveness of sunitinib malate, docetaxel, and prednisone in treating metastatic prostate cancer that is unresponsive to hormone therapy, with eligibility criteria including a histological diagnosis of adenocarcinoma of the prostate, adequate hepatic and renal function, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.",
    "The sample is a phase 1/phase 2 clinical trial for Crohn's disease, testing the effectiveness of chondroitin sulfate as a treatment option, with specific inclusion and exclusion criteria for patient eligibility.",
    "The sample is a phase 1/phase 2 trial for non-small cell lung cancer patients with a list of eligible drugs including bevacizumab, erlotinib, and pemetrexed, and eligibility criteria including age, disease stage, performance status, and adequate organ function.",
    "The sample is a phase 1/phase 2 trial for patients with chronic lymphocytic leukemia, testing the efficacy of a combination of drugs including busulfan, cyclophosphamide, and fludarabine phosphate, with eligibility criteria including poor prognostic features and the availability of an HLA-identical sibling or unrelated donor.",
    "The sample is a phase 1/phase 2 trial for castration-resistant prostate cancer using the drug mdv3100, with inclusion criteria including confirmed adenocarcinoma of the prostate and ongoing androgen deprivation therapy, and exclusion criteria including metastases in the brain and use of bicalutamide within 6 weeks prior to the study.",
    "The sample is a phase 1/phase 2 clinical trial for relapsed or refractory acute myeloid leukemia, testing the efficacy of voreloxin injection and cytarabine, with eligibility criteria including at least 10% blasts by BM biopsy or aspirate and exclusion criteria including allogenic bone marrow transplant/stem cell transplant and prior exposure to vosaroxin.",
    "The sample is a phase 1/phase 2 clinical trial for the drug pci-32765 in the treatment of b-cell chronic lymphocytic leukemia and small lymphocytic lymphoma, with specific eligibility criteria for different patient groups based on their previous treatments and disease progression.",
    "This trial is testing the efficacy of cyclophosphamide, doxorubicin hydrochloride, fludarabine phosphate, paclitaxel, and mesna in treating metastatic infiltrating carcinoma of the breast, with specific eligibility criteria including Karnofsky performance status, ejection fraction, and normal liver function.",
    "The sample is a phase 1/phase 2 trial for women with Her-2 positive and ER-negative or ER-low breast cancer, testing the effectiveness of trastuzumab (herceptin\u00ae) and including eligibility criteria such as not having received prior treatment and not having a BRCA mutation.",
    "The sample is a phase 1/phase 2 trial for infertility in females, using drugs g-csf and saline, with inclusion criteria related to endometrial growth and exclusion criteria related to sickle cell disease, renal insufficiency, respiratory infection, chronic neutropenia, and malignancy.",
    "The sample is a phase 1/phase 2 trial testing the drugs ji-101 and everolimus on patients with refractory solid tumors, including ovarian and colon cancer, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 1/phase 2 trial for chronic hepatitis C, testing the drugs bms-791325 and placebo, with inclusion criteria including HCV genotype 1, treatment-naive or non-responders/intolerant, and BMI 18-35 kg/m\u00b2.",
    "This trial is for patients with metastatic prostate cancer who have failed at least one taxane regimen or are chemotherapy-nai\u0308ve, and will test the drug he3235, with eligibility criteria including confirmed adenocarcinoma of the prostate and progression of disease despite adequate hormone therapy.",
    "This trial is testing the combination of temsirolimus and sunitinib for the treatment of advanced renal cell carcinoma, with specific inclusion and exclusion criteria for the dose escalation and expanded cohort phases.",
    "The sample is a phase 1/phase 2 trial for glioblastoma and gliosarcoma using the drugs enzastaurin and temozolomide, with specific eligibility criteria including recent biopsy or resection and no prior drug therapy for brain tumors.",
    "The sample is a phase 1/phase 2 trial for non-Hodgkin's lymphoma, testing the efficacy of vincristine sulfate liposome injection plus rituximab, with eligibility criteria including prior chemotherapy regimens, measurable disease, and confirmation of CD20 expression on lymphoma cells.",
    "This trial is for patients with relapsed CD20-positive B-cell non-Hodgkin's lymphoma and will test the efficacy of a combination of drugs including y zevalin, in zevalin, rituxan, bcnu, vp -16, ara-c, melphalan, and g-csf. The eligibility criteria include having a prestudy performance status of 0, 1, or 2, and acceptable hematologic status with absolute neutrophil count and platelet counts meeting certain thresholds.",
    "The sample is a phase 1/phase 2 clinical trial for melanoma treatment using Normothermic Isolated Limb Infusion (ILI) of melphalan and ADH-1, with inclusion criteria including measurable disease and availability for immunohistochemical testing of N-cadherin expression tumor tissue, and exclusion criteria including stage IV melanoma and history of tumors that have shown clinically significant evidence of active bleeding within 12 weeks before study entry.",
    "The sample is a phase 1/phase 2 trial for chronic myelogenous leukemia and philadelphia chromosome positive acute lymphoblastic leukemia, testing the drug dasatinib, with eligibility criteria including completion of a previous study and exclusion criteria including pregnancy or breastfeeding.",
    "The sample is a phase 1/phase 2 trial for previously untreated aggressive non-Hodgkin's Lymphoma, using cyclophosphamide, doxorubicin, vincristine and prednisone as drugs, with specific inclusion and exclusion criteria.",
    "This trial is testing the effectiveness of ptk787 and trastuzumab in treating breast cancer patients with HER2 gene amplification and specific eligibility criteria.",
    "This sample is a phase 1/phase 2 trial for patients with metastatic or locally recurrent colorectal cancer who failed prior therapy with fluorouracil, leucovorin calcium, and irinotecan given either sequentially or in combination, and will test the efficacy of zd1839 and oxaliplatin as drugs.",
    "This sample is a phase 1/phase 2 trial testing the effectiveness of bumetanide in treating neonatal seizures in term babies with specific inclusion and exclusion criteria, including EEG monitoring and written informed consent.",
    "This phase 2 trial is testing the efficacy of fulvestrant and tipifarnib in postmenopausal women with estrogen receptor-positive breast cancer, recurrent breast cancer, or stage IIIB/IIIC/IV breast cancer, who have measurable disease and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of a combination of drugs including placebo, scy-635, pegasys, and copegus in treating chronic hepatitis C infection in patients with specific eligibility criteria, including quantifiable serum levels of HCV-specific RNA, HCV genotype 1 infection and IL28B genotype of C/T or T/T, and absence of cirrhosis.",
    "This phase 2 trial will test the efficacy of palonosetron, aprepitant, and dexamethasone in patients with multiple myeloma and lymphoma undergoing high dose chemotherapy and autologous hematopoietic stem cell transplant, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of dexamethasone, thalidomide, and lenalidomide in treating relapsed or refractory multiple myeloma patients who have previously been treated with lenalidomide and thalidomide, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug lbh589 on patients with refractory multiple myeloma who have received at least two prior lines of therapy and have previously been treated with bortezomib or lenalidomide, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for saracatinib, a drug being tested for the treatment of various types of squamous cell carcinoma of the head and neck, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 trial is testing the effectiveness of telmisartan and losartan, two drugs, in treating patients with renal transplant and hypertension, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for postmenopausal women with pre-hypertension, testing the drugs drospirenone/17\u00df-estradiol and sh k 00641 c - medroxyprogesterone acetate / conjugated equine (prempro tm), with inclusion criteria of postmenopausal women 45-65 years old and exclusion criteria of hormone therapy (estrogen/progestin).",
    "This is a phase 2 trial for patients with Hodgkin's disease eligible for autologous transplantation, testing the efficacy of g-csf plus plerixafor, with specific eligibility criteria including prior chemotherapy regimens, blood counts, organ function, and exclusion criteria such as co-morbid conditions and previous experimental therapy.",
    "This phase 2 trial is testing the drug alvocidib on patients with B-cell chronic lymphocytic leukemia, prolymphocytic leukemia, or refractory chronic lymphocytic leukemia who have received prior chemotherapy and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for irritable bowel syndrome using the drug gw876008, with inclusion criteria requiring the presence of irritable bowel syndrome and exclusion criteria excluding those who have taken medication for it within 6 months prior to the study.",
    "The sample is a phase 2 trial for multiple myeloma patients who have received prior bortezomib-based therapy, with inclusion criteria including a sustained 50% reduction in M-Protein and no evidence of disease progression, and exclusion criteria including a history of allergic reaction to certain compounds; the trial will test the efficacy of bortezomib and pegylated liposomal doxorubicin.",
    "This phase 2 trial is testing the drug vinflunine for men with hormone refractory prostate cancer who have received 1 or 2 previous chemotherapy regimens, and have evidence of PSA progression, radiographically or clinically demonstrable metastatic disease, and an ECOG performance status of 0-2.",
    "This phase 2 trial is testing the efficacy of gefapixant and a sugar pill in treating chronic knee osteoarthritis, with inclusion criteria including clinical and radiographic evidence of the disease and an average NPRS score of >=5 and <=9 over a 4-7 day washout period of previous medications.",
    "This phase 2 trial is testing the efficacy of dimethyl sulfoxide and ic cocktail in treating painful bladder syndrome and requires participants to meet specific inclusion and exclusion criteria.",
    "This trial is testing the effectiveness of NucleomaxX and placebo in treating HIV patients with lipoatrophy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for head and neck cancer patients who have undergone surgical resection and are eligible for post-operative radiation and cisplatin, with the drug being tested being iressa (gefitinib). The eligibility criteria include having a tumoral biopsy stored in liquid nitrogen and receiving post-operative radiation associated with cisplatin, while the exclusion criteria include a previous history of cancer.",
    "This phase 2 trial is testing the efficacy of sorafenib tosylate in treating patients with metastatic breast cancer who have previously been treated with anthracycline- and/or taxane-containing regimens, and meet a variety of eligibility criteria.",
    "This phase 2 trial is testing the efficacy of pemetrexed disodium, a chemotherapy drug, in treating patients with recurrent or persistent ovarian or primary peritoneal cavity cancer who have received prior platinum-based chemotherapy, and have platinum-resistant or refractory disease. The eligibility criteria include various disease and patient characteristics, and exclude prior cytotoxic chemotherapy for recurrent or persistent disease, including retreatment with initial chemotherapy regimens, and prior pemetrexed disodium.",
    "This phase 2 trial is testing the efficacy of STA-9090, a drug, in treating metastatic or advanced stage breast cancer patients who have received prior treatment with biologic and/or chemotherapy, excluding hormonal therapy, and have measurable disease by RECIST 1.1.",
    "This phase 2 trial is testing the drug eaa-090 on patients with diabetes mellitus and painful diabetic neuropathy, with inclusion criteria including controlled diabetes and diagnosis of painful diabetic distal symmetric sensory/motor polyneuropathy.",
    "This phase 2 trial is testing the efficacy of placebo, oxaliplatin, leucovorin, and 5-fluorouracil in treating metastatic or locally advanced, unresectable stomach and esophageal cancer, with eligibility criteria including histologic confirmation of adenocarcinoma, ECOG PS of 0-1, and adequate renal, hematological, and hepatic function.",
    "The sample is a phase 2 trial for patients with HER2-positive stage IV breast cancer, testing the efficacy of docetaxel and vinorelbine as chemotherapy drugs, with eligibility criteria including age, sex, performance status, and prior chemotherapy and hormonal therapy.",
    "This phase 2 trial is testing the efficacy of ssp-002358 and PPI combination therapy for gastroesophageal reflux disease in subjects who have persistent symptoms of regurgitation while on PPI therapy, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of capecitabine and oxaliplatin in treating patients with hepatic metastases secondary to colorectal cancer, with specific eligibility criteria including resectable hepatic metastases and measurable disease.",
    "The sample is a phase 2 trial testing the efficacy of dabigatran etexilate and warfarin in preventing thromboembolism in patients with heart valve prosthesis, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of temozolomide and bevacizumab in treating supratentorial glioblastoma multiforme and primary brain tumors in patients aged 70 or older with a KPS score between 30 and 70, and includes a list of inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for type 2 diabetes, testing the efficacy of ertugliflozin and sitagliptin drugs, with inclusion criteria of stable background medication and BMI between 23-45 kg/m^2, and exclusion criteria of type 1 diabetes, recent heart attack or stroke, uncontrolled blood pressure, and significant kidney disease.",
    "This phase 2 trial is testing the drug mitoxantrone on patients with relapsing-remitting multiple sclerosis who meet specific eligibility criteria.",
    "This phase 2 trial will test the efficacy of preladenant, placebo, anticholinergic agents or propanolol, and haloperidol in treating drug-induced akathisia and movement disorders in participants with acute psychoses, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for patients with recurrent or stage IV breast cancer, testing the drug bortezomib, with eligibility criteria including specific disease characteristics, performance status, and laboratory values.",
    "This phase 2 trial is testing the efficacy of dasatinib and imatinib mesylate in treating chronic myelogenous leukemia patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial testing riociguat and placebo on patients with symptomatic pulmonary hypertension due to left ventricular systolic dysfunction, with hypertension, pulmonary and ventricular dysfunction, left as the diseases, and ICD-10 codes I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22 and I47.2, I49.01, I49.02, I49.3, Q21.0, I47.0, I50.1 as the icdcodes.",
    "This phase 2 trial is testing the efficacy of capecitabine, a chemotherapy drug, in treating stage III or IV breast cancer patients who have received prior anthracycline and taxane therapy, and have progressed on or following trastuzumab or hormone therapy.",
    "This phase 2 trial is testing the efficacy of basiliximab induction therapy in patients receiving a primary renal graft from a deceased or living donor with a cold ischemia time < 30 hours and who require basiliximab induction therapy, using drugs such as simulect\u00ae, neoral\u00ae, certican\u00ae, myfortic\u00ae, and corticosteroids, and excluding patients with certain conditions such as positive anti-HLA antibodies and those receiving a graft from an expanded criteria donor.",
    "This phase 2 trial is testing the efficacy of gft505 80mg and placebo in drug-naive patients with type II diabetes mellitus, with inclusion criteria including a BMI between 27 and 45 kg/m\u00b2 and HbA1c levels between 7.0% and 9.5%.",
    "This phase 2 trial is testing the efficacy of pemetrexed, a chemotherapy drug, in treating metastasized or locally inoperable soft tissue sarcoma that has relapsed after previous cytostatic treatment with adriamycin and/or an ifosfamide containing chemotherapeutic substance.",
    "This phase 2 trial is testing the efficacy of iron sucrose in treating unexplained anemia in elderly patients with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of act-078573 oral capsules at 25 and 100 mg and matching placebo in elderly subjects with chronic primary insomnia, with a list of inclusion and exclusion criteria provided.",
    "The sample is a phase 2 trial for patients with active rheumatoid arthritis, testing the efficacy of scio-469 and placebo drugs, with inclusion and exclusion criteria related to medication use, liver enzymes, medical history, and infections.",
    "This phase 2 trial is testing the efficacy of staccato loxapine and staccato placebo in treating migraine headaches in patients who meet specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of tonabersat and placebo in treating migraine with or without aura, with specific inclusion and exclusion criteria for patient selection.",
    "This phase 2 trial is testing the efficacy of 40 mg glatiramer acetate and placebo in treating amyotrophic lateral sclerosis, with inclusion criteria including a diagnosis of definite or probable ALS, slow VC test equal or greater than 70% of the predicted value, and stable dose of riluzole for at least 8 weeks prior to screening.",
    "The sample is a phase 2 trial for chronic hepatitis C infection using pegylated interferon and ribavirin, with specific eligibility criteria including genotype, liver disease status, and laboratory parameters.",
    "This phase 2 trial is testing the effectiveness of nordihydroguaiaretic acid (ndga) in treating rising prostate-specific antigen (PSA) values in patients with prior definitive therapy for prostate cancer, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for asthma patients using gw685698x and placebo drugs, with inclusion criteria including age, gender, asthma diagnosis, severity of disease, and current anti-asthma therapy.",
    "This phase 2 trial is testing the efficacy of lapatinib and lapatinib plus capecitabine in treating metastatic gastroesophageal cancer patients with Her2 overexpression and a history of prior chemotherapy containing a platinum compound, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for gastric cancer using a combination of docetaxel, oxaliplatin, folinic acid, and 5-fu, with eligibility criteria including histologically confirmed adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma, age \u2265 18 years, and ECOG \u2264 2.",
    "The sample is a phase 2 trial for schizophrenia, testing the efficacy of ave1625 and placebo in outpatients with specific inclusion and exclusion criteria, and using icd-10 codes to identify the disease.",
    "The sample is a phase 2 trial for non-Hodgkin's lymphoma using pegfilgrastim as a drug, with eligibility criteria including previously untreated patients and exclusion criteria such as CNS involvement and prior bone marrow or stem cell transplantation.",
    "This phase 2 trial is testing the efficacy of sorafenib and zoledronic acid in patients with unresectable primary hepatocellular carcinoma who meet specific eligibility criteria.",
    "The sample is a phase 2 clinical trial testing erlotinib hydrochloride and sorafenib tosylate in patients with unresectable or metastatic gallbladder or cholangiocarcinoma, with specific eligibility criteria including measurable disease and no prior systemic treatment for metastatic or unresectable locally advanced disease.",
    "The sample is a phase 2 trial for newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue, using cdx-110 with gm-csf and temozolomide as drugs, and with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for infertility using the drugs Org 36286 and placebo, with inclusion criteria including oligomenorrhea or amenorrhea, normal serum prolactin and thyroid stimulating hormone levels, and exclusion criteria including pregnancy, ovarian cysts, and alcohol or drug abuse within the past 12 months.",
    "This phase 2 trial is testing the efficacy of obeticholic acid and placebo in treating liver cirrhosis and biliary disease in participants who meet specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of apremilast, a drug, in treating atopic dermatitis, with eligibility criteria including disease severity and previous systemic therapy, and exclusion criteria including active infections and immunodeficiency.",
    "This phase 2 trial is testing the efficacy of cytarabine and liposomal cytarabine in treating relapsed or refractory diffuse large B-cell non-Hodgkin's lymphoma patients who are ineligible for myeloablative therapy or transplantation, and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for patients with small cell lung cancer, testing the drug vinflunine, with inclusion criteria including previous chemotherapy, measurable disease, and adequate organ function, and exclusion criteria including CNS involvement and serious active infection or underlying medical condition.",
    "This is a phase 2 trial for patients with extensive stage small cell lung cancer, testing the drug bortezomib, with eligibility criteria including prior platinum-based chemotherapy and measurable disease, and patient characteristics such as age, performance status, and hematopoietic and renal function.",
    "This phase 2 trial is testing the drug cp-724,714 on patients with metastatic breast cancer who have HER2 gene amplification and have not responded to previous chemotherapy regimens, with eligibility criteria including limited visceral disease burden and measurable target lesions.",
    "The sample is a phase 2 trial for aggressive non-Hodgkin's lymphoma, testing the efficacy of a combination of drugs including chop regimen, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, prednisone, and vincristine sulfate, with eligibility criteria including confirmed diagnosis, measurable disease, and specific patient characteristics.",
    "The sample is a phase 2 trial for postmenopausal breast cancer patients with locally advanced or locally recurrent disease, testing the efficacy of bevacizumab, anastrozole, and fulvestrant, with eligibility criteria including ER/PR receptor positivity, no prior chemotherapy or hormone therapy for metastatic or inoperable breast cancer, and adequate bone marrow, renal, and liver function.",
    "This phase 2 trial is testing the drug odanacatib and placebo on postmenopausal women with osteoporosis, who meet specific inclusion criteria, and have not had prior osteoporotic fractures or treatment with osteoporosis medications, steroids, or hormone replacement.",
    "This is a phase 2 trial for cystic fibrosis patients with positive lower respiratory tract culture for Pseudomonas aeruginosa, testing the efficacy of aztreonam for inhalation solution (azli) and requiring specific eligibility criteria for inclusion and exclusion.",
    "This phase 2 trial is testing the effectiveness of alendronate in treating osteoporosis in children with a history of multiple fractures and a bone mineral density score of less than 2 standard deviations below the normal mean for age, with exclusion criteria including hypersensitivity to bisphosphonates and renal or liver dysfunction.",
    "The sample is a phase 2 trial for allergic rhinitis, testing the efficacy of qav680 and cetirizine in patients with positive skin prick test to ragweed allergen, with exclusion criteria including use of allergy medication and history of bronchospastic disease, and the study will test multiple drug combinations.",
    "The sample is a phase 2/3 trial for patients with unresectable cancer of the biliary tract, testing the efficacy of cisplatin, gemcitabine hydrochloride, and oxaliplatin, with eligibility criteria including WHO performance status, creatinine levels, and platelet count.",
    "The sample is a phase 2 trial for advanced ovarian cancer with positive BRCA1 or BRCA2 status, testing the efficacy of ku-0059436 (azd2281)(parp inhibitor) and including eligibility criteria such as measurable disease and exclusion criteria such as brain metastases and poor medical risk.",
    "This phase 2 trial is testing the drug temsirolimus on patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer who have received prior platinum-based chemotherapy, and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for patients with papillary renal cell carcinoma, testing the drug sunitinib malate, with eligibility criteria including measurable disease, ECOG performance status 0-1, and various laboratory values within normal limits.",
    "The sample is a phase 2 trial for breast and lung cancer patients receiving docetaxel therapy with dexamethasone as the only permitted corticosteroid, and the eligibility criteria includes age, performance status, neuropathy level, kidney and liver functions, and signed informed consent.",
    "This is a phase 2 trial for patients with atrial flutter, testing the drug azd1305, with inclusion criteria of sinus rhythm and scheduled for curative catheter ablation, and exclusion criteria of QTc >450 ms, abnormal potassium levels, and QRS duration >120 ms.",
    "This phase 2 trial is testing the efficacy of Pleneva and placebo in treating relapsing remitting multiple sclerosis, with specific inclusion and exclusion criteria for patients.",
    "This phase 2 trial is testing the drug ro5185426 on adult patients with metastatic melanoma and BRAF mutation, who have failed at least one previous treatment for brain metastases and require corticosteroids for symptom control. The eligibility criteria include age, disease stage, previous treatment, and performance status, while the exclusion criteria include increasing corticosteroid dose, previous malignancy, concurrent administration of any anticancer therapies, and clinically significant cardiovascular disease or event.",
    "This phase 2 trial is testing the efficacy of migalastat hcl, a drug used to treat Fabry disease, in male patients between 18 and 65 years of age who have stable dose levels of agalsidase and meet other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of ombrabulin and placebo in treating squamous metastatic non-small cell lung cancer patients with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of zemplar capsules in treating diabetic nephropathy and chronic kidney disease, with eligibility criteria including stable ACEi/ARB use and specific laboratory values, while exclusion criteria include previous vitamin D therapy and drug/alcohol abuse.",
    "The sample is a phase 2 trial for advanced or metastatic adenocarcinoma of the stomach, using sorafenib as the drug, with specific eligibility criteria including adequate hepatic, renal, heart, and hematologic functions.",
    "This phase 2 trial is testing the efficacy of paclitaxel, carboplatin, and temozolomide in treating advanced melanoma patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the gamma-secretase/notch signalling pathway inhibitor ro4929097 in patients with stage IV melanoma who have not received prior systemic therapy for stage IV disease, and have measurable disease, with eligibility criteria including Zubrod performance status of 0-1, and various laboratory values within normal ranges.",
    "The sample is a phase 2 trial for cachectic patients with various types of cancer, testing the effectiveness of cyproheptadine hydrochloride and megestrol acetate in increasing weight and appetite, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of GW274150, a drug for migraine disorders, on patients who meet specific inclusion criteria and do not have any exclusion criteria.",
    "This phase 2 trial is testing the drug trastuzumab emtansine (Kadcyla) on patients with HER2-positive metastatic breast cancer who have progressed on HER2-directed therapy and have received up to three chemotherapy regimens.",
    "This phase 2 trial is testing the efficacy of lcz696, valsartan, ahu377, and placebo in treating mild-to-moderate uncomplicated essential hypertension in patients aged 18-75, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial testing the drug everolimus on patients with mantle cell lymphoma who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of placebo and caprelsa (vandetanib) in combination chemotherapy for patients with locally advanced or metastatic pancreatic cancer, with specific inclusion and exclusion criteria for patient eligibility.",
    "This is a phase 2 trial for type 2 diabetes mellitus patients, testing the efficacy of srt2104 and placebo drugs, with eligibility criteria including stable metformin monotherapy, HbA1c of 6.5%-9.5%, and BMI of 22-38 kg/m^2.",
    "This phase 2 trial is testing the efficacy of indacaterol, mometasone furoate, and placebo in treating persistent asthma in patients who meet specific inclusion criteria, while excluding patients with chronic lung disease or respiratory tract conditions.",
    "This phase 2 trial is testing the efficacy of ex1000 and biphasic human insulin in treating type 2 diabetes with specific eligibility criteria, including a BMI less than or equal to 40.0 kg/m2 and HbA1c less than or equal to 9.5%, and exclusion criteria such as treatment with Glucagon-like peptide 1 mimetics or dipeptityl peptidase IV inhibitors.",
    "The sample is a phase 2 trial for restless legs syndrome, testing the efficacy of pregabalin and placebo, with inclusion criteria of moderate to severe idiopathic RLS and exclusion criteria of secondary RLS and symptomatic neuropathies.",
    "The sample is a phase 2/phase 3 trial for type 2 diabetes, testing the efficacy of dapagliflozin and placebo in subjects receiving insulin and metformin and/or a thiazolidinedione, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with clear cell kidney cancer, testing the efficacy of everolimus and imatinib mesylate drugs, with eligibility criteria including prior systemic therapy and specific patient characteristics.",
    "This phase 2 trial is testing the efficacy of bortezomib in treating follicular lymphoma patients who have relapsed or progressed after prior anti-neoplastic treatment, with specific eligibility criteria and exclusion criteria listed.",
    "The sample is a phase 2 trial for post-menopausal osteoporosis, testing the efficacy of ibandronate, risedronate, and alendronate, with inclusion criteria including being female, at least 5 years post-menopausal but <85 years, and having a BMD T-score of less than or equal to 2.5 or T-score less than or equal to -1 with a low trauma fracture, and exclusion criteria including having evidence of a clinically significant organic disease, a BMI less than 18 or greater than 35, and having a history of cancer within the past 5 years excluding skin cancer non melanomas.",
    "The sample is a phase 2 trial for patients with stable plaque-type psoriasis, testing the efficacy of multiple doses of las 41004 and placebo, with eligibility criteria including age, location and severity of psoriasis plaques, and willingness to comply with study protocol.",
    "This phase 2 trial is testing the efficacy of gemcitabine, sorafenib, and capecitabine in treating locally advanced or metastatic breast cancer patients who have progressed after treatment with a bevacizumab-containing regimen, with eligibility criteria including confirmed adenocarcinoma of the breast, ECOG Performance Status of 0 or 1, and adequate bone marrow, liver, and renal function.",
    "This sample is a phase 2 trial for smoking cessation using surinabant and placebo drugs, with eligibility criteria including patients over legal age smoking at least 10 cigarettes/day, and exclusion criteria including patients with limited motivation or a diagnosis of Psychotic Disorder or currently presenting with a Depressive Episode.",
    "This phase 2 trial is testing the efficacy of rwj-445380, a drug, in treating rheumatoid arthritis in patients who have been on methotrexate treatment for at least 6 months and meet certain eligibility criteria.",
    "This phase 2 trial is testing second line chemotherapy and trastuzumab for female patients with metastatic breast cancer and HER2 overexpression, with specific inclusion and exclusion criteria based on previous treatments and medical history.",
    "The sample is a phase 2 trial testing temozolomide for non-small-cell lung cancer with brain metastasis, with inclusion and exclusion criteria listed, and diseases and icd-10 codes including metastases, neoplasm, carcinoma, non-small-cell lung, and brain neoplasms.",
    "This phase 2 trial focuses on renal transplantation and tests the efficacy of sotrastaurin and mycophenolic acid in combination with tacrolimus and standard of care medications, with specific eligibility criteria for recipients of a first or second kidney transplant from a deceased, living unrelated or non-HLA identical living related donor.",
    "The sample is a phase 2 trial for newly diagnosed Ewing's sarcoma family of tumors of the bone or soft tissues, using a combination of drugs including celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, mesna, and filgrastim, with specific eligibility criteria for patients including age, performance status, and renal function.",
    "The sample is a phase 2 trial for metastatic breast cancer patients, testing the efficacy of liposomal doxorubicin and myocet/paclitaxel, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, and temozolomide in treating stage IV melanoma patients who are not amenable to surgery and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for non-small-cell lung cancer using the drug ispinesib, with eligibility criteria including having received only one prior platinum-based chemotherapy regimen and adequate blood counts, and exclusion criteria including having received more than 1 chemotherapy regimen in the past or having less than adequate liver and kidney function.",
    "The sample is a phase 2 trial testing odiparcil, warfarin, and coumadin on patients with deep vein thrombosis, fibrillation, atrial, venous thromboembolism, and pulmonary embolism, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 clinical trial testing the efficacy of topotecan hydrochloride in treating recurrent ovarian, fallopian tube, or primary peritoneal cancer patients who have received only one prior platinum-based chemotherapy regimen, and meet specific eligibility criteria.",
    "This is a phase 2 trial for breast cancer patients with specific disease characteristics and patient characteristics, testing the efficacy of a combination of drugs including capecitabine, celecoxib, cyclophosphamide, docetaxel, and doxorubicin hydrochloride.",
    "This phase 2 trial is testing the drug sjg-136 on patients with recurrent ovarian, primary peritoneal, or fallopian tube carcinoma who are platinum refractory or resistant and have had no more than three prior treatment regimens, with eligibility criteria including measurable disease, adequate bone marrow and organ function, and signed informed consent.",
    "This phase 2 trial is testing the drugs ym155 and docetaxel on patients with unresectable stage III or stage IV melanoma, with inclusion criteria including no prior systemic treatment or cytotoxic chemotherapy for advanced melanoma, and exclusion criteria including hypersensitivity to docetaxel or polysorbate 80.",
    "This phase 2 trial is testing the efficacy of docetaxel in treating breast neoplasms with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for aggressive diffuse large B-cell lymphoma, testing the efficacy of carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, and vincristine sulfate, with eligibility criteria including age, disease characteristics, and medical history.",
    "This phase 2 trial is testing the efficacy of HAART containing nevirapine in treating HIV-positive patients with tuberculosis and includes eligibility criteria such as CD4+ cell count and AFB positive smear, while excluding patients with chronic active liver disease and acute hepatitis.",
    "This is a phase 2 trial for complicated intra-abdominal infection, testing the efficacy of cxa-101/ tazobactam and metronidazole and meropenem plus saline placebo, with eligibility criteria including evidence of intraperitoneal infection and surgical intervention within 24 hours of the first dose of study drug.",
    "The sample is a phase 2 trial for non-small cell lung cancer metastatic patients, testing the efficacy of erlotinib and gemcitabine, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of linagliptin low and medium doses versus placebo in patients with type 2 diabetes mellitus who are currently taking metformin alone or with one other antidiabetic drug, and have a HbA1c between 7.0% - 10.0% and a BMI </=45 kg/m2.",
    "The sample is a phase 2 trial testing the drug perifosine on patients with metastatic or locally advanced soft tissue sarcoma, including endometrial cancer and sarcoma, who are ineligible for standard therapies, and the eligibility criteria include various disease characteristics, patient characteristics, and prior concurrent therapy restrictions.",
    "The sample is a phase 2 trial for metastatic colorectal cancer using capecitabine and cetuximab, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of azacitidine in treating advanced non-small cell lung cancer patients who are not eligible for curative intent treatment and have had up to two prior cytotoxic regimens in the metastatic setting.",
    "This phase 2 trial is testing the efficacy of Herceptin and GM-CSF in treating stage IV breast cancer patients with HER-2/neu overexpression who have received no more than two Herceptin containing regimens, and have measurable disease, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of deferoxamine and deferiprone in treating transfusion-dependent beta-thalassemia patients with left ventricular dysfunction and high serum ferritin levels, while excluding patients with certain conditions such as severe heart failure, renal insufficiency, and HIV infection.",
    "This phase 2 trial is testing erlotinib hydrochloride and sirolimus in patients with renal cell carcinoma who have failed or are intolerant to previous treatment with Sutent\u00ae and/or Nexavar\u00ae, and have measurable disease by CT scan or MRI.",
    "The sample is a phase 2 trial for patients with androgen-independent prostate cancer, using mitoxantrone hydrochloride and prednisone as drugs, and the eligibility criteria include confirmed prostate cancer, metastases, and adequate organ function.",
    "This phase 2 trial is testing the effectiveness of gemcitabine in treating locally advanced or metastatic pancreatic cancer, with specific eligibility criteria including age, disease diagnosis, organ function, and prior treatment history.",
    "This phase 2 trial is testing the effectiveness of fluticasone furoate and fluticasone furoate/vilanterol in treating asthma in children aged 5 to less than 12 years, with specific inclusion and exclusion criteria outlined in the eligibility criteria section.",
    "This phase 2 trial is testing the efficacy of epirubicin, cyclophosphamide, and docetaxel in treating breast cancer patients who meet specific eligibility criteria, including age, tumor size, and organ function.",
    "This phase 2 trial is testing the drug perifosine on patients with various stages of prostate cancer who have had rising PSA levels following local curative therapy, with eligibility criteria including a negative metastatic disease scan and normal blood counts and organ function.",
    "The sample is a phase 2 trial for hepatitis C infection, testing the drugs bms-790052 and bms-650032, with inclusion criteria of HCV genotype 1 and HCV RNA viral load of \u2265 10*5* IU/mL, and exclusion criteria of liver cirrhosis, evidence of HCC, and co-infection with hepatitis B virus or HIV.",
    "This phase 2 trial is testing the efficacy of ciprofloxacin inhalation solution in treating chronic P. aeruginosa colonization in patients with cystic fibrosis, with inclusion criteria including documented diagnosis of CF, chronic colonization with P. aeruginosa, and stable pulmonary status.",
    "This phase 2 trial is testing the efficacy of carmoterol and salmeterol in patients with chronic obstructive pulmonary disease (COPD) who meet specific inclusion criteria, while excluding patients with certain medical conditions or medication use.",
    "The sample is a phase 2 trial for bladder and urethral cancer patients with measurable disease, testing the efficacy of cisplatin, ifosfamide, and paclitaxel, with specific eligibility criteria for patient characteristics and prior concurrent therapy.",
    "The sample is a phase 2/phase 3 trial for esophageal cancer and adenocarcinoma, testing the effectiveness of nimotuzumab, cisplatin, and fluorouracil, with eligibility criteria including age, cancer stage, performance status, and adequate body functions.",
    "This phase 2 trial is testing the efficacy of olodaterol, a long-acting beta-adrenergic, in patients with asthma who are stable on medium to high dose inhaled corticosteroids, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug ridaforolimus on patients with endometrial cancer who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for non-small cell lung cancer using oxaliplatin, gemcitabine, and bevacizumab as drugs, with eligibility criteria including confirmed non-small cell lung cancer, stage IIIB or IV disease, ECOG PS 0-1, no prior treatment, no brain metastases, and measurable disease.",
    "This phase 2 trial is testing the drug bms-275291 in patients with completely resected stage 1c-IIIA breast cancer who are planned to receive systemic therapy with tamoxifen or adriamycin plus cyclophosphamide, followed by taxol, and meet certain eligibility criteria.",
    "This phase 2 trial is testing the effectiveness of sorafenib, a drug used to treat breast cancer, on patients with estrogen receptor and/or progesterone positive metastatic or locally advanced breast cancer who have residual measurable disease after maximal response to endocrine therapy or no response to endocrine therapy or progressive non-visceral disease on endocrine therapy.",
    "The sample is a phase 2 trial for breast cancer patients with clinical stage II or III disease, using carboplatin and docetaxel as drugs, and with eligibility criteria including age, performance status, and no prior therapy for invasive breast cancer.",
    "This is a phase 2 trial for aneurysmal subarachnoid hemorrhage, testing the efficacy of tiopronin and placebo drugs, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of xyrem and placebo in treating fibromyalgia, with strict inclusion and exclusion criteria, and requiring patients to discontinue certain medications and follow specific guidelines during the trial.",
    "This phase 2 trial is testing the efficacy of gemcitabine and cisplatin in treating patients with histologically documented primary International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV or recurrent endometrial carcinoma, who have received prior therapy, and have adequate organ function, with inclusion and exclusion criteria specified.",
    "This phase 2 trial will test the drug R256918 on obese or overweight patients with controlled hypertension and/or treated or untreated dyslipidemia, with the aim of reducing weight, and the eligibility criteria includes stable weight, fasting plasma glucose, and ability to swallow the capsule.",
    "This is a phase 2 trial for the treatment of rheumatoid arthritis with the drugs cf101 and placebo, with specific eligibility criteria including the use of weekly oral or parenteral methotrexate for at least 6 months prior to baseline.",
    "This phase 2 trial is testing the efficacy of clarithromycin, thalidomide, and dexamethasone in treating refractory and various stages of multiple myeloma, with eligibility criteria including prior high dose melphalan therapy and platelet and granulocyte count requirements.",
    "This phase 2 trial is testing the drug ixabepilone for patients with HER2-positive stage IV breast cancer who have measurable disease and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of fasudil hydrochloride and placebo oral tablet in patients with carotid stenosis who are scheduled to undergo elective carotid endarterectomy, with inclusion criteria including >= 70% carotid stenosis and age >= 18 years, and exclusion criteria including pregnancy and prior intolerance to statins.",
    "The sample is a phase 2 clinical trial for patients with recurrent ovarian, fallopian tube, or primary peritoneal carcinoma, testing the effectiveness of gemcitabine, oxaliplatin, and bevacizumab, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of soluble ferric pyrophosphate, a placebo, erythrocyte stimulating agent, and intravenous iron in treating end stage renal disease patients undergoing maintenance hemodialysis.",
    "The sample is a phase 2/phase 3 trial for generalized anxiety disorder, testing the efficacy of pexacerfont, escitalopram, and placebo, with inclusion criteria for outpatient women ages 18-65 meeting DSM-IV TR criteria for GAD, and exclusion criteria for males and patients with inadequate response to three or more adequate trials of any SSRIs for GAD within the last three years.",
    "The sample is a phase 2 trial for liver cancer patients with unresectable disease, testing the efficacy of chemotherapy and embolization therapy, with eligibility criteria including ECOG performance status, blood counts, liver function tests, and prior therapy restrictions.",
    "The sample is a phase 2 trial for glaucoma and ocular hypertension, testing the efficacy of various bimatoprost ophthalmic solutions, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of bevacizumab, carboplatin, docetaxel, gemcitabine, and melphalan in treating advanced ovarian, fallopian or primary peritoneal cancer in second or later complete remission, or untreated or refractory relapse, with specific eligibility criteria.",
    "The sample is a phase 2 trial for rheumatoid arthritis using rituximab as the drug, with inclusion criteria of active rheumatoid arthritis and use of concomitant methotrexate, and exclusion criteria of use of other DMARDs/biologics and serious medical conditions.",
    "The sample is a phase 2 trial for patients with suboptimal glucose control and type 2 diabetes mellitus, testing the efficacy of mk0893 and metformin against placebos, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of n-acetylcysteine and placebo in treating obsessive-compulsive disorder in patients who have failed an adequate trial of an SSRI, with inclusion criteria including a confirmed DSM-IV diagnosis of OCD and symptoms of at least 1 year duration.",
    "This phase 2 trial is testing the effectiveness of a combination of velcade, doxorubicin, prednisone, cyclophosphamide, vindesine, and bleomycin in treating previously untreated non-cutaneous peripheral T-cell lymphoma patients aged 18 to 65 years, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial testing the efficacy of oritavancin, an antibiotic, in treating complicated skin and skin structure infections caused by gram-positive bacteria, with a list of diseases and their corresponding ICD-10 codes, and inclusion and exclusion criteria for patient selection.",
    "This phase 2 trial is testing the efficacy of bibf1120 and placebo in female patients with advanced ovarian carcinoma, fallopian tube carcinoma or primary peritoneal cancer of serous type with recurrent disease who responded to 2nd, 3rd or 4th line chemotherapy, and have a treatment-free interval of < 12 months since commencing prior treatment regimen for relapsed ovarian cancer.",
    "This phase 2 trial is testing the efficacy of xarelto and (LMW) heparin + vitamin k antagonist in treating confirmed acute symptomatic DVT in patients who meet the inclusion criteria, while excluding those with certain contraindications.",
    "This phase 2 trial is testing the efficacy of MK0249, Concerta (methylphenidate), and placebo in treating adults with attention-deficit/hyperactivity disorder (ADHD) who meet specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of docetaxel and trabectedin in treating recurrent or persistent ovarian, fallopian tube, or primary peritoneal cavity carcinoma, with specific eligibility criteria for patients, including prior platinum-based chemotherapeutic regimen and GOG performance status, among others.",
    "The sample is a phase 2/phase 3 trial for idiopathic pulmonary fibrosis, testing the efficacy of bosentan and placebo, with strict inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of simtuzumab, gemcitabine, and placebo in treating metastatic pancreatic cancer, with specific inclusion and exclusion criteria for patients.",
    "This phase 2 trial is testing the efficacy of interleukin 7 in combination with capecitabine for the treatment of metastatic breast cancer, with eligibility criteria including lymphopenia, adequate organ function, and no history of other malignancies.",
    "The sample is a phase 2 trial for patients with coronary artery disease, testing the drugs via-2291 and placebo, with eligibility criteria including recent myocardial infarction and documented coronary artery disease, and exclusion criteria including renal insufficiency and congestive heart failure.",
    "This phase 2 trial is testing the efficacy of gemtuzumab ozogamicin and vorinostat in treating untreated adult acute myeloid leukemia patients with various subtypes of the disease, and includes eligibility criteria such as a WBC count of less than 10,000/uL and a left ventricular ejection fraction of at least 40%.",
    "This phase 2 trial is testing the efficacy of gemcitabine hydrochloride and imatinib mesylate in treating metastatic or unresectable primary renal cell carcinoma, with specific eligibility criteria for patients, including prior treatment regimens and medical conditions.",
    "This phase 2 trial is testing the efficacy of miravirsen and saline in treating hepatitis C patients who are treatment-na\u00efve to interferon-alpha based therapies and have HCV genotype 1, with specific eligibility criteria including BMI, liver biopsy, and laboratory findings.",
    "This phase 2 trial will test the efficacy of paclitaxel, 5-fluorouracil, epirubicin, cyclophosphamide, and rad001 in treating patients with stage IIA to IIIC non-inflammatory breast cancer, with eligibility criteria including histologic confirmation of invasive ER/PR and HER2/neu-negative breast carcinoma, intact primary tumors, and adequate bone marrow, liver, and renal function.",
    "The sample is a phase 2 trial for type 2 diabetes mellitus testing the efficacy of mk-0893 and metformin compared to placebo, with eligibility criteria including BMI, absence of certain medical conditions, and not currently taking certain medications.",
    "This phase 2 trial is testing the drug atrasentan hydrochloride on patients with locally recurrent or metastatic kidney cancer who are not eligible for surgery, and have specific eligibility criteria related to their disease characteristics, patient characteristics, and prior concurrent therapy.",
    "This phase 2 trial is testing the efficacy of AN2728 and placebo in treating stable plaque type psoriasis in patients with two target plaques meeting specific criteria, with exclusion criteria including use of certain medications and dermatological conditions.",
    "The sample is a phase 2 trial for metastatic breast cancer using the drug pyrazoloacridine, with eligibility criteria including measurable disease and prior failed therapy, and patient characteristics such as age, performance status, and negative pregnancy test.",
    "This is a phase 2 trial for multiple sclerosis, relapsing-remitting, testing the efficacy of natalizumab and placebo, with inclusion and exclusion criteria based on age, EDSS score, and prior treatment with GA.",
    "This phase 2 trial is testing the effectiveness of pregabalin in treating acute herpes zoster pain in patients who meet specific inclusion criteria and do not have any exclusion criteria.",
    "This phase 2 trial is testing the efficacy of capecitabine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, and pyridoxine in treating locally advanced colorectal cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for Alzheimer's disease, testing the drugs ly2062430 and placebo, with inclusion criteria including age, diagnosis, and a reliable study partner, and exclusion criteria including history of certain diseases or drug/alcohol abuse.",
    "The sample is a phase 2 trial for heparin-induced thrombocytopenia, testing the efficacy of fondaparinux and warfarin, with eligibility criteria including a high Four Ts score and exclusion criteria such as pregnancy, allergy to fondaparinux, and active major bleeding.",
    "This phase 2 trial is testing the drug bibw 2992 on patients with non-small-cell lung carcinoma who have activating mutations in the EGFR-receptor and have progressed after first-line chemotherapy, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of pramipexole immediate release and placebo in treating Tourette's Disorder in patients aged 6-17 years with a Total Tic Score of at least 22, and who meet certain inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of birinapant (tl32711) in treating advanced metastatic or unresectable epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer that is relapsed and resistant or refractory to prior platinum-based standard care systemic regimen.",
    "This phase 2 trial is testing the efficacy of saracatinib in patients with metastatic adenocarcinoma of the colon or rectum who have received one prior chemotherapy regimen, with specific eligibility criteria, and no other investigational agents or prohibited drugs.",
    "The sample is a phase 2 trial for non-small cell lung cancer testing the efficacy of bevacizumab, cisplatin, and docetaxel, with eligibility criteria including chemotherapy-naive patients with stage IIIb or IV disease, and exclusion criteria including previous treatment for non-small cell lung cancer and recent chronic treatment with aspirin.",
    "This phase 2 trial is testing the efficacy of mk0683, vorinostat, and suberoylanilide hydroxamic acid (saha) in treating relapsed or refractory breast cancer, colorectal cancer, and non-small-cell lung carcinoma, with eligibility criteria including having measurable PET assessable lesions and adequate blood, liver, bone marrow, and kidney functions.",
    "This phase 2 trial is testing the efficacy of nic5-15 and placebo in treating Alzheimer's disease and dementia, with inclusion criteria including NINCDS/ADRDA criteria for probable AD, MMSE between 12-27, and treatment with a cholinesterase inhibitor or an NMDA antagonist with stable dose for at least 12 weeks.",
    "The sample is a phase 2 trial for the treatment of type 2 diabetes mellitus using the drugs azd1656 and placebo, with inclusion criteria for women of non-childbearing potential and T2DM patients with HbA1c \u2265 7.5% but \u2264 10% or treated with one or two oral anti-hyperglycaemic agent(s) with HbA1c \u2265 7.5% but \u2264 9.5%, and exclusion criteria for clinically relevant medical history or concurrent disease, participation in another clinical trial and/or intake of another investigational drug within the last 30 days prior to enrolment visit.",
    "This is a phase 2 trial for Parkinson's disease using sildenafil and placebo drugs, with eligibility criteria including diagnosis of idiopathic Parkinson's disease, drug-induced dyskinesias, and age over 40 years.",
    "The sample is a phase 2 trial for previously untreated Non-Hodgkin's lymphoma patients aged 65 and older, testing the efficacy of CHOP plus rituximab, with inclusion and exclusion criteria specified.",
    "This phase 2 trial will test the efficacy of sunitinib, a drug, in treating solid tumor malignancy with ascites as an inclusion criteria.",
    "This phase 2 trial is testing the efficacy of tamibarotene, a drug, in treating relapsed and/or refractory acute promyelocytic leukemia, with specific eligibility criteria for patients to be admitted into the study.",
    "This is a phase 2 trial for rheumatoid arthritis testing sc12267, placebo, methotrexate, and folic acid as drugs, with eligibility criteria including active RA and stable MTX dose, and exclusion criteria including recent use of certain drugs.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate in treating recurrent or persistent uterine carcinosarcoma, with specific eligibility criteria including prior chemotherapy and certain laboratory values.",
    "The sample is a phase 2 trial for soft tissue sarcoma patients who have failed prior regimens and are anthracyclin na\u00efve, testing the efficacy of palifosfamide tris and doxorubicin in combination with eligibility criteria including age, disease type, and laboratory requirements.",
    "This phase 2 trial is testing the efficacy of cetuximab and irinotecan in treating stage IV colorectal cancer patients with unresectable liver metastases who have shown refractory to 5-FU and/or oxaliplatin, and have k-ras wild-type tumors, with eligibility criteria including measurable liver metastasis, liver only or liver dominant disease, ECOG performance status \u2264 2, and adequate liver and renal function.",
    "This is a phase 2 clinical trial for patients with advanced or metastatic colorectal cancer, testing the efficacy of fluorouracil, irinotecan hydrochloride, and leucovorin calcium as first- or second-line therapy, with eligibility criteria including performance status, blood counts, liver function, and absence of certain medical conditions.",
    "This phase 2 trial is testing the efficacy of cisplatin and pemetrexed disodium in treating non-small cell lung cancer patients who are eligible for curative surgery and meet specific disease and patient characteristics.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate in treating advanced gastrointestinal stromal tumor patients who have limited or generalized progression after adequate therapy with imatinib mesylate, and meet other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of cetuximab in patients with soft tissue or bony sarcoma who have received at least one systemic chemotherapy treatment and have documented symptomatic or radiologic progression to their preceding therapy.",
    "This phase 2 clinical trial is testing the effectiveness of azacitidine, a drug, in treating multiple myeloma, a type of cancer, in patients who have failed to respond to previous treatments and meet certain eligibility criteria.",
    "The sample is a phase 2 trial for moderate to severe persistent asthma, testing the efficacy of L-arginine and placebo drugs, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of ykp3089 and placebo in treating epilepsy patients with a reproducible IPS-induced photo-paroxysmal response, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for dry eye syndrome and dry eye using thymosin beta 4 and placebo, with inclusion criteria including a history of dry eye and use of artificial tear substitute, and exclusion criteria including use of certain medications and past or present evidence of malignancy.",
    "This phase 2 trial is testing the efficacy of telmisartan and placebo in treating hypertension in children and adolescents, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of pemetrexed and gemcitabine in treating metastatic colorectal cancer with specific eligibility criteria, including KRAS mutation and measurable disease according to RECIST.",
    "This phase 2 trial is testing the effectiveness of albuterol spiromax\u00ae and proair\u00ae hfa in treating asthma in patients between 12 years and older with specific eligibility criteria, including FEV1 and reversibility requirements, and exclusion criteria such as severe milk protein allergy and pregnancy.",
    "This is a phase 2 trial for locally advanced breast cancer patients with the drug capecitabine, and the eligibility criteria includes TNM stage, negative pregnancy test, and required laboratory data. Exclusion criteria includes HER2 positive breast cancer, prior chemotherapy, and other serious medical conditions.",
    "The sample is a phase 2 trial for psoriasis, testing the efficacy of an2728 ointment and vehicle ointment, with inclusion criteria of mild-to-moderate plaque-type psoriasis involving 2-35% of total body surface area, and exclusion criteria including use of certain medications and pregnancy/lactation.",
    "This phase 2 trial is testing the efficacy of R788 and placebo in treating rheumatoid arthritis patients who have been receiving weekly doses of methotrexate for at least 180 days, and have been receiving a stable MTX dose of at least 15 mg without any change in route or change in folic acid supplementation for at least 30 days.",
    "The sample is a phase 2 trial for attention deficit disorder with hyperactivity, testing the efficacy of spd503 (guanfacine hcl) and placebo, with inclusion and exclusion criteria based on psychiatric and cardiac conditions, pregnancy, and weight, among others.",
    "This phase 2 trial is testing the efficacy of ropinirole prolonged release/extended release in treating Parkinson's disease, with inclusion criteria including patients with severity of Modified Hoehn & Yahr staging at Stage I to III, limited prior exposure to low or moderate doses of L-dopa or dopamine agonists, and exclusion criteria including patients with serious physical signs and symptoms other than those of PD, symptomatic postural hypotension, and severe dementia.",
    "The sample is a phase 2 trial for ischemic stroke patients, testing the efficacy of placebo, sa4503 low, and sa4503 high drugs, with eligibility criteria including stroke occurrence within 48-72 hours, NIHSS score of >/=4, and medical/neurological stability, while excluding patients with transient ischemic attack or stroke in progression.",
    "The sample is a phase 2 trial for stable coronary artery disease, testing the efficacy of ticagrelor and clopidogrel, with eligibility criteria including previous ACS and treatment with ASA, and exclusion criteria including recent ACS, TIA, or stroke, and concurrent use of blood clotting agents.",
    "This is a phase 2 trial for non-small cell lung cancer patients who are not amenable to curative therapy, testing the efficacy of pemetrexed, cisplatin, and bevacizumab, with eligibility criteria including ECOG performance status of 0 or 1, adequate organ function, and no prior systemic anticancer therapy for lung cancer.",
    "The sample is a phase 2/phase 3 trial for HIV infections, testing the efficacy of chloroquine phosphate and placebo drugs on HIV-1 infected adults with specific inclusion and exclusion criteria.",
    "This is a phase 2/phase 3 trial testing the efficacy of tonapofylline and placebo in treating acute decompensated heart failure in patients with a history of heart failure and clinical evidence of volume overload, with a list of inclusion and exclusion criteria, and a list of diseases including renal insufficiency and congestive heart failure.",
    "The sample is a phase 2 trial for breast cancer patients with HER2/neu positive, using exemestane as the drug, and the eligibility criteria includes age, menopausal status, performance status, and prior concurrent therapy.",
    "This phase 2 trial is testing the effectiveness of rituximab and alemtuzumab in treating chronic lymphocytic leukemia, with specific eligibility criteria including achieving a partial or complete response following prior chemotherapy or chemoimmunotherapy.",
    "This phase 2 trial is testing the drug vismodegib on patients with nodular basal cell carcinoma, with inclusion criteria including biopsy confirmation of the lesion and adequate hematopoietic and hepatic function, and exclusion criteria including prior treatment with vismodegib or any Hedgehog pathway inhibitor and pregnancy or lactation.",
    "The sample is a phase 2 trial for patients with non-small cell lung carcinoma who have received one prior platinum-based chemotherapy regimen, testing the efficacy of motexafin gadolinium and pemetrexed, with specific inclusion and exclusion criteria.",
    "This phase 2 trial will test the efficacy of imatinib mesylate in treating relapsed or refractory ovarian, fallopian tube, or primary peritoneal cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of revamilast and placebo comparator in treating active rheumatoid arthritis in patients who meet specific inclusion criteria, including a documented history of RA and a DAS-28 CRP value \u2265 4.5 at screening, while excluding patients with certain autoimmune rheumatic disorders, uncontrolled diabetes mellitus, and a life expectancy of less than 1 year.",
    "This phase 2 trial is testing the drug Sutent on patients with urothelial carcinoma who have achieved stable disease or better after standard first line chemotherapy, and have not received prior antiangiogenic therapy.",
    "This phase 2 trial is testing the efficacy of gsk2248761 and etravirine in HIV-1 infected adults with NNRTI resistance, and includes eligibility criteria such as a screening plasma HIV-1 RNA greater than or equal to 400copies/mL and exclusion criteria such as ongoing or clinically relevant pancreatitis.",
    "The sample is a phase 2 trial for chronic hepatitis C infection with drugs abt-450, abt-072, ribavirin, and ritonavir, and eligibility criteria including genotype C/C and liver biopsy within 3 years.",
    "The sample is a phase 2 trial for chronic pain due to diabetic peripheral neuropathy and neuralgia, testing the efficacy of epicept np-1 (4% amitriptyline/ 2% ketamine) topical cream versus placebo cream, with inclusion criteria of an average daily pain score of > 4 during the baseline week.",
    "This phase 2 trial is testing the efficacy of sunitinib malate, a tyrosine kinase inhibitor, in treating advanced or metastatic adult diffuse large cell lymphoma that is incurable by standard therapies and has relapsed or is refractory, with eligibility criteria including bidimensionally measurable disease, prior chemotherapy regimens, and normal organ function.",
    "The sample is a phase 2 trial for chronic HCV genotype 1 viral infection, testing the efficacy of alisporivir, peginterferon alfa-2a, ribavirin, and placebo, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of ketoconazole, hydrocortisone, and dutasteride in treating progressive HRPC with inclusion criteria including histologically documented evidence of prostate cancer, PSA of greater than or equal to 2ng/ml, and serum total testosterone less than or equal to 50ng/ml.",
    "The sample is a phase 2 clinical trial for idiopathic Parkinson's disease, testing the efficacy of CVT-301 and Sinemet in reducing \"off\" time, with inclusion criteria including Hoehn and Yahr Stage 1-3 and levodopa responsiveness, and exclusion criteria including pregnancy, previous PD surgery, and significant concurrent disease.",
    "This phase 2 trial is testing the efficacy of preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine in patients with rectal cancer who meet specific eligibility criteria.",
    "This sample is a phase 2 trial for seasonal allergic rhinitis, testing the efficacy of bepotastine besilate formulation, fluticasone propionate, bepotastine besilate-fluticasone propionate, and placebo comparator, with inclusion criteria of a history of Mountain Cedar pollen allergy and exclusion criteria of no active nasal infection or abnormality affecting subject safety or symptom assessments.",
    "The sample is a phase 2 trial for Parkinson's disease, testing the drugs afq056 and placebo, with inclusion criteria including L-dopa induced dyskinesia and L-dopa treatment for at least 3 years, and exclusion criteria including severe allergies and prior surgery for Parkinson's Disease.",
    "This phase 2 trial is testing the efficacy of darifenacin in treating neurogenic detrusor overactivity in children aged 2-15 years who use clean intermittent catheterization, with a list of inclusion and exclusion criteria, and the drug being administered multiple times.",
    "This phase 2 trial is testing the efficacy of temsirolimus in treating myelodysplastic syndrome patients who are not eligible for immediate allogeneic HSCT or conventional chemotherapy, and meet specific inclusion criteria.",
    "This is a phase 2 trial for asthma patients, testing the efficacy of fluticasone propionate and lactose powder, with eligibility criteria including age, weight, BMI, asthma diagnosis, and sensitivity to methacholine, and exclusion criteria including respiratory tract infection, hay fever, and use of certain medications.",
    "The sample is a phase 2 trial for diabetic macular edema, testing the efficacy of ranibizumab 0.3 mg, ranibizumab 0.5 mg, and sham injection, with inclusion criteria including center involvement in at least one eye and exclusion criteria including uncontrolled systemic or ocular diseases.",
    "This phase 2 trial is testing the efficacy of ramelteon and placebo in treating Delayed Sleep Phase Syndrome, with strict inclusion and exclusion criteria, and a prohibition on certain medications and supplements.",
    "This phase 2 trial is testing the efficacy of apricoxib, lapatinib, and capecitabine in treating locally advanced or metastatic HER2/neu+ breast cancer patients who have progressed after treatment with chemotherapy including a taxane and trastuzumab, and have measurable disease by RECIST.",
    "The sample is a phase 2 trial for non-squamous non-small cell lung cancer, testing the efficacy of paclitaxel/carboplatin and bavituximab, with eligibility criteria including confirmed stage IIIB or IV NSCLC, adequate hematologic, renal and hepatic function, and exclusion criteria including bleeding diathesis, brain metastases, and uncontrolled intercurrent disease.",
    "This phase 2 trial is testing the efficacy of iv busulfan and bortezomib in treating relapsed multiple myeloma patients who have had one previous autologous HSCT, and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of bevacizumab and erlotinib in treating non-squamous, non-small cell lung cancer patients with wet stage IIIB-IV or recurrent disease, with specific inclusion and exclusion criteria related to disease history, performance status, and medical conditions.",
    "This phase 2 trial is testing the drug CI-1033 on female patients with metastatic breast cancer who have not been previously exposed to agents that target the erbB receptor family, and have no history of brain metastases or malabsorption syndrome.",
    "This phase 2 trial is testing the efficacy of capecitabine and oxaliplatin in treating patients with histologically confirmed invasive adenocarcinoma of the rectum, with specific eligibility criteria including tumor size and absence of certain medical conditions.",
    "The sample is a phase 2 trial for metastatic pancreatic cancer patients who have received only one prior gemcitabine-containing regimen, testing the combination of rhumab-vegf and docetaxel, with eligibility criteria including measurable disease outside of the pancreas, ECOG 0-1 performance status, and various medical condition exclusions.",
    "The sample is a phase 2 trial for vulvar vestibulitis, testing the efficacy of 5% topical lidocaine ointment and placebo cream, with inclusion criteria of women with dyspareunia and exclusion criteria of postmenopausal, pregnant, breastfeeding, and history of lidocaine treatment for vvs.",
    "The sample is a phase 2 trial for non-hodgkin lymphoma, testing chemotherapy and radioimmunotherapy as a treatment option, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of lenalidomide in treating myelodysplastic syndromes and thrombocytopenia, with placebo as the control, and includes specific inclusion and exclusion criteria for eligible subjects.",
    "This phase 2 trial is testing the efficacy of gemcitabine and vinorelbine in treating unresectable, locally recurrent, or metastatic breast cancer patients who have not received prior chemotherapy for metastatic or locoregionally recurrent disease, and have completed prior radiotherapy at least 30 days before study entry.",
    "This phase 2 trial is testing the efficacy of jnj-42160443, a drug, in treating chronic low back pain with specific inclusion and exclusion criteria, including a list of diseases and their corresponding icd-10 codes.",
    "This phase 2 trial is testing the efficacy of SRT2104 and placebo in treating stable plaque-type psoriasis involving \u226510% of body surface area, with a baseline PASI of \u226510, and eligibility criteria including being a candidate for systemic psoriasis therapy, and exclusion criteria including having received previous treatment with biologic agents within 5 drug half-lives prior to the first dose of SRT2104.",
    "The sample is a phase 2/3 trial for metastatic breast cancer patients who have received prior taxane and anthracycline treatment, testing the efficacy of capecitabine and vinorelbine tartrate, with eligibility criteria including measurable lesions, specific patient characteristics, and prior concurrent therapy restrictions.",
    "This phase 2 trial is testing the efficacy of tzp-101, a drug, in treating gastroparesis in subjects with type 1 or type 2 diabetes mellitus and a confirmed diagnosis of gastroparesis, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the effectiveness of gemcitabine and oxaliplatin in treating resectable or borderline resectable pancreatic cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of capecitabine, a chemotherapy drug, in treating metastatic breast cancer patients with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of rituximab and standard care in preventing acute rejection in kidney transplant patients with positive T-cell and/or B-cell crossmatch, and the eligibility criteria includes age > 18 years, receiving a single organ renal transplant from a living donor, and confirmed donor-specific antibodies on solid-phase assay.",
    "The sample is a phase 2 trial for Duchenne and Becker muscular dystrophy patients with a nonsense mutation in the dystrophin gene, testing the efficacy of ataluren and chronic corticosteroid therapy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for postmenopausal women with primary breast cancer, testing the effectiveness of fulvestrant and anastrazole, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cisplatin, gemcitabine, and bevacizumab in treating previously untreated or relapsed locally advanced or metastatic transitional cell carcinoma of the bladder, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of the \"ixo regimen\" drug on patients with rectal cancer who meet specific eligibility criteria, including having resectable locally advanced cancer and no prior treatment for this disease.",
    "The sample is a phase 2 trial comparing cyclosporine A and mycophenolate mofetil for moderate-to-severe psoriasis, with inclusion criteria of a PASI score of 10 or greater and exclusion criteria including previous treatment with either drug, reduced liver or kidney function, and severe infections or psychiatric symptoms.",
    "This phase 2 trial is testing the drug tanespimycin in patients with metastatic adenocarcinoma of the prostate who have received at least one prior chemotherapy regimen, and have no brain metastases requiring active therapy, with the goal of measuring disease progression or rising PSA levels.",
    "The sample is a phase 2 trial for the common cold, testing the efficacy of paracetamol hot drink and tablets, with inclusion criteria including symptoms of the common cold, congestion, and at least four symptoms of common cold or flu.",
    "This phase 2 trial is testing the drug imexon on patients with various types of lymphoma who have relapsed or refractory disease and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for previously untreated acute myeloid leukemia in patients over 60 years old, using the drug vosaroxin, with specific eligibility criteria including at least 20% blasts by BM biopsy or aspirate and adequate cardiac, renal, and liver function.",
    "This phase 2 trial is testing the efficacy of the drugs osi-906, erlotinib, and placebo in treating non-small cell lung cancer patients with confirmed EGFR mutations and other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of panitumumab + paclitaxel in treating metastatic or recurrent head and neck cancer, with specific eligibility criteria including measurable lesions, ECOG performance status score, and adequate organ function.",
    "This phase 2 trial is testing the efficacy of various drugs, including ustekinumab and cnto 1959, in combination with methotrexate for the treatment of rheumatoid arthritis in patients who meet specific inclusion criteria.",
    "This phase 2 trial is testing the efficacy of cisplatin and gemcitabine hydrochloride in treating inoperable or metastatic pancreatic carcinoma, with eligibility criteria including normal hematopoietic, hepatic, renal, and pulmonary function, as well as no prior cisplatin or gemcitabine treatment.",
    "This phase 2 trial is testing the efficacy of ganaxolone in treating partial and catamenial epilepsy, with specific inclusion and exclusion criteria for subjects.",
    "This phase 2 trial is testing the efficacy of gemcitabine hydrochloride and triapine in treating pancreatic adenocarcinoma, with eligibility criteria including measurable lesions, specific hematopoietic, hepatic, renal, and cardiovascular levels, and no prior chemotherapy except fluorouracil.",
    "This phase 2 trial is testing the efficacy of azacitidine and oral vorinostat in treating myelodysplastic syndrome patients who have not responded to azacitidine alone, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of lenalidomide in treating refractory cancer pain in patients with advanced cancer, who meet specific eligibility criteria, and are willing to comply with the requirements of RevAssist\u00ae.",
    "The sample is a phase 2 trial testing the drug radafaxine on patients with major depressive disorder, with inclusion and exclusion criteria listed, and the disease is identified as depressive disorder, major with icd-10 codes F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40.",
    "The sample is a phase 2 trial for stomach neoplasms using oxaliplatin as the drug, with specific inclusion and exclusion criteria for patients.",
    "The sample is a phase 2 trial for ADHD, testing the drugs abt-089 and placebo, with inclusion and exclusion criteria listed, and the icd-10 codes for ADHD provided.",
    "This phase 2 clinical trial is testing the efficacy of teriflunomide, interferon-\u03b2, and placebo in patients with relapsing multiple sclerosis who meet specific inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with relapsed multiple myeloma, testing the efficacy of a combination of drugs including velcade, thalidomide, adriamycin, and dexamethasone, with specific eligibility and exclusion criteria.",
    "The sample is a phase 2/phase 3 trial for type 2 diabetes mellitus, testing the efficacy of alogliptin and glimepiride drugs on patients who have been taking a sulfonylurea for at least 4 weeks, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for eosinophilic esophagitis, testing the efficacy of fluticasone and placebo, with inclusion and exclusion criteria based on biopsy results, dysphagia questionnaire, and previous treatments.",
    "This phase 2 trial is testing the drug org 34517 on patients with major depressive disorder and psychotic disorders who meet specific eligibility criteria, including being on a stable dose of usual treatment consisting of an anti-depressant, an antipsychotic, a mood stabilizer or any combination of these three drug classes.",
    "This phase 2 trial is testing the effectiveness of velcade, a drug used to treat multiple myeloma, on previously untreated patients with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of gemcitabine, docetaxel, and capecitabine in treating biliary cancer patients who meet specific eligibility criteria, including having measurable disease and not being eligible for other high priority studies.",
    "This phase 2 trial is testing the efficacy of dasatinib, a drug, in treating advanced/metastatic non-small cell lung cancer patients who meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of erlotinib and sorafenib combination therapy versus erlotinib and placebo in patients with non-small cell lung cancer who have failed at least one prior chemotherapy regimen, and have met specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of ulipristal acetate and placebo in treating uterine leiomyoma, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for psoriasis using the drug ruxolitinib, with inclusion criteria based on psoriatic lesions and exclusion criteria for certain affected areas and types of psoriasis.",
    "This phase 2 trial is testing the efficacy of sb681323 and placebo in treating peripheral neuropathic pain caused by nerve injury, lumbo-sacral radiculopathy, or carpal tunnel syndrome, with inclusion criteria including baseline pain intensity score averaging \u2265 4 and exclusion criteria including recent start or change in dosing regimen of any medication that may interfere with pain assessments or introduce a risk of drug-drug interactions.",
    "The sample is a phase 2 trial for childhood lymphomas and leukemia, testing a combination of drugs including doxorubicin hydrochloride, cyclophosphamide, methotrexate, and rasburicase, with eligibility criteria including specific disease subtypes and FAB prognostic groups.",
    "This phase 2 trial is testing the efficacy of celecoxib, a drug used for osteoarthritis and rheumatoid arthritis, in treating patients with progressive thyroid carcinoma who have failed or are ineligible for standard therapy with iodine I 131 and/or surgery, and who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of cep-701, high-dose cytarabine, and mitozantrone, etoposide, cytarabine combination chemotherapy in treating relapsed acute myeloid leukemia patients with FLT-3 activating mutation positive status, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for previously untreated mantle cell lymphoma patients, testing the efficacy of rituximab and first line chemotherapy, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of liposomal doxorubicin in treating breast cancer patients with relapsed/recurrent brain metastasis, with specific inclusion and exclusion criteria for eligibility.",
    "This phase 2 trial is testing the drug E7389 on males with prostate cancer that has progressed despite castration or chemotherapy, with inclusion criteria including a minimum of 3 consecutive rises in PSA and failure of no more than one previous chemotherapeutic regimen with tubulin binding agents such as docetaxel.",
    "This phase 2 trial is testing the efficacy of the drug cf101 versus placebo control in treating active rheumatoid arthritis in patients who meet specific inclusion criteria and have not received certain medications within a washout period.",
    "This phase 2 trial is testing the drug bortezomib on patients with sarcoma, who meet specific eligibility criteria related to disease characteristics, patient characteristics, and prior concurrent therapy.",
    "This phase 2 trial is testing the drug tarceva on patients with metastatic triple receptor-negative breast cancer that is resistant to taxanes and anthracyclines, and have not had prior exposure to an EGFR inhibitor or antibody, with eligibility criteria including tissue availability for correlative studies and adequate bone marrow, liver, and renal function.",
    "This phase 2 trial is testing the drug gefitinib on patients with non-small cell lung cancer who meet specific eligibility criteria, including having tissue for the detection of EGFR mutation and adequate hematologic, renal, and liver function.",
    "This phase 2 trial is testing lapatinib ditosylate in patients with hormone-sensitive prostate cancer who have evidence of biochemical progression, with a list of eligibility criteria including prior treatment, disease stage, and laboratory values.",
    "This is a phase 2 clinical trial for patients with multi-vessel coronary artery disease scheduled for CABG, testing the drug 6R-BH4, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of thalidomide in treating recurrent or metastatic colorectal cancer, with eligibility criteria including specific disease characteristics and patient characteristics such as age and hematopoietic and hepatic function.",
    "The sample is a phase 2 trial for advanced breast cancer with positive BRCA1 or BRCA2 status, using the drugs ku-0059436 (azd2281) (parp inhibitor), and the eligibility criteria includes having failed at least one prior chemotherapy and no curative standard therapy exists.",
    "This phase 2 trial is testing the efficacy of prednisone, cyclophosphamide, doxorubicin, and vincristine in treating various types of lymphoma, with specific eligibility criteria including stage I or II disease, measurable disease parameters, and certain risk factors.",
    "The sample is a phase 2/3 trial for HIV infected individuals, testing the efficacy of various anti-HIV drugs including nrtis, nnrtis, and pis, with eligibility criteria including age, HIV status, and previous anti-HIV drug use, and exclusion criteria including toxicity, infections, and certain medical conditions, while the diseases are limited to HIV infections and the icd-10 codes are limited to Z21.",
    "This phase 2 trial is testing the drug decitabine on newly diagnosed myelodysplastic syndrome patients who meet specific eligibility criteria related to their age, disease subtype, and organ function.",
    "This phase 2 trial is testing the efficacy of palifermin and its placebo in HIV infected patients with a CD4 count of 200 cells/mm3 or less, who are receiving potent ART and have a persistent viral load less than or equal to 200 copies/ml for at least 6 months prior to study entry.",
    "The sample is a phase 2 trial for schizophrenia, testing the efficacy of sca-136 (200 mg and 400 mg), olanzapine (15 mg), and placebo, with inclusion criteria of clinical diagnosis of schizophrenia and ability to remain hospitalized for at least first 4 weeks of study, and exclusion criteria of type 1 or 2 diabetes, previous use of clozapine, and serious medical illness other than schizophrenia.",
    "The sample is a phase 2 trial for advanced or recurrent endometrial cancer using carboplatin and docetaxel as drugs, with eligibility criteria including confirmed diagnosis, failed local therapy, and specific blood count and liver function requirements.",
    "This phase 2 trial is testing the efficacy of carboplatin, paclitaxel, and sorafenib tosylate in treating patients with various types of intraocular melanoma who have documented disease progression during or after one prior systemic treatment, and meet a range of eligibility criteria.",
    "The sample is a phase 2 trial testing the efficacy of pegylated liposomal doxorubicin and rituximab in treating B-cell non-Hodgkin's lymphoma, Burkitt or Burkitt-like lymphomas, and primary effusion lymphomas in HIV-positive patients who have failed or relapsed after at least one prior chemotherapy treatment, with eligibility criteria including measurable or evaluable tumor, Karnofsky performance status greater than 50%, and normal hematologic and organ function.",
    "This phase 2 trial is testing the drug fulvestrant on patients with recurrent or persistent ovarian epithelial carcinoma who have received at least 2 prior cytotoxic chemotherapy regimens, including at least 1 platinum-containing regimen, and have measurable disease or rising serum cancer antigen 125 (CA-125) levels, and meet other eligibility criteria.",
    "The sample is a phase 2 trial for HIV-1 infected participants on their first-line treatment with HAART, testing the efficacy of darunavir, ritonavir, and 2 nucleoside reverse transcriptase inhibitors (nrtis) as a more convenient regimen, with eligibility criteria including plasma HIV-1 RNA less than 50 cp/ml, CD4 count more than 100/mm3, and exclusion criteria including history of virological failure on highly active antiretroviral therapy and use of lipid-lowering drugs within 4 weeks prior to study entry.",
    "The sample is a phase 2 trial for narcolepsy patients using the drug gsk189254, with inclusion criteria including BMI between 18-32 kg/m2 and exclusion criteria including history of major psychiatric disorder or depression, recent drug or alcohol abuse, and pregnancy or breastfeeding.",
    "This phase 2 trial is testing the efficacy of drugs GR205171 and GW597599 in treating primary insomnia in male and female outpatients aged 18-65 with a usual total sleep time of less than 6 hours, SOL of at least 30 minutes, and at least 3 awakenings per night in at least 3 nights per week.",
    "This phase 2 trial is testing the efficacy of afq056 and placebo in treating dyskinesias in Parkinson's disease patients who have been on a stable anti-parkinsonian treatment regimen for at least four weeks, and have not undergone surgical treatment for PD, with specific exclusion criteria, and the diseases and icd-10 codes are listed.",
    "The sample is a phase 2 trial for patients with relapsed or refractory indolent B cell non-Hodgkin's lymphoma, testing the efficacy of dexamethasone, with eligibility criteria including lymph node or visceral lesions at least 2 cm in diameter and no prior monoclonal antibody therapy for lymphoma.",
    "The sample is a phase 2 trial for prostate cancer using vandetanib and placebo drugs, with inclusion criteria including a PSA level of \u22655 ng/mL and recent completion of first hormone treatment, and exclusion criteria including bone or soft tissue metastases and significant cardiovascular disease.",
    "This phase 2 trial is testing the effectiveness of quetiapine fumarate in reducing alcohol dependence in patients with alcoholism and alcohol abuse, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of nilotinib, a tyrosine kinase inhibitor, in patients with gastrointestinal stromal tumors who have progressed on imatinib and sunitinib, and have met certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of sunitinib malate in treating recurrent bladder cancer and transitional cell carcinoma of the bladder, with eligibility criteria including previous treatment history and various medical conditions.",
    "The sample is a phase 2 trial for asthma patients, testing the efficacy of oc000459 and placebo drugs, with inclusion criteria including positive skin prick test to an allergen associated with the subject's asthma and exclusion criteria including use of inhaled or local corticosteroids in the period from 28 days prior to screening.",
    "This phase 2 clinical trial is testing the effectiveness of oxaliplatin and vinorelbine in treating metastatic breast cancer patients who meet specific eligibility criteria, including having measurable lesions and adequate organ function.",
    "This phase 2 trial is testing the efficacy of mitoxantrone and GM-CSF in treating hormone-refractory prostate cancer with specific eligibility criteria, including a minimum PSA level and exclusion criteria such as concomitant second malignancy and serious infection.",
    "The sample is a phase 2/phase 3 trial for patients with colorectal carcinoma and liver metastases, testing the efficacy of folfox6 and bevacizumab in treating the disease, with specific eligibility and exclusion criteria.",
    "This is a phase 2 trial for asthma patients, testing the efficacy of gw870086 at different doses, with eligibility criteria including documented history of bronchial asthma, BMI within 18.5-29.0 kg/m2, and no history of smoking within 6 months, while exclusion criteria include a history of life-threatening asthma, regular alcohol consumption within 6 months, and inability to use the DISKHALER\u00ae device correctly.",
    "This phase 2 trial is testing the efficacy of etravirine and darunavir, two HIV antiretroviral medications, in patients with documented HIV-1 infection and a plasma viral load above 500 HIV-1 RNA copies/mL, who have been on a current HAART regimen for at least 12 weeks, and meet other eligibility criteria.",
    "The sample is a phase 2 trial for relapsing multiple sclerosis, testing the efficacy of atacicept and placebo, with specific inclusion and exclusion criteria, and the use of icd-10 codes to identify the disease; the study aims to test the ability of extended release nifedipine to decrease the dose of glucocorticoid medication in children with congenital adrenal hyperplasia.",
    "The sample is a phase 2 trial for patients with rheumatoid arthritis and chronic anemia, testing the effectiveness of epoetin alfa, with inclusion and exclusion criteria including hypertension, thromboembolic events, and psychiatric disease.",
    "This phase 2 trial is testing the efficacy of qaw039 and montelukast compared to placebo in treating intermittent allergic rhinitis with seasonal onset and offset of nasal allergy symptoms during each of the last two grass pollen allergy seasons, with inclusion criteria including a positive skin prick test to dactylis glomerata and a TNSS score \u22656 on at least one assessment during the 2h EEC challenge at Screening.",
    "This is a phase 2 trial for patients with prostate cancer, testing the efficacy of dutasteride and gadolinium-chelate, with eligibility criteria including specific disease characteristics and patient characteristics, and excluding prior concurrent therapy with certain medications or participation in other drug trials.",
    "This phase 2 trial is testing the efficacy of busulfan, fludarabine phosphate, methotrexate, and tacrolimus in patients with adult acute myeloid leukemia in remission or acute myeloid leukemia arising from previous myelodysplastic syndrome who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of arsenic trioxide in treating locally advanced or metastatic hepatocellular carcinoma or cholangiocarcinoma, with specific inclusion and exclusion criteria for eligible subjects.",
    "The sample is a phase 2 trial for scleroderma using imatinib mesylate as a potential treatment, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the drug erlotinib on women with metastatic breast cancer who have previously been treated with anthracycline and taxane chemotherapy, and have measurable disease, with specific eligibility criteria including EGFR-positive status and negative hormone receptor and HER2/neu status.",
    "This phase 2 trial is testing the efficacy of azd9773 and placebo in treating severe sepsis and septic shock in Japanese adults with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for rheumatoid arthritis testing the efficacy of a p38 inhibitor drug and placebo, with specific inclusion and exclusion criteria, and the presence of multiple icd-10 codes for the disease.",
    "The sample is a phase 2/phase 3 trial testing the drug alt-711 on sedentary elderly individuals with cardiovascular disease, aging, endothelial dysfunction, and physical activity as the diseases of interest, and with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of paclitaxel poliglumex and pemetrexed in treating advanced non-small cell lung cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of anecortave acetate sterile suspension in treating open-angle glaucoma, with inclusion criteria being a diagnosis of the disease and exclusion criteria including pseudoexfoliation and pigment dispersion component.",
    "This phase 2 trial is testing the effectiveness of a combination of oxaliplatin, 5-fluorouracil, leucovorin, bevacizumab, irinotecan, and cetuximab in treating locally advanced or metastatic colorectal cancer patients who have progressed after 1st line therapy with FOLFOX/AVASTIN, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for Alzheimer's disease, testing the efficacy of chf 5074 and placebo drugs on patients with mild cognitive impairment, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for patients with refractory nasopharyngeal carcinoma, testing the efficacy of ifosfamide and doxorubicin, with specific eligibility criteria including prior chemotherapy and normal organ function.",
    "This phase 2 trial is testing the efficacy of salmeterol xinafoate and serevent\u00ae diskus\u00ae compared to placebo in patients with chronic obstructive pulmonary disease who meet specific spirometric criteria and have no significant comorbidities, with a focus on improving FEV1, and excluding patients with a history of asthma, allergic rhinitis, or atopy, or a total blood eosinophil count \u2265600/mm3.",
    "This phase 2 trial is testing the drug bortezomib on female patients with metastatic breast cancer who have previously undergone chemotherapy, and the eligibility criteria includes various medical and demographic factors.",
    "This phase 2 trial is testing the efficacy of arsenic trioxide, idarubicin, and tretinoin in treating acute promyelocytic leukemia (APL) in patients who meet specific eligibility criteria, including having a confirmed diagnosis of APL and meeting certain performance and health status requirements.",
    "This phase 2 trial is testing the drug Sutent (sunitinib) on patients with advanced stage III or IV melanoma with aberration of the KIT gene or KIT receptor, and measurable disease by RECIST criteria, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of minocycline and placebo (tetracycline) in treating cognitive impairment in HIV-infected patients on stable ART regimens, with inclusion criteria including a Karnofsky performance score of 60 or higher and a neuropsychological test indicating cognitive impairment.",
    "The sample is a phase 2 trial for Parkinson's disease testing the efficacy of pym50028 and placebo drugs on early-stage idiopathic PD patients who are not currently receiving any PD treatment, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of combined systemic and intrathecal chemotherapy followed by hd-asct in treating highly-malignant non-Hodgkins-Lymphoma, mantle-cell lymphoma or follicular lymphoma 3\u00b0 with CNS relapse, and the eligibility criteria includes adequate renal and bone marrow function, negative HIV-serology, and normal bilirubin and AST levels.",
    "This is a phase 2/phase 3 trial for adolescents and adults with mild to moderate asthma, testing the efficacy of the drug vr506 compared to placebo, with eligibility criteria including documented clinical history of asthma, ability to use the new inhaler correctly, and negative drug, alcohol, and urine cotinine screen.",
    "This phase 2 trial is testing the drug pemetrexed on patients with recurrent or persistent endometrial adenocarcinoma, with inclusion criteria including prior chemotherapy and negative pregnancy test, and exclusion criteria including prior therapy with pemetrexed and radiation to more than 25% of marrow bearing areas.",
    "The sample is a phase 2 trial for patients with advanced or metastatic colorectal cancer, testing the drug enzastaurin hcl, with inclusion criteria including ability to visit the doctor's office every 28 days for at least 6 months and ability to swallow tablets.",
    "The sample is a phase 2 trial for overweight and obesity, testing the efficacy of pramlintide acetate and metreleptin compared to placebos, with eligibility criteria including stable body weight and exclusion criteria including prior treatment with the drugs being tested or other anti-obesity agents.",
    "This phase 2 trial is testing the efficacy of GSK573719 and salbutamol/albuterol in treating asthma, with specific inclusion and exclusion criteria, and the study will require subjects to replace their current short-acting beta-2-agonist with albuterol/salbutamol aerosol inhaler for the duration of the study.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, and paclitaxel in treating early-stage HER2-positive breast cancer patients who have undergone mastectomy or lumpectomy with axillary node or sentinel node dissection, and meet specific eligibility criteria.",
    "This is a phase 2 trial for asthma patients, testing the effectiveness of placebo and two doses of r940343, with inclusion criteria of clinical history of asthma and ability to perform spirometry, and exclusion criteria of chronic obstructive pulmonary disease or bronchiectasis and upper or lower respiratory infection.",
    "The sample is a phase 2 trial for postmenopausal women with hormone-sensitive invasive breast cancer, testing the drug fulvestrant, with inclusion criteria including biopsy confirmation of cancer and hormone sensitivity, and exclusion criteria including previous breast cancer treatment and severe concurrent conditions.",
    "The sample is a phase 2 trial for type 2 diabetes mellitus, testing the drugs vi-0521 and placebo, with inclusion criteria including informed consent, type 2 diabetes, BMI 27-42, and specified diet/exercise and/or diabetes medications, and exclusion criteria including BP > 150/95, stroke/MI/unstable cardiovascular disease within 6 months, clinically significant renal, hepatic, or psychiatric disease, unstable thyroid disease or replacement therapy, nephrolithiasis, obesity of known genetic or endocrine origin, participation in a formal weight loss program or lifestyle intervention, history of glaucoma, pregnancy or breastfeeding, alcohol abuse, eating disorder, and excluded medications.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease (COPD) testing the efficacy of formoterol, salmeterol, and placebo, with inclusion and exclusion criteria based on smoking history, medication use, and medical history.",
    "This is a phase 2 trial for patients with gastrointestinal stromal tumor, testing the drug imatinib mesylate, with eligibility criteria including confirmed diagnosis, c-kit expression, and measurable lesions, among other requirements.",
    "This phase 2 trial is testing the efficacy of gemcitabine hydrochloride and irinotecan hydrochloride in treating patients with carcinoma of unknown primary, with specific eligibility criteria including histologically confirmed carcinoma of undetermined origin and no brain or meningeal involvement.",
    "The sample is a phase 2 clinical trial for patients with primary peritoneal cavity cancer or recurrent ovarian epithelial cancer, testing the drug imatinib mesylate, with eligibility criteria including prior platinum-based chemotherapy and specific medical conditions.",
    "This phase 2 trial is testing the effectiveness of exenatide, a drug used to treat type 2 diabetes, on patients with moderate Parkinson's disease who are on L-dopa treatment and meet specific eligibility criteria.",
    "This is a phase 2 clinical trial for amyotrophic lateral sclerosis testing the efficacy of pioglitazone and placebo drugs on patients who meet specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2/phase 3 trial for lupus nephritis, testing the efficacy of atacicept, mycophenolate mofetil, and corticosteroids compared to placebo, with inclusion criteria based on SLE diagnosis and active ISN/PRS class III or IV lupus nephritis, and exclusion criteria including prior treatment with certain medications and GFR less than or equal to 30 mL/min per 1.73 m^2.",
    "This phase 2 trial aims to test the efficacy of zonisamide and bupropion in treating obesity, with eligibility criteria including BMI, blood pressure, and medical history, and the study will test six different drug combinations.",
    "This phase 2 trial is testing the efficacy of bibw2992 and bibw2992 + paclitaxel in treating non-small-cell lung carcinoma patients with activating mutations in exon 18 to exon 21 of the EGFR or HER2-neu-receptor, who have had up to 3 lines of chemotherapy, and have at least one tumor lesion that can be measured by CTscan or MRI, among other eligibility criteria.",
    "This phase 2 trial is testing the drug tanespimycin for patients with recurrent or metastatic breast cancer who have not responded to previous treatments, and the eligibility criteria includes specific disease stages, previous treatments, and various medical conditions.",
    "The sample is a phase 2 trial for patients with type 2 diabetes, testing the efficacy of placebo and ro4876904, with inclusion criteria of age, diabetes diagnosis, and BMI, and exclusion criteria of type 1 diabetes and recent use of anti-hyperglycemic or weight-lowering drugs.",
    "The sample is a phase 2 trial for a vaccine (vak694) and immunotherapy (alutard avanz sq) for seasonal allergic rhinitis, with inclusion criteria including a history of atopy and positive skin prick test to grass pollen allergen, and exclusion criteria including recent treatment with intranasal corticosteroids or history of asthma with corticosteroid treatment.",
    "This phase 2 trial is testing the drug ispinesib on patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have had a maximum of one prior chemotherapy regimen, and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of radezolid and linezolid in treating adult patients with uncomplicated skin and skin structure infections caused by various bacterial pathogens, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for metastatic breast cancer using gemcitabine, with inclusion criteria including prior chemotherapy with anthracycline and taxane regimen, measurable region, and adequate organ function, and exclusion criteria including interstitial pneumonia or pulmonary fibrosis, inflammatory carcinoma, brain metastasis with symptom, and severe complications.",
    "This phase 2 trial aims to investigate the efficacy of degarelix mid-luteal and placebo in pre-menopausal females with regular menstrual cycles and BMI between 18 and 29 kg/m2 who are willing to donate retrieved oocytes and use contraception, and have no abnormal karyotype, clinically significant systemic disease, endocrine or metabolic abnormalities, polycystic ovarian syndrome, endometriosis stage III/IV, poor responder, history of recurrent miscarriage, pregnancy or lactation, hypersensitivity to any trial product, and have not used any investigational drug during 3 months prior to the start of the current COH cycle, to treat infertility.",
    "This phase 2 trial is testing the efficacy of ezetimibe, a lipid-lowering drug, in patients with hyperlipidemia who are not at LDL-C goal, and the eligibility criteria include being on stable lipid-lowering therapy and having fasting triglycerides < 400 mg/dL.",
    "The sample is a phase 2 trial for asthma patients treated with the drug GSK256066, with inclusion criteria including documented history of asthma, positive reaction to allergens, and pre-bronchodilator FEV1 >75% of predicted, and exclusion criteria including history of cardiovascular disease and positive drugs of abuse test.",
    "This phase 2 trial is testing the drug cladribine on patients with relapsed acute myelocytic leukemia who meet certain eligibility criteria, while excluding those with prior cladribine therapy or severe organ impairment, and requiring written informed consent.",
    "The sample is a phase 2 trial for sleep initiation and maintenance disorders, testing the efficacy of zolpidem tartrate and sodium oxybate, among others, with inclusion criteria including insomnia for at least six months and exclusion criteria including clinically significant drug sensitivity to sodium oxybate or sedative hypnotics.",
    "This phase 2 trial is testing the efficacy of LY2828360 and placebo in treating osteoarthritis of the knee, with eligibility criteria including a Kellgren and Lawrence grade of I-IV and a mean score of at least 4 on the 24-hour average pain score, while exclusion criteria include a history of seizures, autoimmune disorder, and significant active neurological or psychiatric disease.",
    "This phase 2 trial is testing the efficacy of bortezomib, dexamethasone, and rituximab in treating Waldenstrom's macroglobulinemia, with specific eligibility criteria including measurable disease and CD20 positive disease.",
    "The sample is a phase 2 trial for head and neck cancer and radiation toxicity, testing the efficacy of cisplatin and fluorouracil in combination with primary radiotherapy, with eligibility criteria including confirmed stage I-IVB squamous cell carcinoma of the nasopharynx, Zubrod 0-1 performance status, and no evidence of distant metastasis.",
    "The sample is a phase 2 trial for patients with recurrent or progressive non-small cell lung cancer who have received prior platinum-based therapy and a taxane, and will test the efficacy of eribulin mesylate as a treatment option. The eligibility criteria include measurable disease, Zubrod performance status \u2264 2 or Karnofsky PS 60-100%, and no uncontrolled illness.",
    "This phase 2 trial is testing the efficacy of nasal carbon dioxide and placebo in treating migraine in patients aged 18-65 with a history of 2-8 migraine attacks per month, and who meet the inclusion and exclusion criteria.",
    "This is a phase 2 trial for non-small cell lung cancer patients with gemcitabine, carboplatin, and bevacizumab as drugs, and the eligibility criteria includes measurable or non-measurable disease status, ECOG performance status of 0 or 1, and adequate organ function.",
    "This is a phase 2 clinical trial for ulcerative colitis testing the efficacy of vedolizumab and placebo, with inclusion criteria including confirmed and active UC and exclusion criteria including recent treatment with cyclosporine, FK506 (tacrolimus) or infliximab within 60 days prior to study.",
    "The sample is a phase 2/phase 3 trial for patients scheduled for elective cardiac or thoracic surgery with a history of deep venous thrombosis, testing the efficacy of desirudin and heparin as anticoagulants, with eligibility criteria and exclusion criteria listed.",
    "The sample is a phase 2 trial for metastatic prostate cancer patients who have received docetaxel as first-line chemotherapy and at least 1 prior regimen of hormone therapy, testing the efficacy of etoposide, mitoxantrone hydrochloride, prednisone, and vinorelbine tartrate, with eligibility criteria including specific disease characteristics and patient characteristics.",
    "This phase 2 trial is testing the drug ipi-504 on patients with ALK mutation and stage IIIB or IV lung cancer, who have refused or are intolerant to standard systemic therapy, and have measurable disease by RECIST criteria.",
    "This phase 2 trial is testing the efficacy of cisplatin and 5-fluorouracil in treating pancreatic cancer patients who have undergone a potentially curative gross total resection by pancreaticoduodenectomy, and have met specific eligibility criteria.",
    "The sample is a phase 2 trial for knee pain due to osteoarthritis, testing oxycodone, placebo, and pf-000592379, with inclusion criteria of age 18-75 and exclusion criteria of pregnancy and history of malignancy or recent arthroscopy.",
    "This phase 2 trial is testing the efficacy of paclitaxel and carboplatin in treating advanced non-small cell lung cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of emtricitabine in HIV-positive patients with chronic hepatitis B virus infection, with specific inclusion and exclusion criteria, and using a list of icd-10 codes to identify eligible patients.",
    "This phase 2 trial is testing the efficacy of zoledronic acid in women with stage I-III breast cancer who have bone marrow aspirate positive by IC/FC assay, and have normal liver and renal function, and are not pregnant.",
    "The sample is a phase 2 trial for irritable bowel syndrome, testing the efficacy of dronabinol and placebo, with inclusion criteria including age, positive IBS symptoms, and baseline geometric center values, and exclusion criteria including significant depression and anxiety.",
    "The sample is a phase 2 trial for mild Alzheimer's disease and amnestic mild cognitive impairment, testing the drugs aqw051 and placebo, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of sunitinib malate in treating patients with 1-3 newly diagnosed brain metastases amenable to stereotactic radiosurgery, with specific eligibility criteria for disease and patient characteristics.",
    "This phase 2 trial is testing the efficacy of regorafenib, a drug used to treat gastrointestinal stromal tumor, in patients who have failed conventional tyrosine kinase inhibitors, and includes eligibility criteria such as measurable disease per RECIST 1.1 and ECOG Performance Status 0 or 1.",
    "This phase 2 trial is testing the efficacy of forodesine hydrochloride in treating patients with precursor T-lymphoblastic leukemia/lymphoma who have failed to respond to or relapsed after two or more treatment regimens, and have a performance status of 2 by ECOG criteria, with a list of inclusion and exclusion criteria.",
    "The sample is a phase 2/phase 3 trial for patients with stage IIIB or IV non-small cell lung cancer, testing the efficacy of vorinostat and several comparators, with eligibility criteria including confirmed diagnosis of NSCLC, adequate organ function, and ECOG performance status of 0 or 1.",
    "The sample is a phase 2 trial for schizophrenia with inclusion criteria based on DSM-IV, PANSS score, and duration of diagnosis, and exclusion criteria based on physical examination and first episode of psychosis, with drugs including placebo, cariprazine, and risperidone.",
    "This phase 2 trial is testing the efficacy of 5-fluorouracil, bevacizumab, leucovorin, and oxaliplatin in treating patients with unresectable hepatic colorectal metastasis, with specific eligibility criteria including confirmed biopsy and radiological evidence of measurable liver metastasis, and exclusion criteria including previous chemotherapy treatment for metastatic disease and known hypersensitivity to any of the components of the drugs.",
    "This phase 2 trial is testing the efficacy of tacrolimus, mycophenolate, etanercept, and methoxsalen in preventing graft versus host disease in patients undergoing unrelated donor hematopoietic stem cell transplant for various hematologic conditions, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for patients with metastatic colorectal cancer, testing the drug folfiri, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of carboplatin, cisplatin, gemcitabine hydrochloride, and paclitaxel in treating bladder and urethral cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for metastatic colorectal cancer using the drug rad001, with inclusion criteria of refractory to at least 2 chemo/biologic regimens, measurable disease, and ECOG 0-2, and exclusion criteria of CNS disease, chemotherapy or radiotherapy < 4 weeks prior, and active bleeding diathesis.",
    "This phase 2 trial is testing the efficacy of dasatinib, a drug, in treating stage IV pancreatic cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of Avastin and docetaxel in treating patients with fallopian tube cancer, ovarian cancer, or malignant tumor of peritoneum who have had up to three prior chemotherapy regimens and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of perampanel and placebo in treating epilepsy in adolescents aged 12-18 with partial-onset seizures, who are on a stable dose of 1-3 antiepileptic drugs, and meet specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of bimatoprost eye drops and placebo in controlling IOP in patients with chronic glaucoma or ocular hypertension, with inclusion criteria of IOP controlled on Xalatan and exclusion criteria of uncontrolled medical conditions and known hypersensitivity to study medications.",
    "This phase 2 trial aims to test the effectiveness of Haelan in treating anorexia, weight loss, and cachexia in patients with advanced solid tumors, with specific inclusion and exclusion criteria, and using ICD-10 codes to identify the diseases, while the drug being tested is Haelan.",
    "This phase 2 trial will test the effects of aliskiren and amlodipine on high blood pressure, metabolic syndrome, insulin resistance, and endothelial dysfunction in adults with specific inclusion and exclusion criteria, including abnormal PET and euglycemic clamp results, and exclude African Americans.",
    "This is a phase 2 trial testing the effects of estetrol and desogestrel or progesterone on healthy women who meet specific eligibility criteria, including age, BMI, and absence of certain medical conditions or medication use.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone in treating previously untreated Stage III, IV, or bulky Stage II diffuse large B-cell non-Hodgkin's lymphoma patients who are positive for CD20.",
    "The sample is a phase 2 trial for patients with colorectal cancer and metastases, testing the efficacy of cetuximab, bevacizumab, leucovorin, oxaliplatin, and fluorouracil in combination with major liver resection, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of erlotinib, vinorelbine, and carboplatin in treating non-small cell lung cancer in patients over 70 years old with specific eligibility criteria.",
    "The sample is a phase 2 trial for non-Hodgkin's lymphoma, testing the efficacy of pro95780 and rituximab in patients who have progressed after a previous rituximab-containing regimen, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for the drug TD-1211 and placebo in treating opioid-induced constipation in patients with a history of constipation and a total daily dose of opioids \u226530 mg, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of ffns nasal spray and placebo in treating acute rhinosinusitis, with eligibility criteria including age, diagnosis, and willingness to comply with study procedures.",
    "This phase 2 trial is testing the efficacy of lu ae58054 and placebo in treating Alzheimer's disease in patients aged 50 or older who have been treated with donepezil for at least 3 months, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of topotecan and taxotere in treating recurrent ovarian and uterine neoplasms, with eligibility criteria including specific histologic types, performance status, and hepatic function, among others.",
    "This phase 2 trial is testing the efficacy of Leo 90100, calcipotriol, and betamethasone in treating psoriasis vulgaris, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial aims to test the efficacy of tamsulosin hydrochloride, solifenacin succinate, and placebo in treating lower urinary tract symptoms associated with prostatic hyperplasia, with inclusion criteria including male patients with IPSS score > 13 and maximum flow rate of > 4 mL/s and < 15 mL/s.",
    "This phase 2 trial is testing the efficacy of methylprednisolone and temozolomide in treating recurrent primary CNS non-Hodgkin's lymphoma, with eligibility criteria including measurable disease and stable steroid therapy, among other requirements.",
    "The sample is a phase 2 clinical trial for multiple myeloma, testing the efficacy of fludarabine as induction therapy followed by high dose treatment supported by autologous stem cell transplantation, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for coronary disease using otamixaban, unfractionated heparin, and eptifibatide as drugs, with specific inclusion and exclusion criteria for patient eligibility.",
    "The sample is a phase 2 trial for major depressive disorder using quetiapine fumarate (seroquel) as the drug, with inclusion criteria of being na\u00efve to any atypical antipsychotic and having a diagnosis of major depressive disorder, and exclusion criteria of having a history of bipolar I or II disorder or a diagnosis of psychotic major depression disorder.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma who have previously responded to bortezomib therapy, and the eligibility criteria includes measurable disease, previous tolerance to bortezomib, and life expectancy >3 months. The drug being tested is bortezomib.",
    "This phase 2 trial is testing the efficacy of dexamethasone and trabectedin in treating progressive metastatic breast cancer with specific eligibility criteria, including measurable disease and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.",
    "This is a phase 2 trial for patients with metastatic hormone refractory prostate cancer, testing the drug panobinostat, with inclusion criteria including confirmed diagnosis of adenocarcinoma of the prostate and evidence of disease progression, and exclusion criteria including history of CNS disease and impaired cardiac function.",
    "The sample is a phase 2 trial for previously untreated, resectable adenocarcinoma of the esophagus using docetaxel, floxuridine, leucovorin, and oxaliplatin, with eligibility criteria including specific disease characteristics and patient characteristics, and no prior chemotherapy or radiotherapy to the esophagus.",
    "The sample is a phase 2/3 trial for previously untreated diffuse large B-cell or peripheral T-cell non-Hodgkin's lymphoma patients, testing the efficacy of chop and epoch regimens, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, and vincristine sulfate, with eligibility criteria including age over 70, WHO performance status 0-2, and various hematopoietic, hepatic, renal, and cardiovascular requirements.",
    "This phase 2 trial is testing the efficacy of lapatinib ditosylate, an EGFR and erbB2 targeting therapy, in patients with recurrent and/or metastatic malignant salivary gland carcinomas expressing EGFR and/or erbB2, who have measurable disease and have not received any other investigational agents or concurrent anticancer therapy.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory multiple myeloma, testing the efficacy of lenalidomide as a treatment option, with specific eligibility criteria and restrictions on prior and concurrent therapies.",
    "This is a phase 2 clinical trial for the treatment of psoriasis vulgaris using the drug LEO 90100, with specific eligibility criteria including disease severity, duration, and extent, as well as normal HPA axis function and calcium levels, and exclusion criteria such as recent systemic treatments and other medical conditions.",
    "This phase 2 trial is testing the efficacy of perampanel and placebo in treating Parkinson's disease patients who meet specific inclusion criteria, while excluding patients with certain medical and psychiatric conditions or who are taking certain medications.",
    "This phase 2 trial is testing the effectiveness of bendamustine hydrochloride in treating non-Hodgkin's lymphoma and mantle cell lymphoma patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of acamprosate and placebo in treating alcohol use disorder, with eligibility criteria including a diagnosis of current alcohol dependence and a minimum of 48 standard alcoholic drinks in a consecutive 30-day period, while exclusion criteria include subjects with evidence of substance dependence other than alcohol or nicotine dependence and known hypersensitivity to acamprosate.",
    "This phase 2 trial is testing the efficacy of ketamine and placebo in treating major depressive disorder in patients who have had inadequate response to at least one antidepressant, with inclusion criteria including a minimum IDS-C30 score and exclusion criteria including allergies or intolerance to ketamine.",
    "The sample is a phase 2 trial for non-small cell lung cancer, testing the efficacy of carboplatin, paclitaxel, and sunitinib, with specific inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial is testing the efficacy of docetaxel, cisplatin, and fluorouracil in treating gastric adenocarcinoma, with eligibility criteria including specific stages of the disease, acceptable hematological and organ function, and exclusion criteria such as other types of gastric cancer and prior chemotherapy.",
    "The sample is a phase 2 trial for non small cell lung cancer using gemcitabine and cisplatin, with specific eligibility and exclusion criteria listed.",
    "This phase 2 trial will test the efficacy of taxotere, cisplatin, and irinotecan in treating patients with incurable esophageal, gastric, or ge junction cancer, with specific eligibility criteria including measurable disease and adequate bone marrow and renal function.",
    "This phase 2 trial is testing the drug aslan001 in patients with inoperable locally-advanced metastatic adenocarcinoma of the stomach, gastro-oesophageal junction or distal oesophagus who have received prior chemotherapy, and have measurable and non-measurable disease, with eligibility criteria including expression of HER-1 and HER-2, ECOG performance status of 0 or 1, and adequate organ and haematological function.",
    "The sample is a phase 2 trial for coronary disease patients undergoing primary CABG surgery, testing the efficacy of ins50589 intravenous infusion, with specific inclusion and exclusion criteria related to bleeding tendencies and previous surgeries or medication use.",
    "The sample is a phase 2 trial for relapsed non-small cell lung cancer, testing the efficacy of pemetrexed, gemcitabine, and carboplatin, with eligibility criteria including good organ function and ability to carry out light work, and exclusion criteria including previous treatment with pemetrexed or gemcitabine and inability to take corticosteroid drugs or required supplements.",
    "This phase 2 trial is testing the efficacy of ro5024048, ribavirin, and peginterferon alfa-2a in treating chronic hepatitis C with genotype 1 or 4, and includes eligibility criteria such as being treatment-na\u00efve and having a negative pregnancy test.",
    "This phase 2 trial is testing the drug clofarabine on patients with myelodysplastic syndrome or leukemia who meet certain eligibility criteria, including having not received prior intensive chemotherapy or high-dose ara-C, and having adequate organ function.",
    "This phase 2 trial is testing the efficacy of imatinib and dasatinib in treating chronic phase Ph^+ chronic myeloid leukemia (CML) patients who have shown suboptimal response to imatinib monotherapy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for non-small cell lung cancer, testing the effectiveness of tarceva, carboplatin, and paclitaxel, with eligibility criteria including age, ECOG performance status, and positive EGFR pathway markers.",
    "The sample is a phase 2 trial for metastatic melanoma using taxoprexin as a drug, with eligibility criteria including confirmation of malignant eye melanoma, measurable lesion, ECOG performance status of 0-2, and adequate liver and renal function.",
    "The sample is a phase 2 trial for lymphoma patients who have relapsed after prior autologous bone marrow transplantation, and the treatment involves a combination of fludarabine phosphate, melphalan, methotrexate, and tacrolimus, with eligibility criteria including specific disease types, HLA-identical donor availability, and various patient characteristics.",
    "This phase 2 trial is testing the effectiveness of panobinostat (lbh589) on patients with cutaneous t-cell lymphoma and leukemia-lymphoma, adult t-cell, who have received at least two systemic therapy regimens and have had disease progression on or following their most recent treatment regimen.",
    "The sample is a phase 2/phase 3 trial for tobacco dependence, testing the effectiveness of s-adenosyl-l-methionine as a treatment, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for prostate cancer patients with PSA progression, ongoing androgen deprivation, and ECOG performance status <=2, testing the efficacy of abiraterone acetate and prednisone as treatment, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for patients with chronic obstructive pulmonary disease (COPD) testing the efficacy of glycopyrrolate compared to a comparator drug, with inclusion criteria including age and prior therapy, and exclusion criteria including pregnancy and exacerbation, and the trial will use ICD-10 codes to identify the disease.",
    "This phase 2 trial is testing the drug panobinostat on patients with relapsed or refractory acute myeloid leukemia or acute lymphoblastic leukemia, with eligibility criteria including ECOG performance status 0-2, no active CNS disease, and no other concurrent anticancer therapy or investigational therapy.",
    "This phase 2 trial is testing the efficacy of birb 796 bs, low to high dose, and placebo in treating stable moderate to severe plaque-type psoriasis involving \u22655% body surface area, with a list of exclusion criteria including prior treatment failure with a TNF-blocking agent, primary guttate, erythrodermic, or pustular psoriasis, and clinically significant abnormal baseline hematology, blood chemistry or urinalysis.",
    "This phase 2 trial is testing the efficacy of paclitaxel/carboplatin/gefitinib and paclitaxel/carboplatin in treating non-small cell lung cancer with metastasis or locally advanced disease, with specific eligibility criteria for patients, including age, disease stage, and adequate hematologic, renal, and liver function.",
    "This phase 2 trial is testing the drug bortezomib on patients with various types of transitional cell carcinoma who have received only one prior systemic chemotherapy regimen and have measurable disease, with specific eligibility criteria including performance status, peripheral neuropathy, and organ function.",
    "The sample is a phase 2 clinical trial for patients with Cushing's disease, testing the efficacy of rosiglitazone maleate as a steroid-lowering therapy, with eligibility criteria including clinically demonstrable ACTH-secreting pituitary tumor, elevated 24-hour urinary-free cortisol levels, lack of suppression of serum cortisol, and no prior or concurrent radiotherapy for pituitary tumor.",
    "This phase 2 trial is testing the efficacy of tiotropium 2.5 \u00b5g b.i.d and tiotropium 5 \u00b5g q.d. versus placebo in patients with moderate persistent asthma who are symptomatic despite their current maintenance treatment with medium doses of inhaled corticosteroids.",
    "This phase 2 trial is testing the efficacy of docetaxel+cddp and docetaxel+s-1 in treating head and neck squamous cell carcinoma, with specific inclusion and exclusion criteria for eligible patients.",
    "This phase 2 trial is testing the efficacy of prednisone, vinblastine, doxorubicin, and gemcitabine in treating Hodgkin's lymphoma in patients aged 18-60 with no prior therapy, and includes eligibility criteria such as clinical stage and age range.",
    "This trial is testing the drug ono-2506 for patients with acute cortical ischemic stroke, with specific inclusion and exclusion criteria based on patient characteristics and medical history.",
    "The sample is a phase 2 trial for the drug SPM 927 in treating postherpetic neuralgia, with inclusion criteria of postherpetic neuralgia and exclusion criteria of not benefiting from long term treatment.",
    "This is a phase 2 trial for metastatic pancreatic cancer patients, testing the combination of erlotinib hydrochloride and gemcitabine hydrochloride, with eligibility criteria including ECOG performance status 0-1, certain blood counts, and no prior anti-EGFR therapy.",
    "The sample is a phase 2 trial for paricalcitol in patients with metastatic prostate cancer and bone metastasis, with eligibility criteria including androgen refractory disease, secondary hyperparathyroidism, and normal liver and kidney function.",
    "This is a phase 2 trial for osteoporosis that will test the efficacy of ronacaleret, teriparatide, and alendronate, with eligibility criteria including menopausal status, T-score, suitable vertebra, and protocol compliance, and exclusion criteria including vertebral fractures, non-vertebral fractures, spine deformity, BMI, bone metabolic diseases, GI disease, malabsorption, liver disease, rheumatoid arthritis, nephrolithiasis, osteosarcoma risk, malignancy, and other biological abnormalities.",
    "This phase 2 trial is testing the efficacy of abt-874, a human monoclonal antibody against il-12, and placebo in treating multiple sclerosis, with eligibility criteria including age, relapse history, and ability to self-administer injections.",
    "This phase 2 trial is testing the efficacy of memp1972a and placebo in treating mild, stable allergic asthma with specific inclusion and exclusion criteria, including positive skin prick test and allergen-induced airway response.",
    "This phase 2 trial is testing the efficacy of high-dose melphalan in patients with histologically confirmed AL amyloidosis who have previously undergone autologous stem cell transplantation and have shown significant initial improvement in organ function, with the goal of improving performance status and stabilizing disease, while excluding patients with myelodysplastic syndromes or abnormal bone marrow cytogenetics.",
    "The sample is a phase 2 trial for rheumatoid arthritis patients taking etoricoxib and a comparator drug, with inclusion criteria requiring stable anti-rheumatic medication and exclusion criteria excluding patients with interfering medical conditions.",
    "This phase 2 trial is testing the efficacy of the drug cr845 compared to placebo for acute pain relief in patients undergoing elective primary unilateral first metatarsal bunionectomy surgery, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for primary insomnia, testing the efficacy of mk-6096 and its placebo, with eligibility criteria including willingness to stay overnight at a sleep laboratory and exclusion criteria including history of neurological or cardiovascular disorders.",
    "This phase 2 trial is testing sorafenib tosylate in patients with extensive or recurrent small cell lung cancer who have previously been treated with cisplatin or carboplatin, and have measurable disease per RECIST criteria, with eligibility criteria including specific laboratory values and performance status.",
    "This phase 2 trial is testing the efficacy of irinotecan hydrochloride, in combination with fluorpyrimidines and bevacizumab, in treating metastatic colorectal cancer patients who have previously been treated with oxaliplatin and fluorpyrimidines, and have wild type KRAS, with eligibility criteria including measurable disease, WHO performance status of 0-2, and no significant cardiovascular disease.",
    "This phase 2 trial is testing the efficacy of docetaxel and cddp in treating squamous cell carcinoma of non-small cell lung cancer, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of saracatinib in treating patients with metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of trastuzumab emtansine, trastuzumab, and docetaxel in treating HER2-positive metastatic breast cancer with specific eligibility and exclusion criteria.",
    "This is a phase 2 trial for patients with type 2 diabetes, testing the efficacy of Ormd-0801 and placebo, with eligibility criteria including age, BMI, HbA1c, and exclusion criteria including use of certain medications and presence of certain conditions.",
    "This phase 2 trial is testing the use of dexamethasone in patients with organ-confined prostate cancer who are scheduled for radical prostatectomy and meet specific eligibility criteria.",
    "This is a phase 2 trial for small cell lung cancer patients with extensive disease, using a combination of amrubicin, cisplatin, and etoposide, with specific eligibility criteria including normal cardiac function and no prior systemic chemotherapy for small cell lung cancer.",
    "This phase 2 trial is testing the efficacy of semapimod and placebo in treating Crohn's disease, with inclusion criteria including a baseline Crohn's Disease Activity Index of 250-400 and confirmed diagnosis of colitis, ileitis, or ileocolitis, while exclusion criteria include any ostomy or extensive bowel resection and current evidence of bowel obstruction or history within the preceding six months.",
    "This phase 2 trial is testing the efficacy of sorafenib tosylate in patients with locally advanced or distant metastatic cholangiocarcinoma or gallbladder carcinoma who have not received prior therapy for unresectable or metastatic disease, and have measurable disease, with eligibility criteria including performance status, serum bilirubin, transaminase, and creatinine levels, as well as leukocyte count, ANC, and platelets, and exclusion criteria including prior therapy with BAY 43-9006 or any inhibitor of VEGFR or the MAPK pathway, and clinically significant cardiac disease that is not well controlled by medication.",
    "This phase 2 trial is testing the efficacy of fluticasone furoate, ff/vilanterol, and placebo in treating bronchial asthma in non-smoking females with a documented history of asthma and specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for asthma patients, testing the effectiveness of arformoterol and levalbuterol, with inclusion criteria including age, weight, and duration of asthma, and exclusion criteria including pregnancy, hospitalization for asthma, and certain medical conditions.",
    "The sample is a phase 2/phase 3 trial for patients with HIV and chronic hepatitis B, testing the efficacy of Truvada (emtricitabine + tenofovir df) in reducing viral load, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of bevacizumab and abraxane in treating patients with epithelial ovarian cancer and primary peritoneal carcinoma who have had prior platinum-based chemotherapy, and have adequate hematologic and hepatic function, while excluding patients with certain medical conditions or prior use of bevacizumab.",
    "This phase 2 trial is testing the efficacy of irinotecan in treating refractory/relapsed ovarian, primary peritoneal, or fallopian tube cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial testing the efficacy of sorafenib plus doxorubicin versus doxorubicin/placebo in patients with advanced hepatocellular carcinoma who meet specific eligibility criteria.",
    "This is a phase 2 trial for metastatic breast cancer patients who have progressed despite taxane or other chemotherapeutic therapies, and are eligible for the study based on certain criteria, including ER and PR negativity, evaluable disease and symptoms, and a performance status of 0, 1, or 2. The trial will test the efficacy of fluoxymesterone and anastrozole as drugs.",
    "The sample is a phase 2 trial for insulin-na\u00efve type 2 diabetes patients with HbA1c 7.0-11.0%, testing the efficacy of insulin glargine and insulin degludec in combination with metformin and other oral anti-diabetic drugs, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for open-angle glaucoma and ocular hypertension, using the drug brinzolamide/timolol, with eligibility criteria for adults of either sex and any race diagnosed with open-angle glaucoma, and exclusion criteria for those under 18.",
    "The sample is a phase 2 trial for patients with coronary heart disease, testing the efficacy of dalcetrapib and placebo drugs, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for major depressive disorder, testing the efficacy of LY2216684, escitalopram, and placebo, with inclusion and exclusion criteria based on psychiatric and medical history, and the ability to communicate with study personnel.",
    "This phase 2 trial is testing the effectiveness of abiraterone acetate in combination with prednisone for the treatment of prostate cancer in males over 18 years of age with rising PSA levels and specific eligibility criteria.",
    "This phase 2 trial is testing the effectiveness of rituximab, chop, and intrathecal methotrexate in treating primary testicular CD20-positive diffuse large B-cell non-Hodgkin's lymphoma in patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for non-small cell lung cancer patients, testing the efficacy of bevacizumab and carboplatin-based chemotherapy, with eligibility criteria including age, ECOG performance status, and absence of prior chemotherapy or CNS metastases.",
    "This phase 2 trial is testing the efficacy of the drug cf101 and placebo in treating moderate-to-severe keratoconjunctivitis sicca, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for metastatic colorectal cancer testing the efficacy of bevacizumab, eloxatin, capecitabine, and erlotinib, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for cystic fibrosis patients with the G551D-CFTR mutation, testing the efficacy of ivacaftor and placebo, with inclusion criteria of FEV1 >90% and exclusion criteria of recent participation in another clinical study or use of inhaled hypertonic saline treatment.",
    "This is a phase 2 trial for non-small cell lung cancer using pemetrexed, cisplatin, folic acid, vitamin b12, and dexamethasone as drugs, with eligibility criteria including confirmed tissue biopsy, stage IIIAN2 disease, good performance status, and measurable disease according to RECIST criteria.",
    "This phase 2 trial is testing the efficacy of mirabegron and solifenacin succinate, along with a placebo, in treating overactive bladder symptoms in subjects with various urologic diseases and urinary bladder manifestations, who meet specific inclusion criteria and do not have any exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of fluticasone furoate and matching placebo in treating asthma in children aged 5-11 years, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with unresectable, metastatic esophageal cancer, testing the efficacy of bortezomib, carboplatin, and paclitaxel, with eligibility criteria including age, performance status, and various medical conditions.",
    "The sample is a phase 2 trial for status epilepticus, testing the efficacy of levetiracetam (add-on) with specific inclusion and exclusion criteria, including age, pregnancy status, and daily dose limit.",
    "This phase 2 trial is testing the efficacy of erlotinib hydrochloride in treating malignant peripheral nerve sheath tumors, with eligibility criteria including measurable disease, Zubrod 0-2 performance status, and no other concurrent investigational or commercial agents or therapies for the malignancy.",
    "This phase 2 trial is testing the efficacy of induction and consolidation carboplatin and paclitaxel in patients with Stage IIIA or IIIB non-small cell lung cancer, with eligibility criteria including measurable disease, positive mediastinal lymph nodes, and a Zubrod performance status of 0-1.",
    "This phase 2 trial is testing the efficacy of temozolomide, velban, cisplatin, interleukin-2, and thalidomide in treating advanced stage IV or unresectable stage III melanoma patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for CD20+ chronic lymphocytic leukemia, testing the efficacy of rituximab and chlorambucil, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug ls11 (talaporfin sodium) on patients with primary or recurrent glioblastoma multiforme or anaplastic astrocytoma, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of intravenous sildenafil in treating persistent pulmonary hypertension and respiratory failure in neonates with specific eligibility criteria, including absence of structural heart disease and not participating in another concurrent experimental study.",
    "This phase 2 trial is testing the efficacy of lapatinib, a drug used to treat metastatic breast cancer, in patients who have had a partial response or stable disease for 24 weeks or longer on hormonal therapy, and have stopped fulvestrant at least four weeks prior to enrollment.",
    "The sample is a phase 2 clinical trial for metastatic breast cancer using gemcitabine and cisplatin, with inclusion and exclusion criteria listed, and icd-10 codes provided for the disease.",
    "The sample is a phase 2 trial for biliary tract cancer using gemcitabine and cisplatin as drugs, with inclusion criteria including a histological or cytological diagnosis of biliary tract cancer, measurable disease, chemotherapy-na\u00efve, ECOG performance status 0 or 1, and estimated life expectancy no less than 3 months, and exclusion criteria including radiological or clinical evidence of pulmonary fibrosis or interstitial pneumonia.",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus, testing the efficacy of bi 10773 at different doses, with eligibility criteria including stable basal insulin treatment and exclusion criteria including recent MI, stroke, or TIA, impaired hepatic or renal function, and treatment with other anti-diabetics, anti-obesity medications, steroids or thyroid hormones.",
    "This is a phase 2 clinical trial for Crohn's disease, testing the drugs cp-690,550 and placebo, with inclusion criteria of clinical evidence of Crohn's disease for at least 3 months and a CDAI score of 220-450, and exclusion criteria of currently receiving immunosuppressants, interferon, anti-TNFa, evidence of hematopoietic disorders, and evidence of active or latent TB.",
    "The sample is a phase 2 trial for pancreatic cancer patients, testing the efficacy of gemcitabine, erlotinib, and oxaliplatin, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide, doxorubicin, prednisone, and vincristine in treating Waldenstrom's macroglobulinemia, with specific eligibility criteria including bone marrow lymphoplasmacytosis and a measurable IgM monoclonal protein level.",
    "This phase 2 trial is testing the efficacy of dasatinib, a drug used in chemotherapy, in treating malignant mesothelioma, with specific eligibility criteria for patients including prior treatment with pemetrexed disodium and no known brain metastases.",
    "The sample is a phase 2 trial for Alzheimer's disease testing the efficacy of lecozotan sr and donepezil, with inclusion criteria of probable AD diagnosis and informed consent, and exclusion criteria of recent cognitive enhancement medication use and significant neurologic disease.",
    "This sample is a phase 2 trial for diabetic gastroparesis, testing the efficacy of 10 mg tzp-102 and placebo drugs, with inclusion and exclusion criteria listed.",
    "This is a phase 2 trial for lung cancer using sorafenib as the drug, with eligibility criteria including biopsy-proven BAC or adenocarcinoma and selected IIIB or stage IV cancer that is incompletely resected or unresectable.",
    "This phase 2 trial is testing the efficacy of taxteral, 5-fluorouracil, and leucovorin in treating inoperable advanced gastric adenocarcinoma, with specific eligibility criteria including bi-dimensionally measurable disease and adequate bone marrow reserves.",
    "The sample is a phase 2 trial for the drug tak-700 in patients with prostate cancer, with inclusion criteria including rising PSA and confirmed diagnosis of prostate adenocarcinoma, and exclusion criteria including prior therapy with aminoglutethimide or ketoconazole and uncontrolled cardiovascular condition.",
    "This is a phase 2 trial for individuals with acute exacerbation of asthma, testing the efficacy of MN-221 and its safety in combination with other medications, with inclusion and exclusion criteria specified.",
    "This phase 2 trial aims to test the efficacy of transdermal bupivacaine patch in treating postherpetic neuralgia and pain, with specific inclusion and exclusion criteria, and no recent use of topically applied pain medication.",
    "This phase 2 trial is testing the efficacy of ziprasidone and placebo in treating bipolar disorder and depression, with specific inclusion criteria for patients, including meeting DSM-IV criteria for a major depressive episode and presence of 2 or 3 DSM-IV manic criteria.",
    "This phase 2 trial will investigate the efficacy of different oral contraceptives, including 91-day and 28-day levonorgestrel and desogestrel, in premenopausal women with a regular menstrual cycle and a BMI between 18 and 30 kg/m\u00b2, who do not have a history of thromboembolic disease or genetic thrombophilia, and who meet other FDA-approved protocol criteria, for the treatment of hemostasis and as an oral contraceptive.",
    "The sample is a phase 2 trial for patients with stage IV renal cell carcinoma, testing the efficacy of recombinant interleukin-21 and sunitinib, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of abiraterone acetate, a drug used to treat castration-resistant prostate cancer, in patients who have previously been treated with ketoconazole and have evidence of progression, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of 0.25% ar-12286 / 0.004% travoprost and 0.5% ar-12286, 0.004% travoprost in treating open angle glaucoma and ocular hypertension, with eligibility criteria including unmedicated IOP \u2265 24 mm Hg and corrected visual acuity in each eye +1.0 logMAR or better by ETDRS.",
    "This phase 2 trial is testing the efficacy of alemtuzumab, a drug used to treat chronic lymphocytic leukemia, in patients who have not responded to previous treatments or have a specific genetic mutation, and meet certain eligibility criteria.",
    "The sample is a phase 2 trial for patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, testing the efficacy of asparaginase erwinia chrysanthemi for those with a hypersensitivity reaction to other asparaginase treatments, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug everolimus on patients with advanced kidney cancer who meet specific eligibility criteria, including having clear cell, papillary or chromophobe histology and being deemed surgical candidates for cytoreductive nephrectomy, while excluding patients with certain medical conditions or prior systemic anticancer therapies.",
    "The sample is a phase 2 trial for chronic moderate to severe plaque psoriasis, testing the efficacy of tofacitinib and placebo drugs, with inclusion and exclusion criteria for eligible participants.",
    "The sample is a phase 2 trial for diabetes mellitus type 2, testing the efficacy of ranolazine and placebo, with inclusion criteria including stable non-insulin antidiabetic therapy, BMI between 25-40 kg/m^2, and HbA1c between 7-11%.",
    "This phase 2 trial is testing the efficacy of celecoxib in preventing recurrent or second primary tumors in patients with a prior history of a definitively treated stage I/II head and neck or non-small cell cancer who are current or former smokers, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of AMG 151 and metformin in treating type 2 diabetes mellitus in patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of cabazitaxel in treating metastatic or recurrent head and neck cancer patients who have progressed after receiving cisplatin, cetuximab, and taxanes, and meet certain eligibility criteria.",
    "The sample is a phase 2/phase 3 trial for dry eye using carboxymethylcellulose sodium and glycerin as the drug, with inclusion criteria of mild, moderate, or severe dry eye symptoms and current eye drop use, and exclusion criteria of none, with a list of icd-10 codes for dry eye included.",
    "This is a phase 2 clinical trial for previously untreated chronic lymphocytic leukemia patients, testing the efficacy of ABT-263 and rituximab, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug neu-p11 for the treatment of primary insomnia, with eligibility criteria including reported subjective sleep latency and WASO, and exclusion criteria including use of benzodiazepines or other hypnotics in the preceding two weeks.",
    "The sample is a phase 2 trial for the drug z-338 in patients with functional dyspepsia, with inclusion criteria based on Rome II criteria and moderate gastrointestinal symptoms.",
    "The sample is a phase 2 clinical trial for patients with hepatocellular carcinoma, testing the efficacy of oxaliplatin, fluorouracil, and leucovorin as palliative systemic chemotherapy, with specific inclusion and exclusion criteria for patient eligibility.",
    "The sample is a phase 2 trial for patients with non ST-elevation myocardial infarction, testing the drugs ro4905417 and placebo, with eligibility criteria including age, BMI, and contraception use, and exclusion criteria including recent PCI or thrombolytic therapy, bleeding disorders, and uncontrolled diabetes.",
    "This phase 2 trial is testing the effectiveness of sildenafil citrate in treating subarachnoid hemorrhage, cerebral vasospasm, and rupture of intracranial aneurysm, with inclusion criteria including confirmation of hemorrhage and aneurysm, surgery within 72 hours, and signed consent form, and exclusion criteria including previous cardiac ischemic disease, pregnancy, and hypersensitivity to sildenafil.",
    "The sample is a phase 2 trial for sarcoma patients with high-risk disease, using ifosfamide as the drug, and with specific eligibility criteria including measurable disease, refractory to standard therapies, and normal blood counts and kidney function.",
    "This phase 2 trial is testing the efficacy of carmoterol and salmeterol, along with a placebo, in treating chronic obstructive pulmonary disease (COPD) in patients who meet specific inclusion criteria and do not have any exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cnto 136, a drug, in treating rheumatoid arthritis in patients who have had an inadequate response to methotrexate, and have specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for advanced epithelial ovarian cancer and primary peritoneal cancer, testing the drug iniparib, with inclusion criteria including previous platinum/taxane therapy and confirmed BRCA1 or BRCA2 status, and exclusion criteria including active viral infection and persistent grade 2 or greater toxicities from prior therapy.",
    "The sample is a phase 2 trial for chronic hepatitis C, testing the efficacy of telaprevir, peg-ifn-alfa-2a, peg-ifn-alfa-2b, ribavirin (rbv) tablet, and ribavirin (rbv) capsule, with inclusion criteria including never being treated for HCV infection and having a certain level of HCV RNA in the blood.",
    "The sample is a phase 2 trial for chronic hepatitis C infection, testing the efficacy of abt-450, abt-333, ribavirin, and ritonavir, with eligibility criteria including treatment-naive or partial responders to previous treatment, BMI between 18-35 kg/m^2, and exclusion criteria including cirrhosis or extensive bridging fibrosis, history of cardiac disease, and positive screen for certain drugs or alcohol.",
    "This phase 2 trial is testing the drug Sutent on patients with hepatocellular carcinoma and fibrolamellar hepatocellular carcinoma who meet specific eligibility criteria, while excluding those with certain medical conditions or who are on other clinical trials.",
    "This phase 2 trial is testing the efficacy of fostamatinib disodium and placebo in treating rheumatoid arthritis patients who have failed biologic therapy, and have been stable on certain medications for at least 30 days prior to Day 1 dosing.",
    "This phase 2 trial is testing the efficacy of docetaxel and azd6244 versus docetaxel and placebo in patients with unresectable stage 3 or 4 melanoma, with inclusion criteria including evidence of wt BRAF status and at least one measurable lesion, and exclusion criteria including prior treatment with EGFR, ras, raf or MEK inhibitors.",
    "This is a phase 2 clinical trial for participants with primary hypercholesterolemia, testing the efficacy of alirocumab and atorvastatin in reducing LDL-C levels, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for diabetic nephropathies, testing pf-00489791 and placebo drugs, with inclusion criteria based on eGFR and UACR levels, and exclusion criteria including poorly controlled diabetes and combination ACE inhibitor/ARB therapy.",
    "This phase 2 trial is testing the efficacy of nitazoxanide, placebo, and ribavirin in treating chronic hepatitis C patients who failed to respond to previous treatment, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of paclitaxel in combination with Trastuzumab for HER-2 positive breast cancer patients who are eligible for adjuvant chemotherapy, and meet specific inclusion criteria.",
    "The sample is a phase 2 trial testing the drug azd2281 on patients with ovarian carcinoma and breast cancer who meet specific eligibility criteria, including being BRCA positive and having a performance status of no more than 2.",
    "This phase 2 trial aims to test the efficacy of strontium chloride hexahydrate and placebo in reducing moderate-to-severe pain in patients with lower limb amputation stumps, who meet the inclusion criteria and do not meet any of the exclusion criteria.",
    "This phase 2 trial is testing the efficacy of Procrit and placebo in treating anemia in trauma patients with specific inclusion and exclusion criteria, including a hemoglobin level of <=12g/dL and an expected ICU stay of >=2 days.",
    "This phase 2 trial is testing the efficacy of nab paclitaxel, cyclophosphamide, and trastuzumab in treating HER2/neu positive or negative breast cancer patients who have undergone definitive surgical treatment and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of abt-869, bevacizumab, oxaliplatin, folinic acid, and fluorouracil in treating advanced colorectal cancer and adenocarcinoma of the colon and rectum, with eligibility criteria including prior chemotherapy and measurable disease by RECIST criteria.",
    "The sample is a phase 2 trial for chronic low back pain, testing the efficacy of naproxen, placebo, and pf-04383119 (rn624) in patients with specific inclusion and exclusion criteria, including a minimum score for low back pain intensity and no history of certain diseases or conditions.",
    "This phase 2 trial is testing the efficacy of JNJ-39758979 and placebo in treating atopic dermatitis in patients with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with stage IV malignant melanoma with measurable and unresectable disease limited to the central nervous system, testing the efficacy of temozolomide, with eligibility criteria including age, performance status, hematopoietic, hepatic, renal, and other factors.",
    "The sample is a phase 2/phase 3 trial for patients with type 2 diabetes and dyslipidemia, testing the efficacy of fenofibrate, metformin, and placebo, with inclusion criteria being patients with type 2 diabetes mellitus and dyslipidemia, and exclusion criteria being type 1 diabetes.",
    "The sample is a phase 2 trial for esophageal cancer, testing the efficacy of cisplatin, fluorouracil, hydroxyurea, and leucovorin calcium, with eligibility criteria including histologically or cytologically proven stage I-III squamous cell carcinoma or adenocarcinoma of the esophagus and gastro-esophageal junction, and no serious chronic medical illness or prior malignancy within the past 5 years.",
    "This phase 2 trial is testing the efficacy of trabectedin in treating malignant mesothelioma, with eligibility criteria including confirmed diagnosis, measurable lesions, and specific patient characteristics, while excluding prior chemotherapy and concurrent treatment for other neoplastic disease.",
    "This phase 2 trial is testing the drug fg-4592 on patients with chronic kidney disease and anemia, with inclusion criteria including age, weight, and disease status, and exclusion criteria including prior treatment with fg-4592 or any hypoxia-inducible factor prolyl hydroxylase inhibitor.",
    "This phase 2 trial is testing the efficacy of paclitaxel and paclitaxel loaded polymeric micelle in treating non small cell lung cancer patients who meet certain eligibility criteria, including having no previous palliative chemotherapy and adequate hematologic, hepatic, and renal function.",
    "This phase 2 trial is testing the efficacy of bendamustine and rituximab in treating previously untreated, histologically confirmed diffuse large B-cell lymphoma in patients over 65 years old with measurable disease and an ECOG performance status of 0-3, who are poor candidates for CHOP-R chemotherapy.",
    "This phase 2 trial is testing the efficacy of vibegron and tolterodine er, along with their placebos, in treating overactive bladder in participants who meet specific inclusion criteria and do not have any exclusion criteria.",
    "The sample is a phase 2/phase 3 trial for Huntington disease, testing the efficacy of minocycline and matching placebo as a treatment option, with inclusion criteria including age, clinical features of HD, and confirmatory family history or genetic confirmation, and exclusion criteria including hypersensitivity or intolerability to minocycline, vestibular disease, and underlying hematologic, hepatic or renal disease.",
    "This phase 2 trial is testing the efficacy of paclitaxel, carboplatin, and everolimus in treating metastatic melanoma patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of ro5024048, danoprevir, peginterferon alfa-2a, ribavirin, and ritonavir in treating chronic hepatitis C with genotype 1 or 4, and confirmed cirrhosis in patients who are 18 to 65 years old, treatment-na\u00efve or prior null responder to treatment with approved doses of pegylated interferon plus ribavirin, and have compensated cirrhosis.",
    "This phase 2 trial is testing the drug Nexavar (sorafenib) on patients with breast cancer who meet specific eligibility criteria, including having a tumor size of at least 2 cm and normal cardiac function, while excluding patients with prior chemotherapy or radiation therapy for breast cancer, pre-existing motor or sensory neuropathy of a severity >= grade 2 by NCI criteria, and other serious illnesses or medical conditions.",
    "This phase 2 trial is testing the efficacy of docetaxel and cisplatin in treating unresectable esophageal cancer patients who meet specific staging and patient criteria.",
    "This phase 2 trial is testing the efficacy of cisplatin, docetaxel, and etoposide in treating non-small cell lung cancer patients who meet specific eligibility criteria, including having no brain metastases and being a candidate for potential future pulmonary resection.",
    "This phase 2 trial is testing the drug nc-503 (eprodisate disodium) on patients with type 2 diabetes mellitus and metabolic syndrome x, who are treated with metformin or sulfonylurea agents, and have specific eligibility criteria, including central obesity and reduced HDL cholesterol, while excluding patients with insulin or thiazolidinediones treatment, significant heart disease or stroke, and other conditions.",
    "This phase 2 trial is testing the efficacy of various drugs, including olodaterol and formoterol, on patients with asthma who meet specific inclusion criteria, such as having a history of asthma and taking inhaled corticosteroids for at least 12 weeks prior to screening.",
    "This phase 2 trial is testing the effectiveness of abiraterone acetate and prednisone in treating prostate neoplasms with specific eligibility criteria, including ongoing gonadal androgen deprivation therapy and presence of metastatic bone disease.",
    "The sample is a phase 2 trial testing the efficacy of bisoprolol and placebo in treating symptomatic NYHA II or III chronic heart failure with left ventricular systolic dysfunction and moderate or severe chronic obstructive pulmonary disease, with or without significant reversibility, and the eligibility criteria includes beta-blocker contraindications, recent coronary percutaneous intervention or coronary artery bypass graft surgery, and serious concurrent systemic disease, among others.",
    "The sample is a phase 2 trial for non-Hodgkin's lymphoma patients with specific inclusion and exclusion criteria, testing the effectiveness of GM-CSF, CHOP, and rituximab drugs, with a list of diseases and corresponding ICD-10 codes.",
    "The sample is a phase 2 trial testing the drug temsirolimus on patients with various stages of pancreatic cancer, with eligibility criteria including confirmed diagnosis, radiographic evidence of disease, and specific health parameters.",
    "This phase 2 trial is testing the efficacy of pemetrexed and bevacizumab in treating metastatic or locally recurrent squamous cell carcinoma of the head and neck, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 clinical trial is testing the effectiveness of bevacizumab, docetaxel, and trastuzumab in treating HER2/neu positive metastatic breast cancer patients who have not received prior chemotherapy for metastatic breast cancer, and have a life expectancy of at least 24 weeks. The eligibility criteria and exclusion criteria are also provided.",
    "This phase 2 trial is testing the drug Velcade\u2122 for patients with relapsed or progressive multiple myeloma, with eligibility criteria including measurable disease and adequate organ function.",
    "This phase 2 trial is testing the efficacy of tivozanib, bevacizumab, and mfolfox6 in treating metastatic colorectal cancer, with specific eligibility and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of apremilast, a drug, in treating plaque-type psoriasis in patients who are unresponsive to standard systemic therapy or cannot receive it, and have a Static Physician Global Assessment (sPGA) score of at least 3 and a Body surface area (BSA) \u2265 10%.",
    "The sample is a phase 2 trial for ADHD, testing the drugs abt-089 and placebo, with inclusion criteria including meeting diagnostic criteria for ADHD and being generally in good health, and exclusion criteria including a history of significant allergic reaction to any drug and requiring ongoing treatment with any psychiatric medication.",
    "This is a phase 2 trial testing the efficacy of various doses of gen and pregabalin in treating diabetic peripheral neuropathy, with specific inclusion and exclusion criteria, and a list of prohibited medications and medical conditions.",
    "The sample is a phase 2/3 trial for esophageal cancer, testing the efficacy of capecitabine and cisplatin in patients with localized, nonmetastatic disease who are not suitable for surgery, and have met specific eligibility criteria.",
    "The sample is a phase 2 trial for patients with recurrent, stage III, or stage IV melanoma, testing the drug tanespimycin, with eligibility criteria including measurable disease, performance status, and no prior serious allergic reactions to similar compounds.",
    "The sample is a phase 2 trial for opioid-induced constipation (OIC) testing the efficacy of placebo and NKTR-118 drugs, with inclusion criteria including stable opioid regimen and documented OIC, and exclusion criteria including active substance abuse and specific medical disorders.",
    "This phase 2 trial is testing the efficacy of setipiprant and placebo in treating asthma patients with specific inclusion and exclusion criteria, including a pre-bronchodilator FEV1 of less than or equal to 85% of predicted normal value and an ACQ score of greater than or equal to 1.5.",
    "The sample is a phase 2 trial for multiple sclerosis testing the efficacy of placebo and bms 188667 (abatacept) drugs, with inclusion criteria of relapsing-remitting MS and at least 1 MRI lesion, and exclusion criteria of progressive MS and current or previous treatment with an approved MS drug.",
    "This is a phase 2 trial for gastroparesis using GSK962040 and placebo, with inclusion criteria including Type I or II Diabetes Mellitus, gastroparesis, and relevant symptoms, and exclusion criteria including acute severe gastroenteritis, gastric pacemaker, and regular opiate use.",
    "This phase 2 trial is testing the efficacy of g-csf plus plerixafor in autologous transplantation for patients with non-Hodgkin's lymphoma or multiple myeloma, with specific eligibility criteria including prior chemotherapy regimens, blood counts, organ function, and exclusion criteria such as brain metastases or previous experimental therapy.",
    "The sample is a phase 2/phase 3 trial for pancreatic cancer using a combination of fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin, with eligibility criteria including confirmed adenocarcinoma of the pancreas, measurable disease, and specific patient characteristics.",
    "The sample is a phase 2 trial for patients with non-small cell lung cancer who underwent prior surgical resection and are eligible for cisplatin-based adjuvant chemotherapy, testing the efficacy of cisplatin and docetaxel as drugs, with eligibility criteria including performance status, blood counts, liver function, and no prior chemotherapy or radiation therapy.",
    "This phase 2 trial is testing the efficacy of desvenlafaxine succinate sustained-release tablets (dvs sr) in treating major depressive disorder in children between 7 and 17 years old, with specific inclusion and exclusion criteria based on medical history and symptoms.",
    "This phase 2 trial is testing the efficacy of gsk1120212 and docetaxel in treating non-small cell lung cancer patients with a positive mutational status for the KRAS, NRAS, BRAF, or MEK1 gene who have progressed after receiving one prior approved platinum-containing chemotherapy regimen, and meet other eligibility criteria.",
    "This phase 2 trial is testing the effectiveness of various forms of Clenil Modulite in treating asthma in patients aged 18-65 who meet specific inclusion criteria, while excluding those with certain medical histories or who have taken certain medications within a certain timeframe.",
    "This phase 2 trial is testing the efficacy of multiple drugs, including bicalutamide and paclitaxel, in treating high-risk adenocarcinoma of the prostate, with eligibility criteria including clinical stage D2 disease and no evidence of untreated spinal cord compression.",
    "This is a phase 2 trial for ulcerative colitis testing the efficacy of krp203 and placebo matching krp203 in patients who have inadequately responded or are intolerant to 5-ASA therapy, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of 90y ibritumomab tiuxetan and rituximab in treating CD20+ve follicular lymphoma patients with specific eligibility criteria, including nodal mass, B symptoms, and elevated serum LDH or beta2-microglobulin.",
    "The sample is a phase 2 clinical trial for post-menopausal women with breast adenocarcinoma and positive hormone receptor, testing the efficacy of ave1642 and fulvestrant drugs, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of cariprazine and placebo in treating moderate to severe major depressive disorder in patients who have had an inadequate response to antidepressant therapy, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for smoking cessation using nicotine as the drug, with specific eligibility criteria and exclusion criteria, and the icd-10 codes for the disease are provided.",
    "This phase 2 trial is testing the efficacy of rituximab, carmustine, etoposide, filgrastim, anti-thymocyte globulin, cyclosporine, mycophenolate mofetil, cyclophosphamide, acetaminophen, diphenhydramine, hydrocortisone, and methylprednisolone in treating relapsed or non-remission diffuse large B-cell lymphoma patients with matched donors available.",
    "The sample is a phase 2 trial for lymphoma patients suitable for an autologous PBPC transplant, testing the efficacy of pegfilgrastim 12 mg, filgrastim, and pegfilgrastim 6 mg, with eligibility criteria including no previous bone marrow or PBPC transplant.",
    "The sample is a phase 2 trial for non-Hodgkin's lymphoma patients who have undergone autologous stem cell transplant and meet specific eligibility criteria, with the drugs rituximab and aldesleukin being used, and exclusion criteria including active infections and previous solid organ transplant.",
    "This phase 2 trial is testing the efficacy of gi262570, a PPARg agonist, in treating cirrhosis of the liver in patients who have failed previous interferon/ribavirin treatment, with eligibility criteria including age between 40 and 70 years, positive serology for HCV antibody, and Ishak fibrosis score of 2, 3 or 4.",
    "This phase 2 trial is testing the efficacy of gemcitabine and TH-302 in treating locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma, with eligibility criteria including measurable disease, ECOG performance status of 0 or 1, and acceptable liver and renal function.",
    "This sample is a phase 2 trial testing the efficacy of febuxostat and placebo in patients with renal impairment and a history of gout, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug px-12 for patients with advanced pancreatic cancer who have progressed on gemcitabine or a gemcitabine-containing combination, and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of arsenic trioxide in treating refractory testicular or extragonadal germ cell cancer, with specific eligibility criteria for patients, including measurable disease and normal organ function.",
    "This phase 2 trial will test the efficacy of irinotecan, cisplatin, floxuridine, and capecitabine in treating untreated patients with histologically documented gastric/GEJ adenocarcinoma, clinical American Joint Committee on Cancer (AJCC) stage grouping IB-IV (Mo) by CT scan and laparoscopy/endoscopic ultrasound, who meet certain eligibility criteria.",
    "The sample is a phase 2 trial for males with type 2 diabetes and hypogonadism, testing the effectiveness of androgel (testosterone gel), with inclusion and exclusion criteria listed.",
    "This is a phase 2 trial for patients with metastatic breast adenocarcinoma who have developed acquired resistance to letrozole, and the trial will test the efficacy of bibw 2992 and letrozole as drugs. The eligibility criteria include a confirmed diagnosis of breast adenocarcinoma, documented menopause, and disease progression within 6 weeks prior to trial entry. The exclusion criteria include premenopausal patients, rapidly progressive disease in major organs, and previous treatment with an EGFR and/or HER-2 inhibiting drug.",
    "The sample is a phase 2 trial for Alzheimer's disease using simvastatin and placebo as drugs, with inclusion criteria of age 35 to 69 and a parent with Alzheimer's disease, and exclusion criteria including current use of cholesterol-lowering medication and history of dementia.",
    "This phase 2 trial is testing the drug panobinostat on patients with myelodysplastic syndromes who have failed hypomethylating therapy, and have up to 30% blasts, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of int131 besylate and pioglitazone hcl, along with a placebo, in treating type 2 diabetes mellitus patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of at-101 and docetaxel versus placebo and docetaxel in treating non-small cell lung cancer patients who have progressed after one prior systemic chemotherapeutic regimen, and have measurable disease, with specific inclusion and exclusion criteria.",
    "This sample is a phase 2 trial for chemotherapy-induced nausea and vomiting, using carbamazepine as a drug, with inclusion criteria of patients over 18 years old starting moderate or highly emetogenic chemotherapy and signing the informed consent form, and exclusion criteria of previous chemotherapy, low emetogenic antiemetic potential, and disagreement with signing the consent form.",
    "This phase 2 trial is testing the drug arbaclofen on individuals with Autism Spectrum Disorders, with inclusion criteria including stable pharmacological treatment and continuous non-pharmacologic interventions, and exclusion criteria including any condition that might interfere with the study or endanger the subject's well-being.",
    "This phase 2 trial is testing the effectiveness of AMG 827, a biologic therapy, on psoriatic arthritis patients who meet specific inclusion criteria and do not have any exclusion criteria.",
    "This phase 2 trial is testing the efficacy of rituximab in patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who have measurable or assessable disease and have received prior therapies, with specific eligibility criteria outlined.",
    "The sample is a phase 2 trial testing the drug TG-0054 in patients with multiple myeloma, non-hodgkin's lymphoma, or hodgkin's disease who are potential candidates for autologous stem cell transplantation, with specific eligibility criteria including recent chemotherapy treatment, certain laboratory values, and contraception requirements.",
    "This is a phase 2 trial for patients with unresectable/metastatic renal cell carcinoma, testing the efficacy of sorafenib escalated dose and sorafenib standard dose, with eligibility criteria including age, diagnosis, performance status, and adequate bone marrow, liver, and renal function.",
    "This phase 2 trial is testing the efficacy of mim-d3 ophthalmic solution and placebo ophthalmic solution in treating dry eye, with eligibility criteria including a reported history of dry eye and a history of use or desire to use eye drops for dry eye.",
    "This phase 2 trial is testing the effectiveness of budesonide, a corticosteroid, in treating asthma in patients who have been treated with inhaled and oral corticosteroids for at least 3 months, and have a documented increase in FEV1 after using inhaled Salbutamol, with specific inclusion and exclusion criteria.",
    "This phase 2 trial will test the efficacy of celecoxib and placebo in reducing oral mucositis in patients receiving at least 5000 cGy radiation therapy to at least 2 of 14 pre-defined areas in the oral cavity, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of 7-hydroxystaurosporine and topotecan hydrochloride in treating patients with fallopian tube cancer, ovarian cancer, or primary peritoneal cavity cancer, who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of carboplatin, gemcitabine hydrochloride, and thalidomide in treating non-small cell lung cancer patients with specific eligibility criteria, including measurable disease and Karnofsky performance status of 70-100%.",
    "The sample is a phase 2 trial for epilepsy patients using lacosamide as a drug, with inclusion criteria being completion of a previous study and expected benefit from participation, and exclusion criteria being withdrawal from the previous study or experiencing a serious adverse event.",
    "The sample is a phase 2 trial for patients with chronic obstructive pulmonary disease, testing the efficacy of bea 2180 br and tiotropium, with eligibility criteria including age, smoking history, and lung function measurements, while excluding patients with other significant diseases, asthma, or allergic rhinitis.",
    "The sample is a phase 2 trial for glioblastoma multiforme, testing the efficacy of bevacizumab and metronomic temozolomide, with inclusion criteria including confirmed diagnosis, KPS score, and measurable primary CNS neoplasm, and exclusion criteria including inadequate hypertension control and progression to metronomic temozolomide.",
    "This phase 2 trial will test the efficacy of escitalopram and placebo in treating major depressive disorder and chronic hepatitis C in patients who are initiating treatment with peginterferon alfa2a + ribavirin, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing reduced-intensity hematopoietic cell transplantation in patients with poor-risk Langerhans cell histiocytosis who have progressive disease after standard therapies, and require HLA-matched related or unrelated donor or unrelated umbilical cord blood, with the use of fludarabine phosphate and melphalan as drugs.",
    "The sample is a phase 2 trial for metastatic colorectal cancer patients receiving FOLFOX or FOLFIRI chemotherapy regimens, testing the efficacy of aprepitant, dexamethasone, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, and palonosetron hydrochloride in preventing emesis, with eligibility criteria including ECOG performance status 0-2, life expectancy > 4 months, and various blood count and liver function requirements.",
    "The sample is a phase 2 trial testing the efficacy of gft505 80mg and placebo in treating insulin resistance and abdominal obesity in patients with specific inclusion and exclusion criteria, including waist circumference, BMI, HOMA-IR, blood pressure, diabetes, bariatric surgery, lipid-decreasing medication, and plasma triglycerides and LDL-c concentrations.",
    "This is a phase 2 trial for patients with chronic myelogenous leukemia, testing the drug danusertib for those who have relapsed after prior imatinib mesylate or c-ABL therapy and have certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of doxorubicin hydrochloride and sunitinib malate in treating hepatocellular carcinoma in patients who meet specific eligibility criteria, including having measurable disease by CT scan or MRI and meeting certain patient characteristics such as having Child-Pugh class A or B cirrhosis and no active congestive heart failure.",
    "This phase 2 trial is testing the efficacy of zd6474 and docetaxel in treating squamous cell carcinoma of head and neck, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of sunitinib malate in treating refractory or relapsed extragonadal germ cell tumor, ovarian cancer, teratoma, and testicular germ cell tumor patients who have measurable disease and meet specific eligibility criteria.",
    "This is a phase 2 trial for patients with recurrent glioblastoma, testing the drug panobinostat, with eligibility criteria including age, disease confirmation, surgical candidacy, and various health parameters.",
    "This is a phase 2 trial for patients with locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, testing the efficacy of edotecarin as a treatment option, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of non-pegylated liposomal doxorubicin and docetaxel in treating metastatic or locally advanced metastatic HER2/neu negative breast cancer, with specific eligibility criteria for patients, including normal LVEF and hematological, hepatic, and renal parameters.",
    "This phase 2 trial is testing the efficacy of lidocaine 5% medicated plaster and placebo topical plaster in treating moderate to severe chronic daily postoperative neuropathic pain in patients with allodynia or dysesthesia, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of Xoma 052 and placebo in treating type 2 diabetes mellitus patients who have been on a stable regimen of metformin monotherapy for at least 12 weeks prior to Day 0, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for Hodgkin's disease patients using rituximab, adriamycin, bleomycin, vinblastine, and dacarbazine (dtic) as drugs, with inclusion criteria including measurable disease, adequate bone marrow reserve, and LVEF >/= 50%, and exclusion criteria including HIV positive and prior chemotherapy.",
    "This phase 2 trial is testing the efficacy of ibritumomab tiuxetan (zevalin) + rituximab in treating non-hodgkin's lymphoma patients who meet specific criteria, including having no prior chemotherapy, radiotherapy or immunotherapy for lymphoma, and meeting FLIPI criteria for intermediate or high risk.",
    "This phase 2 trial is testing the efficacy of carboplatin in treating non-small cell lung cancer patients with specific eligibility criteria, including measurable disease and ECOG performance status 0-1.",
    "This phase 2 trial is testing the efficacy of ulodesine versus placebo in treating gout, hyperuricemia, arthritis, and joint disease, with eligibility criteria including a documented diagnosis of gout and a baseline sUA \u2265 6.0 mg/dL after at least 2 weeks of treatment on a stable 300 mg dose of allopurinol.",
    "This phase 2 trial is testing the effectiveness of levalbuterol hfa mdi followed by racemic albuterol hfa mdi and racemic albuterol followed by levalbuterol hfa mdi in treating asthma, with eligibility criteria including a documented diagnosis of asthma for at least 6 months and exclusion criteria including a history of hospitalization for asthma within 4 weeks prior to study start.",
    "This phase 2 trial is testing the efficacy of ketoprofen, an NSAID, in treating moderate pain in patients with osteoarthritis of both knees who have used an oral NSAID on at least three days per week for the last three months, and have x-ray evidence of osteoarthritis in the most involved knee during the last six months.",
    "This phase 2 trial is testing the efficacy of pazopanib eye drops in treating macular degeneration, with specific inclusion and exclusion criteria for eligible subjects.",
    "This phase 2 trial is testing the efficacy of trastuzumab emtansine in treating HER2-positive breast cancer patients who have received anthracycline-based chemotherapy or similar treatment, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of alemtuzumab, a drug, in treating peripheral T-cell lymphoma, with specific inclusion and exclusion criteria for patients.",
    "This phase 2 trial will test the effectiveness of raltegravir-maraviroc in treating lipohypertrophy in HIV patients who have been on stable antiretroviral therapy for at least 5 years, have undetectable viral loads, and have never been treated with these drugs before.",
    "This phase 2 trial is testing the use of treosulfan in allogeneic transplantation for patients with myelodysplastic syndrome, with specific eligibility criteria including age, HLA-identity, and adequate contraception in female patients.",
    "This phase 2 trial is testing the efficacy of the drug rvx000222 and placebo in patients with coronary artery disease and dyslipidemia who are taking statin therapy, with inclusion and exclusion criteria outlined in the eligibility criteria section.",
    "This phase 2 trial is testing the effectiveness of tenofovir and abacavir, two drugs, in treating HIV infections in patients who meet certain eligibility criteria.",
    "The sample is a phase 2 trial for overactive bladder and urinary incontinence, using a placebo drug, with specific inclusion and exclusion criteria, and icd-10 codes provided for the diseases.",
    "This phase 2 trial is testing the drug sunitinib on patients with urothelial carcinoma and bladder cancer who have undergone neoadjuvant chemotherapy and radical cystectomy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus, testing the efficacy of pf-04937319 and sitagliptin drugs, with eligibility criteria including age between 18-55 yrs and exclusion criteria including type 1 diabetes and unacceptable clinical laboratory test results at screening.",
    "The sample is a phase 2 trial for chronic hepatitis C patients who failed previous treatment, testing the efficacy of drugs such as copegus, pegasys, ro5024048, and danoprevir, with inclusion criteria including age, genotype, and treatment history, and exclusion criteria including cirrhosis and co-infection with other viruses.",
    "This phase 2 trial is testing the efficacy of iti-007, risperidone, and placebo in treating acute exacerbation of psychosis in patients with schizophrenia who have a prior response to antipsychotic therapy, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cdx-011 and \"investigator's choice\" chemotherapy in treating locally advanced or metastatic breast cancer patients who have previously undergone at least two but no more than seven chemotherapy treatments, and whose tumors express GPNMB.",
    "This phase 2 trial is testing the efficacy of pazopanib hydrochloride in treating advanced, localized, and recurrent malignant mesothelioma, with strict eligibility criteria including no concurrent medications that act through the CYP450 system and no uncontrolled blood pressure.",
    "The sample is a phase 2 trial for asthma with the drug amg 853 and placebo, testing eligibility criteria for inclusion and exclusion, and the icd-10 codes for the disease include J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, and J45.40.",
    "This phase 2 trial is testing the efficacy of indacaterol and salmeterol, along with a placebo, on Japanese asthmatic patients with a list of specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for chronic hepatitis C, testing the efficacy of albuferon and ribavirin in patients with specific eligibility criteria, including HCV genotype 2 or 3 and compensated liver disease.",
    "The sample is a phase 2 clinical trial for relapsed or refractory small cell lung cancer using the drug gefitinib, with inclusion criteria including written informed consent, histologically confirmed SCLCr, and age over 18 with a life expectancy of more than 2 months, and exclusion criteria including clinically active interstitial lung disease and other co-existing malignancies diagnosed within the last 5 years.",
    "The sample is a phase 2 trial for metastatic or inoperable locally advanced colorectal cancer, testing the efficacy of capecitabine, oxaliplatin, and bevacizumab, with inclusion criteria of having at least one measurable target lesion and exclusion criteria of previous systemic therapy for advanced or metastatic disease or previous treatment with bevacizumab.",
    "The sample is a phase 2 trial for HIV patients with virologic failure, testing the efficacy of enfuvirtide and optimized background ARV therapy, with inclusion criteria including being Fuzeon-naive and exclusion criteria including coinfection with HIV-2, active opportunistic infection, cirrhosis, or severe renal disease.",
    "This is a phase 2 trial for idiopathic pulmonary arterial hypertension using gleevec as a drug, with eligibility criteria including age, disease diagnosis, functional classification, and pulmonary vascular resistance, and exclusion criteria including pre-existing lung disease, congenital heart disease, and pregnancy.",
    "This phase 2 trial is testing the drug E2007 on male and female patients with idiopathic Parkinson's disease who have completed a previous study, with a list of exclusion criteria including pregnancy, hepatic disease, and previous stereotactic surgery.",
    "The sample is a phase 2 trial testing the efficacy of pulmozyme and placebo in treating cystic fibrosis patients who have undergone sinus surgery, with inclusion criteria including clinical and laboratory diagnosis of cystic fibrosis, age greater than or equal to 5 years, and FEV1 greater than or equal to 40% predicted, and exclusion criteria including pregnancy and intolerance of orally inhaled Pulmozyme (dornase alfa).",
    "The sample is a phase 2 trial testing the efficacy of cisplatin, fluorouracil, and leucovorin calcium in treating adenocarcinoma of the gastroesophageal junction and gastric cancer, with eligibility criteria including confirmed histology, operability, and specific patient characteristics.",
    "The sample is a phase 2 trial for patients with polycythemia vera, testing the efficacy of dasatinib as a treatment option, with specific inclusion and exclusion criteria, and requirements for organ function and ability to take oral medication.",
    "This phase 2 trial is testing the efficacy of docetaxel and cisplatin in treating loco regionally advanced unresectable non-small-cell lung carcinoma, with specific eligibility criteria for patients to be included in the study.",
    "The sample is a phase 2 trial for rheumatoid arthritis testing the efficacy of ISIS CRP RX or placebo in patients with active RA, who are on stable doses of allowed RA medications and currently receiving at least 10 mg of methotrexate a week, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 clinical trial for patients with platinum-sensitive epithelial ovarian cancer, testing the efficacy of docetaxel and carboplatin as treatment options, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for pre-menopausal women with ER+ advanced breast cancer, testing the efficacy of goserelin acetate, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of romidepsin in treating cutaneous T-cell lymphoma, with specific eligibility criteria including prior failed therapies and certain cardiac and medical conditions being exclusion criteria.",
    "This phase 2 trial is testing the efficacy of denileukin diftitox, cyclophosphamide, doxorubicin, vincristine, and prednisone in treating peripheral T-cell lymphoma, with specific inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial is testing the efficacy of homoharringtonine and imatinib mesylate in treating Philadelphia chromosome positive chronic myelogenous leukemia patients who are refractory or resistant to prior imatinib mesylate therapy, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for the drug NBI-98854 in treating tardive dyskinesia, with inclusion and exclusion criteria listed, and the use of stable doses of antipsychotic medication required.",
    "This phase 2 trial is testing the efficacy of du-176b and enoxaparin sodium in preventing venous thromboembolism in patients undergoing unilateral total hip arthroplasty, with a list of diseases and icd-10 codes, and eligibility criteria including age and exclusion criteria such as risks of hemorrhage and thromboembolic risks.",
    "This phase 2 trial is testing the efficacy of allogeneic HSCT in patients with hematologic or oncologic diagnoses and related donors who are a two or more allele mismatch at the HLA-A, B, C, DR loci, using cyclophosphamide, tacrolimus, and mycophenolate mofetil as drugs, and with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of Tarceva (erlotinib) in treating biopsy-proven stage I/II non-small cell lung cancer patients who are candidates for surgical resection and meet the inclusion criteria, while excluding patients who had prior treatment with any EGFR inhibitor or chemotherapy or radiation for this disease, and those with other active cancers or gastro-intestinal abnormalities.",
    "This phase 2 trial is testing the efficacy of cetuximab and chemotherapy in treating esophageal carcinoma patients with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of thalidomide in treating chronic prostatitis and pelvic pain, with strict inclusion and exclusion criteria including the need for male subjects to comply with FDA-mandated contraceptive measures, and the exclusion of subjects with prior urologic surgeries or known malignancies in the last 2 years.",
    "The trial is a phase 2/phase 3 study testing the drug indacaterol maleate on patients with chronic obstructive pulmonary disease (COPD) and obstructive lung diseases, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for prostate cancer patients who have undergone radical prostatectomy, with inclusion criteria including low levels of circulating prostate cancer cells and exclusion criteria including prior treatment with ADT or bisphosphonate therapy, and the trial will test the efficacy of zoledronic acid and docetaxel.",
    "This phase 2 trial is testing the efficacy of omalizumab and placebo in treating allergic asthma, with specific inclusion and exclusion criteria, and a list of icd-10 codes associated with the disease.",
    "The sample is a phase 2 trial for Chinese female patients with metastatic breast cancer, using gemcitabine and paclitaxel as drugs, and with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of enzastaurin and placebo in treating lung cancer patients with brain metastases who have received whole brain radiotherapy, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of ykp3089 and placebo in treating treatment-resistant partial epilepsy in patients who have been on a stable dose of 1-3 AEDs for at least 12 weeks prior to randomization and have at least 3 simple partial with motor component, complex partial or secondarily generalized seizures per month with no consecutive 21 day seizure free period.",
    "This phase 2 trial is testing the effectiveness of erlotinib and bevacizumab in treating non-small cell lung cancer patients who meet specific eligibility criteria, including having no prior chemotherapy or hormonal therapy, and having measurable disease according to RECIST.",
    "The sample is a phase 2 clinical trial for type 2 diabetes mellitus, testing the efficacy of GSK256073 and sitagliptin as compared to placebo, with inclusion criteria including HbA1c levels between 7.0% and 9.5%, and exclusion criteria including renal impairment and history of myopathy.",
    "The sample is a phase 2 trial testing the efficacy of topical testosterone gel in treating aging, obesity, insulin resistance, and hypogonadism, with specific inclusion and exclusion criteria, and the use of icd-10 codes to identify diseases.",
    "This phase 2 trial will test the drug sr141716 (rimonabant) on healthy participants who drink alcohol, with strict eligibility criteria including normal vital signs, laboratory results, and dietary habits.",
    "This sample is a phase 2 trial for non-small cell lung cancer, testing the efficacy of pazopanib plus paclitaxel as a first-line therapy for patients with Stage IIIB/IV NSCLC who have not received prior systemic therapy, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of docetaxel and erlotinib hydrochloride in treating stage IV or recurrent adenocarcinoma of the breast, with eligibility criteria including measurable disease, stable brain metastases, and specific hematopoietic, hepatic, renal, and cardiovascular requirements.",
    "This is a phase 2/phase 3 trial for endometriosis using pioglitazone as a drug, with eligibility criteria including regular cycles, pelvic pain, and scheduled surgery for endometriosis diagnosis.",
    "This is a phase 2 trial for new-onset type 1 diabetes mellitus, testing the efficacy of antithymocyte globulin and placebo, with eligibility criteria including diagnosis of type 1 diabetes within 100 days of enrollment, positive autoantibodies, and prior EBV infection.",
    "The sample is a phase 2 trial for patients with moderate chronic obstructive pulmonary disease (COPD) and tests the efficacy of salmeterol, tiotropium, and gsk233705 drugs, with inclusion criteria including history of COPD and moderate COPD responsive to ipratropium and salbutamol, and exclusion criteria including no unstable COPD and max 1000 mcg inhaled steroids per day.",
    "The sample is a phase 2 trial for patients with chronic obstructive pulmonary disease, testing the efficacy of bea 2180 br and tiotropium, with eligibility criteria including age, smoking history, and lung function measurements, while excluding patients with other significant diseases, asthma, or allergic rhinitis.",
    "This phase 2 trial aims to test the efficacy of org 34517 and placebo in treating severe depressive episode with psychotic features, and the eligibility criteria includes having a DSM-IV diagnosis of depression and psychotic disorders, being on stable dose of usual treatment, and being willing to be hospitalized for at least 11 days.",
    "This is a phase 2 clinical trial for patients with multiple myeloma, testing the efficacy of bortezomib and dexamethasone as third-line therapy, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of GSK189075, a drug for type 2 diabetes, compared to placebo, in treatment-na\u00efve subjects with HbA1c \u22657.0% and \u22649.5%, and eligibility criteria including age, gender, and absence of certain diseases and medications.",
    "The sample is a phase 2/phase 3 trial for type 2 diabetes, testing the efficacy of rivoglitazone, pioglitazone, and placebo, with inclusion criteria of HbA1c between 7.5% and 10.5%, and exclusion criteria of insulin therapy and history of certain medications.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease (COPD) with inclusion criteria for patients with an established diagnosis of COPD who are being admitted to the hospital to treat an exacerbation, and exclusion criteria for certain diseases and medications, with drugs including open-label, placebo comparator, and odsh.",
    "This is a phase 2 clinical trial for idiopathic pulmonary fibrosis, testing the efficacy of pirfenidone and placebo, with inclusion criteria including diagnosis of IPF and certain pulmonary function tests, and exclusion criteria including use of certain medications and serious underlying diseases.",
    "This phase 2 trial is testing the efficacy of capecitabine and cetuximab in treating operable T3-T4NxM0 rectal cancer with specific eligibility criteria, including adequate bone marrow and hepatic function, and exclusion criteria such as former chemotherapy and general contraindications to the drugs.",
    "This phase 2 trial is testing the effectiveness of campath and fludarabine in treating chronic myelogenous leukemia patients who have demonstrated refractoriness/resistance to STI571, and have a human leukocyte antigen (HLA) matched sibling donor or an unrelated hematopoietic stem cell donor.",
    "The sample is a phase 2 trial for mild-to-moderate dry eye syndrome, testing the efficacy of pro-148 ophthalmic solution and active comparator: systane \u00ae ophthalmic solution, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the drug sagopilone for patients with small cell lung carcinoma who meet specific eligibility criteria.",
    "This phase 2 trial will test the effectiveness of valsartan and placebo in reducing intima-media thickness of the carotid artery in patients with carotid artery diseases and atherosclerosis, with specific inclusion and exclusion criteria for eligibility.",
    "The sample is a phase 2 trial for major depressive disorder (MDD) using the drug radafaxine, with inclusion criteria including a diagnosis of MDD and a current depressive episode lasting 12 weeks to 24 months, and exclusion criteria including previous non-response to antidepressant therapy and current substance abuse or pregnancy/lactation.",
    "This phase 2 trial is testing the drug ucn-01 on patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (ALCL) and mature T-cell lymphoma, with specific eligibility criteria including measurable disease, confirmed histology, and certain laboratory values.",
    "This phase 2 trial is testing the efficacy of folfox4 and cetuximab in treating metastatic colorectal cancer patients who are not suitable for curative-intent resection and have at least one measurable lesion, with eligibility criteria including a Karnofsky performance status of > 80, leucocytes \u2265 3.0 x 10 9/L, and neutrophils \u22651.5 x 10 9/L, among others.",
    "This phase 2 trial is testing the efficacy of capecitabine in treating pancreatic cancer patients who meet specific eligibility criteria, including having no prior therapy for pancreatic cancer and adequate organ function, while excluding pregnant or lactating women and those with comorbid conditions with a life expectancy of less than 6 months.",
    "This phase 2 trial is testing the efficacy of roflumilast and placebo in treating allergic asthma, with eligibility criteria including a documented allergy to a common aeroallergen and positive allergen-induced early and late airway bronchoconstriction.",
    "The sample is a phase 2 trial for patients with elevated risk, surgical stage II, stage IC, grade 2 or 3 adenocarcinoma of the endometrium, testing the efficacy of paclitaxel and carboplatin combination, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cisplatin, fluorouracil, paclitaxel, and gemcitabine in treating operable primary muscle invasive bladder cancer with specific eligibility criteria, including adequate functioning bladder and prior transurethral resection of the bladder tumor within the past 8 weeks.",
    "This phase 2 trial is testing the efficacy of allopurinol, fludarabine, cyclophosphamide, levetiracetam, and busulfan in treating acute myelogenous leukemia and refractory acute myelogenous leukemia in patients aged 2 to 45 years who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of 5-fluorouracil and oxaliplatin in treating esophageal and gastroesophageal cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2/phase 3 trial for previously untreated metastatic non-small cell lung cancer patients, testing the efficacy of chemotherapy +/- disulfiram, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for Huntington's disease and chorea, testing the efficacy of atomoxetine and matching placebo in improving attention in patients with mild HD, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of bexarotene and gemcitabine hydrochloride in treating cutaneous T-cell lymphoma (CTCL) in patients who have developed progressive disease after receiving or have been refractory to at least 1 course of prior standard, systemic, skin-directed therapy, and meet certain eligibility criteria.",
    "The sample is a phase 2/phase 3 trial for multiple sclerosis, testing the effectiveness of colecalciferol, with inclusion criteria of RRMS EDSS 0-5 and Betaferon use, and exclusion criteria including hypercalcaemia, kidney stones, and use of other IMD than interferon-beta.",
    "This phase 2 trial is testing the efficacy of GSK189075 and pioglitazone in treating type 2 diabetes mellitus in subjects who are treatment-na\u00efve or newly diagnosed, with specific inclusion and exclusion criteria.",
    "This phase 2 trial will test the drug vorinostat on patients with stage IV breast cancer, who have had prior chemotherapy and radiation therapy, and have measurable disease, with the aim of determining its efficacy and safety.",
    "This phase 2 trial is testing the drug tak-442 and placebo in patients with acute coronary syndrome who meet specific eligibility criteria, including having at least one additional ischemic risk factor, and excluding those with certain medical conditions or who have taken certain medications.",
    "This phase 2 trial is testing the efficacy of four drugs, including Org 36286 and Puregon, in treating infertility related to in vitro fertilization, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the efficacy of docetaxel and gemcitabine hydrochloride in treating advanced, persistent, or recurrent uterine leiomyosarcoma with specific eligibility criteria for patients.",
    "This phase 2 trial is testing the drug saracatinib on patients with metastatic melanoma, with specific eligibility criteria including measurable disease, no brain metastases, and normal blood counts and organ function.",
    "The sample is a phase 2 trial for patients with anaplastic thyroid cancer or recurrent thyroid cancer, testing the effectiveness of sorafenib tosylate as a treatment option, with eligibility criteria including measurable or evaluable disease, no brain metastases, and no prior sorafenib or other inhibitors of MAP kinase signaling intermediates.",
    "This phase 2 trial is testing the efficacy of sorafenib and tegafur/uracil in treating hepatocellular carcinoma, with specific eligibility criteria including age, ECOG PS, Child-Pugh score, and various laboratory values.",
    "This phase 2 trial will test the efficacy of NPS 1776 (800 mg and 400 mg) and placebo in treating migraine headaches in patients who meet specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for benign prostatic hyperplasia, testing the use of botulinum toxin type A and normal saline, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of avastin, temozolomide, and irinotecan in treating patients with glioblastoma, gliosarcoma, or brain tumor, with specific inclusion and exclusion criteria, and avastin-specific concerns.",
    "This phase 2 trial is testing the efficacy of ixabepilone, a chemotherapy drug, in treating HER-2 negative metastatic breast cancer in female patients who have previously undergone chemotherapy in the adjuvant or neo-adjuvant setting, with specific eligibility criteria and exclusion criteria.",
    "This is a phase 2 trial for the treatment of secondary hypogonadism in adult males using Androxal and Testim, with specific inclusion and exclusion criteria based on medical history and lab values.",
    "The sample is a phase 2 trial for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD) using the drugs ph-797804 and placebo, with inclusion criteria including age, smoking history, and prior treatment with a LABA/ICS combination.",
    "This phase 2 clinical trial is testing the efficacy of docetaxel in treating female patients with breast adenocarcinoma who have previously received a Taxotere-based chemotherapy regimen and meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug tnp-470 for locally advanced pancreatic cancer patients who have not received prior chemotherapy or irradiation, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of bortezomib, cyclophosphamide, doxorubicin hydrochloride, prednisone, and vincristine sulfate in treating newly diagnosed, previously untreated mantle cell lymphoma patients with stage III-IV or bulky stage II disease, who have confirmed positivity for CD19 (or CD20) and Cyclin D1 or evidence of t(11;14) translocation, and meet other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of docetaxel plus bavituximab or placebo in treating non-small-cell lung cancer patients who have progressed after 1 chemotherapy regimen and meet certain eligibility criteria.",
    "This phase 2 trial is testing carboplatin and paclitaxel with pelvic radiation therapy or radiation therapy for patients with uterine papillary serous carcinoma who meet specific eligibility criteria.",
    "This is a phase 2 clinical trial for Crohn's disease patients who underwent ileal or ileo-colonic resection, testing the efficacy of ciprofloxacin versus placebo in preventing recurrence of the disease, with inclusion and exclusion criteria specified.",
    "This phase 2 trial aims to test the efficacy of spd602 in treating transfusional iron overload in patients with beta-thalassemia and other anemias who require chronic treatment with deferoxamine, deferasirox, and/or deferiprone, and are willing to discontinue all existing iron chelation therapies throughout the study period.",
    "This phase 2 trial is testing the efficacy of rituximab and cytarabine in treating primary cerebral or oculocerebral non-Hodgkin lymphoma and diffuse large B-cell lymphomas with cerebral and/or neuromeningeal involvement, with specific inclusion and exclusion criteria.",
    "This is a phase 2 clinical trial for patients with relapsed and refractory multiple myeloma, testing the drug cc-5013, with eligibility criteria including measurable levels of myeloma paraprotein, ECOG performance status score, and exclusion criteria including prior use of CC-5013 and recent anti-myeloma drug therapy.",
    "This phase 2 trial is testing the efficacy of abt-450/r/abt-267, abt-333, and ribavirin in treating chronic hepatitis C infection in subjects who are treatment naive or have previous pegylated interferon/ribavirin treatment experience, and have specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for an investigational vaccine for HIV in healthy, HIV seronegative adults at high risk of acquiring HIV infection, with the comparator being placebo. The eligibility criteria includes exclusion of individuals with a history of immunodeficiency, malignancy, and contraindication to intramuscular injection, among others.",
    "This is a phase 2 trial for postherpetic neuralgia, testing the efficacy of gen (at different doses) and placebo, with specific inclusion and exclusion criteria, including hepatic and renal impairment, uncontrolled hypertension, and history of drug or alcohol abuse.",
    "The sample is a phase 2 trial for HIV-positive patients with anemia, testing the effectiveness of epoetin alfa, with inclusion criteria including stable antiretroviral regimen and hemoglobin level <12.0 g/dL, and exclusion criteria including HCV co-infection and uncontrolled or severe cardiovascular disease.",
    "The sample is a phase 2 trial for Parkinson's disease, testing preladenant and other Parkinson's disease treatments in participants over 30 years old who have a diagnosis of moderate to severe idiopathic Parkinson's disease and have been on a regimen of L-Dopa and/or a dopamine agonist, with exclusion criteria including drug-induced or atypical parkinsonism, cognitive impairment, or psychosis, and participants taking tolcapone or participating in any other clinical study.",
    "The sample is a phase 2 trial for patients with metastatic or inoperable locoregional head and neck cancer, testing the efficacy of irinotecan hydrochloride, with specific eligibility and exclusion criteria listed.",
    "The sample is a phase 2 trial for rheumatoid arthritis using abatacept as the drug, with inclusion criteria being completion of the short term portion of IM101-101.",
    "The sample is a phase 2 trial for kidney transplantation patients, testing the drugs aeb071, certican, and neoral, with inclusion and exclusion criteria listed, and icd-10 codes including N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, and N20.0.",
    "This is a phase 2 clinical trial for patients with B-cell chronic lymphocytic leukemia (CLL) who are refractory to or have relapsed after prior first-line therapy, and the drug being tested is fludarabine phosphate. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy.",
    "This phase 2 trial is testing the efficacy of ec17 (folate-fitc), interleukin-2, and interferon-alpha in treating relapsed or Stage IV renal cell carcinoma patients who have progressed after systemic therapy, and have measurable/evaluable metastatic disease sites that have not previously received radiotherapy and which does not require palliative intervention, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of istaroxime and placebo in treating heart failure patients with LV Ejection Fraction less or equal to 35%, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial will test the efficacy of vorapaxar, aspirin, and clopidogrel in reducing cardiac ischemia related chest discomfort in patients with atherosclerosis, myocardial ischemia, or myocardial infarction who meet specific inclusion criteria, while also excluding patients with certain conditions or taking certain medications.",
    "This phase 2 trial is testing the efficacy of sunitinib malate, an antiangiogenic agent, in treating patients with pancreatic adenocarcinoma who have evidence of disease progression following first-line therapy and have received gemcitabine-containing cytotoxic combination or chemoradiation therapy containing gemcitabine as prior therapy.",
    "This phase 2 trial is testing the efficacy of docetaxel, gemcitabine, and carboplatin in treating unresectable locally advanced non-small cell lung cancer patients who have not received previous therapy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for chronic pain, testing the efficacy of matrix transdermal fentanyl/chadd drug delivery system and placebo patch, with inclusion criteria of moderate to severe non-malignant chronic pain and opioid-tolerance, and exclusion criteria of active cancer, substance abuse disorder, and pregnancy/breastfeeding.",
    "This sample is a phase 2 trial for patients with prostate cancer, testing the drug triptorelin (decapeptyl\u00ae) for hormonal deprivation therapy, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the effectiveness of ip chemotherapy in treating epithelial ovarian cancer, with eligibility criteria including confirmed diagnosis, specific blood counts, and performance status, while exclusion criteria include history of other cancers or unapproved therapy.",
    "This phase 2 trial is testing the efficacy of docetaxel and LY2181308 in treating non-small cell lung cancer patients who have progressed after 1 line of chemotherapy, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of Alks 37 and placebo in managing opioid-induced constipation in patients receiving prescribed opioid medication for chronic non-cancer pain, with inclusion criteria including age, BMI, and meeting OIC criteria, and exclusion criteria including pregnancy, certain medical conditions, and recent participation in a clinical trial.",
    "This is a phase 2 trial for patients with migraine with aura, testing the efficacy of tonabersat and placebo, with inclusion and exclusion criteria including age, contraceptive use, medication history, and other medical conditions.",
    "This phase 2 trial is testing the drug WBI-1001 on patients with stable plaque psoriasis, with specific inclusion and exclusion criteria for eligibility.",
    "This phase 2 trial is testing the efficacy of various drugs, including fp mdpi and advair diskus, on patients with asthma who meet specific inclusion criteria and do not have any exclusion criteria.",
    "The sample is a phase 2 trial for transitional cell carcinoma, testing the efficacy of gemcitabine and cisplatin, with specific inclusion and exclusion criteria listed.",
    "This sample is a phase 2 trial testing the efficacy of two oral contraceptives, sh t04769g and ethinyl estradiol / dienogest (sh d00659 af), on healthy female volunteers aged 18-35 years with normal blood values and confirmation of ovulation during the cycle before treatment, who are willing to apply non-hormonal methods of contraception during the course of the study, and have no contraindications for the use of oral contraceptives. The study will test the safety and efficacy of the contraceptives on the participants.",
    "This phase 2 trial is testing the efficacy of s-1, irinotecan, and bevacizumab in treating patients with inoperable, locally advanced, or metastatic colorectal cancer who have not received previous treatment, with eligibility criteria including measurable disease, adequate organ function, and ability to take capsules orally.",
    "This phase 2 trial is testing the efficacy of tmc114 (darunavir) / ritonavir in treating HIV infections in patients with CD4+ cell count above 100 cells/\u00b5l, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for postmenopausal osteoporosis, testing the efficacy of PTH analog, placebo, and Forsteo, with inclusion criteria of healthy postmenopausal women with a diagnosis of osteoporosis and exclusion criteria of use of certain medications and medical conditions affecting calcium metabolism or bone metabolism.",
    "This phase 2 trial is testing the efficacy of dasatinib, a drug used to treat leukemia, in male or female patients over 55 years old with Philadelphia chromosome or BCR-ABL positive acute lymphoblastic leukemia who have not been previously treated, and have or do not have documented CNS involvement, with a set of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug triptorelin in combination with chemotherapy for early-stage, operable breast cancer in premenopausal women under 45 years old who have estrogen receptor (ER)- or progesterone receptor (PR)-positive tumors, and aims to evaluate its efficacy and safety in reducing the risk of premature ovarian failure.",
    "The sample is a phase 2 trial for insulin na\u00efve type 2 diabetes subjects, testing the efficacy of insulin degludec/insulin aspart, insulin glargine, and metformin, with inclusion criteria including HbA1c levels between 7.0-11.0% and BMI between 25.0-37.0 kg/m^2.",
    "This phase 2 trial is testing the effectiveness of simvastatin, a cholesterol-lowering drug, in treating Waldenstrom's macroglobulinemia, a type of lymphoma, with specific inclusion and exclusion criteria.",
    "This is a phase 2 clinical trial for patients with Huntington disease, testing the efficacy of PBT2 and placebo drugs, with inclusion criteria such as a CAG repeat number \u2265 36 and a MoCA score of \u2265 12, and exclusion criteria such as allergy to PBT2 or its excipients and other known primary neurodegenerative disorders associated with dementia.",
    "This phase 2 trial is testing the efficacy of bitopertin and olanzapine, along with a placebo, in treating acute exacerbation of schizophrenia in adult patients who meet certain inclusion criteria and do not meet any of the exclusion criteria.",
    "This phase 2 trial is testing the efficacy of erlotinib, 5-fluorouracil, leucovorin, and oxaliplatin in treating surgically unresectable or metastatic esophageal cancer patients who have not received prior chemotherapy, and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of sch 486757 and placebo dose 1 in treating chronic cough in male and female subjects with a history of dry cough for more than 6 months, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for locally advanced or metastatic breast cancer patients who have demonstrated resistance to anthracycline and have received at least two regimens of chemotherapy, testing the efficacy of capecitabine and docetaxel, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of cisplatin in treating cervical cancer patients with specific eligibility criteria, including FIGO Stage I to IVA and no evidence of metastatic disease outside of the pelvis, while excluding patients with poorly controlled diabetes mellitus and abnormal liver function tests.",
    "The sample is a phase 2 trial for hypertension and concurrent obesity, testing the drugs lcz696, amlodipine, and placebo, with inclusion criteria including mild to moderate essential hypertension and waist circumference \u2265 102 cm (men) and \u2265 88 cm (women), and exclusion criteria including severe hypertension, type 1 or type 2 diabetes mellitus, and concomitant use of anti-hypertensives or anti-diabetics.",
    "This phase 2 trial is testing the efficacy of ro5083945, cisplatin, gemcitabine, and pemetrexed in treating non-squamous non-small cell lung cancer patients with confirmed presence of EGFR in tumor tissue and adequate hematological, renal and liver function, while excluding patients with prior chemotherapy or treatment with another systemic anti-cancer agent, recent history of poorly controlled hypertension, and requirement for steroids > 40 mg prednisolone.",
    "This phase 2 trial is testing the drug ispinesib on patients with metastatic adenocarcinoma of the prostate who have received one prior taxane-containing chemotherapy regimen and have evidence of disease progression, with various eligibility criteria listed.",
    "The sample is a phase 2 trial for metastatic melanoma and skin neoplasms using the drug axitinib [ag-013736], with eligibility criteria including no more than 1 prior systemic therapy for metastatic disease and exclusion criteria including history of hemoptysis and brain metastases.",
    "This is a phase 2 trial for patients with gastrointestinal stromal tumors or soft tissue sarcomas, testing the drug azd2171 for those who are resistant or intolerant to imatinib mesylate or refractory to standard therapies, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug ORM-12741 and placebo for Alzheimer's disease patients who are between 55-90 years old, have a diagnosis of probable Alzheimer's disease, and are being treated with donepezil, rivastigmine or galantamine. The eligibility criteria includes a mini-mental state examination score of 12-21 and at least a mild level of behavioral symptoms.",
    "The sample is a phase 2 trial for non-small-cell lung cancer, testing the efficacy of pemetrexed and cisplatin, with eligibility criteria including locally advanced or metastatic disease and possibility of curative surgery.",
    "The sample is a phase 2 trial for patients with peritoneal, ovarian, or fallopian tube cancer, using the drug GW786034, with specific inclusion and exclusion criteria, and lists of diseases and icd-10 codes provided.",
    "The sample is a phase 2 trial for menopausal women with symptoms of estrogen and/or androgen deficiency, testing the effectiveness of two drugs, esterified estrogens 1.25 mg and methyltestosterone 2.5 mg and esterified estrogens 1.25 mg, with the inclusion criteria of non-hysterectomized women between the ages of 35 and 65 years.",
    "This is a phase 2 trial for patients with renal cell carcinoma, testing the efficacy of pazopanib and sunitinib, with eligibility criteria including no prior systemic therapy, measurable disease, and adequate organ function.",
    "The sample is a phase 2 trial for recurrent or metastatic soft tissue sarcoma using dolastatin 10 as the drug, with eligibility criteria including age, performance status, blood counts, liver and kidney function, and prior therapy history.",
    "This phase 2 trial is testing the combination of abi-007 (abraxane) and bevacizumab in patients with stage IV breast cancer and measurable disease, who are not candidates for Herceptin therapy, and meet other eligibility criteria.",
    "This phase 2 trial will test the efficacy of CK-2017357, a drug, in treating intermittent claudication and peripheral artery disease in patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of bevacizumab, irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin in treating patients with unresectable and measurable metastatic colorectal cancer, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for advanced non-small cell lung cancer, testing the drugs pf-00299804, with eligibility criteria including prior chemotherapy failure and availability of tissue for KRAS/EGFR testing.",
    "The sample is a phase 2 clinical trial for postmenopausal females with advanced or metastatic breast cancer, testing the efficacy of gefitinib and fulvestrant, with specific eligibility and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of naltrexone sr 32 mg/ bupropion sr 360 mg daily in treating major depression in subjects with a BMI greater or equal to 27 and less than or equal to 43kg/m2, with a list of inclusion and exclusion criteria, and icd-10 codes including F32.A, F53.0, P91.4, Z13.31, and Z13.32.",
    "This phase 2 trial is testing the effectiveness of bicillin l-a on chronic plaque type psoriasis that is unresponsive to topical treatments, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the efficacy of lapatinib, a tyrosine kinase inhibitor, in treating stage IV cutaneous melanoma patients with no more than two oncogenic somatic ERBB4 mutations, and who have not received chemotherapy, molecular therapy, radiation therapy, or biological therapy for at least 4 weeks prior to starting study medication.",
    "This phase 2 trial is testing the efficacy of lenalidomide in patients with relapsed or progressed chronic lymphocytic leukemia/small lymphocytic lymphoma or non-Hodgkin lymphoma who have undergone allogeneic hematopoietic cell transplantation, and have not responded to immunosuppressive medications, with a list of diseases and ICD-10 codes, and eligibility criteria including ANC, platelet count, creatinine clearance, bilirubin, AST, and ALT levels, and FCBP requirements.",
    "This phase 2 trial is testing the drug vorinostat on patients with cutaneous t-cell lymphoma, who meet specific eligibility criteria, and have not received any prior systemic therapies.",
    "This phase 2 clinical trial is testing the drug cp-4055 (elacyt) on patients with stage IV or unresectable stage III non-ocular malignant melanoma who have not undergone prior chemotherapy for the treatment of melanoma, and meet certain eligibility criteria.",
    "The sample is a phase 2 trial for renal transplantation patients, testing the effectiveness of Campath 1H\u00ae, rituximab, and mycophenolate mofetil, with inclusion criteria being renal transplant recipients and exclusion criteria being HLA-identical living-donor renal transplants, multi-organ transplant, and known hypersensitivity to the drugs.",
    "The sample is a phase 2 trial for chronic hepatitis C genotype 1 infection, testing the efficacy of drugs abt-450, abt-333, abt-267, ribavirin, and ritonavir, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the drug saracatinib on patients with extensive stage small cell lung cancer, lung metastases, malignant pleural effusion, or recurrent small cell lung cancer, who meet a set of eligibility criteria.",
    "The sample is a phase 2 trial for esophageal cancer patients with clinical stage II or III disease, using fluorouracil and oxaliplatin as drugs, and with eligibility criteria including performance status, hematopoietic, hepatic, renal, cardiovascular, and pulmonary conditions.",
    "The sample is a phase 2 trial for the drug ym178 and placebo in patients over 20 years suffering from overactive bladder, with exclusion criteria for pregnant and breastfeeding women and any clinically significant abnormal conditions, and the diseases and icd-10 codes are listed as 'urinary bladder, overactive' and \"['N32.81']\" respectively.",
    "This phase 2 trial is testing the efficacy of 5-fluorouracil, oxaliplatin, cetuximab, and docetaxel in treating newly diagnosed adenocarcinoma of the esophagus or gastroesophageal junction, with specific eligibility criteria for tumor stage, performance status, and other health factors.",
    "The sample is a phase 2 trial testing the drugs art-123 and placebo on patients with sepsis and disseminated intravascular coagulation, with eligibility criteria including infection or suspected infection resulting in sepsis and DIC, and exclusion criteria including renal failure and history of solid organ, bone marrow or stem cell transplantation.",
    "This phase 2 trial is testing a combination of drugs including cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, liposomal cytarabine, methotrexate, therapeutic hydrocortisone, and vincristine sulfate for the treatment of Burkitt's lymphoma and B-cell lymphoma unclassified, with specific eligibility criteria for disease risk, patient characteristics, and prior concurrent therapy.",
    "This phase 2 trial is testing the drug cediranib maleate in patients with various types of acute myeloid leukemia and myelodysplastic syndromes who have relapsed, are resistant to treatment, or are untreated and meet certain criteria.",
    "This phase 2 trial is testing the efficacy of gemcitabine and capecitabine in treating metastatic adenocarcinoma of the colon or rectum that has failed CPT-11 and oxaliplatin based therapies, with specific eligibility criteria for patients.",
    "This phase 2 trial is testing the drug entinostat for patients with relapsed or refractory Hodgkin's lymphoma who have measurable disease and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of temsirolimus, bevacizumab, sunitinib, and interferon alpha-2a in treating metastatic renal cell carcinoma, with eligibility criteria including no prior systemic treatment, normal blood and organ function, and absence of brain metastases.",
    "The sample is a phase 2 trial for patients with metastatic colorectal cancer who have failed therapy with irinotecan and fluoropyrimidine containing regimen, and will test the efficacy of vandetanib and folfox regimen in treating the disease, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for glucose intolerance, testing the efficacy of sitagliptin 25mg and 50mg, with eligibility criteria including impaired glucose tolerance and glycemic parameters, and exclusion criteria including history of diabetes mellitus and previous treatment with antihyperglycemic drugs.",
    "The sample is a phase 2 trial for hepatitis C patients, testing the drugs lcq908 and placebo, with inclusion criteria including no prior therapy or inadequate response to therapy, and exclusion criteria including use of other investigational drugs and women of child-bearing potential.",
    "This phase 2 trial is testing the efficacy of simvastatin, aspirin, and placebo in treating pulmonary arterial hypertension (PAH) in patients who meet specific inclusion criteria, while excluding those with certain conditions or taking certain medications.",
    "The sample is a phase 2 trial for Friedreich's Ataxia, testing the drugs alpha-tocopherolquinone and placebo, with inclusion criteria of genetically confirmed Friedreich's Ataxia and impaired glucose tolerance, and exclusion criteria of overt diabetes mellitus and clinically significant cardiovascular disease.",
    "The sample is a phase 2 trial for melanoma patients with c-kit mutation, testing the efficacy of imatinib and interferon, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for the acute treatment of migraine, testing the efficacy of rimegepant, placebo, and sumatriptan in patients with a history of migraines, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of sorafenib and erlotinib in treating non-small cell lung cancer patients who have experienced clinical benefit from prior erlotinib therapy, with specific eligibility criteria including histologically confirmed stage IIIB/IV or relapsed non-small cell lung carcinoma and no more than 2 prior lines of therapy.",
    "This phase 2 trial is testing the efficacy of amg 386 and paclitaxel in treating ovarian, fallopian tube, and primary peritoneal cancer patients who have received no more than 3 previous regimens of anti-cancer therapy and have adequate organ and hematological function.",
    "The sample is a phase 2 trial for postmenopausal osteoporosis, testing the efficacy of bazedoxifene and placebo, with inclusion criteria based on bone mineral density and/or vertebral fracture, and exclusion criteria for diseases affecting bone metabolism.",
    "The sample is a phase 2 trial for patients with type 2 diabetes, testing the efficacy of actos, placebo, and aleglitazar, with inclusion criteria including age, HbA1c levels, and previous treatment, and exclusion criteria including type 1 diabetes, insulin or thiazolidinedione treatment, and cardiovascular disease.",
    "The sample is a phase 2/phase 3 trial for patients with active rheumatoid arthritis and incomplete response to methotrexate, testing the efficacy of ce-224,535 and placebo, with inclusion and exclusion criteria related to biologic therapies and recent infections.",
    "This phase 2 trial is testing the drug erlotinib on chemo-na\u00efve patients with inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer, who are not medically suitable for chemotherapy, and have measurable disease according to the RECIST criteria, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for Crohn's disease using interferon beta-1a as a drug, with inclusion criteria being established diagnosis and remission using corticosteroids within 4 weeks before the study, and exclusion criteria being any other treatment for the maintenance of remission of Crohn's disease.",
    "This phase 2 trial is testing the drug trastuzumab (Herceptin) on adult patients with breast carcinoma and HER-2 overexpression who have at least one measurable brain metastasis and for whom whole brain radiotherapy is the best therapeutic option, while excluding patients with neoplastic meningitis or any prior radiotherapy to the brain, and those for whom stereotactic radiotherapy is the best therapeutic option.",
    "This phase 2 trial is testing the combination of gemcitabine, capecitabine, and bevacizumab in patients with metastatic clear cell renal cell cancer who meet certain eligibility criteria, while excluding those with prior treatment with pyrimidine analogs or VEGF binding agents, serious nonhealing wounds or fractures, and known brain metastases.",
    "The sample is a phase 2 trial for multiple sclerosis, relapsing-remitting, using interferon beta 1b (betaseron, bay86-5046) as the drug, with inclusion criteria including signed informed consent and negative pregnancy test results, and exclusion criteria including pregnancy or lactation and history of alcohol or drug abuse.",
    "The sample is a phase 2 trial for patients with ER positive endometrial carcinoma who have received one line of chemotherapy prior to enrollment and progressed after that line, testing the drug bn83495, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2/phase 3 trial for chronic myelogenous leukemia, malignant melanoma, and renal cell carcinoma, testing the efficacy of pegylated interferon alfa-2a and recombinant interferon alfa 2a, with specific eligibility criteria for participants.",
    "This phase 2 trial is testing the efficacy of miya-bm fine granules and placebo in treating clostridium difficile infection in adults who meet specific inclusion criteria and do not have any exclusion criteria.",
    "This phase 2 trial is testing the efficacy of zd1839 and docetaxel in treating non-small cell lung cancer patients who have had one prior chemotherapy regimen and have disease progression or recurrence within 6 months of last dose of chemotherapy in first chemotherapy regimen.",
    "The sample is a phase 2/3 trial for breast neoplasm testing the efficacy of paclitaxel weekly in combination with capecitabine and docetaxel every 3 weeks in combination with capecitabine, with eligibility criteria including measurable and/or evaluable disease, adequate organ functions, and exclusion criteria including severe hepatic or renal impairment and known dihydropyrimidine dehydrogenase deficiency.",
    "This phase 2 trial is testing the efficacy of ixabepilone, paclitaxel, and carboplatin in treating advanced/metastatic non-small cell lung cancer, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of hydroxychloroquine and imatinib mesylate in treating chronic myeloid leukemia patients who have achieved major cytogenetic response and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for pulmonary disease, chronic obstructive, with icd-10 codes J44.9, J44.1, and J44.0, testing the drugs gw642444m, gw642444h, and placebo, with inclusion criteria including history of COPD and smoker or ex-smoker status, and exclusion criteria including recent respiratory tract infection and history of drug or alcohol abuse.",
    "The sample is a phase 2 trial for cervical cancer patients with measurable disease, not amenable to chemoradiotherapy or surgery, and eligible based on specific criteria, testing the efficacy of isotretinoin and paclitaxel.",
    "This phase 2 trial will test the efficacy of pioglitazone in treating newly diagnosed stage Ia-IIb resectable non-small cell lung cancer patients who will undergo definitive surgery, with a list of eligibility and exclusion criteria.",
    "The sample is a phase 2 clinical trial for multiple myeloma patients, testing the efficacy of bortezomib, dexamethasone, and pd 0332991, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for pancreatic cancer patients with non-metastatic, unresectable disease, testing the efficacy of cetuximab, gemcitabine, oxaliplatin, and capecitabine, with eligibility criteria including a Karnofsky performance status greater than or equal to 70 and exclusion criteria including prior therapy targeting the estimated EGFR pathway.",
    "The sample is a phase 2 trial for leiomyosarcoma and uterine neoplasm using gemcitabine, docetaxel, and doxorubicin as drugs, with specific eligibility criteria including pathology review and ANC, and exclusion criteria such as prior therapy with the drugs and cardiac ejection fraction <50%.",
    "This phase 2 trial aims to alleviate pain and discomfort during scaling and root planning in patients with periodontitis using bupivacaine lozenge and lidocaine-adrenalin injection, and includes inclusion and exclusion criteria such as age, ability to speak Danish, and allergy to local anesthetics.",
    "The sample is a phase 2 trial for HER2-positive early breast cancer using trastuzumab and taxane drugs, with eligibility criteria including at least 10 months of Herceptin treatment and exclusion criteria including previous chemotherapy for metastatic breast cancer and brain metastases.",
    "The sample is a phase 2 trial for edotecarin in patients with locally advanced or metastatic breast cancer who have received previous chemotherapy, with inclusion criteria including measurable disease and adequate organ function, and exclusion criteria including prior use of a topoisomerase I inhibitor and brain metastases.",
    "This phase 2 trial is testing the efficacy of tamibarotene and placebo in treating stage IIIB and IV non-small cell lung cancer with pleural effusion or radiographically measurable disease, with eligibility criteria including age, ECOG performance status, bone marrow function, and negative pregnancy test, and exclusion criteria including prior chemotherapy or antibody therapy, serious medical or psychiatric illness, and pregnancy or breastfeeding.",
    "The sample is a phase 2 trial for patients with gastroesophageal reflux disease, testing the effectiveness of pumosetrag, with inclusion and exclusion criteria listed, and icd-10 codes provided; the drugs and diseases are important values.",
    "This phase 2 trial is testing the drug omacetaxine mepesuccinate on patients with chronic myeloid leukemia who have the T315I BCR-ABL gene mutation and have failed prior imatinib therapy, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of TMC114 and ritonavir in treating HIV-1 and HIV infections in participants failing their current antiretroviral therapy, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of td-9855 and placebo in treating attention-deficit/hyperactivity disorder (ADHD) in subjects who meet specific inclusion criteria, including having a total score of 24 or greater on the AISRS and a CGI-S score \u22654, while excluding those with certain psychiatric disorders or a history of mental retardation or organic mental disorders.",
    "This phase 2 trial is testing the efficacy of agomelatine and placebo in treating Obsessive Compulsive Disorder (OCD) with specific inclusion and exclusion criteria, and the icd-10 codes associated with OCD are F42.8, F42.9, and F60.5.",
    "This phase 2 trial is testing the efficacy of bortezomib, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in treating previously untreated patients with Primary Mediastinal Large B-cell Lymphoma who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of aflibercept in treating symptomatic malignant ascites resulting from advanced ovarian epithelial cancer that is platinum and topotecan/liposomal doxorubicin-resistant, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with active seropositive rheumatoid arthritis, testing the efficacy of tru-015, methylprednisolone, and prednisone, with inclusion criteria of stable methotrexate use and exclusion criteria of prior use of rituximab or other B cell depleting agents and significant health problems other than rheumatoid arthritis.",
    "The sample is a phase 2 trial for post herpetic neuralgia and nerve pain, testing the efficacy of epicept-np-1 cream and gabapentin capsules against a placebo, with inclusion criteria of pain for \u2265 3 months following onset of a herpes zoster rash and exclusion criteria of clinically significant intercurrent illness.",
    "This phase 2 trial is testing the efficacy of cetuximab, a drug, in treating advanced cancer patients with specific eligibility criteria, including adequate recovery from previous therapy and measurable or evaluable disease.",
    "This phase 2 trial is testing the efficacy of cisplatin, cyclophosphamide, etoposide, lomustine, and vincristine in treating medulloblastoma, a type of brain tumor, with specific eligibility criteria for patients to be included in the study.",
    "This phase 2 trial is testing induction chemotherapy, cisplatin, and fluorouracil in patients with newly diagnosed and resectable squamous cell carcinoma of the hypopharynx or base of the tongue, with specific eligibility criteria for disease stage, patient characteristics, and prior therapy.",
    "This phase 2 trial is testing the drug gsk1120212 on patients with metastatic cutaneous melanoma with a positive BRAF mutation, and the eligibility criteria includes having measurable tumors, adequate organ function, and not being pregnant or breastfeeding.",
    "This phase 2 trial is testing the efficacy of pioglitazone and placebo in treating poorly-controlled asthma in patients who meet specific inclusion and exclusion criteria, including a history of asthma, non-smoking status, and a stable dose of inhaled corticosteroid for at least 4 weeks prior to study entry.",
    "This phase 2 trial will test the efficacy of paroxetine in treating post-traumatic stress disorder in patients who experienced a motor vehicle accident with severe physical injury, using DSM-IV-TR criteria for diagnosis, and whose combined score of the CAPS-SX standard B, C, and D is over 50.",
    "The sample is a phase 2/phase 3 trial for patients with Parkinson's disease and troublesome dyskinesia following levodopa dosing, testing the drug ads-5102 (extended release amantadine hcl) and includes inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for prostate cancer patients with eligibility criteria including clinical stage, PSA level, and biopsy Gleason's sum, and the trial will test the efficacy of capecitabine and docetaxel as drugs.",
    "The sample is a phase 2 trial for Alzheimer's disease testing the drugs azd3480 and donepezil, with inclusion criteria requiring informed consent, probable Alzheimer's diagnosis, and a visiting caregiver, and exclusion criteria including other neurologic diseases or major psychiatric disorders.",
    "The sample is a phase 2 trial for patients with refractory tumors, testing the drug azd2171, a VEGFR tyrosine kinase inhibitor, with inclusion criteria requiring histological or cytological confirmation of advanced solid tumor and exclusion criteria including prior treatment with a VEGF inhibitor and poorly controlled hypertension.",
    "This phase 2 trial is testing the efficacy of cilengitide in treating recurrent or progressive glioblastoma multiforme, with eligibility criteria including measurable disease, availability of tumor tissue specimens, and a Karnofsky Performance Score of >=70%.",
    "This phase 2 trial is testing the drug bexarotene on patients with cutaneous T-cell lymphoma, with eligibility criteria including specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions.",
    "This phase 2 trial is testing the efficacy of bortezomib, vorinostat, dexamethasone, methotrexate, and imatinib mesylate in treating refractory or relapsed acute lymphoblastic leukemia in patients aged 2 to 30 years with acceptable organ function and who have recovered from prior therapy, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for chronic constipation, testing the efficacy of linaclotide acetate and matching placebo, with inclusion and exclusion criteria based on bowel movement frequency, IBS symptoms, and medical history.",
    "The sample is a phase 2 trial testing the efficacy of ambroxol spray and placebo spray for acute pharyngitis and pain, with specific inclusion and exclusion criteria, and lists of diseases and icd-10 codes.",
    "This phase 2 trial is testing the efficacy of ritonavir and lopinavir in treating high grade glioma patients who have progressed after radiation therapy with or without chemotherapy, and have recovered from toxicity of prior therapy, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug sunitinib on patients with histologic or cytologic confirmed SCLC who have progressed during or after prior first line chemotherapy, and meet a list of eligibility criteria.",
    "This phase 2 trial is testing the efficacy of bevacizumab, docetaxel, and oxaliplatin in treating ovarian cancer patients with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of interferon beta-1a and placebo in treating Alzheimer's disease in subjects aged 50-75 with a MMSE score of 20-26, and includes inclusion and exclusion criteria for subject eligibility.",
    "The sample is a phase 2/phase 3 trial testing the efficacy of lansoprazole and placebo in treating chronic cough and bronchoreactivity in patients with gastroesophageal reflux and asthma, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for hypertension, testing the efficacy of lcz696 and placebo, with inclusion criteria including mild to moderate essential hypertension and exclusion criteria including severe hypertension, history of angioedema, and heart failure.",
    "This phase 2 trial is testing the efficacy of bosentan and placebo in treating stage IV melanoma patients who have not received prior therapy with DTIC, and have met certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of capecitabine, oxaliplatin, and bevacizumab in treating locally advanced unresectable biliary tract or gallbladder adenocarcinoma, with eligibility criteria including confirmed diagnosis, ECOG performance status of 0-2, and various blood count and organ function requirements.",
    "This is a phase 2 trial for patients with non-small cell lung cancer, testing the efficacy of carboplatin, paclitaxel, and zactima, with eligibility criteria including specific disease staging, performance status, blood counts, and absence of certain medical conditions or medications.",
    "The sample is a phase 2 trial for psoriasis, testing the drugs cp-690,550 and placebo, with inclusion criteria including a diagnosis of plaque psoriasis for at least 6 months and plaque psoriasis covering at least 15% of the body, and exclusion criteria including non-plaque forms of psoriasis and participation in another trial using an investigational agent or procedure.",
    "This phase 2 trial is testing the drug sbi-087 and placebo on patients with active rheumatoid arthritis who meet specific inclusion criteria, including being seropositive and receiving a stable dose of methotrexate.",
    "The sample is a phase 2/phase 3 trial for venous thromboembolism, using fondaparinux sodium as the drug, with inclusion criteria based on risk factors for VTE and exclusion criteria including prisoners and pregnant patients.",
    "The sample is a phase 2 trial for patients with major cutaneous abscess, cellulitis, or erysipelas, using the drug tr701 fa, with eligibility criteria including suspected or documented gram-positive infection and exclusion criteria including postsurgical or open wound infections and severe sepsis or septic shock.",
    "This phase 2 trial is testing the efficacy of bortezomib and doxorubicin hydrochloride in treating locally advanced, recurrent, or metastatic adenoid cystic carcinoma of the head and neck, with specific eligibility criteria for patients, including no prior anthracyclines and no pre-existing neuropathy greater than grade 1.",
    "This is a phase 2 trial for patients with follicular lymphoma, testing the efficacy of lenalidomide and r-chop, with eligibility criteria including signs requiring treatment, age, performance status, and negative pregnancy test for females.",
    "This phase 2 trial is testing the efficacy of gemcitabine, oxaliplatin, and erlotinib in treating locally advanced pancreatic adenocarcinoma with specific eligibility criteria, including measurable disease and a negative pregnancy test for women of childbearing potential.",
    "This phase 2 trial is testing the effectiveness of pravastatin, aspirin, ramipril, and vitamins B6, B12, and folate in preventing ASVD in patients with systemic lupus erythematosus and lupus, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for non-Hodgkin's lymphoma patients who have received at least one prior chemotherapy regimen, and will test the efficacy of bortezomib, bendamustine, and rituximab, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of BIA 9-1067 and levodopa/carbidopa in treating Parkinson's disease patients who have predictable signs of end-of-dose deterioration despite \"optimal\" therapy, and have a mean duration of \"off\" state \u2265 1.5 h during waking hours.",
    "This phase 2 trial is testing the efficacy of ofatumumab, cyclophosphamide, doxorubicin, vincristine, and prednisolone/prednisone in treating follicular lymphoma patients who meet certain inclusion criteria and do not meet any exclusion criteria.",
    "This is a phase 2 trial for patients with gastric cancer, testing the drug abi-007, with inclusion criteria including prior treatment with fluoropyrimidine analogs and measurable lesions, and exclusion criteria including history of taxans use and pre-existing peripheral neuropathy.",
    "The sample is a phase 2 trial for COPD patients, testing the efficacy of bio-11006 inhalation solution and placebo, with inclusion criteria including FEV1, chronic bronchitis, and smoking history, and exclusion criteria including recent use of oral prednisone or changes in inhaled corticosteroid or long acting bronchodilator dose.",
    "This is a phase 2 clinical trial for the drug cc-5013 in the treatment of Crohn's disease, with specific inclusion and exclusion criteria for eligible subjects.",
    "The sample is a phase 2 trial for asthma, testing the efficacy of ff/gw642444m, gw642444m, fluticasone furoate, and placebo, with eligibility criteria including BMI, non-smoking status, and FEV1, and exclusion criteria including liver disease, hay fever, and recent participation in other clinical studies.",
    "This phase 2 trial is testing the efficacy of pegylated liposomal doxorubicin and epirubicin in treating breast cancer patients who meet specific eligibility criteria, including no prior anthracycline-based chemotherapy and measurable disease, while excluding patients with congestive heart failure, brain metastases without prior radiation therapy, and other invasive malignancies.",
    "The sample is a phase 2 trial testing the drug du-176b and placebo on patients undergoing unilateral total knee arthroplasty for venous thromboembolism and deep vein thrombosis, with eligibility criteria including exclusion of patients with risks of hemorrhage, thromboembolic risks, weight less than 40 kg, and pregnancy.",
    "This is a phase 2 trial for chronic hepatitis C, testing the efficacy of ribavirin, pegylated interferon alfa 2a, placebo, and telaprevir, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for hyperlipidemia, testing the effectiveness of rosuvastatin and atorvastatin, with inclusion criteria of age and hyperlipidemia, and exclusion criteria of previous rosuvastatin treatment, statin intolerance, severe hypertension, and diabetes.",
    "The sample is a phase 2 trial for type 2 diabetes mellitus using alogliptin and voglibose as drugs, with eligibility criteria including completion of a previous study and exclusion criteria related to hepatic and renal impairment.",
    "The sample is a phase 2 trial for interstitial cystitis using lidocaine releasing intravesical system (Liris\u00ae) as the drug, with inclusion criteria including women over 18 diagnosed with interstitial cystitis and able to complete questionnaires and diary, and exclusion criteria including pregnant or lactating women and those with bladder or urethra anatomical features that would prevent safe indwelling or insertion of the investigational product.",
    "This phase 2 trial aims to evaluate the efficacy of peginterferon alfa-2a and ribavirin in treating HIV-infected patients with chronic viral hepatitis C and liver disease, with specific inclusion and exclusion criteria, and icd-10 codes for the diseases.",
    "This phase 2 trial is testing the efficacy of bevacizumab and paclitaxel in treating advanced stage cervical and uterine cancer patients who meet specific eligibility criteria, while excluding patients with certain medical histories or conditions.",
    "This phase 2 trial is testing the efficacy of carboplatin, erlotinib, erlotinib hydrochloride, and paclitaxel in treating patients with various types of lung cancer who meet specific eligibility criteria, including having not received prior chemotherapy or treatment with certain targeted therapies.",
    "This phase 2 trial is testing the efficacy of fludarabine phosphate in treating B-cell chronic lymphocytic leukemia, with specific eligibility criteria including a diagnosis of CLL, lymphocytosis, and intermediate- or high-risk categories of the modified three-stage Rai staging system.",
    "The sample is a phase 2 trial for polycystic ovary syndrome, testing the effectiveness of lipitor and placebo on women with specific inclusion and exclusion criteria, including elevated serum total testosterone and LDL cholesterol, and excluding current use of oral contraceptives and insulin sensitizing medications.",
    "The sample is a phase 2 trial for squamous cell carcinoma of the head and neck, testing the efficacy of gefitinib and cisplatin, with inclusion criteria including confirmed diagnosis, no prior treatment, measurable disease, and life expectancy of more than 12 weeks, and exclusion criteria including certain cancers and coexisting malignancies.",
    "This phase 2 trial is testing the efficacy of cinaciguat and placebo in treating acute heart failure, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the combination of ridaforolimus and dalotuzumab with exemestane or ridaforolimus alone in post-menopausal women with estrogen receptor positive and HER-2 negative metastatic or locally advanced breast cancer who have received at least one line of endocrine therapy for metastatic disease, and have had a recurrence or progression of cancer after prior treatment, with eligibility criteria including having an available archival tumor specimen and a life expectancy of at least 3 months.",
    "This is a phase 2/phase 3 trial for talsaclidine in Alzheimer's disease patients who completed the preceding talsaclidine trial within the last four weeks with adequate compliance, and have a relative or caregiver who is willing and capable of supporting the clinical trial, with a list of exclusion criteria and concomitant therapy exclusion.",
    "This phase 2 trial is testing the efficacy of HQK-1001 and placebo in treating sickle cell disease patients who have experienced acute complications in the past year, with inclusion criteria including a diagnosis of SCD, type Hb SS or Hb S-B0 Thalassemia, and exclusion criteria including chronic opiate use and current abuse of alcohol or drugs.",
    "This phase 2 trial is testing the efficacy of flovent, a drug used to treat asthma, in treating eosinophilic esophagitis in patients who have not responded to elimination diets or proton-pump inhibitors.",
    "This phase 2 trial is testing the efficacy of at-101, prednisone and docetaxel and placebo, prednisone and docetaxel in treating hormone refractory prostate cancer patients who meet specific eligibility criteria.",
    "This phase 2 clinical trial is testing the effectiveness of velcade and irinotecan in treating cervical cancer patients who meet specific eligibility criteria, including having measurable disease and adequate hematopoietic, renal, and hepatic function.",
    "This phase 2 trial is testing the efficacy of docetaxel, oxaliplatin, and capecitabine in treating irresectable, metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of exenatide and placebo in treating type 2 diabetes in patients with stable body weight and HbA1c levels, who have been treated with metformin for at least 3 months, and meet other eligibility criteria.",
    "This trial is a phase 2/phase 3 study for systemic lupus erythematosus, testing the efficacy of corticosteroids, abatacept, and mycophenolate mofetil, with eligibility criteria including meeting at least 4 of the 11 classification criteria for SLE and having active proliferative lupus glomerulonephritis.",
    "The sample is a phase 2 trial for pancreatic cancer using oxaliplatin, fluorouracil, and gemcitabine hydrochloride as drugs, with eligibility criteria including confirmed adenocarcinoma of the pancreas, locally advanced disease, and ECOG performance status of 0-1.",
    "This phase 2 trial is testing the efficacy of adl5747, placebo, and pregabalin in treating postherpetic neuralgia, with eligibility criteria including a diagnosis of PHN, a minimum pain score, and certain medical conditions, while excluding those with allergies to acetaminophen or intolerance to pregabalin.",
    "The sample is a phase 2 trial for postmenopausal osteoporosis testing the efficacy of abaloparatide transdermal and injection drugs, with inclusion and exclusion criteria based on age, BMD T-score, physical exam, laboratory tests, and medical history.",
    "The sample is a phase 2/phase 3 trial testing the efficacy of memantine in treating cognitive dysfunction in patients with multiple sclerosis, with inclusion criteria based on diagnosis and cognitive dysfunction, and exclusion criteria including history of depression, pregnancy, and use of certain medications.",
    "This is a phase 2 trial for systemic lupus erythematosus, testing the efficacy of lupuzor and placebo, with eligibility criteria including a diagnosis of SLE, positive ANA or anti-dsDNA Ab test, and stable use of certain medications.",
    "This phase 2 trial is testing the effectiveness of ondansetron and palonosetron in reducing chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for the treatment of hepatitis C with drugs pf-00868554 and placebo, with inclusion criteria such as treatment-naive status and genotype 1, and exclusion criteria such as severe liver disease and exposure to investigational anti-HCV agents.",
    "This is a phase 2 trial for previously untreated classical Hodgkin Lymphoma patients with CD30+ HL, using brentuximab vedotin and ABVD drugs, with eligibility criteria including age, disease stage, absence of bulky disease, and required baseline laboratory data.",
    "This phase 2 trial aims to evaluate the efficacy of cb-183,315, vancomycin, and placebo in treating established non-severe or severe Clostridium difficile infection (CDI) with positive stool test for toxin A and/or B, and to determine the eligibility criteria and exclusion criteria for participants.",
    "This phase 2 trial will test the efficacy of lenalidomide and placebo in treating complex regional pain syndrome type 1, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for pain management during surgical removal of impacted mandibular third molar, using azd1386, naproxen, or placebo, with inclusion and exclusion criteria listed. The disease is pain and the icd-10 codes are listed in the icdcodes column.",
    "This phase 2 trial is testing the efficacy of varespladib and placebo in patients with coronary artery disease undergoing elective PCI, with a list of exclusion criteria including recent coronary bypass surgery, severe liver disease, and uncontrolled diabetes.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate and clag in treating refractory or relapsed acute myeloid leukemia and chronic myeloid leukemia blast crisis, with specific eligibility criteria including age, disease diagnosis, performance status, and contraceptive use.",
    "This phase 2 trial is testing the efficacy of 5-fluorouracil, hydroxyurea, and bevacizumab in treating stage II-III head and neck cancer patients with curative intent, and includes eligibility criteria such as no prior exposure to chemotherapy or radiotherapy for a malignancy of the head and neck, ECOG performance status of 0-2, and normal organ and bone marrow function.",
    "This phase 2 trial is testing the efficacy of decitabine in treating acute myeloid leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndrome patients who have failed therapy with azacitidine and have specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of ixabepilone, fluoropyrimidine, and irinotecan in treating metastatic colorectal adenocarcinoma, with specific eligibility criteria for patients including prior treatment and performance status.",
    "This phase 2 trial is testing the drugs gtx-024 and placebo on patients with cachexia caused by various types of cancer, who have experienced at least 2% weight loss in the past 6 months, and meet other eligibility criteria.",
    "This phase 2 trial is testing the drug bibf1120 on patients with recurrent glioblastoma who meet specific eligibility criteria, including having received prior radiotherapy and TMZ, and having an ECOG performance status of 0-1.",
    "The sample is a phase 2 trial for locally advanced T3/T4 rectal carcinoma using capecitabine and oxaliplatin as drugs, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of ccx140-b and pioglitazone, along with placebo, in treating type 2 diabetes mellitus patients who meet specific eligibility criteria, including having a BMI between 25 and 45 kg/m2 and being on a stable dose of metformin for at least 8 weeks prior to randomization.",
    "This phase 2 trial is testing the efficacy of cisplatin and docetaxel in treating non-small cell lung cancer patients who meet specific disease and patient characteristics criteria.",
    "The sample is a phase 2 trial for metastatic prostate cancer using sagopilone and prednisone as drugs, with inclusion criteria such as confirmed metastatic prostate cancer and progressing disease despite anti-androgen therapy, and exclusion criteria such as previous cytotoxic chemotherapy and use of investigational drugs.",
    "This phase 2 trial will test the efficacy of estradiol versus placebo in treating menopausal symptoms such as vulvovaginal atrophy, painful intercourse, and dyspareunia, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of BIRT 2584 XX and placebo in treating moderate to severe plaque-type psoriasis in patients who are candidates for systemic psoriasis treatment or phototherapy, with a list of exclusion criteria including liver disease, abnormal laboratory values, and drug or alcohol abuse.",
    "This phase 2 trial is testing the efficacy of bortezomib and cisplatin in treating malignant mesothelioma in patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of boceprevir, peginterferon-alfa 2b, and ribavirin in treating chronic hepatitis C, with eligibility criteria including age, weight, genotype, liver biopsy, and contraception use, and exclusion criteria including prior treatment, co-infection, decompensated liver disease, and psychiatric conditions.",
    "This phase 2 trial is testing the efficacy of oxaliplatin and docetaxel in treating non-small-cell lung cancer, with specific eligibility criteria including measurable disease, ECOG performance score of 0-2, and absence of prior chemotherapy for lung cancer.",
    "The sample is a phase 2 trial testing the effectiveness of aripiprazole on Asperger's Disorder and Pervasive Developmental Disorder, with inclusion and exclusion criteria listed, and the drug being the only treatment mentioned.",
    "This is a phase 2 trial for HIV patients with gastrointestinal symptoms, testing the efficacy of a placebo drug, with eligibility criteria including stable CD4 count and HIV-1 RNA, and exclusion criteria including active opportunistic infection and substance abuse.",
    "The sample is a phase 2/phase 3 trial for allergic rhinoconjunctivitis, testing the efficacy of avanz phleum pratense and placebo, with inclusion criteria including a history of grass pollen allergy and positive skin prick and Immunoglobulin E tests to grass, and exclusion criteria including severe asthma and other allergies overlapping the grass pollen season.",
    "This phase 2 trial is testing the efficacy of fosbretabulin, carboplatin, paclitaxel, and bevacizumab in treating Stage IIIB NSCLC with malignant pleural effusion or Stage IV disease, with specific eligibility criteria including measurable disease on CT scan, adequate blood counts, and adequate liver and kidney function.",
    "This phase 2 trial is testing the efficacy of lenalidomide in treating chronic graft-versus-host disease in patients who have failed previous treatments, with strict inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of na-1 and placebo drugs in treating ruptured or unruptured brain aneurysms in patients with a diagnosis of stroke, with eligibility criteria including absence of ongoing ischemic symptoms, normal or abnormal but not clinically significant findings in physical examination, and informed consent.",
    "This phase 2 trial aims to investigate the efficacy of vardenafil and placebo in men with benign prostate hypertrophy requiring surgical treatment, with a list of exclusion criteria including cardiovascular conditions, bleeding disorders, and use of certain medications.",
    "The sample is a phase 2 trial for patients with peritoneal and ovarian cancer, testing the efficacy of topotecan and gemcitabine, with specific eligibility criteria including prior platinum-based chemotherapy and a treatment-free interval of greater than 6 months following response to platinum.",
    "This phase 2 trial is testing the drug vcap/amp/vecp(mlsg15) on subjects with adult T-cell leukemia-lymphoma who meet specific eligibility criteria, including positive serum anti-human T-cell lymphotropic virus type I antibody and poor prognostic factors, and excluding those with active multiple cancer or a history of allergic reactions to therapeutic antibodies.",
    "This phase 2 trial is testing the efficacy of 5-fu, folfox regimen, placebo, bevacizumab [avastin], leucovorin, and onartuzumab [metmab] in treating metastatic colorectal cancer patients with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of wf10 and nacl solution in treating persistent allergic rhinitis in patients who meet specific inclusion criteria and do not have any exclusion criteria.",
    "This is a phase 2 trial for patients with biopsy-proven primary squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal junction, using erlotinib hydrochloride as the drug, and with specific eligibility criteria for both disease and patient characteristics.",
    "This phase 2 trial is testing the efficacy of gefitinib, a drug, in treating locally advanced esophageal cancer in patients who have undergone potentially curative therapy and have no evidence of residual tumor or metastatic disease, with specific eligibility criteria for patient characteristics and prior concurrent therapy.",
    "This phase 2 trial is testing the efficacy of oxycodone naloxone prolonged release tablets and placebo tablets in treating severe pain due to Bladder Pain Syndrome (BPS) in patients who have not received opioid-containing medication in the last 6 months and have no contraindications, with a focus on interstitial cystitis, painful bladder syndrome, and pain.",
    "This phase 2 trial is testing the efficacy of bevacizumab (avastin) in treating myelofibrosis patients who are not candidates for bone marrow transplant and have recovered from previous IM-directed therapy.",
    "The sample is a phase 2 trial for type 2 diabetes with a list of drugs including placebo and denosumab, and eligibility criteria including not taking any medicine for diabetes or taking one oral medicine for their diabetes.",
    "This phase 2 trial is testing the efficacy of temsirolimus and selumetinib in treating unresectable stage IV melanoma with BRAF V600E mutation positive tumors, with eligibility criteria including a variety of medical and demographic factors.",
    "The sample is a phase 2 trial for primary open angle glaucoma and ocular hypertension, testing the efficacy of pf-03187207 and latanoprost 0.005% compared to their respective vehicles, with eligibility criteria including age and diagnosis, and exclusion criteria including contraindications to the drugs and known non-responders.",
    "This phase 2 trial is testing the efficacy of citalopram and pipamperone or citalopram alone in treating moderate to severe major depressive disorder (MDD) in patients aged 18-65, with confirmed diagnosis by the Mini International Neuropsychiatric Interview (MINI) version 5.0.0, and meeting specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of lapatinib/nab-paclitaxel in treating invasive breast cancer with Stage IV disease, and includes eligibility criteria such as confirmed ErbB2 amplification, prior chemotherapy limitations, and normal organ function.",
    "This phase 2 trial is testing the efficacy of telaprevir, ribavirin, and pegylated interferon alfa 2a in treating chronic hepatitis C (genotype 1) in patients who have already received at least one prior course of pegylated interferon alfa 2a with ribavirin, and have no significant liver disease in addition to hepatitis C.",
    "This phase 2 trial is testing the efficacy of daclatasvir, peg-interferon alfa-2a, and ribavirin in treating chronic hepatitis C virus genotype 1 or 4 infections, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for osteoarthritis using lacosamide as a drug, with inclusion criteria requiring symptomatic osteoarthritis of the knee and the need for NSAIDs, COX-2 NSAIDs, and/or paracetamol/acetaminophen for pain relief, and exclusion criteria including the inability to withdraw from these medications and the use of other analgesics.",
    "This phase 2 trial is testing the efficacy of AC-201, a drug for type 2 diabetes mellitus, with eligibility criteria including stable oral anti-diabetic medication regimen for at least 3 months, HbA1c between 7.5% and 10%, and BMI less than or equal to 45 kg/m2.",
    "This is a phase 2 trial for patients with hormone refractory prostate cancer, testing the drug patupilone, with eligibility criteria including prior docetaxel based chemotherapy and hormone refractory status.",
    "This is a phase 2 trial for patients with recurrent or stage IV melanoma, testing the efficacy of carboplatin and paclitaxel as treatment options, with a list of eligibility criteria including performance status, blood counts, and absence of certain medical conditions.",
    "The sample is a phase 2 clinical trial testing the drug cositecan on patients with primary peritoneal carcinoma or recurrent ovarian carcinoma that are platinum-resistant, with a list of eligibility criteria including measurable lesions, performance status, blood counts, and no prior anticancer therapy that would preclude study therapy.",
    "This is a phase 2 trial for lung cancer patients with nonsquamous histology, testing the efficacy of enzastaurin, pemetrexed, cisplatin, and placebo, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for breast cancer using pegylated liposomal doxorubicin (doxil) and includes eligibility criteria such as clinical T1c-T3, N0-1, M0 breast cancer, negative bone scan, and adequate bone marrow, renal, and liver function.",
    "This phase 2 trial is testing the efficacy of the drugs mk-8777 and placebo in treating attention deficit hyperactivity disorder, with strict eligibility criteria including age, gender, and clinical diagnosis.",
    "The sample is a phase 2 trial for restless legs syndrome, testing the drugs asp8825 and placebo, with inclusion criteria based on the International RSL Study Group Diagnostic Criteria and exclusion criteria including a history of RLS symptom augmentation or end-of-dose rebound with previous dopamine agonist treatment, and the presence of a sleep disorder or neurologic disease.",
    "This phase 2 trial is testing the efficacy of abt-089 and placebo in treating attention-deficit/hyperactivity disorder in adults who meet certain eligibility criteria, including having failed to respond to two or more adequate trials of FDA-approved ADHD medication.",
    "The sample is a phase 2 trial for relapsed or recurrent colorectal cancer patients, testing the efficacy of irinotecan, capecitabine, folfox, capeox/xelox, and folfiri, with eligibility criteria including measurable disease, ECOG performance status of <=2, and adequate organ function, while exclusion criteria include history of another malignancy, leptomeningeal metastasis, recent myocardial infarction, and clinically significant hepatitis.",
    "The sample is a phase 2 trial for osteoporosis testing the efficacy of amg 162 and placebo on postmenopausal women with specific BMD values and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of deferasirox, a drug used to treat iron overload, in patients who have undergone allogeneic hematopoietic stem cell transplantation and have no evidence of relapse or progression of their primary disease, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug STA-5326 for the treatment of Crohn's disease, with specific eligibility criteria including a CDAI score of 220 to 450 and stable doses of certain medications, while exclusion criteria include a history of cancer within the past 5 years and regular use of certain medications within 2 weeks prior to randomization.",
    "This phase 2 trial is testing the efficacy of gemcitabine and erlotinib in potentially resectable pancreatic cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2/phase 3 trial for cytomegalovirus infections, testing the drug valganciclovir (valcyte) in pediatric solid organ transplant recipients who are at risk of developing CMV disease, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of gemcitabine, avastin, 5fu/folinic acid, and oxaliplatin in treating Stage III unresectable or Stage IV colorectal cancer patients who have not received prior chemotherapy, immunotherapy, or hormonal treatment for metastatic disease. The eligibility criteria includes having a histological or cytological diagnosis of colon or rectum, and no known central nervous system (CNS) metastasis.",
    "This phase 2 trial is testing the efficacy of memantine and placebo in treating mild-to-moderate or moderate dementia associated with Parkinson's disease or dementia with Lewy bodies, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of bortezomib and carboplatin in treating metastatic pancreatic cancer patients who have received only one prior systemic regimen, with specific eligibility criteria, including measurable disease and ECOG performance status, and exclusion criteria, such as prior treatment with carboplatin or bortezomib, and significant history of cardiac disease.",
    "This phase 2 trial is testing the drug bsi-201 on patients with platinum-resistant ovarian cancer who have completed only one previous course of chemotherapy, and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for non-small cell lung cancer patients with measurable lesions, using cisplatin, etoposide, and irinotecan hydrochloride, with eligibility criteria including ECOG performance status 0-2, no brain metastasis, and no prior chemotherapy or radiotherapy for NSCLC.",
    "This phase 2 trial is testing the efficacy of docetaxel, liposomal doxorubicine and cyclophosphamide in treating breast adenocarcinoma in female patients who meet specific eligibility criteria, including being HER2 negative and having proper organic function, while excluding patients with previous breast cancer treatment, neurotoxicity grade 2, and other severe diseases.",
    "The sample is a phase 2 trial for metastatic colorectal cancer using the drugs azd6244 and capecitabine, with specific eligibility criteria including previous failed chemotherapeutic regimens and exclusion criteria such as previous therapy with EGFR inhibitor, MEK inhibitor or capecitabine.",
    "This phase 2 trial is testing the drugs mm-121 and paclitaxel on patients with locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who have received at least one prior platinum based chemotherapy regimen and are platinum-resistant or refractory, and are eligible for weekly paclitaxel, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of abatacept and placebo in treating psoriatic arthritis, with key inclusion criteria including meeting classification criteria for psoriatic arthritis, prior failure of therapy with disease-modifying antirheumatic drugs, and active psoriasis with a qualifying target lesion, while key exclusion criteria include recent history of clinically significant drug or alcohol abuse, current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, pulmonary, cardiac, neurologic, ophthalmologic, or cerebral disease, and cancer within the last 5 years.",
    "This phase 2 trial is testing the efficacy of capecitabine, oxaliplatin, and folfox in treating colorectal cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of Abraxane and cetuximab in treating patients with metastatic or locally recurrent squamous cell carcinoma of the head and neck, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2/3 trial for type 2 diabetes mellitus, testing the efficacy of alogliptin and glimepiride or alogliptin and metformin as add-ons to sulfonylurea or metformin, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of g-csf plus plerixafor in treating non-hodgkin lymphoma and hodgkin disease patients who have relapsed following initial treatment with an anthracycline-containing regimen or have disease that is refractory or progresses during initial therapy with an anthracycline-containing regimen.",
    "This phase 2 trial is testing the effectiveness of a combination of cyclophosphamide, cyclosporine, fludarabine phosphate, methotrexate, mycophenolate mofetil, and tacrolimus in treating chronic lymphocytic leukemia or non-Hodgkin's lymphoma patients who have relapsed after prior therapy and have a 6/6 HLA identical sibling donor, with specific eligibility criteria for age, performance status, and other medical conditions.",
    "The sample is a phase 2 trial for hormone refractory prostate cancer, testing the efficacy of metformin hydrochloride, docetaxel, and prednisone, with eligibility criteria including confirmed prostate cancer with PSA increasing despite androgen deprivation therapy, and exclusion criteria including symptomatic brain metastases and uncontrolled diabetes mellitus.",
    "This phase 2 trial is testing the efficacy of carboplatin and pegylated liposomal doxorubicin hydrochloride in treating endometrial cancer patients who meet specific eligibility criteria, including measurable disease and GOG performance status 0-2.",
    "This phase 2 trial is testing the efficacy of bol-303259-x and latanoprost in reducing intraocular pressure in subjects with open angle glaucoma or ocular hypertension, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for rheumatoid arthritis (RA) using methotrexate (mtx) as the drug, with inclusion criteria of patients \u226518 years of age diagnosed with RA and exclusion criteria of pregnant females or any other clinically significant disease or disorder that might put the subject at risk.",
    "This is a phase 2 trial for asymptomatic HIV-1-infected individuals who are treatment-experienced and have limited treatment options, testing the drug kp-1461, with inclusion criteria including prior non-suppressive ART and >2,500 copies/mL of HIV-1 RNA at screening.",
    "This is a phase 2 trial for patients with triple negative locally advanced non-resectable and/or metastatic breast cancer, testing the efficacy of ixabepilone and ixabepilone + cetuximab, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with multiple myeloma, testing the efficacy of lenalidomide and dexamethasone as treatment options, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the effectiveness of amitriptyline in treating cystic fibrosis patients who are pulmonal colonized with bacteria and do not have signs of pulmonary exacerbation, with a list of diseases and icd-10 codes provided, and eligibility criteria including age, lung function, and absence of certain conditions.",
    "This is a phase 2 trial for the treatment of detrusor muscle hyperactivity with placebo as the drug, and the eligibility criteria includes being refractory to anticholinergic medication and having a minimum of 2 incontinences per day, while exclusion criteria includes previous treatment with detrusor Botulinum Toxin injection.",
    "The sample is a phase 2/phase 3 trial for systemic lupus erythematosus (SLE) using rituximab, placebo, prednisone, acetaminophen, and diphenhydramine as drugs, with inclusion and exclusion criteria listed.",
    "This is a phase 2 clinical trial for the treatment of urinary tract infection using lactin-v and placebo drugs, with eligibility criteria including pre-menopausal women aged 18-40 years who have completed screening procedures and have a history of at least two prior symptomatic UTIs treated within the past 12 months or one prior symptomatic UTI treated in the past six months.",
    "This phase 2 trial is testing the efficacy of ipilimumab and various corticosteroids in treating malignant melanoma brain metastasis, with specific eligibility criteria including measurable lesions and laboratory test values.",
    "This is a phase 2 trial for the drug gsk1349572 and placebo in individuals with HIV-1 infection and a screening plasma HIV-1 RNA >/ 5000 copies/mL, with inclusion criteria including CD4+ cell count >/ 100 cells/mm3 and exclusion criteria including prior treatment with an integrase inhibitor and inadequate renal function at Screening.",
    "This phase 2 trial is testing the efficacy of oxaliplatin and taxotere in treating advanced muscle invasive bladder cancer in patients who meet specific eligibility criteria, including having no prior exposure to oxaliplatin and meeting certain age, blood count, and organ function requirements.",
    "This phase 2 trial is testing the drug enzastaurin on participants with recurrent or persistent epithelial ovarian or primary peritoneal carcinoma who have had one prior platinum-based chemotherapeutic regimen, and have measurable disease and at least one \"target lesion\" to be used to assess response on this protocol.",
    "This phase 2 trial is testing the efficacy of oxaliplatin in treating advanced or metastatic breast cancer that has failed prior anthracycline/taxane based chemotherapy, with eligibility criteria including bidimensionally measurable disease and no brain metastases, and patient characteristics such as age over 18, female sex, and WHO 0-2 performance status.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis testing the efficacy of clazakizumab and placebo, with eligibility criteria including inadequate response to TNF inhibitors, minimum dose of Methotrexate, and elevated hsCRP and/or ESR.",
    "The sample is a phase 2 trial for the drug sb-681323 in patients with rheumatoid arthritis, with specific inclusion and exclusion criteria, and the use of other RA medications must be stable for a certain period of time before the trial.",
    "This phase 2 trial is testing the efficacy of esketamine and placebo in treating major depressive disorder in patients who have had inadequate response to at least one antidepressant, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of Adderall-XR and Concerta in treating neurotoxicity, depression, and unspecified childhood solid tumors in patients between the ages of 6-17 who have been off treatment and cancer-free for at least 6 months, and meet other eligibility criteria.",
    "The sample is a phase 2 trial for primary refractory or relapsed AML patients, using the drug as1411, with inclusion and exclusion criteria listed. The disease being studied is leukemia, myeloid, and the icd-10 codes associated with it are provided.",
    "The sample is a phase 2/phase 3 trial for smoking cessation, testing the effectiveness of varenicline, bupropion, and nicotine patches in Duke employees and their dependents who smoke at least 10 cigarettes per day and express a desire to quit within 30 days, with exclusion criteria including various medical conditions and previous adverse reactions to smoking cessation aids.",
    "This phase 2 trial is testing the efficacy of ec145, ec145 + docetaxel, docetaxel, and ec20 in treating non-small cell lung cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug alemtuzumab on patients with leukemia, aplastic anemia, or T-LGL who have not received cytotoxic, immunosuppressive, or targeted therapy for at least 2 weeks prior to the study, and have adequate organ function and an indication for therapy for their disease.",
    "This phase 2 trial is testing the efficacy of an2728 and an2898 ointments, along with their respective vehicles, in treating atopic dermatitis with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of fp mdpi, flovent diskus, albuterol/salbutamol, and placebo mdpi in treating asthma in subjects who meet specific inclusion criteria, including having a best forced expiratory volume in one second (FEV1) of 40%-85% of the predicted normal value and being on a short-acting \u03b22-agonist alone or a non-corticosteroid maintenance medication for \u2265 3 months preceding the Screening Visit.",
    "This is a phase 2 clinical trial for the drug nbi-98854 to treat moderate or severe Tardive Dyskinesia symptoms in patients with schizophrenia or schizoaffective disorder, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of lapatinib oral tablets and placebo in combination with chemoradiation therapy for stage III, IVA, and IVB squamous cell carcinoma of head and neck, with specific eligibility criteria including adequate haematological, renal and hepatic function, and a life expectancy of at least 6 months.",
    "The sample is a phase 2 trial testing the drug l-alanosine on patients with various types of advanced cancers, including lung cancer, pancreatic cancer, and sarcoma, who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for rheumatoid arthritis testing the efficacy of rituximab and methotrexate in patients who have failed treatment with at least one DMARD, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the use of txa127 in cord blood transplant for hematologic malignancy or inherited metabolic disease, with specific eligibility criteria including age, HLA-matching, and organ function.",
    "The sample is a phase 2 trial for kidney disease patients not yet on dialysis, testing the efficacy of lanthanum carbonate and placebo in controlling serum phosphorus levels, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the effectiveness of aripiprazole and a sugar pill in treating attention deficit hyperactivity disorder (ADHD) in non-responders or partial responders to stimulant treatment, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for rheumatoid arthritis with a stable dose of methotrexate, testing the efficacy of ak106-001616 and an active comparator, with inclusion criteria of class I to III RA diagnosis and exclusion criteria of pregnancy or breastfeeding and abnormal screening laboratory test values.",
    "The sample is a phase 2/3 trial for allergy patients with a history of house dust mite induced asthma, testing the efficacy of various drugs including salbutamol inhaler, budesonide/formoterol inhaler, prednisone tablet, desloratadine tablet, and budesonide nasal spray, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, and pld, cyclophosphamide, trastuzumab, paclitaxel in treating HER2-positive breast carcinoma with specific eligibility criteria.",
    "The sample is a phase 2 trial testing the efficacy of ferumoxytol and iron sucrose in treating iron deficiency anemia in patients with kidney disease, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of placebo, EPA-E 300mg capsules, and EPA-E 300mg capsules in patients with definite NASH, excluding those with cirrhosis and using certain anti-NASH agents, to determine their effect on the disease.",
    "This phase 2 trial is testing the efficacy of second generation antipsychotics, including risperidone and olanzapine, in treating schizophrenia in patients who meet specific symptom and cognitive performance criteria, while excluding those with certain medical conditions or recent substance abuse.",
    "This is a phase 2 clinical trial for patients with metastatic or locally recurrent gastric adenocarcinoma, testing the efficacy of docetaxel + oxaliplatin, docetaxel + oxaliplatin + 5-fu, and docetaxel + oxaliplatin + capecitabine, with specific eligibility criteria for patients to participate.",
    "This phase 2 trial is testing the efficacy of temozolomide and abt-888 in treating colorectal cancer patients who have progressed on or are intolerant to standard therapies, and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for exudative age-related macular degeneration, testing the efficacy of esba1008 solution and aflibercept, with specific inclusion and exclusion criteria for patients.",
    "The sample is a phase 2 trial for painful diabetic neuropathy, testing the drugs agn 203818 and placebo capsule, with inclusion criteria of moderate to severe neuropathic pain and exclusion criteria of uncontrolled disease or pregnancy/nursing.",
    "This phase 2 trial is testing the efficacy of afq056 and placebo in treating dyskinesias and other movement disorders in patients with Parkinson's disease who meet specific inclusion and exclusion criteria, including being on a stable treatment regimen with L-dopa and other anti-parkinsonian treatment for 4 weeks prior to baseline.",
    "This phase 2 trial is testing the efficacy of trabectedin in treating recurrent or refractory sarcoma tumors, including rhabdomyosarcoma, nonrhabdomyosarcomatous soft tissue sarcoma, and Ewing's sarcoma, in patients aged 12 months to 21 years, with specific eligibility criteria including measurable disease by imaging studies and no concurrent CYP3A4 inhibitors.",
    "This phase 2 trial is testing the effectiveness of lapatinib and bevacizumab in treating HER2-overexpressing unresectable or metastatic breast cancer, with eligibility criteria including adequate hepatic, renal and cardiac function, ECOG score 0-1, and a life expectancy of at least 12 weeks.",
    "The sample is a phase 2 trial for hypercholesterolemia, testing the efficacy of isis 301012 or placebo, with specific eligibility criteria including BMI, LDL-cholesterol, and exclusion criteria such as liver disease and blood pressure.",
    "This phase 2 trial is testing the efficacy of akt inhibitor mk2206 and selumetinib in patients with incurable unresectable stage III or IV melanoma with V600-mutant BRAF disease who have progressed after therapy on selective BRAF inhibitor, and have received prior therapy and progressed following a selective BRAF inhibitor.",
    "The sample is a phase 2 trial for knee osteoarthritis, testing the efficacy of pg-530742 and placebo drugs, with inclusion criteria of mild to moderate knee osteoarthritis confirmed by radiographic technique and exclusion criteria of secondary knee osteoarthritis and drugs that act potentially on the bone or cartilage component of the knee joint.",
    "This phase 2 trial is testing the drug ptc124 on patients with cystic fibrosis who meet specific eligibility criteria, including abnormal nasal epithelial TEPD total chloride conductance and FEV1 \u2265 40% of predicted, while excluding patients with certain medical conditions or who are pregnant or breastfeeding.",
    "This phase 2 trial is testing chemotherapy in patients with primary soft tissue sarcoma of the upper or lower extremity that is surgically resectable, with eligibility criteria including Zubrod performance status 0-1, no metastases, and no prior excisional biopsy or radiotherapy to the region of the study cancer, and the drug being tested is chemotherapy.",
    "The sample is a phase 2/phase 3 trial for hypertension, testing the effectiveness of irbesartan and atenolol, with eligibility criteria including age, blood pressure, and left ventricular mass, and exclusion criteria including significant cardiac, renal, or gastrointestinal conditions, and uncontrolled diabetes mellitus.",
    "This phase 2 trial is testing the efficacy of tenofovir df, ftc, and placebo in treating chronic hepatitis b, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is for symptomatic stage I or II and III myeloma patients who have undergone standard first-line non-melphalan containing induction treatment and achieved at least a partial response, and will test the efficacy of vinorelbine, g-csf, & plerixafor, vinorelbine and plerixafor, g-csf and plerixafor, and vinorelbine & plerixafor on day when cd34 count is at least 15'000 cd34+ cells/ml of peripheral blood as consolidation therapy with high-dose chemotherapy with melphalan with autologous stem cell support.",
    "This phase 2 trial is testing the efficacy of gsk2118436 and gsk1120212 drugs on BRAF mutation positive melanoma or colorectal cancer patients with measurable disease, who meet certain eligibility criteria.",
    "The sample is a phase 2 trial for primary open angle glaucoma, testing the drugs t2345 and prostaglandin, with eligibility criteria for untreated bilateral newly diagnosed patients, and exclusion criteria for ocular hypertension other than chronic open angle glaucoma.",
    "The sample is a phase 2 trial for chronic lymphocytic leukemia, testing the efficacy of a combination of fludarabine, cyclophosphamide, alemtuzumab, and rituximab, with specific eligibility criteria including previous chemotherapy treatment and a Zubrod performance status of 0-3.",
    "This phase 2 trial is testing the efficacy of two drugs, 500mcg/25mcg once daily and placebo once daily, in treating chronic obstructive pulmonary disease (COPD) in patients who meet specific inclusion criteria, including a history of cigarette smoking and a post-bronchodilator FEV1/FVC ratio of 0.70 or less.",
    "This phase 2 trial is testing the efficacy of celecoxib, a nonsteroidal anti-inflammatory drug, in treating metastatic nasopharyngeal carcinoma in patients who have failed previous treatments, and have no active CNS metastases, with specific eligibility criteria for patient characteristics and prior concurrent therapy.",
    "This is a phase 2 trial for obesity using exenatide and placebo drugs, with eligibility criteria including a BMI >= 30kg/m^2 and exclusion criteria such as previous use of anti-diabetic medications for > 3 months and having had bariatric surgery.",
    "The sample is a phase 2 trial for refractory or recurrent hepatoblastoma with metastatic disease allowed, using irinotecan hydrochloride as the drug, and with specific eligibility criteria for patient characteristics and prior concurrent therapy.",
    "This phase 2 trial is testing the drug carfilzomib on patients with relapsed and/or refractory multiple myeloma who have responded to standard first line therapy, and have met certain eligibility criteria.",
    "This is a phase 2 clinical trial for metastatic pancreatic cancer, testing the efficacy of capecitabine, ruxolitinib, and placebo as second-line therapy for gemcitabine-intolerant patients, with inclusion criteria including age 18 or older, histologically confirmed measurable or evaluable disease, and Karnofsky performance status of \u2265 60, and exclusion criteria including more than 1 prior chemotherapy regimen for metastatic disease, evidence of CNS metastases, ongoing or prior radiation therapy, and inadequate renal, hepatic, and bone marrow function.",
    "This phase 2 trial will test the drug ci-1040 on patients with colorectal, breast, non-small-cell lung, and pancreatic cancer who meet specific eligibility criteria.",
    "The sample is a phase 2 trial testing the efficacy of gft505 80mg and placebo in treating impaired glucose tolerance and abdominal obesity, with specific inclusion and exclusion criteria.",
    "This trial is testing the efficacy of carboplatin, cediranib maleate, and paclitaxel in treating non-small cell lung cancer patients with measurable or nonmeasurable disease, who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of docetaxel and capecitabine in treating recurrent or metastatic squamous cell carcinoma of the head and neck, with eligibility criteria including prior radiation therapy and exclusion criteria including prior chemotherapy for recurrent/metastatic disease and hypersensitivity to taxanes or 5 FU.",
    "The sample is a phase 2 trial for metastatic breast cancer patients who have received prior antiestrogen therapy and are postmenopausal, testing the efficacy of tamoxifen, anastrozole, letrozole, exemestane, and fulvestrant, with eligibility criteria including ER/PgR positivity and glucose levels, and exclusion criteria including prior chemotherapy regimens and poorly controlled diabetes mellitus.",
    "The sample is a phase 2/phase 3 clinical trial for patients with chronic sinusitis and nasal polyps, testing the efficacy of S8 Sinus Implant and mometasone furoate nasal spray as treatments, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of gemcitabine in treating localized pancreatic cancer that meets specific NCCN criteria, with eligibility criteria including ECOG performance status 0-1, no metastatic disease, and no prior treatment for pancreatic cancer.",
    "This phase 2 trial is testing the drug clofarabine on patients with multiple myeloma who have had at least one prior therapy and meet certain eligibility criteria.",
    "This trial is for patients with newly diagnosed acute myeloid leukemia, testing the effectiveness of a combination of drugs including cytarabine, idarubicin, etoposide, all-trans retinoic acid, and pegfilgrastim, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing an experimental drug and placebo comparator for the treatment of painful diabetic neuropathy in patients who are either pain treatment naive or have inadequate relief from their current pain medication, and have stable diabetes with HbA1c <10%.",
    "The sample is a phase 2 trial for type 2 diabetes, testing the efficacy of pf-04991532 and sitagliptin against a placebo, with inclusion criteria of stable background medication and BMI between 22.5 and 45.5 kg/m2, and exclusion criteria of type 1 diabetes, recent heart attack or stroke, uncontrolled blood pressure, and significant kidney disease.",
    "The sample is a phase 2 trial for rheumatoid arthritis testing cetrorelix and placebo, with inclusion criteria including moderate to severe disease activity and negative pregnancy test, and exclusion criteria including pregnancy, breastfeeding, and use of biologic therapy or prednisolone >7.5mg.",
    "This phase 2 trial is testing the efficacy of efv/ftc/tdf, calcium carbonate, and vitamin d3 in treating HIV-1 infection, with strict inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for type 2 diabetes, testing the efficacy of exenatide once weekly and exenatide once monthly suspension, with eligibility criteria including HbA1c levels and exclusion criteria including previous exposure to certain medications.",
    "This phase 2 trial is testing the efficacy of cetuximab, irinotecan, oxaliplatin, and uft in treating metastatic colorectal cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing a combination of drugs including cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, imatinib mesylate, methotrexate, methylprednisolone, pegaspargase, and vincristine sulfate for the treatment of newly diagnosed acute lymphoblastic leukemia in adults aged 18 to 60.",
    "The sample is a phase 2 trial for patients with mantle cell lymphoma, testing the efficacy of a combination of cyclophosphamide, doxorubicin, vincristine, prednisone, dexamethasone, and il-2, with eligibility criteria including confirmed diagnosis, specific disease stage, and various patient characteristics and prior therapies.",
    "This phase 2 trial is testing the drug sr57667b on patients with Parkinson's disease who meet specific eligibility criteria, including being optimized on monotherapy by levodopa or a dopamine agonist and having a modified Hoehn and Yahr stage <= 2.5.",
    "This phase 2 trial is testing the efficacy of pemetrexed disodium, a chemotherapy drug, in treating patients with persistent or recurrent endometrial adenocarcinoma who are refractory to curative or standard therapy and have received 1 prior chemotherapy regimen for endometrial cancer.",
    "This phase 2 trial is testing the efficacy of rivoglitazone hcl and pioglitazone hcl in treating type 2 diabetes, with inclusion criteria including HbA1c levels between 6.5% and 10.0% and FPG levels between 126 mg/dL and 270 mg/dL, and exclusion criteria including a history of type 1 diabetes, ketoacidosis, and current insulin therapy.",
    "The sample is a phase 2 trial for patients with essential hypertension, testing the effectiveness of lcz696, amlodipine, and hydrochlorothiazide (hctz) as drugs, with eligibility criteria including successful completion of a previous protocol and ability to comply with study requirements.",
    "This phase 2 trial is testing the efficacy of regular insulin and placebo in treating mild cognitive impairment and Alzheimer's disease, with eligibility criteria including age 55 or greater, good physical health, and stable doses of Memantine or cholinesterase inhibitors.",
    "The sample is a phase 2 trial testing the efficacy of patiromer and losartan in treating chronic kidney disease, hypertension, and hyperkalemia in patients with type 2 diabetes mellitus, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for multiple sclerosis using the drug ono-4641 and placebo, with inclusion criteria of patients with relapsing-remitting multiple sclerosis and exclusion criteria of other multiple sclerosis courses, history of malignancy, clinically significant chronic disease of the immune system, inability to undergo Gd-enhanced MRI scans, and diagnosis of diabetes mellitus.",
    "The sample is a phase 2 trial for idiopathic pulmonary fibrosis, testing the efficacy of qax576 and placebo drugs, with inclusion and exclusion criteria including confirmation of diagnosis and exclusion of smokers and those with high lung residual volume.",
    "This is a phase 2 trial for hypertension using clonidine as the drug, with specific inclusion and exclusion criteria, and the presence of multiple diseases with their corresponding ICD-10 codes.",
    "The sample is a phase 2 trial for prostatic hyperplasia, testing the efficacy of tamsulosin and uk-369,003, with inclusion criteria including male subjects aged 40 years and above with documented LUTS and a clinical diagnosis of BPH, and exclusion criteria including urinary tract infection and primary neurological conditions affecting bladder function.",
    "This phase 2 trial is testing the efficacy of cediranib maleate in treating patients with neurofibromatosis type 1 and extensive plexiform and/or paraspinal neurofibromas, with specific eligibility criteria including diagnostic criteria for NF1, measurable disease, and normal laboratory values, among others.",
    "The sample is a phase 2 trial testing riociguat and placebo on patients with pulmonary hypertension due to left ventricular systolic dysfunction, with inclusion and exclusion criteria specified, and the diseases are hypertension, pulmonary and ventricular dysfunction, left.",
    "The sample is a phase 2 clinical trial testing the efficacy of docetaxel and oxaliplatin in treating locally advanced unresectable or metastatic esophageal and gastric cancer, with eligibility criteria including specific disease characteristics and patient characteristics.",
    "This phase 2 trial is testing the efficacy of alirocumab, a drug used to lower cholesterol, in patients with hypercholesterolemia who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of risperidone, placebo, and ly2140023 in treating schizophrenia in patients who meet specific inclusion criteria, including a diagnosis of schizophrenia and a history of illness exacerbation.",
    "The sample is a phase 2 trial for arthritis, rheumatoid with icd-10 codes M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, testing the drugs cp-195,543, celecoxib, and methotrexate, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of amonafide l-malate and cytarabine in treating acute myeloid leukemia patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of various drugs, including sertraline and [s,s]-reboxetine, in treating major depressive disorder with specific inclusion and exclusion criteria, and using icd-10 codes to identify the disease.",
    "This phase 2 trial is testing the efficacy of capecitabine and oxaliplatin in treating incurable head and neck cancer patients who have received radiation therapy, with specific eligibility criteria including measurable disease and adequate organ function.",
    "The sample is a phase 2 trial for hepatitis C and hepatitis, testing the efficacy of merimepodib, peg-interferon-alpha 2a, and ribavirin, with eligibility criteria including prior treatment with pegylated interferon and ribavirin, non-responsiveness to treatment, and absence of illegal drug or significant alcohol use.",
    "This phase 2 trial is testing the efficacy of carboplatin and paclitaxel in treating non-small cell lung cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for Alzheimer's disease testing the efficacy of ABT-384, donepezil, and placebo, with inclusion criteria such as meeting NINCDS/ADRDA criteria for probable AD, having a MMSE score of 10 to 24, and having a reliable caregiver.",
    "This is a phase 2 trial for diabetic macular edema using danazol as a drug, with eligibility criteria including HbA1c less than or equal to 10%, stable diabetic and metabolic control, and specific study eye inclusion criteria.",
    "This phase 2 trial is testing the efficacy of sovaprevir, ach-3102, rbv, and placebo in treating chronic hepatitis C in patients who meet specific inclusion criteria, including having a liver biopsy within the last 3 years without evidence of cirrhosis, and excluding those with a history of major organ transplantation or ongoing alcohol abuse.",
    "This phase 2 trial is testing the efficacy of sorafenib, paclitaxel, and carboplatin in treating stage III or IV epithelial ovarian carcinoma with measurable or evaluable disease, and patients must meet certain eligibility criteria.",
    "The sample is a phase 2/phase 3 trial for patients with atrial flutter, testing the efficacy of vernakalant injection 20 mg/ml, with inclusion criteria including age over 18, sustained atrial arrhythmia with dysrhythmic symptoms, and adequate anticoagulant therapy, and exclusion criteria including serious diseases/illnesses that could interfere with the study or compromise patient safety, and recent use of certain antiarrhythmic drugs.",
    "This phase 2 trial aims to evaluate the efficacy of sildenafil and placebo in treating sickle cell disease and pulmonary hypertension in patients aged 12 to 70 years old, with specific inclusion and exclusion criteria, and requires informed consent and assent.",
    "This phase 2 trial is testing the efficacy of temsirolimus in treating recurrent uterine sarcoma and uterine carcinosarcoma, with specific eligibility criteria including prior treatments and laboratory values, and exclusion criteria such as prior therapy with temsirolimus or other mTOR inhibitors.",
    "This phase 2 trial is testing the efficacy of capecitabine and oxaliplatin in treating gastrointestinal cancer patients with specific eligibility criteria.",
    "The sample is a phase 2/phase 3 trial for patients with inoperable or refused surgery stage I-III non-small cell lung cancer, testing the efficacy of cisplatin and vinorelbine tartrate, with eligibility criteria including ECOG 0-1 performance status, no prior chemotherapy or radiotherapy, and meeting various hematopoietic, hepatic, renal, cardiovascular, pulmonary, and other medical stability requirements.",
    "This is a phase 2 trial for patients with radiotherapy-induced nausea and vomiting, testing the efficacy of syb d-0701 and placebo drugs, with eligibility criteria including histologically verified malignant tumors, radiotherapy alone, and Eastern Cooperative Oncology Group performance status of 0 to 2.",
    "This phase 2 trial aims to test the efficacy of inhaled alprazolam and iv doxapram in treating induced panic attacks in subjects who meet DSM-IV criteria for panic disorder, with or without agoraphobia, and have had at least one panic attack per week in each of the four weeks prior to the start of treatment, while also meeting other inclusion criteria and not meeting any exclusion criteria.",
    "This phase 2 trial is testing the efficacy of sunitinib malate, a tyrosine kinase inhibitor, in treating patients with unresectable, locally recurrent or metastatic transitional cell carcinoma of the urinary tract who are ineligible for cisplatin-based chemotherapy due to creatinine clearance < 60 mL/min but > 30 mL/min.",
    "This phase 2 trial is testing the efficacy of gabapentin (gen) at different doses for postherpetic neuralgia (PHN) patients who have inadequate response to treatment, with specific inclusion and exclusion criteria.",
    "This phase 2 trial aims to treat infertility with a combination of r-hlh, r-hfsh, r-hcg, and gnrh antagonist in premenopausal women aged 35 to 42 years with regular menstrual cycles and FSH baseline plasma levels less than or equal to 10 IU/L, and having both ovaries and a uterine cavity capable of sustaining the implantation of embryo or carrying a pregnancy.",
    "This phase 2 trial is testing erlotinib and docetaxel in patients with non-small cell lung cancer who meet specific eligibility criteria, including having wild type or unknown EGFR mutational status and measurable target lesions, while excluding those with previous treatment with anti-EGFR agents or docetaxel, among other exclusion criteria.",
    "The sample is a phase 2 trial for advanced or metastatic non-small cell lung cancer, testing the drug sunitinib, with specific inclusion and exclusion criteria listed in the eligibility criteria section.",
    "This phase 2 trial is testing the effectiveness of avastin, gemcitabine, and abraxane in treating treatment-na\u00efve patients with newly diagnosed her2neu non-overexpressing metastatic breast cancer or HER2/neu-negative patients with metastasis diagnosed 6 or more months after completing primary systemic treatment, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease (COPD) testing the efficacy of aclidinium/formoterol and formoterol drugs in patients with stable moderate to severe COPD and a smoking history of at least 10 pack-years, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of pioglitazone, interferon alfa-2a, and ribavirin in treating chronic hepatitis C patients who have failed prior treatment, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for patients with high risk superficial bladder cancer, testing the drug apaziquone, with eligibility criteria including histologically confirmed carcinoma in situ and absence of upper urinary tract tumor, while exclusion criteria include muscle-invasive disease and prior intravesical treatment.",
    "This phase 2 trial is testing the efficacy of silymarin 700 mg and silymarin 420 mg in treating non-alcoholic steatohepatitis, with strict inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the efficacy of capecitabine, a chemotherapy drug, in treating metastatic or recurrent colorectal cancer patients who are not eligible for surgical resection and meet certain eligibility criteria.",
    "The sample is a phase 2 trial for locally advanced or metastatic NSCLC of nonsquamous histology, testing the efficacy of pemetrexed and erlotinib, with eligibility criteria including failure of previous platinum-based chemotherapy and good performance status.",
    "This phase 2 trial is testing the efficacy of capecitabine in patients with histologically confirmed squamous cell carcinoma of the head and neck who have undergone curative surgical resection, radiotherapy, and/or chemotherapy at least 1 month, but no more than 4 years ago, and meet a range of eligibility criteria.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate in treating recurrent small cell lung cancer patients who meet specific eligibility criteria.",
    "This is a phase 2 trial for psoriasis vulgaris, testing the efficacy of four drugs including leo 90100 and betamethasone plus calcipotriol, with eligibility criteria including age 18 or above, all skin types, and negative pregnancy test for females of childbearing potential.",
    "The sample is a phase 2 trial for acute coronary syndrome, testing the efficacy of rivaroxaban and placebo, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of bavituximab plus paclitaxel and carboplatin in treating non-small cell lung cancer patients with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of sorafenib tosylate in patients with various types of bladder cancer who have progressed on one prior systemic chemotherapy, and have met certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of vorinostat and bortezomib in treating recurrent adult brain tumors, including glioblastoma multiforme and gliosarcoma, with specific eligibility criteria for patients including measurable disease, performance status, and laboratory values.",
    "The sample is a phase 2 trial for Alzheimer's disease and cognitive impairment, testing the efficacy of sodium oligo-mannurarate 600mg, sodium oligo-mannurarate 900mg, and placebo, with inclusion criteria including education level, MMSE score, and stable accompanying person, and exclusion criteria including previous nervous system diseases, abnormal laboratory results, and drug therapy of Alzheimer's disease that cannot be stopped.",
    "This is a phase 2 clinical trial for Parkinson's disease, testing the drugs biib014 and placebo, with eligibility criteria including a diagnosis of idiopathic PD, stable dose of L-DOPA, and exclusion criteria including a Mini Mental State Examination score <26 and history of certain malignancies.",
    "The sample is a phase 2 trial for interstitial cystitis, testing the efficacy of pf-04383119 and placebo drugs, with inclusion criteria of moderate to severe interstitial cystitis and exclusion criteria of recent onset of symptoms, history of recurrent urinary tract infections or genitourinary cancer, and use of certain drugs given into the bladder up to 1 month prior to study entry.",
    "The sample is a phase 2/phase 3 trial for extended treatment of nicotine dependence in adolescents, with the inclusion criteria of age 14-18, smoking at least 10 cigarettes per day, and at least one quit attempt in the previous 6 months, and the exclusion criteria of current DSM-IV disorder, daily or heavy use of drugs, positive urine pregnancy test, current use of certain medications, and current formal treatment for substance abuse problem, depression or anxiety. The drug being tested is not specified.",
    "This phase 2 trial is testing the drug azd4877 on patients with urothelial cancer of the bladder, renal pelvis, ureter, or urethra who have had a maximum of 2 prior chemotherapeutic regimens and meet certain eligibility criteria.",
    "This phase 2 trial is testing the drugs dlbs1033 and placebo on healthy male participants with specific inclusion and exclusion criteria related to cardiovascular disease, hypertension, diabetes mellitus, and dyslipidemia.",
    "The sample is a phase 2 trial for patients with malignant pleural effusion and non-small cell lung cancer, testing the efficacy of zoledronic acid in combination with chemotherapy, with specific eligibility criteria including prior chemotherapy regimens, performance status, and serum creatinine levels.",
    "This phase 2 trial is testing the efficacy of vernakalant (oral) compared to placebo in cardioversion of symptomatic atrial fibrillation patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug IPI-926 on patients with primary myelofibrosis or post ET/PV MF, with specific eligibility criteria, including intermediate-1, intermediate-2, or high risk disease according to the IWG prognostic scoring system, and a life expectancy of at least 3 months.",
    "This phase 2 trial will test the efficacy of GSK2330672, metformin, and placebo in treating type 2 diabetes mellitus in subjects who meet specific inclusion criteria, including having a C-peptide level >0.8 ng/mL and a BMI of 24-40 kg/m^2.",
    "This sample is a phase 2 trial for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, testing the efficacy of bortezomib and irinotecan hydrochloride, with specific eligibility criteria including prior chemotherapy and no prior treatment with the drugs, and exclusion criteria such as brain metastases and grade 2 or higher peripheral neuropathy.",
    "This phase 2 trial is testing the efficacy of the drugs int-747 and placebo in treating patients with type 2 diabetes and presumed non-alcoholic fatty liver disease (NAFLD), with specific inclusion and exclusion criteria for eligibility.",
    "This phase 2 trial is testing the drug WBI-1001 on patients with chronic atopic dermatitis, with specific inclusion and exclusion criteria listed in the eligibility criteria section.",
    "This sample is a phase 2 trial for graft-versus-host disease, testing the drug methoxsalen, with inclusion criteria including documented chronic GvHD that is corticosteroid refractory, corticosteroid dependent or corticosteroid intolerant, and exclusion criteria including active gastrointestinal bleeding and previous treatment with ECP.",
    "This phase 2 trial is testing the efficacy of qrx-101 75 mcg/g ointment applied bid and qrx-101 75 mcg/g ointment applied qd in treating stable plaque-type psoriasis affecting 2% to 10% of the body surface area, with a list of inclusion and exclusion criteria.",
    "This phase 2 clinical trial is testing the efficacy of docetaxel, cisplatin, and 5-fluorouracil in treating squamous cell carcinoma and oral cancer, with specific eligibility criteria for patients, including stage 3 or 4 disease without evidence of distant metastases and a WHO performance status of 2 or less.",
    "This phase 2 trial is testing the drug paquinimod on patients with systemic sclerosis who meet specific eligibility criteria, including ANA-positivity and a modified Rodnan Skin score of at least 16 at baseline.",
    "This phase 2 trial is testing the effectiveness of x-22 smoking cessation product and active control cigarettes in helping subjects quit smoking, with inclusion and exclusion criteria outlined.",
    "This phase 2 trial is testing the efficacy of docetaxel and vandetanib in treating metastatic gastric adenocarcinoma or gastroesophageal junction cancer, with specific eligibility criteria for patients, including ECOG performance status, ANC, platelet count, and various other factors.",
    "The sample is a phase 2 trial for chronic hepatitis C, testing the efficacy of sofosbuvir, gs-0938, rbv, and placebos, with inclusion criteria of naive patients with chronic HCV-infection and exclusion criteria of positive tests for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab, history of any other clinically significant chronic liver disease, and medical history that makes the patient unsuitable for the study.",
    "The sample is a phase 2 trial for malignant pleural mesothelioma, testing the efficacy of morab-009 (amatuximab), pemetrexed, and cisplatin, with specific eligibility criteria including confirmed diagnosis of MPM, measurable disease, KPS of greater than or equal to 70%, and life expectancy of at least 3 months.",
    "This phase 2 trial is testing the efficacy of enzastaurin and fulvestrant in treating locally advanced or metastatic breast cancer in postmenopausal women who are resistant to aromatase inhibitors, with eligibility criteria including ER and/or PtR positivity, adequate organ function, and an estimated life expectancy of at least 24 weeks.",
    "This phase 2 trial is testing the drug fipamezole on patients with Parkinson's disease who have peak-dose dyskinesia, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of capecitabine and bevacizumab in treating stage IV colorectal cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of pazopanib, a targeted agent therapy, in patients with metastatic or unresectable locally recurrent clear cell renal carcinoma who have had only one previous targeted agent therapy with either sunitinib or bevacizumab and have progressed either during or within 3 months of discontinuing treatment with one of these agents.",
    "This phase 2 trial is testing the efficacy of indacaterol and placebo in treating chronic obstructive pulmonary disease (COPD) in patients with a history of smoking and specific lung function criteria.",
    "This is a phase 2 clinical trial for the treatment of restless legs syndrome using the drugs ipx159 and placebo, with eligibility criteria including a history of primary RLS for at least 6 months, negative alcohol and drug abuse screen, and willingness to comply with the protocol.",
    "The sample is a phase 2 trial for previously treated, therapy-refractory or -intolerant, Stage III or Stage IV melanoma patients, testing the effectiveness of ipilimumab drugs, with the inclusion criteria being patients with melanoma.",
    "This phase 2 trial is testing the efficacy of 5-fu, cisplatin, and taxotere in treating histologically confirmed esophageal cancer with specific eligibility criteria, including no previous cancer therapy and adequate hematological and liver function.",
    "This phase 2 trial is testing the efficacy of docetaxel in treating metastatic adenocarcinoma of the prostate, with eligibility criteria including hormone-resistance and elevated PSA levels, and patient characteristics such as WHO performance status 0-2 and no prior malignancy within the past 5 years.",
    "This is a phase 2 trial for obsessive-compulsive disorder using ketamine as a drug, with inclusion criteria including treatment-refractory OCD and exclusion criteria including known hypersensitivity to ketamine.",
    "This phase 2 trial is testing the efficacy of mk-0646 and placebo in treating metastatic colorectal cancer, with eligibility criteria including measurable disease, adequate organ function, and negative pregnancy test.",
    "The sample is a phase 2 trial for locally advanced and unresectable adenocarcinoma of the pancreas, testing the efficacy of gemcitabine, amg 479, and placebo, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial testing the drug OPC-41061 (tolvaptan) on patients with congestive heart failure and edema, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the effectiveness of pazopanib hydrochloride in treating metastatic transitional cell cancer of the urothelium or bladder, with eligibility criteria including measurable disease, ECOG performance status 0-2, and no history of allergic reactions to pazopanib hydrochloride or similar compounds.",
    "This phase 2 trial is testing the efficacy of azacytidine and GM-CSF in treating low- or intermediate-1-risk MDS patients with leukemia, who have not been previously treated with azacytidine or decitabine, and have no adverse reaction to GM-CSF, while excluding patients with unresolved diarrhea.",
    "The sample is a phase 2 trial for non-Hodgkin's lymphoma and marginal zone lymphoma, using gemcitabine as the drug, with eligibility criteria including histologically confirmed lymphoma, measurable lesions, and laboratory values within certain ranges.",
    "This phase 2 trial is testing the drug enzastaurin on patients with Grade 1 or 2 follicular lymphoma who are chemo-naive or have relapsed disease, and have Ann Arbor Stage III or IV disease, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of sunitinib malate (sutent) in treating renal cell carcinoma in patients who have not undergone nephrectomy and meet certain eligibility criteria.",
    "This sample is a phase 2 clinical trial for pediatric patients with refractory or relapsed acute lymphoblastic leukemia, testing the drug clofarabine, with specific eligibility criteria including normal cardiac, hepatic, and renal function, and an exclusion criteria of prior use of clofarabine or allergy to fludarabine or cladribine.",
    "This phase 2 trial is testing the effectiveness of huperzine a, a drug used to treat Alzheimer's disease, on patients who meet specific eligibility criteria, including having a Mini Mental State Examination score between 10 and 24, and not taking certain excluded medications.",
    "The sample is a phase 2 trial for arthritis, rheumatoid with a list of drugs including placebo and cp-690,550, and eligibility criteria requiring subjects to have failed an adequate trial of therapy with at least 1 DMARD due to lack of efficacy or toxicity.",
    "This phase 2 trial is testing the efficacy of org 25935 and placebo in treating panic disorder, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for patients with type 2 diabetes, testing the efficacy of the drugs mk0533 and pioglitazone, with eligibility criteria including inadequate blood glucose control and exclusion criteria including certain medications and medical conditions.",
    "This phase 2 trial is testing the efficacy of sorafenib tosylate in treating primary peritoneal carcinoma and recurrent ovarian carcinoma patients who have received 1 prior platinum-based chemotherapeutic regimen and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of tac-101 and placebo in treating advanced unresectable hepatocellular carcinoma in patients who have discontinued from first line treatment with sorafenib monotherapy, and have recovered from any significant sorafenib-related treatment toxicities prior to randomization.",
    "This phase 2 trial is testing the efficacy of carboplatin, gm-csf, and interferon gamma in treating potentially platinum-sensitive patients with M\u00fcllerian carcinomas, including ovarian, peritoneal, and fallopian tube cancer, who have had a response to platinum-based chemotherapy and have a chemotherapy treatment-free interval of at least 6 months, with specific eligibility and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of dexamethasone and doxorubicin in treating metastatic hormone refractory prostate cancer with specific eligibility criteria, including measurable disease or PSA > 5, and adequate organ function, while excluding patients with previous chemotherapy or cardiac disease.",
    "The sample is a phase 2 trial for patients with relapsed ovarian cancer who have undergone primary therapy with platin and taxan, and will test the efficacy of topotecan as a treatment option.",
    "The sample is a phase 2 trial for chronic cough, testing the efficacy of gefapixant and placebo, with inclusion and exclusion criteria related to smoking, ACE-inhibitor use, and lung function.",
    "This phase 2 trial will investigate the safety and efficacy of Xeomin injections in treating troublesome sialorrhea in patients with Parkinson's disease and amyotrophic lateral sclerosis, using incobotulinum toxin A and placebo as drugs, and eligibility criteria including diagnosis by clinical criteria, age between 20-80, and grade 3 or more on the UPDRS Part 2 Sialorrhea grading scale.",
    "The sample is a phase 2 trial for advanced, EGFR-positive non-small-cell lung carcinoma, testing the drugs pf-3512676 + erlotinib and erlotinib, with inclusion criteria of measurable disease and ECOG Performance Status 0, 1 or 2, and exclusion criteria of known CNS metastasis and pre-existing autoimmune or antibody mediated disease.",
    "This phase 2 trial is testing the efficacy of natura-alpha capsules in treating moderate to severe ulcerative colitis in patients who are refractory or intolerant to other therapies, with eligibility criteria including endoscopic evidence of active mucosal disease and exclusion criteria including a history of colonic or rectal surgery and use of TNF-alpha antibody or any other biologic therapy within 2 months prior to the screening visit.",
    "This phase 2 trial is testing the efficacy of mometasone furoate, nortriptyline hcl, and vehicle (placebo) in treating chronic plaque psoriasis in subjects between 18 and 70 years of age, with specific inclusion and exclusion criteria.",
    "This phase 2 trial will test the efficacy of bupivacaine collagen sponge versus placebo collagen sponge for postoperative pain management in patients undergoing unilateral inguinal herniorrhaphy, with inclusion criteria of male patients aged 18 or older with BMI between 19 and 40 kg/m2 and exclusion criteria of hypersensitivity to certain medications or undergoing major surgery within 3 months of the scheduled herniorrhaphy.",
    "This phase 2 trial is testing the efficacy of bps804 and placebo in postmenopausal women with low bone mineral density and a range of inclusion and exclusion criteria, including restrictions on previous use of certain medications and exclusion of subjects with certain bone diseases or abnormalities.",
    "The sample is a phase 2 trial for postmenopausal women with hormone receptor-positive early breast cancer, testing the effectiveness of fulvestrant and anastrozole, with eligibility criteria including a positive Disseminated Tumour Cell immunocytochemical result from bone marrow aspiration prior to randomisation.",
    "The sample is a phase 2 trial for patients with stage IV breast cancer and HER2 overexpression, testing the efficacy of gemcitabine and trastuzumab, with specific eligibility and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of bevacizumab, sunitinib, carboplatin, and paclitaxel in treating advanced non-small cell lung cancer patients with measurable or non-measurable disease, who meet certain eligibility criteria and do not have any exclusion criteria.",
    "The sample is a phase 2 trial for metastatic or recurrent breast cancer patients who have been previously treated with both an anthracycline and a taxane, and will test the efficacy of enzastaurin, placebo, and capecitabine, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug talampanel on patients with malignant glioma, including glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic mixed oligoastrocytoma, who have failed prior radiation therapy and have recovered from the toxic effects of prior therapy.",
    "The sample is a phase 2/phase 3 trial for patients with colorectal cancer and liver metastases, testing the efficacy of various chemotherapy drugs (folfiri, folfox-4, folfiri-hd, folfox-7, folfirinox) with specific eligibility criteria for inclusion and exclusion.",
    "The sample is a phase 2 trial for metastatic breast cancer testing cetuximab and cisplatin, with eligibility criteria including ER negative, PgR negative, and HER2 less than 3+ expression, and exclusion criteria including prior platinum agent and known history of brain metastases.",
    "This phase 2 trial is testing the efficacy of azd7268 and escitalopram, along with placebo capsules and tablets, in treating major depressive disorder with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of clofarabine, cytarabine, and thymoglobulin in patients with myelodysplastic syndromes, acute myeloid leukemia, or chronic myelomonocytic leukemia who meet specific eligibility criteria, including age, performance status, and donor criteria.",
    "This is a phase 2 clinical trial for Crohn's disease testing the effectiveness of ain457 and placebo drugs on moderately active Crohn's disease patients who have been diagnosed for at least 3 months and have confirmation of the disease by endoscopic or imaging examination, with specific inclusion and exclusion criteria.",
    "This sample is a phase 2 trial for endometriosis, testing the efficacy of high and low doses of bgs649 and placebo, with specific inclusion and exclusion criteria for patients.",
    "This phase 2 trial is testing the efficacy of EGT0001442 and placebo in treating type 2 diabetes with specific inclusion and exclusion criteria, including stable doses of anti-diabetic, anti-hypertensive, and lipid modifying therapies, and exclusion of patients with certain medical conditions or taking certain medications.",
    "This phase 2 trial aims to test the efficacy of exenatide, a drug used to treat type 2 diabetes, in reducing fatty liver in patients with diabetes complications and a BMI over 35, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of paclitaxel and cisplatin in treating non-small cell lung cancer, with specific eligibility criteria including confirmed diagnosis, age, ECOG range, and various blood count and liver function requirements.",
    "The sample is a phase 2 trial for rheumatoid arthritis testing the efficacy of mdx-1100 and placebo in combination with methotrexate, with inclusion criteria including meeting ACR criteria for RA, active RA, and seropositivity for rheumatoid factor or anti-cyclic citrullinated peptide antibody, and exclusion criteria including prior treatment with B cell depleting therapy and any other autoimmune disease other than RA.",
    "This phase 2 trial is testing the drug incb013739 and metformin on patients with type 2 diabetes who have a stable dose of metformin for more than 8 weeks, and the eligibility criteria includes exclusion of subjects with Addison's disease or Cushing's Syndrome, type 1 diabetes mellitus or secondary forms of diabetes, uncontrolled thyroid disease, and history of renal impairment.",
    "This phase 2 trial is testing the efficacy of docetaxel in treating prostate cancer patients who have not responded to previous chemotherapy regimens and meet specific eligibility criteria.",
    "This phase 2 trial will test the efficacy of apixaban versus placebo in preventing thrombosis, cancer, and pulmonary embolism in patients receiving first- or second-line chemotherapy for various cancers, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the drug ipi-504 on patients with castration-resistant prostate cancer, with specific inclusion and exclusion criteria based on prior treatments and medical conditions.",
    "The sample is a phase 2 trial for primary open angle glaucoma and ocular hypertension, testing the drug dorzolamide-timolol-brimonidine, with inclusion criteria of adult subjects with visual acuity of 20/40 to 20/80 or better, and exclusion criteria of clinically relevant ophthalmic or systemic conditions.",
    "This phase 2 trial is testing the effectiveness of cyclosporine, fludarabine, and mycophenolate mofetil in treating morphologically confirmed acute myeloid leukemia (AML) or secondary AML, with specific eligibility criteria including age range, performance status, and prior chemotherapy.",
    "This phase 2 trial is testing the efficacy of tpi-1020 and budesonide in treating mild to moderate allergic asthma in smokers with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for mild atopic asthma using drugs such as jnj 40929837 and montelukast, with eligibility criteria including positive prick skin test to dust mite, mixed grass pollen, or cat dander.",
    "The sample is a phase 2 clinical trial for mesothelioma patients, testing the efficacy of bevacizumab, cisplatin, and pemetrexed, with specific eligibility and exclusion criteria.",
    "This is a phase 2 trial for atopic dermatitis, testing the efficacy of drugs including gw870086 and fp 0.05%, with inclusion criteria such as BSA disease involvement of >5% and exclusion criteria such as recent use of topical or transdermal treatments on or near the intended site of application within 14 days prior to first application of study medication.",
    "This phase 2 trial is testing the efficacy of bortezomid (Velcade\u00ae) in treating stage IIIB or IV non-small cell lung cancer, with eligibility criteria including no prior chemotherapy or therapy with systemic anti-tumour therapy, measurable disease, and an ECOG performance status of 0-2.",
    "This phase 2 trial is testing the efficacy of methylphenidate and placebo in helping smokers quit, with inclusion criteria including daily smoking for the past 6 months and exclusion criteria including clinically significant depression or drug abuse, and contraindications for methylphenidate use such as narrow angle glaucoma or history of GI obstruction.",
    "The sample is a phase 2 trial for breast cancer patients with specific eligibility criteria, testing the effectiveness of ac regimen, cyclophosphamide, and doxorubicin hydrochloride drugs on various diseases including depression, malnutrition, and psychosocial effects of cancer and its treatment.",
    "This phase 2 trial is testing the efficacy of chemotherapy in treating newly diagnosed muscle-invasive transitional cell bladder cancer patients who are eligible for neoadjuvant chemotherapy, and the study includes eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the drug tanespimycin on patients with metastatic melanoma, who meet specific eligibility criteria related to their disease characteristics, patient characteristics, and prior concurrent therapy.",
    "The sample is a phase 2 trial testing the efficacy of topical minocycline foam for impetigo treatment, with inclusion criteria including patients with 2-7 lesions and no known medical conditions that could interfere with study participation, and exclusion criteria including presence of skin diseases at or near the investigational area and use of other investigational drugs within 30 days prior to entry into the study.",
    "This phase 2 trial is testing the efficacy of botulinum toxin a and normal saline in treating chronic prosthetic knee joint pain in patients who have failed traditional treatments, with inclusion criteria including pain rating of 6 or greater on a 10 point Numerical Pain Rating scale and exclusion criteria including use of aminoglycoside antibiotics or known disorders of neuromuscular function.",
    "This phase 2 trial is testing the efficacy of linagliptin and sitagliptin in treating type 2 diabetes mellitus, with inclusion criteria of HbA1c levels between 6.5% and 10.0%, and exclusion criteria including recent myocardial infarction or stroke, impaired hepatic function, and recent treatment with certain diabetes medications.",
    "This phase 2 trial is testing the efficacy of triapine and gemcitabine hydrochloride in treating recurrent non-small cell lung cancer patients who have failed one prior cytotoxic chemotherapy regimen, with specific eligibility criteria including measurable disease, ECOG performance status of 0 or 1, and various laboratory values within normal limits.",
    "The sample is a phase 2 trial for malignant glioma using the drug enzastaurin, with inclusion criteria including a diagnosis of recurrent brain tumor and ability to swallow tablets, and exclusion criteria including pregnancy or significant heart, liver, kidney, or psychiatric disease.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide, dexamethasone, and lenalidomide in treating newly diagnosed symptomatic multiple myeloma patients with measurable or evaluable disease, while meeting specific patient eligibility criteria.",
    "The sample is a phase 2 trial for rheumatoid arthritis patients, testing the efficacy of birb 796 bs (low and high dose) compared to placebo, with eligibility criteria including failure of at least one DMARD and meeting specific RA activity criteria.",
    "The sample is a phase 2 trial testing the efficacy of epoetin alfa in treating chronic anemia in elderly patients with specific inclusion and exclusion criteria, including no active cancer and a Short Physical Performance Summary Score of 4-10, and the trial includes a list of diseases and icd-10 codes.",
    "This phase 2 trial is testing the drug inno-206 for patients with locally advanced, unresectable, and/or metastatic pancreatic ductal adenocarcinoma who have progressed after treatment with gemcitabine and fluoropyrimidine-containing chemotherapy regimens.",
    "This phase 2 trial will test the efficacy of rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate, leucovorin, ifosfamide, etoposide, cytarabine, and mesna in treating Burkitt lymphoma, non-Hodgkins lymphoma, and atypical Burkitt lymphoma, with specific eligibility criteria for patients.",
    "The sample is a phase 2 trial for Parkinson's disease, testing the efficacy of topiramate in reducing levodopa-induced dyskinesias, with specific inclusion and exclusion criteria for patient selection.",
    "This phase 2 trial is testing the efficacy of via-2291 and placebo in reducing inflammation in patients with acute coronary syndrome and carotid or ascending aorta artery plaque inflammation, who are also receiving concomitant statin therapy, while excluding patients with certain medical conditions and medication use.",
    "This phase 2 trial is testing the efficacy of rosiglitazone and placebo in treating HIV infections with specific inclusion and exclusion criteria, including prior thymidine NRTIs and no diabetes or heart failure.",
    "This phase 2 trial is testing the efficacy of dronedarone and placebo in patients with permanent atrial fibrillation, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for rheumatoid arthritis testing the drugs incb018424 and placebo, with inclusion criteria requiring an established diagnosis of rheumatoid arthritis and exclusion criteria including recent use of certain drugs and investigational medication.",
    "The sample is a phase 2 trial for pre-menopausal women with ER+ breast cancer who have undergone radical surgery, testing the efficacy of goserelin acetate in combination with eligibility criteria including WHO performance status and exclusion criteria such as evidence of metastatic disease or previous chemotherapy.",
    "This is a phase 2 trial for patients with locally advanced or metastatic prostate cancer, testing the efficacy of metformin, with eligibility criteria including PSA progression, testosterone level, and prior concurrent therapy restrictions.",
    "This phase 2 trial is testing the efficacy of intravenous gr270773-phospholipid emulsion in treating sepsis caused by Gram-negative infections, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of vinorelbine and lapatinib in treating metastatic breast adenocarcinoma patients with HER2 positive status who have previously undergone anthracycline and taxane regimens, and trastuzumab treatment, with specific eligibility criteria for age, performance status, liver, renal and bone marrow function, and exclusion criteria for infection, cardiac disease, other invasive malignancy, and pregnancy or lactation.",
    "This phase 2 trial is testing the drug lbh589 on patients with myelodysplastic syndrome who meet specific eligibility criteria.",
    "This is a phase 2 trial for obesity using beloranib and placebo drugs, with inclusion criteria for obese volunteers with stable body weight and type 2 diabetes mellitus allowed, and exclusion criteria for recent use of weight loss agents and type 1 diabetes mellitus.",
    "The sample is a phase 2 trial for patients with myelodysplastic syndrome, testing the drug dn-101 (calcitriol) and requiring eligibility criteria such as a diagnosis of low or intermediate-1 risk MDS and dependence on monthly blood transfusions.",
    "This phase 2 trial is testing the efficacy of trabectedin, a drug, in treating advanced, persistent, or recurrent uterine leiomyosarcoma, with specific eligibility criteria for patients and prior concurrent therapy restrictions.",
    "This phase 2 trial is testing the drug tezosentan on patients with pulmonary arterial hypertension who meet specific eligibility criteria, including having a documented hemodynamic diagnosis of PAH and being in modified NYHA functional class II-III.",
    "This phase 2 trial is testing the efficacy of cisplatin, fluorouracil, and iressa in treating esophageal cancer with specific disease characteristics and patient eligibility criteria.",
    "This phase 2 trial is testing the efficacy of medi-545, a drug, in treating lupus erythematosus and lupus, with specific eligibility criteria including meeting at least 4 of the 11 revised ACR classification criteria for SLE and having positive antinuclear antibody test (ANA) at \u2265 1:80 serum dilution documented in the past or at screening.",
    "The sample is a phase 2 trial testing the efficacy of paroxetine and placebo in treating Generalized Anxiety Disorder (GAD) in patients who meet specific inclusion criteria and do not have certain exclusion criteria, with a focus on patients who have not received psychotherapy or cognitive behavioral therapy other than supportive psychotherapy within 24 weeks, and have not taken St. John's Wort in the past 4 weeks, and have not had electroconvulsive therapy (ECT) in the past 12 weeks, and do not have a history of convulsive disorder (epilepsy, etc.), significant unstable medical illness, glaucoma, cancer or malignant tumor, or hypersensitivity to paroxetine.",
    "The sample is a phase 2 trial for relapsing-remitting multiple sclerosis (RRMS) testing the effectiveness of ain457 and placebo drugs, with inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with recurrent ovarian or primary peritoneal cancer, testing the efficacy of carboplatin as a platinum-based chemotherapy regimen, with eligibility criteria including measurable disease and prior platinum-based chemotherapy, and patient characteristics such as age, performance status, and hematopoietic, hepatic, renal, cardiovascular, and neurologic health.",
    "This phase 2 trial is testing the efficacy of ofatumumab and lenalidomide in treating chronic lymphocytic leukemia, with eligibility criteria including prior rituximab therapy and normal organ and bone marrow function.",
    "The sample is a phase 2 trial for diabetes mellitus type 2, testing the efficacy of pf-04937319 at different doses and glimepiride as compared to placebo, with inclusion criteria of age 18-70 years and exclusion criteria of recent cardiovascular events or evidence of diabetic complications.",
    "The sample is a phase 2/phase 3 trial for type 2 diabetes mellitus, testing the efficacy of alogliptin and metformin in patients who have been taking stable doses of metformin for at least 12 weeks, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of tarafenacin in treating overactive bladder, with inclusion criteria including symptoms documented in a 3-day diary card and exclusion criteria including significant urogenital disease and contraindications to antimuscarinic drugs.",
    "This phase 2 trial is testing the efficacy of carfilzomib, a drug used to treat multiple myeloma, in patients who have relapsed or progressed after receiving at least two prior treatment regimens, and have achieved a minimal response or better to at least one of the regimens, and have renal insufficiency.",
    "The sample is a phase 2 trial for Rett syndrome, testing the drugs epi-743 and placebo, with inclusion criteria including confirmed MeCP2 mutation and abnormality of at least two disease biomarker levels, and exclusion criteria including lack of confirmation of MeCP2 mutation and clinically significant allergy or hypersensitivity to EPI-743 or Vitamin E.",
    "This phase 2 trial is testing the efficacy of pralatrexate and erlotinib in treating relapsed non-small cell lung cancer patients who have received prior chemotherapy regimens, and have adequate blood, liver and kidney function, and meet other eligibility criteria.",
    "This phase 2 trial is testing the effectiveness of cisplatin and panitumumab in treating stage III or IVa-b squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for patients with histologically or cytologically confirmed squamous cell carcinoma of the head and neck, using docetaxel as the drug, with eligibility criteria including ECOG performance status 0-1, no prior chemotherapy or radiotherapy, and no other concurrent anticancer therapy.",
    "The sample is a phase 2 trial for hypertension, testing the efficacy and safety of PS433540 and placebo, with inclusion and exclusion criteria for subjects, including age range, blood pressure levels, and medical history.",
    "This phase 2 trial is testing the efficacy of taxotere/cisplatin in treating operable stage IIIB non-small cell lung cancer, with eligibility criteria including age, performance status, and absence of prior or concurrent metastatic disease, among others.",
    "This phase 2 trial is testing the efficacy of simvastatin in treating advanced or metastatic colorectal cancer patients who have failed prior fluorouracil-, oxaliplatin- and irinotecan-containing regimens and have mutant-type k-ras status, with specific patient characteristics and prior concurrent therapy requirements.",
    "This phase 2 trial is testing the efficacy of erlotinib and satraplatin in treating unresectable stage III or stage IV non-small cell lung cancer in patients aged 70 or older, who have not received prior EGFR targeted therapy or platinum agent, and meet other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of rituximab in treating severe congenital hemophilia A patients with historical inhibitor titer to factor VIII of at least 5 BU/mL.",
    "This phase 2 trial focuses on kidney transplantation and tests the effectiveness of alefacept, tacrolimus, basiliximab, mycophenolate mofetil, and corticosteroids in preventing rejection, with specific inclusion and exclusion criteria for the recipients.",
    "This phase 2 trial is testing the efficacy of eculizumab and placebo in treating myasthenia gravis patients who have failed at least two immunosuppressants, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with relapsed/refractory multiple myeloma, testing the drug syb l-0501, with eligibility criteria including specific disease progression and organ function requirements.",
    "This phase 2 trial is testing the combination therapy of irinotecan with 5-fu, leucovorin plus bevacizumab in the neoadjuvant setting for patients with colorectal and liver neoplasms, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial testing the efficacy of alvimopan in treating opioid-induced constipation in cancer patients, with a list of diseases and icd-10 codes, and inclusion and exclusion criteria, while testing different doses of the drug and a placebo.",
    "This phase 2 trial is testing the efficacy of cisplatin, docetaxel, and pemetrexed disodium in treating non-small cell lung cancer patients who meet specific disease and patient characteristics criteria.",
    "This phase 2 trial is testing the efficacy of wx-671 and placebo in treating metastatic breast cancer patients who meet specific eligibility criteria, including having HER2-negative breast cancer and normal organ and marrow function, while excluding patients with brain metastasis, active cardiac disease, or other medical conditions that might significantly affect their study participation.",
    "This phase 2 trial is testing the drug voreloxin injection on patients with platinum-resistant epithelial ovarian cancer who have completed at least one Platinum Based Therapy regimen and meet other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of CK-2017357, a drug, in treating myasthenia gravis, a disease characterized by muscle weakness, and has specific inclusion and exclusion criteria for patient eligibility.",
    "This is a phase 2 clinical trial for the treatment of migraine headaches, testing the efficacy of placebo, 800mg and 1200mg of ESL, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the efficacy of docetaxel in treating stage IV HER2-negative breast cancer patients who have not received prior chemotherapy for metastatic breast cancer, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for diabetic peripheral neuropathy, testing the efficacy of bicifadine with inclusion criteria such as chronic bilateral pain due to diabetic neuropathy and exclusion criteria such as clinically significant psychiatric or other neurological disorder, and the presence of amputations other than toes.",
    "The sample is a phase 2/phase 3 trial testing the efficacy of telmisartan and bisoprolol versus placebo in patients with diabetes mellitus, heart failure, and coronary artery disease, with inclusion criteria including age over 18, known diabetes mellitus for over 6 months, and increased Nt-proBNP above 125pg/ml, and exclusion criteria including chronic infection or malignant disease, history of cardiac disease, and systemic cortisone treatment.",
    "The sample is a phase 2 trial for staphylococcal skin infection, testing the efficacy of td-1792 and vancomycin, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for metastatic breast cancer patients using docetaxel as the drug, with eligibility criteria including age over 70, measurable disease, and no prior or concurrent trastuzumab therapy.",
    "The sample is a phase 2 trial for breast cancer patients with specific inclusion and exclusion criteria, testing the effectiveness of gemcitabine, paclitaxel, and bevacizumab, with a list of icd-10 codes provided.",
    "This phase 2 trial is testing the efficacy of bevacizumab, a targeted therapy drug, in patients with metastatic renal cell carcinoma who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for patients with hypercholesterolemia, testing the efficacy of ezetimibe and placebo, and eprotirome and ezetimibe, with inclusion criteria of age, LDL-cholesterol level, and diet compliance, and exclusion criteria of certain medical conditions.",
    "The sample is a phase 2 trial testing the drug mgcd0103 on patients with relapsed or refractory lymphoma, with specific eligibility criteria including prior treatment and measurable disease, while excluding patients with certain medical conditions or who have been treated with investigational drugs within 28 days prior to study initiation.",
    "This phase 2 trial is testing the efficacy of saf312 and placebo in treating neurogenic detrusor overactivity due to spinal cord lesions, with a focus on patients who are inadequately managed by antimuscarinic medication and have a cystometric bladder capacity of max. 400 mL. The trial excludes patients with chronic inflammation, previous pelvic radiation therapy, or previous or current malignant disease of the pelvic organs, and those with pelvic or genitourinary tract anomalies impacting on bladder function.",
    "The sample is a phase 2 clinical trial for knee osteoarthritis, testing the efficacy of sar113945 and placebo drugs, with inclusion and exclusion criteria based on disease diagnosis, age, gender, and other factors.",
    "This phase 2 trial is testing the efficacy of sorafenib in treating patients with advanced, incurable non-small cell lung cancer who have failed at least one front-line metastatic NSCLC chemotherapy regimen and meet specific eligibility criteria.",
    "The sample is a phase 2 clinical trial for ankylosing spondylitis, testing the efficacy of sarilumab and placebo, with eligibility criteria including a diagnosis of AS, active disease for at least 3 months, and adequate trial of NSAIDs, while exclusion criteria include past non-response to anti-TNFs treatment or any other biological treatment for AS.",
    "This phase 2 trial is testing the efficacy of fluocinonide cream in treating mild to severe atopic dermatitis in patients 12 years or older, with inclusion criteria including an IGA rating of 2-4 and a VAS score of itch greater than or equal to 50, while exclusion criteria include use of systemic or topical anti-inflammatory medication within a certain time frame and allergy to the cream.",
    "This phase 2 trial is testing the efficacy of GSK962040 and placebo in treating gastroparesis in mechanically ventilated patients with nasogastric tube feeding, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for metastatic breast cancer using sagopilone and requiring previous treatment with anthracyclines and taxanes, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for non-small cell lung cancer, testing the efficacy of pemetrexed, cisplatin, and gefitinib, with specific eligibility criteria including never having smoked and an ECOG performance status of 0 to 1.",
    "The sample is a phase 2 trial for perioperative chemotherapy in patients with stage IV colorectal cancer isolated to the liver, with inclusion criteria including one measurable lesion, completely resectable or ablatable metastases, and adequate bone marrow, hepatic, and renal function, while exclusion criteria include previous chemotherapy for metastatic colorectal cancer and concurrent medical or psychiatric conditions, with the drug being tested being perioperative chemotherapy.",
    "This phase 2 trial is testing the efficacy of capecitabine and celecoxib in treating rectal adenocarcinoma, with specific eligibility criteria for patients, including no distant metastatic disease and ability to tolerate major surgery, among other requirements.",
    "This phase 2 trial is testing the drug Faslodex on postmenopausal women with HER2-positive, ER-positive and/or PR-positive breast cancer who have not received prior chemotherapy, endocrine therapy, Herceptin, or other biologic or investigational therapy for metastatic breast cancer, and have no more than two prior endocrine agents in the adjuvant setting as single- or sequential-therapy is permitted, but no prior Faslodex therapy is permitted.",
    "This phase 2 trial is testing the efficacy of tiotropium bromide, an anticholinergic drug, in children between 6 and 11 years old with asthma who have been on maintenance treatment with inhaled corticosteroids at a stable medium dose.",
    "This phase 2 trial is testing the drug romidepsin on patients with colorectal cancer who have previously undergone chemotherapy, and have no known brain metastases, while meeting specific eligibility criteria.",
    "The sample is a phase 2 clinical trial for multiple myeloma patients, testing the efficacy of bortezomib, cyclophosphamide, and dexamethasone, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of celecoxib, a COX-2 inhibitor, in combination with cetuximab for patients with metastatic or unresectable colorectal cancer who have progressed after at least 1 chemotherapy regimen for advanced disease.",
    "The sample is a phase 2 trial for female breast cancer patients with CNS progression, testing the efficacy of capecitabine (Xeloda) with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for patients with relapsed, refractory or previously untreated low-grade non-Hodgkin lymphoma, testing the efficacy of mitoxantrone/cyclophosphamide, fludarabine, rituximab and gm-csf, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of pentostatin and alemtuzumab in treating various T-lymphoid malignancies, including T-cell-prolymphocytic leukemia and peripheral T-cell lymphoma, with specific eligibility criteria for patients, such as age, diagnosis, and performance status.",
    "This phase 2 trial is testing the drug fulvestrant in post-menopausal women with metastatic breast cancer who have received an aromatase inhibitor, and have measurable or nonmeasurable disease, with specific eligibility criteria.",
    "This is a phase 2 clinical trial for Alzheimer's disease using rosiglitazone as a drug, with specific eligibility criteria including meeting NINCDS-ADRDA criteria for Alzheimer's disease, having a Mini Mental State Examination score of 16-26, and having a permanent caregiver.",
    "This phase 2 trial is testing the drug act-050089 on patients with pulmonary arterial hypertension who meet specific inclusion criteria, while excluding those with certain medical conditions or who have taken certain medications within 28 days of Visit 1.",
    "The sample is a phase 2 clinical trial for early stage breast cancer patients using docetaxel and capecitabine, with eligibility criteria including confirmed breast carcinoma, no evidence of disease outside the breast or chest wall, and no prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancer.",
    "This phase 2 trial is testing the efficacy of temsirolimus in treating ovarian cancer patients who have received first-line platinum based chemotherapy and have documented CA125 progression, with inclusion criteria including age 18 or older, ECOG PS 0-2, and adequate baseline hepatic function, while exclusion criteria include other histological types, history of atrial or ventricular arrhythmias, and any evidence of severe or uncontrolled systemic disease.",
    "This phase 2 trial is testing the efficacy of gemcitabine and pertuzumab in treating platinum-resistant ovarian, primary peritoneal, or fallopian tube carcinoma, with eligibility criteria including measurable disease, HER2 activation, and ECOG performance status 0 or 1.",
    "The sample is a phase 2 trial for patients with chronic obstructive pulmonary disease, testing the efficacy of bi 1744 cl/tiotropium bromide fixed dose combination and tiotropium bromide, with eligibility criteria including age, smoking history, and spirometric criteria.",
    "This is a phase 2 trial for patients with chronic obstructive pulmonary disease (COPD) testing the efficacy of GSK961081, salmeterol, and placebo drugs, with eligibility criteria including age, smoking history, and lung function measurements, and exclusion criteria including pregnancy, asthma, and use of certain medications.",
    "The sample is a phase 2 trial testing the efficacy of methadone and morphine in treating moderate to severe cancer-related pain, with eligibility criteria including age, life expectancy, pain severity, and exclusion criteria including drug allergies, respiratory compromise, and recent substance abuse history.",
    "This phase 2 trial is testing the efficacy of Pro 140, a humanized monoclonal antibody to CCR5, compared to a placebo in treating HIV-1 infection in patients with exclusive CCR5-tropic virus and meeting other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of lobeline sulfate, methylphenidate hcl, and placebo in treating attention deficit disorder with hyperactivity, with eligibility criteria including a diagnosis of ADHD, healthy BMI, negative drug test, and non-smoking status.",
    "This phase 2 trial is testing the efficacy of amg 386 in combination with cisplatin and capecitabine for patients with metastatic gastrointestinal cancer who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of gs-5885, gs-9451, ribavirin tablet, and gs-9451 placebo in treating chronic HCV infection with genotype 1, and the eligibility criteria includes liver biopsy results indicating the absence of cirrhosis, HCV RNA > 10^4 IU/mL at Screening, and BMI 18-36 kg/m2.",
    "The sample is a phase 2 trial for Alzheimer's disease, testing the efficacy of a placebo drug on patients who meet specific inclusion criteria such as having a diagnosis of probable Alzheimer's disease and a Mini-mental status exam score of 16-26 inclusive.",
    "This phase 2 trial is testing the efficacy of cetuximab 5mg/ml in treating non-resectable and/or non-operable metastatic colorectal carcinoma in patients over 70 years old with proper hematological, renal and hepatic function, and who have not received chemotherapy for advanced or metastatic disease, with a set of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of sargramostim, docetaxel, and prednisone in treating hormone refractory prostate cancer patients who have progressed despite androgen deprivation, with specific eligibility criteria including prior hormone therapy and a serum testosterone <50 ng/dL.",
    "This phase 2 trial is testing the efficacy of carboplatin and pemetrexed in treating non-small cell lung cancer patients who meet specific eligibility criteria, including having no known CNS metastases and meeting certain hematopoietic, hepatic, renal, cardiovascular, and other patient characteristics.",
    "This phase 2 trial is testing the efficacy of amg 108 and placebo in treating rheumatoid arthritis in patients who have been taking methotrexate for at least 12 weeks, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of ofatumumab and placebo in treating relapsing-remitting multiple sclerosis patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of bortezomib in treating malignant mesothelioma, with specific inclusion and exclusion criteria for patients, and restrictions on prior and concurrent therapies.",
    "This phase 2 trial is testing the efficacy of zoledronic acid versus placebo in treating low back pain with specific inclusion and exclusion criteria, including Modic type I or II change in lumbar MRI and an intensity of low back pain of at least 6 on 10-cm VAS or Oswestry disability score at least 30%.",
    "The sample is a phase 2 trial for advanced ovarian cancer with positive BRCA1 or BRCA2 status, using drugs azd2281 and liposomal doxorubicin, and the eligibility criteria includes having measurable disease by RECIST and excluding previous anthracycline treatment and brain metastases.",
    "This phase 2 trial is testing the efficacy of pf-04191834, naproxen, and their placebos in treating osteoarthritis of the knee, with eligibility criteria including a confirmed diagnosis of osteoarthritis and willingness to stop current pain therapy.",
    "This phase 2 trial is testing the efficacy of gemcitabine hydrochloride and oxaliplatin in treating metastatic or recurrent colorectal cancer patients who have received at least one prior chemotherapy regimen, and have measurable disease, while meeting specific eligibility criteria.",
    "The sample is a phase 2 trial for depression, testing the efficacy of duloxetine, escitalopram, and bms-820836, with inclusion criteria including a history of inadequate response to 1-3 adequate trials of antidepressant treatment and a HAM-D17 score \u2265 18, and exclusion criteria including failure of duloxetine and escitalopram at an adequate dose and duration.",
    "This is a phase 2 trial for patients with clear cell renal cell carcinoma who have experienced disease progression on sorafenib or sunitinib, and will test the efficacy of perifosine as a treatment option.",
    "The sample is a phase 2 trial for chronic hepatitis C, testing the efficacy of interferon-alpha and placebo lozenges, with specific inclusion and exclusion criteria, and a list of associated icd-10 codes.",
    "This phase 2 trial is testing the efficacy of Pro 140, a CCR5 co-receptor inhibitor, and placebo in treating HIV infections in patients with exclusive CCR5-tropic virus, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for gefitinib in patients with oestrogen receptor negative primary breast cancer, with T2-3, N0-2, M0 tumour stage, and the eligibility criteria includes no prior anticancer therapy and WHO performance score 0-1.",
    "This phase 2 trial is testing the efficacy of axl1717 and docetaxel in treating locally advanced or metastatic squamous cell carcinoma or adenocarcinoma histological subtypes of non-small-cell lung cancer, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for hyperlipidemia using ezetimibe as the drug, with specific inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for various diseases including chronic myelogenous leukemia, lymphoma, and myelodysplastic syndromes, using a combination of drugs including rituximab, mycophenolate mofetil, and tacrolimus, with specific inclusion and exclusion criteria for patients and donors.",
    "This phase 2 trial is testing the efficacy of single low dose cyclophosphamide in combination with chemo-radiation therapy for unresectable stage III non-small-cell lung carcinoma and lung neoplasms.",
    "This is a phase 2 trial for patients with recurrent uterine corpus carcinoma, testing the drug gefitinib, with eligibility criteria including prior chemotherapy, measurable lesions, and specific medical conditions.",
    "The sample is a phase 2 trial for asthma and bronchoconstriction, testing the efficacy of levalbuterol hfa mdi and racemic albuterol, with inclusion criteria including age, asthma diagnosis, and good health, and exclusion criteria including pregnancy, recent hospitalization for asthma, and substance abuse.",
    "The sample is a phase 2/3 trial for patients with primary progressive multiple sclerosis, testing the efficacy of rituximab and placebo drugs, with specific eligibility criteria including disease duration, EDSS score, and CSF specimen results.",
    "This phase 2 trial is testing the efficacy of disulfiram and chelated zinc in treating stage IV melanoma cancer patients who have progressed after or not responded to at least one cycle of first line therapy, and have no known allergy to disulfiram or zinc gluconate.",
    "This phase 2 trial is testing the efficacy of everolimus and bevacizumab in treating metastatic renal cell carcinoma with specific inclusion and exclusion criteria, including limitations on prior treatments and organ function.",
    "This phase 2 trial is testing the efficacy of doxorubicin and trabectedin in treating non-operable and/or metastatic soft tissue sarcoma, with specific inclusion and exclusion criteria for patients.",
    "The sample is a phase 2 trial for patients with radioiodine-refractory metastatic or unresectable locally-advanced thyroid cancer, testing the drug ag-013736, with inclusion criteria of at least 1 measurable target lesion and exclusion criteria of previous treatment with anti-angiogenesis agents or recent cardiovascular events.",
    "The sample is a phase 2 trial for lung cancer patients with unresectable Stage IIIB, IV, or recurrent bronchoalveolar carcinoma (BAC) using paclitaxel as the drug, and the eligibility criteria include age, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, and other factors.",
    "This phase 2 trial is testing the efficacy of erlotinib hydrochloride and sunitinib malate in treating unresectable or metastatic kidney cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of tmc435, psi-7977 (gs7977), and ribavirin in treating chronic genotype 1 hepatitis C virus (HCV) infection in null responders to PegIFN/ribavirin, with inclusion criteria including plasma HCV RNA of more than 10,000 IU/mL at screening and liver biopsy showing Metavir F3 or F4 fibrosis.",
    "The sample is a phase 2 trial for non-small cell lung cancer patients with specific eligibility criteria, testing the efficacy of carboplatin, nitroglycerin, and paclitaxel as drugs.",
    "The sample is a phase 2 trial for Parkinson's disease and movement disorder syndrome, using istradefylline (kw-6002) as the drug, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of indacaterol and placebo in treating moderate to severe chronic obstructive pulmonary disease (COPD) in Japanese patients aged 40 to 75 years old with a smoking history of at least 20 pack years.",
    "The sample is a phase 2 clinical trial for Crohn's disease, testing the efficacy of drugs including d9421-c and placebo, with inclusion criteria of age and diagnosis, and exclusion criteria of previous surgeries and infections.",
    "This phase 2 trial is testing the efficacy of pemetrexed and gemcitabine in treating advanced non-clear cell renal cell carcinoma patients with measurable disease, and the eligibility criteria includes adequate organ and marrow function, ECOG performance status 0-2, and no prior chemotherapy for RCC.",
    "This phase 2 trial is testing the efficacy of pentostatin in treating chronic graft versus host disease in patients who have failed prior corticosteroid treatment, with eligibility criteria including extensive stage chronic GvHD and certain laboratory values.",
    "The sample is a phase 2 trial for metastatic colorectal cancer, testing the efficacy of oxaliplatin, capecitabine, and bevacizumab, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for rheumatoid arthritis patients receiving methotrexate, testing the efficacy of amg 719 compared to placebo, with eligibility criteria including a disease duration of at least 24 weeks and no recent history of substance or alcohol abuse.",
    "The sample is a phase 2/phase 3 trial testing the efficacy of sertraline in treating depressive disorder, major, with specific inclusion and exclusion criteria listed, including the requirement of a HDRS score greater than 18.",
    "This phase 2 trial is testing cisplatin, etoposide, gemcitabine, and methylprednisolone in patients with peripheral T-cell non-Hodgkin's lymphoma who have bulky stage II or stage III or IV disease and have not responded to non-platinum based chemotherapy, and the eligibility criteria includes various disease characteristics and patient characteristics.",
    "The sample is a phase 2 clinical trial testing the efficacy of gemcitabine hydrochloride, lenalidomide, and oxaliplatin in treating aggressive non-Hodgkin lymphoma that is refractory or relapsed, with eligibility criteria including ECOG performance status, absolute neutrophil count, platelet count, and prior concurrent therapy.",
    "This is a phase 2 trial for patients with locally advanced and metastatic basal cell carcinoma, testing the drug LDE225, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the drug cilengitide on patients with recurrent intracranial glioblastoma multiforme who require a surgical procedure for tumor removal and meet various eligibility criteria.",
    "This phase 2 trial focuses on patients with coronary heart disease and tests the effectiveness of dalcetrapib and placebo drugs, with inclusion criteria being completion of treatment on study NC19453 and exclusion criteria being significant lymph node abnormalities at the end of the same study.",
    "This phase 2 trial is testing the efficacy of tipranavir, saquinavir, and ritonavir in treating HIV infections in patients who have failed previous PI-containing regimens, with inclusion criteria including exposure to current PI therapy for at least 6 months and availability of at least two new NRTI options.",
    "This phase 2 trial is testing the efficacy of vorinostat, a histone deacetylase inhibitor, in treating relapsed or untreated acute myeloid leukemia patients who are ineligible for stem cell transplantation and have no clinical evidence of CNS or pulmonary leukostasis, disseminated intravascular coagulation, or CNS leukemia.",
    "This phase 2 trial is testing the drug YM178 for overactive bladder, with inclusion criteria of patients over 18 years suffering from OAB for more than 3 months and exclusion criteria of pregnant and breastfeeding women or any medical condition that interferes with YM178 or the comparator drug tolterodine.",
    "The sample is a phase 2/phase 3 trial for cardiac surgery patients using sodium bicarbonate and sodium chloride to prevent acute kidney injury, with eligibility criteria including age, preoperative plasma creatinine levels, and insulin dependent diabetes mellitus.",
    "This phase 2 trial is testing the efficacy of gemcitabine hydrochloride and imatinib mesylate in treating patients with non-small cell lung cancer who have received at least one prior chemotherapy regimen and meet specific eligibility criteria.",
    "The sample is a phase 2 clinical trial for recurrent glioblastoma multiforme, testing the efficacy of bevacizumab and fotemustine, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of pf-04217329 and latanoprost in treating primary open angle glaucoma and ocular hypertension, with a list of various doses of the drugs, and specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for cystic fibrosis patients with diabetes, testing the efficacy of sitagliptin and placebo drugs, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for major depressive disorder, testing the efficacy of alks 5461 and placebo in patients who have been treated with an adequate dose of SSRI/SNRI for at least 8 weeks, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug cediranib maleate on patients with clear cell renal cell carcinoma, recurrent renal cell cancer, or stage iv renal cell cancer, who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for patients with histologically proven adenocarcinoma, using pemetrexed and gemcitabine as drugs, with eligibility criteria including ECOG Performance Status 0-1 and exclusion criteria including prior treatment with chemotherapy and bilirubin greater than or equal to 40 mol/L.",
    "The sample is a phase 2 trial for indolent B-cell lymphoma using cyclophosphamide as the drug, with eligibility criteria including confirmed stage III or IV lymphoma and lymph node or visceral lesion at least 2 cm in diameter.",
    "The sample is a phase 2 trial for metastatic breast cancer patients with ER+ and/or PgR+ receptor positive disease, HER2 negative, progressing from prior hormonal therapy, testing the efficacy of lapatinib and metformin, with eligibility criteria including adequate bone marrow, liver, and renal function, normal respiratory function, and NYHA Classification \u2264 2.",
    "This phase 2 trial is testing the efficacy of gemcitabine, carboplatin/cisplatin, and erlotinib in treating patients with nasopharyngeal cancer who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of cisplatin, etoposide, and sorafenib tosylate in treating extensive-stage small cell lung cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for diabetes using the drug vi-0521, with inclusion criteria including completion of a previous trial and willingness to comply with study procedures, and exclusion criteria including the development of morbidities during the previous trial.",
    "This phase 2 trial is testing the drug everolimus on patients with newly diagnosed, localized adenocarcinoma of the prostate who are recommended for radical prostatectomy and meet certain disease and patient characteristics criteria.",
    "This phase 2 trial will test the efficacy of vorapaxar, aspirin, and placebo in treating cerebral infarction, with eligibility criteria including confirmed cerebral infarction lesion and exclusion criteria including pregnancy, bleeding diathesis, and contraindication to aspirin.",
    "This phase 2 trial is testing the efficacy of lenalidomide, a drug, in treating liver cancer patients who have previously been treated with sorafenib and meet certain eligibility criteria.",
    "The sample is a phase 2 trial for rheumatoid arthritis with the drugs nnc0142-0002 and placebo, and the eligibility criteria includes a diagnosis of RA meeting ACR1987 criteria, active RA with a DAS28-CRP score of 4.5 or more, and concomitant treatment with methotrexate.",
    "The sample is a phase 2 trial for non-small cell lung cancer, testing the efficacy of drugs including enzastaurin, pemetrexed, docetaxel, and carboplatin, with specific inclusion and exclusion criteria for patient eligibility.",
    "This is a phase 2 trial for patients with migraine with or without aura, testing the efficacy of tonabersat and placebo, with inclusion and exclusion criteria including age, migraine history, medication use, and medical conditions.",
    "This trial is testing the efficacy of s-1 + irinotecan and irinotecan in treating inoperable advanced gastric adenocarcinoma, with eligibility criteria including confirmed PD status after first-line chemotherapy and exclusion criteria including hypersensitivity to fluoropyrimidines and CPT-11.",
    "This phase 2 trial is testing lapatinib, paclitaxel, 5-fluorouracil, epirubicin, and cyclophosphamide in patients with ErbB2-overexpressing inflammatory breast cancer who have measurable or clinically evaluable skin disease and meet other eligibility criteria.",
    "This phase 2 trial is testing a combination of drugs including asparaginase, busulfan, cyclophosphamide, cyclosporine, cytarabine, daunorubicin hydrochloride, etoposide, gemtuzumab ozogamicin, and methotrexate for the treatment of newly diagnosed primary acute myeloid leukemia (AML) in children aged 1 month to 21 years who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for prostate cancer patients with PSA progression, who have undergone prior chemotherapy with Docetaxel, and are currently on androgen deprivation therapy, using abiraterone acetate and prednisolone as drugs, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for patients with high- or intermediate-grade malignant soft tissue sarcoma, including ovarian cancer, sarcoma, and small intestine cancer, testing the efficacy of brostallicin and doxorubicin hydrochloride, with eligibility criteria including age, performance status, blood counts, liver and kidney function, and exclusion of certain tumor types and serious medical conditions.",
    "This phase 2 trial is testing the efficacy of growth hormone and corticosteroid drugs in treating moderate to severely active Crohn's disease in patients aged 5 years and above, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of everolimus and temozolomide in treating unresectable stage IV malignant melanoma with measurable disease, and includes eligibility criteria for patient characteristics and prior concurrent therapy.",
    "The sample is a phase 2 trial for vulvodynia and vulvar vestibulitis, testing the efficacy of pregabalin, with inclusion criteria including pain level and reliable birth control, and exclusion criteria including chronic pain disorders and contraindication to pregabalin.",
    "This phase 2 trial is testing the safety and efficacy of TAK-442 and enoxaparin in preventing venous thromboembolism in patients undergoing knee replacement surgery, with strict inclusion and exclusion criteria including disallowed medications and medical conditions.",
    "The sample is a phase 2 trial for Alzheimer's disease, testing the drugs pf-04494700 and placebo, with inclusion criteria including a diagnosis of Alzheimer's disease and use of cholinesterase inhibitor and/or memantine for at least 4 months, and exclusion criteria including evidence of neurological or psychiatric illness that could contribute to dementia and poorly controlled high blood pressure.",
    "The sample is a phase 2 trial for metastatic melanoma using bevacizumab as a drug, with eligibility criteria including confirmed progression on standard first line treatment with dacarbazine, measurable disease according to RECIST criteria, and recovered from prior chemotherapy.",
    "This phase 2 trial is testing the drug talabostat mesylate on patients with metastatic kidney cancer who have progressed after multikinase inhibitor therapy, and have no history of CNS or brain metastasis, with specific eligibility criteria for patient characteristics and prior concurrent therapy.",
    "This phase 2 trial is testing the effectiveness of high intensity focused ultrasound (HIFU) in combination with thermodox for patients with painful bone metastases, breast carcinoma, non-small cell lung cancer, small cell lung cancer, or adenocarcinoma who have failed at least one prior attempt or are not eligible for external beam radiation therapy (EBRT).",
    "This phase 2 trial is testing the efficacy of gemcitabine hydrochloride and irinotecan hydrochloride in treating locally advanced unresectable or metastatic kidney cancer, with eligibility criteria including confirmed renal cell carcinoma, measurable disease, and specific hematopoietic, hepatic, and renal levels, among others.",
    "This phase 2 trial is testing the efficacy of sorafenib and gemcitabine in treating advanced unresectable and/or metastatic hepatocellular carcinoma, with specific inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial is testing the efficacy of docetaxel and carboplatin in treating stage IIIA or IIIB non-small-cell lung cancer patients with measurable disease who have not received previous chemotherapy, radiation therapy or other systemic therapy for their NSCLC, and meet other eligibility criteria.",
    "The sample is a phase 2 trial for bacterial infections and infection, using drugs bc-3781 and vancomycin, with eligibility criteria including documented acute bacterial skin and skin structure infection and exclusion criteria including uncomplicated skin and skin structure infection.",
    "This phase 2 trial is testing the efficacy of eslicarbazepine acetate and placebo in treating acute manic episodes in patients with bipolar I disorder, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for coronary heart disease with the drugs placebo and dalcetrapib, and the eligibility criteria includes age range, body weight, and exclusion criteria such as recent coronary events and history of malignancy.",
    "This phase 2 trial is testing the efficacy of bosentan (tracleer) in treating systemic scleroderma, skin fibrosis, and hand functionality, with specific inclusion and exclusion criteria for patient eligibility.",
    "This is a phase 2 trial for fibromyalgia, testing the efficacy of droxidopa, carbidopa, droxidopa/carbidopa, and placebo, with inclusion criteria including a clinical diagnosis of fibromyalgia and a score of between 20mm and 90mm on the Visual Analog Scale for Pain (VAS-P).",
    "This phase 2 trial is testing the efficacy of zoledronate and atorvastatin in treating bone metastases in patients with renal cell carcinoma, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 trial is testing the drugs ly2623091 and eplerenone on patients with chronic kidney disease and stable renal function who have been taking an ACE inhibitor and/or ARB for at least 3 months, and have an estimated glomerular filtration rate between 30-70 milliliter/minute/1.73 square meters.",
    "The sample is a phase 2 trial for lymphoma patients who have received first-line therapy with R-CHOP or equivalent, and will test the efficacy of sgn-40, placebo, rituximab, etoposide, carboplatin, and ifosfamide, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for Crohn's disease, testing the efficacy of ldp-02 and placebo drugs on patients with specific inclusion and exclusion criteria, including a CDAI score between 220 and 400, and stable 5-ASA compound dosage.",
    "This phase 2 trial is testing the drug everolimus on patients with refractory colorectal cancer who have mutations in the PI3K gene, and have measurable lesions with certain characteristics, while meeting specific patient criteria.",
    "This phase 2 trial is testing the efficacy of ofatumumab and chemotherapy in treating patients with active B-CLL, with a list of inclusion and exclusion criteria, and a list of drugs including ofatumumab, fludarabine, and cyclophosphamide.",
    "This phase 2 trial is testing the efficacy of bortezomib, dexamethasone, and ifosfamide, as well as mesna, cisplatin, etoposide, and rituximab in treating CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma patients who have relapsed after or not responded to at least one standard, upfront multi-agent chemotherapy for DLBCL, and have measurable PET positive disease, with various inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for atopic dermatitis, testing the efficacy of different doses of jnj-26113100 compared to placebo, with eligibility criteria including a minimum body surface area involvement and exclusion criteria including evidence of significant abnormalities in various bodily systems and recent use of investigational drugs or biologics.",
    "The sample is a phase 2 trial for myelodysplastic syndrome (MDS) patients with lower risk and red blood cell transfusion dependency, testing the drugs lbh589 and epoetin alfa, with key inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of cytarabine, etoposide, leucovorin calcium, methotrexate, and temozolomide in treating newly diagnosed primary CNS lymphoma patients with measurable contrast-enhancing disease by MRI of the brain and spine, and who meet specific eligibility criteria.",
    "This phase 2 trial is testing the effectiveness of bevacizumab, pemetrexed, and carboplatin in treating non-small cell lung cancer patients who meet specific eligibility criteria, including having no prior treatment for the disease.",
    "This phase 2 trial is testing the efficacy of celecoxib in treating metastatic or recurrent breast cancer patients who have undergone at least 4 prior courses of chemotherapy resulting in stable disease, partial response, or complete response, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of irinotecan hydrochloride, gefitinib, leucovorin calcium, and fluorouracil in treating patients with advanced or recurrent adenocarcinoma of the colon or rectum, with specific eligibility criteria for patient selection.",
    "This phase 2 trial is testing the efficacy of cimicoxib and placebo in treating major depression, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the efficacy of pazopanib hydrochloride, leuprolide acetate, and goserelin acetate in treating recurrent prostate cancer with specific eligibility criteria, including no brain metastases and normal bilirubin levels.",
    "This phase 2 trial is testing the efficacy of bortezomib, cyclophosphamide, doxorubicin hydrochloride, vincristine, and dexamethasone in treating mantle cell lymphoma patients who meet specific eligibility criteria, including having measurable disease and an ECOG performance status of 0-2.",
    "This trial is testing the effectiveness of caffeine and placebo in reducing excessive daytime somnolence in patients with Parkinson's disease, with specific inclusion and exclusion criteria for eligibility.",
    "This phase 2 trial is testing the efficacy of FTC/RPV/TDF, a drug combination, in treating HIV-1 infection, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 trial is testing the drug vandetanib on patients with relapsed or refractory ovarian, fallopian tube, or primary peritoneal cancer, who meet specific eligibility criteria.",
    "This clinical trial is testing the efficacy of infliximab and placebo in treating lupus erythematosus and lupus nephritis, with eligibility criteria including biopsy-proven membranous glomerulonephritis and proteinuria > 3 g/day despite adequate therapy with ACE inhibitors and steroids.",
    "This phase 2 trial is testing the efficacy of nva237, placebo, and tiotropium in treating moderate to severe chronic obstructive pulmonary disease (COPD) in patients with a smoking history of at least 10 pack years, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for rheumatoid arthritis patients who have active disease despite current methotrexate treatment, and the drugs being tested are apremilast 30 mg, apremilast 20 mg, and placebo. The eligibility criteria include specific lab requirements, stable methotrexate treatment, and meeting certain laboratory criteria at screening.",
    "This phase 2 trial is testing erlotinib, a drug used to treat non small cell lung cancer, in patients with unresectable locally advanced or metastatic NSCLC who have not received previous therapy for advanced/metastatic NSCLC and meet specific eligibility criteria.",
    "This trial is testing the efficacy of bosentan and placebo in treating patients with sarcoidosis and pulmonary arterial hypertension, with specific inclusion and exclusion criteria.",
    "This phase 2 trial will test the efficacy of gw685698x and placebo in treating asthma patients who meet specific eligibility criteria, including a diagnosis of asthma, a best FEV1 of 40%-90% of the predicted normal value, and a stable dose of inhaled corticosteroids for four weeks prior to Visit 1.",
    "This phase 2 trial is testing the drug fenretinide on patients with histologically proven oral mucosal intraepithelial neoplasia, with eligibility criteria including no concurrent biologic, chemotherapy, endocrine, or radiotherapy, and patients must not be pregnant or nursing.",
    "This is a phase 2 trial for breast cancer patients with specific inclusion and exclusion criteria, testing the efficacy of cyclophosphamide, docetaxel, doxorubicin, and nov 002.",
    "This phase 2 trial is testing the effectiveness of lamotrigine, a drug used to treat bipolar disorder, on children aged 10-20 with bipolar disorder, and includes eligibility criteria such as exclusion of those with certain medical conditions and pregnancy, and the use of fMRI to study brain activity.",
    "The sample is a phase 2 trial for Alzheimer's disease using the drug abt-089 and placebo, with inclusion criteria such as mild to moderate Alzheimer's disease and a stable dose of an acetylcholinesterase inhibitor, and exclusion criteria such as living in a nursing home and a history of drug or alcohol abuse/dependence.",
    "This phase 2 trial is testing the efficacy of mp-376 and placebo in treating cystic fibrosis patients who meet specific inclusion and exclusion criteria, including a confirmed diagnosis of cystic fibrosis and positive sputum culture for P. aeruginosa within the past 18 months.",
    "The sample is a phase 2 trial for acromegaly patients who have completed a core study and achieved biochemical control with pasireotide, with inclusion and exclusion criteria listed, and the drug pasireotide being the focus of the trial.",
    "The sample is a phase 2 trial for gastric cancer patients with specific disease characteristics and patient characteristics, testing the efficacy of capecitabine and oxaliplatin as treatment options.",
    "This phase 2 trial is testing the efficacy of sorafenib, a drug, in treating myelodysplastic syndromes and chronic myelomonocytic leukemia, with specific eligibility criteria for patients, including age, disease severity, and medical history.",
    "The sample is a phase 2 trial for kidney neoplasms using thalidomide and capecitabine as drugs, with inclusion and exclusion criteria listed.",
    "This is a phase 2 trial for patients with relapsing multiple sclerosis, testing the efficacy of fty720 and placebo drugs, with inclusion criteria of at least two documented relapses in the previous 2 years or one documented relapse in the last year, and exclusion criteria of other chronic diseases of the immune system, malignancies, pulmonary or heart disease, and pregnant or nursing women.",
    "This phase 2 trial is testing the efficacy of sunitinib malate in treating various connective tissue neoplasms, including adult malignant fibrous histiocytoma of bone, desmoid tumor, endometrial cancer, ovarian cancer, sarcoma, and small intestine cancer, with specific eligibility criteria for patients, including prior standard neoadjuvant or adjuvant systemic therapy, and no untreated brain metastases or symptomatic brain metastases or leptomeningeal disease.",
    "This phase 2 trial is testing the efficacy of vardenafil hcl and placebo in treating overactive bladder and detrusor overactivity, with specific inclusion and exclusion criteria for patients.",
    "This trial is for patients with relapsing multiple sclerosis and will test the effectiveness of mycophenolate mofetil (cellcept) as a treatment option, with specific inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for gout patients who have completed four weeks of double-blind dosing in Study TMX-00-004, and the trial will test the efficacy of febuxostat in reducing serum uric acid levels, with inclusion criteria including hyperuricemia and adequate renal function, and exclusion criteria including xanthinuria and active liver disease.",
    "This phase 2 trial is testing the efficacy of metformin and glucophage in treating diabetic foot, with strict inclusion and exclusion criteria for eligible participants.",
    "The sample is a phase 2 trial for HIV infections testing the efficacy of fosamprenavir and saquinavir in protease inhibitor naive patients with wild type genotype and CD4 count greater than 200/mm3, and viral load between 10,000 copies/ml and 750,000 copies/ml, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of GSK2336805, pegylated interferon alfa-2a, and ribavirin in treating chronic genotype 1 or genotype 4 HCV infection in patients who are treatment-naive and have a non-cirrhotic fibrosis classification, with key inclusion criteria including IL28B genotyping and a BMI between 18-36 kg/m2, and key exclusion criteria including a positive test for HBsAg or anti-HIV antibody, history of other clinically significant chronic liver disease, and abnormal hematological and biochemical parameters.",
    "This phase 2 trial is testing the efficacy of cisplatin, panitumumab, and docetaxel in treating metastatic or recurrent squamous cell carcinoma of head and neck, with eligibility criteria including confirmed diagnosis, measurable disease, ECOG performance score of 0 or 1, and adequate organ function.",
    "This phase 2 trial aims to test the efficacy of ferric carboxymaltose and iron dextran injection in treating iron deficiency anemia in female subjects with heavy uterine bleeding, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for patients with type 1 diabetes mellitus, testing the efficacy of ly2605541 and insulin glargine, with inclusion criteria including a maximum daily dose of 1 unit per kilogram of insulin glargine, HbA1c of no greater than 10.5%, and BMI of 19 to 45 kg/m\u00b2.",
    "This phase 2 trial is testing the efficacy of dasatinib, a tyrosine kinase inhibitor, in treating patients with recurrent skin cancer, squamous cell carcinoma of the skin, and stage 0 or I chronic lymphocytic leukemia, who meet a set of eligibility criteria.",
    "The sample is a phase 2 trial for non-small cell lung cancer patients with specific eligibility criteria, testing the efficacy of gemcitabine plus pemetrexed and paclitaxel plus gemcitabine as treatment options.",
    "The sample is a phase 2 trial testing the efficacy of aprepitant and granisetron in preventing nausea and vomiting in patients with bone metastases receiving palliative radiotherapy, with specific inclusion and exclusion criteria. The trial focuses on patients with bone metastases from any primary solid tumor site scheduled to receive a single 8 Gy fraction of palliative radiotherapy considered to be moderately emetogenic.",
    "This phase 2 trial is testing the efficacy of irinotecan hydrochloride, a chemotherapy drug, in treating metastatic breast cancer patients who have previously received trastuzumab-containing regimens, and have measurable disease, while meeting certain eligibility criteria.",
    "The sample is a phase 2 clinical trial for prostate cancer using thalidomide as a drug, with eligibility criteria including high-risk disease and appropriate medical candidacy for radical prostatectomy.",
    "The sample is a phase 2 trial for type 2 diabetes mellitus, testing the efficacy of omarigliptin, pioglitazone, and metformin, with eligibility criteria including age, BMI, and medication history.",
    "This phase 2 trial aims to test the efficacy of zonisamide, a mood stabilizer, in reducing or stopping drinking in patients with bipolar disorder and alcohol use disorders, while also assessing the safety and tolerability of the drug.",
    "This phase 2 trial is testing the efficacy of e/c/f/tdf and e/c/f/taf in treating acquired immunodeficiency syndrome and HIV infections, with eligibility criteria including plasma HIV 1 RNA levels \u2265 5,000 copies/mL and no prior use of any approved or experimental anti-HIV drug for any length of time.",
    "This phase 2 trial is testing the use of cyclophosphamide at different dose levels in allogeneic transplantation for genetic lymphohematological diseases in patients aged 0 to 21 years with a histocompatible sibling or related donor, and includes diseases such as thalassemia, combined immune deficiency, and Wiskott-Aldrich syndrome.",
    "The sample is a phase 2 clinical trial for endometrial carcinoma, testing the drug fulvestrant, with inclusion criteria of postmenopausal hormone receptor positive patients who have not previously been treated with fulvestrant, and exclusion criteria of previous endocrine therapy or malignancy less than 3 years ago.",
    "This phase 2 trial is testing the efficacy of pth (1-34) gel versus placebo gel in treating stable plaque psoriasis with a minimum of 2% affected BSA, and the eligibility criteria includes being mentally competent, between the ages of 18 to 65 years, and having a clinical diagnosis of stable plaque psoriasis for at least 3 months.",
    "This phase 2 trial is testing the efficacy of postoperative radiotherapy and panitumumab in treating salivary gland malignancy, with specific eligibility criteria including no prior chemotherapy or radiotherapy for head and neck cancer, normal organ and marrow function, and a disease-free survival of 3 years or more for prior invasive malignancy.",
    "This phase 2 trial is testing the effectiveness of capsaicin dermal patch on patients with herpes zoster, neuralgia, pain, HIV infections, and peripheral nervous system diseases, with specific eligibility criteria including a washout period for topical pain medications and stable chronic, non-topical pain medications, and successful completion of a past trial of NGX-4010.",
    "This is a phase 2 clinical trial for non-small cell lung cancer patients, testing the efficacy of docetaxel, oxaliplatin, and bevacizumab, with eligibility criteria including no prior systemic chemotherapy, measurable disease, and adequate renal and hematologic function.",
    "This phase 2 trial is testing the efficacy of low dose bibf1120 and other drugs in treating pulmonary fibrosis, with eligibility criteria including FVC>50% and single breath DLCO 30-79% of predicted value.",
    "This phase 2 trial is testing the efficacy of BMS-663068 and ritonavir in treating Clade B HIV-1 infected subjects who are antiretroviral naive or experienced, have a plasma HIV RNA \u2265 5,000 copies/mL, and a CD4+ lymphocyte \u2265 200 cells/\u00b5L, among other eligibility criteria.",
    "This phase 2 trial is testing the drug Abi-007 (Abraxane\u00ae) on patients with metastatic or locally recurrent urothelial or bladder cancer who are not eligible for higher priority trials, and have recovered from radiation therapy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for ADHD with hyperactivity, testing the efficacy of nrp104, Adderall XR, and placebo in children aged 6-12 years who have shown adequate response to stimulants without unacceptable side effects, with exclusion criteria including co-morbid psychiatric diagnosis, seizure history, tic disorder, Tourette's, clinically significant ECG or laboratory abnormalities, and taking clonidine or anticonvulsant drugs or medications that affect blood pressure or heart rate.",
    "This phase 2 trial is testing the effectiveness of palonosetron hydrochloride, a selective 5-HT3 receptor antagonist, in reducing nausea and vomiting in patients with various gastrointestinal cancers who are undergoing radiation therapy, and have no hypersensitivity to the drug.",
    "The sample is a phase 2 trial for chronic hepatitis C patients with genotype 1 and 4, using drugs such as copegus, danoprevir, and pegasys, with eligibility criteria including HCV RNA >/=50,000 IU/mL and exclusion criteria including cirrhosis or incomplete/transition to cirrhosis and other forms of liver disease, HIV infection, hepatocellular carcinoma or severe cardiac disease.",
    "This phase 2 trial is testing the efficacy of clofarabine and cytarabine in treating acute myelogenous leukemia in patients over 60 years old with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of erlotinib hydrochloride, a drug, in treating bladder cancer in former smokers who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for locally advanced prostate cancer with high-risk characteristics, testing the efficacy of bicalutamide, leuprolide acetate, and squalamine lactate, with eligibility criteria including PSA levels, performance status, and various medical conditions.",
    "This phase 2 trial is testing the efficacy of endostar and paclitaxel/carboplatin in treating non-small cell lung cancer patients with measurable disease, stage IIIA or IIIB, and ECOG performance status 0-1, while excluding patients with distant metastasis, small cell carcinoma of lung, and other contraindications for radiotherapy.",
    "This phase 2 trial is testing the efficacy of jx-594 followed by sorafenib in treating primary hepatocellular carcinoma in patients who are not surgically resectable for cure, with specific eligibility criteria including Child Pugh A or B, KPS score of \u2265 70, and acceptable kidney function, while excluding patients with known contraindications to sorafenib, significant immunodeficiency, and current, known CNS malignancy.",
    "The sample is a phase 2 trial for the drug AGN 203818 in patients with painful bladder syndrome/interstitial cystitis, with inclusion criteria of moderate or severe bladder pain and exclusion criteria of uncontrolled disease or pregnancy/nursing.",
    "This phase 2 trial is testing the efficacy of latanoprost and travatan z in treating ocular hypertension, open angle glaucoma, and chronic angle closure glaucoma, with eligibility criteria including age, diagnosis, and willingness to follow study procedures.",
    "The sample is a phase 2 trial for hypercholesterolemia, testing the efficacy of etc-1002, placebo, and atorvastatin, with specific eligibility criteria for LDL-C levels and exclusion criteria for cardiovascular disease and uncontrolled hypertension.",
    "The sample is a phase 2 trial for patients with progressive or recurrent stage IV non-small cell lung cancer, testing the drug temozolomide, with eligibility criteria including age, performance status, and prior treatments.",
    "The sample is a phase 2 trial for postmenopausal females with locally advanced or metastatic breast cancer, testing the drug TAS-108, with eligibility criteria including positive estrogen receptor and/or progesterone receptor status, prior hormonal anti-tumor therapies, and adequate liver and renal function.",
    "The sample is a phase 2 trial for depressive disorder using bupropion hydrochloride as the drug, with inclusion and exclusion criteria outlined.",
    "This clinical trial is testing the efficacy of eb-1010 and SSRIs in treating major depressive disorder in patients who have had an inadequate response to one or no adequate SSRI or SNRI treatment, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with refractory acute myeloid leukemia, testing the drug troxatyl\u2122 (troxacitabine) with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug irofulven on patients with metastatic or locally recurrent adenocarcinoma of the colon or rectum, with specific eligibility criteria including measurable disease and certain laboratory values.",
    "The sample is a phase 2 trial for non-small cell lung cancer using the drug ps-341 (velcade-drug) and includes eligibility criteria for patients with confirmed NSCLC stage III B or Stage IV and no prior chemotherapy regimen.",
    "This phase 2 trial is testing the effectiveness of paclitaxel, topotecan, and carboplatin in treating ovarian cancer, fallopian tube cancer, and malignant tumor of peritoneum, with specific eligibility criteria for patients.",
    "The sample is a phase 2 trial for endometriosis, testing the efficacy of proellex 25 mg and 50 mg compared to placebo, with inclusion criteria including premenopausal women with documented endometriosis and clinical symptoms for at least 3 months, and exclusion criteria including prior hysterectomy or bilateral oophorectomy and abnormal screening endometrial biopsy.",
    "The sample is a phase 2 trial for asthma patients, testing the efficacy of drugs including azd5423 and budesonide 200 microgram, with inclusion criteria such as positive allergen induced airway bronchoconstriction and positive skin prick test to common aeroallergens.",
    "The sample is a phase 2 trial for locally advanced or metastatic bladder cancer, testing the efficacy of gemcitabine hydrochloride and irinotecan hydrochloride, with eligibility criteria including age over 18, ECOG 0-2 performance status, and no prior irinotecan or gemcitabine treatment.",
    "This is a phase 2 trial for Alzheimer's disease using the drug hf0220, with eligibility criteria including a diagnosis of probable Alzheimer's disease, mild to moderate dementia, and written consent from the patient and responsible carer.",
    "This phase 2 trial is testing the drug mitomycin c on patients with metastatic cancer and peritoneal metastases, who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of single and multiple low dose cyclophosphamide in treating MUC1-expressing multiple myeloma, with eligibility criteria including documented disease and a treatment-free interval of at least 3 months, while exclusion criteria include previous exposure to MUC1 targeting therapy and autoimmune disease that could compromise subject safety.",
    "This phase 2 trial is testing the efficacy of azd6765 iv and placebo in treating major depressive disorder in patients who have had inadequate response to at least 3 antidepressants, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of pegylated liposomal doxorubicin, docetaxel, and trastuzumab in treating metastatic breast carcinoma with HER2 overexpression, and includes eligibility criteria such as age, prior chemotherapy, and laboratory requirements.",
    "This phase 2 trial is testing the effectiveness of gemcitabine hydrochloride and paclitaxel in treating previously untreated metastatic or locoregionally advanced bladder cancer, transitional cell cancer of the renal pelvis and ureter, and urethral cancer, with specific eligibility criteria for patients including age, performance status, and prior concurrent therapy.",
    "This phase 2 trial is testing the efficacy of interferon-beta-1a, 44 microgram and 66 microgram, compared to placebo, in treating moderately active ulcerative colitis in patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of gemcitabine and abraxane in treating potentially resectable adenocarcinoma of the pancreas, with strict inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for irritable bowel syndrome, testing the drugs ym060 and placebo, with inclusion criteria based on Rome III Diagnostic Criteria and exclusion criteria including a history of surgical resection or diagnosis of inflammatory bowel disease, and a history of drug or alcohol abuse within 1 year.",
    "This phase 2 trial is testing the drug GDC-0449 on patients with pancreatic ductal adenocarcinoma who meet specific eligibility criteria, including having a confirmed tissue diagnosis and adequate organ function, while excluding those with certain medical conditions or infections.",
    "The sample is a phase 2 trial for irritable bowel syndrome with diarrhea, testing the efficacy of placebo, mesalamine granules 750 mg, and mesalamine granules 1500 mg, with inclusion criteria based on Rome III criteria and IBS symptom scores, and exclusion criteria including inflammatory bowel disease, Type 1 or 2 diabetes, pregnancy or lactation, and history of HIV or hepatitis B or C.",
    "This phase 2 trial is testing the efficacy of apremilast and placebo in treating psoriatic arthritis, with specific inclusion and exclusion criteria for patients, including the requirement of a negative pregnancy test for females of childbearing potential.",
    "The sample is a phase 2 clinical trial for patients with metastatic or recurrent nasopharyngeal carcinoma, testing the efficacy of gemcitabine and oxaliplatin as chemotherapy drugs, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of placebo and ethosuximide in treating complex regional pain syndromes, with inclusion criteria including a diagnosis of CRPS and stable but suboptimal pain pharmacotherapy, and exclusion criteria including optimal response to opioids, antidepressants, anticonvulsants or anti-inflammatory medications, and any history or indication of kidney or liver disease.",
    "This phase 2 trial will test the efficacy of msdc-0602, a drug for type 2 diabetes, compared to placebo and pioglitazone, in patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of gemcabene, a drug, in treating hypercholesterolemia and hypertriglyceridemia, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus, testing the efficacy of linagliptin and glimepiride as compared to placebo, with inclusion criteria including HbA1c levels and exclusion criteria including cardiovascular disease and recent insulin treatment.",
    "This phase 2 trial is testing the drugs gw873140 and combivir on HIV-infected subjects with specific eligibility criteria, including a screening lab result of plasma HIV-1 RNA and CD4 cell count, and exclusion criteria such as detection of any CXC Receptor4-tropic virus and active Class C AIDS-defining illness.",
    "This phase 2 trial is testing the efficacy of sorafenib and interferon in treating metastatic renal cell carcinoma with clear cell histology, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of alirocumab and atorvastatin in treating primary hypercholesterolemia, with inclusion criteria based on LDL-C levels and exclusion criteria including diabetes and pregnancy.",
    "This phase 2 trial is testing the efficacy of mk-8457, methotrexate, and a dose-match placebo in treating rheumatoid arthritis in patients who have failed treatment with 1 or 2 anti-tumor necrosis factor alpha therapies, and have met specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of azd1940, naproxen, and placebo in managing pain in patients undergoing surgical removal of impacted mandibular third molar, with a list of icd-10 codes for pain as the disease, and eligibility criteria including signed informed consent and absence of certain somatic and psychiatric conditions.",
    "The sample is a phase 2 trial for acute pain, testing the efficacy of sufentanil nanotab 20 mcg, sufentanil nanotab 30 mcg, and placebo nanotab on patients scheduled for bunion surgery, with exclusion criteria including daily opioid use, drug or alcohol abuse, and pregnancy or breastfeeding.",
    "The sample is a phase 2/phase 3 trial for metastatic colorectal cancer testing the efficacy of cmab009 plus irinotecan and irinotecan-only, with eligibility criteria including KRAS wild-type tumors and failure of fluoropyrimidine and oxaliplatin treatment, and exclusion criteria including previous irinotecan or anti-EGFR therapies and hematologic, liver, and renal function limitations.",
    "This phase 2 trial is testing the efficacy of epirubicin, cyclophosphamide, docetaxel, and trastuzumab in treating HER2-positive breast cancer in non-pregnant females aged 18 or older with no evidence of metastatic disease, and who meet other eligibility criteria.",
    "This phase 2 trial will test the efficacy of febuxostat and placebo for febuxostat in reducing gout flares in participants with hyperuricemia and a history of \u22642 flares, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of SPM 962 in treating idiopathic restless legs syndrome in patients who have previously received treatment with L-dopa or dopamine agonists and have a score of \u226515 on the IRLS sum score and RLS symptoms occur twice or more a week, while excluding patients with certain medical conditions or taking certain medications.",
    "The sample is a phase 2 trial for the treatment of knee osteoarthritis using diclofenac, with inclusion criteria including confirmed knee osteoarthritis and Lequesne Functional Index score of 10-14, and exclusion criteria including history of knee trauma and use of COX-II inhibitors or glucosamine/chondroitin.",
    "This phase 2 trial is testing the efficacy of bevacizumab, first-line and second-line chemotherapy agents in treating non-small cell lung cancer and brain neoplasms, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the drug STA-9090 in patients with metastatic colorectal cancer who have received prior treatment, and the eligibility criteria includes specific disease and lab values, as well as the need for adequate contraception and informed consent.",
    "The sample is a phase 2 trial for obesity using topiramate as the drug, with inclusion criteria including BMI and waist circumference, and exclusion criteria including endocrine disease and abnormal liver function tests.",
    "This phase 2 trial is testing the efficacy of filorexant and placebo in treating recurrent major depressive disorder with specific inclusion and exclusion criteria, including an adequate trial of an antidepressant and no history of bipolar disorder or substance abuse.",
    "This phase 2 trial is testing the drug crlx101 in patients with non-small cell lung cancer who have failed 1 or 2 lines of chemotherapy, and the eligibility criteria includes measurable disease, ECOG performance status of 0 or 1, and adequate hepatic and renal function.",
    "This trial is a phase 2/phase 3 study testing the efficacy of tadalafil and placebo in treating benign prostatic hyperplasia, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the drug pd-0325901 on patients with non-small cell lung cancer, with specific eligibility criteria including evidence of disease progression within 6 months of prior therapy and no active seizure disorders or untreated brain metastases.",
    "This phase 2 trial will test the efficacy of rvx000222, a drug, versus placebo in reducing the risk of atherosclerosis and coronary artery disease in patients with stable angina, coronary artery bypass graft, myocardial infarction, or a history of percutaneous coronary intervention, who are taking a stable dose of statin therapy for at least 30 days prior to enrollment, and meet the inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with myocardial infarction or percutaneous coronary intervention, testing the use of clopidogrel as an indication for treatment, with inclusion criteria including age between 18 and 75 and exclusion criteria including conditions that alter platelet function or increase bleeding risk.",
    "The sample is a phase 2 trial for seasonal allergic rhinitis, testing the efficacy of bilastine, fexofenadine, cetirizine, and placebo, with inclusion criteria of a positive skin prick or RAST test and exclusion criteria of clinically significant illness or disease, unstable asthma, and participation in a clinical trial within 30 days prior to the screening visit.",
    "This phase 2 trial is testing the efficacy of sevelamer HCl and SBR759 in treating chronic kidney disease patients with high serum phosphate levels, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of regorafenib, oxaliplatin, folinic acid, and 5-fu (mfolfox6) in treating colorectal neoplasms with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate in treating high-risk primary gastrointestinal stromal tumor patients who have undergone complete gross resection, and have met certain eligibility criteria.",
    "The sample is a phase 2 trial for psoriasis, testing the effectiveness of cp-690,550 ointment and its vehicle, with inclusion criteria of mild to moderate chronic plaque psoriasis and exclusion criteria of non-plaque form of psoriasis, psoriatic arthritis, and current systemic therapy or phototherapy for psoriasis.",
    "The sample is a phase 2 trial for osteoarthritis, testing the efficacy of ibuprofen and placebo in patients aged 40 or older with primary osteoarthritis in a single knee joint, and the inclusion and exclusion criteria for the trial are also provided.",
    "The sample is a phase 2 trial for the drug NBI-98854 in treating tardive dyskinesia in patients with schizophrenia or schizoaffective disorder, with inclusion and exclusion criteria listed, and the value of drugs and diseases being tested.",
    "This phase 2 trial will test the efficacy of placebo and romosozumab in promoting fracture healing in males and females aged 55 to 95 years with fresh unilateral low energy intertrochanteric or femoral neck fracture, and confirmed by X-ray, who underwent internal fixation of the fracture with devices approved by local regulatory agency, and meet the inclusion criteria, while excluding those with severe symptomatic osteoarthritis of the lower extremity, inability to independently rise from armchair or walk 200 meters before hip fracture, and other conditions listed in the exclusion criteria.",
    "This is a phase 2 trial for patients with hormone refractory prostate cancer and bone metastases, testing the drug radium-223 dichloride (bay88-8223), with eligibility criteria including confirmed adenocarcinoma of the prostate, multifocal skeletal metastases, and bone pain, among others.",
    "The sample is a phase 2 trial for colorectal neoplasms testing the efficacy of sunitinib, mfolfox6, bevacizumab, and mfolfox6, with specific eligibility criteria for patients.",
    "This phase 2 trial is testing the efficacy of pt005 mdi, formoterol fumarate 12 \u03bcg (foradil\u00ae aerolizer\u00ae), and formoterol fumarate 24 \u03bcg (foradil\u00ae aerolizer\u00ae) in treating chronic obstructive pulmonary disease (COPD) in patients aged 40-80 with a history of COPD, a post-bronchodilator FEV1/FVC ratio of < or = 0.70, and a post-bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of predicted normal values, among other criteria.",
    "This phase 2 trial is testing the efficacy of paclitaxel and carboplatin in treating patients with pathologically documented bulky T2, III and IV squamous cell carcinoma, with specific eligibility criteria including age, performance status, and medical fitness.",
    "The sample is a phase 2 trial for postmenopausal women with hormone receptor positive advanced breast cancer, testing the drugs cp-751,871, exemestane, and fulvestrant, with inclusion criteria of HbA1c <5.7% and exclusion criteria of previous treatment for advanced disease.",
    "The sample is a phase 2 trial for patients with type 1 diabetes, testing the effectiveness of regular insulin and insulin lispro, with inclusion criteria of stable control with HbA1c <= 9.0% and exclusion criteria of BMI > 32 kg/m2, gastroparesis, impaired renal function, or lipodystrophy.",
    "The sample is a phase 2 trial for adult females with inflammatory breast cancer and HER2-positive tumors, testing standard chemotherapy, bevacizumab, and trastuzumab, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2/phase 3 trial for vortioxetine and placebo in patients with major depressive disorder, with inclusion and exclusion criteria specified, and the value of diseases being 'depressive disorder, major' and drugs being 'vortioxetine' and 'placebo'.",
    "This phase 2 trial is testing the efficacy of GSK256066 and azelastine hydrochloride in treating seasonal allergic rhinitis in healthy subjects who exhibit a moderate response to grass pollen, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease, testing the efficacy of ssr180711c, donepezil, and placebo, with inclusion criteria of mild AD and exclusion criteria of previous treatment with acetylcholinesterase inhibitors and/or memantine, medical conditions that may interfere with the study, history of epileptic seizures, lens opacity, and lack of reliable caregiver.",
    "The sample is a phase 2 trial for migraine, testing the efficacy of mk3207 at various doses compared to placebo, with inclusion and exclusion criteria including age, frequency and severity of migraines, and cardiovascular history.",
    "This is a phase 2 trial for patients with non-Hodgkin's lymphoma localized in the central nervous system, cranial nerves or eyes, testing the efficacy of high dose methotrexate and high dose cytarabine, with eligibility criteria including age, performance status, and absence of other malignancies.",
    "This phase 2 trial is testing the efficacy of pioglitazone, peginterferon, and ribavirin in treating HIV-1 and hepatitis C co-infection, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial aims to test the efficacy of teriparatide (forteo), calcium, and calcitriol in treating hypocalcemia in patients who undergo total thyroidectomy or neck dissections, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of azd1722 and placebo in treating end stage renal disease, chronic kidney disease stage 5, and esrd, with inclusion criteria including age, BMI, and stable dialysis treatment regimen, and exclusion criteria including diuretic medication and predialysis systolic BP.",
    "The sample is a phase 2/3 trial for multiple myeloma, CLL/SLL, non-Hodgkin's lymphoma, Waldenstroms, and mantle cell lymphoma, using fludarabine as a drug, with specific eligibility criteria including age, disease stage, and organ function.",
    "This phase 2 trial is testing the effectiveness of histamine for treating seasonal allergic rhinitis with ragweed allergy symptoms, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the effectiveness of rostafuroxin, a drug, on patients with essential hypertension, with specific inclusion and exclusion criteria based on risk factors and medical conditions.",
    "This phase 2 trial is testing the efficacy of cisplatin and docetaxel in treating histologically confirmed squamous cell carcinoma of the head and neck, with specific eligibility criteria for patients, including age, performance status, and hematopoietic, hepatic, renal, cardiovascular, pulmonary, and neurologic health.",
    "The sample is a phase 2 trial for rheumatoid arthritis, testing the efficacy of azd9056, etanercept, and placebo, with inclusion criteria requiring active disease and at least 6 months of methotrexate treatment, and exclusion criteria including other inflammatory diseases and abnormal liver function enzymes.",
    "This phase 2 trial is testing the drug RAD001 on patients with pancreatic cancer who have progressed on gemcitabine-based chemotherapy and have not had more than one prior chemotherapy regimen for metastatic disease.",
    "This phase 2 trial is testing the use of amifostine in combination with IMRT for head and neck cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for melanoma patients using azd6244 and temozolomide drugs, with eligibility criteria including late stage diagnosis and exclusion criteria including previous radiotherapy or chemotherapy.",
    "The sample is a phase 2 trial testing the efficacy of epoetin alfa in treating chronic anemia in elderly patients with specific inclusion and exclusion criteria, including no active cancer and a Short Physical Performance Summary Score of 4-10, and the trial includes a list of diseases and icd-10 codes.",
    "This phase 2 trial is testing cisplatin and etoposide in patients with Ewing's family tumor who meet specific eligibility criteria, including age range, performance status, and hematopoietic, hepatic, renal, and cardiovascular health requirements.",
    "This phase 2 trial is testing the efficacy of amifostine, carboplatin, and taxol in treating locally advanced squamous cell carcinoma of the head and neck, with eligibility criteria including measurable disease, adequate renal and bone marrow function, and no evidence of distant metastatic disease.",
    "The sample is a phase 2 trial for lung cancer patients with specific disease characteristics and patient characteristics, testing the drug pemetrexed, with eligibility criteria including no more than 2 prior systemic therapies and at least 28 days since prior systemic therapy.",
    "This phase 2 trial is testing the efficacy of cediranib maleate, docetaxel, and prednisone in treating patients with adenocarcinoma of the prostate and stage IV prostate cancer, with specific eligibility criteria including rising PSA levels and castrate levels of testosterone.",
    "This phase 2 trial is testing the effects of risperidone and mifepristone-matched placebo on healthy individuals with a stable weight, with specific inclusion and exclusion criteria, to evaluate their safety and efficacy.",
    "The sample is a phase 2 trial for recurrent or metastatic breast cancer with negative ER, PR, and HER2/neu receptor status, testing the efficacy of su011248 and chemotherapy in patients who have relapsed within 6 months of adjuvant chemotherapy, with exclusion criteria including more than two chemotherapy regimens and uncontrolled/symptomatic spread of cancer to the brain.",
    "The sample is a phase 2 trial testing tesetaxel in patients with adenocarcinoma of the stomach or esophagogastric junction who have progressed after first-line therapy, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the drug temsirolimus on patients with metastatic or recurrent breast cancer who have measurable disease and meet certain eligibility criteria.",
    "This phase 2 trial is testing the drug phx1149t on subjects with type 2 diabetes mellitus who meet specific eligibility criteria, including having a BMI of 25 to 48 kg/m2 and a fasting plasma glucose of 118 - 220 mg/dL, and who are currently being treated with metformin or TZD.",
    "This phase 2 trial is testing the efficacy of octreotide acetate in treating neuroendocrine tumors metastatic to the liver, with specific eligibility criteria for patients, including measurable disease and Karnofsky performance status, and prior concurrent therapy allowed.",
    "This phase 2 trial is testing the efficacy of topotecan in treating recurrent or persistent endometrial cancer in female subjects who have received one prior chemotherapy regimen, and have at least one measurable lesion according to GOG-modified RECIST criteria, while meeting a set of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of tiotropium bromide, an anticholinergic drug, in treating moderate persistent asthma in adolescents aged 12-17 who have been on maintenance treatment with inhaled corticosteroids, and have a pre-bronchodilator FEV1 above 60% and less than or equal to 90% of predicted normal, and an increase in FEV1 of equal or above 12% and 200 mL 15 min after 400 mcg salbutamol, among other inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with super-infected or impetiginized eczema, using drugs las41003, las189962, and las189961, with eligibility criteria including exclusion of patients with systemic infections or certain skin infections, and localization of the eczema on palms, soles, or face.",
    "This phase 2 trial is testing the efficacy of ly2599506 and glyburide, along with placebo, in treating type 2 diabetes mellitus patients who meet specific inclusion criteria and do not meet any of the exclusion criteria.",
    "This phase 2 trial is testing the efficacy of placebo, daclatasvir, pegylated interferon alfa-2a, and ribavirin in treating chronic hepatitis C virus genotype 2 or 3, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of etelcalcetide and placebo in treating secondary hyperparathyroidism, with specific inclusion and exclusion criteria for subjects.",
    "The sample is a phase 2 trial for vulvodynia, testing the efficacy of lidocaine/diphenhydramine, lidocaine, and placebo, with inclusion criteria of seeking doctor's care and having menstrual cycles, and exclusion criteria of having vaginal infections, being pregnant or nursing, and not receiving any other medicinal therapies or medications that would interfere with the study outcome.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma, testing the efficacy of sar3419 and rituximab, with inclusion criteria including CD19 and CD20 positive disease and exclusion criteria including absence of bi-dimensionally measurable lesion by CT scan.",
    "This phase 2 trial is testing the efficacy of capecitabine, irinotecan, oxaliplatin, and cetuximab in treating metastatic colorectal cancer with specific eligibility criteria, including EGF-receptor testing and no prior chemotherapy for colorectal cancer.",
    "This phase 2 trial is testing the efficacy of various salmeterol doses and placebos in patients with chronic obstructive pulmonary disease who meet specific spirometric criteria and have a smoking history of more than 10 pack-years.",
    "This phase 2 trial is testing the efficacy of hydrocortisone modified release capsules in treating patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with chronic hepatitis C infection, testing the efficacy of drugs including bms-790052, peginterferon alfa-2b, and ribavirin, with inclusion criteria including HCV RNA viral load \u226510*5* IU/mL and exclusion criteria including cirrhosis and hepatocellular carcinoma.",
    "The sample is a phase 2 trial testing the effectiveness of pravastatin in treating HIV patients with hypercholesterolemia, with specific inclusion and exclusion criteria, while the drugs and diseases involved are pravastatin and HIV infection with hypercholesterolemia.",
    "This phase 2 trial is testing the efficacy of capecitabine, fluorouracil, and gemcitabine hydrochloride in treating unresectable adenocarcinoma of the pancreas, with specific eligibility criteria for patients, including ECOG performance status 0-1 and no distant metastases.",
    "This phase 2 trial is testing the efficacy of radium-223 chloride in treating breast cancer patients with bone metastases who have progressed on endocrine therapy and have been on bisphosphonate therapy for at least 3 months prior to treatment start, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for non-small cell lung cancer, testing the efficacy of enzastaurin, pemetrexed, carboplatin, bevacizumab, and placebo, with specific inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial is testing the efficacy of tv-1106 and recombinant human growth hormone in treating adult growth hormone deficiency, with specific inclusion and exclusion criteria outlined in the eligibility criteria section.",
    "This phase 2 trial is testing the efficacy of d-amphetamine transdermal system and placebo patch in treating attention deficit hyperactivity disorder in children aged 6-17 years old, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of belotaxel and belloxa in treating non-small cell lung cancer patients who meet specific eligibility criteria, including having measurable lesions and meeting certain hematologic and hepatic profile requirements.",
    "This phase 2 trial is testing the efficacy of canakinumab, placebo, and methotrexate in treating rheumatoid arthritis, with eligibility criteria including recent diagnosis of RA, active disease, and negative tuberculosis skin test reaction.",
    "The sample is a phase 2 clinical trial for rheumatoid arthritis, testing the efficacy of ssr150106 and placebos, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of abt-894 and duloxetine in treating diabetic neuropathy, with specific inclusion and exclusion criteria for subjects.",
    "The sample is a phase 2 trial for major depressive disorder, testing the efficacy of lu aa24530, duloxetine, and placebo, with inclusion criteria of a major depressive episode lasting at least 3 months and moderate to severe depression, and exclusion criteria including current or past history of certain psychiatric disorders and ongoing formal cognitive or behavioral therapy.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate and tall-104 cells in treating chronic myelogenous leukemia patients who have failed to achieve or have lost an adequate response to IM, with specific eligibility criteria outlined.",
    "This phase 2 trial is testing the efficacy of palonosetron, an antiemetic drug, in reducing chemotherapy-induced nausea and vomiting in patients with non-Hodgkin's lymphoma who are candidates for initial chemotherapy treatment.",
    "This phase 2 trial is testing the efficacy of lenalidomide, pegylated liposomal doxorubicin, and dexamethasone in treating multiple myeloma, with specific eligibility criteria including measurable myeloma paraprotein levels and adequate bone marrow and renal function.",
    "The sample is a phase 2 trial for patients with coronary arteriosclerosis and acute coronary syndrome, testing the efficacy of prasugrel and clopidogrel in reducing the risk of cardiovascular events, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for losmapimod and placebo in patients with chronic obstructive pulmonary disease (COPD), with inclusion criteria including clinical history of COPD, FEV1/FVC ratio of \u22640.70, FEV1 \u2264 80% of predicted normal, and a 6MWD < 350m, and exclusion criteria including current diagnosis of asthma, pregnant or lactating, and long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day.",
    "The sample is a phase 2 trial for rheumatoid arthritis with the drug cp-690,550, testing its efficacy in patients with inadequate response to methotrexate, and the inclusion and exclusion criteria for the trial.",
    "The sample is a phase 2 clinical trial for multiple myeloma patients, testing the efficacy of bortezomib, lenalidomide, and dexamethasone, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for the treatment of hepatitis C using sofosbuvir, placebo, peg, and rbv, with specific inclusion and exclusion criteria, and the presence of genotype 1 HCV infection and negative pregnancy test as important values.",
    "This phase 2 trial will test the efficacy of z160 and placebo in treating postherpetic neuralgia, with inclusion criteria including a diagnosis of PHN, pain score of 3-8 on the PI-NRS, and willingness to comply with study procedures.",
    "The sample is a phase 2/phase 3 trial for patients with chronic hepatitis C and liver fibrosis, testing the efficacy of ribavirin and ribavirin-placebo in combination with interferon, with eligibility criteria including previous non-response to antiviral treatment and a Metavir fibrosis score \u2265 2.",
    "This phase 2 trial is testing the efficacy of lenalidomide and darbepoetin alfa in treating low or intermediate-1 IPSS risk category MDS patients with red blood cell transfusion-dependent anemia, excluding 5q deletion, and the eligibility criteria includes laboratory test results, disease-free period, and contraception requirements.",
    "This phase 2 trial is testing the efficacy of fluorouracil, leucovorin calcium, and oxaliplatin in treating advanced, recurrent, or metastatic colorectal adenocarcinoma patients who have progressed on at least 1 prior, but no more than 2 prior, fluorouracil and/or irinotecan containing treatment regimens for metastatic colorectal cancer and have documented HER-2/neu overexpression by immunohistochemistry staining.",
    "This phase 2 trial is testing the efficacy of vintafolide and etarfolatide in treating advanced, progressive adenocarcinoma of the lung, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 trial aims to test the effectiveness of ropinirole in combination with physical therapy compared to placebo and physical therapy in improving motor function in stroke patients with hemiparesis and confirmed ischemic or hemorrhagic stroke onset between 4 weeks to 12 months prior, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for relapsed or progressive lung cancer patients with measurable disease outside of radiation port, who have not received more than one prior chemotherapy regimen, and are able to perform activities of daily living without assistance. The trial will test the efficacy of topotecan and docetaxel as treatment options.",
    "This phase 2 trial is testing the efficacy of fulvestrant and selumetinib in treating breast cancer patients who have relapsed or progressed after aromatase inhibitor therapy, with specific eligibility criteria for patients' disease and health status.",
    "This phase 2 trial is testing the efficacy of gemcitabine, cisplatin, docetaxel, cisplatin, vinorelbine, and pemetrexate in treating non-small-cell lung cancer patients with certain eligibility criteria, including having no previous anticancer treatment for metastatic/advanced disease and adequate hematologic parameters.",
    "The sample is a phase 2 trial testing the efficacy of sildenafil citrate and placebo in patients with chronic obstructive pulmonary disease (COPD) or emphysema, with inclusion criteria including a clinical diagnosis of COPD or emphysema, FEV1/FVC ratio < 70%, and FEV1 < 80%, and exclusion criteria including heart disease, contraindication to sildenafil, and pulmonary hypertension at rest.",
    "The sample is a phase 2/phase 3 trial for heart and liver transplant patients with bone resorption, testing the effectiveness of zoledronic acid and alendronate, with eligibility criteria including age, exclusion criteria including hyperparathyroidism and Paget's disease.",
    "This phase 2 trial is testing the efficacy of zd6474, carboplatin, and paclitaxel in treating stage IIIb or stage IV non-small cell lung cancer patients with measurable disease that is amenable to biopsy, and who meet specific eligibility criteria.",
    "This is a phase 2 trial for asthma patients using gw685698x 200mcg and 400mcg, with eligibility criteria including age, gender, asthma diagnosis, severity of disease, reversibility of disease, concurrent anti-asthma therapy, and compliance. Exclusion criteria include history of life-threatening asthma, use of certain medications, respiratory infection, asthma exacerbation, and other concurrent diseases/abnormalities.",
    "The sample is a phase 2 trial for non-Hodgkin's lymphoma, testing the drug intravenous t900607-sodium, with eligibility criteria including prior chemotherapy, measurable disease, and certain lab values, while exclusion criteria include severe concurrent disease and prior investigational agent use.",
    "The sample is a phase 2 trial testing the efficacy of orlistat versus placebo in treating obesity-related comorbidities in adolescents with specific inclusion and exclusion criteria, and the trial includes a list of diseases, icd-10 codes, and eligibility criteria.",
    "The sample is a phase 2 trial for the drug ONO-2506PO in patients with amyotrophic lateral sclerosis (ALS), with inclusion criteria including previous completion of a related study and exclusion criteria including various medical conditions that may pose a risk to the patient.",
    "This phase 2 trial is testing the efficacy of topotecan and bevacizumab in treating platinum-resistant ovarian, fallopian tube, and peritoneal cancer patients who have received primary taxane and platinum-based chemotherapy and no more than one other chemotherapy regimen, and meet certain eligibility criteria.",
    "The sample is a phase 2 trial for patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, testing the drug ly573636-sodium, with inclusion criteria including prior platinum treatment and exclusion criteria including more than 2 prior systemic treatments and serious pre-existing medical conditions.",
    "This phase 2 trial is testing the efficacy of mirabegron and placebo in treating lower urinary tract symptoms and bladder outlet obstruction in men aged 45 or older with documented bladder outlet obstruction, while excluding those with a history of urinary retention or symptomatic and recurrent UTI.",
    "This is a phase 2 trial for ovarian cancer patients who failed prior chemotherapy with paclitaxel/carboplatin regimen and have a treatment-free interval of more than 6 months, and will test the efficacy of docetaxel, carboplatin, liposomal doxorubicin in combination, with eligibility criteria including age \u2265 18 years, adequate bone marrow, liver, and renal function, and exclusion criteria including pregnancy or nursing, psychiatric illness, and other concurrent uncontrolled illness.",
    "The sample is a phase 2 trial for patients with stage IV melanoma, testing the efficacy of thalidomide as a second-line therapy, with specific eligibility criteria including age, performance status, and prior treatments.",
    "This phase 2 trial is testing the drug radium-223 dichloride (bay88-8223) on patients with hormone refractory prostate cancer and multifocal skeletal metastases, with eligibility criteria including rising PSA levels and ECOG performance status of 0-2.",
    "This phase 2 trial is testing the drug bortezomib on patients with Philadelphia chromosome-positive chronic myelogenous leukemia who have failed prior treatment with imatinib mesylate or are intolerant, unable, or unwilling to receive it, and have specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of gmi-1070 and placebo in treating sickle cell disease with vaso-occlusive crisis, with eligibility criteria including confirmed diagnosis of sickle cell disease, hospitalization or in process of admission, and exclusion criteria including recent major surgery, hospitalization for other than VOC, and documented serious bacterial infection requiring antibiotic treatment.",
    "This phase 2 trial is testing the drug glufosfamide on patients with platinum-resistant ovarian cancer who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of trastuzumab and pf03512676 in treating locally advanced or metastatic HER2-overexpressing breast cancer, with eligibility criteria including achieved partial response, stable disease, and specific patient characteristics.",
    "This phase 2 trial will test the efficacy of pazopanib and placebo comparator in treating stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma patients who have undergone surgical debulking and at least five cycles of platinum-taxane doublet chemotherapy.",
    "This phase 2 trial is testing the efficacy of cetuximab and emd 1201081 in treating squamous cell carcinoma of the head and neck cancer, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of s-1 and s-1 plus leucovorin in treating inoperable or advanced pancreatic cancer patients who have failed one prior gemcitabine-based regimen, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for phenylketonuria using the drug Kuvan, with inclusion criteria including age, weight, and exclusion criteria including smoking, cardiovascular disease, and pregnancy.",
    "This phase 2 trial aims to test the efficacy of various drugs, including bi 67100 and montelukast, in treating seasonal allergic rhinitis and asthma, with eligibility criteria including a positive skin prick test and TNSS score.",
    "The sample is a phase 2 trial for multiple sclerosis testing the efficacy of fty720 and placebo, with inclusion criteria of patients aged 18-60 with a diagnosis of multiple sclerosis and exclusion criteria of chronic disease of the immune system other than MS, malignancy, pulmonary or heart disease, and pregnant or nursing women.",
    "The sample is a phase 2 trial for hypertension using spironolactone as an additional antihypertensive drug, with specific inclusion and exclusion criteria, and the study will test the ability of Procardia XL to decrease the dose of glucocorticoid medication for children with congenital adrenal hyperplasia.",
    "This phase 2 trial is testing the efficacy of paclitaxel and capecitabine in treating metastatic breast cancer in female patients who meet specific eligibility criteria, while excluding patients with certain medical conditions or allergies to the study compounds.",
    "This phase 2 trial is testing the efficacy of the drug fp187, along with placebo, in treating plaque psoriasis in patients who meet specific eligibility criteria.",
    "This phase 2 trial will investigate the use of doxycycline hyclate in adult patients with acute leukemia and mucositis, with specific inclusion and exclusion criteria.",
    "This sample is a phase 2 trial for patients with type 2 diabetes mellitus, testing the efficacy of bosentan and placebo in reducing albuminuria, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of pramipexole in treating restless legs syndrome, with inclusion criteria including specific diagnostic criteria and severity scores, and exclusion criteria including certain medications and medical conditions.",
    "The sample is a phase 2/phase 3 trial for women with breast cancer and no sign of depression, testing the effectiveness of melatonin versus placebo as a sleep aid for patients undergoing lumpectomy or mastectomy, with a list of inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for inoperable adenocarcinoma of the pancreas, testing the efficacy of gemcitabine alone or in combination with endotag-1, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing ly2181308 sodium, cytarabine, and idarubicin in patients with relapsed or refractory acute myeloid leukemia or chronic myeloid leukemia in myeloid blast crisis who have failed at least 1 previous tyrosine kinase inhibitor, and have discontinued all previous therapies for cancer for at least 21 days for myelosuppressive agents or 14 days for non-myelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy, with adequate organ function, and no serious pre-existing medical conditions.",
    "The sample is a phase 2 trial for epilepsy, testing the drug brivaracetam, with inclusion criteria including a clinical diagnosis of epilepsy and at least one seizure in the past three weeks, and exclusion criteria including pregnancy or nursing, concomitant use of levetiracetam, and history of suicide attempt.",
    "This phase 2 trial is testing the drugs mb07803 and placebo on patients with type 2 diabetes mellitus, with specific eligibility criteria including fasting plasma glucose and HbA1c measurements, BMI range, and exclusion criteria such as history of outpatient insulin use and cardiac disease.",
    "This phase 2 trial is testing the efficacy of oral hycamtin and iv avastin in treating recurrent small-cell lung cancer, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of bortezomib and lenalidomide in treating recurrent mantle cell lymphoma, with specific eligibility criteria including prior therapy with traditional cytotoxic agents and/or biologic agents, and no prior bortezomib or lenalidomide therapy.",
    "This phase 2 trial is testing the combination of vandetanib and anastrozole in postmenopausal women with hormone receptor-positive breast cancer, with specific eligibility criteria and exclusion criteria listed.",
    "The sample is a phase 2 trial for advanced or metastatic breast cancer, testing the efficacy of gemcitabine, paclitaxel, and docetaxel, with eligibility criteria including prior chemotherapy completed at least 6 months prior to enrollment, and exclusion criteria including prior gemcitabine treatment and brain metastases.",
    "The sample is a phase 2 trial for patients with breast cancer and metastatic bone disease, testing the efficacy of drugs za and odanacatib, with eligibility criteria including confirmed breast cancer and documented skeletal metastases, and exclusion criteria including current or recent use of oral bisphosphonate therapy.",
    "This is a phase 2 trial for psoriasis using anti-IL-12 monoclonal antibody/abt-874 and placebo drugs, with inclusion criteria of moderate to severe plaque psoriasis and exclusion criteria of previous anti-IL-12 therapy and use of oral or injectable corticosteroids.",
    "This phase 2 trial is testing the efficacy of carboplatin and docetaxel in treating non-small cell lung cancer that is resectable and has no CNS or brain metastases, with eligibility criteria including ECOG performance status 0-1, adequate pulmonary and cardiovascular function, and no history of serious systemic disease or active infection.",
    "This phase 2 trial is testing the efficacy of bortezomib, rituximab, fludarabine, mitoxantrone, and dexamethasone in treating persistent, relapsed, or refractory grade 1-3 follicular lymphoma, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for macular degeneration using brimonidine tartrate implants, with inclusion criteria of geographic atrophy and visual acuity between 20/40 to 20/320, and exclusion criteria of allergy to brimonidine, uncontrolled systemic disease or infection of the eye, recent eye surgery or injections in the eye, and female patients who are pregnant, nursing or planning a pregnancy.",
    "This phase 2 trial is testing the drug abt-126 and placebo on patients with Alzheimer's disease who meet specific inclusion criteria, including having a stable dose of an AChEI for at least 90 days prior to screening.",
    "The sample is a phase 2 trial for stomach neoplasms using sunitinib as a drug, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of activated recombinant human factor vii and placebo in treating acquired bleeding disorder and trauma patients who have received 6 units of PRBC within a 4 hour period following admittance to the trauma centre and 8 units of PRBC upon administration of trial drug. The trial also has inclusion and exclusion criteria for the patients.",
    "This phase 2 trial is testing the efficacy of gemcitabine and cisplatin plus sorafenib in treating urothelial cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for chronic lymphocytic leukemia testing the efficacy of maintenance lenalidomide, with inclusion criteria including previous induction treatment with bendamustine and rituximab, age 18 or older, ECOG performance status less than or equal to 2, and absolute neutrophile count more than 1,000, and exclusion criteria including serious medical condition that would prevent treatment with lenalidomide, evidence of tumor lysis syndrome, and any prior treatment with lenalidomide.",
    "The sample is a phase 2 trial for moderate to severe ulcerative colitis, testing the efficacy of placebo and rhumab beta7, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of zevalin, rituximab, and ^111 in ibritumomab tiuxetan in previously treated patients with refractory/relapsed indolent lymphomas, including extranodal marginal lymphoma of MALT type, nodal marginal zone B-cell lymphoma, and splenic marginal B-cell lymphoma, who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for patients with stage IIIB or IV non-small cell lung cancer who have failed first-line chemotherapy, and will test the efficacy of gemcitabine hydrochloride and oxaliplatin as treatment options, with eligibility criteria including ECOG performance status, absolute neutrophil count, platelet count, and absence of symptomatic brain metastases.",
    "The sample is a phase 2 trial for metastatic colorectal cancer using a combination of 5-fluorouracil, leucovorin, oxaliplatin, and avastin, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of lapatinib and capecitabine in treating metastatic colorectal cancer patients who have had progression of disease on prior therapy with an oxaliplatin-containing or irinotecan containing regimen, and have met certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of zd6474 (vandetanib), bicalutamide, and placebo in treating metastatic prostate cancer in males with a confirmed histological diagnosis, evidence of metastases, and biochemical progression of prostate cancer, with eligibility criteria and exclusion criteria listed.",
    "The sample is a phase 2/phase 3 trial for persistent asthma, testing the drug indacaterol maleate, with inclusion criteria including daily treatment with a bronchodilator and daily dose of at least 100 \u00b5g beclomethasone dipropionate or equivalent, and exclusion criteria including use of tobacco products within 6 months prior to Visit 1 or a smoking history of more than 10 pack years.",
    "The sample is a phase 2 trial for adult asthmatics with mild to moderate persistent asthma, testing the efficacy of multiple drugs including map0010 and budesonide inhalation suspension, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial testing the effectiveness of nicotine lower and higher doses and placebo in smoking cessation for generally healthy smokers with specific inclusion and exclusion criteria, and the trial includes two diseases related to smoking.",
    "This phase 2 trial is testing the efficacy of ustekinumab in treating primary biliary cirrhosis, with inclusion criteria including a stable dose of ursodeoxycholic acid and a screening alkaline phosphatase level > 1.67 ULN, and exclusion criteria including a previous diagnosis of steatohepatitis or chronic autoimmune hepatitis, and recent use of colchicine, methotrexate, azathioprine, or systemic corticosteroids.",
    "This phase 2 trial is testing the efficacy of lapatinib and topotecan in treating platinum-refractory and/or -resistant ovarian and peritoneal cavity cancer, with eligibility criteria including confirmed histology, measurable or evaluable disease, and specific patient characteristics and prior concurrent therapy restrictions.",
    "This phase 2 trial is testing the efficacy of pazopanib in treating non-small cell lung cancer patients who meet specific eligibility criteria, including having a single measurable lesion and no prior anti-cancer therapy, and excludes patients with certain medical conditions or taking certain medications.",
    "This phase 2 trial is testing the efficacy of AP214 versus placebo in patients undergoing cardiac surgery for various diseases, including coronary artery bypass and aortic aneurysm, with inclusion criteria such as age over 18 and not of childbearing potential, while exclusion criteria include a history of cancer within the last 2 years and current abuse of alcohol or substance.",
    "This phase 2 trial is testing the efficacy of cabazitaxel, prednisone, and granulocyte colony-stimulating factor in treating castrate-resistant metastatic prostate cancer in patients who have previously undergone therapy with docetaxel and have shown progressive disease, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is for HIV infection, testing the efficacy of tenofovir disoproxil fumarate and placebo.         The eligibility criteria include being a healthy biologic male, aged 18-60, with adequate renal function and normal liver and blood parameters.          Exclusion criteria include current HIV antiretroviral use, chronic systemic steroids, and other serious medical conditions.",
    "This phase 2 trial is testing the efficacy of naltrexone-hcl versus placebo in patients with Crohn's disease, with inclusion criteria including confirmed diagnosis and a Crohn's Disease Activity Index of at least 220 at baseline, and exclusion criteria including recent use of infliximab or humira and abnormal liver enzymes.",
    "This phase 2 trial is testing the efficacy of bevacizumab, sunitinib, and paclitaxel in treating metastatic breast cancer patients who meet certain eligibility criteria, while excluding patients with certain medical histories or conditions.",
    "The sample is a phase 2 trial for patients with lung cancer and brain metastases, testing the efficacy of pemetrexed disodium as a treatment, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of stem cell transplant using unrelated UCB donors and drugs such as busulfan, clofarabine, and fludarabine in treating various hematologic malignancies including acute myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hodgkins disease, non-hodgkins lymphoma, aplastic anemia, multiple myeloma, and myelodysplastic syndrome.",
    "The sample is a phase 2 trial testing the efficacy of oral nicotine and placebo in treating smoking dependence, with inclusion criteria of regular smokers who smoke more than 20 cigarettes per day and good general health, and exclusion criteria of any disease that may interfere with the study product and medical conditions that may jeopardize the safety of the subject or the validity of the study results.",
    "This phase 2 trial is testing the efficacy of mcn36 and placebo in treating symptomatic bipolar disorder patients who meet specific inclusion criteria and do not have any exclusion criteria, with a list of diseases and icd-10 codes provided.",
    "This phase 2 trial is testing the efficacy of abr-215050 and tasquinimod compared to placebo in treating asymptomatic metastatic castration-resistant prostate cancer patients who have evidence of progressive disease after castration levels of testosterone have been achieved, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of vorinostat and bortezomib in treating relapsed or refractory T-cell NHL in patients who have had at least one prior systemic regimen, with eligibility criteria including measurable disease sites, adequate bone marrow and liver function, and negative pregnancy test for female patients.",
    "The sample is a phase 2 trial for asthma patients, testing the efficacy of interferon beta 1a and placebo, with eligibility criteria including documented history of asthma symptoms, regular use of inhaled corticosteroids, and recent asthma exacerbation caused by respiratory virus.",
    "This sample is a phase 2 trial for metastatic breast cancer patients who have responded to salvage regimens, and will test the efficacy of etoposide, ifosfamide, and topotecan hydrochloride as treatment options. The eligibility criteria includes various patient characteristics such as age, sex, and medical history.",
    "The sample is a phase 2 trial for patients with recurrent adult acute lymphoblastic leukemia, testing a combination of drugs including asparaginase, methotrexate, dexamethasone, leucovorin calcium, mercaptopurine, and vincristine, with specific inclusion and exclusion criteria.",
    "This phase 2 trial will test the efficacy of bortezomib in treating patients with various types of non-small cell lung cancer who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for non-small cell lung cancer using erlotinib plus digoxin as a treatment, with specific eligibility criteria including prior chemotherapy regimen, creatinine levels, and Zubrod performance status.",
    "The sample is a phase 2 trial for HER2-positive metastatic breast cancer patients who progressed on trastuzumab-based therapy, testing the efficacy of pertuzumab and trastuzumab combination or pertuzumab monotherapy, with inclusion and exclusion criteria, and the list of diseases and drugs used in the trial.",
    "The sample is a phase 2 trial for chronic hepatitis C, testing the efficacy of Debio 025, peg-ifn\u03b12a, and ribavirin, with specific inclusion and exclusion criteria for patient eligibility.",
    "The sample is a phase 2 trial for the treatment of hospital-acquired pneumonia with tigecycline and imipenem/cilastatin, with eligibility criteria including the presence of a new or evolving infiltrate on a chest x-ray film and exclusion criteria including hypersensitivity to any of the test articles.",
    "This phase 2 trial is testing the drugs ym150 and warfarin in patients undergoing elective primary knee arthroplasty, with inclusion and exclusion criteria related to VTE and bleeding risk, and the disease being studied is arthroplasty, replacement, knee.",
    "This phase 2 trial is testing the efficacy of iloprost and placebo in patients with moderate to severe chronic obstructive pulmonary disease and confirmed pulmonary hypertension, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial testing the drug belinostat on patients with recurrent adult Burkitt lymphoma or recurrent adult diffuse large cell lymphoma, with specific eligibility criteria including measurable disease, Zubrod performance status 0-2, and no history of allergic reactions to similar compounds.",
    "This phase 2 trial is testing the effectiveness of androgel and placebo in treating prostate cancer patients who have received primary definitive local therapy to the prostate, have had a previous trial of anti-androgen therapy, and have a rising PSA, while excluding patients with a history of previous cytotoxic therapy or radionuclide therapy, uncontrolled intercurrent illness, renal dialysis, significant pulmonary disease, or known hypersensitivity to any of the AndroGel ingredients.",
    "This phase 2 trial is testing the efficacy of capecitabine and bevacizumab in treating rectal cancer in patients who meet specific eligibility criteria, including having no prior chemotherapy or radiotherapy, adequate bone marrow and hepatic function, and a life expectancy of at least 3 months.",
    "This phase 2 trial is testing the drug ps341 (bortezomib) on patients with relapsed or refractory B cell lymphoma, with specific eligibility criteria including ANC, Plt, and HIV status.",
    "This phase 2 trial is testing the efficacy of lenvatinib, a drug, in treating endometrial cancer patients who have progressed after one prior systemic, platinum-based chemotherapy regimen and meet certain eligibility criteria.",
    "The sample is a phase 2 trial for constipation predominant irritable bowel syndrome, testing the drug rdx5791, with inclusion criteria including meeting Rome III criteria for IBS-C and active disease during the screening period, and exclusion criteria including having IBS-D or IBS-M, and use of medications that affect stool consistency.",
    "This phase 2 trial is testing the efficacy of mk-6096 and placebo in treating migraine and headache in patients who meet specific inclusion and exclusion criteria, with a list of icd-10 codes and eligibility criteria provided.",
    "This phase 2 trial is testing the efficacy of erlotinib and capecitabine in treating metastatic colorectal cancer patients who meet certain eligibility criteria, including having measurable or evaluable disease, adequate liver and renal function, and an expected life expectancy of at least 12 weeks.",
    "The sample is a phase 2 trial for anemia, testing the efficacy of epoetin alfa, with inclusion criteria including diabetes mellitus and proteinuria/microalbuminuria, and exclusion criteria including poorly controlled hypertension and active malignancy.",
    "This phase 2 trial is testing the efficacy of the drug org 24448 versus placebo in treating major depression in subjects who have not responded to previous antidepressant trials, with eligibility criteria including DSM-IV criteria for Major Depression, a history of at least one previous episode of depression, and an initial score of greater than or equal to 32 on the Inventory of Depressive Symptoms, Clinician version (IDS-C).",
    "The sample is a phase 2 trial for lupus erythematosus, systemic, testing the efficacy of different doses of belimumab compared to placebo, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of modafinil in treating attention deficit hyperactivity disorder (ADHD) in patients aged 18-65, with specific inclusion and exclusion criteria, and requiring patients to be willing to comply with study restrictions and remain at the clinic for the required duration of the study.",
    "This phase 2 trial is testing the efficacy of methotrexate and temozolomide, and methotrexate, procarbazine, vincristine, cytarabine in treating primary central nervous system lymphoma in patients over 60 years old with certain eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of pemetrexed and carboplatin in treating metastatic or recurrent esophageal cancer, with specific eligibility criteria including no prior chemotherapy treatment, measurable disease, and adequate bone marrow, liver, and renal function.",
    "This phase 2 trial is testing the drug bibf 1120 on patients with recurrent glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma, who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of dexamethasone and pomalidomide in treating symptomatic multiple myeloma patients who have received 1-3 prior treatment regimens and meet specific measurable disease criteria, while also ensuring patient eligibility based on various patient characteristics and prior concurrent therapy.",
    "This phase 2 trial is testing the efficacy of g-csf plus plerixafor in autologous transplantation for patients with non-Hodgkin's lymphoma or multiple myeloma, with specific eligibility criteria including prior chemotherapy regimens, blood counts, and organ function.",
    "This phase 2 trial is testing the efficacy of ff/vilanterol and placebo in treating persistent asthma, with inclusion criteria including the use of an inhaled corticosteroid for at least 12 weeks prior to screening and a screening pre-bronchodilator FEV1 \u2265 60% of predicted.",
    "This phase 2 trial is testing the efficacy of oral lapatinib tablets or placebo tablets in treating ErbB2-positive cancer, with specific eligibility criteria including tumor progression after receiving all standard/approved chemotherapies per NCCN guidelines and availability of archived tumor tissue for biomarker analysis.",
    "This phase 2 trial is testing the effectiveness of cyproheptadine hydrochloride in treating unintended weight loss in children with various cancers and malnutrition, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of dapagliflozin, metformin, and placebo in treating type 2 diabetes with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug talnetant on subjects with irritable colon, who must meet specific inclusion and exclusion criteria, and are allowed to take certain permitted medications while avoiding prohibited ones.",
    "This phase 2 trial is testing the efficacy of ixabepilone in treating refractory or recurrent diseases such as rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma, synovial sarcoma, and Wilms' tumor in patients aged 21 or younger, with specific eligibility criteria, and no prior taxane therapy.",
    "This is a phase 2 trial for chronic obstructive pulmonary disease (COPD) testing theophylline, placebo, and budesonide drugs with inclusion criteria such as confirmed diagnosis of COPD, moderate to severe COPD, and history of \u2265 10-pack years of cigarette smoking, and exclusion criteria such as respiratory tract infection and/or an exacerbation of COPD within 30 days, use of systemic corticosteroids, and previous history or diagnosis of asthma.",
    "The sample is a phase 2 trial for advanced or metastatic liver cancer, testing the efficacy of bevacizumab and erlotinib, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of erlotinib and temsirolimus in treating advanced squamous cell carcinoma of the head and neck that is platinum-refractory or platinum-ineligible, with specific eligibility criteria outlined.",
    "This phase 2 trial is testing the efficacy of gemcitabine/carboplatin and iniparib in treating metastatic breast cancer patients who have had 0-2 prior chemotherapy regimens, with specific eligibility criteria including ER-negative, PR-negative, and HER-2 nonoverexpressing breast cancer and adequate organ function.",
    "The sample is a phase 2 trial for diabetes mellitus type 2, testing the efficacy of alogliptin and voglibose compared to placebo, with inclusion criteria including a HbA1c value of 6.5% or more and exclusion criteria including recent use of antidiabetic drugs.",
    "The sample is a phase 2 trial for essential tremor, testing the efficacy of sodium oxybate, with inclusion criteria including moderate or severe classic essential tremor and willingness to abstain from ethanol and caffeine intake, and exclusion criteria including clinically significant unstable medical abnormality and history of sleep apnea.",
    "This phase 2 trial is testing the efficacy of ly2140023, placebo, and standard of care in treating schizophrenia patients who have been receiving monotherapy treatment for at least 3 months with one of 4 atypical antipsychotic medications, and have evidence of prominent negative symptoms of schizophrenia.",
    "This phase 2 trial is testing the efficacy of SyB L-0501 and rituximab in treating various types of lymphoma, with eligibility criteria including CD20-positive cells, measurable lesions, and prior treatment failure, while exclusion criteria include serious infections, bleeding tendencies, and autoimmune hemolytic anemia.",
    "The sample is a phase 2 trial for patients with colorectal cancer who have failed previous therapy, testing the efficacy of vandetanib and folfiri, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug zd6474 on patients with stage IIIB, stage IV, or advanced, incurable NSCLC who have failed at least one front-line metastatic NSCLC chemotherapy regimen and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of albiglutide or exenatide in treating type 2 diabetes mellitus with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for the treatment of moderate to severe vasomotor symptoms in postmenopausal women, using drugs such as mk-6913 and 17-\u03b2 estradiol, with inclusion criteria such as at least 50 hot flash episodes per week and exclusion criteria such as a history of cancer or undiagnosed vaginal bleeding.",
    "This phase 2 trial is testing the efficacy of siltuximab, placebo, and best supportive care in treating measurable and symptomatic Multicentric Castleman's Disease, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug e7070 on female patients with metastatic breast cancer who have received 2-3 prior chemotherapies and have at least one measurable lesion, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of a combination of drugs including imatinib, cyclophosphamide, daunorubicin, vincristine, prednisolone, methotrexate, cytarabine, and dexamethasone in treating previously untreated BCR-ABL-positive acute lymphoblastic leukemia in patients aged 15-64 years with adequate liver, kidney, and heart function, while excluding those with uncontrolled active infection, other severe and/or life-threatening diseases, positive HIV antibody and/or hepatitis B surface antigen tests, another primary malignancy, pregnancy and/or lactation, and past history of renal failure.",
    "This phase 2 trial is testing the effectiveness of simvastatin in treating advanced or metastatic colorectal cancer with specific genetic mutations, and includes eligibility criteria related to patient characteristics and prior therapy.",
    "The sample is a phase 2 trial for high risk indolent or intermediate B-cell lymphoma, using a combination of cyclophosphamide, doxorubicin hydrochloride, prednisone, and vincristine sulfate, with eligibility criteria including specific disease characteristics and patient characteristics, and no prior therapy for lymphoma.",
    "This phase 2 trial is testing the efficacy of docetaxel in treating unresected clinical stage T1c, T2, T3, or T4 infiltrating carcinoma of the breast in female patients with ECOG 0-2 performance status, and other eligibility criteria.",
    "The sample is a phase 2 trial for patients with primary or recurrent biliary duct carcinoma, using fluorouracil as the drug, and with specific eligibility criteria including age, performance status, hematopoietic and renal function, and prior concurrent therapy.",
    "This phase 2 trial is testing the efficacy of vandetanib and best supportive care in treating locally advanced or metastatic hepatocellular carcinoma patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of sorafenib and placebo in treating advanced non-small cell lung cancer that has progressed after at least 2 prior chemotherapy regimens, with eligibility criteria including measurable or nonmeasurable disease, certain blood counts, and liver function tests, while exclusion criteria include prior exposure to a ras pathway inhibitor and concurrent medications with a narrow therapeutic index.",
    "This is a phase 2 trial for acute myeloid leukemia patients aged 61 or older, testing the efficacy of sorafenib and placebo drugs, with specific eligibility and exclusion criteria.",
    "This is a phase 2 clinical trial for osteoarthritis, testing the efficacy of naproxen, ce-224535, and placebo, with eligibility criteria including a diagnosis of knee OA and exclusion criteria including other joint diseases and pregnancy/lactation.",
    "This phase 2 trial is testing the efficacy of preladenant, l-dopa, and other Parkinson's disease treatments in participants with moderate to severe idiopathic Parkinson's disease for at least 5 years, with a list of diseases and icd-10 codes provided, and eligibility criteria including normal clinical laboratory tests and exclusion criteria such as drug-induced or atypical parkinsonism, cognitive impairment, and poorly controlled diabetes.",
    "This phase 2 trial is testing the efficacy of rm-131 and placebo in treating diabetic gastroparesis in patients with Type 1 or Type 2 diabetes mellitus, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of canakinumab and placebo in patients with type 2 diabetes mellitus or impaired glucose tolerance, who meet specific inclusion criteria, and have HbA1c between 6.5% and 8%, inclusive, at screening.",
    "This phase 2 trial is testing the efficacy of gleevec and valproic acid in patients with chronic myelogenous leukemia who have been on imatinib therapy for at least 9 months and have a relative plateau in the effect of imatinib on the detected level of the transcript, while excluding patients with severe medical problems, hypersensitivity to valproic acid, and hepatic disease or significant impairment.",
    "The sample is a phase 2/3 trial for type 2 diabetes mellitus, testing the efficacy of alogliptin and pioglitazone, with inclusion and exclusion criteria related to hepatic and renal impairment and cardiac failure.",
    "This phase 2 trial is testing the efficacy of carboplatin, rad 001, and prednisone in treating metastatic adenocarcinoma of the prostate that has progressed after prior docetaxel-based chemotherapy, with specific eligibility criteria for patients, including castrate testosterone levels and certain laboratory values.",
    "The sample is a phase 2 trial for schizophrenia, testing the efficacy of lurasidone and haloperidol compared to placebo, with inclusion criteria including a primary diagnosis of schizophrenia, recent hospitalization, and specific symptom scores.",
    "This phase 2 trial aims to evaluate the efficacy of TAK-875 and sitagliptin in treating type 2 diabetes in patients who have not used anti-diabetic therapy for at least 8 weeks or are stable on metformin monotherapy, with a focus on eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing lapatinib, trastuzumab, and endocrine drugs on female patients with HER2 overexpressing breast cancer, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of leuprolide acetate depot and matched placebo in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma who are eligible for hematopoietic stem cell transplant, and meet certain eligibility criteria.",
    "The sample is a phase 2 trial for HIV-positive patients taking anti-HIV therapy that includes abacavir sulfate, with eligibility criteria including viral load and age restrictions, and exclusion criteria including previous use of abacavir and certain medical conditions.",
    "The sample is a phase 2 trial for patients with solid tumors or nonmyeloid hematologic malignancies and anemia, testing the efficacy of darbepoetin alfa and epoetin alfa, with eligibility criteria including hemoglobin \u2264 10.5 g/dL and ferritin > 20 ng/mL, and patient characteristics including ECOG performance status 0-2 and life expectancy \u2265 6 months.",
    "This phase 2 trial is testing the efficacy of capecitabine, oxaliplatin, and trastuzumab in treating metastatic breast cancer with HER2 gene amplification, with specific eligibility and exclusion criteria.",
    "The sample is a phase 2 trial for pain after shingles, testing the efficacy of [s,s]-reboxetine + pregabalin and pregabalin, with inclusion criteria of pain present for more than 3 months and a pain visual analogue scale score >/=40 mm, and exclusion criteria of significant renal and hepatic impairment, other severe pain that may impair self-assessment, and clinically abnormal electrocardiogram.",
    "The sample is a phase 2 trial for chronic hepatitis C patients with genotype 1, using drugs such as copegus, pegasys, and ro4588161, and the eligibility criteria includes age, liver disease consistency, and exclusion of other infections and previous treatments.",
    "The sample is a phase 2 trial for relapsing-remitting multiple sclerosis, using placebo as the drug, with specific eligibility criteria based on diagnosis, MRI results, and exclusion criteria such as history of malignancy or abnormal laboratory results.",
    "The sample is a phase 2 trial for squamous cell carcinoma of the head and neck, testing the efficacy of cyclophosphamide, indomethacin, zinc, and omeprazole, with specific inclusion and exclusion criteria for patient eligibility.",
    "The sample is a phase 2 trial for bladder neoplasms using gemcitabine as the drug, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of cp-316,311, placebo, and sertraline in treating outpatients with DSM-IV major depressive disorder, with exclusion criteria including women of childbearing potential.",
    "The sample is a phase 2 clinical trial for major depressive disorder, testing the efficacy of vasopressin v1b receptor antagonist (ssr149415) compared to placebo, with inclusion and exclusion criteria based on DSM-IV-TR and MINI criteria.",
    "This phase 2 trial is testing the efficacy of bia 9-1067 and levodopa/carbidopa or levodopa/benzerazide in treating Parkinson's disease patients who have predictable signs of end-of-dose deterioration despite \"optimal\" therapy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for schizophrenia, testing the efficacy of sb-773812 and olanzapine, with inclusion criteria based on PANSS score and DSM-IV diagnosis, and exclusion criteria including epilepsy, substance dependence, and other psychiatric disorders.",
    "This is a phase 2/phase 3 trial for Parkinson's disease, testing the efficacy of cep-1347 at different doses, with specific inclusion and exclusion criteria, and requiring cancer screening before randomization.",
    "This phase 2 clinical trial aims to test the efficacy of mf59 adjuvant and placebo in preventing cytomegalovirus infections in mothers who have delivered a newborn infant within the previous 12 months and are CMV seronegative, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for patients with advanced non-small cell lung cancer, testing the drug erlotinib [tarceva], with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of cromoglicate and placebo in treating stable plaque psoriasis with inclusion criteria such as clinical diagnosis of psoriasis, itchy psoriasis on both intended treatment areas, and exclusion criteria such as systemic treatment with biological therapies within certain time periods prior to randomization.",
    "The sample is a phase 2 trial for acute heart failure, testing the drug acipimox, with inclusion criteria including NYHA class III-IV and ejection fraction <35, and exclusion criteria including age <18 or >85, renal failure, and recent myocardial infarction, among others.",
    "This phase 2 trial is testing the efficacy of lenalidomide in patients with myelodysplastic syndromes and acute myelogenous leukemia who have undergone allogeneic hematopoietic stem cell transplantation, and the eligibility criteria includes specific karyotype abnormalities and laboratory test results.",
    "This phase 2 trial is testing erlotinib hydrochloride, a targeted therapy against the epidermal growth factor receptor, in patients with non-small cell lung cancer who are lifelong nonsmokers and have measurable or nonmeasurable disease outside a previous radiotherapy field or a new lesion inside the port.",
    "This phase 2 trial is testing the drug aminocamptothecin on patients with advanced stages IIB/III/IV cutaneous T-cell lymphoma, with eligibility criteria including measurable or evaluable disease and certain patient characteristics.",
    "This is a phase 2 trial for patients with ErbB2-overexpressing invasive breast cancer, testing the efficacy of trastuzumab, paclitaxel, fec75, and lapatinib, with eligibility criteria including confirmed diagnosis, organ function, and ability to tolerate chemotherapy.",
    "This phase 2 trial is testing the drug A-002 on patients with stable coronary artery disease who meet certain eligibility criteria, while excluding those with certain medical conditions or recent treatments.",
    "The sample is a phase 2 trial for patients with myeloproliferative neoplasms (MPN) using the drug itacitinib, with specific inclusion and exclusion criteria for eligibility.",
    "This phase 2 trial is testing the efficacy of docetaxel plus doxercalciferol and docetaxel plus placebo in treating metastatic prostate cancer patients who meet specific eligibility criteria, including having a histologic diagnosis of adenocarcinoma of the prostate and evidence of metastatic disease within 4 weeks of registration.",
    "The sample is a phase 2 trial for Parkinson's disease patients with peripheral edema, testing the effectiveness of domperidone while excluding patients with certain medical conditions and requiring stable medication regimen, with the inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for constipation using the drug a3309, with inclusion and exclusion criteria specified, and the diseases are constipation and chronic constipation with corresponding icd-10 codes.",
    "The sample is a phase 2 trial for asthma patients, testing the efficacy of mometasone, montelukast, and placebo, with inclusion criteria including decreased breathing capacity and recent use of a fast-acting inhaler, and exclusion criteria including hypersensitivity to certain medications and recent use of oral corticosteroids.",
    "This phase 2 trial is testing the efficacy of topotecan hydrochloride and 7-hydroxystaurosporine in treating patients with extensive stage small cell lung cancer who have relapsed or progressed after first-line platinum-based chemotherapy, and have met certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of paclitaxel in patients with metastatic or locally advanced unresectable transitional cell carcinoma who have received one prior platinum-containing regimen, and have measurable disease according to RECIST criteria, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for patients with recurrent lung cancer who have previously undergone surgery or radiation and received prior adjuvant treatment or neoadjuvant with erlotinib or gefitinib, and will test the efficacy of erlotinib as a treatment option.",
    "This phase 2 trial is testing the efficacy of custirsen sodium and docetaxel in treating metastatic or locally advanced breast cancer that is not curable with standard therapy, with specific eligibility criteria for patients including platelet count, hormone receptor status, and prior concurrent therapy.",
    "This phase 2 trial is testing the effectiveness of lisinopril, losartan potassium, benazepril hydrochloride, and ramipril in treating hypertension in patients with solid tumor malignancy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for type 2 diabetes mellitus, testing the efficacy of ly2189265 and placebo drugs, with inclusion and exclusion criteria related to cardiovascular health, weight, and medication history.",
    "The sample is a phase 2 trial for newly diagnosed metastatic renal cell carcinoma testing the drugs zd6126 and placebo, with inclusion criteria of suitable for nephrectomy and exclusion criteria of prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma or within the last 3 years for any other cancer, significant cardiac event within 3 months of entry, and any history of coronary angioplasty or history of myocardial infarction.",
    "This phase 2 trial is testing the efficacy of vinorelbine, cisplatin, bevacizumab, docetaxel, and gemcitabine in treating non-small cell lung cancer patients who meet specific eligibility criteria.",
    "This sample is a phase 2 trial for patients with metastatic renal cell carcinoma, testing the drug su011248 capsule, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of ridaforolimus and trastuzumab in treating HER2-positive metastatic breast cancer patients who are trastuzumab-resistant, with specific eligibility criteria including no prior treatment with mTOR inhibitors and adequate cardiovascular, hematological, hepatic, and renal function.",
    "This phase 2 trial is testing the efficacy of capecitabine and mitomycin c in treating metastatic breast cancer with specific eligibility criteria, including confirmed breast cancer, at least one target lesion, and no prior usage of the drugs as adjuvant or neoadjuvant treatment.",
    "The sample is a phase 2 trial for non-squamous non-small cell lung cancer patients with pleural effusion or stage IV disease, testing the efficacy of paclitaxel, carboplatin, bevacizumab, and pf-3512676, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial testing the efficacy of cisplatin, liposomal doxorubicin, and paclitaxel in treating stage III ovarian epithelial, fallopian tube, or primary peritoneal carcinoma with specific eligibility criteria for patients.",
    "The sample is a phase 2 trial for lymphoma patients, testing a combination of drugs including campath-1h, g-csf, gm-csf, bcnu, stem cell transplant, preparative regimen for allogenic stem cell transplantation, cytarabine, etoposide, melphalan, campath, fludarabine, and cyclophosphamide, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of low and high dose budesonide tablets and suspension, as well as placebo, in treating eosinophilic esophagitis in patients aged 18 to 75 with confirmed clinicopathological diagnosis of EoE and active symptomatic and histological EoE at baseline.",
    "The sample is a phase 2 trial testing systematic chemotherapy and antibodies on patients with various types of leukemia, lymphoma, myelodysplastic syndrome, and paroxysmal nocturnal hemoglobinuria who meet specific eligibility criteria, including age, cardiac function, and performance score.",
    "This phase 2 trial is testing the efficacy of irinotecan, carboplatin, and sunitinib in treating small cell lung cancer with extensive-stage disease, with eligibility criteria including confirmed diagnosis, measurable disease, and normal organ function.",
    "The sample is a phase 2 trial for colorectal cancer patients with disease progression after first-line therapy, testing the efficacy of folfiri, ro5083945, and cetuximab, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of tenofovir df and emtricitabine/tenofovir df in treating chronic hepatitis b in patients who meet specific eligibility criteria, including nucleoside naivety and absence of co-infection with HCV, HIV, or HDV.",
    "This phase 2 trial is testing the drug everolimus on patients with stage IV melanoma, with specific eligibility criteria including measurable disease and certain hematopoietic, hepatic, and renal levels, as well as restrictions on prior and concurrent therapies.",
    "This is a phase 2 trial for etelcalcetide, a drug used to treat secondary hyperparathyroidism, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the effectiveness of anastrozole and goserelin acetate in treating patients with recurrent or metastatic breast cancer, with specific eligibility criteria including hormone receptor status and prior concurrent therapies.",
    "The sample is a phase 2 trial testing the efficacy of etanercept and placebo in treating stomatitis in oncology patients undergoing PBSCT/BMT, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for rheumatoid arthritis using the drugs nnc 0151-0000-0000 and placebo, with inclusion criteria including a diagnosis of RA and stable doses of methotrexate, and exclusion criteria including allergy to trial product and BMI less than 18.0 or more than 38.0 kg/m2.",
    "This phase 2 trial aims to test the efficacy of adl5859 and duloxetine, compared to placebo, in treating neuropathic pain caused by diabetic peripheral neuropathy in male and female participants between 18 and 75 years of age, who have a stable glycemic control and meet other inclusion criteria, while excluding those with certain medical conditions or taking certain medications.",
    "The sample is a phase 2 trial for eosinophilic esophagitis, testing the efficacy of budesonide plus prevacid and placebo plus prevacid, with inclusion criteria of histologic evidence of EE and ages 1 yrs and older, and exclusion criteria including adverse reaction or allergy to budesonide and chronic diseases requiring immunomodulatory therapy.",
    "This phase 2 trial is testing the drug cts-1027 for patients with chronic hepatitis C virus infection who have failed previous therapy, and have liver impairment, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of bendamustine, velcade, and dexamethasone in treating symptomatic multiple myeloma patients who have received conventional chemotherapy in 1st line treatment and are in 1st relapse or refractory to 1st line therapy.",
    "This phase 2 trial is testing the efficacy of bi671800, placebo, and montelukast in treating reversible asthma in patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of thalomid, lenalidomide, clarithromycin, and dexamethasone in treating newly diagnosed multiple myeloma patients with measurable disease, while also assessing eligibility criteria such as laboratory parameters and exclusion criteria such as prior history of other malignancies.",
    "This phase 2 trial is testing the combination of everolimus and imatinib in patients with metastatic melanoma who have received up to one prior cytotoxic regimen, with eligibility criteria including measurable disease, ECOG performance status <1, and organ and marrow function within certain parameters.",
    "This phase 2 trial is testing the efficacy of TRx0014, a drug, in treating mild to moderate dementia of the Alzheimer type in patients who meet specific inclusion criteria and do not have any exclusion criteria.",
    "This phase 2 trial is testing the efficacy of dabigatran etexilate, a blood thinner, in reducing the risk of stroke in patients with non-rheumatic atrial fibrillation and a history of coronary artery disease, while also evaluating eligibility criteria and exclusion criteria.",
    "This clinical trial is testing the efficacy of tozadenant in treating Parkinson's disease, with a list of inclusion and exclusion criteria, and a variety of dosages of the drug being tested against a placebo and levodopa.",
    "The sample is a phase 2 trial for amyotrophic lateral sclerosis (ALS) using thalidomide as a drug, with inclusion criteria of clinically proven ALS, disease duration less than or equal to 5 years, and ALSFRS-R score equal to or greater than 30, and exclusion criteria of patients with known deep venous thrombosis or hypercoagulable state and patients with FVC less than 80%.",
    "This phase 2 trial is testing the effectiveness of rituximab in treating previously untreated symptomatic classical C-GVHD, with eligibility criteria including at least 3 sites of organ involvement or individual organ score of at least 2, and exclusion criteria including uncontrolled infection and previous systemic therapy for C-GVHD.",
    "This phase 2 trial is testing the efficacy of afn-12520000, an antibiotic, in treating skin and subcutaneous tissue bacterial infections, wound infections, cutaneous abscesses, burn infections, and cellulitis caused by staphylococci, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the drug rad001 (everolimus) on patients with systemic mastocytosis, with inclusion criteria including age, liver function, and performance status, and exclusion criteria including prior treatment with an mTOR inhibitor and hypersensitivity to the drug.",
    "This phase 2 trial is testing the efficacy of ivacaftor in patients with cystic fibrosis and G551D mutation, with inclusion criteria including a minimum weight of 40 kg, FEV1 of at least 40% of predicted normal, and willingness to remain on stable medication regimen, while exclusion criteria include ongoing acute respiratory infection, abnormal liver or renal function, and concomitant use of CYP3A4 inhibitors or inducers.",
    "The sample is a phase 2/phase 3 trial for low-grade B-cell lymphoma using rituximab in combination with standard chop or bi-weekly chop, with eligibility criteria including CD20 positivity, age between 20 and 69, and bidimensionally measurable disease >1.5cm, and exclusion criteria including CNS involvement, liver cirrhosis, and pregnancy or lactation.",
    "This phase 2 trial is testing the efficacy of ataciguat, placebo, and cilostazol in treating stable intermittent claudication caused by chronic occlusive arterial disease, with specific inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial is testing the efficacy of RAD001 and bicalutamide in treating castration-resistant prostate cancer with specific eligibility criteria, including a baseline PSA of 2ng/mL or greater and testosterone of 50ng/mL or less.",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus, testing the efficacy of gk activator and metformin, with inclusion criteria of age and prior metformin monotherapy, and exclusion criteria of type 1 diabetes and use of other oral anti-hyperglycemic medication.",
    "This trial is testing the efficacy of tadalafil, a drug used to treat pulmonary hypertension, on patients with biopsy-proven sarcoidosis and specific eligibility criteria.",
    "This phase 2 trial is testing the drug nnc126-0083 and placebo on adults with growth hormone deficiency and specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of gemcitabine and lapatinib in treating metastatic pancreatic cancer, with strict eligibility criteria including no prior chemotherapy, ECOG performance status 0-1, and adequate hematologic, hepatic, and renal function.",
    "This phase 2 trial is testing the efficacy of gemcitabine in treating stage IV breast cancer patients with measurable disease, and the eligibility criteria includes various patient characteristics and prior concurrent therapies.",
    "This phase 2 trial is testing the efficacy of bortezomib, dexamethasone, and doxorubicin hcl liposome in treating relapsed/refractory multiple myeloma patients who have received at least 1 prior treatment regimen.",
    "This phase 2 trial will test the efficacy of metyrosine and placebo in treating patients with velo-cardio-facial syndrome and psychosis, with specific inclusion and exclusion criteria, such as a confirmed diagnosis of VCFS, a total PANSS composite score >65, and no evidence of acute suicidality.",
    "This phase 2 trial is testing the efficacy of cetuximab and docetaxel in treating prostatic neoplasms with specific eligibility criteria, including histologic proof of prostatic adenocarcinoma and recent negative bone scan and MRI of abdomen and pelvis.",
    "This phase 2 trial is testing the drug pivanex on patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, with specific eligibility criteria including adequate organ function and a predicted life expectancy of at least 6 months.",
    "The sample is a phase 2 trial for patients with early rheumatoid arthritis, testing the efficacy of tasocitinib and tofacitinib in combination with methotrexate, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of cytarabine liposome injection in treating neoplastic meningitis and lymphoma, with eligibility criteria including confirmed diagnosis, adequate hematologic function, and prior CNS prophylaxis with intrathecal or intravenous cytarabine or methotrexate.",
    "This phase 2 trial is testing the efficacy of ritonavir and fosamprenavir, two drugs, in treating HIV infection in male and female subjects aged 2 to 18 years, who meet certain eligibility criteria.",
    "The sample is a phase 2 clinical trial for Parkinson's disease, testing the efficacy of afq056 with l-dopa and placebo, with inclusion criteria of outpatients experiencing OFF time and dyskinesias for at least three months, and exclusion criteria of surgical treatment for PD, cancer within the past 5 years, and advanced, severe or unstable disease that may interfere with the study outcome evaluations.",
    "This phase 2 trial is testing the efficacy of temozolomide in treating metastatic intraocular melanoma, with eligibility criteria including confirmed uveal melanoma, no curative surgical treatment envisaged, and various patient characteristics such as hemoglobin levels and absence of uncontrolled active disease.",
    "This phase 2 trial is testing the efficacy of odm-101 and stalevo in treating Parkinson's disease patients with end-of-dose motor fluctuations who meet specific inclusion criteria, including a daily levodopa dose in the range of 400-1400 mg, while excluding patients with secondary or atypical parkinsonism, current use of tolcapone, and severe dyskinesias, among other exclusion criteria.",
    "This is a phase 2 trial for patients with intermittent claudication, testing the efficacy of sapropterin dihydrochloride, with eligibility criteria including age, diagnosis of PAD, and stable antihypertensive and cholesterol-lowering therapy.",
    "This is a phase 2 clinical trial for the drug laquinimod in patients with Crohn's disease, with inclusion criteria based on disease duration and severity, and exclusion criteria including recent bowel surgery and unstable medication doses.",
    "This phase 2 trial is testing the drug fg-4592 on patients with dialysis and anemia, with inclusion criteria including age, type of dialysis, low hemoglobin levels, and weight range, and exclusion criteria including previous use of erythropoiesis-stimulating agents, recent IV iron or blood transfusions, certain infections or medical conditions, and history of substance abuse or allergies to iron.",
    "This phase 2 trial is testing the drug tmc125 on individuals with documented HIV-1 infection who have prior NNRTI-experience with genotypic evidence of resistance to currently available NNRTIs and are sensitive to the 2 NRTIs to be used as underlying ART.",
    "The sample is a phase 2 trial for patients with congestive heart failure who remain fluid overloaded despite standard treatment, using the drug extraneal, and with eligibility criteria including exclusion of patients with reversible CHF or contraindications to peritoneal dialysis.",
    "This phase 2 trial is testing the efficacy of capecitabine and oxaliplatin in treating locally advanced, unresectable, or metastatic gastric cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of tadalafil and placebo in treating Lower Urinary Tract Symptoms (LUTS) in men with Benign Prostatic Hyperplasia (BPH), with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of depsipeptide, a drug, in treating stage III unresectable or AJCC stage IV cutaneous, mucosal, ocular, or unknown primary melanoma with measurable disease, and the eligibility criteria includes normal organ and marrow function, negative pregnancy test, and normal electrocardiogram.",
    "This phase 2 trial is testing the efficacy of levetiracetam, an antiepileptic drug, on pediatric patients with refractory partial onset seizures and requires subjects to have a minimum IQ of 70 and be fluent in English.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide in treating unresectable AJCC Stage III/IV malignant melanoma, with eligibility criteria including measurable disease, laboratory test values, and exclusion criteria such as autoimmune disease and prior treatment with ipilimumab or other immunotherapy regimens.",
    "This phase 2 trial is testing the efficacy of aplindore and placebo in treating Restless Legs Syndrome in patients who meet specific inclusion criteria, including a diagnosis of primary RLS using ICSD-2 criteria and an IRLSSG RLS rating scale score > 15 at screening.",
    "The sample is a phase 2 trial for esophageal cancer using paclitaxel as a drug, with eligibility criteria including measurable disease, previous chemotherapy regime, and ECOG PS of 0-1, and exclusion criteria including previous therapy with Taxanes.",
    "This phase 2 trial is testing the efficacy of pemetrexed and cisplatin in treating mesothelioma patients who meet specific eligibility criteria, including having a performance status of 0-2 and estimated life expectancy of at least 12 weeks.",
    "This phase 2 trial is testing the efficacy of akb-6548 and placebo in treating anemia in patients with chronic kidney disease, with inclusion criteria including age range, eGFR, Hgb, TSAT, and ferritin levels, and exclusion criteria including BMI, recent transfusions or therapies, liver function, hypertension, and heart failure.",
    "The sample is a phase 2 trial for painful diabetic neuropathy, testing the drugs grt3938y and placebo, with inclusion criteria of symmetrical painful diabetic peripheral neuropathy and exclusion criteria including hypersensitivity to opioids and acetaminophen, confounding painful conditions, and significant vascular disease.",
    "This phase 2 trial is testing the efficacy of docetaxel in treating breast cancer patients with distant metastatic disease, with specific eligibility criteria including age, performance status, and prior concurrent therapy.",
    "This phase 2 trial is testing the efficacy of glycopyrronium bromide in patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are responsive to ipratropium, with inclusion criteria including age 40-75, smoking history, and post-bronchodilator FEV1/FVC ratio < 70%, and exclusion criteria including recent hospitalization for airway disease, primary diagnosis of asthma, and use of systemic steroids within three months prior to the screening visit.",
    "This phase 2 trial is testing the effectiveness of fulvestrant, a drug, in treating prostate cancer patients who have had a rise in PSA despite anti-androgen withdrawal and exhibit two consecutive rises in PSA after the last hormonal manipulation, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of dasatinib, a drug, in treating patients with various stages of melanoma, and includes a list of eligibility criteria for participants.",
    "This phase 2 trial is testing the efficacy of carboplatin, cediranib maleate, and gemcitabine hydrochloride in treating non-small cell lung cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of estramustine, docetaxel, and carboplatin in treating metastatic prostate adenocarcinoma that is unresponsive to hormone therapy and mitoxantrone-based chemotherapeutic regimens, with eligibility criteria including prior hormonal and mitoxantrone therapy, castrate level of testosterone, and pain attributable to metastatic prostate cancer.",
    "The sample is a phase 2 trial for psoriasis patients, testing the drug cc10004, with inclusion criteria including severe plaque type psoriasis, and exclusion criteria including use of systemic therapy for psoriasis and history of malignancy within previous five years.",
    "The sample is a phase 2 trial for essential tremor, using the drug t2000, with specific inclusion and exclusion criteria listed in the eligibility criteria section.",
    "This phase 2 trial is testing the efficacy of gs-9450 and gs-9450 placebo in treating chronic hepatitis C infection in patients who have previously been treated with interferon therapy, and have not achieved a sustained viral response or have not tolerated the therapy.",
    "The sample is a phase 2 trial for patients with advanced ovarian or primary peritoneal cancer who have been treated with one prior platin-containing chemotherapy regimen and have platin-resistant disease, and it will test the efficacy of cisplatin, alvocidib, and cisplatin/flavopiridol.",
    "This phase 2 trial is testing the effectiveness of melphalan, velcade, thalidomide, and dexamethasone in treating relapsed or progressive multiple myeloma, with specific eligibility criteria for patients including platelet count, renal and hepatic function, and exclusion criteria such as recent chemotherapy or radiotherapy, neurotoxicity, and heart failure.",
    "This phase 2 trial is testing the effectiveness of vorinostat and tamoxifen in treating stage I-III invasive breast cancer, with a list of specific inclusion and exclusion criteria, and a list of associated diseases and icd-10 codes.",
    "This phase 2 trial is testing the efficacy of cdb-2914 (ulipristal acetate) and placebo for contraception in women aged 18-35 with regular menstrual cycles, who are not at risk of pregnancy and meet other eligibility criteria.",
    "The sample is a phase 2/phase 3 trial for anal cancer, testing the efficacy of cisplatin, fluorouracil, and mitomycin c, with eligibility criteria including confirmed squamous cell anal carcinoma and specific patient characteristics.",
    "This is a phase 2 trial for patients with gastrointestinal stromal tumors, testing the drug imatinib mesylate (gleevec) and its eligibility criteria.",
    "This phase 2 trial is testing the efficacy of gsk372475 and paroxetine in treating depressive disorder with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with neuropathic pain due to painful diabetic polyneuropathy, testing the efficacy of azd2423 and placebo, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for neuropathic pain and allodynia after a peripheral nerve injury, testing the drugs ns1209 and lidocaine, with inclusion criteria of age >18 and exclusion criteria including previous treatment with ns1209 and treatment with certain other medications.",
    "The sample is a phase 2 trial for Parkinson's disease, testing xp21279 and carbidopa (experimental) against sinemet (comparator) and placebo, with eligibility criteria based on motor fluctuations and stable QID or 5 times daily regimens of Sinemet\u00ae or carbidopa-levodopa.",
    "The sample is a phase 2 trial for patients with HER2-positive and ER/PR-positive breast cancer, testing the efficacy of lapatinib ditosylate and letrozole as neoadjuvant therapy before surgery, with specific eligibility criteria for patients, and exclusion criteria for prior concurrent therapy.",
    "This phase 2 trial is testing the effectiveness of rosuvastatin and atorvastatin in treating hyperlipidemia, urinary protein, and diabetes in patients with diabetes mellitus, with exclusion criteria including previous rosuvastatin treatment, statin intolerance, and severe hypertension.",
    "This phase 2 trial is testing the efficacy of Ontak and CHOP chemotherapy in treating peripheral T-cell lymphoma, with eligibility criteria including a pathological diagnosis of the disease, treatment-naive status, and measurable disease sites, among others.",
    "This is a phase 2 trial for patients with recurrent or persistent leiomyosarcoma of the uterus, testing the efficacy of sunitinib malate, with specific eligibility criteria including prior cytotoxic regimens, measurable disease, and normal cardiac function.",
    "This phase 2 trial is testing the efficacy of apatinib in treating advanced hepatocellular carcinoma, with eligibility criteria including confirmed diagnosis, measurable lesion, and adequate organ function, while exclusion criteria include CNS metastasis and recent clinical trial participation.",
    "This phase 2 trial is testing the efficacy of adriamycin and trofosfamide in treating metastatic or non-resectable soft tissue sarcoma, with specific eligibility criteria including measurable tumor parameters, grading II/III, and no previous chemotherapy for metastatic disease.",
    "The sample is a phase 2/phase 3 trial for relapsed or refractory diffuse large B-cell lymphoma, testing the efficacy of lenalidomide, gemcitabine, oxaliplatin, rituximab, and etoposide, with specific eligibility criteria for patients.",
    "The sample is a phase 2 trial for bladder cancer testing the efficacy of cisplatin, doxorubicin hydrochloride, methotrexate, and vinblastine, with eligibility criteria including confirmed diagnosis of invasive bladder cancer, specific patient characteristics, and no prior systemic chemotherapy.",
    "This phase 2 trial is testing the efficacy of clofarabine, busulfan, fludarabine, thymoglobulin (atg), and filgrastim in treating acute myeloid leukemia, myelodysplastic syndrome, and chronic myeloid leukemia patients who have failed previous chemotherapy and are </= 60 years old, with a related or unrelated donor who is HLA-matched or mismatched in 1 HLA, A, B, C, DR or DQ locus being acceptable.",
    "This phase 2 trial is testing the effectiveness of vorinostat, a histone deacetylase inhibitor, in treating various types of melanoma with specific eligibility criteria, including no prior therapy or only one prior treatment allowed.",
    "This phase 2 trial is testing the efficacy of aclidinium 200 \u03bcg / formoterol 12 \u03bcg, placebo, formoterol 12 \u03bcg, aclidinium 200 \u03bcg, and aclidinium 200 \u03bcg / formoterol 6 \u03bcg in treating stable moderate to severe chronic obstructive pulmonary disease (COPD) in patients aged 40-80 years old with a smoking history of at least 10 pack-years, and whose FEV1 values meet certain criteria.",
    "This phase 2 trial is testing the efficacy of Prochymal\u2122 and placebo in treating moderate to severe chronic obstructive pulmonary disease (COPD) in current or ex-smokers with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for hypertension with the drugs mk0736, mk0916, and placebo, and the inclusion criteria being hypertension with specific blood pressure ranges and the exclusion criteria being pre-menopausal women, patients taking more than two blood pressure lowering medications, BMI>40 kg/m2, history of alcohol abuse, diabetes, chronic kidney disease, active liver disease, recent heart attack or stroke.",
    "This is a phase 2 trial for patients with inoperable IIIA and selected IIIB NSCLC with measurable disease, who have not received prior chemotherapy or chest radiation therapy, and have an ECOG performance status of 0-1. The trial will test the efficacy of carboplatin and pemetrexed disodium as treatment, and patients must meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of cisplatin and irinotecan hydrochloride in treating esophageal cancer that is surgically or medically unresectable, with specific eligibility criteria for patients, including disease characteristics and patient characteristics.",
    "This is a phase 2 trial for patients with moderate to severe chronic obstructive pulmonary disease (COPD) using uk-432,097 and placebo drugs, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for metastatic colorectal carcinoma testing the efficacy of zd6126, placebo, 5-fluorouracil, leucovorin, and oxaliplatin, with inclusion criteria of metastatic colorectal carcinoma and exclusion criteria of peripheral neuropathy greater than Grade 1, adjuvant therapy within 6 months prior to study treatment, prior oxaliplatin, prior pelvic or whole abdomen radiation, and any history of coronary angioplasty or history of myocardial infarction.",
    "This phase 2 trial is testing the efficacy of nilotinib and pegylated interferon 2a in treating chronic myelogenous leukemia, with eligibility criteria including performance status, adequate organic functions, and negative pregnancy test, while exclusion criteria include prior TKI or interferon treatment, pregnancy, and other uncontrolled severe diseases.",
    "This phase 2 trial is testing the efficacy of g-csf plus plerixafor in patients with non-Hodgkin's lymphoma or multiple myeloma who are eligible for autologous transplantation, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of calcipotriol plus hydrocortisone in treating psoriasis vulgaris involving the face and intertriginous areas, with specific inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial is testing the efficacy of cetuximab, a drug, in treating non-small cell lung cancer patients who have progressed while receiving treatment with a tyrosine kinase inhibitor targeting the EGFR pathway, and have measurable disease, suitable tissue sample for EGFR mutational analysis, and meet other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of arry-371797, p38 inhibitor, oxycodone hydrochloride (hcl) extended release (er), and placebo in treating moderate to severe pain due to osteoarthritis of the knee, with eligibility criteria including a confirmed diagnosis of OA of the knee and being on NSAID 28 days prior to study start.",
    "This phase 2 trial is testing the effectiveness of vinorelbine and bevacizumab in treating metastatic breast adenocarcinoma with specific eligibility criteria, including previous chemotherapy regimen, measurable disease, and adequate liver, renal, and bone marrow function.",
    "This phase 2 trial is testing the efficacy of captopril, an ACE inhibitor, in combination with radiotherapy for patients with lung cancer, pulmonary complications, and radiation fibrosis, with specific eligibility criteria for disease and patient characteristics, and restrictions on concurrent therapies.",
    "This phase 2 trial is testing the efficacy of zaleplon ap formulation and placebo capsule in treating primary insomnia, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of amg 223, a drug, versus placebo in treating end stage renal disease, chronic kidney disease, hyperphosphatemic kidney disease, and other related diseases, with specific eligibility criteria for participants.",
    "The sample is a phase 2 trial for HIV infections, testing the efficacy of various tenofovir-based drugs and placebo, with eligibility criteria including sexually active participants willing to use contraception and without certain medical conditions or recent procedures.",
    "The sample is a phase 2 trial for Crohn's disease and ulcerative colitis patients with mild or moderate anemia, testing the effectiveness of iron supplement and vitamin E, with inclusion criteria of being over 18 years old and diagnosed with IBD, and exclusion criteria of not having bowel obstruction or short bowel syndrome and not taking iron supplement or antioxidant vitamins and minerals.",
    "The sample is a phase 2/phase 3 trial testing the efficacy of gabapentin in reducing pain after open unilateral inguinal herniorraphy surgery, with a focus on patients who are not currently on gabapentin therapy and do not have a history of alcohol or drug abuse, and with a list of diseases including pain, analgesia, and inguinal hernia.",
    "The sample is a phase 2 trial for irritable bowel syndrome with diarrhea subtype, testing the efficacy of eluxadoline and placebo, with specific eligibility criteria for female patients, and exclusion criteria for patients with certain gastrointestinal disorders or surgeries.",
    "This phase 2 trial is testing the efficacy of clofarabine, idarubicin, and cytarabine in chemotherapy-na\u00efve patients with acute myeloid leukemia who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of everolimus and gdc-0980 in treating incurable metastatic renal cell carcinoma with clear-cell component that progressed on or within 6 months of stopping VEGF-targeted therapy, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone in treating previously untreated stage III, IV, or bulky stage II diffuse large B-cell non-Hodgkin's lymphoma patients who are positive for CD20 and have an age-adjusted International Prognostic Index score of 0 or 1.",
    "This phase 2 trial is testing the efficacy of bortezomib and panobinostat in treating locally advanced or metastatic pancreatic cancer that has progressed after standard first line therapy, with strict eligibility criteria including laboratory and cardiac function requirements.",
    "The sample is a phase 2 trial testing the efficacy of gft505 80mg and placebo in treating atherogenic dyslipidaemia and abdominal obesity, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing a combination of drugs including cytarabine, decitabine, doxorubicin hydrochloride, imatinib mesylate, methotrexate, pegaspargase, prednisone, vincristine sulfate, and vorinostat for patients with refractory or relapsed lymphoblastic lymphoma or acute lymphoblastic leukemia, with specific eligibility criteria including performance status, creatinine clearance, and prior therapy.",
    "The sample is a phase 2 trial for metastatic or recurrent renal cell carcinoma, testing the efficacy of cediranib and cediranib placebo, with inclusion and exclusion criteria related to previous anti-cancer therapy, diabetes, and high blood pressure.",
    "This phase 2 trial is testing the efficacy of KRP-104 and metformin in treating type 2 diabetes in patients who are already on a stable dose of metformin monotherapy, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for acute schizophrenia and schizoaffective disorder, testing the efficacy of rp5063 and aripiprazole compared to placebo, with inclusion criteria based on DSM-IV-TR criteria for schizophrenia and normal physical examination, laboratory, vital signs, and ECG.",
    "The sample is a phase 2 clinical trial for psoriasis, testing the efficacy of a placebo drug, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the drug SU011248 for palliative treatment of recurrent and metastatic squamous cell head and neck carcinoma, with eligibility criteria including confirmed recurrence, measurable lesions, and previous chemotherapy failure, while exclusion criteria include brain metastases and previous treatment with certain therapies.",
    "This phase 2 trial is testing the effects of Lovaza, an omega-3 fatty acid supplement, on patients with stable coronary artery disease or atrial fibrillation who are not on antiplatelet or anticoagulation therapy, and have no planned procedures or changes in medical therapies over the 24-week duration of the study.",
    "This phase 2 trial is testing the efficacy of aclidinium bromide and formoterol in patients with moderate to severe chronic obstructive pulmonary disease (COPD) who meet specific inclusion criteria, including a smoking history of at least 10 pack-years and a post-salbutamol FEV1/FVC <70%, and exclusion criteria such as a history of asthma or clinically significant respiratory or cardiovascular conditions.",
    "This phase 2 trial is testing a combination of drugs including cytarabine, daunorubicin hydrochloride, etoposide, imatinib mesylate, leucovorin calcium, methotrexate, prednisolone, therapeutic hydrocortisone, and vincristine sulfate for the treatment of newly diagnosed acute lymphoblastic leukemia (ALL) or acute mixed lineage leukemia with specific patient eligibility criteria.",
    "This phase 2 trial is testing the efficacy of minocycline in treating optic neuritis in patients with multiple sclerosis, with specific inclusion and exclusion criteria for eligibility.",
    "The sample is a phase 2/phase 3 trial for colorectal cancer, testing the efficacy of cediranib, bevacizumab, 5-fluorouracil, leucovorin, and oxaliplatin, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of temozolomide in treating unresectable stage IV melanoma with specific eligibility criteria for patients, including disease characteristics and patient characteristics.",
    "This phase 2 trial is testing the combination of mk-1775 and carboplatin in patients with recurrent epithelial ovarian cancer who have previously received standard 1st line platinum therapy, and have proven p53 mutated pathway by PCR/Sequencing, with eligibility criteria including measurable disease, adequate safety laboratory values, and negative pregnancy test.",
    "This phase 2 trial is testing the efficacy of carboplatin, cisplatin, and paclitaxel in treating endometrial cancer patients who meet specific eligibility criteria, including having undergone hysterectomy and bilateral salpingo-oophorectomy within the past 56 days and having no evidence of metastatic extrauterine disease or distant metastases.",
    "This phase 2 trial is testing the efficacy of dasatinib, a drug, in treating de novo acute lymphoblastic leukemia patients with Ph+ and/or BCR/ABL+ ALL, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of dasatinib, a drug, in treating non-small cell lung cancer in patients who are surgical candidates and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for head and neck cancer using the drug tas-106, with inclusion criteria including prior platinum-based regimen and measurable disease according to RECIST guidelines, and exclusion criteria including brain involvement or leptomeningeal disease and history of another malignancy.",
    "This is a phase 2 trial for pancreatic cancer patients with measurable disease, using a combination of fluorouracil, gemcitabine hydrochloride, and oxaliplatin, with eligibility criteria including ECOG performance status 0-1, ANC \u22651,500/mm\u00b3, and no prior chemotherapy or radiotherapy for pancreatic cancer.",
    "This phase 2 trial is testing the efficacy of lapatinib and capecitabine in treating refractory metastatic breast cancer patients with ErbB2 overexpression and progressive disease, with specific eligibility criteria including prior treatment with taxane and anthracycline regimens, and exclusion criteria such as malabsorption syndrome and active infection.",
    "This phase 2 trial is testing the efficacy of eribulin mesylate in patients with locally advanced, unresectable or metastatic pancreatic carcinoma who have received up to one prior line of gemcitabine-based systemic therapy, with evidence of disease progression, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of XPF-002 and placebo in treating postherpetic neuralgia, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the efficacy of carboplatin, celecoxib, and paclitaxel in treating potentially resectable esophageal cancer, with eligibility criteria including no distant metastases and various medical conditions.",
    "This phase 2 trial is testing the drug rad001 on patients with advanced non-small-cell lung carcinoma who have received \u2264 2 chemotherapy regimens, one of which must have included cisplatinum or carboplatin, and have documented evidence of tumor progression, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug e7070 on ambulant female patients with metastatic breast cancer who have been previously treated with an anthracycline and a taxane, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug pemetrexed on patients with recurrent or persistent ovarian or primary peritoneal cancer who have received prior platinum-based chemotherapy, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for patients with prostate cancer who have undergone radical prostatectomy within the past year, and the study will test the efficacy of bicalutamide, docetaxel, flutamide, and lhrh agonist drugs in combination with eligibility criteria including specific disease characteristics and patient characteristics.",
    "The sample is a phase 2 trial for osteoporosis, testing the drugs placebo and dp001, with inclusion criteria including postmenopausal females with osteopenia and exclusion criteria including history of certain diseases and current use of certain medications.",
    "This phase 2 trial is testing the efficacy of CCX-354-C and placebo in treating rheumatoid arthritis in patients who meet specific eligibility criteria, including having active RA and being on a stable dose of methotrexate for at least 8 weeks prior to randomization.",
    "This phase 2 trial is testing the efficacy of the drugs rv568 and placebo in treating chronic obstructive pulmonary disease (COPD) in subjects who conform to the current severity classification for GOLD Stage II/III disease in terms of post-bronchodilator spirometry at screening.",
    "This phase 2 trial is testing the efficacy of riociguat, sildenafil, and placebo in treating symptomatic pulmonary hypertension in subjects who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug rdea806 in male HIV patients with no prior antiretroviral therapy, with inclusion criteria including chronic HIV-1 infection and viral load above 5000 copies/ml, and exclusion criteria including CD4 count below 350 cells/mm3 and history of severe drug allergy or hypersensitivity.",
    "This phase 2 trial is testing the efficacy of paclitaxel albumin-stabilized nanoparticle formulation in treating patients with fallopian tube carcinoma, primary peritoneal carcinoma, or recurrent ovarian carcinoma who have received prior platinum-based chemotherapy and have platinum-resistant or refractory disease, as well as paclitaxel-resistant disease.",
    "This phase 2 trial is testing the drug cediranib maleate in patients with recurrent non-small cell lung cancer who have received prior platinum-based chemotherapy and meet specific eligibility criteria.",
    "This is a phase 2 trial for advanced, surgically unresectable CRC using bevacizumab, capecitabine, and oxaliplatin, with eligibility criteria including measurable disease, ECOG performance status of 0-2, and adequate organ function.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate and paclitaxel in treating non-small cell lung cancer patients who meet specific eligibility criteria, including age, disease stage, and adequate organ function.",
    "This phase 2 trial is testing the drug tandutinib on patients with metastatic prostate cancer who have had one prior taxane-based regimen and have evidence of progressive disease, with eligibility criteria including a castrate level of testosterone, adequate organ and marrow function, and no co-medication with an agent that causes QTc prolongation.",
    "This phase 2 trial is testing the drugs GW873140 and Kaletra for HIV infected, therapy-naive subjects with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of e2007 (perampanel) and placebo in treating epilepsy patients who have uncontrolled partial seizures despite being treated with at least three different anti-epileptic drugs for at least 2 years, and have averaged at least 4 partial seizures per month, with no 21-day seizure-free period during the 2 months preceding randomization.",
    "This is a phase 2 clinical trial for the drug SB010 and placebo in adult male Caucasian patients aged 18-60 with mild asthma, who meet specific inclusion criteria and do not have any exclusion criteria.",
    "The sample is a phase 2 trial for heart failure patients, testing the effectiveness of jnj-39588146 at different doses and a placebo, with inclusion and exclusion criteria, and the list of icd-10 codes for heart failure.",
    "The sample is a phase 2 trial for endometriosis testing the efficacy of TAK-385 and leuprorelin acetate as drugs, with a list of inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for HIV infection, testing the efficacy of raltegravir film-coated tablet, raltegravir chewable tablet, and other anti-retroviral therapy, with eligibility criteria including HIV positive status, weight of at least 7 kg, and HIV RNA \u22651000 copies/mL within 45 days before study treatment.",
    "This is a phase 2/phase 3 trial for chronic idiopathic constipation, testing the drug plecanatide, with specific inclusion and exclusion criteria for patient eligibility.",
    "The sample is a phase 2 trial for influenza, testing the efficacy of nitazoxanide and placebo drugs, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the effectiveness of naltrexone in treating metastatic, hormone-receptor positive breast cancer that has progressed despite previous systemic hormonal therapy, with specific eligibility criteria including measurable disease, adequate organ function, and use of effective contraception.",
    "This is a phase 2 trial for generalized anxiety disorder, testing the efficacy of eszopiclone and placebo, with specific inclusion and exclusion criteria for subjects.",
    "This phase 2 trial is testing the efficacy of fluorouracil, leucovorin calcium, and oxaliplatin in treating patients with colorectal cancer and metastatic cancer who have isolated hepatic metastases and are not amenable to curative resection, with specific eligibility criteria for patient characteristics and prior concurrent therapy.",
    "The sample is a phase 2 trial for patients with moderate to severe chronic obstructive pulmonary disease (COPD), testing the efficacy of tiotropium, salmeterol, fluticasone, ciclesonide low, ciclesonide high, and placebo, with inclusion criteria of male or female patients 40 years of age or older who are current or ex-smokers with a smoking history of more than 10 pack years, and exclusion criteria of other significant disease that can influence the study results or be a safety risk for the patient, other medication that can influence the study results, hypersensitivity to the study medication, and patients with unstable COPD.",
    "This is a phase 2 trial for patients with recurrent or persistent endometrial carcinoma, testing the efficacy of thalidomide as a treatment option, with specific eligibility criteria including prior chemotherapy regimen, measurable lesions, and performance status, among others.",
    "This is a phase 2 trial for sickle cell disease testing the effectiveness of nitric oxide and oxygen in reducing pain scores, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of psi-7977, daclatasvir, and ribavirin in treating chronic hepatitis C in patients who have not been previously exposed to interferon formulations or other HCV-specific direct-acting antivirals. The eligibility criteria include age range, HCV genotype, and exclusion of other medical conditions associated with chronic liver disease.",
    "The sample is a phase 2 trial for non-small cell lung cancer patients with measurable disease, testing the efficacy of bevacizumab and erlotinib, with eligibility criteria including ECOG PS 0-1 and age 70 or older, and exclusion criteria including prior treatment with EGFR pathway or anti-angiogenesis agents, squamous cell histology, and pregnancy or lactation.",
    "This phase 2 trial is testing the efficacy of sorafenib tosylate and gemcitabine hydrochloride in treating metastatic pancreatic carcinoma, with specific eligibility criteria including measurable disease and no prior chemotherapy for metastatic disease.",
    "This phase 2 trial is testing the efficacy of peficitinib and placebo in treating moderate to severe plaque psoriasis with inclusion criteria of at least 10% BSA affected and exclusion criteria of non-plaque psoriasis or drug-induced psoriasis, recent systemic psoriasis therapy, positive TB skin test, and abnormal chest x-ray.",
    "This phase 2 trial is testing the efficacy of gw786034 and placebo in treating metastatic or locally recurrent renal cell carcinoma, with eligibility criteria including prior therapy and adequate organ function.",
    "This phase 2 trial is testing the efficacy of nilotinib and placebo in treating pulmonary arterial hypertension, with specific inclusion and exclusion criteria for patients.",
    "This phase 2 trial is testing the efficacy of tenofovir gel and placebo in preventing HIV infections in sexually active individuals aged 18-40 with negative HIV and pregnancy tests, and who agree to use non-barrier contraception, while excluding those with adverse reactions to latex, creatinine clearance <50ml/min, active Hepatitis B infection, and other conditions that may interfere with achieving the study objectives.",
    "This phase 2 trial focuses on obesity and tests the efficacy of placebo, diazoxide, and metformin + diazoxide in male participants aged 25-50 years with BMI 30-35 kg/m2 and stable body weight, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of carboplatin and pemetrexed in treating platinum-sensitive recurrence of ovarian, peritoneal, or fallopian tube cancer, with specific eligibility criteria including prior platinum-containing regimen and measurable lesions, while excluding patients with certain medical conditions or prior malignancies.",
    "This phase 2 trial focuses on infertility and tests the effectiveness of fsh-gex(tm) and gonal-f(r) drugs in patients who meet specific eligibility criteria, while excluding those with certain medical histories or conditions.",
    "This phase 2 trial is testing cetuximab +/- dexamethasone for patients with relapsed or refractory multiple myeloma, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of the drugs rv568 and placebo in treating seasonal allergic rhinitis, with eligibility criteria including a history of the disease, positive skin prick test and total IgE result for grass pollen, and a moderate response to exposure to grass pollen in the challenge chamber.",
    "This phase 2 trial is testing the efficacy of a combination of capecitabine, irinotecan, oxaliplatin, folinic acid, and fluorouracil in treating potentially resectable adenocarcinoma of the rectum originating at or below 12 cm from the anal verge without evidence of distant metastases.",
    "This phase 2 trial is testing the efficacy of gemcitabine hydrochloride and topotecan hydrochloride in treating recurrent or persistent platinum-refractory ovarian, fallopian tube, or primary peritoneal cavity cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for locally advanced or metastatic unresectable pancreatic adenocarcinoma, testing the combination of arq 197 and gemcitabine, with eligibility criteria including measurable disease, KPS \u2265 70%, and various laboratory values within normal limits.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide and fludarabine phosphate in treating metastatic melanoma and skin cancer patients who have previously received high dose interleukin-2 (IL-2) and have been either non-responders or have recurred, and meet a list of eligibility criteria.",
    "This phase 2 trial is testing the efficacy of fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride, and dexamethasone in combination with radiation therapy for patients with stage III or IV squamous cell carcinoma of the oral cavity, oropharynx, larynx, hypopharynx, or nasopharynx, who meet specific eligibility criteria.",
    "This phase 2 trial is testing the effectiveness of certolizumab pegol in treating moderate to severe chronic plaque psoriasis in adults, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2/phase 3 trial for rheumatoid arthritis, testing the efficacy of rituximab in combination with methotrexate and prednisone, with specific inclusion and exclusion criteria for patient selection.",
    "This phase 2 trial is testing the effectiveness of cyclosporine in treating large granular lymphocytic leukemia, with eligibility criteria including a histologic or cytologic diagnosis of T-cell LGL leukemia, hemocytopenias, and a creatinine level less than 2.0 mg/dl.",
    "The sample is a phase 2 trial for depression using the drug azd6765, with inclusion criteria of inadequate response to antidepressants and exclusion criteria of other psychiatric disorders, pregnancy/lactation, and current cancer diagnosis.",
    "The sample is a phase 2 trial for locally advanced or metastatic pancreatic cancer using gemcitabine and etoposide as drugs, with specific eligibility criteria including hematologic and chemical parameters, and exclusion criteria such as previous chemotherapy and concurrent radiation therapy.",
    "This is a phase 2 trial for liver cancer patients with measurable disease, testing the efficacy of epirubicin hydrochloride and thalidomide, with eligibility criteria including age over 18, ECOG 0-2 performance status, and various medical requirements such as platelet count and creatinine level.",
    "The sample is a phase 2 trial for schizophrenia using Merck L-830982 and placebo drugs, with inclusion criteria including male participants between 18 and 50 years old who meet diagnostic criteria for schizophrenia or schizoaffective disorder and are clinically stable for a minimum of 3 months on current medication, and exclusion criteria including substance dependence or abuse, neurological disorder, medical illness or medications that may be affected by study participation, mental retardation, seizure disorder, and history of heart disease.",
    "The sample is a phase 2 trial for bladder cancer using gemcitabine and cisplatin as drugs, with eligibility criteria including T2b-T3, N0/Nx, M0 stage and measurable disease, and exclusion criteria including prior or concomitant malignant diseases and concurrent administration of any other tumor therapy.",
    "This phase 2 trial is testing the efficacy of sorafenib tosylate in treating metastatic clear cell renal cell carcinoma in patients who are eligible for cytoreductive nephrectomy, with specific eligibility criteria including measurable disease, ECOG performance status =< 1, and various laboratory values within normal limits.",
    "This phase 2 trial is testing the efficacy of docetaxel and asa404 in treating urothelial carcinoma, with specific eligibility criteria including prior chemotherapy with cisplatin, carboplatin, or gemcitabine, and exclusion criteria such as prior treatment with docetaxel and certain medical conditions.",
    "This phase 2 trial is testing the efficacy of fludarabine, mitoxantrone and rituximab in treating mantle cell lymphoma, with eligibility criteria including a pathologic diagnosis of the disease, measurable or evaluable disease, and a Karnofsky performance status greater or equal to 50%.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate in treating various forms of chronic myelogenous leukemia, with specific eligibility criteria including disease stage, prior treatment, and various health parameters.",
    "The sample is a phase 2 trial for locally advanced pancreatic cancer patients with measurable disease, using cisplatin, fluorouracil, and gemcitabine hydrochloride as drugs, and with eligibility criteria including ECOG 0-2 performance status, bilirubin less than 2 mg/dL, and no prior chemotherapy for this disease.",
    "This phase 2 trial will test the efficacy of gemcitabine hydrochloride and cisplatin in treating patients with urothelial carcinoma of the bladder or urethra who are candidates for radical cystectomy, and have no radiographic evidence of metastatic disease, with inclusion criteria including ECOG performance status of 0 or 1, adequate renal function, and negative pregnancy test for women of child-bearing potential.",
    "This is a phase 2 trial for osteoarthritis patients, testing the efficacy of cg100649 and celecoxib, with eligibility criteria including confirmed diagnosis of osteoarthritis, normal blood pressure and heart rate, and exclusion criteria including use of analgesics or corticosteroids within 3 months of screening, and history of congestive heart failure or cancer.",
    "The sample is a phase 2 trial for rheumatoid arthritis testing the efficacy of GLPG0634 and placebo, with inclusion criteria including active RA and stable methotrexate use, and exclusion criteria including previous use of GLPG0634 and treatment with DMARDs or biological agents.",
    "This phase 2 trial is testing a combination of drugs including cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, prednisone, and vincristine sulfate for the treatment of Burkitt's leukemia or Burkitt's or Burkitt-like lymphoma in patients aged 16 and over, with specific eligibility criteria including confirmed diagnosis and no prior treatment, among others.",
    "This phase 2 trial is testing the efficacy of naltrexone sr 32 mg/bupropion sr 360 mg/day versus placebo in treating obesity in female subjects aged 18 to 45 years with a BMI \u2265 27 and \u2264 40 kg/m\u00b2, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of 131-i-tm-601 and 131i-tm601 drugs on patients with malignant glioma, glioblastoma multiforme, anaplastic astrocytoma, oligo-astrocytoma, and gliosarcoma, who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of crx-102, prednisolone, dipyridamole, and placebo in treating rheumatoid arthritis in patients who meet specific inclusion criteria and do not have any exclusion criteria.",
    "This phase 2 trial is testing the efficacy of sunitinib, a drug used to treat cancer, on patients with progressive thyroid cancer who are not candidates for surgery, external beam radiotherapy, or radioiodine.",
    "This phase 2 trial is testing the efficacy of a combination of mometasone furoate nasal spray and oxymetazoline nasal spray, as well as individual use of each, versus placebo, in treating seasonal allergic rhinitis in patients over 12 years old with a positive skin-prick test response to an appropriate seasonal allergen, with various inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of bortezomib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ganciclovir, valganciclovir, and zidovudine in treating primary effusion lymphoma (PEL) involving a body cavity, with eligibility criteria including confirmed PEL, HIV infection allowed, and specific patient characteristics such as age, performance status, and organ function.",
    "The sample is a phase 2 trial for Parkinson's disease, testing the efficacy of istradefylline and placebo in reducing OFF time, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for primary HER2-negative operable breast cancer, testing the efficacy of bevacizumab, docetaxel, and standard chemotherapy, with eligibility criteria including tumor size and ECOG performance status, and exclusion criteria including previous treatment for breast cancer and clinically significant cardiovascular disease.",
    "This phase 2 trial is testing the efficacy of octreotide and dg3173 in treating acromegaly of pituitary origin, with inclusion criteria including age adjusted IGF-1 concentrations and random hGH levels, and exclusion criteria including previous treatment for acromegaly, uncontrolled hypertension, and pregnancy or lactation.",
    "The sample is a phase 2 trial for chronic hepatitis C infection, testing the drugs idn-6556 and placebo, with inclusion criteria including unsuccessful prior HCV treatment and liver impairment, and exclusion criteria including hepatocellular carcinoma and HIV infection.",
    "This phase 2 trial is testing the efficacy of gw856553 and seretide, along with placebo, in treating chronic obstructive pulmonary disease in male and female adults between 40 and 75 years of age with a smoking history of \u226510 pack years, and with a post-bronchodilator FEV1 to FVC ratio (FEV1:FVC) < 0.7 at Visit 1.",
    "The sample is a phase 2 trial for diabetic neuropathic pain, testing the drugs bvt.115959 and placebo, with inclusion criteria of documented painful, symmetrical, sensorimotor polyneuropathy for at least 6 months and exclusion criteria of clinically significant or unstable hepatic, respiratory, renal, hematologic, cardiovascular or peripheral vascular disease.",
    "This phase 2 trial is testing the efficacy of various drugs, including fp/sal 250/50mcg bid and montelukast, in treating asthma in patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug dvd-r in patients with relapsed or refractory multiple myeloma, with specific eligibility criteria including measurable disease and laboratory test results within certain ranges.",
    "This phase 2 trial aims to investigate the effects of omega 3 fats and folic acid on infertile men aged 35 to 55 with difficulty timing relations to their partner's ovulation, while excluding those with hypertension, heart disease, marked semen abnormalities, and use of anticoagulants or PDE 5 inhibitors, and prohibiting the use of other supplements during the study.",
    "The sample is a phase 2 trial for non-small cell lung cancer patients who have previously received one platinum-containing or taxane-containing chemotherapy regimen, testing the efficacy of cetuximab and pemetrexed, with eligibility criteria including ECOG performance status, prior treatments, and bone marrow, renal, and hepatic function.",
    "This phase 2 trial is testing the efficacy of 4-aminosalicylic acid and paser placebo granules in treating Crohn's disease involving predominantly the ileum and/or cecum, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of tac-101 and placebo in treating advanced hepatocellular carcinoma, with strict eligibility criteria including confirmed nodular type lesions in the liver and adequate organ function.",
    "This phase 2 trial is testing the drug sunitinib for patients with liver neoplasms and unresectable hepatocellular carcinoma, with eligibility criteria including confirmed diagnosis, measurable disease, and adequate organ function.",
    "This phase 2 trial is testing the efficacy of lapatinib, capecitabine, docetaxel, and nab-paclitaxel in treating relapsed breast cancer with ErbB2 gene amplification or protein overexpression, and eligibility criteria include having measurable lesions, no prior anti-cancer therapy for metastatic breast cancer, and adequate organ function.",
    "This phase 2 trial is testing the efficacy of gw572016 (lapatinib) in patients with advanced non-small cell lung cancer who have had a maximum of 1 prior systemic therapy, and have measurable lesions and adequate organ function, among other eligibility criteria.",
    "This phase 2 trial will test the efficacy of matuzumab, epirubicin, cisplatin, and capecitabine in treating metastatic esophageal and gastric adenocarcinoma patients with EGFR expression, who have not received chemotherapy in the past 12 months, and have an ECOG PS of 0-1.",
    "This phase 2 trial is testing the efficacy of a placebo in treating active rheumatoid arthritis in patients who have failed or were intolerant to biologic tumor necrosis factor-alpha (TNF\u03b1) inhibitor therapy, and are currently on a stable dose of Methotrexate, with a list of inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for glioblastoma multiforme, testing the efficacy of talampanel, temozolomide, and adjuvant tmz 200mg, with inclusion criteria including age, confirmed diagnosis, no prior therapy, stable corticosteroid regimen, and Karnofsky performance of at least 60%.",
    "This phase 2 trial is testing the efficacy of act-128800 doses 1-3 versus placebo in treating RRMS, with inclusion criteria based on the revised McDonald Diagnostic Criteria for Multiple Sclerosis.",
    "This phase 2 trial is testing the efficacy of cisplatin, dexamethasone, vitamin b12, and folic acid, and cisplatin and gemcitabine in chemotherapy-naive patients with non-small cell lung cancer and large-cell carcinoma, who are not amenable to curative treatment or have stage IV disease, and meet certain eligibility criteria.",
    "This is a phase 2 trial for patients with locally recurrent or metastatic HER2-positive breast cancer, testing the efficacy of eribulin mesylate, with specific eligibility and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of IV bisphosphonate q 4 weeks in patients with bone metastases in various types of cancer, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of clofarabine in treating acute myeloid leukemia in patients above 40 years old who have not responded to standard induction therapy and meet specific eligibility criteria related to renal and hepatic function, refractory disease, and other factors.",
    "This phase 2 trial is testing the efficacy of amg 747 and placebo in treating schizophrenia, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the efficacy of sorafenib tosylate in treating refractory multiple myeloma patients who have relapsed or are resistant to prior therapy, with specific eligibility criteria including disease status, prior treatment, performance status, and absence of certain medical conditions or medications.",
    "This phase 2 trial is testing the efficacy of lenalidomide, a drug, in treating relapsed adult acute lymphocytic leukemia, with specific eligibility criteria for patients including age, performance status, and prior treatment history.",
    "This phase 2 trial is testing the efficacy of carboplatin and paclitaxel albumin-stabilized nanoparticle formulation in treating unresectable stage IV melanoma patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the safety and efficacy of GSK1292263 and sitagliptin in treating type 2 diabetes mellitus patients who meet specific eligibility criteria, including stable metformin therapy and BMI within the range of 21.8-37.5 kg/m2.",
    "The sample is a phase 2 trial for non-small-cell lung carcinoma testing the efficacy of zd6474, paclitaxel, and carboplatin, with eligibility criteria including confirmed NSCLC, no prior therapy, and measurable lesions.",
    "This phase 2 trial is testing the drug lenalidomide on patients with myelodysplastic syndromes who meet specific criteria, including having an associated del 5q[31], while excluding those who have received prior therapy with lenalidomide or have clinical neuropathy of greater than grade 2.",
    "The sample is a phase 2 trial for the treatment of acute, confirmed gout flare with dexamethasone, with inclusion criteria of a score over 50 on the 0-100 VAS pain scale and exclusion criteria including treatment with biological anti-tumor necrosis factor (anti-TNF) within the past 3 months and anti-inflammatory medication for the treatment of acute gout within the previous 24 hours.",
    "The sample is a phase 2 trial for bladder cancer testing the efficacy of gemcitabine, cisplatin, and gefitinib in patients with locally advanced or metastatic disease, with specific inclusion and exclusion criteria listed.",
    "The sample is a phase 2 clinical trial for systemic sclerosis, testing the efficacy of sar100842 and placebo, with eligibility criteria including meeting ACR criteria for systemic sclerosis and having a Modified Rodnan Skin Score \u2265 15.",
    "The sample is a phase 2 trial for kidney transplantation, testing the drugs cyclosporine and cp-690,550, with inclusion criteria of first-time kidney transplant recipients between 18 and 70 years old, and exclusion criteria of non-kidney transplant recipients.",
    "This phase 2 trial is testing the efficacy of bortezomib in treating various types of advanced gastrointestinal cancers, including adenocarcinoma of the extrahepatic bile duct and gallbladder, and requires patients to meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug enzastaurin on patients with Waldenstrom's Macroglobulinemia or Multiple Myeloma who have been previously treated with up to 5 therapies, and have specific laboratory values and performance status, while excluding those with certain medical histories or treatments.",
    "This phase 2 trial will test the efficacy of d/c/f/taf, drv, cobi, and ftc/tdf in treatment-naive patients with acquired immunodeficiency syndrome and HIV infections, who meet specific eligibility criteria, including having plasma HIV-1 RNA levels \u2265 5,000 copies/mL and CD4+ cell count > 50 cells/\u00b5L.",
    "The sample is a phase 2 trial for metastatic breast cancer using capecitabine and oxaliplatin, with inclusion criteria of preserved organ function and good performance status, and exclusion criteria of no prior capecitabine or oxaliplatin and no concurrent therapy.",
    "The sample is a phase 2 trial for diabetic neuropathic pain, testing the efficacy of abt-894 and placebo drugs, with inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the efficacy of lapatinib ditosylate and tamoxifen citrate in treating locally advanced or metastatic estrogen and/or progesterone receptor positive breast cancer that has failed hormonal manipulation with tamoxifen, and has specific eligibility criteria for patients.",
    "This phase 2 trial is testing the efficacy of lanthanum carbonate and placebo in treating chronic kidney disease patients who meet specific eligibility criteria, including having a screening serum c-terminal FGF23 > 50.0RU/mL and a screening estimated glomerular filtration rate (eGFR) of 30-59mL/min/1.73m2 using the MDRD formula.",
    "This phase 2 trial is testing the effectiveness of abatacept, a drug used to treat ankylosing spondylitis, in patients who have had inadequate response to conventional therapy or TNFalpha inhibitors, and have active disease defined by a BASDAI score of >= 4, back pain score of >= 4, or intolerance to NSAIDs or prior TNFalpha inhibitors.",
    "This phase 2 trial is testing the effectiveness of bevacizumab + erlotinib hydrochloride and gemcitabine hydrochloride + cisplatin or carboplatin in treating non-squamous non-small cell lung cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of topotecan, cyclophosphamide, and melphalan in treating multiple myeloma in patients who meet specific eligibility criteria.",
    "This is a phase 2 clinical trial for patients with persistent asthma, testing the efficacy of dupilumab and other drugs in combination with ICS plus LABA therapy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for the treatment of depression using the drugs mk-8777 and placebo, with inclusion criteria including a diagnosis of major depressive disorder and exclusion criteria including a history of bipolar disorder or suicide attempt.",
    "The sample is a phase 2 trial for patients with non-small-cell lung carcinoma or lung neoplasms, testing the drug HKI-272, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the combination of RAD001 and erlotinib in patients with advanced pancreatic adenocarcinoma who have received at least one prior chemotherapy regimen, with eligibility criteria including adequate hematologic, hepatic and renal parameters, and exclusion criteria including prior treatment with an mTor inhibitor and known hypersensitivity to erlotinib or RAD001.",
    "This phase 2 trial is testing the efficacy of sorafenib and pegylated interferon \u03b1-2b in treating metastatic melanoma patients who have not received any systemic treatment for stage IV disease, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of reduced glutathione sodium salt and normal saline in treating cystic fibrosis patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug CO-1.01 in patients with gemcitabine-refractory metastatic pancreatic adenocarcinoma who have no hENT1 expression in their tumor sample and have not responded to first-line gemcitabine-based therapy.",
    "This is a phase 2 trial for patients with coronary artery disease, testing the efficacy of drugs e5555 and placebo, with eligibility criteria including confirmed coronary artery disease and high risk factors such as elevated hsCRP or diabetes mellitus.",
    "This phase 2 trial is testing the efficacy of tc-5619-238 and placebo in treating inattentive predominant ADHD, with specific inclusion and exclusion criteria, and no other CNS-related clinical trial participation in the last 3 months.",
    "This is a phase 2 trial for acute respiratory infection, testing the efficacy of mucinex and placebo, with eligibility criteria including symptoms of cough and chest congestion, ability to produce sputum, and non-smoking status.",
    "This phase 2 trial is testing the efficacy of KNS-760704 and placebo in treating patients with familial or sporadic amyotrophic lateral sclerosis (ALS) who meet specific inclusion criteria, while excluding those with prior exposure to KNS-760704 or R(+)-pramipexole, or taking other investigational agents.",
    "This phase 2 trial is testing the efficacy of las100977 and salbutamol in treating persistent asthma in patients aged 18-70, with specific inclusion and exclusion criteria, and using ICD-10 codes to identify the disease.",
    "This phase 2 trial is testing the efficacy of doxorubicin, cyclophosphamide, paclitaxel, and bevacizumab in treating high-risk ER+ or PR+ breast cancer patients with normal organ function and no prior cytotoxic chemotherapy or radiation, while excluding patients with HER2 positive disease, metastatic disease, or inadequate control of hypertension.",
    "This phase 2 trial is testing the efficacy of anastrozole and gefitinib in postmenopausal women with estrogen receptor and/or progesterone receptor positive breast cancer, who have failed prior tamoxifen therapy, and have radiologically or clinically evident metastatic or locally recurrent disease, with bone metastases only allowed.",
    "The sample is a phase 2 trial for levodopa-induced dyskinesia in Parkinson's disease patients, testing the efficacy of levetiracetam and placebo, with inclusion criteria including age, disease severity, and willingness to adhere to protocol requirements.",
    "This phase 2 trial is testing the efficacy of EVT 302, nicotine replacement therapy, and placebo in male smokers aged 18-55 with a BMI between 18-30 and a smoking history of \u226517 and \u226434 cigarettes per day for the past year, who are willing and able to quit for about 12 hours in each of three subsequent study periods, and have previous experience of craving following smoking cessation.",
    "This phase 2 trial is testing the efficacy of memantine and placebo in treating multiple sclerosis patients with severe cognitive impairment, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with colorectal neoplasms and metastases, testing the effectiveness of irinotecan as a chemotherapy drug, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for the drug azd2624, olanzapine, and placebo in females with a diagnosis of schizophrenia, with inclusion criteria of non-childbearing potential and exclusion criteria of clinically relevant disease and/or abnormalities, alcohol or substance abuse not in remission, and enrollment in another investigational study within 30 days.",
    "This phase 2 trial is testing the efficacy of bea 2180 br and tiotropium in patients with chronic obstructive pulmonary disease who meet specific spirometric criteria and have a smoking history of more than 10 pack years. The eligibility criteria includes patients being able to perform pulmonary function tests and inhale medication from the Respimat\u00ae inhaler, while exclusion criteria includes patients with significant diseases other than COPD and a history of life-threatening pulmonary obstruction.",
    "The sample is a phase 2 trial for non-hodgkin lymphoma using intravenous vitamin c as a drug, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 clinical trial for relapsed or refractory follicular lymphoma, testing the efficacy of bortezomib and rituximab as treatment options, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for untreated acute myeloid leukemia, testing the effectiveness of lintuzumab, low dose cytarabine, and placebo, with specific inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial is testing the efficacy of pemetrexed and cisplatin in treating non-small cell lung cancer and carcinoma, with specific eligibility criteria including accessible tumor tissue and no prior systemic chemotherapy or radiation therapy for NSCLC.",
    "This phase 2 trial is testing the efficacy of gefitinib, a drug, in treating esophageal cancer in patients aged 70-85 years with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of bevacizumab and rad001 in treating metastatic or unresectable locally recurrent clear cell renal carcinoma, with eligibility criteria including previous nephrectomy, ECOG performance status 0 or 1, and no previous treatment with bevacizumab or m-TOR inhibitors.",
    "This is a phase 2 trial for HIV patients with central fat accumulation, using raltegravir as a drug, and requiring specific eligibility criteria including current antiretroviral therapy with two nucleoside analogues and either a non-nucleoside analogue or an approved protease inhibitor.",
    "This phase 2 trial is testing the efficacy of indacaterol/glycopyrrolate, indacaterol, and glycopyrrolate in treating moderate to severe chronic obstructive pulmonary disease (COPD) in patients with a smoking history of at least 10 pack years, with specific inclusion and exclusion criteria.",
    "This phase 2 trial aims to test the efficacy of methylphenidate hydrochloride, placebo capsule, and galantamine in treating cognitive symptoms in patients with chronic PTSD and/or traumatic brain injury, who also have clinically significant cognitive complaints, as indicated by a T score \u2265 60 on the postmorbid Cognitive scale of the RNBI.",
    "This phase 2 trial is testing the efficacy of glpg0259 oral capsule and placebo in treating rheumatoid arthritis in patients who meet specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of bendamustine hydrochloride, dexamethasone, and etoposide in patients with relapsed or primary refractory lymphoid malignancy or multiple myeloma who have had three or fewer prior myelotoxic treatment regimens.",
    "This is a phase 2 clinical trial for patients with refractory or relapsed multiple myeloma, testing the drug pxd101, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of bevacizumab, a drug used to treat malignant ascites, in patients with persistent or symptomatic ascites due to any histologically confirmed tumor type not amenable to cytoreductive surgery or additional chemotherapy.",
    "This phase 2 trial is testing the efficacy of lixivaptan and placebo in treating congestive heart failure patients with volume overload, with specific inclusion and exclusion criteria outlined.",
    "This phase 2 trial will test the efficacy of baricitinib and methotrexate in treating adult-onset rheumatoid arthritis patients who have been on a stable dose of methotrexate for at least 8 weeks, with inclusion criteria including at least 6 swollen and tender joints and a CRP measurement > 0.5 mg/dL or ESR > 28 mm/hr.",
    "This is a phase 2 trial for patients with non-small cell lung cancer, testing the efficacy of paclitaxel and carboplatin, with specific eligibility and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of anti-CD3 monoclonal antibody and sodium chloride placebo in treating chronic hepatitis C patients who have failed previous treatments, with specific eligibility criteria including liver biopsy diagnosis, HCV RNA level, and liver function tests.",
    "This phase 2 trial is testing the efficacy of g-csf and placebo in treating Parkinson's disease patients who meet specific eligibility criteria, including Hoehn & Yahr stage I-III and a good response to levodopa, while excluding patients with YOPD, major depression, and cognitive impairment.",
    "The sample is a phase 2 trial for HER2-positive breast cancer patients with metastatic or recurrent disease, testing the efficacy of capecitabine and trastuzumab, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for schizophrenia with the drugs pf-02545920, risperidone, and placebo, and the inclusion criteria require a diagnosis of schizophrenia with acute exacerbation of illness less than 4 weeks prior to evaluation.",
    "This phase 2 trial is testing the drug everolimus on patients with resectable invasive breast cancer, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for advanced prostate cancer using dasatinib as a drug, with inclusion criteria including rising PSA levels and castrate levels of testosterone, and exclusion criteria including symptomatic CNS metastasis and prior anti-cancer medical therapy for prostate cancer.",
    "This phase 2 trial is testing the efficacy of daptomycin and vancomycin in treating complicated soft tissue infections caused by gram-positive pathogens, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for type 2 diabetes with ipragliflozin, metformin, and placebo as drugs, and the eligibility criteria includes having a HbA1c value between 6.8 and 9.5% and not currently taking anti-diabetic medication or willing to discontinue them during the study.",
    "This phase 2 trial is testing the efficacy of erlotinib, bevacizumab, gemcitabine, and cisplatin in treating non-small cell lung cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial testing the efficacy of amifostine trihydrate, carboplatin, cisplatin, and paclitaxel in treating locoregionally advanced undifferentiated nasopharyngeal cancer, with eligibility criteria including age range, performance status, hematopoietic, hepatic, renal, and cardiovascular conditions, and exclusion criteria including prior chemotherapy or radiotherapy for UNPC, concurrent immunotherapy, hormonal therapy, and other concurrent anticancer drugs.",
    "This phase 2 trial is testing the drug everolimus (rad001) on patients with metastatic colorectal cancer who have documented disease progression within 6 months of their most recent dose of chemotherapeutic regimens and have at least one measurable lesion, while excluding patients who have previously received RAD001 or have untreated central nervous system (CNS) metastases or neurologically unstable CNS metastases.",
    "This phase 2 trial is testing the drug everolimus on patients with low or intermediate-1 risk myelodysplastic syndromes who require transfusion of 2 units of red blood cells at least once a month and have high levels of endogenous epoetin alfa, while meeting certain patient characteristics and prior concurrent therapy requirements.",
    "The sample is a phase 2 trial for asthma patients with moderate or severe asthma, testing the effectiveness of chf 5188 pmdi, budesonide extrafine pmdi, and seretide(r) evohaler(r) drugs, with inclusion criteria of FEV1 \u2265 60% and \u2264 90% of predicted for the patient normal value, and exclusion criteria of COPD, significant cardiovascular disease, and uncontrolled concomitant disease.",
    "This is a phase 2 trial for primary insomnia, using the drug pd 0200390, with specific eligibility criteria including sleep duration and comorbidities.",
    "This phase 2 trial is testing the efficacy of paclitaxel poliglumex and carboplatin in treating non-small-cell lung carcinoma patients with specific eligibility criteria, including disease stage and prior therapy.",
    "The sample is a phase 2 trial for non-small cell lung cancer patients who failed first line chemotherapy and are scheduled for second line therapy with Tarceva, testing the efficacy of doxycline and erlotinib, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cetuximab, a drug used to treat squamous cell carcinoma of the head and neck, in patients who meet specific eligibility criteria and do not have any exclusion criteria.",
    "The sample is a phase 2 clinical trial for the treatment of dry eye using loteprednol etabonate ophthalmic suspension, 0.5% and its vehicle, with eligibility criteria including a diagnosis of dry eye, history of artificial tear use, and response to CAE exposure.",
    "This phase 2 trial is testing the effectiveness of allogeneic stem cell transplantation in patients with metastatic renal cell cancer who meet specific eligibility criteria, and the treatment includes fludarabine, melphalan, and cyclophosphamide.",
    "This is a phase 2 trial for the drug atx08-001 and placebo in treating postherpetic neuralgia, with eligibility criteria including a diagnosis of postherpetic neuralgia, moderate pain, and a BMI between 17 and 36.",
    "The sample is a phase 2 trial for heart failure patients with renal impairment, using furosemide and rolofylline as drugs, with inclusion criteria of systolic blood pressure >95 mm Hg and exclusion criteria of active infection, recent heart problems, and use of diuretic within 3 hours of screening visit.",
    "This phase 2 trial is testing the efficacy of nva237 100 \u00b5g and nva237 200 \u00b5g, compared to placebo, in treating moderate to severe chronic obstructive pulmonary disease (COPD) in patients aged 40 or older with a smoking history of at least 10 pack years, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for metastatic colorectal cancer using a combination of fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin, with eligibility criteria including measurable disease, ECOG 0-2 performance status, and no prior chemotherapy for advanced colorectal cancer.",
    "This phase 2 trial is testing the efficacy of gefitinib, a drug, in treating resectable, localized esophageal cancer with no known distant metastases, and the eligibility criteria includes adequate bone marrow, hepatic, renal, and cardiovascular function, as well as no other significant clinical disorder or laboratory finding that would preclude study participation.",
    "The sample is a phase 2 clinical trial for Crohn's disease, testing the efficacy of tu-100 and matching placebo drugs, with eligibility criteria including a CDAI score of 220-300 and exclusion criteria such as recent treatment with Anti-TNF agents or corticosteroids.",
    "This phase 2 trial is testing the efficacy of pd 0332991 in treating recurrent, intracranial glioblastoma multiforme or gliosarcoma, with eligibility criteria including Rb positive disease and prior external beam radiation and temozolomide chemotherapy.",
    "This phase 2 trial is testing the use of l-arginine in patients with cystic fibrosis who meet specific inclusion and exclusion criteria, with the goal of improving lung function.",
    "The sample is a phase 2 trial testing the drug jnj16269110 and metformin on patients with type 2 diabetes mellitus, with inclusion criteria including a stable dose of metformin, BMI between 25 and 45 kg/m2, and HbA1c between 7% and 10%, and exclusion criteria including diabetes other than type 2 diabetes mellitus, treatment with oral anti-diabetic agents (other than metformin) or insulin during the 12 weeks before baseline visit, and history of intolerance or hypersensitivity to sulfonylurea or sitagliptin.",
    "The sample is a phase 2 trial testing the efficacy of docetaxel and bortezomib in treating various types of non-small cell lung cancer, with specific eligibility criteria including prior treatment history and certain lab values.",
    "This phase 2 trial is testing the efficacy of MK-8457, a drug, in combination with methotrexate for the treatment of rheumatoid arthritis in patients who meet specific inclusion criteria, including a diagnosis of rheumatoid arthritis for at least 6 months, presence of swollen and tender joints, and a stable weekly dose of methotrexate for at least 4 weeks prior to screening.",
    "This is a phase 2 trial for patients with paranoid schizophrenia, testing the efficacy of mk0249 and placebo, with inclusion and exclusion criteria related to patient stability, health, and medication history.",
    "This phase 2 trial is testing the efficacy of bevacizumab, a drug used to treat hepatocellular carcinoma, in patients with histologically confirmed HCC not suitable for OLT or resection, with specific inclusion and exclusion criteria.",
    "This phase 2 trial focuses on patients with ventilator-associated pneumonia, respiratory infection, and tracheobronchitis, and tests the effectiveness of aerosolized vancomycin or gentamicin as a treatment option, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of Abraxane and Bevacizumab in treating recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma, with specific eligibility criteria including prior platinum-based chemotherapeutic regimen and normal organ and marrow function.",
    "This phase 2 clinical trial is testing the efficacy of iniparib, gemcitabine, and cisplatin in treating non-small cell lung cancer stage IV patients who meet specific eligibility criteria, including having no prior systemic therapy and at least one measurable lesion according to RECIST version 1.1.",
    "The sample is a phase 2 trial for locally advanced or metastatic thyroid cancer using the drug amg 706, with eligibility criteria including measurable disease and evidence of disease progression within 6 months before starting the study.",
    "This phase 2 trial will test the efficacy of atomoxetine, a drug used to treat ADHD, in individuals with cocaine dependence and adult ADHD, who meet specific inclusion and exclusion criteria, and have a history of certain physical and psychiatric disorders. The trial will focus on two diseases, attention deficit disorder with hyperactivity and cocaine-related disorders, and will use a list of icd-10 codes to identify eligible participants.",
    "This phase 2 trial is testing the effectiveness of gnrh (leuprolide), testosterone gel, and docetaxel in treating prostate cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug su011248 on patients with metastatic colorectal cancer who have failed previous cancer therapies, and have not been treated with certain tyrosine kinase inhibitors or VEGF inhibitors.",
    "This phase 2 trial is testing the efficacy of apatinib and placebo in treating advanced non-squamous and non-small cell lung cancer patients who have failed 2 lines of chemotherapy including EGFR-TKI, with eligibility criteria including age, measurable lesion, ECOG performance scale, and adequate hepatic, renal, heart, and hematologic functions.",
    "This phase 2 trial is testing the efficacy of celecoxib and eflornithine in reducing the number of polyps in patients with familial adenomatous polyposis, with eligibility criteria including a diagnosis of FAP, willingness to abstain from NSAIDs, and assessable colonic and/or rectal segment.",
    "This phase 2 trial is testing the efficacy of elb245 and tolterodine in treating overactive bladder and urinary incontinence, with specific inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial is testing the drug riociguat (bay63-2521) and placebo on patients with symptomatic pulmonary hypertension due to left ventricular diastolic dysfunction, with a list of associated diseases and ICD-10 codes, and specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of docetaxel and prednisone in treating patients with measurable or evaluable stage I or II adenocarcinoma of the prostate, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for patients with type 2 diabetes mellitus not adequately controlled by metformin, testing the efficacy of lixisenatide, liraglutide, and metformin as drugs, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of a placebo drug on patients with allergic rhinoconjunctivitis, with specific inclusion and exclusion criteria, and no other concurrent clinical trials or immunotherapy allowed.",
    "This phase 2 trial is testing the efficacy of docetaxel, cisplatin, and cetuximab in treating stage III-IVB head and neck cancer with squamous cell or poorly differentiated carcinomas, or WHO types I-III of the nasopharynx, and the eligibility criteria includes having no prior chemotherapy, biologic/molecular targeted therapy, or radiotherapy for head and neck cancer.",
    "The sample is a phase 2 trial for patients with metastatic colorectal cancer, using capecitabine and oxaliplatin as drugs, with eligibility criteria including ECOG performance status, blood counts, liver function, and absence of extrahepatic metastases.",
    "The sample is a phase 2 trial for patients with bipolar disorder, using memantine hcl as the drug, with inclusion and exclusion criteria specified in the eligibility criteria section.",
    "This is a phase 2 trial for leukemia patients using cyclophosphamide, methotrexate, and prednisone, with specific eligibility criteria including CD3+ and CD57+ cells, clonal T-cell receptor gene rearrangement, and exclusion criteria such as prior therapy with oral MTX or oral Cy, and previous or concurrent malignancies.",
    "This phase 2 trial is testing the efficacy of docetaxel and trovax in treating hormone refractory prostate cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of enzastaurin hydrochloride in treating metastatic or recurrent breast cancer that has previously been treated with an anthracycline and a taxane, but not positive for HER2, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug roflumilast on patients with inadequately controlled type 2 diabetes, with specific inclusion and exclusion criteria, and the primary outcome is the change in HbA1c levels.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide and fludarabine in treating metastatic melanoma and skin cancer patients with autologous tumor infiltrating lymphocytes, with specific eligibility criteria including age, disease status, and serology.",
    "This phase 2 trial is testing the effectiveness of thalidomide in treating amyotrophic lateral sclerosis (ALS) in patients aged 25-80 years with a clinical diagnosis of probable or definite ALS, who have onset of pareses for no more than 4 years, and meet other inclusion criteria, while excluding patients with certain medical conditions or taking certain medications.",
    "This phase 2 trial is testing the efficacy of ly2599506, a drug, in treating type 2 diabetes mellitus in patients who are being treated with diet and exercise therapy and may be treated with metformin, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide, mitoxantrone, vincristine, prednisone, and rituximab in treating large B-cell, CD20-positive non-Hodgkin's lymphoma in patients over 70 years old with clinical stage II, III, or IV by the Ann Arbor Staging Criteria, and with adequate bone marrow, liver and kidney function.",
    "The sample is a phase 2 trial for metastatic breast cancer patients with stable brain metastases, testing the efficacy of bevacizumab, docetaxel, cpt-11, paclitaxel, vinorelbine tartrate, and gemcitabine, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of biib041 (pr fampridine) in treating multiple sclerosis patients with EDSS 4 to 7, with a list of exclusion criteria including history of seizures, epilepsy, or other convulsive disorder, and presence of any psychiatric disorder likely to interfere with the subject's participation in the study.",
    "The sample is a phase 2 trial for glioblastoma multiforme using tln-4601 as a drug, with specific eligibility criteria including prior treatment and normal organ function.",
    "This phase 2 trial will test the efficacy of sch 619734 and placebo in reducing nausea and vomiting in patients receiving cisplatin-based chemotherapy, with inclusion criteria including a Karnofsky performance score of >=60 and adequate bone marrow, kidney, and liver function.",
    "This phase 2 trial is testing the efficacy of amg 747 and placebo in treating schizophrenia, with specific inclusion and exclusion criteria, and the use of PANSS Marder Negative and Positive Symptom Factor Scales to measure outcomes.",
    "The sample is a phase 2/phase 3 trial testing the efficacy of high dose multivitamin in patients with chronic kidney disease, cardiovascular disease, and death, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for rheumatoid arthritis, testing the drugs cp-690,550 and placebo, with inclusion criteria based on ACR classification and active disease, and exclusion criteria related to recent infections and vaccinations.",
    "This phase 2 trial is testing the efficacy of carboplatin, cisplatin, and paclitaxel in treating uterine neoplasms in patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of carboplatin and bevacizumab in treating metastatic breast cancer patients who meet specific eligibility criteria, including having normal organ and marrow function, measurable disease, and not having received prior chemotherapy for metastatic breast cancer.",
    "This is a phase 2 trial for Huntington's disease, testing the drug dimebon, with inclusion criteria based on clinical features and family history of HD, and exclusion criteria including unstable medical illness and pregnancy/lactation.",
    "The sample is a phase 2 trial for schizophrenia, testing the efficacy of olanzapine-raim and placebo drugs, with inclusion and exclusion criteria based on disease diagnostic criteria, PANSS-EC scores, and prior medication history.",
    "The sample is a phase 2 trial for brain metastases from non small cell lung cancer, using iressa (gefitinib) as the drug, with inclusion criteria of radiologically confirmed brain metastases and no previous radiotherapy treatment for the brain metastases, and exclusion criteria of no prior chemotherapy and no other co-existing malignancies or malignancies diagnosed within the last 5 years.",
    "This phase 2 trial is testing the efficacy of decitabine in treating myelodysplastic syndrome and chronic myelomonocytic leukemia patients who have failed therapy with azacytidine and meet certain eligibility criteria.",
    "The sample is a phase 2 trial for prostate cancer using the drug Sandostatin, with eligibility criteria including confirmed adenocarcinoma, biochemical disease progression, and no prior chemotherapy, while exclusion criteria include diabetes mellitus and prior treatment with chemotherapy or certain medications.",
    "This phase 2 trial is testing the efficacy of tp-434 and ertapenem, along with a placebo, in treating complicated intra-abdominal infection in patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide and fludarabine phosphate in treating recurrent ovarian, fallopian tube, or primary peritoneal cancer patients who have failed to respond to at least 2 salvage chemotherapy regimens, and have an available related HLA-haploidentical natural killer (NK) cell donor.",
    "The sample is a phase 2 trial for trauma patients, testing the effectiveness of propranolol and propranolol er versus sugar pills, with inclusion criteria including at least one fracture, ages 18-60 yrs, and pain score >= 4, and exclusion criteria including pregnancy, propranolol use within the last 6 months, and heart block > 1 degree.",
    "This trial is testing the efficacy of duloxetine and placebo in treating daily pain attributed to multiple sclerosis, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for chronic hepatitis C, testing celgosivir and peginterferon alfa 2b + ribavirin, with inclusion criteria including age, genotype, and treatment-na\u00efve status, and exclusion criteria including previous interferon-based therapy and diabetes mellitus.",
    "This phase 2 trial is testing the efficacy of gemcitabine, erlotinib, and sorafenib in treating pancreatic cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of irinotecan, avastin, and erbitux in treating locally advanced or metastatic colorectal cancer with specific eligibility criteria, including measurable disease and adequate liver, renal, and bone marrow function.",
    "This phase 2 trial is testing the effectiveness of gemcitabine, carboplatin, and trastuzumab in treating locally advanced or metastatic breast cancer with specific eligibility criteria, including no prior chemotherapy in the metastatic breast setting and normal organ and bone marrow function.",
    "This phase 2 trial is testing the drug panobinostat on patients with recurrent malignant gliomas, with specific eligibility criteria including no more than three prior therapies and certain laboratory values within normal limits.",
    "This phase 2 trial is testing the efficacy of mk-0873 and usual care in treating lung diseases, including chronic obstructive pulmonary disease (COPD), with specific inclusion and exclusion criteria, and using icd-10 codes to identify the diseases.",
    "This phase 2 trial is testing the efficacy of EVT 302 and placebo, with or without open label nicotine replacement, for smoking cessation in individuals who smoke at least 10 cigarettes daily and have had at least one unsuccessful attempt to quit in the last 2 years.",
    "This phase 2 trial is testing the efficacy of tiotropium bromide in patients with asthma who meet specific inclusion criteria and do not have any of the exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of warfarin and placebo in treating pulmonary hypertension in patients with sickle cell anemia or sickle cell beta zero thalassemia who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of mk0639 and indinavir sulfate in treating HIV infections, with nelfinavir mesylate as the comparator drug, and includes eligibility criteria such as being HIV positive and having no active heart disease.",
    "This phase 2 trial is testing the efficacy of gemcitabine hydrochloride, carboplatin, and dexamethasone in treating a variety of relapsed or primary refractory lymphoid malignancies, including adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, and recurrent adult hodgkin lymphoma, among others.",
    "The sample is a phase 2 trial for small cell lung cancer patients with measurable disease, testing the drug pemetrexed as a second-line treatment option, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for non-squamous non-small cell lung cancer patients with measurable disease, testing the efficacy of erlotinib and gemcitabine, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of s-1 and bevacizumab in treating patients with inoperable, locally advanced, or metastatic colorectal cancer who have not received previous treatment, with specific eligibility criteria including age, organ function, and absence of certain conditions.",
    "This phase 2 trial is testing the efficacy of lenalidomide and bortezomib in treating multiple myeloma, with eligibility criteria including measurable disease and a Karnofsky Performance Status score of \u226550%.",
    "This phase 2 trial is testing the efficacy of cisplatin, gleevec\u2122, and irinotecan in treating small cell lung cancer patients who meet specific eligibility criteria, including having no untreated or symptomatic brain or leptomeningeal metastases and meeting certain hematopoietic, hepatic, renal, and cardiovascular requirements.",
    "The sample is a phase 2 trial for ovarian cancer patients who have received no more than 3 previous platinum containing treatments and were progression free for at least 6 months following the end of the last platinum treatment, and the trial will test the effectiveness of olaparib, paclitaxel, and carboplatin.",
    "This phase 2 trial is testing the drug ly2090314 in participants with refractory or relapsed acute myelogenous leukemia (AML) or untreated AML who are not candidates for standard therapy, and have adequate organ function and performance status, among other eligibility criteria.",
    "The sample is a phase 2 trial for ulcerative colitis, testing the efficacy of hmpl-004 low and high dose compared to placebo, with inclusion criteria of active mild to moderate ulcerative colitis and exclusion criteria of Crohn's Disease.",
    "This phase 2 trial is testing the efficacy of mitoxantrone, prednisone, and sorafenib in treating metastatic prostate cancer that has progressed despite adequate castration, with eligibility criteria including a minimum of 4 weeks off certain medications and adequate bone marrow, liver, and renal function.",
    "This phase 2 trial is testing the drug rad001 on patients with predominantly clear cell renal cancer and evidence of metastatic disease, who have received no more than two prior regimens, and meet certain eligibility criteria.",
    "This phase 2 trial is testing the drug Abraxane on patients with recurrent epithelial ovarian or primary peritoneal carcinoma who have received at least 3 cycles of a front-line taxane and platinum-containing regimen, and meet other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of glufosfamide in treating soft tissue sarcoma patients who have progressed since the most recent therapy, with specific eligibility criteria including prior chemotherapy, ECOG performance status score, and normal blood counts and liver function tests.",
    "This phase 2 trial is testing the drug VX-509, along with a placebo, for patients with rheumatoid arthritis who have failed at least one nonbiologic DMARD, and have not been treated with Rituximab previously. The eligibility criteria includes a diagnosis of RA, a swollen and tender joint count, and a baseline CRP level, while the exclusion criteria includes a history of other inflammatory rheumatological disorders, hematologic disorders, and active infections.",
    "The sample is a phase 2 trial for pancreatic cancer, testing the efficacy of rp101 and gemcitabine, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of escalating doses of casodex in men with histologically-confirmed prostate cancer who have received treatment with Zoladex and have a serum testosterone level < 50 ng/ml, with the goal of reducing PSA levels.",
    "This phase 2 trial will test the efficacy of prasugrel, clopidogrel, and placebo in hospitalized patients with acute coronary syndrome who are anticipated to undergo percutaneous coronary intervention within 24 hours of the loading dose.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate and paclitaxel in treating non-small cell lung cancer patients with pleural effusion or stage IV disease, who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of BMS-791325, peg-interferon alfa-2a, and ribavirin in treating chronic HCV genotype 1 infection in patients who meet specific inclusion criteria, while excluding liver transplant recipients, those with chronic hepatitis B virus, and those with a history of cancer within 5 years prior to enrollment.",
    "This phase 2 clinical trial is testing the effectiveness of nitazoxanide, an anti-parasitic drug, in treating Crohn's disease with colonic or perianal involvement, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cnto 136 and placebo in treating lupus nephritis, with inclusion criteria including a diagnosis of SLE and persistently active nephritis, and exclusion criteria including cyclophosphamide use within 3 months of randomization and serum creatinine > 2.5 mg/dL.",
    "This phase 2 trial is testing epothilone d for patients with advanced or metastatic colorectal cancer who have failed prior treatment with a fluoropyrimidine in combination with either irinotecan or oxaliplatin, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of azacitidine, erythropoietin, and azacitidine (monotherapy) in treating myelodysplastic syndromes with specific eligibility criteria for randomization.",
    "This sample is a phase 2 trial for patients with advanced metastatic or nonmetastatic prostate cancer, testing the efficacy of azacitidine for injectable suspension, with specific eligibility criteria including PSA progression and a Karnofsky Performance Status >70.",
    "This phase 2 trial is testing the efficacy of Irinotecan/Bevacizumab chemotherapy in patients with primary malignant glioma who are either chemotherapy na\u00efve or non-na\u00efve, and scheduled to receive palonosetron (aloxi) and dexamethasone as anti-emetic medication.",
    "This phase 2 trial is testing the efficacy of LCP Tacro and Prograf in renal transplant patients with stable doses and trough levels of tacrolimus, who are also on concurrent immunosuppression with mycophenolate mofetil or mycophenolic acid, and have serum creatinine < 2.0mg/dL, while excluding patients with certain medical conditions and those taking certain medications.",
    "The sample is a phase 2 trial for myelodysplastic syndromes and other blood and bone marrow diseases, using the drugs vorinostat, with inclusion criteria including previously untreated or up to one prior treatment regimen for lower-risk MDS, and adequate organ function.",
    "The sample is a phase 2 trial for non-small-cell lung cancer using pemetrexed, cisplatin, and carboplatin as drugs, with eligibility criteria including confirmed NSCLC Stage IIIb or IV and ECOG Performance status of 0 or 1.",
    "The sample is a phase 2 trial for patients with metastatic prostate cancer who have failed initial hormonal therapy and have disease progression after at least one chemotherapy regimen, and the trial will test the drug docetaxel. The eligibility criteria include specific disease characteristics and patient characteristics, and prior concurrent therapy is also specified.",
    "This phase 2 trial is testing the efficacy of lb80380 and entecavir in treating chronic hepatitis B, with specific inclusion and exclusion criteria for patients.",
    "This phase 2 trial is testing the efficacy of sorafenib, a drug, in treating soft tissue sarcoma, with eligibility criteria including confirmed histology, evidence of unresectable residual disease, and normal hematopoietic, hepatic, renal, and cardiovascular function.",
    "The sample is a phase 2 clinical trial for patients with early recurrent prostate cancer, testing the drug fulvestrant, with eligibility criteria including prior curative treatment and normal hematopoietic, hepatic, renal, cardiovascular, and pulmonary function.",
    "This phase 2 trial is testing the efficacy of pemetrexed, cisplatin, and cixutumumab in treating non-small-cell lung carcinoma patients with Stage IV disease, who have an estimated life expectancy of at least 12 weeks, and meet other eligibility criteria.",
    "This is a phase 2 clinical trial for patients with esophageal cancer, testing the efficacy of ppx with cisplatin and radiation, with eligibility criteria including confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction, no evidence of distant organ metastases, and ANC > 1,500/ul, among others.",
    "This phase 2 trial is testing the efficacy of pentostatin, cyclosporin, mycophenolate mofetil, and methotrexate in treating relapsed non-Hodgkin's or Hodgkin's lymphoma patients who have undergone high dose chemotherapy or autologous stem cell transplantation, and have a suitable bone marrow donor, while meeting certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of capecitabine, a chemotherapy drug, in patients with metastatic colorectal cancer who have progressed during prior fluoropyrimidine-containing therapy, and meet certain eligibility criteria.",
    "This phase 2 trial is testing chlorambucil and r-etodolac + chlorambucil for the treatment of chronic lymphocytic leukemia in patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for prostate cancer patients with rising PSA levels, requiring concurrent LHRH analogue or DES, and using dexamethasone as the drug, with eligibility criteria including ECOG 0-2, life expectancy \u2265 12 weeks, and various laboratory values within normal limits.",
    "This phase 2 trial will test the efficacy of eltoprazine and placebo in treating cognitive impairment and schizophrenia in patients who meet specific inclusion criteria, including being treated with certain antipsychotics for the previous two months, with no change in dose in the last month, and having no clinically significant abnormalities in laboratory results or ECG.",
    "This phase 2 trial is testing the efficacy of fluocinolone acetonide/medidur in patients with age-related macular degeneration who have reached a plateau with Lucentis injections, and have specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cenicriviroc and truvada in HIV-1 infected patients with CCR5-tropic-only virus and a CD4 cell count of at least 250 cells/mm3, while excluding patients with certain conditions such as CXCR4- or dual/mixed-tropic HIV-1 virus and active CDC category C disease.",
    "This phase 2 trial is testing the efficacy of clarithromycin, lenalidomide, and dexamethasone in treating multiple myeloma patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug plerixafor on patients with myeloma or lymphoma who meet certain eligibility criteria for autologous transplant.",
    "This phase 2 clinical trial is testing the efficacy of chitosan-n-acetylcysteine eye drops and placebo in treating dry eye syndrome, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for metastatic breast cancer patients with the drugs gemcitabine and paclitaxel, and eligibility criteria including prior anthracycline chemotherapy, measurable disease, and adequate organ function.",
    "This phase 2 trial is testing the efficacy of lexiva and ritonavir in treating human immunodeficiency virus i infection in children aged 2 to 18 years old, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of azacitidine in treating chronic myeloproliferative disorders and secondary myelofibrosis, with eligibility criteria including confirmed myelofibrosis with myeloid metaplasia, absence of t(9;22), and ECOG performance status 0-2, among other requirements.",
    "The sample is a phase 2 trial for non-small cell lung cancer patients, testing the efficacy of gemcitabine hcl and pemetrexed disodium, with eligibility criteria including specific disease characteristics and patient characteristics, and restrictions on prior and concurrent therapies.",
    "This phase 2 trial is testing the efficacy of atrasentan in patients with chronic kidney disease and diabetic nephropathy who are receiving a maximum tolerated dose of an ACEi or ARB, with specific inclusion and exclusion criteria, and comparing the effects of a low dose and high dose of atrasentan to a placebo group.",
    "The sample is a phase 2 trial for nasopharyngeal carcinoma using cetuximab as a drug, with eligibility criteria including confirmed diagnosis, measurable disease, and certain blood count and liver function levels, while exclusion criteria include previous treatment for NPC, systemic metastatic disease, and certain medical or psychological conditions.",
    "This phase 2 trial is testing the efficacy of androgen ablation, cabazitaxel, salvage therapy, neoadjuvant treatment - hormonal therapy, and neoadjuvant treatment - cabazitaxel in treating prostate cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of moxifloxacin and diphenhydramine in treating advanced or metastatic malignant solid tumors that have not responded to standard therapy, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of MSDC-0160 and placebo in treating Alzheimer's disease in patients aged 55-85 who meet specific inclusion criteria and do not have any exclusion criteria, including significant neurological/psychiatric disease other than AD, heart failure, or a history of alcohol or drug abuse within 6 months of screening.",
    "This phase 2 trial is testing the effectiveness of insulin nph and ex1000 in treating type 2 diabetes with specific eligibility criteria, including a BMI less than or equal to 40 kg/m2 and HbA1c less than or equal to 9.5%, for patients who have been on NPH treatment for at least 3 months.",
    "The sample is a phase 2 trial for osteoarthritis of the knee, testing the efficacy of drugs such as fx006 and tca ir 40, with eligibility criteria including a confirmed diagnosis of OA and a BMI \u2264 40 kg/m2.",
    "The sample is a phase 2 trial for primary central nervous system lymphoma, testing the efficacy of rituximab, methotrexate, and cytarabine, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for diabetes and obesity, testing the drugs placebo and incb013739, with eligibility criteria including a diagnosis of type 2 diabetes, postmenopausal females, and exclusion criteria such as hypertriglyceridemia and BMI over 40 kg/m2.",
    "This is a phase 2 trial for locally advanced or metastatic pancreatic cancer, testing the efficacy of gemcitabine, erlotinib, and apricoxib against a placebo, with specific eligibility and exclusion criteria.",
    "This is a phase 2 trial for liver transplantation patients with the drug fk778, testing eligibility criteria for inclusion and exclusion, with icd-10 codes for diseases including Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, and K70.0.",
    "The sample is a phase 2/phase 3 trial for pancreatic cancer using the drug rubitecan, with eligibility criteria including non-resectable Stage II-IV primary adenocarcinoma of the pancreas and a Karnofsky Performance Status between 50 and 100.",
    "This phase 2 trial is testing the effectiveness of celecoxib and doxorubicin hydrochloride in treating metastatic androgen-independent prostate cancer with osteoblastic metastases, and the eligibility criteria includes having no more than 3 prior cytotoxic treatments and more than 6 months since prior celecoxib or rofecoxib.",
    "This phase 2 trial is testing the drug bendamustine on patients with chronic lymphocytic leukemia (CLL) who meet specific eligibility criteria, including having a B-lymphocyte count of at least 5,000/uL and meeting certain disease-related symptoms, while excluding those with refractory CLL or previous stem cell transplantation.",
    "This phase 2 trial is testing the efficacy of gemcitabine, cisplatin, carboplatin, capecitabine, and 5fu in treating cholangiocarcinoma, hepatobiliary neoplasm, liver cancer, bile duct cancer, and cancer of gallbladder, with specific eligibility criteria including liver tumors not exceeding 8 cm and adequate liver function.",
    "This is a phase 2 trial for postmenopausal osteoporosis, testing the efficacy of alendronate, denosumab, and placebo, with specific eligibility criteria for women between 50 and 70 years old who have low bone mineral density and are generally in good health.",
    "The sample is a phase 2/phase 3 trial for multiple myeloma, testing the efficacy of tanespimycin and bortezomib in patients who have had at least three prior treatment regimens for multiple myeloma that included both drugs, with specific eligibility criteria for enrollment.",
    "The sample is a phase 2 trial for patients with severe cognitive impairment and paratonia, testing the effectiveness of botulinum toxin and saline as treatments, with specific inclusion and exclusion criteria based on disease diagnosis and paratonic rigidity assessment.",
    "This phase 2 trial is testing the drug gw685698/gw642444 in male subjects or female subjects of non-child bearing potential with a clinical history of chronic obstructive pulmonary disease (COPD) who have smoked at least 10 pack-years, and who conform to the current severity classification for Stage II/III disease in terms of post-bronchodilator spirometry.",
    "The sample is a phase 2 trial for liver transplantation patients, testing the efficacy of various drug combinations including mmf and tacrolimus, and sotrastaurin and tacrolimus, with specific eligibility criteria and exclusion criteria.",
    "This is a phase 2 trial for hypertension with the drug pf-00489791 and placebo, with inclusion criteria of mild to moderate hypertension and exclusion criteria of diabetes and significant cardiovascular events.",
    "The sample is a phase 2/phase 3 trial for amyotrophic lateral sclerosis, testing the efficacy of memantine, riluzole, and placebo, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for hepatocellular carcinoma using darinaparsin as a drug, with eligibility criteria including a diagnosis of HCC, measurable lesions, and adequate hepatic function, while exclusion criteria include previous malignancy and substance abuse.",
    "The sample is a phase 2 trial for patients with confirmed rectal cancer who would benefit from pre-operative combined chemo-radiotherapy, using drugs such as bevacizumab, capecitabine, and 5-fluorouracil, with eligibility criteria including age, performance status, and absence of prior radiotherapy or chemotherapy for rectal cancer.",
    "The sample is a phase 2 trial for non-small cell lung cancer testing the efficacy of gemcitabine, docetaxel, cisplatin, and etoposide, with eligibility criteria including no prior chemotherapy or radiation therapy and exclusion criteria including pregnancy or breastfeeding and serious concomitant systemic disorder.",
    "The sample is a phase 2 trial for patients with urinary bladder neoplasms, testing the drug tamoxifen, with inclusion criteria including previous systemic therapy and spread of cancer, and exclusion criteria including uncontrolled nervous system metastasis and recent systemic therapies.",
    "This phase 2 trial is testing the efficacy of everolimus in treating relapsing/refractory marginal zone B-cell lymphoma, with eligibility criteria including prior systemic treatment, measurable or evaluable disease, and ECOG performance status 0-1.",
    "This phase 2 trial will test the efficacy of docetaxel, cisplatin, fluorouracil, bevacizumab, and leucovorin in treating metastatic or unresectable gastric or esophageal adenocarcinoma, with eligibility criteria including no prior chemotherapy for metastatic or unresectable disease and Karnofsky performance status > or = 70%.",
    "The sample is a phase 2 trial for relapsed follicular B-cell lymphoma, testing the efficacy of sargramostim and rituximab, with specific inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for patients with GIST who have imatinib resistance, testing the drug ptk787/zk222584, with inclusion criteria such as measurable tumor lesions, age 18 or older, and blood neutrophil count of 1.5 x 10^9/L or higher, and exclusion criteria such as major surgery within 2 weeks prior to entry, acute or chronic liver disease, and confirmed diagnosis of HIV infection.",
    "This phase 2 trial is testing the efficacy of rituximab, fludarabine, and mitoxantrone in treating low grade, follicular, B cell lymphoma patients who have failed first line chemotherapy and have bulky disease, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of irinotecan hydrochloride and temozolomide in treating recurrent or refractory adult glioblastoma and gliosarcoma, with strict eligibility criteria including radiographic evidence of tumor progression, Karnofsky performance status, and various medical parameters.",
    "This phase 2 trial is testing the efficacy of rituximab and bendamustine in treating follicular lymphoma patients who are \u226560 years old, have not been previously treated, and have an intermediate or high risk FLIPI score, with specific eligibility criteria outlined.",
    "This phase 2 trial is testing the efficacy of diacerein and placebo in treating rheumatoid arthritis patients who have had insufficient response to methotrexate, with specific inclusion and exclusion criteria.",
    "This trial is testing the efficacy of 5-fluorouracil, leucovorin, and oxaliplatin in treating patients with neuroendocrine tumors, including gastrointestinal carcinoid tumor, islet cell tumor, lung cancer, and neoplastic syndrome, who meet specific eligibility criteria.",
    "The sample is a phase 2 trial testing the efficacy of bta798 and placebo in treating asthma patients with presumptive human rhinovirus infection, with inclusion and exclusion criteria specified, and the disease and icd-10 code being 'rhinovirus' and 'J20.6' respectively.",
    "This phase 2 trial is testing the efficacy of taribavirin and ribavirin in treating compensated chronic hepatitis C patients who have not been treated with interferon, peginterferon, ribavirin or any experimental therapy for >28 days, and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for chronic myeloid leukemia using reduced intensity conditioning, busulfan and fludarabine as drugs, with eligibility criteria including age, organ function, and disease status.",
    "This phase 2 trial is testing the efficacy of bevacizumab and rituximab in treating follicular NHL with specific eligibility criteria, including evidence of disease progression, previous chemotherapy regimens, and adequate organ function.",
    "This phase 2 trial is testing the drug edotecarin for locally advanced or metastatic breast cancer patients who are not amenable to surgery or radiotherapy with curative intent and have previously been treated with anthracycline and concurrent or sequential taxane therapy or are resistant to prior chemotherapy, and meet specific eligibility criteria.",
    "The sample is a phase 2/phase 3 trial testing the efficacy of natural source vitamin E 400IU/day in diabetic patients aged 55 and above with a history of myocardial infarction, cardiovascular disease, and other related diseases, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of vinflunine in patients with locally advanced or metastatic urothelium cells transition cancer who have had stabilization or objective response after first-line treatment with cisplatin+gemcitabine, and have met certain eligibility criteria.",
    "The sample is a phase 2 trial testing the drug ixabepilone on patients with metastatic adenocarcinoma of the prostate, with a list of eligibility criteria including disease progression and specific blood counts, liver function, and heart health requirements.",
    "The sample is a phase 2 trial testing the efficacy of vigabatrin and placebo in treating alcoholism and cocaine dependence, with specific inclusion and exclusion criteria, and a list of ICD-10 codes for the diseases.",
    "The sample is a phase 2 trial for myelofibrosis using obatoclax mesylate, with inclusion criteria including histologically confirmed myelofibrosis and normal organ function, and exclusion criteria including prior exposure to obatoclax and uncontrolled intercurrent illness.",
    "This phase 2 trial is testing the efficacy of filgrastim and pegfilgrastim in treating myeloid leukemia, with specific eligibility criteria and exclusion criteria based on disease history and cytogenetics.",
    "This phase 2 trial is testing the efficacy of gemcitabine, capecitabine, and sorafenib in treating unresectable and/or metastatic renal clear cell carcinoma patients who are ineligible for immunotherapy treatment and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of clofarabine and cytarabine in treating refractory or relapsed acute lymphoblastic leukemia patients who meet specific eligibility criteria, including having evidence of ALL in bone marrow or peripheral blood and meeting certain patient characteristics such as Zubrod performance status 0-2 and negative HIV status.",
    "This phase 2 trial is testing the drug su11248 in patients with metastatic breast cancer who have received taxane-based chemotherapy resulting in PR or CR, and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate in treating inoperable stage III or IV melanoma that began on acral skin or mucosa, and requires patients to meet specific eligibility criteria including having a true amplification of 4q12 or a detectable mutation of c-KIT, and having no known untreated brain or epidural metastases.",
    "This phase 2 trial is testing the efficacy of telotristat etiprate and placebo in treating ulcerative colitis in patients who meet specific inclusion criteria and do not have any exclusion criteria.",
    "The sample is a phase 2 trial for breast cancer patients, testing the efficacy of AC (adriamycin and cyclophosphamide) followed by paclitaxel, with eligibility criteria including adenocarcinoma breast cancer and ECOG performance status of 0 or 1, and exclusion criteria including prior chemotherapy with an anthracycline and prior Herceptin therapy.",
    "This phase 2 trial is testing the efficacy of bevacizumab, temozolomide, and topotecan in treating malignant glioma, glioblastoma, and gliosarcoma, with specific inclusion and exclusion criteria for patients, including age, prior treatment, and medical history.",
    "This phase 2 trial is testing the drug romidepsin on patients with stage IIa or IIIa multiple myeloma who have had 1-4 prior lines of therapy, with inclusion criteria including measurable disease and a Karnofsky Performance Status of at least 70%.",
    "The sample is a phase 2 trial for neuropathic pain caused by ARTs, testing the efficacy of dimiracetam compared to a sugar pill, with inclusion criteria including CD4+ cell count > 200/L, pain intensity \u226540 mm on the VAS, and signed written informed consent.",
    "This phase 2 trial is testing the efficacy of carboplatin and paclitaxel in treating advanced non-small cell lung cancer patients with certain eligibility criteria, including ECOG performance status 0-1 and no serious cardiovascular disease.",
    "This phase 2 trial is testing the drug temsirolimus on patients with recurrent mantle cell lymphoma who meet specific eligibility criteria, including measurable disease and no other concurrent treatment for MCL.",
    "The sample is a phase 2 trial for geographic atrophy secondary to age-related macular degeneration, testing the efficacy of fcfd4514s and sham drugs, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of cytarabine in treating Ewing's sarcoma or primitive neuroectodermal tumor (PNET) that has recurred or not responded to prior therapy, with specific eligibility criteria for patients' disease and health status.",
    "This phase 2 trial is testing the efficacy of various doses and forms of mometasone furoate/formoterol and placebo in treating persistent allergic asthma in subjects with an FEV1 >65% predicted, who are allergic to at least one common allergen, and meet other inclusion criteria, while excluding those who have used systemic glucocorticosteroids within 3 months before screening, have had a respiratory tract infection within 4 weeks before screening, or have experienced a clinical asthma exacerbation between screening and baseline visits.",
    "This phase 2 trial is testing the efficacy of cetuximab in treating squamous cell cancer of the head and neck that has recurred in previously irradiated areas, with specific eligibility criteria including Karnofsky Performance Status, blood counts, and previous treatment history.",
    "The sample is a phase 2 trial for breast cancer patients with T2-3, N0-1, M0 tumors, using a combination of 5-fluorouracil, capecitabine, cyclophosphamide, docetaxel, and epirubicin, with specific inclusion and exclusion criteria for eligibility.",
    "This phase 2 trial is testing the efficacy of the drug rad001 and placebo in treating breast cancer patients with bone metastasis, who have received an aromatase inhibitor in any previous breast cancer therapy, and have measurable or non-measurable target lesions according to the WHO criteria.",
    "This phase 2 trial is testing the drug lbh589 on patients with refractory metastatic colorectal cancer who have failed at least 2 standard chemotherapy/biologic regimens, and have specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of bevacizumab and erlotinib in treating hepatocellular carcinoma patients who meet specific eligibility criteria, including having measurable or evaluable disease, adequate organ functions, and a life expectancy of >3 months.",
    "This phase 2 trial is testing the drug sch 530348 on patients with arterial obstructive diseases and coronary disease who are scheduled to undergo a percutaneous coronary intervention or a heart catheterization, with specific inclusion and exclusion criteria.",
    "This phase 2 trial will test the efficacy of oral sufentanil and placebo in managing pain for patients undergoing major upper or lower abdominal surgery, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of Panzem\u00ae NCD and sunitinib malate in treating metastatic renal cell carcinoma, with eligibility criteria including prior treatment with sunitinib malate and normal organ function.",
    "This is a phase 2 trial for patients with relapsed low grade CD20+ B cell non-Hodgkin lymphoma, testing the efficacy of bexxar and potassium iodide, with eligibility criteria including failed chemotherapy, age 19 or older, and expected survival of at least 6 months.",
    "This phase 2 trial is testing the drug perifosine on patients with metastatic, androgen-independent prostate cancer, with eligibility criteria including specific disease characteristics and patient characteristics.",
    "The sample is a phase 2 trial for the drug NGX267 in patients with xerostomia and Sj\u00f6gren's syndrome, with inclusion criteria including dry mouth and exclusion criteria including kidney function abnormalities and previous participation in a NGX267 clinical trial.",
    "The sample is a phase 2 trial for multiple sclerosis testing the drugs cdp323 and placebo, with inclusion criteria including relapsing form of MS and failed prior treatment with beta-interferons or glatiramer acetate.",
    "This phase 2 trial is testing the drug STA-9090 in patients with unresectable stage III or stage IV melanoma who have previously been treated with a tyrosine kinase inhibitor, and have sufficient tumor available to determine if they express wild-type or mutated BRAF or KIT, among other eligibility criteria.",
    "The sample is a phase 2 trial testing the drug depsipeptide on patients with metastatic bladder, renal pelvis, ureter, or urethra cancer who have had disease progression or recurrence after one prior systemic chemotherapy regimen that included cisplatin or carboplatin, and who are not curable by surgery or radiotherapy, with eligibility criteria including specific disease characteristics and patient characteristics.",
    "This phase 2 trial is testing the efficacy of act-280778 and amlodipine, along with a placebo, in treating essential hypertension in adults aged 18 to 75 years with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of duloxetine, an antidepressant, on male and female outpatients aged 7 to 17 years with major depressive disorder, and the eligibility criteria includes a Children's Depression Rating Scale-Revised (CDRS-R) score greater than or equal to 40 and a Clinical Global Impressions of Severity (CGI-Severity) rating of greater than or equal to 4 at Visit 1, Visit 2, and Visit 3.",
    "This phase 2 trial is testing the drug cc-930 on patients with idiopathic pulmonary fibrosis, pulmonary fibrosis, fibrosis, interstitial lung disease, and lung diseases, with specific eligibility criteria including age, diagnosis, and exclusion criteria such as medication use and smoking.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease (COPD) testing the drugs ph-797804 and placebo, with inclusion criteria including age, smoking history, and COPD diagnosis, and exclusion criteria including cardiovascular disease and organ/blood disorders.",
    "The sample is a phase 2 trial for age-related macular degeneration, testing the drugs OT-551 and vehicle placebo, with inclusion criteria of clinical diagnosis of GA and non-childbearing potential, and exclusion criteria of BCVA of 20/200 or worse in the non-study eye and concomitant treatment with any systemic or ocular medication that is known to be toxic to the lens, retina, or optic nerve.",
    "The sample is a phase 2/phase 3 trial testing the efficacy of Lamictal in treating post-herpetic neuralgia, with inclusion criteria including a minimum score on the Likert Pain Scale and exclusion criteria including a history of Stevens-Johnson syndrome or TEN, and patients on Fibrates (Tricor and Lopid), and Lidocaine Patch, and use of hormonal contraceptives.",
    "The sample is a phase 2 trial for type 2 diabetes mellitus using exenatide (ly2148568) and placebo, with inclusion criteria of being diagnosed with type 2 diabetes and having a body weight of >=50 kg, and exclusion criteria including previous participation in exenatide or other GLP-1 analog studies and severe allergy or hypersensitivity to any drug.",
    "This is a phase 2 clinical trial for patients with glioblastoma multiforme, testing the drug everolimus, with inclusion criteria including age, confirmed diagnosis, radiographic evidence of disease progression, and a Karnofsky Performance Status of greater than or equal to 60%. Exclusion criteria include prior treatment with mTOR inhibitor, history of another malignancy within 3 years, and unstable systemic diseases.",
    "This phase 2 trial aims to test the efficacy of 20mg daily citalopram and placebo in treating mild stage Huntington disease with mild executive dysfunction, and includes eligibility criteria such as gene positive HD test, aged between 18 and 75, and ability to complete all study assessments.",
    "This phase 2 trial is testing the efficacy of pennsaid gel and vehicle in treating primary osteoarthritis of the knee, with specific inclusion and exclusion criteria listed.",
    "The sample is a phase 2/3 trial testing the safety and efficacy of ati-5923 and coumadin in patients with various cardiovascular diseases, including atrial fibrillation, myocardial infarction, and cardiomyopathy, who require chronic anticoagulation, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for liver cancer patients with specific disease characteristics and patient characteristics, testing the drug octreotide acetate, with prior concurrent therapies allowed but no concurrent chemotherapy, radiotherapy, or immunotherapy.",
    "The sample is a phase 2 trial for advanced breast cancer patients with HER-2 amplification, testing the efficacy of trastuzumab and letrozole, with eligibility criteria including measurable disease, prior treatment with nonsteroidal aromatase inhibitor, and specific patient characteristics.",
    "This phase 2 trial is testing the efficacy of ar-12286 and latanoprost ophthalmic solutions in reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension who are currently being treated with ocular hypotensive medication and meet specific eligibility criteria.",
    "The sample is a phase 2/phase 3 trial for chronic lymphocytic leukemia testing the efficacy of bendamustine and fludarabine in patients who have not responded to initial chemotherapy, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug sunitinib (su011248) on patients with metastatic or locally recurrent prostate cancer that is not curable with standard therapy, who have previously responded to docetaxel chemotherapy, and meet other eligibility criteria.",
    "The sample is a phase 2 trial for Parkinson's disease, testing the efficacy of adx48621 and placebo in reducing dyskinesia, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the drug tivozanib on subjects with unresectable locally recurrent or metastatic renal cell carcinoma who have undergone prior nephrectomy, and have not received more than one prior systemic treatment for metastatic RCC.",
    "This phase 2 trial will test the efficacy of celecoxib and placebo in patients with adenocarcinoma of the prostate and planned prostatectomy, with inclusion and exclusion criteria listed, and diseases and icd-10 codes provided.",
    "The sample is a phase 2 trial for non-squamous non-small cell lung cancer, testing standard chemotherapy and bevacizumab, with inclusion and exclusion criteria based on another trial.",
    "This phase 2 trial is testing the efficacy of rituxan and 1018 iss in treating non-hodgkin's lymphoma in patients who have received at least one previous chemotherapy regimen, with eligibility criteria including CD20+ B-cell follicular non-Hodgkin's lymphoma and various blood count and performance status requirements.",
    "This phase 2 trial is testing the drug SNS-595 on patients with recurrent or refractory small cell lung cancer who have previously received first-line chemotherapy, and have measurable disease and an ECOG Performance Status score of 0, 1, or 2, while excluding patients with prior exposure to SNS-595, pregnant or breastfeeding women, and those with other active malignancies or medical conditions that would contraindicate their participation in the clinical trial.",
    "The sample is a phase 2 clinical trial for patients with venous thromboembolism and hypercholesterolemia, testing the effectiveness of atorvastatin in reducing LDL cholesterol levels after treatment withdrawal, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for non-small-cell lung cancer using pemetrexed and gemcitabine as drugs, with inclusion criteria including NSCLC Stage IIIB or IV diagnosis and no prior systemic chemotherapy, and exclusion criteria including estimated life expectancy of 12 weeks and significant weight loss over the previous 6 weeks.",
    "This trial is for HIV-infected individuals with measurable HIV Neurocognitive Impairment who are under consideration to initiate or change their HAART regimens and are willing to undergo at least 3 lumbar punctures safely during the course of the study. The trial will test the efficacy of FDA approved antiretroviral therapy in treating the disease.",
    "This trial is testing the effectiveness of rituximab for transplant rejection in pediatric renal allograft recipients with a decline in renal function, and includes eligibility criteria and exclusion criteria such as previous treatment with rituximab, ongoing use of high dose steroids, and significant cardiac or pulmonary disease.",
    "This phase 2 trial is testing the drug irofulven on patients with recurrent or metastatic gastric adenocarcinoma, with specific eligibility criteria including measurable disease and certain hematopoietic, hepatic, renal, and cardiovascular requirements.",
    "The sample is a phase 2 trial for Alzheimer's disease using experimental bapineuzumab, with inclusion criteria including a diagnosis of probable AD, age from 50 to less than 89, and a Mini-Mental Status Exam score of 18-26 inclusive, and exclusion criteria including significant neurological disease other than AD and major psychiatric disorder.",
    "This phase 2 trial is testing the efficacy of 250mg rilapladib and placebo in treating Alzheimer's disease in patients between 50 and 80 years old with stable dosing of Alzheimer's disease therapy, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for asthma patients, testing the efficacy of ff/gsk573719 and ff/vi drugs, with inclusion criteria such as pre-bronchodilator FEV1 of 40-80% and a need for regular controller therapy, and exclusion criteria such as history of life-threatening asthma and current smokers.",
    "The sample is a phase 2 clinical trial for patients with unresectable or metastatic esophageal neoplasms, testing the efficacy of oxaliplatin + cisplatin + 5-fluorouracil (5-fu) as a treatment option, with specific inclusion and exclusion criteria listed.",
    "This is a phase 2 clinical trial for alcohol dependence, testing the efficacy of ondansetron, olanzapine, and placebo, with inclusion criteria including DSM-IV-R diagnosis of alcohol dependence and drinking on average \u226521 and \u226528 drinks/week for women and men, respectively, and exclusion criteria including any current axis I DSM-IV psychiatric disorder other than alcohol or nicotine dependence that warrants treatment or would preclude safe participation in the protocol.",
    "The sample is a phase 2 trial for the drug ly2127399 and placebo in patients with rheumatoid arthritis who are biologic DMARD na\u00efve and have had an insufficient response to at least 1 oral DMARD, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of bortezomib, dexamethasone, thalidomide, and cyclophosphamide in treating multiple myeloma patients who are candidates for high-dose therapy combined with an autologous stem cell transplant, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for women with myocardial ischemia, testing the efficacy of ranolazine and placebo drugs, with inclusion criteria including abnormal stress testing and \u226510% myocardial ischemia by CMR perfusion, and exclusion criteria including hepatic insufficiency, prolonged QT, and pregnancy or breast feeding.",
    "This phase 2 trial is testing the efficacy of methotrexate and mercaptopurine in treating recurrent childhood acute lymphoblastic leukemia, with specific eligibility criteria including diagnosis of ALL, CD52 expression, and performance status requirements.",
    "The sample is a phase 2 trial for bladder cancer testing cisplatin and fluorouracil, with eligibility criteria including confirmed unifocal or multifocal transitional cell carcinoma of the bladder and no prior systemic chemotherapy.",
    "This phase 2 trial is testing the efficacy of zgn-440 for injectable suspension on individuals with Prader-Willi Syndrome and a BMI \u226525 kg/m2, with inclusion criteria including confirmed diagnosis of Prader-Willi Syndrome and stable body weight, and exclusion criteria including use of weight loss agents and chronic use of narcotics or opiates.",
    "The sample is a phase 2 trial for chronic lymphocytic leukemia (CLL) using drugs fludarabine and campath, with eligibility criteria including advanced or progressive disease with \u2265 2 active clinical signs and no prior treatment for CLL.",
    "This is a phase 2 trial for rheumatoid arthritis patients treated with methotrexate, testing the efficacy of canakinumab compared to placebo, with strict inclusion and exclusion criteria including wash-out periods for previous biological therapies and stable doses of other medications.",
    "The sample is a phase 2 trial for patients with recurrent, locally advanced, or metastatic breast cancer with expression of ER/PR receptor and/or overexpression of Her2/neu, testing the efficacy of dasatinib and dasatinib 100 mg, with eligibility criteria including prior chemotherapy with an anthracycline and/or a taxane, and exclusion criteria including metastatic disease confined to bone only and symptomatic central nervous system (CNS) metastasis.",
    "The sample is a phase 2 trial for cystic fibrosis patients, testing the efficacy of biaxin (clarithromycin) with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of oxaliplatin, capecitabine, and celecoxib in treating surgically incurable gastric and gastroesophageal junction carcinoma patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of 1.5 mg or 2.0 mg cjc-1134-pc and placebo in treating stable type 2 diabetes mellitus patients with a BMI of 27 to 45 kg/m2, stable lifestyle, and stable metformin daily dose \u22651000 mg for at least 3 months, with glycosylated hemoglobin (HbA1c) at screening \u2265 7.1% and \u2264 11%.",
    "This phase 2 trial is testing the efficacy of idarubicin in treating non-Hodgkin's lymphoma that is exclusively localized into the CNS, with eligibility criteria including previous treatment with HDMTX containing CHT and/or RT, bidimensionally measurable target lesion, and adequate bone marrow, renal, hepatic, and cardiac function.",
    "This phase 2 trial is testing the efficacy of rob 803 and placebo in treating rheumatoid arthritis, with inclusion criteria including a diagnosis of RA, active disease, and use of methotrexate, and exclusion criteria including certain infections and other systemic rheumatic diseases.",
    "The sample is a phase 2 trial for patients with undifferentiated arthritis, testing the efficacy of abatacept and placebo, with inclusion and exclusion criteria listed, and the diseases are listed as 'arthritis, rheumatoid' with corresponding icd-10 codes.",
    "The sample is a phase 2 trial for insulin-na\u00efve type 2 diabetes patients with HbA1c between 7.0-11.0%, testing the efficacy of insulin degludec/insulin aspart, biphasic insulin aspart, and metformin, with inclusion criteria including treatment with one or two oral anti-diabetic drugs and BMI between 25.0-37.0 kg/m^2.",
    "This phase 2 trial is testing the efficacy of docetaxel and gemcitabine hydrochloride in treating metastatic or unresectable uterine or soft tissue leiomyosarcoma, with specific eligibility criteria for patients including prior treatment with anthracycline-based chemotherapy and no other uterine sarcomas, while also considering patient characteristics such as age, performance status, and hematopoietic, hepatic, renal, cardiovascular, and immunologic health.",
    "This phase 2 trial is testing the efficacy of two induction regimens, r-chop14 and r-acvbp14, in treating CD20+ diffuse large B-cell lymphoma patients with specific inclusion and exclusion criteria, including a minimum life expectancy of 3 months and negative HIV, HBV, and HCV serologies.",
    "This phase 2 trial is testing the efficacy of gemcabene, atorvastatin, and placebo in treating hypercholesterolemia in patients who meet specific inclusion criteria and do not have any exclusion criteria.",
    "This phase 2 trial is testing the efficacy of pemetrexed and matuzumab in treating non-small cell lung cancer patients who have demonstrated PD on or after first-line chemotherapy for Stage IIIB/IV disease, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for schizophrenia with GSK239512 and placebo as drugs, and the eligibility criteria includes a clinical diagnosis of schizophrenia and no acute exacerbation of symptoms in the previous six months.",
    "This phase 2 trial is testing the effectiveness of sulindac, an NSAID, in preventing lung cancer in current or former smokers with certain eligibility criteria and precancerous conditions or stage I non-small cell lung cancer.",
    "The sample is a phase 2 trial for Huntington's disease, testing the efficacy of creatine monohydrate and placebo, with inclusion criteria of expansion positive or 50% at risk for HD and not diagnosed clinically, and exclusion criteria of unstable medical conditions.",
    "This phase 2 trial is testing the efficacy of clofarabine and ara-c in treating previously untreated acute myeloid leukemia and high-risk myelodysplastic syndrome in patients over 60 years old with adequate liver and renal function, and an ECOG performance status of 2 or less. The study has inclusion and exclusion criteria, and the diseases are listed with their corresponding ICD-10 codes.",
    "This phase 2 trial is testing the efficacy of lapatinib and lapatinib-placebo in treating primary breast cancer, with eligibility criteria including tumor size, age, and cardiac ejection fraction, and exclusion criteria including prior malignancy and use of hormonal therapy.",
    "This phase 2 trial is testing the efficacy of selumetinib and selumetinib sulfate in treating patients with low grade serous ovarian or peritoneal carcinoma, with specific eligibility criteria including measurable disease and confirmation of low grade serous carcinoma, while excluding patients with certain medical histories or conditions.",
    "The sample is a phase 2 trial for oglemilast and placebo in patients with chronic obstructive pulmonary disease (COPD) who are current or former smokers, with specific inclusion and exclusion criteria based on GOLD criteria, and the trial will use ICD-10 codes J44.9, J44.1, and J44.0 to identify patients with COPD.",
    "This is a phase 2 trial for patients with advanced androgen-independent prostate cancer, testing the efficacy of fulvestrant, with eligibility criteria including rising PSA levels, measurable or evaluable disease, and specific patient characteristics and prior concurrent therapy requirements.",
    "The sample is a phase 2 trial for patients with nonsquamous non-small cell neoplasm of lung or non-small cell lung cancer metastatic or non-small cell lung cancer stage iiib, who have completed 4 induction cycles of platinum-based doublet therapy and have not progressed, and will receive pemetrexed as a treatment option, with specific eligibility criteria.",
    "The sample is a phase 2 trial for osteoporosis, testing the efficacy of teriparatide and other drugs, with eligibility criteria including bone mineral density T-score and exclusion criteria including prior bone disorder or treatment with bone-acting investigational agents.",
    "This phase 2 trial is testing the efficacy of azd4547 and paclitaxel in treating locally advanced or metastatic gastro-oesophageal junction cancer and gastric cancer patients who have progressed after prior chemotherapy or chemoradiotherapy, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for non-small-cell lung carcinoma testing the efficacy of anamorelin hcl and placebo in combination with paclitaxel and carboplatin +/- bevacizumab, with inclusion criteria of stage IIIB or IV NSCLC and exclusion criteria of mixed large and small cell histologies for lung cancer and significant obesity.",
    "This phase 2 trial is testing the efficacy of mecamylamine, a drug, in treating major depressive disorder, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the efficacy of seliciclib and placebo in treating recurrent non-small cell lung cancer patients who have had at least two prior systemic treatment regimens, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2/phase 3 trial for patients with primary or mixed dementia, testing the efficacy of megestrol acetate and placebo in treating weight loss and malnutrition, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of tamoxifen and zarnestra in post-menopausal patients with metastatic or locally advanced inoperable breast cancer who are progressing on tamoxifen treatment, and have at least one measurable lesion according to the Response Evaluation Criteria for Solid Tumors (RECIST) criteria.",
    "This phase 2 trial is testing the efficacy of dalotuzumab and erlotinib in treating relapsed non-small-cell lung carcinoma, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for Alzheimer's disease, testing the efficacy of abt-288, donepezil, and placebo drugs, with inclusion criteria including meeting diagnostic criteria for probable AD and having an identified, reliable caregiver, and exclusion criteria including currently taking or having taken medication for the treatment of AD or dementia within 60 days of screening visit.",
    "This phase 2 trial is testing the efficacy of sorafenib and placebo in treating locally advanced or metastatic urothelial carcinoma of the bladder or upper urinary tract with specific eligibility criteria, including measurable lesions on CT or MRI, adequate hematologic, renal, hepatic and coagulation-physiological functions, and informed consent.",
    "The sample is a phase 2 trial for depression and excessive daytime sleepiness, testing the efficacy of mirtazapine treatment, with inclusion criteria including fulfilling DSM-IV criteria for Major Depressive Disorder and a score of HDRS-17 > 17, and exclusion criteria including a history of bipolar disorder or schizophrenia, substance abuse during the last 6 months, and any physical disease that may explain the symptoms of depression.",
    "This phase 2 trial is testing the efficacy of ogx-427 and prednisone in treating castration resistant prostate cancer patients with metastatic disease and progression of prostate cancer, who have not had a surgical orchiectomy and fulfill certain prior therapy and baseline laboratory criteria.",
    "This phase 2 trial is testing the efficacy of multiple drugs, including bms-790052 and ribavirin, in treating chronic hepatitis C in null responders to current standard of care, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of arsenic trioxide in treating patients with leukemia who are ineligible for bone marrow transplant, and includes eligibility criteria such as age, performance status, and laboratory values.",
    "This phase 2 trial is testing the efficacy of sky0402 and bupivacaine hcl in managing pain after unilateral inguinal hernia repair surgery in males, with specific inclusion and exclusion criteria.",
    "This phase 2 trial focuses on the treatment of obesity with drugs such as nasal placebo, placebo capsule, pyy3-36, and sibutramine, and includes eligibility criteria such as BMI 30-43 kg/m2 and exclusion criteria such as previous surgical treatment for obesity and serious medical conditions.",
    "This trial is for patients with advanced and/or metastatic soft tissue sarcoma who have not received prior anticancer therapy, and will test the efficacy of doxorubicin hydrochloride and trabectedin as treatment options.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease using the drugs evp-6124 and placebo, with inclusion criteria including a Mini-Mental State Examination score of 14 to 24 and a CDR-SB score \u22652, and exclusion criteria including a history of stroke within 18 months of screening and inability to swallow capsules.",
    "This phase 2 trial is testing the efficacy of fludarabine phosphate and alemtuzumab in treating patients with b-cell chronic lymphocytic leukemia who have relapsed or are refractory to primary or secondary treatment, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug lbh589 on patients with metastatic or locally unresectable clear cell renal carcinoma who have documented disease progression or intolerance while receiving treatment with sunitinib, sorafenib, or both, and temsirolimus, and have a maximum of 4 prior systemic regimens allowed, with measurable disease by RECIST criteria, ECOG PS 0 or 1, and other laboratory values within normal range.",
    "This phase 2 trial is testing the efficacy of cediranib maleate and irinotecan hydrochloride in treating metastatic colorectal cancer patients who have received one prior regimen, and have measurable disease, while meeting specific eligibility criteria.",
    "The sample is a phase 2 trial for patients with castration-resistant prostate cancer, testing the use of testosterone therapy with the drug testosterone, and the eligibility criteria includes a history of response to medical or surgical castration therapy, a minimum serum PSA level of 1 ng/ml, and a documented castrate level of testosterone.",
    "The sample is a phase 2 trial for patients with inoperable locally advanced or metastatic squamous cell carcinoma of the head and neck, using oxaliplatin and 5-fu as drugs, with specific eligibility criteria for inclusion and exclusion.",
    "This phase 2 trial will test the efficacy of losmapimod and placebo in reducing inflammation in patients with atherosclerosis who have experienced a cardiovascular event or have peripheral vascular disease, and meet other eligibility criteria.",
    "The sample is a phase 2 trial for painful diabetic neuropathy, testing the efficacy of placebo gel and clonidine topical gel (arc-4558) with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for sirolimus in patients with type 1 diabetes mellitus who meet specific inclusion and exclusion criteria, including reduced awareness of hypoglycemia and a history of severe hypoglycemia, and have not received a previous islet or pancreas transplant.",
    "The sample is a phase 2 clinical trial for advanced melanoma patients who have previously been treated with ipilimumab, with eligibility criteria including prior treatment and documented progressive disease, and the drug being tested is ipilimumab.",
    "The sample is a phase 2 trial for patients with moderate persistent asthma, testing the efficacy of tiotropium 5 mcg qd and tiotropium 2.5 mcg bid as an add-on to medium doses of ICS, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of various doses of glycopyrrolate inhalation solution compared to placebo in patients with chronic obstructive pulmonary disease (COPD) who meet specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of ipilimumab, placebo, paclitaxel, and carboplatin in treating lung cancer, specifically non-small-cell lung cancer and small cell lung cancer, with eligibility criteria including measurable tumor lesion and Eastern Cooperative Oncology Group performance status of \u22641.",
    "This phase 2 trial is testing the efficacy of gemcitabine and paclitaxel in treating recurrent, persistent, or newly diagnosed metastatic squamous cell carcinoma of the head and neck, with specific eligibility criteria for patients' disease characteristics, prior concurrent therapy, and patient characteristics.",
    "This phase 2 trial will test the efficacy of vanoxerine and placebo in treating symptomatic atrial fibrillation and atrial flutter, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for gastric cancer testing the efficacy of irinotecan associated to fluorouracil and leucovorin, with eligibility criteria including age, cancer type, previous treatment, and ECOG score.",
    "This phase 2 trial is testing the efficacy of topotecan/docetaxel combination and docetaxel in treating advanced non-small cell lung carcinoma (NSCLC) patients who have received one prior chemotherapy for metastatic NSCLC excluding TAXOTERE or HYCAMTIN, and have adequate bone marrow reserve, CBC/Platelet, kidney and liver function.",
    "The sample is a phase 2 trial for patients with relapsed or refractory Hodgkin's disease, using alemtuzumab (Campath-1H) as the drug, and the eligibility criteria includes a minimum of 2 prior treatment regimens, including autologous bone marrow transplantation, and a platelet count equal to or greater than 50,000/uL.",
    "This phase 2 trial is testing the efficacy of bl-1020, risperidone, and placebo in treating acute exacerbation of psychosis in patients with schizophrenia, with eligibility criteria including a DSM-IV-TR diagnosis of schizophrenia and a PANSS score greater than 70, while exclusion criteria include pregnancy, prior participation in a clinical study of BL-1020 or any of its excipients, and judgment by the PI to be inappropriate for the study.",
    "This phase 2 trial is testing erlotinib hydrochloride and celecoxib in patients with recurrent non-small cell lung cancer, stage IIIB or IV, who have progressed after 1 or 2 prior chemotherapy regimens, and meet a list of eligibility criteria.",
    "This phase 2 trial is testing the efficacy of cg100649 and silicified microcrystalline cellulose + talc in reducing chronic pain in patients with osteoarthritis of the knee or hip who are already taking NSAIDs or COX-2 inhibitors, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug pentostatin on patients with various hematologic neoplasms, including leukemia and lymphoma, who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for hypercholesterolemia, testing the drugs etc-1002 and placebo, with eligibility criteria including a history of statin intolerance and specific LDL-C and triglyceride levels.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate (sti571) in treating metastatic melanoma patients with specific biomarkers, and includes eligibility criteria such as prior treatments, organ function, and exclusion criteria such as uncontrolled illness and pregnancy.",
    "This phase 2 trial is testing the drug itraconazole on male patients with castrate-resistant prostate cancer who have progressed during or after docetaxel-based chemotherapy, and meet certain eligibility criteria.",
    "The sample is a phase 2 trial for patients with myelodysplastic syndrome (MDS) using arsenic trioxide as the drug, with inclusion criteria including diagnosis of MDS, ECOG performance status of 0-2, and serum electrolyte levels within specified limits.",
    "The sample is a phase 2 clinical trial testing erlotinib hydrochloride and cisplatin for patients with stage III or IV squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx, with specific eligibility criteria, and a list of diseases and icd-10 codes.",
    "The sample is a phase 2 trial for chronic HCV genotype 1, 2, or 3 infection using abt-450, abt-267, ribavirin, and ritonavir, with inclusion criteria including general good health and FibroTest score <= 0.72, and exclusion criteria including positive drug screen and previous use of anti-HCV agents.",
    "This phase 2 trial is testing the effectiveness of atomoxetine, a drug used to treat attention deficit hyperactivity disorder, on patients who meet specific inclusion and exclusion criteria related to their mental health history.",
    "The sample is a phase 2 trial for acute coronary syndrome, testing the efficacy of placebo and cer-001 drugs, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for diabetic neuropathic pain, testing the efficacy of abt-639, placebo, and lidocaine, with inclusion and exclusion criteria based on age, pain score, and medical conditions.",
    "The sample is a phase 2 trial for depressive disorder using mecamylamine hydrochloride (inversine) as a drug, with inclusion criteria of major depression, ages 18-65, and on SSRI monotherapy, and exclusion criteria of suicidal or homicidal ideation, need for inpatient or partial hospital care, systolic blood pressure <100 mm Hg, and history of hypersensitivity to mecamylamine or its excipients.",
    "This is a phase 2 trial for patients with persistent atrial fibrillation, testing the effectiveness of eplerenone and placebo, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of infliximab and placebo in treating rheumatoid arthritis patients who meet specific eligibility criteria, including having a clinical diagnosis of rheumatoid arthritis for at least 6 months, having at least 6 tender joints and 6 swollen joints, and having a C-reactive protein \u2265 1.0 mg/L OR Erythrocyte Sedimentation Rate (ESR) \u2265 28 mm/hr.",
    "This phase 2 trial will test the efficacy of ngx-1998, a topical capsaicin-based treatment, versus placebo in reducing postherpetic neuralgia-associated pain in patients with intact, unbroken skin over the painful area(s) to be treated, and who meet other inclusion criteria.",
    "The sample is a phase 2 trial for smoking cessation using nicotine as the drug, with inclusion criteria for current cigarette smokers who smoke their first cigarette more than 30 minutes after waking up and exclusion criteria for prior use of nicotine replacement therapy or any other treatment for smoking cessation within one month of screening visit, and any disease that may interfere with the absorption, metabolism or excretion of the study product.",
    "This phase 2 trial is testing the efficacy of ngr-htnf and doxorubicin in treating small cell lung cancer patients who have previously undergone treatment, with specific eligibility criteria including confirmed SCLC diagnosis, measurable disease, and adequate baseline bone marrow, hepatic, and renal function.",
    "This phase 2 trial is testing the efficacy of Nuvigil\u00ae and placebo in treating supratentorial WHO grade 3 anaplastic glioma or WHO grade 4 glioblastoma, with eligibility criteria including adequate renal and liver function, adequate bone marrow function, and Karnofsky Performance Status \u2265 60%.",
    "The sample is a phase 2 trial for liver cirrhosis patients, testing the effectiveness of conivaptan and placebo drugs, with inclusion criteria of euvolemia or hypervolemia secondary to cirrhosis and clinical evidence of portal hypertension, and exclusion criteria of volume depletion or dehydration and history of bleeding from esophageal varices within three months before the start of the study.",
    "The sample is a phase 2 trial for hypertension, using perindopril as the drug, with inclusion criteria of hypertensive children treated for at least four months with S90652 and exclusion criteria of poorly controlled hypertension and girls with signs of pubescence.",
    "This phase 2 trial is testing the efficacy of trastuzumab (herceptin) in treating non-small cell lung cancer patients with HER2 FISH positive tumors or HER2 gene mutation in exon 20, who have been pretreated with at least one chemotherapy regimen and are not suitable for radiotherapy or surgery with curative intent.",
    "The sample is a phase 2/phase 3 trial for type 2 diabetes mellitus, testing the efficacy of alogliptin and voglibose drugs, with eligibility criteria including completion of a phase 2 study and exclusion criteria related to hepatic and renal impairment.",
    "This phase 2 trial is testing chemotherapy for patients with myelodysplasia and leukemia, with inclusion criteria including histological confirmation of disease, refractory or relapsed AML, and an expected life expectancy of >12 weeks, while excluding patients with an active second malignancy other than non-melanoma skin cancers and co-existing medical illnesses which would limit survival <12 weeks.",
    "This phase 2 trial is testing the efficacy of ck-2017357 and riluzole 50 mg in treating amyotrophic lateral sclerosis, with eligibility criteria including a diagnosis of ALS, grip strength requirements, and the ability to swallow tablets with water.",
    "This phase 2 trial is testing the efficacy of anastrozole and pazopanib hydrochloride in treating estrogen receptor-positive breast cancer patients with clinical stage II or III disease, who have no evidence of distant metastatic disease and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of lacosamide, an antiepileptic drug, in patients with uncontrolled epilepsy and primary generalized tonic-clonic seizures, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of tc-6987 and placebo in treating type 2 diabetes mellitus patients who are being treated with oral antidiabetic agents, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for locally advanced, unresectable, non-metastatic pancreatic adenocarcinoma, testing the efficacy of gemcitabine hydrochloride and serine proteinase inhibitor WX-671, with eligibility criteria including ECOG performance status \u2264 1, normal 12-lead ECG, and ANC \u2265 1,500/mm\u00b3.",
    "This phase 2 trial is testing neoadjuvant therapy with cisplatin plus docetaxel for patients with non-small-cell lung carcinoma who are fit for surgery and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of mk-6213 and atorvastatin calcium, along with their placebos, in treating hypercholesterolemia in patients aged 18 to 75 who have stable weight and are not currently on lipid lowering therapy, but have exclusion criteria such as significant cardiovascular, renal, neurologic, respiratory, hepatic or metabolic disease, history of mental instability or drug/alcohol abuse within the past 5 years, pregnant or nursing, human immunodeficiency virus (HIV) positive, history of cancer within the past 5 years or participation in an investigational trial within the last 30 days.",
    "This phase 2 trial is testing the efficacy of placebo in treating MDS and thrombocytopenia in patients who meet specific eligibility criteria, including having low or intermediate-1 risk MDS and platelet counts below a certain threshold, and excluding those who have received disease-modifying treatment for MDS or have a history of leukemia or other bone marrow disorders.",
    "The sample is a phase 2 trial for the treatment of overactive bladder with urinary urgency incontinence, using the drugs agn-214868 and agn-214868 placebo, with eligibility criteria including inadequate response or limiting side effects with anticholinergics, and exclusion criteria including overactive bladder caused by neurological condition and previous treatment with botulinum toxin therapy.",
    "This phase 2 trial is testing the drug bkm120 on patients with advanced solid tumors, including lung cancer, breast cancer, colorectal cancer, cholangiocarcinoma, and solid tumors, who have a specific PIK3CA mutation and have not responded to standard treatment, with a list of inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for hematologic diseases using G-CSF and GM-CSF drugs for allogeneic peripheral blood stem cell transplantation, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug sunitinib for patients with metastatic prostate cancer who have received 1 or 2 prior chemotherapy regimens, with eligibility criteria including an elevated PSA level, and exclusion criteria including prior treatment with Sutent and uncontrolled arrhythmia or hypertension.",
    "This phase 2 trial is testing the efficacy of fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin in treating metastatic or locally recurrent colorectal adenocarcinoma, with specific eligibility criteria for patients.",
    "This is a phase 2 trial for patients with non-small-cell lung cancer, testing the efficacy of gemcitabine and uft as treatment options, with specific eligibility criteria including age, performance status, and adequate bone marrow, liver, and renal function.",
    "This is a phase 2 trial for type 2 diabetes mellitus testing the efficacy of ipragliflozin and metformin against placebo, with inclusion criteria including a stable dose of metformin monotherapy for at least 6 weeks prior to Visit 1 and a BMI of 20-45 kg/m2 at Visit 1.",
    "This phase 2 trial is testing the efficacy of aegr-733 and atorvastatin in treating hypercholesterolemia, with a list of inclusion and exclusion criteria, and a variety of drug options including placebo.",
    "This phase 2 trial is testing the efficacy of lapatinib oral tablets, radiotherapy, and cisplatin chemotherapy in treating squamous cell carcinoma of the head and neck, with specific eligibility criteria including ErbB1 over-expression and exclusion criteria such as peripheral neuropathy and prior treatment for invasive head and neck cancer.",
    "This phase 2 trial is testing the efficacy of pemetrexed disodium in treating stage IIIB or IV non-small cell lung cancer patients who have previously undergone chemotherapy, with specific eligibility criteria for patient characteristics and prior concurrent therapy.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate and docetaxel in treating recurrent or metastatic head and neck squamous cell cancer, with eligibility criteria including a written informed consent, histologically documented diagnosis of the cancer, and adequate hepatic, renal, and bone marrow function.",
    "The sample is a phase 2 trial for the treatment of head and neck cancer using panitumumab and cisplatin, with eligibility criteria including confirmed SCC of the oral cavity, oropharynx, hypopharynx or larynx Stage III or Stage IVa-b disease and ECOG performance status of 0 or 1.",
    "This phase 2 trial is testing the efficacy of multiple drugs, including bortezomib and lenalidomide, in treating newly diagnosed active multiple myeloma patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of various combined oral contraceptives, including estetrol and estradiol valerate, dienogest, in women with good physical and mental health and regular menstrual cycles, who are willing to use the contraceptive for 6 subsequent cycles.",
    "This phase 2 trial is testing the efficacy of lapatinib ditosylate, a drug, in treating persistent or recurrent ovarian epithelial or primary peritoneal cancer with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of lapatinib and capecitabine in treating untreated, newly diagnosed, advanced metastatic or unresectable gastric cancer, including the gastro-esophageal junction, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of velcade, bendamustine, and rituximab in treating relapsed or progressed follicular lymphoma patients who have received 4 or more prior doses of rituximab, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for schizophrenia using lurasidone and placebo, with inclusion criteria based on DSM-IV criteria for schizophrenia and voluntary hospitalization, and exclusion criteria including previous use of the compound or an investigational drug within the past 30 days.",
    "This phase 2 trial aims to test the efficacy of mycophenolate mofeteil (mmf) and daclizumab (dzb) in treating type 1 diabetes mellitus, with eligibility criteria including recent diagnosis, age range, C-peptide levels, and presence of certain autoantibodies, while exclusion criteria include complicating medical issues, HIV/Hepatitis B/C infections, abnormal liver function tests, and chronic use of steroids or other immunosuppressive agents.",
    "This phase 2 trial is testing the efficacy of celecoxib and docetaxel in treating non-small cell lung cancer patients who have progressed after platinum-based chemotherapy, with specific eligibility criteria including disease stage, performance status, and various medical history exclusions.",
    "This phase 2 trial is testing the effectiveness of memantine hydrochloride in treating autism spectrum disorder, with inclusion criteria including meeting DSM-IV-TR diagnostic criteria for autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS), and exclusion criteria including having any primary psychiatric diagnosis other than autism, Asperger's Disorder, and PDD-NOS.",
    "This phase 2 trial is testing the efficacy of vinorelbine, lapatinib, and capecitabine in female breast cancer patients with Stage IV disease and overexpression of ErbB2, who have progressive disease following prior therapy, and have met certain eligibility criteria.",
    "The sample is a phase 2/phase 3 trial testing the efficacy of moxaverine in treating macular degeneration, glaucoma, and regional blood flow, with eligibility criteria including age, ametropia, and clear ocular media, and exclusion criteria including hypersensitivity to moxaverine and presence of ocular pathology interfering with the study's aims.",
    "The sample is a phase 2 trial for advanced breast cancer using dasatinib as a drug, with specific eligibility criteria including no CNS metastases, normal liver and kidney function, and negative serum pregnancy test.",
    "The sample is a phase 2 trial testing the drug combination of g-csf and plerixafor on patients with non-hodgkin lymphoma and multiple myeloma who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug tivantinib on participants with triple-negative breast carcinoma who have received 1-3 prior chemotherapeutic regimens for metastatic breast cancer and have discontinued all biologic therapy, with eligibility criteria including measurable disease, recent evidence of progressive disease, and confirmed availability of formalin-fixed, paraffin-embedded (FFPE) tumor tissue.",
    "The sample is a phase 2 trial testing the efficacy of avp-923 and placebo in treating central neuropathic pain in patients with multiple sclerosis, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for female patients with stage IV breast cancer who have previously received anthracycline-based regimens and progressed to metastatic disease, and will test the efficacy of gemcitabine, paclitaxel, carboplatin, and cisplatin as treatment options.",
    "The sample is a phase 2 trial for the drug uk-500,001 in patients with moderate-severe chronic obstructive pulmonary disease (COPD) and a smoking history of at least 10 pack-years, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of bimatoprost ophthalmic solutions in lowering intraocular pressure in ethnically Japanese patients with glaucoma or ocular hypertension, who require IOP-lowering therapy in both eyes, and have not used bimatoprost or an ocular prostaglandin within 6 weeks prior to baseline.",
    "The sample is a phase 2 trial for metastatic breast cancer using imatinib and docetaxel, with eligibility criteria including confirmed biopsy, limited prior chemotherapy, and adequate organ function.",
    "The sample is a phase 2 trial for schizophrenia with the drugs bl-1020 and risperidone, and the eligibility criteria includes completion of 6 weeks of treatment and negative pregnancy test for females.",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus, testing the efficacy of bi 10773 and placebos of varying doses, with eligibility criteria including HbA1c levels and exclusion criteria including uncontrolled hyperglycemia and impaired renal function.",
    "The sample is a phase 2 trial for metastatic breast cancer testing the efficacy of sagopilone (bay86-5302, zk 219477) with eligibility criteria including no previous treatment with taxanes and vinca alkaloids, while exclusion criteria include previous participation in another trial within the last 4 weeks and active infections.",
    "The sample is a phase 2 trial for breast cancer patients with measurable disease and no metastases, testing the efficacy of docetaxel and doxorubicin hydrochloride, with eligibility criteria including adequate organ function and no prior chemotherapy for breast cancer.",
    "This phase 2 trial is testing the efficacy of azd9668 and placebo in treating chronic obstructive pulmonary disease (COPD) with specific inclusion and exclusion criteria, including a history of COPD exacerbation and FEV1/FVC ratio.",
    "This phase 2 trial is testing the efficacy of eribulin mesylate and capecitabine in treating estrogen receptor positive tumor and breast cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of carboplatin, cisplatin, docetaxel, and fluorouracil in treating newly diagnosed squamous cell carcinoma of the head and neck, with specific eligibility criteria for patients' disease characteristics and medical history.",
    "This phase 2 trial is testing the efficacy of avastin and gemcitabine in potentially resectable pancreatic neoplasms patients who meet specific eligibility criteria.",
    "This phase 2 clinical trial is testing the efficacy of lenalidomide in combination with rituximab for patients with relapsed or progressed CD20+ multiple myeloma, with specific eligibility criteria for patient characteristics and prior concurrent therapy.",
    "This phase 2 trial is testing the efficacy of cisplatin, gemzar, docetaxel, and alimta in treating non-small cell lung cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for metastatic breast cancer patients, testing the efficacy of gefitinib and docetaxel, with specific eligibility criteria including prior treatment restrictions and histological confirmation of mammary carcinoma.",
    "The sample is a phase 2 trial for recurrent or metastatic head and neck squamous carcinoma or nasopharyngeal carcinoma, using direct injection and measurement, with inclusion and exclusion criteria, and treatment with e10a, cisplatin, and paclitaxel.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease, testing the efficacy of drugs mk0249 and placebo, with specific inclusion and exclusion criteria for patients, including age, disease severity, and concomitant therapy restrictions.",
    "This phase 2 trial is testing the effectiveness of lenalidomide in treating previously untreated adult acute myeloid leukemia patients with del (5q) abnormality who have declined standard AML cytotoxic chemotherapy regimens and meet other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of elacytarabine plus idarubicin in treating acute myeloid leukemia patients who have received one previous standard dose ara-C-containing regimen aiming at induction of complete remission and have more than 5% remaining blast cells in bone marrow following the first course of remission-induction or by other means documented residual disease.",
    "This phase 2 trial is testing the efficacy of panitumumab and folfiri in treating metastatic colorectal cancer patients who meet specific eligibility criteria, including having measurable disease and adequate organ function.",
    "The sample is a phase 2 trial testing the efficacy of two oral contraceptives, desogestrel/ethinyl estradiol and ethinyl estradiol, in treating hemostasis and preventing pregnancy, with inclusion criteria including premenopausal women aged 18-40 with a regular menstrual cycle and a BMI between 18 and 30, and exclusion criteria including a history of thromboembolic disease or contraindications to oral contraceptives.",
    "This phase 2 trial is testing the efficacy of fulvestrant and sorafenib tosylate in postmenopausal women with incurable breast cancer who have previously been treated with a third-generation aromatase inhibitor and have measurable or evaluable disease, while meeting specific patient characteristics and having no prior chemotherapy for metastatic or unresectable locally advanced breast cancer.",
    "The sample is a phase 2 trial for pancreatic cancer patients, testing the efficacy of erlotinib and gemcitabine, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of the CMF regimen, cyclophosphamide, fluorouracil, and methotrexate in treating metastatic breast cancer with c-erbB2 positive, with specific eligibility criteria for patients, including no prior anti-c-erbB2 antibody therapy and no bone lesions as the only target lesions.",
    "This phase 2 trial is testing the efficacy of MK-6096, a drug, versus placebo in treating painful diabetic neuropathy, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for infantile, congenital, or pediatric fibrosarcoma, testing the efficacy of cyclophosphamide, etoposide, ifosfamide, and vincristine sulfate, with eligibility criteria including age under 2 at diagnosis, available tissue for central review, and certain hematopoietic, hepatic, and renal requirements.",
    "The sample is a phase 2 trial for non-small cell lung cancer using the drug sta 9090, with inclusion criteria including confirmed diagnosis, measurable disease, ECOG performance status, and adequate organ function, and exclusion criteria including poor venous access, pregnancy or lactation, ventricular ejection fraction, and uncontrolled intercurrent illness.",
    "This phase 2 trial is testing the drug gsk1363089 (foretinib) on patients with recurrent and/or metastatic SCCHN who are not eligible for curative intent surgery or radiotherapy, and have measurable disease, with eligibility criteria including confirmation of diagnosis, performance status, and organ and marrow function.",
    "This phase 2 trial is testing the efficacy of SYR-472 and placebo in treating type 2 diabetes mellitus, with inclusion criteria including a historical diagnosis of diabetes, glycosylated hemoglobin concentration between 7.0% and 10.0%, and fasting plasma glucose concentration less than 275 mg/dL.",
    "This phase 2 trial is testing the efficacy of temozolomide, a chemotherapy drug, in treating patients with Acute Myeloid Leukemia who are unfit for conventional induction chemotherapy and have poor risk cytogenetics or secondary leukemia, and have normal organ and marrow function, with exclusion criteria including prior chemotherapy or radiotherapy within 4 weeks and ongoing or active infection.",
    "The sample is a phase 2 trial for the treatment of raised intraocular pressure, using the drugs azd4017 and placebo, with specific eligibility criteria including a stable dose of anti-glaucoma medication and exclusion criteria such as uncontrolled intra-ocular hypertension and severe eye trauma.",
    "The sample is a phase 2 trial for submassive pulmonary embolism, testing the efficacy of drotrecogin alfa (activated), enoxaparin, and placebo, with eligibility criteria based on symptoms and echocardiographic evidence of right ventricular dysfunction.",
    "The sample is a phase 2 clinical trial for endometriosis, testing the efficacy of drugs including placebo and leuprorelin acetate, with eligibility criteria including premenopausal women with dysmenorrhea and pelvic pain associated with endometriosis, and exclusion criteria including previous or current history of thyroid dysfunction and treatment with certain drugs.",
    "The sample is a phase 2 trial for patients with atrial fibrillation, testing the drug ati-5923, with inclusion criteria including documented atrial fibrillation and a CHADS2 score of 0 to 2, and exclusion criteria including contraindications to anticoagulation and recent history of myocardial infarction or coronary revascularization procedure.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide, doxorubicin, prednisone, and vincristine in treating peripheral T-cell or natural killer cell neoplasm, with specific eligibility criteria including measurable disease parameters, age, performance status, and various laboratory values.",
    "This phase 2 trial is testing the efficacy of gemcitabine hydrochloride and mitoxantrone hydrochloride in treating patients with acute myeloid leukemia who are not candidates for bone marrow transplantation and are in their first relapse after induction chemotherapy. The eligibility criteria include specific disease characteristics and patient characteristics, and prior concurrent therapy is also taken into consideration.",
    "This phase 2 trial is testing the efficacy of capecitabine, a chemotherapy drug, in treating patients with HER2-negative local recurrence of breast cancer who have undergone previous mastectomy surgery and do not have evidence of metastatic disease, with specific eligibility criteria for age, performance status, and laboratory results.",
    "This phase 2 trial is testing the efficacy of nitric oxide and placebo in patients with acute myocardial infarction and ST elevation, who have undergone successful percutaneous coronary intervention, and meet certain inclusion criteria, while excluding those with prior myocardial infarction, left bundle branch block, and other medical conditions.",
    "The sample is a phase 2 trial for endometriosis pain, testing the efficacy of elagolix and placebo drugs, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of folfox and bevacizumab in treating patients with recurrent, metastatic or unresectable gastroesophageal or gastric adenocarcinoma, with specific eligibility criteria including ECOG Performance Status of 0-1 and laboratory parameters within certain ranges.",
    "The sample is a phase 2 trial for metastatic breast cancer using pegylated liposomal doxorubicin and docetaxel, with inclusion and exclusion criteria listed, and icd-10 codes provided for the disease.",
    "The sample is a phase 2/phase 3 trial for mild or moderate persistent asthma, testing the efficacy of rosiglitazone, theophylline, beclomethasone, and inhaled beclomethasone and oral theophylline, with eligibility criteria including a minimum 6-month history of asthma, current cigarette smoking, and a baseline FEV1 greater than 50% predicted.",
    "This phase 2 trial is investigating the drug sb-705498 for the treatment of irritable colon in patients who meet specific inclusion and exclusion criteria, including having irritable bowel syndrome and rectal hyperalgesia.",
    "The sample is a phase 2/3 trial for postmenopausal women with estrogen and/or progesterone positive breast cancer, testing the efficacy of letrozole, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the effectiveness of cyclosporine in treating moderate to severe plaque psoriasis that has been resistant to other treatments, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for patients with prostate cancer and bone metastases, testing the efficacy of zd4054 at different doses, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2/phase 3 trial for pregnant women with documented HIV-1 infection without indication for ARV therapy, assessing the efficacy of kaletra (lopinavir/ritonavir) and kaletra (lopinavir/ritonavir) + combivir (zidovudine/lamivudine) in reducing mother-to-child transmission of HIV-1.",
    "The sample is a phase 2 trial for advanced, inoperable stage IV melanoma using bevacizumab and fotemustine as drugs, with eligibility criteria including cutaneous malignant melanoma and measurable and/or evaluable sites of metastases.",
    "This phase 2 trial is testing the efficacy of suramin, docetaxel, and carboplatin versus placebo, docetaxel, and carboplatin in treating non-small cell lung cancer patients with specific eligibility criteria, including measurable disease and adequate organ function.",
    "This is a phase 2 trial for locally advanced/inflammatory adenocarcinoma of the breast, testing the efficacy of gemcitabine, epirubicin, and albumin-bound paclitaxel, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of gemcitabine and docetaxel in treating breast cancer patients who meet specific eligibility criteria, including having a histologically verified diagnosis of breast carcinoma and adequate bone marrow and liver/renal functions.",
    "The sample is a phase 2 trial for non-small cell lung carcinoma, testing the drug celecoxib, with specific inclusion and exclusion criteria listed in the eligibility criteria column.",
    "This phase 2 trial is testing the efficacy of gwp42003 and gwp42004, along with placebo, in treating dyslipidemias and type 2 diabetes mellitus patients who meet specific eligibility criteria, while excluding those with certain medical conditions or taking certain medications.",
    "This phase 2 trial is testing the effectiveness of anastrozole and goserelin in premenopausal women with histologically-confirmed, bi-dimensionally measurable, recurrent or metastatic breast cancer that is progressive, and who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of capecitabine and fulvestrant in treating metastatic breast cancer patients who meet specific eligibility criteria, including having estrogen receptor and/or progesterone receptor positive tumors and adequate hematologic, renal, and hepatic function.",
    "This phase 2 trial is testing the efficacy of LY2300559 and placebo in treating migraine headaches in patients who meet specific inclusion criteria, while excluding those with certain medical conditions or who are taking certain medications.",
    "This phase 2 trial is testing the efficacy of intravenous immunoglobulin in treating mild to moderate Alzheimer's disease, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the efficacy of ixabepilone, capecitabine, and docetaxel in treating metastatic breast cancer with measurable disease, and eligibility criteria includes having received up to 1 chemotherapy regimen, having an Eastern Cooperative Oncology Group Performance status of 0-1, and not having prior treatment with any epothilone, capecitabine, or docetaxel.",
    "The sample is a phase 2 trial for emphysema patients, testing the efficacy of placebo and RAR gamma drugs, with specific inclusion and exclusion criteria, including age, smoking history, and previous medication use.",
    "This sample is a phase 2 trial for psoriasis vulgaris using calcipotriol plus betamethasone dipropionate gel, with inclusion criteria including involvement of trunk and/or arms and/or legs amenable to treatment with a maximum of 100 g of topical medication per week and an investigator's global assessment of disease severity of at least mild.",
    "This phase 2 trial is testing docetaxel, gemcitabine, and bevacizumab in patients with non-small cell lung cancer who have not received previous systemic chemotherapy and meet certain eligibility criteria.",
    "The sample is a phase 2 clinical trial for participants with type 2 diabetes mellitus, testing the efficacy of insulin glargine/lixisenatide fixed ratio combination, insulin glargine, and metformin, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of dasatinib in treating advanced lung cancer patients who have developed acquired resistance to erlotinib hydrochloride or gefitinib, and have previously undergone a biopsy of a site of progressive disease, while meeting certain eligibility criteria.",
    "This phase 2 trial is testing the drug pazopanib on patients with macular degeneration, with specific inclusion and exclusion criteria listed in the eligibility criteria section.",
    "This phase 2 trial is testing the drugs sd-6010 and placebo on subjects with osteoarthritis, with inclusion criteria including a BMI between 25 and 40 kg/m2 and a past diagnosis of knee OA, and exclusion criteria including a diagnosis of any other rheumatic disease and current conditions in the study knee that would confound efficacy.",
    "This phase 2 trial is testing the drug saracatinib on patients with metastatic adenocarcinoma of the pancreas who have received at least one prior chemotherapy regimen, and have no brain metastases, with a list of eligibility criteria.",
    "This phase 2 trial is testing the efficacy of erlotinib, a drug used to treat pancreatic cancer, in patients with locally advanced, unresectable or metastatic pancreatic carcinoma who have received up to 1 prior line of gemcitabine based systemic therapy, and have normal organ and marrow function.",
    "This phase 2 trial is testing the efficacy of capecitabine and oxaliplatin in treating liver cancer patients who meet specific disease and patient characteristics criteria, and have not had prior EGFR-targeting therapy or systemic chemotherapy.",
    "This phase 2 trial is testing the efficacy of topotecan hydrochloride in treating recurrent extensive stage small cell lung cancer, with eligibility criteria including measurable disease, prior response to first-line therapy, and no symptomatic brain metastases affecting performance status.",
    "This phase 2 trial is testing the efficacy of liposome encapsulated botulinum toxin a and normal saline instillation in treating overactive bladder in patients who have not responded to antimuscarinic agents, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for endometrial cancer using cisplatin, doxorubicin hydrochloride, and paclitaxel, with eligibility criteria including confirmed endometrial epithelial carcinoma and various patient characteristics such as age, performance status, and hematopoietic and renal function.",
    "This phase 2 trial is testing the efficacy of fluorouracil, leucovorin, and oxaliplatin in treating unresected primary tumor of the colon and radiographically confirmed metastatic colon cancer, with eligibility criteria including confirmed adenocarcinoma of the colon and Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.",
    "The sample is a phase 2 trial for patients with angioimmunoblastic T-cell lymphoma, testing the efficacy of cyclosporine as a treatment option, with specific inclusion and exclusion criteria listed.",
    "This is a phase 2 trial for rheumatoid arthritis testing the efficacy of BMS-817399 and placebo in patients who have been treated with and tolerated Methotrexate therapy, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of int-747 and ursodeoxycholic acid (urso) compared to placebo in treating liver cirrhosis and biliary disease, with specific inclusion and exclusion criteria for patient selection.",
    "This phase 2 trial will test the efficacy of arhalofenate, febuxostat, and colchicine in treating hyperuricemia and gout in patients who meet specific eligibility criteria, including having a serum uric acid value of at least 8.0 mg/dL and estimated CrCl \u2265 50 mL/min.",
    "This phase 2 trial is testing the effectiveness of aprepitant/ramosetron/dexamethasone in reducing chemotherapy-induced nausea and vomiting in ovarian cancer patients, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial testing the drug radafaxine on patients with major depressive disorder, with inclusion and exclusion criteria listed, and the disease is identified as depressive disorder, major with icd-10 codes F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40.",
    "This phase 2 trial is testing cetuximab and chemotherapy combinations in patients with non-resectable colorectal cancer and liver metastases, with specific eligibility criteria including Karnofsky Performance Status \u2265 80 and adequate bone marrow, liver, and renal function.",
    "The sample is a phase 2 trial for patients with multiple sclerosis, testing the efficacy of masitinib, with inclusion criteria including age range, EDSS score, and EDSS progression, and exclusion criteria including other diseases, recent treatments, and active infections.",
    "The sample is a phase 2 trial for gastroesophageal reflux disease, testing the drug rabeprazole 20 mg, with eligibility criteria including a minimum three-month history of GERD symptoms and at least 4 days with heartburn per week in each of the 2 weeks prior to screening.",
    "This phase 2 trial is testing the efficacy of sunitinib malate and paclitaxel in treating recurrent or metastatic esophageal or gastro-esophageal junction squamous cell or adenocarcinoma, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of cinaciguat and placebo in treating decompensated chronic congestive heart failure patients with NYHA functional class III-IV, either ischemic or non-ischemic, requiring hospitalization, and with clinical indication for parenteral pharmacotherapy and invasive hemodynamic monitoring, with exclusion criteria including females of child-bearing potential, acute de-novo heart failure, acute myocardial infarction and/or myocardial infarction within 30 days, and valvular heart disease requiring surgical intervention during the course of the study.",
    "The sample is a phase 2 trial for lupus nephritis, testing the efficacy of laquinimod, mycophenolate mofetil, and prednisolone/prednisone compared to placebo, with inclusion criteria including a recent kidney biopsy and clinically active lupus nephritis.",
    "The sample is a phase 2 trial for pancreatic cancer patients with non-metastatic disease that is unresectable, using fluorouracil and gemcitabine hydrochloride as drugs, and the eligibility criteria includes age, performance status, hematopoietic, hepatic, renal, and cardiovascular conditions, as well as prior concurrent therapy.",
    "This phase 2 trial is testing the efficacy of bevacizumab and tac in treating stage II or III HER2-negative breast cancer, with eligibility criteria including normal cardiac function and no prior chemotherapy, radiotherapy, or endocrine therapy for invasive or noninvasive breast cancer.",
    "This phase 2 trial is testing the efficacy of capecitabine and oxaliplatin in treating rectal adenocarcinoma involving the distal 12 cm of the rectum, with eligibility criteria including no evidence of distant metastases, ECOG performance status of 0-1 or Karnofsky PS of 70-100%, and no prior radiotherapy or chemotherapy to the pelvis.",
    "This phase 2 trial is testing the effectiveness of various drugs, including allopurinol and bcx4208, in treating gout in patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug triapine on patients with locally recurrent or metastatic kidney cancer that is incurable by standard therapy, and the eligibility criteria includes various patient characteristics and prior concurrent therapies.",
    "This phase 2 trial is testing the efficacy of cabazitaxel in treating metastatic advanced colorectal cancer patients who have progressed after standard treatment, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for autism, testing the drug aripiprazole, with inclusion criteria including a diagnosis of autism and indication for medication treatment, and exclusion criteria including major medical problems and prior exposure to aripiprazole.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease (COPD) testing the drugs azd4818 and placebo, with inclusion criteria including a clinical diagnosis of COPD, a smoking history of at least 10 pack-years, and lung function between 40 to 80% of predicted normal value after using a short acting bronchodilator.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate in treating severe cutaneous or systemic scleroderma, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cetirizine dihydrochloride and placebo in treating seasonal allergic rhinitis in patients with specific IgE or positive SPT to aero allergens, with various exclusion criteria, and inclusion criteria including age, BMI, and history of pollen-induced seasonal allergic rhinitis.",
    "This phase 2 trial is testing the drug pemetrexed on patients with metastatic or locally recurrent liver cancer who have not received prior therapy with pemetrexed, and have measurable disease, while excluding patients with a history of other invasive malignancies or who have received radiation to more than 25% of marrow.",
    "The sample is a phase 2 trial for chronic hepatitis C infection with genotype 1, testing the efficacy of drugs including abt-450, abt-072, abt-333, ritonavir, peginterferon alpha-2a, and ribavirin, with eligibility criteria including liver biopsy, negative drug and alcohol screen, and no prior treatment with anti-HCV agents.",
    "The sample is a phase 2 trial for prostate cancer with drugs including enzastaurin, placebo, docetaxel, and prednisone, and eligibility criteria including no prior chemotherapy treatment and proper organ function.",
    "This is a phase 2 clinical trial for patients with multiple myeloma, testing the effectiveness of bevacizumab, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the effectiveness of gemcitabine, tarceva, and oxaliplatin in treating potentially resectable pancreatic cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of sunitinib malate, a drug, in treating advanced renal cell carcinoma of papillary or other non-clear cell histology, with specific eligibility criteria for patients.",
    "This phase 2 trial will test the efficacy of lithium carbonate, citalopram, and placebo in treating major depressive disorder, dysthymia, depression not otherwise specified, and borderline personality disorder, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for narcolepsy, testing the efficacy of adx-n05 and placebo drugs, with inclusion and exclusion criteria listed, and icd-10 codes provided for the disease.",
    "The sample is a phase 2 trial for postherpetic neuralgia, testing the efficacy of ph-797804 and placebo drugs, with inclusion criteria including pain present for more than 3 months and a score \u226540 mm on the Pain Visual Analog Score (VAS).",
    "This phase 2 trial is testing the combination of pertuzumab and erlotinib in patients with histologically-confirmed pancreatic adenocarcinoma who have had disease progression following therapy with gemcitabine, and meet other eligibility criteria.",
    "This phase 2 trial will test the efficacy of treprostinil sodium for inhalation in treating idiopathic pulmonary fibrosis and pulmonary hypertension, with strict inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial is testing the efficacy of liposomal doxorubicin and docetaxel in treating metastatic breast cancer with specific inclusion and exclusion criteria, and the presence of certain icd-10 codes.",
    "This phase 2 trial is testing the efficacy of multiple drugs, including gs-5885 and ribavirin tablet, in treating chronic hepatitis C in HCV treatment-na\u00efve patients with specific inclusion and exclusion criteria.",
    "This trial is a phase 2/phase 3 study testing the efficacy of oros methylphenidate and placebo in treating adults with attention deficit hyperactivity disorder who meet specific inclusion and exclusion criteria, including being in general good health and not having other current DSM-IV Axis I Disorders or significant medical or psychiatric illnesses.",
    "The sample is a phase 2 trial for non-small cell lung cancer patients with measurable disease, testing the efficacy of vandetanib induction and maintenance, docetaxel, carboplatin, and placebo, with eligibility criteria including ECOG Performance Status 0 or 1 and no prior cytotoxic chemotherapy or targeted therapy for advanced or metastatic disease.",
    "This phase 2 trial is testing the efficacy of abiraterone acetate and glucocorticoid in treating prostate neoplasms with specific eligibility criteria, including PSA progression and ongoing androgen deprivation, while excluding participants with active autoimmune disease or uncontrolled hypertension.",
    "The sample is a phase 2 trial for acute diverticulitis, testing the efficacy of mesalamine, probiotic, placebo, and antibiotic, with eligibility criteria including a clinical diagnosis of acute diverticulitis and exclusion criteria including presence of diverticular complications and recent use of mesalamine.",
    "This phase 2 trial is testing taxotere, cytoxan, and herceptin in women with HER2+ breast cancer who have had no prior chemotherapy, and have undergone complete surgical resection of the primary breast tumor.",
    "This phase 2 trial is testing nab-paclitaxel for patients with metastatic breast cancer who have relapsed within 12 months of completing adjuvant chemotherapy, and have previously been treated with a solvent based taxane.",
    "This phase 2 trial is testing the efficacy of lidoderm and placebo patches in treating moderate-to-severe osteoarthritis of the knee, with specific eligibility criteria including age, BMI, and functional capacity, and exclusion criteria including recent knee injury or surgery and hypersensitivity to lidocaine.",
    "This phase 2 trial is testing the efficacy of cyclo-z and placebo in treating type 2 diabetes mellitus patients who are inadequately controlled by diet and exercise alone or oral medications, and have a hemoglobin A1c level of 6.5% to 8.0% inclusive, with a list of exclusion criteria including taking insulin, history of diabetic ketoacidosis or hyper osmolar non-ketotic coma, and any disease likely to limit life span and/or increase risks of interventions.",
    "This phase 2 trial is testing the efficacy of ocrelizumab and Avonex compared to placebo in treating relapsing-remitting multiple sclerosis, with strict inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of erlotinib hydrochloride and letrozole in post-menopausal females with estrogen and/or progesterone receptor-positive breast cancer, who have had no more than 1 prior chemotherapy regimen for metastatic disease and have fully recovered from any grade 2-4 toxicities related to chemotherapy, and meet other eligibility criteria.",
    "This is a phase 2 clinical trial for patients with unresectable or metastatic renal cell carcinoma, testing the efficacy of sunitinib and bibf 1120 drugs, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for patients with malignant pleural mesothelioma, testing the efficacy of cisplatin, sodium thiosulfate, and alimta, with eligibility criteria including histopathologic confirmation of the disease, ability to tolerate surgical cytoreduction, and no evidence of spread outside the ipsilateral hemithorax.",
    "This phase 2 trial is testing the efficacy of ph-10 (rose bengal) on mild to moderate plaque psoriasis, with a list of inclusion and exclusion criteria, including restrictions on previous treatments and medical conditions.",
    "This phase 2 trial is testing the efficacy of ezetimibe and simvastatin in treating type 2 diabetes with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with type 2 diabetes and overt diabetic nephropathy, testing the efficacy of pyridoxamine dihydrochloride and placebo, with eligibility criteria including age, disease history, medication use, and exclusion criteria including other medical conditions and drug use.",
    "The sample is a phase 2 trial for patients with chronic obstructive pulmonary disease and bronchitis, testing the effectiveness of bibw 2948 bs and placebo drugs, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for small cell lung cancer patients with measurable disease, using carboplatin and irinotecan as drugs, and with specific eligibility criteria for patient characteristics and prior concurrent therapy.",
    "The sample is a phase 2 trial for glioblastoma multiforme patients, testing the drug axitinib, with inclusion criteria including age above 70, Karnofsky score of 50-80, and no prior chemotherapy or radiation treatment, while exclusion criteria include extensive tumor hemorrhage and prior myocardial infarction or cerebrovascular accident.",
    "This phase 2 trial is testing the drug tipifarnib on patients with recurrent or stage IV melanoma, who have at least 2 cutaneous lesions amenable to excisional biopsy for correlative studies, and meet other eligibility criteria.",
    "The sample is a phase 2 trial for ovarian cancer, peritoneal cancer, fallopian tube cancer, stage 3 and 4 cancer, using bevacizumab, carboplatin, and paclitaxel, with specific inclusion and exclusion criteria.",
    "This sample is a phase 2 trial for mycosis fungoides using 0.04% mechlorethamine gel as a drug, with eligibility criteria requiring completion of a previous study and exclusion criteria for pregnant or nursing females or those not using effective contraception.",
    "This phase 2 trial is testing the efficacy of carboplatin, gefitinib, and paclitaxel in treating metastatic or unresectable non-small cell lung cancer patients who have no other potentially curative treatment options available, and who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for irritable bowel syndrome, testing the efficacy of asimadoline and placebo drugs, with inclusion criteria including a diagnosis of IBS and willingness to comply with daily diary entry.",
    "This phase 2 trial is testing the effectiveness of leuprolide acetate in preserving ovarian function in hematopoietic stem cell transplantation candidates with amenorrhea, premature ovarian failure, or ovarian function insufficiency, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of pemetrexed (Alimta) in patients with locally recurrent or metastatic nasopharyngeal carcinoma who have previously received one platinum-based chemotherapy regimen for palliative therapy of locally advanced or metastatic disease.",
    "The sample is a phase 2/phase 3 trial for atopic dermatitis, testing the drug fexofenadine/allegra (m016455), with inclusion criteria of patients aged 6 months through 11 years with atopic dermatitis and exclusion criteria of main itching scores of 4 or less than 2 on last three consecutive days before registration and patients who have itching only on face, head, or diaper area.",
    "This phase 2 trial is testing the efficacy of carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, and vincristine in treating diffuse large B-cell non-Hodgkin's lymphoma with measurable disease, while excluding certain lymphoma types and patients with prior chemotherapy or radiation therapy for lymphoma.",
    "This sample is a phase 2 trial for kidney transplantation using the drug fk778, with inclusion criteria including primary or retransplanted cadaveric or non-HLA-identical living donor kidney recipients, and exclusion criteria including patients who have received an organ transplant other than kidney or a kidney transplant from a cadaveric donor >= 60 years of age.",
    "This is a phase 2 trial for rheumatoid arthritis patients who have not responded to methotrexate, testing the efficacy of natalizumab compared to placebo, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for patients with metastatic non-small-cell lung cancer, testing the drug ly573636-sodium, with inclusion criteria of having received 2 previous treatment regimens and exclusion criteria of serious pre-existing medical conditions and having received 3 or more previous treatment regimens.",
    "This phase 2 trial is testing the efficacy of dos (docetaxel, oxaliplatin and s-1) in treating unresectable, locally advanced or metastatic gastric adenocarcinoma patients who meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of cytarabine and gemtuzumab ozogamicin in treating patients with acute myeloid leukemia who are in their first relapse after prior complete response and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for non-small cell lung cancer patients with node positive stage II or IIIA disease, who have not received prior tumor therapy, and are eligible for curative surgical resection, using gemcitabine and cisplatin as drugs, with inclusion and exclusion criteria specified.",
    "This is a phase 2 trial for HIV-1 infection testing the efficacy of BMS-986001, efavirenz, lamivudine, and tenofovir, with eligibility criteria including antiretroviral treatment-naive patients with CD4+ T-cell count > 200 cells/mm3 and exclusion criteria including resistance to study medications and contraindications to any of the study drugs.",
    "This phase 2 trial is testing the efficacy of amg 951, bevacizumab, and carboplatin in combination with paclitaxel for the treatment of advanced non-small cell lung cancer, with specific eligibility criteria and exclusion criteria outlined.",
    "This phase 2 trial is testing the efficacy of cisplatin, gemcitabine hydrochloride, and sorafenib tosylate in treating muscle-invasive bladder cancer, with eligibility criteria including confirmed TCC histology and negative serology for infectious diseases.",
    "This phase 2 trial is testing the drug belinostat on patients with advanced malignant mesothelioma, and the eligibility criteria includes having received only 1 prior systemic chemotherapy regimen for advanced mesothelioma and having measurable disease.",
    "This phase 2 trial is testing the efficacy of gemcitabine and cisplatin in treating patients with unresectable, locally recurrent, or metastatic breast cancer who have been pre-treated with anthracyclines with/without taxanes containing chemotherapy, and have recovered from all acute chemotherapy related toxicities.",
    "The sample is a phase 2 trial for atherosclerosis patients currently undergoing statin therapy, testing the efficacy of sb480848 at different doses, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of baricitinib and placebo in treating chronic plaque psoriasis, with specific eligibility criteria and exclusion criteria listed.",
    "This is a phase 2 clinical trial for patients with ocular hypertension or open angle glaucoma, testing the efficacy of ar-13324 ophthalmic solution 0.01%, 0.02%, and 0.04% in reducing intraocular pressure, with specific inclusion and exclusion criteria.",
    "This sample is a phase 2 trial for patients with recurrent or metastatic breast cancer, testing the efficacy of gemcitabine and oxaliplatin as a chemotherapy regimen, with specific eligibility criteria including prior chemotherapy regimens, measurable disease, and certain lab values.",
    "The sample is a phase 2 trial for non-small cell lung cancer patients with measurable or evaluable disease, using cisplatin and pemetrexed disodium as drugs, and with eligibility criteria including ECOG 0-1 performance status, no prior chemotherapy or radiotherapy for lung cancer, and no other active malignancy within the past 2 years except nonmelanoma skin cancer or carcinoma in situ of the cervix.",
    "The sample is a phase 2 trial for patients with stage IV colorectal cancer with p185 HER2 overexpression, testing the efficacy of irinotecan hydrochloride, with eligibility criteria including performance status, blood counts, liver and kidney function, and absence of other malignancies or serious medical conditions.",
    "This phase 2 trial is testing the efficacy of tygacil, an antibiotic, in treating serious bacterial infections such as intra-abdominal infections, pneumonia, and skin diseases, in patients aged 8 to 11 years who require hospitalization and IV antibiotic therapy for at least 5 days, with various exclusion criteria.",
    "The sample is a phase 2 trial for metastatic colorectal cancer, testing the efficacy of irinotecan hydrochloride and placebo in patients who have failed previous regimens, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the combination of fulvestrant and erlotinib in patients with estrogen or progesterone receptor positive stage IIIb/IV non-small cell lung cancer who have stable disease on erlotinib monotherapy for at least 2 months, with specific inclusion and exclusion criteria.",
    "This is a phase 2 clinical trial for sickle cell disease patients, testing the effectiveness of ketamine for acute pain relief, with specific inclusion and exclusion criteria, and requiring parental consent and child assent.",
    "This phase 2 trial is testing the efficacy of cisplatin in treating melanoma, with specific eligibility criteria including measurable lesions, KPS > 70, and laboratory values within certain ranges.",
    "This phase 2 trial is testing the efficacy of bortezomib in patients with recurrent adult diffuse large cell lymphoma, recurrent grade 1-3 follicular lymphoma, or recurrent mantle cell lymphoma who are refractory to or have recurrent disease after prior rituximab-containing treatment and are either transplant ineligible or have refused high dose therapy, and have radiographically measurable disease, as defined by the International Working Group criteria.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, and paclitaxel in treating HER2/neu-positive breast cancer, with eligibility criteria including confirmed adenocarcinoma of the breast, no stage IV disease, and specific patient characteristics such as ECOG performance status and LVEF.",
    "This phase 2 trial is testing the drug S-1 in patients with advanced non-small cell lung cancer who have received prior 1st line chemotherapy and have not received any 2nd line therapy, and the eligibility criteria includes having measurable disease and adequate organ function.",
    "The sample is a phase 2 trial for lung cancer using the drug kos-862, with inclusion criteria including measurable disease and previous platinum-based treatment, and exclusion criteria including brain metastases and significant heart rhythm changes.",
    "This phase 2 trial is testing the effectiveness of exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, and antiandrogen drugs in treating prostate cancer, with eligibility criteria including a documented diagnosis of prostate cancer, ECOG performance status score of 0 or 1, and having received at least one cycle of IAS with an LHRH agonist and anti-androgen.",
    "This phase 2 trial is testing the efficacy of treprostinil in treating severe pulmonary arterial hypertension in patients with interstitial lung disease, idiopathic pulmonary fibrosis, and pulmonary arterial hypertension, with eligibility criteria including a resting mean pulmonary artery pressure > 35 mm Hg and planned treatment with treprostinil.",
    "This phase 2 trial is testing the drug RAD001 on patients with metastatic renal cancer refractory to sorafenib or sunitinib therapy, with inclusion criteria including measurable disease and adequate bone marrow, liver, and kidney function.",
    "This phase 2 trial is testing the efficacy of cariprazine and placebo in treating acute manic or mixed episodes in patients with bipolar I disorder, with inclusion criteria including a total YMRS score >= 20 and a score of at least 4 on two specific YMRS items.",
    "The sample is a phase 2 trial for type 2 diabetes mellitus, testing the efficacy of exenatide and placebo combinations, with inclusion criteria of HbA1c 6.0% to 11.0%, and exclusion criteria of recent use of certain medications or participation in other clinical trials.",
    "This phase 2 trial is testing erlotinib hydrochloride in patients with metastatic papillary histology renal cell carcinoma, who have not received prior chemotherapy or immunotherapy, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of paclitaxel albumin nanoparticle and sorafenib in treating HER2-negative locally advanced or metastatic breast cancer patients who have received prior adjuvant chemotherapy, with eligibility criteria including adequate liver and renal function, normal baseline left ventricular ejection fraction, and exclusion criteria including prior chemotherapy with Abraxane or Nexavar, serious intercurrent medical or psychiatric illness, and active brain metastases.",
    "This phase 2 trial will test the efficacy of tzp-102, a drug, in treating gastroparesis in patients with type 1 or type 2 diabetes mellitus, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug Nexavar (sorafenib) on patients with chronic myelogenous leukemia who have hematologic resistance to Gleevec, and have specific inclusion and exclusion criteria.",
    "This trial is a phase 2/phase 3 study testing the efficacy of anakinra and saline in treating type 1 diabetes with specific inclusion and exclusion criteria, including positive GAD auto-antibodies and peak C-peptide levels, and excluding patients with severe liver or renal disease, heart disease, malignancy, and immune-suppressive treatment.",
    "The sample is a phase 2 trial for patients with incurable squamous cell carcinoma of the head and neck, using paclitaxel as the drug, and with specific eligibility criteria including age, performance status, hematopoietic, hepatic, renal, and cardiovascular conditions, as well as prior concurrent therapy.",
    "This phase 2 trial is testing the efficacy of 5-azacytidine, valproic acid, and atra in treating myelodysplastic syndromes with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for relapsed or refractory multiple carcinoma, using the drug gw786034, with inclusion and exclusion criteria related to bone marrow, renal, and heart function, as well as prior treatments and medical history.",
    "The sample is a phase 2 trial for cystic fibrosis patients, testing the efficacy of mannitol, mannitol + pulmozyme, and dornase alpha, with inclusion criteria including a diagnosis of cystic fibrosis, age between 8 and 18 years, and a baseline FEV1 of <70% of the predicted normal value.",
    "The sample is a phase 2 trial for patients with chronic obstructive pulmonary disease (COPD) testing the efficacy of various drugs including olodaterol and tiotropium bromide, with specific eligibility criteria including spirometric criteria and smoking history.",
    "This phase 2 trial is testing the efficacy of teriflunomide and interferon-\u03b2-1 in treating relapsing multiple sclerosis, with specific inclusion and exclusion criteria for patients.",
    "This phase 2 trial is testing the drug bibw 2992 on patients with HER2-positive metastatic breast cancer who have progressed following prior trastuzumab treatment or standard chemotherapy in conjunction with trastuzumab, and have measurable disease as defined by RECIST criteria.",
    "This phase 2 trial is testing the efficacy of oxaliplatin and pemetrexed disodium in treating stage III-IVB head and neck cancer patients with measurable disease, who meet specific eligibility criteria, while excluding patients with certain medical conditions or who have received certain treatments.",
    "The sample is a phase 2 trial for patients with type 1 diabetes, testing the efficacy of insulin degludec, insulin glargine, and insulin aspart, with inclusion criteria of HbA1c 7-11% and exclusion criteria of recent systemic treatment with products that could interfere with glucose or lipid metabolism.",
    "This phase 2 trial is testing the efficacy of iressa and tamoxifen in treating primary breast cancers that are HER2 overexpressing and ER positive, with eligibility criteria including adequate bone marrow and liver function, negative pregnancy test, and performance status <2.",
    "The sample is a phase 2 trial for hepatocellular carcinoma patients using the drug patupilone, with inclusion criteria of at least 1 previously un-irradiated, measurable lesion and exclusion criteria of additional protocol-defined criteria.",
    "The sample is a phase 2 trial for patients with active rheumatoid arthritis, testing the efficacy of ch-1504 and methotrexate (mtx) as drugs, with eligibility criteria including specific blood test values and exclusion criteria such as previous biologic therapy or active infections.",
    "The sample is a phase 2 trial for schizophrenia, testing the drug RO4917838 and standard antipsychotic therapy, with inclusion criteria including adult patients with a diagnosis of schizophrenia and exclusion criteria including previous use of RO4917838.",
    "This phase 2 trial is testing the efficacy of rituximab and gemcitabine in treating biopsy-proven DLBCL and transformed DLBCL, with measurable disease and prior gemcitabine therapy allowed.",
    "This phase 2 trial is testing the efficacy of tiotropium and placebo via the HandiHaler\u00ae devices in patients with chronic obstructive pulmonary disease who meet specific spirometric criteria and have a smoking history of more than 10 pack-years.",
    "This phase 2 trial will investigate the efficacy of bevacizumab in combination with chemotherapy for the treatment of primary breast cancer, with eligibility criteria including age, disease stage, and various health parameters.",
    "This phase 2 trial is testing the efficacy of lenalidomide and epoetin beta in treating myelodysplastic syndromes in patients who meet specific eligibility criteria, including transfusion dependence and resistance to previous treatments, while excluding those with certain medical conditions or taking certain medications.",
    "The sample is a phase 2 trial for osteoporosis in postmenopausal Asian women, testing the efficacy of lasofoxifene and placebo, with inclusion criteria of low BMD and exclusion criteria of metabolic bone disease or use of other osteoporosis drugs or drugs interfering with normal bone metabolism.",
    "This phase 2 trial is testing the efficacy of Leo 29102 and Elidel in treating mild to moderate atopic dermatitis in patients between 18 and 65 years old, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of pt001 mdi, tiotropium bromide, and pt001 placebo mdi in treating chronic obstructive pulmonary disease (COPD) in patients who meet specific inclusion criteria, such as having a clinical history of COPD with airflow limitation and a measured post-bronchodilator FEV1/FVC ratio of < or = 0.70.",
    "The sample is a phase 2 trial for chronic HCV infection testing the efficacy of gs-9256, gs-9190, ribavirin, and peginterferon alfa-2a in treatment-naive patients with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of a combination of etoposide, cyclophosphamide, doxorubicin hydrochloride, lamivudine, prednisone, vincristine sulfate, and zidovudine in treating HTLV-1-associated adult T-cell leukemia/lymphoma (ATLL) in patients who meet specific eligibility criteria.",
    "This phase 2 trial aims to test the efficacy of 3,4-methylenedioxymethamphetamine (MDMA) and lactose (placebo) in treating chronic posttraumatic stress disorder (PTSD) in patients who have had at least one unsuccessful attempt at treatment, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for non-small cell lung cancer, testing erlotinib, placebo, gemcitabine, cisplatin, and carboplatin, with eligibility criteria including histologically documented advanced or recurrent stage IIIB or IV non-small cell lung cancer and no previous chemotherapy for non-small cell lung cancer.",
    "This phase 2 trial is testing the efficacy of sunitinib malate in treating hepatocellular carcinoma patients who meet specific inclusion criteria, while excluding those with certain medical conditions or who have received certain prior treatments.",
    "This phase 2 trial is testing the effectiveness of irinotecan, capecitabine, cetuximab, and oxaliplatin in treating locally advanced or metastatic colorectal cancer with specific eligibility criteria, including measurable or evaluable disease, ECOG performance status \u2264 2, and a paraffin block from the primary tumor for mutational analysis of the KRAS gene.",
    "This phase 2 trial is testing the efficacy of duloxetine and placebo matching with bms-820836 in treating Major Depressive Disorder, with inclusion criteria including inadequate response to 1-3 adequate trials of antidepressant treatment and a HAM-D17 total score =>18 at Screening.",
    "This phase 2 trial is testing the efficacy of mk0683, vorinostat, and suberoylanilide hydroxamic acid (saha) in treating relapsed Diffuse Large B-cell Lymphoma (DLBCL) with eligibility criteria including stable disease or better for at least 3 months on most recent treatment and not having failed more than 3 prior treatment regimens.",
    "The sample is a phase 2 trial for advanced ovarian cancer patients with recurrence or disease progression, testing the efficacy of azd0530, carboplatin, and paclitaxel, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of lenalidomide and dexamethasone in treating previously untreated, symptomatic multiple myeloma patients who are at least 65 years old or not candidates for hematopoietic stem cell transplantation, and meet other eligibility criteria.",
    "This phase 2 trial will test the effectiveness of pomegranate polyphenol extract (POMx) in treating cardiomyopathy and heart failure in adult subjects with specific eligibility criteria, while comparing it to a sugar pill.",
    "This phase 2 trial is testing the efficacy of dt pace + rituxan in treating Waldenstrom's Macroglobulinemia, with eligibility criteria including cytopenias, lymphadenopathy, B symptoms, severe neuropathy, and progressive disease.",
    "This phase 2 trial is testing the drug panhematin on patients with myelodysplastic syndrome who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of rabeprazole sodium, a proton pump inhibitor, in treating symptomatic gastroesophageal reflux disease in children aged 12 to 16 years, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cetuximab and gemcitabine in treating advanced non-small cell lung cancer patients who are ineligible for platinum-based therapy due to contraindications, and have at least one site of metastasis, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of avastin and preservative-free triamcinolone acetonide in treating age-related macular degeneration with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of 10% imcooh cream and placebo in treating atopic dermatitis, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the efficacy of peramivir and oseltamivir in treating influenza in patients with certain eligibility criteria, including age, symptoms, and positive rapid antigen test, while excluding those with certain medical conditions or recent treatments.",
    "This phase 2 trial is testing the drug cilengitide on patients with various stages of prostate cancer who have PSA-only progression despite androgen deprivation therapy and antiandrogen withdrawal, and meet other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of nitazoxanide, placebo, and ribavirin in treating chronic hepatitis C genotype 1, with a list of exclusion criteria including liver disease, alcohol consumption, and psychiatric disorders.",
    "The sample is a phase 2 trial for patients with HER2 positive breast cancer, testing the efficacy of su011248/trastuzumab, with specific eligibility criteria and exclusion criteria listed.",
    "The sample is a phase 2 trial for metastatic renal cell carcinoma, testing the efficacy of nexavar and placebo drugs, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of LY500307 and placebo in treating benign prostatic hyperplasia, with inclusion criteria including a history of BPH, high IPSS score, and signs of bladder outlet obstruction, while exclusion criteria include a history of prostate cancer, deep venous thrombosis, or pulmonary embolism disease.",
    "This phase 2 trial is testing the efficacy of bevacizumab, carboplatin, and gemcitabine in treating patients with myeloproliferative disorder, urothelial carcinoma, or cancer who are ineligible for cisplatin, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial testing the efficacy of pirfenidone and placebo in treating pulmonary fibrosis in patients with HPS, with strict inclusion and exclusion criteria, and requiring patients to come to the NIH Clinical Center every 4 months for three years.",
    "This phase 2 trial is testing the efficacy of clofarabine in salvaging patients with myelodysplastic syndromes who have failed at least six cycles of 5-azacytidine, with inclusion criteria including ECOG performance status of 0-2, adequate renal and hepatic functions, and negative pregnancy test for female patients of childbearing potential.",
    "The sample is a phase 2 trial for pancreatic cancer patients who failed first line gemcitabine therapy, testing the efficacy of azd6244 and capecitabine, with specific inclusion and exclusion criteria.",
    "This phase 2 trial will test the efficacy of SYL040012 and placebo in treating ocular hypertension and open angle glaucoma, with eligibility criteria including elevated IOP and normal results in various ocular assessments, while exclusion criteria include use of beta blockers or corticosteroids for concurrent diseases and previous surgery for glaucoma.",
    "This phase 2 trial is testing the efficacy of amg 386 and sorafenib, along with a placebo, in treating advanced renal cell carcinoma in patients who meet specific eligibility criteria.",
    "This is a phase 2 trial for patients with squamous cell carcinoma of the head and neck, testing the efficacy of cisplatin and docetaxel, with eligibility criteria including specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions.",
    "This phase 2 trial is testing the efficacy of CP-4055 and sorafenib in treating stage IV or unresectable stage III non-ocular malignant melanoma, with eligibility criteria including measurable disease, performance status 0-1, and adequate hematological and biological functions.",
    "This phase 2 trial is testing the efficacy of sunitinib malate, a tyrosine kinase inhibitor, in treating refractory or relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of a combination of drugs including bevacizumab, carboplatin, paclitaxel, and placebo in treating non-squamous non-small cell lung cancer patients who meet certain eligibility criteria.",
    "The sample is a phase 2/phase 3 trial for acute myocardial infarction, testing the efficacy of mesenchymal stem cell therapy versus a control group, with eligibility criteria including age, ischemic chest pain, and ST segment elevation, and exclusion criteria including cardiogenic shock, history of malignancy, and positive viral markers.",
    "This phase 2 trial is testing the efficacy of eplivanserin and placebo in treating fibromyalgia, sleep disorders, and chronic pain, with inclusion criteria including a confirmed diagnosis of fibromyalgia and complaints of unrefreshing sleep, and exclusion criteria including pregnancy and a history of significant medical disorders.",
    "This phase 2 trial is testing the efficacy of carboplatin and abi-007 in treating locally recurrent or metastatic HER-2-negative breast cancer patients with measurable disease, who have not received prior chemotherapy for locally recurrent or metastatic disease, and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of nnc 0142-0000-0002, a drug, versus placebo in treating inflammation and Crohn's disease, with specific eligibility criteria for subjects.",
    "The sample is a phase 2 trial for chronic hepatitis C, testing the drugs sofosbuvir, rbv, and peg, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for lung cancer patients using erlotinib (tarceva) as the drug, with specific eligibility criteria including performance status, weight loss, age, organ function, and exclusion criteria such as no prior chemotherapy for systemic disease.",
    "This is a phase 2 clinical trial for multiple myeloma patients who have undergone high dose chemotherapy and autologous stem cell transplantation, and are being treated with bortezomib. The eligibility criteria include laboratory requirements, postmenopausal status or contraception use, and exclusion criteria include peripheral neuropathy and severe cardiovascular disease.",
    "This phase 2 trial is testing the efficacy of rdc-1036 and placebo in treating opioid-induced constipation in patients receiving prescribed opioid medication for chronic non-cancer pain, with inclusion criteria including a diagnosis of OIC and willingness to stop all laxatives and other bowel regimens.",
    "This is a phase 2 trial for HIV infections using a combination of indinavir, lamivudine, and ritonavir, with specific eligibility criteria including confirmed HIV-1 infection, CD4 count over or equal to 200/mm3, and failure of two antiretroviral regimens with 2 PI and one NNRTI.",
    "This phase 2 trial is testing the effectiveness of dienogest (Visanne, Bay86-5258) in treating endometriosis in female adolescents, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for Crohn's disease testing the efficacy of amg 827 and placebo, with inclusion criteria including a CDAI score >250 and <450 at baseline and evidence of active inflammation, and exclusion criteria including short bowel syndrome, ulcerative colitis, and recent use of certain medications.",
    "This phase 2 trial is testing the efficacy of milnacipran and placebo in treating irritable bowel syndrome in patients who meet specific inclusion criteria and do not have any exclusion criteria.",
    "The sample is a phase 2 trial for metastatic or locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction, testing the efficacy of docetaxel, 5-fluorouracil, oxaliplatin, and folinic acid, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of entecavir and lamivudine in treating hepatitis B virus in participants who have previously received these drugs, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the drugs bms-914392 and placebo on patients with paroxysmal atrial fibrillation, with inclusion criteria including a 1-50% AF burden and exclusion criteria including persistent or permanent AF, neurological diseases, and mental disorders.",
    "The sample is a phase 2 trial for colorectal cancer testing the combination therapy of sol and mfolfox6, with eligibility criteria including age, prior treatment, and measurable lesions, and exclusion criteria including drug hypersensitivity, peripheral neuropathy, diarrhea, and simultaneous double cancer.",
    "This is a phase 2 trial for patients with non-squamous cell Stage IVA Wet or Stage IVB metastatic non-small cell lung cancer, testing the efficacy of pazopanib and pemetrexed as a treatment option, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for hypercholesterolemia using gemcabene and placebo, with specific inclusion and exclusion criteria based on age, LDL-C levels, and various health conditions.",
    "This phase 2 trial is testing the efficacy of fludarabine/busulfan x 4 days in treating biologic high risk multiple myeloma, including plasma cell leukemia, in patients up to 70 years old with specific disease status and organ function requirements.",
    "This phase 2 trial is testing the efficacy of jnj-40411813 and antipsychotic medication in treating schizophrenia in patients who meet specific inclusion criteria, while excluding those with certain medical conditions or a PANSS score outside of a specific range.",
    "This phase 2 trial is testing the effectiveness of erlotinib hydrochloride, a drug, in treating patients with various stages of pancreatic cancer and intraductal papillary mucinous neoplasm of the pancreas, with specific eligibility criteria for patients to participate in the study.",
    "The sample is a phase 2 trial for patients with non-small cell lung cancer who have progressed after one prior gemcitabine-containing chemotherapy regimen, and will test the efficacy of gemcitabine hydrochloride and triapine as drugs, with eligibility criteria including measurable disease and specific patient characteristics.",
    "The sample is a phase 2 trial for patients with chronic obstructive pulmonary disease, testing the efficacy of bi 1744 cl plus tiotropium bromide, with inclusion criteria including a smoking history of more than 10 pack years and spirometric criteria, and exclusion criteria including a history of asthma or clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis.",
    "The sample is a phase 2 trial for hyperlipidemia, testing the efficacy of mbx-8025 and atorvastatin compared to placebo, with eligibility criteria including abnormal cholesterol levels and exclusion criteria including a history of diabetes mellitus and adverse effects from atorvastatin.",
    "This phase 2 trial is testing the efficacy of cetuximab and irinotecan in treating advanced, surgically unresectable colon and rectum cancer patients who have failed a first line metastatic regimen, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of 5-fluorouracil, bevacizumab, leucovorin, and irinotecan in treating metastatic colorectal cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the use of tacrolimus (Advagraf or Prograf) in heart, lung, and pancreas transplant recipients who meet certain eligibility criteria, while excluding those with certain medical conditions or who are pregnant or breastfeeding.",
    "This phase 2 trial is testing the efficacy of multiple drugs, including tiotropium inhalation powder, in treating chronic obstructive pulmonary disease (COPD) in patients who meet specific inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for advanced mesothelioma of the pleura, testing the efficacy of pemetrexed disodium, gemcitabine hydrochloride, and carboplatin, with eligibility criteria including measurable disease, ECOG Performance Status of 0 or 1, and normal organ and marrow function.",
    "This phase 2 trial is testing the efficacy of the epoch regimen, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, and vincristine sulfate drugs in treating primary mediastinal (thymic) large B-cell lymphoma, with specific eligibility criteria for patients including ECOG performance status, ANC, platelet count, and prior therapy.",
    "This sample is a phase 2 trial for multiple myeloma and plasma cell neoplasm using dexamethasone acetate as a drug, with eligibility criteria including measurable disease, ECOG performance status 0, and no active myeloma or primary amyloidosis requiring chemotherapy or any agents that may interact with anakinra.",
    "The sample is a phase 2 trial testing the drug ci-1040 on patients with metastatic or inoperable non-small cell lung, breast, or colon cancer or duct cell carcinoma of the exocrine pancreas, with specific eligibility criteria for patients, including no brain metastases and certain hematopoietic, hepatic, and renal levels, as well as restrictions on prior concurrent therapy.",
    "This is a phase 2 trial for female subjects with primary intraductal or lobular invasive breast cancer, using the drug bn83495, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of pemetrexed and gemcitabine in treating squamous cell cancer of the head and neck, with specific eligibility criteria including prior treatment and organ function requirements.",
    "The sample is a phase 2 trial for metastatic pancreatic cancer using gemcitabine as a drug, with eligibility criteria including confirmed pancreatic adenocarcinoma, measurable or non-measurable disease with elevated CA19-9 level, and adequate hematologic, hepatic, and renal function.",
    "This is a phase 2 trial for breast cancer patients with ER-negative tumors, using epirubicin as the drug, and evaluating biological markers such as topo II alpha gene and protein, HER-2 gene, p-53 gene, and oligonucleotides microarrays. The eligibility criteria include age less than 70 years, tumor size 2 cm at ultrasound examination, normal CBC, hepatic and renal functions, and negative pregnancy test for all women of childbearing potential. The exclusion criteria include metastatic breast cancer, serious medical conditions, and previous treatment with anthracyclines for breast cancer.",
    "The sample is a phase 2 trial for irritable bowel syndrome, testing the efficacy of tc-6499 and placebo drugs on male and female subjects with specific age and BMI criteria, and with ICD-10 codes K58.2, K58.8, K58.0, K58.1, K58.9.",
    "This phase 2 trial is testing the efficacy of sorafenib and bevacizumab in treating metastatic breast cancer, with eligibility criteria including prior trastuzumab therapy for Her-2 positive patients and exclusion criteria including prior therapy with VEGF inhibitors and history of cerebrovascular disease or deep venous thrombosis.",
    "The sample is a phase 2 trial for atopic dermatitis, testing the drugs sun13834 and placebo, with inclusion criteria including a diagnosis of AD and exclusion criteria including recent use of systemic immunosuppressive drugs or biologicals.",
    "The sample is a phase 2 trial for prostate cancer using the drug alvocidib, with eligibility criteria including specific patient characteristics and prior concurrent therapy restrictions.",
    "The sample is a phase 2/phase 3 trial for patients with relapsed ovarian, fallopian tube or primary peritoneal cancer, testing the efficacy of paclitaxel and saracatinib compared to a matched placebo, with eligibility criteria including prior chemotherapy and adequate haematological and biochemical function.",
    "The sample is a phase 2 trial for Alzheimer's disease, testing the efficacy of SB-742457 and donepezil as drugs, with inclusion criteria including a clinical diagnosis of Alzheimer's disease and a history of ongoing donepezil therapy, and exclusion criteria including a diagnosis of vascular dementia and hypersensitivity to sunlight.",
    "This phase 2 trial is testing the efficacy of bevacizumab and platinum-based chemotherapy in treating squamous non-small cell lung cancer patients who are suitable for platinum-based treatment as first line chemotherapy.",
    "The sample is a phase 2/phase 3 trial for hematological malignancies, testing the efficacy of darbepoetin alpha and iron saccharate in patients who have undergone PBSC transplantation, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of revamilast and placebo in treating asthma, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for premenopausal women with locally advanced or metastatic breast cancer, testing the efficacy of anastrozole and goserelin, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of rhnrg-1 doses 1 and 2 compared to placebo in treating chronic heart failure patients with NYHA classification of II or III, who have a stable regimen of ACEI/ARB and/or beta-blocker, and have an LVEF of < 35%, while also meeting other inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of sorafenib tosylate in treating patients with unresectable or metastatic melanoma, with specific eligibility criteria including measurable disease, certain laboratory values, and no prior treatment with certain drugs.",
    "This phase 2 trial is testing the efficacy of etravirine and optimized background regimen in HIV-1 infected patients with certain eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of paclitaxel and carboplatin in treating ovarian cancer, peritoneal neoplasms, and fallopian tube neoplasms, with eligibility criteria including positive EGFR expression and a Karnofsky Performance Status of \u2265 70%.",
    "This phase 2 trial is testing the efficacy of ly2541546 and placebo in postmenopausal women with low bone mineral density due to osteoporosis, with specific inclusion and exclusion criteria for eligibility.",
    "This is a phase 2 clinical trial for Alzheimer's disease using the drug sam-531, with inclusion criteria including a diagnosis of probable Alzheimer's disease and age between 50 and 90, and exclusion criteria including significant neurological disease other than Alzheimer's disease and current diagnosis of major depressive disorder or other major psychiatric symptom.",
    "This phase 2 trial is testing the efficacy of ziprasidone and placebo in treating major depressive disorder, with strict inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of pemetrexed, cetuximab, and cisplatin in treating recurrent or metastatic squamous cell carcinoma of head and neck, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 clinical trial testing the efficacy of vintafolide and ertafolide in treating advanced epithelial ovarian cancer and endometrial cancer, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the effectiveness of trastuzumab, a drug used to treat breast cancer in patients with confirmed non-metastatic infiltrating carcinoma of the breast and HER-2 amplified determination, with eligibility criteria including normal LVEF, adequate bone marrow, renal and liver function, and signed informed consent.",
    "This phase 2 trial is testing the efficacy of tarceva, paclitaxel, and carboplatin in treating stage IIIA and IIIB non-small cell lung cancer patients with measurable disease and a Zubrod performance status of 0 or 1, while excluding those with N3 disease or prior chemotherapy or radiation for NSCLC.",
    "This phase 2 trial is testing the efficacy of irinotecan, cisplatin, and celecoxib in treating unresectable or metastatic esophageal cancer, with eligibility criteria including measurable disease, adequate renal and hepatic function, and a Zubrod performance status of 0-2.",
    "This phase 2 trial is testing the efficacy of CK-2017357 and riluzole in treating amyotrophic lateral sclerosis (ALS) patients who meet specific inclusion criteria, including having a grip strength between 10-60 pounds and an upright slow vital capacity >50% of predicted, while excluding those with a life expectancy <3 months or prior treatment with CK-2017357.",
    "The sample is a phase 2 trial for non-small cell lung cancer testing the efficacy of enzastaurin, placebo, and pemetrexed, with inclusion criteria including confirmed diagnosis of NSCLC and disease progression after 1 prior systemic cytotoxic chemotherapy regimen, and exclusion criteria including previous treatment with enzastaurin or pemetrexed and concurrent administration of any other antitumor therapy.",
    "This phase 2 trial is testing the efficacy of panitumumab, oxaliplatin, and gemcitabine in treating metastatic or unresectable Kras and Braf wild-type biliary tract adenocarcinoma, with strict eligibility criteria including no prior chemotherapy for biliary tract or gallbladder cancer and normal organ and marrow function.",
    "The sample is a phase 2 clinical trial for patients with esophageal cancer, testing the efficacy of oncogel (paclitaxel gel), cisplatin, and 5-fu in combination with chemoradiation therapy and esophagectomy, with eligibility criteria including histologically or cytologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus, medically able to tolerate major abdominal and/or thoracic surgery, and Karnofsky Performance Status of \u2265 60.",
    "This phase 2 trial is testing the efficacy of canagliflozin, sitagliptin, and placebo in treating type 2 diabetes mellitus in patients with specific eligibility criteria, including stable daily dose of metformin and BMI between 25 to 45 kg/m2, and excluding patients with prior exposure or known contraindication to canagliflozin or sitagliptin, history of diabetic ketoacidosis or type 1 diabetes mellitus, and history of active proliferative diabetic retinopathy.",
    "This phase 2 trial is testing the efficacy of sep-225289, venlafaxine, and placebo in treating major depressive disorder, with specific inclusion and exclusion criteria for subjects.",
    "The sample is a phase 2 trial for dry eye disease, testing ecabet ophthalmic solution and placebo, with inclusion criteria of being diagnosed with dry eye disease and exclusion criteria of having dry eye disease secondary to surgery.",
    "The sample is a phase 2 trial for type 2 diabetes using the drug lixisenatide, with inclusion criteria of age 30-75, BMI 25-40 kg/m2, HbA1C \u22657.0% and <9.0%, and exclusion criteria of type 1 diabetes, pregnancy, lactation, and treatment with other antidiabetic agents than metformin.",
    "The sample is a phase 2 trial for opioid-induced constipation, testing the efficacy of placebo and two doses of adl5945, with eligibility criteria including stable daily dose of opioids, history of OIC, and exclusion criteria including recent history of myocardial infarction, taking methadone as a maintenance medication, and taking any \u03bc-opioid receptors antagonist.",
    "This phase 2 trial aims to test the efficacy of tosedostat, cytarabine, and decitabine in treating untreated acute myeloid leukemia and high-risk myelodysplastic syndromes in adults, with specific eligibility criteria including age, performance status, and laboratory values.",
    "This phase 2 trial is testing the efficacy of letrozole, an aromatase inhibitor, in postmenopausal women with advanced or recurrent endometrial cancer who are ER and/or PgR positive and have measurable disease, with specific eligibility criteria including age, histology, and adequate organ function.",
    "This is a phase 2 trial for colorectal neoplasms testing the efficacy of bevacizumab, folfiri, ag-013736, and folfox, with eligibility criteria including prior treatment failure and exclusion criteria including prior irradiation of more than 25% of bone marrow.",
    "The sample is a phase 2 trial for gastroesophageal reflux disease, testing the efficacy of spd557 and placebo drugs on subjects with a history of GERD symptoms and a stable dose of PPIs, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2/phase 3 trial for locally advanced head and neck cancer, testing the efficacy of docetaxel, cisplatin, 5-fluorouracil (5-fu), radiotherapy and cisplatin, 5-fluorouracil (5-fu), radiotherapy, with eligibility criteria including good hematologic, hepatologic, and renal function, and exclusion criteria including previous treatment for the disease and symptomatic peripheral neuropathy.",
    "The sample is a phase 2/phase 3 trial for patients with metastatic, recurrent or persistent squamous cell carcinoma of the head and neck region, testing the efficacy of erlotinib, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of dasatinib, a drug, in treating patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, who have had one prior platinum-based chemotherapeutic regimen, and meet specific eligibility criteria.",
    "This phase 2 trial aims to treat patients with hematologic malignancies using cyclophosphamide, tacrolimus, and mycophenolate mofetil, and requires patients to meet specific eligibility criteria including having two related donors and adequate organ function.",
    "The sample is a phase 2 trial for patients with mycosis fungoides, testing the drug mechlorethamine-mch (nitrogen mustard) and requiring confirmed diagnosis, prior treatment with certain therapies, normal lab values, and willingness to give consent, while excluding patients with certain medical histories or concurrent illnesses, and those who have had radiation therapy within one year of study start.",
    "This phase 2 trial is testing the drug perifosine for patients with relapsed or refractory Waldenstrom's macroglobulinemia, with specific inclusion and exclusion criteria listed in the eligibility criteria section.",
    "The sample is a phase 2 trial for mesothelioma, testing the effectiveness of vinorelbine and vandetanib, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of oc000459 and placebo in treating grass pollen related allergic rhinitis in males aged 18 to 50 years with a positive cutaneous response to mixed grass pollen, while excluding those with medical conditions likely to affect the outcome of the study, nasal conditions likely to affect the outcome of the study, presence of any respiratory disease other than a history of mild stable asthma not requiring treatment and associated with normal lung function, and immunotherapy treatment course including inhaled or local corticosteroids in the past 28 days.",
    "This phase 2 trial is testing the efficacy of docetaxel and prednisone in treating hormone-resistant prostate cancer, with specific eligibility criteria including metastatic disease, castrate-resistant disease, and progressive disease while receiving androgen deprivation treatment.",
    "This phase 2 trial is testing the efficacy of biib014 and placebo in treating idiopathic Parkinson's Disease, with specific inclusion and exclusion criteria for subjects.",
    "This phase 2 trial is testing the efficacy of azacitidine and decitabine in treating myelodysplastic syndromes and thrombocytopenia, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial will test the efficacy of BOL-303259-X and timolol maleate in reducing intraocular pressure in patients with ocular hypertension and open angle glaucoma who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of ramelteon and placebo in treating chronic insomnia in patients with Alzheimer's disease, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for major depressive disorder, testing the efficacy of prx-00023 and placebo, with eligibility criteria including exclusion of pregnant or nursing females, recent electroconvulsive therapy, and certain medical conditions.",
    "This phase 2 trial is testing the efficacy of pazopanib, carboplatin, and paclitaxel in treating advanced gynecological malignancies, with eligibility criteria including histological confirmation of specific cancers, ECOG 0-1 performance status, and adequate organ function.",
    "The sample is a phase 2 clinical trial for Alzheimer's disease, testing the efficacy of t-817ma and placebo drugs, with inclusion criteria including patients receiving Donepezil and exclusion criteria including patients with clinically significant cardiac, hepatic or renal impairment and those taking other Alzheimer's drugs within 12 weeks of the baseline visit.",
    "The sample is a phase 2 trial for asthmatic patients with reversible airway obstruction, testing the efficacy of azd3199 and formoterol compared to placebo, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of Comtan\u00ae, Nebicapone, Levodopa/DDCI, and placebo in treating Parkinson's disease patients who have end-of-dose \"wearing-off\" phenomenon, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for patients with metastatic gastric or esophageal adenocarcinoma, testing the drug Jevtana, with specific eligibility criteria including prior chemotherapy and measurable disease, and exclusion criteria such as severe hypersensitivity reaction to Cabazitaxel or other drugs formulated with polysorbate 80.",
    "This phase 2 trial is testing the efficacy of zileuton and placebo in treating asthma in patients aged 12 and older, with specific inclusion and exclusion criteria, and a list of prohibited medications.",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus, testing the efficacy of ta-7284-low, ta-7284-low-middle, ta-7284-high-middle, ta-7284-high, and placebo drugs, with inclusion and exclusion criteria based on age, HbA1c levels, blood glucose, eGFR, blood pressure, medical history, and other factors.",
    "The sample is a phase 2 trial for patients with non-Hodgkin's lymphoma and cancer, testing the efficacy of a combination of drugs including vincristine, vp-16, rituximab, dexamethasone, and levofloxacin, with eligibility criteria including previous chemotherapy regimens and adequate bone marrow, hepatic, and renal function.",
    "The sample is a phase 2 trial for squamous cell cancer and cancer of head and neck, using the drugs gefitinib, cisplatin, and 5-fluorouracil, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with mycosis fungoides/S\u00e9zary syndrome who have failed prior topical treatments, using lenalidomide as the drug, with eligibility criteria including measurable disease and specific patient characteristics.",
    "This phase 2 trial is testing the drug lenalidomide on previously untreated patients with follicular lymphoma, with specific eligibility criteria including disease stage, risk factors, and HIV status.",
    "This phase 2 trial is testing the efficacy of erlotinib and avastin in treating metastatic or advanced inoperable esophageal neoplasms and diseases, with specific eligibility criteria including prior chemotherapy treatment, measurable disease, and adequate hepatic and renal function.",
    "The sample is a phase 2 trial for Alzheimer's disease, testing the efficacy of elnd005 compared to placebo control, with inclusion criteria including diagnosis of probable AD, age 50-85, MMSE score of 16-26, and stable doses of medications, and exclusion criteria including significant neurological disease, major psychiatric disorder, and history of stroke or seizure.",
    "This phase 2 trial is testing the efficacy of bevacizumab, a drug used to treat cancer, in combination with other treatments for patients with stage III-IVB head and neck cancer, with specific eligibility criteria including no prior chemotherapy or radiotherapy for head and neck cancer, and ECOG performance status 0-1.",
    "This phase 2 trial is testing the efficacy of mifepristone in treating recurrent or refractory ovarian, primary peritoneal, or fallopian tube carcinoma in patients who have previously received platinum-based chemotherapy, and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of bortezomib, cyclophosphamide, prednisone, and vincristine sulfate in treating stage III or IV follicular non-Hodgkin's lymphoma patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for respiratory syncytial virus infections, testing the drugs gs-5806 and placebo, with inclusion criteria of healthy individuals aged 18-45 and exclusion criteria of medical illness, HIV/Hepatitis B or C positivity, nose/nasopharynx abnormalities, and abnormal lung function.",
    "The sample is a phase 2 trial for attention deficit disorder with hyperactivity, testing the effectiveness of atomoxetine and buspirone, with inclusion criteria being adults with ADHD and exclusion criteria being other Axis I Psychiatric Disorders.",
    "This phase 2 trial is testing the efficacy of bezafibrate + diflunisal and bezafibrate + placebo in treating type 2 diabetes patients with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of jnj-37822681 and olanzapine, along with placebo, in treating acute exacerbation of schizophrenia in patients who have been diagnosed with the disease for at least a year, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of AZD1656, glipizide, and placebo in treating type II diabetes mellitus in patients who have been treated with metformin for at least 10 weeks, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of docetaxel and capecitabine in treating advanced, inoperable gastric adenocarcinoma with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the drug xl147 (sar245408) on patients with advanced or recurrent endometrial cancer who have received one platinum based chemotherapy regimen and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of temsirolimus in treating advanced renal cell carcinoma in Japanese, Chinese, or Korean patients who have not received prior systemic RCC treatment, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug su011248 in patients with von Hippel-Lindau syndrome, renal cell carcinoma, and hemangioblastoma, who have at least one measurable lesion and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of a wt1 peptide vaccine for patients with various types of leukemia and myelodysplastic syndrome who are unsuitable for stem cell transplantation and are HLA-A0201 positive.",
    "The sample is a phase 2 trial for gastroesophageal reflux disease, testing the drug azd3355 and placebo, with eligibility criteria including history of GERD and persistent symptoms despite treatment with PPI.",
    "This phase 2 trial is testing the efficacy of cisplatin and gemcitabine hydrochloride in treating locally resectable adenocarcinoma of the pancreatic head, with specific eligibility criteria for patients.",
    "This phase 2 trial is testing the efficacy of maraviroc and its placebo in treating active rheumatoid arthritis in patients who have been receiving methotrexate for at least 12 weeks, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of atrasentan, a drug used to treat diabetic nephropathy, in patients with chronic kidney disease and Type 2 diabetes who are currently receiving an angiotensin converting enzyme inhibitor or Angiotensin II receptor blocker, and meet specific laboratory value criteria.",
    "This phase 2 trial is testing the efficacy of sb-705498, fp, and placebo in treating rhinitis, with eligibility criteria including a positive skin prick test for seasonal pollen and a TNSS score of >=4 following screening allergen challenge chamber.",
    "This phase 2 trial is testing the efficacy of anastrozole and gefitinib in treating metastatic or locally advanced unresectable breast cancer patients who have progressive disease after more than 2 months of aromatase inhibitor therapy, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of capecitabine and imatinib mesylate in treating metastatic breast cancer in patients who meet specific eligibility criteria, including having hormone-sensitive tumors and no clinical evidence of brain or CNS disease.",
    "This phase 2 trial is testing the efficacy of dasatinib, melphalan, and prednisone in treating relapsed or refractory myeloma patients who have previously received Thalidomide or Lenalidomide and Bortezomib, and have measurable disease, with eligibility criteria including age, performance status, and laboratory values.",
    "This is a phase 2 trial for patients with unresectable stage III or IV non-small cell lung cancer, testing the efficacy of gemcitabine, docetaxel, and cetuximab, with specific eligibility criteria including confirmation of biopsy, measurable disease, and no prior chemotherapy for lung cancer.",
    "This phase 2 trial aims to test the efficacy of sertraline, placebo, and gabapentin in treating cocaine dependence and depressive symptoms in subjects who meet specific inclusion criteria, while excluding those with certain medical conditions or drug dependencies.",
    "The sample is a phase 2 trial for previously untreated chronic lymphocytic leukemia patients under 70 years old, using a combination of cyclophosphamide, fludarabine, alemtuzumab, and rituximab, with specific eligibility criteria including disease stage, performance status, and organ function.",
    "This is a phase 2 clinical trial for metastatic prostate cancer patients with eligibility criteria including chemotherapy-naive patients, adequate hematologic, hepatic and renal function, and a KPS score of >70%, and the drug being tested is docetaxel.",
    "This phase 2 trial is testing the efficacy of bevacizumab and erlotinib in treating relapsed ovarian neoplasms, with eligibility criteria including prior platinum-based therapy and adequate hepatic and renal function.",
    "This phase 2 trial is testing the efficacy of gemcitabine, carboplatin, and sorafenib in treating unresectable, locally advanced or metastatic bladder cancer, with eligibility criteria including histologic documentation of diagnosis, adequate bone marrow, liver and renal function, and negative serum pregnancy test.",
    "This phase 2 trial is testing the efficacy of vinorelbine, gemcitabine, and cisplatin in combination with high dose palliative radiation therapy for patients with non-small cell lung carcinoma who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for bronchiolitis using fluticasone propionate as the drug, with inclusion criteria including patients over 18 years of age who have new onset airflow obstruction and exclusion criteria including active pulmonary infection and known hypersensitivity to corticosteroids.",
    "The sample is a phase 2 trial for metastatic breast cancer using perillyl alcohol as a drug, with eligibility criteria including confirmed metastatic breast cancer, failed or recurrent hormonal therapy, and specific hematopoietic and hepatic levels, among others.",
    "This phase 2 trial aims to evaluate the efficacy of beclomethasone dipropionate, methotrexate, and tacrolimus in preventing acute graft-versus-host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) for various hematopoietic/lymphoid cancers, myelodysplastic syndromes, and lymphomas. The sample includes patients who meet specific inclusion criteria, such as having an HLA-matched or single-allele or antigen mismatched related or unrelated donor and using myeloablative pre-transplant conditioning regimen with > 800 cGy total body irradiation and cyclophosphamide or high-dose busulfan and cyclophosphamide.",
    "This phase 2 trial is testing the drug fosbretabulin disodium for patients with anaplastic or poorly differentiated variant thyroid cancer who have relapsed or progressed during or after prior combined modality therapy, and have measurable or evaluable disease, with specific eligibility criteria for patient characteristics and prior concurrent therapy.",
    "The sample is a phase 2 trial for lung cancer patients with specific disease characteristics and patient characteristics, testing the effectiveness of cisplatin and gemcitabine hydrochloride as treatment options.",
    "The sample is a phase 2 trial for rheumatoid arthritis using the drug vx-702, with inclusion criteria of adult patients taking MTX for at least 6 months and exclusion criteria of planned major surgery or recent corticosteroid injections.",
    "This phase 2 trial will test the efficacy of mdco-2010, a drug, versus placebo in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass, and the eligibility criteria includes age, weight, medical history, and preoperative laboratory values.",
    "This trial is a phase 2/phase 3 study testing the efficacy of various doses and combinations of valsartan and amlodipine in treating essential hypertension, with strict inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of bortezomib, melphalan, and prednisone in treating multiple myeloma patients who have not received prior therapy and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of rituximab and velcade in treating patients with relapsed or non-responsive indolent non-follicular and mantle cell non-Hodgkin's lymphoma, with specific eligibility criteria including prior chemotherapy and measurable disease.",
    "This is a phase 2 trial for metastatic, progressive hormone refractory prostate cancer, testing the drugs cp-751,871, docetaxel, and prednisone, with inclusion criteria of adequate bone marrow, liver and kidney function, and exclusion criteria of previous chemotherapy treatment.",
    "This phase 2 trial is testing the drug pomalidomide for patients with relapsed or resistant multiple myeloma who have high-risk disease, and have received prior therapy with lenalidomide-containing regimen and have been determined to be refractory, resistant, or relapsed.",
    "This phase 2 trial is testing the effectiveness of ldv/sof and rbv drugs in treating chronic hepatitis C virus in patients who meet specific eligibility criteria, including age, HCV RNA levels, and liver biopsy results.",
    "This phase 2 trial is testing the efficacy of cinaciguat and placebo in treating acute heart failure in subjects who have been diagnosed with CHF and have experienced worsening of dyspnea and clinical evidence of volume overload leading to hospitalization, with inclusion criteria including age, gender, and prior diagnosis of CHF.",
    "The sample is a phase 2 trial for acute heart failure, testing the drugs rlx030 and placebo, with inclusion criteria including hospitalization for acute heart failure and exclusion criteria including systolic blood pressure below 115 mmHg and treatment with mechanical support, and the trial will use icd-10 codes to identify patients with acute heart failure.",
    "The sample is a phase 2 trial for irritable bowel syndrome, testing the efficacy of 250 mg lx1033 tablets and placebo tablets, with inclusion criteria including IBS-D symptoms and weekly average of worst abdominal pain, and exclusion criteria including concomitant use of opioid analgesic drugs or drugs that affect bowel motility.",
    "This phase 2 trial is testing the efficacy of docetaxel and capecitabine in treating patients with adenocarcinoma of the stomach or GE-junction with distant metastases or locally advanced disease, who have not received prior palliative chemotherapy and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of gliadel/avastin/cpt-11 in treating patients with malignant glioma, glioblastoma multiforme, or gliosarcoma, with specific eligibility criteria including age, disease progression, and laboratory values.",
    "This phase 2 trial is testing the efficacy of pivanex and docetaxel in treating non-small cell lung cancer patients who have received one prior platinum-based chemotherapy regimen, with specific eligibility criteria including adequate organ function and predicted life expectancy of at least 12 weeks.",
    "This phase 2 trial will test the efficacy of lapatinib oral tablets and paclitaxel infusion in treating ER+ and/or PR+ metastatic breast cancer with documented amplification of ErbB2, and requires eligible female subjects to have a life expectancy of at least 3 months and adequate organ function.",
    "This phase 2 trial is testing the efficacy of fulvestrant, anastrozole, bevacizumab, and best supportive care in postmenopausal women with non-small cell lung cancer who have responded to induction chemotherapy, and have met other eligibility criteria.",
    "This phase 2 trial will test the efficacy of decadron\u00ae, benadryl\u00ae, ativan\u00ae, and ondansetron hydrochloride in preventing nausea and vomiting in children aged 8-19 who are newly diagnosed with cancer and scheduled to receive moderately or highly emetogenic chemotherapy, and meet other eligibility criteria.",
    "This phase 2 trial is testing the drug vorinostat on patients with metastatic prostate cancer that has progressed despite prior chemotherapy and androgen deprivation therapy, with eligibility criteria including a minimum PSA level, normal organ function, and willingness to provide blood samples for correlative studies.",
    "The sample is a phase 2 trial for patients with non-small cell lung cancer, testing the efficacy of cisplatin and pemetrexed disodium as chemotherapy drugs, with eligibility criteria including specific disease characteristics and patient characteristics, and excluding prior or concurrent treatments.",
    "This phase 2 trial is testing the efficacy of different concentrations of OPC-12759 and placebo in treating moderate to severe dry eye syndrome, with specific inclusion and exclusion criteria for patients.",
    "This phase 2 trial is testing the efficacy of rosiglitazone xr and placebo in treating Alzheimer's disease in post-menopausal females with a permanent caregiver, who meet specific inclusion criteria and do not have certain exclusion criteria.",
    "The sample is a phase 2 trial for advanced and metastatic breast cancer patients, testing the drug fulvestrant, with eligibility criteria including previous treatment with anti-estrogen hormonal treatment and requiring hormonal treatment, and exclusion criteria including previous treatment with multiple regimens of systemic anticancer therapy or endocrine therapy, and an existing condition that prevents compliance.",
    "The sample is a phase 2 trial for patients with follicular lymphoma grade 1 or 2, testing the effectiveness of rituximab, with specific inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for ovarian cancer, fallopian tube neoplasms, and peritoneal neoplasm, testing the efficacy of enzastaurin, carboplatin, paclitaxel, and placebo, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial testing the efficacy of sublingual methadone for cancer and pain patients who are able to hold a volume of 1.0cc of water under tongue for a 2-minute period, with exclusion criteria including severe respiratory disease and prior sensitivity to methadone.",
    "This phase 2 trial is testing the efficacy of azilsartan and candesartan cilexetil in treating mild to moderate essential hypertension, with inclusion criteria based on blood pressure levels and exclusion criteria including cardiovascular disease and recent use of multiple antihypertensives.",
    "This phase 2 trial is testing the efficacy of atacicept, a drug, in treating rheumatoid arthritis in patients who have been on methotrexate for at least 3 months and have active disease, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of m118 and unfractionated heparin in patients with stable coronary artery disease (CAD) who are undergoing planned single vessel intervention, with specific inclusion and exclusion criteria, and includes a substudy for blood specimens.",
    "This phase 2 trial is testing the efficacy of oxaliplatin in treating high-risk squamous cell carcinoma of the head and neck region, with specific inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial is testing the effectiveness of Polyphenon E, a drug made from green tea extract, in treating multiple sclerosis patients who meet specific eligibility criteria, including having a diagnosis of MS by McDonald criteria, stable therapy with certain drugs, and normal organ and marrow function.",
    "This phase 2 trial is testing the drug amifostine trihydrate on patients aged 1-21 with myelodysplastic syndromes, with specific disease characteristics and patient characteristics required for eligibility.",
    "The sample is a phase 2 trial for small cell lung cancer, testing the efficacy of bevacizumab, chemotherapy, and placebo, with eligibility criteria including histologically or cytologically documented small cell carcinoma of the bronchus, measurable disease or lesions, and Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.",
    "The sample is a phase 2 trial for mantle cell lymphoma using carmustine, cytarabine, etoposide, and melphalan as drugs, with eligibility criteria including achieving partial remission, HLA-matched donor availability, and specific patient characteristics.",
    "The sample is a phase 2 trial for metastatic breast cancer patients with available tissue block, who have received prior chemotherapy with anthracycline or taxane, and are eligible for dasatinib treatment.",
    "This phase 2 trial is testing the drug dacogen on patients with chronic myeloproliferative disorders and secondary myelofibrosis, who meet specific eligibility criteria including having an ECOG performance status of 0-3, ANC \u2265 1,000/mm\u00b3, and platelet count \u2265 50,000/mm\u00b3.",
    "This phase 2 clinical trial is testing the efficacy of lixisenatide, liraglutide, insulin glargine, and metformin in treating type 2 diabetes mellitus with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the use of argatroban and heparin in patients with stable coronary artery disease or unstable angina who require percutaneous coronary angioplasty or stent insertion, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for Parkinson's disease testing the drugs placebo and tozadenant, with inclusion criteria including a diagnosis of Parkinson's disease, stable anti-parkinsons treatment, and age between 40 to 75 years.",
    "This is a phase 2 trial for head and neck cancer using cisplatin as the drug, with eligibility criteria including histologically confirmed high-risk/limited stage III or IV squamous cell carcinoma and no distant metastases.",
    "This phase 2 trial is testing the combination of PCI-27483 and gemcitabine for the treatment of metastatic and locally advanced ductal adenocarcinoma of the pancreas, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of abt-894 and atomoxetine compared to placebo in treating attention-deficit/hyperactivity disorder, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for prostate cancer using polyphenon e (egcg) as the drug, with inclusion criteria such as recent biopsy positive for prostate cancer and scheduled for prostatectomy, and exclusion criteria such as abnormal liver function and prior hormonal or surgical therapy for prostate cancer.",
    "The sample is a phase 2 trial for colorectal neoplasms using bevacizumab, oxaliplatin, capecitabine, and irinotecan as drugs, with inclusion criteria of pathological diagnosis of colon or rectal cancer and adequate organ function, and exclusion criteria of anal cancer, previous treatments, pregnancy or lactation, and history of chronic disease(s) or other serious medical conditions.",
    "This phase 2 trial is testing the drug plx3397 on patients with relapsed or refractory classical Hodgkin lymphoma who have progressed after or been ineligible for autologous stem cell transplantation, and have measurable disease, with eligibility criteria including age, pathology confirmation, and adequate hematologic, hepatic, and renal function.",
    "This phase 2 trial is testing the efficacy of avastin and capecitabine in treating rectal cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for patients with stable coronary artery disease, testing the efficacy of cangrelor and prasugrel, with eligibility criteria including age and previous myocardial infarction or revascularization, and treatment with aspirin.",
    "This is a phase 2 trial testing the efficacy of GSK256066 and placebo in male and female adults with moderate COPD, with inclusion criteria including a cigarette smoking history of \u2265 10 pack years and a post-bronchodilator FEV1 to FVC ratio (FEV1/FVC) < 0.7, and exclusion criteria including a current diagnosis of asthma and treatment with inhaled corticosteroids or other specified medications.",
    "This phase 2 trial is testing chemotherapy and porfimer sodium in patients with non-small cell lung cancer with pleural spread who have received 2-4 courses of front-line chemotherapy, and are medically fit for surgery, with no prior treatment for NSCLC except pleurodesis or standard front-line chemotherapy, and no concurrent chemotherapy or radiotherapy during the active study treatment period.",
    "This phase 2 trial is testing the efficacy of a drug called aqw051 and placebo in treating schizophrenia, with specific eligibility criteria including stable symptomatology and treatment with certain antipsychotics.",
    "This phase 2 trial is testing the efficacy of vinorelbine, capecitabine, and trastuzumab in treating HER2 positive breast cancer with specific eligibility criteria, including previous treatment with trastuzumab and taxanes, measurable or non-measurable disease, and a life expectancy of at least 12 weeks.",
    "The sample is a phase 2 trial for lower urinary tract symptoms, using tamsulosin as the drug, with inclusion criteria for men 18 years and older who can speak, read and understand English, and exclusion criteria for those employed in certain healthcare-related fields.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease (COPD) with the drugs being tested being mk633 and a placebo, and the eligibility criteria including documented COPD and age range of 40-75 years.",
    "This phase 2 trial is testing the effectiveness of imatinib mesylate in treating gastrointestinal stromal tumors, with inclusion criteria including age between 18 and 80 years and a diagnosis of GIST not previously treated, and exclusion criteria including presence of metastatic disease and use of other antineoplastic treatment.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide, doxorubicin hydrochloride, prednisone, and vincristine sulfate in treating patients with diffuse large B-cell lymphoma who meet specific eligibility criteria, including measurable disease and Eastern Cooperative Oncology Group performance status of 0-3.",
    "This phase 2 trial is testing the combination of azacitidine and entinostat in patients with various types of myeloid malignancies, including myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia with multilineage dysplasia, who have not received prior treatment with azacitidine, decitabine, or entinostat.",
    "The sample is a phase 2 trial for patients with non-small cell lung cancer, testing the efficacy of erlotinib, sunitinib, and placebo, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of temozolomide and radiotherapy in treating non-small cell lung cancer brain metastasis, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for chronic Genotype 1 Hepatitis C infection, with a list of comparator drugs including vaniprevir, pegylated-interferon, ribavirin, and placebo, and eligibility criteria including exclusion of previous HCV treatment and clinically significant medical conditions.",
    "This phase 2 trial is testing the efficacy of metformin and DPP-4 inhibitor monotherapy or combination therapy in male or female patients with type 2 diabetes mellitus who meet specific eligibility criteria, using met dr, met xr, or placebo as drugs.",
    "The sample is a phase 2 trial for cervical cancer and cervical intraepithelial neoplasia grade 1 patients with HPV positivity, testing the efficacy of placebo as a treatment, with a list of eligibility criteria including medical history, physical condition, and lifestyle habits.",
    "This phase 2 trial is testing the efficacy of ct327 0.05%, ct327 0.1%, ct327 0.5%, and placebo in treating stable psoriasis vulgaris in male and female subjects aged at least 18 years, with exclusion criteria for guttate, erythrodermic, exfoliative or pustular psoriasis.",
    "The sample is a phase 2 trial for rheumatoid arthritis, testing the efficacy of methotrexate, rituximab, corticosteroids, and placebo, with eligibility criteria including a diagnosis of rheumatoid arthritis for at least 6 months and failure of treatment with at least 1 but no more than 5 disease-modifying anti-rheumatic drugs or biologics (other than methotrexate).",
    "This phase 2 trial is testing the efficacy of doxorubicin, rituxan, cyclophosphamide, vincristine and prednisone in treating Non-Hodgkin's lymphoma of B-cell origin, with specific eligibility criteria including measurable or evaluable tumor parameters, age greater than 17 years old, and Karnofsky performance status greater or equal to 50%.",
    "This phase 2 trial is testing the efficacy of thalidomide, lenalidomide, and rituximab in treating Waldenstrom macroglobulinemia, with eligibility criteria including confirmed diagnosis, prior systemic therapy, and measurable disease.",
    "The sample is a phase 2 trial for non-alcoholic steatohepatitis, testing the drugs asp9831 and placebo, with inclusion criteria of histologically confirmed NASH and elevated serum ALT levels, and exclusion criteria including hepatic cirrhosis, uncontrolled diabetes mellitus type 2, and recent use of drugs associated with steatohepatitis.",
    "The sample is a phase 2 trial for hand-foot skin reaction and rash, with a list of drugs including urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, and bland emollient cream, and eligibility criteria including exclusion of patients with pre-existing dermatological conditions affecting the hands or feet.",
    "This phase 2 trial is testing the efficacy of GSK232802, premarin, and placebo in reducing moderate to severe hot flashes in postmenopausal women with a minimum average frequency of seven daily hot flashes, who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of NBI-98854 and placebo in treating tardive dyskinesia in patients with schizophrenia or schizoaffective disorder, with inclusion and exclusion criteria including stable medication use, negative drug and alcohol tests, and no previous exposure to NBI-98854.",
    "The sample is a phase 2 trial for patients with metastatic renal cell carcinoma, testing the drug foretinib (formerly gsk1363089 or xl880), with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the effectiveness of goserelin with dutasteride, bicalutamide, and ketoconazole in treating prostate cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of cisplatin, erlotinib, and gemcitabine in treating various types of bile duct and liver cancers, with specific eligibility criteria for patients, including adequate bone marrow and hepatic function, and exclusion criteria such as active infection or prior malignancy within the past 5 years.",
    "This phase 2 trial is testing the drug resminostat (4sc-201) on patients with relapsed or refractory Hodgkin's Lymphoma, who have measurable anatomical disease present on CT scan and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of decitabine and interferon alfa-2b in treating metastatic or unresectable clear cell renal carcinoma, with eligibility criteria including prior standard therapy and adequate organ function.",
    "This phase 2 trial is testing the drug imatinib on patients with metastatic ocular melanoma, with specific inclusion and exclusion criteria listed in the eligibility criteria section.",
    "This phase 2 trial is testing the efficacy of bevacizumab, oxaliplatin, and pemetrexed in treating non-small cell lung cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of jnj-40411813 and placebo in treating Major Depressive Disorder (MDD) with comorbid Generalized Anxiety Disorder, Social Anxiety Disorder, or Panic Disorder, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of ym155 and docetaxel in treating HER2-negative breast cancer patients who have not received prior chemotherapy, with inclusion criteria including hormone receptor status and Eastern Cooperative Oncology Group performance status, and exclusion criteria including hypersensitivity to docetaxel and neuropathy.",
    "The sample is a phase 2 trial for breast cancer patients who have undergone surgery and radiation therapy, and are treated with anastrozole and cyclophosphamide, with eligibility criteria including age, tumor characteristics, and menstrual history.",
    "The sample is a phase 2 trial for type 1 diabetes mellitus using the drug bi 10773, with inclusion criteria including HbA1C levels and insulin usage, and exclusion criteria including macroalbuminuria and use of certain medications.",
    "This phase 2 trial is testing the efficacy of anastrozole, exemestane, letrozole, and sorafenib tosylate in postmenopausal women with metastatic estrogen receptor- and/or progesterone receptor-positive breast cancer, who have measurable disease and have shown objective evidence of progression within the past 3 months, and meet a range of patient characteristics and prior concurrent therapy criteria.",
    "This is a phase 2 trial for patients with paranoid schizophrenia and schizophrenia, testing the efficacy of mk0557 and placebo, with inclusion and exclusion criteria related to patient stability, health, and medication history.",
    "The sample is a phase 2/phase 3 trial for patients with unresectable advanced gastric carcinoma and recurrent gastric carcinoma, testing the efficacy of tegafur/gimeracil/oteracil potassium (s-1), krestin (psk) and tegafur/gimeracil/oteracil potassium (s-1) drugs, with eligibility criteria including age, organ function, and performance status.",
    "This is a phase 2 trial for asthma patients testing the efficacy of MN-221 and placebo, with eligibility criteria including a diagnosis of asthma, non-use of inhaled corticosteroids for control within 1 month of study, and an increase in FEV1 of at least 12% and 200 cc over the pre-albuterol FEV1 within 30 minutes after inhalation of up to 4 puffs of albuterol via a metered dose inhaler.",
    "The sample is a phase 2 trial for ovarian hyperstimulation syndrome using norprolac as a drug, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of 0.5 mg ranibizumab, 3 mg pf-04523655, and 1 mg pf-04523655 in treating age-related macular degeneration, with specific inclusion and exclusion criteria for eligible participants.",
    "This phase 2 trial is testing the drug degarelix on patients with prostate cancer, who meet certain eligibility criteria, including having a serum testosterone level above 2.2 ng/mL and a serum PSA level above 2 ng/mL.",
    "This phase 2 trial is testing the efficacy of lenalidomide in treating chronic lymphocytic leukemia patients with specific risk factors, and includes detailed inclusion and exclusion criteria.",
    "This phase 2 trial aims to test the efficacy of ar-12286 ophthalmic solution 0.7%, ar-12286 ophthalmic solution 0.5%, and timolol maleate ophthalmic solution 0.5% in treating open-angle glaucoma and ocular hypertension, with strict inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of multiple drugs, including bortezomib and thalidomide, in treating Waldenstrom macroglobulinemia, with eligibility criteria including measurable disease and specific symptoms, and excluding patients with certain medical conditions or prior treatments.",
    "This phase 2 trial is testing the efficacy of cc-5103 (lenalidomide) and rituximab in treating Waldenstrom's macroglobulinemia, with specific eligibility criteria including measurable disease and prior cancer therapy cessation, while excluding patients with serious medical conditions or prior therapy with rituximab or CC-5103.",
    "This phase 2 trial is testing the drug tandutinib on patients with clear cell renal cell carcinoma, recurrent renal cell cancer, or stage IV renal cell cancer who have received at least one prior FDA approved therapy for metastatic renal cell carcinoma, and have measurable disease, with eligibility criteria including a life expectancy of >= 3 months, ECOG performance status of 0-1, and various laboratory values within normal limits.",
    "The sample is a phase 2 trial for chronic constipation, testing the efficacy of ati-7505, with inclusion criteria including constipation symptom onset and negative colonoscopy or air contrast barium enema, and exclusion criteria including transabdominal surgery and use of prohibited medications.",
    "The sample is a phase 2 trial for patients with neuralgia, testing the efficacy of agn201781 and placebo drugs, with inclusion criteria of moderate or severe pain associated with postherpetic or post-traumatic peripheral neuralgia.",
    "The sample is a phase 2/3 trial for prostate cancer using celecoxib as a drug, with specific inclusion and exclusion criteria, and the trial is looking for participants who are either fully active and asymptomatic or symptomatic but fully ambulatory.",
    "The sample is a phase 2 trial for patients over 18 years old with in-hospital cardiac arrest due to specific ventricular arrhythmias, testing the effectiveness of epinephrine and metoprolol, with inclusion and exclusion criteria specified, and disease names and icd-10 codes provided.",
    "This phase 2 trial is testing the drug np001 and placebo on subjects with amyotrophic lateral sclerosis who meet specific eligibility criteria, including having onset of symptoms less than 3 years prior to study entry and forced vital capacity at least 70% of that predicted for age and height.",
    "This phase 2 trial is testing the efficacy of lenalidomide, melphalan, and dexamethasone in treating newly diagnosed multiple myeloma patients with specific eligibility criteria.",
    "The sample is a phase 2 trial for metastatic colorectal cancer using a combination of erlotinib, fluorouracil, leucovorin, oxaliplatin, and irinotecan, with specific eligibility criteria including prior progression on first-line oxaliplatin-based or irinotecan-based regimens and radiographically measurable disease.",
    "This phase 2 trial is testing the efficacy of bortezomib, cyclophosphamide, dexamethasone, and thalidomide in treating multiple myeloma and plasma cell neoplasm, with specific eligibility criteria for patients, including measurable disease and no prior chemotherapy or immunotherapy.",
    "The sample is a phase 2 trial for ovarian cancer using the drug ispinesib, with inclusion criteria based on CA-125 levels and prior chemotherapy, and exclusion criteria including pregnancy, other medical conditions, and recent treatment with investigational drugs or chemotherapy.",
    "The sample is a phase 2 trial for patients with prostate cancer who are refractory to hormone therapy and have had prior taxane-based chemotherapy, testing the efficacy of pemetrexed, with specific eligibility and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of dasatinib, a drug, in treating stage III/B or IV squamous NSCLC, a type of lung cancer, with specific eligibility criteria including measurable disease, ECOG performance status of 0 or 1, and normal organ and marrow function.",
    "This phase 2 trial is testing the efficacy of las100977 and placebo in patients with stable chronic obstructive pulmonary disease (COPD) who meet specific inclusion and exclusion criteria.",
    "This trial is testing the efficacy of AGI-1067, a drug for Type 2 diabetes, compared to a placebo, and has strict inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the efficacy of temozolomide in treating metastatic breast cancer patients who have completed first line of metastatic chemotherapy and have achieved complete or partial response or disease stability for at least 6 months, and have no clinical sign of brain progression, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of interferon alfa-2a in patients with cancer who have received a prior cancer vaccine, and have measurable disease, with specific eligibility criteria, while excluding patients with certain medical conditions or on certain medications.",
    "This phase 2 trial is testing the efficacy of cisplatin and fluorouracil in treating newly diagnosed pancreatic cancer patients with locally advanced inoperable disease, who have not received prior systemic chemotherapy or radiation therapy, and meet a range of eligibility criteria.",
    "The sample is a phase 2/phase 3 trial for the treatment of recurrent respiratory papillomatosis using propranolol, with inclusion criteria including biopsy-proven disease and at least 4 previous surgeries, and exclusion criteria including heart failure, asthma, and hypersensitivity to propranolol.",
    "This phase 2 trial is testing the drug bi 10773 on patients with type 2 diabetes mellitus or impaired glucose tolerance, who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of celecoxib, docetaxel, and pemetrexed disodium in treating \"COX dependent\" non-small cell lung cancer patients who have undergone \u22642 different chemotherapy regimens, with eligibility criteria including age \u226518 years, ECOG PS 0, 1 or 2, and adequate renal and hematologic function.",
    "This phase 2 trial is testing the efficacy of amrubicin and topotecan in treating small cell lung cancer patients who have responded to first-line platinum-based chemotherapy and have extensive disease, with specific eligibility criteria including measurable disease and adequate organ function.",
    "This phase 2 trial is testing the efficacy of sunitinib and capecitabine in treating patients with Stage IV breast cancer and measurable CNS metastases, with eligibility criteria including age, disease history, and cardiac and hematological adequacy.",
    "This phase 2 trial is testing the efficacy of carfilzomib, cyclophosphamide, and dexamethasone in treating newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplantation and have measurable disease, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for bipolar I depression, testing the efficacy of armodafinil and placebo in patients currently being treated with lithium, olanzapine, or valproic acid, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of prednisone, azithromycin, montelukast, and symbicort in treating respiratory tract infections, bronchiolitis obliterans, cryptogenic organizing pneumonia, and interstitial lung diseases in patients who have undergone allogeneic transplant within the prior year, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of sorafenib and capecitabine in treating hepatocellular carcinoma, with eligibility criteria including adequate bone marrow and renal function, ECOG/Zubrod/SWOG performance status, and exclusion criteria including prior systemic therapy, uncontrolled ascites, and uncontrolled hypertension.",
    "This is a phase 2 trial for patients with multiple myeloma, testing the drug plerixafor for autologous transplantation eligibility, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of drugs fx006 and tca ir in treating osteoarthritis of the knee, with specific eligibility criteria including a diagnosis of OA according to American College of Rheumatology criteria and a qualifying mean score on the 24-h average pain score.",
    "This phase 2 trial is testing the efficacy of irinotecan, carboplatin, and bevacizumab in treating small cell lung cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for dry eye syndrome, testing the efficacy of 1% and 2% opc-12759 ophthalmic suspension compared to placebo, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the effectiveness of doxorubicin hcl liposome, bevacizumab, and carboplatin in treating relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer patients with specific eligibility criteria.",
    "The sample is a phase 2 trial for hormone refractory prostate cancer, testing the drug docetaxel, with inclusion criteria including confirmed adenocarcinoma of the prostate with metastatic disease and disease progression during antiandrogen therapy, and exclusion criteria including prior treatment with cytotoxic agents or radioisotopes and brain or leptomeningeal metastases.",
    "This phase 2 trial will test the efficacy of valproic acid and HAART in HIV-positive patients with viral load <50 copies/ml and CD4+ cell count \u00b3 200 cells/ml, who do not exhibit evidence of advanced cirrhosis or liver disease, and meet other eligibility criteria.",
    "The sample is a phase 2 trial for irritable bowel syndrome with constipation, testing the efficacy of linaclotide acetate and matching placebo, with inclusion and exclusion criteria including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria, as well as various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study.",
    "This phase 2 trial is testing the efficacy of dalteparin and gemcitabine hydrochloride in treating metastatic or locally advanced adenocarcinoma of the pancreas, with eligibility criteria including no clinical evidence of active venous thromboembolism and Karnofsky performance status of 60-100% or WHO PS 0-2.",
    "This phase 2 trial is testing the efficacy of carboplatin and paclitaxel in treating advanced locally recurrent or metastatic collecting duct renal cell carcinoma, with eligibility criteria including measurable disease and specific patient characteristics such as ECOG performance status and hematopoietic and renal function.",
    "The sample is a phase 2 trial for rheumatoid arthritis with inadequate response to methotrexate, testing the efficacy of multiple doses of cp-690,550 and placebo, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for HIV-uninfected individuals willing to use contraception, testing the efficacy of 1% tenofovir gel for prevention of HIV and hepatitis B, with exclusion criteria including prior participation in similar studies and use of certain medications.",
    "This phase 2 trial is testing the effectiveness of nabilone, a cannabinoid, in managing pain for patients with fibromyalgia who have not responded to other pain medications.",
    "This phase 2 trial is testing the efficacy of etravirine, nucleotide reverse transcriptase inhibitors, protease inhibitors, and enfuvirtide in treating human immunodeficiency virus type 1, with specific inclusion and exclusion criteria for participants.",
    "The sample is a phase 2 trial for irritable bowel syndrome with diarrhea, testing the efficacy of ibodutant and placebo drugs, with inclusion and exclusion criteria for patient selection.",
    "The sample is a phase 2 trial for acute myeloid leukemia, testing the drug decitabine, with inclusion criteria including a recent diagnosis of AML or transformed MDS and ineligibility for intensive chemotherapy, and exclusion criteria including previous treatment for AML or previous receipt of Vidaza.",
    "The sample is a phase 2 clinical trial for advanced non-small cell lung cancer, transitional cell carcinoma, soft tissue sarcoma, gastric/esophageal adenocarcinoma, and pancreatic cancer including ampulla of vater, testing the efficacy of brivanib versus placebo, with eligibility criteria including life expectancy of at least 3 months, unresectable solid tumor, and adequate tumor sample.",
    "This phase 2 trial is testing the efficacy of brostallicin and cisplatin in treating triple-negative breast cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for non-small cell lung cancer using induction chemotherapy as the drug, with specific inclusion and exclusion criteria listed in the eligibility criteria section.",
    "This phase 2 trial is testing the efficacy of mipomersen and placebo in treating patients with statin intolerance, coronary artery disease, and hypercholesterolemia, with a focus on metabolic and lipid disorders, as well as specific ICD-10 codes, and eligibility criteria including stable weight for >6 weeks and exclusion criteria such as recent significant health problems.",
    "This phase 2 trial is testing the efficacy of dexamethasone in treating relapsed or refractory multiple myeloma patients who have failed at least 2 prior lines of therapy and have measurable secretory disease, while excluding those with serious concurrent illnesses or infections.",
    "The sample is a phase 2 trial for rheumatoid arthritis testing the efficacy of adalimumab and cp-690-550 compared to placebo, with inclusion criteria of active rheumatoid arthritis and failure of at least 1 DMARD, and exclusion criteria of previous adalimumab therapy and evidence of blood disorders, chronic infections or untreated tuberculosis.",
    "This phase 2 trial aims to investigate the efficacy of asp1585 and sevelamer hydrochloride in treating hyperphosphatemia in stable chronic kidney disease patients on hemodialysis, with inclusion criteria including stable doses of phosphate binders and Vitamin D or calcitonin agents, while exclusion criteria include history of major gastrointestinal surgery and uncontrolled hypertension.",
    "The sample is a phase 2 trial for Alzheimer's disease using tideglusib and placebo as drugs, with inclusion criteria including a diagnosis of probable Alzheimer's disease, age of 50 to 85 years, and MMSE score 14 to 26.",
    "This phase 2 trial is testing the efficacy of gemcitabine, cisplatin, and dexamethasone in treating aggressive non-Hodgkin's lymphoma patients who have progressed after prior first-line chemotherapy containing anthracyclines associated or not with Rituximab, and meet other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of SCH 727965, capecitabine, and erlotinib in treating breast neoplasms and non-small-cell lung carcinoma, with specific eligibility criteria for participants including prior treatment regimens and organ function.",
    "This is a phase 2 trial for patients with non-small cell lung cancer who have undergone complete resection and must begin adjuvant chemotherapy within 8 weeks of surgery. The trial will test the efficacy of carboplatin and docetaxel as treatment options.",
    "The sample is a phase 2 trial for relapsed or refractory acute lymphocytic leukemia, using cytarabine, fludarabine phosphate, and idarubicin, with eligibility criteria including bone marrow blast cells greater than 10% and no uncontrolled infection.",
    "This phase 2 trial is testing the efficacy of nilutamide and dasatinib in treating metastatic prostate cancer patients who have evidence of disease progression on androgen deprivation therapy, with eligibility criteria including confirmed diagnosis of adenocarcinoma of the prostate, radiographic evidence of metastatic disease amenable to image-guided biopsy, and adequate organ and marrow function.",
    "The sample is a phase 2 trial for hyperlipidemia and type 2 diabetes, testing the efficacy of etc-1002 and placebo, with specific eligibility criteria including fasting C-peptide, HbA1C, fasting glucose, BMI, and LDL-C levels.",
    "The sample is a phase 2 trial for opioid-induced constipation, testing the efficacy of placebo and naldemedine drugs, with inclusion criteria of non-malignant chronic pain and <3 spontaneous bowel movements per week, and exclusion criteria of clinically significant gastrointestinal disease and severe constipation.",
    "This is a phase 2 trial for patients with type 2 diabetes mellitus, testing the efficacy of ly2189265 and placebo in combination with two oral antihyperglycemic medications, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for Friedreich's ataxia, testing the efficacy of epoetin alfa, with inclusion criteria based on molecular diagnosis and age range, and exclusion criteria including treatment with Idebenone, wheelchair-bound patients, and certain medical conditions.",
    "The sample is a phase 2/phase 3 trial for kidney transplantation, testing the effectiveness of rituximab and placebo drugs on renal transplant recipients with specific eligibility and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of lasmiditan and placebo in treating migraine in patients who meet specific inclusion criteria, including having a history of migraine for at least 1 year and a history of 1-8 migraine attacks per month.",
    "This phase 2 trial is testing the efficacy of pex168 or placebo in treating type 2 diabetes in patients who have been treated with metformin monotherapy for at least 12 weeks and have a stable HbA1c level, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of perifosine, a drug, in treating advanced soft tissue sarcoma, with specific eligibility criteria including measurable disease and ECOG performance status of 0 or 1.",
    "This phase 2 trial is testing the efficacy of capecitabine, celecoxib, and methotrexate in treating metastatic colorectal cancer with specific eligibility criteria, including prior treatment limitations and intact organ function.",
    "The sample is a phase 2 clinical trial for Crohn's disease, testing the efficacy of hmpl-004 and placebo drugs, with inclusion criteria of active confirmed Crohn's Disease and a CDAI of 220-400 at baseline screen, and exclusion criteria of recent use of anti-TNF-\u03b1 antibody, cyclosporine, tacrolimus, thalidomide or mycophenolate mofetil.",
    "The sample is a phase 2 trial for the treatment of female sexual arousal disorder using the drug cp-866,087 and placebo, with inclusion criteria of healthy pre-menopausal women with primary female sexual arousal disorder causing distress and exclusion criteria of any other significant disease causing Female Sexual Dysfunction including psychiatric disease, subjects on drugs known to cause Female Sexual Dysfunction, and subjects who have given birth in the last 12 months or who are planning to become pregnant during the study.",
    "The sample is a phase 2 trial for rheumatoid arthritis with the drugs nnc109-0012 and placebo, and the eligibility criteria includes a stable dose of methotrexate treatment for at least 4 weeks prior to trial start.",
    "The sample is a phase 2 trial for chronic hepatitis C infection, testing the efficacy of a combination of drugs including abt-267, abt-450, abt-333, ritonavir, and ribavirin, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the drug bevirimat on patients with HIV-1 infection who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of albumin-bound paclitaxel, carboplatin, and Herceptin\u00ae in treating stage IV breast cancer patients with confirmed adenocarcinoma and 3+ overexpression of HER-2, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of amonafide and cytarabine in treating acute myeloid leukemia, with specific eligibility criteria and exclusion criteria listed.",
    "The sample is a phase 2 trial for cancer patients, testing the drugs cediranib and cediranib 30-90 mg, with inclusion criteria of advanced solid tumor diagnosis and ability to eat a high fat breakfast, and exclusion criteria of poorly controlled high blood pressure and history of significant gastrointestinal problems.",
    "This phase 2 trial is testing the drug ixabepilone on patients with recurrent or stage IV melanoma, with specific eligibility criteria including measurable lesions, stable brain metastases, and normal blood counts, liver function, and cardiac health.",
    "This phase 2 trial is testing the drug vorinostat on patients with stage I-III breast cancer who have not received prior hormonal therapy, and have met various eligibility criteria.",
    "The sample is a phase 2 trial for metastatic pancreatic cancer, testing the efficacy of ixabepilone and cetuximab, with eligibility criteria including a histologic or cytologic diagnosis of pancreatic adenocarcinoma, measurable disease, no prior chemotherapy, and a KPS of 70-100.",
    "The sample is a phase 2 trial for hormone-refractory prostate cancer with rising PSA levels and bone metastasis, testing the efficacy of zoledronic acid tablets, and excluding patients already on bisphosphonate treatment.",
    "The sample is a phase 2 trial for allergic rhinitis, testing the drugs qax576 and placebo, with inclusion criteria of a history of allergic rhinitis and exclusion criteria including respiratory disease other than mild intermittent asthma and history of clinically significant drug allergy.",
    "This phase 2 trial is testing the efficacy of gm-ct-01 plus 5-fluorouracil in treating locally advanced or metastatic colorectal cancer that has progressed after at least two lines of therapy, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the drug apo866 on patients with cutaneous t-cell lymphoma who have relapsed or are refractory to prior systemic therapy, and have met certain eligibility criteria.",
    "The sample is a phase 2 trial for chemotherapy naive patients with non-small-cell lung carcinoma, using carboplatin, paclitaxel, and vinorelbine, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for previously untreated participants with CD20 positive B-cell chronic lymphocytic leukemia, using rituximab and chlorambucil as drugs, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of a combination of fluorouracil, leucovorin, bevacizumab, capecitabine, and oxaliplatin in treating metastatic colorectal cancer patients who have progressed after prior FOLFIRI + Avastin therapy and are not candidates for primary metastasectomy, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of paliperidone and placebo in treating obsessive-compulsive disorder in patients who have not responded to at least two adequate SRI monotherapy trials, and have met other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of GW642444 and placebo in treating asthma in children aged 5-11 years who are controlled on their existing asthma treatment, and have been taking a stable regimen of fluticasone propionate for at least 4 weeks prior to screening.",
    "This phase 2 trial aims to test the effectiveness of Sativex at reducing cancer-related pain in patients with advanced active cancer who are not wholly alleviated with their current opioid treatment, and have a clinical diagnosis of cancer-related pain. The trial will exclude patients who have received or are due to receive chemotherapy, hormone therapy or radiotherapy, and those with a history of diagnosed dependence disorder, current heavy alcohol consumption, current use of an illicit drug or current non-prescribed use of any prescription drug.",
    "This phase 2 trial is testing the efficacy of ltx-109, a topical antibacterial therapy, on patients with uncomplicated, Gram-positive skin infections, including mild eczema/dermatoses such as atopic dermatitis, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for locally recurrent and metastatic breast cancer, testing the efficacy of amg 706, bevacizumab, and paclitaxel, with eligibility criteria including HER2 negative status and adequate organ and hematologic function.",
    "This phase 2 trial is testing the efficacy of elagolix and subcutaneous depot medroxyprogesterone acetate (dmpa-sc) compared to placebo in treating endometriosis in females aged 18 to 49 years with a diagnosis of endometriosis made following laparoscopic visualization of the disease within 8 years of the start of screening with recurrent or persistent symptoms.",
    "This phase 2 trial aims to test the efficacy of bupropion sr in treating nicotine dependence and use disorder in adolescents aged 12-21 with a baseline urine cotinine level greater than 100 ng/ml, with inclusion and exclusion criteria outlined in the eligibility criteria section.",
    "The sample is a phase 2 trial for primary insomnia using sb-649868 and placebo drugs, with inclusion criteria of males aged 18-64 years with symptoms for at least three months and exclusion criteria of any clinically significant unstable medical or surgical condition or any history of abnormality of the neurological system or seizure.",
    "This is a phase 2 trial for prostate cancer using the drug kos-862, with eligibility criteria including metastatic disease and previous treatment with docetaxel, and exclusion criteria including active brain metastases.",
    "This phase 2 trial will test the efficacy of various concentrations of e6201 and calcipotriene in treating chronic stable plaque psoriasis, with strict inclusion and exclusion criteria for subjects.",
    "This phase 2 trial is testing the drug jnj-37822681 on patients with schizophrenia who meet specific inclusion criteria, including a diagnosis of schizophrenia by DSM-IV and a Positive and Negative Syndrome Scale score at Screening less than 70.",
    "This phase 2 trial is testing the drug XL184 in patients with glioblastoma multiforme who have received prior standard radiation and temozolomide therapy, and have one or two progressions as Grade 4 astrocytic tumor since the original diagnosis of any grade glioma.",
    "This phase 2 trial is testing the efficacy of vismodegib, bevacizumab, modified folfox, and folfiri in treating metastatic colorectal cancer, with eligibility criteria including confirmed diagnosis, ECOG performance status 0 or 1, and adequate hematopoetic, hepatic, and renal function.",
    "This phase 2 trial is testing the efficacy of sen0014196 and placebo in treating Huntington's disease in patients aged 30-70 with genetically confirmed, manifest HD and motor signs of HD, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 clinical trial testing the efficacy of clofarabine in treating acute myeloid leukemia in patients over 60 years old with specific prognostic factors and adequate organ function.",
    "This phase 2 trial is testing the efficacy of telaprevir, ribavirin, and pegylated interferon alfa 2a in treating chronic hepatitis C with specific inclusion and exclusion criteria.",
    "The sample is a phase 2/phase 3 trial for heart failure patients, testing the effectiveness of relaxin and placebo drugs, with inclusion and exclusion criteria based on hospitalization, dyspnea, pulmonary congestion, blood pressure, and renal function.",
    "The sample is a phase 2 trial for coronary artery disease, testing the efficacy of e5555 and placebo drugs, with specific eligibility criteria including age, confirmed disease, and aspirin use.",
    "This phase 2 trial is testing the efficacy of gemcitabine hydrochloride and imatinib mesylate in treating locally advanced or metastatic breast cancer patients who have progressed after at least one prior chemotherapy regimen, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of semaglutide and liraglutide in treating type 2 diabetes in patients who meet specific inclusion and exclusion criteria, with a focus on stable treatment regimens and body weight, and the trial includes a placebo group.",
    "This phase 2 trial is testing the efficacy of various drugs, including FP 100 and montelukast, in treating asthma in patients who meet specific inclusion criteria, while excluding those with certain medical histories or allergies.",
    "The sample is a phase 2 trial for type 2 diabetes, testing the efficacy of pf-00734200 at different doses, with inclusion criteria of stable metformin use and Hb1AC levels between 7%-11%, and exclusion criteria of recent heart attack or stroke, alcohol dependency, and evidence of diabetic complications with significant end-organ damage.",
    "This phase 2 trial is testing the efficacy of ave5530, placebo, and ezetimibe in treating mild to moderate primary hypercholesterolemia with stabilized LDL-C, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of dasatinib and leuprolide acetate in treating prostate cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for lung cancer patients using cisplatin, etoposide, paclitaxel, and topotecan hydrochloride, with eligibility criteria including measurable non-CNS lesions and specific hematopoietic, hepatic, renal, and cardiovascular requirements.",
    "This phase 2 trial is testing the efficacy of ixabepilone in treating patients with unresectable recurrent cervical cancer, with eligibility criteria including prior therapy with cisplatin or carboplatin and suitable candidate for receiving planned therapy.",
    "This phase 2 trial is testing the efficacy of rx-0201 plus gemcitabine in treating metastatic pancreatic cancer, with eligibility criteria including having at least one measurable lesion by RECIST criteria and a Karnofsky Performance Status of > 70.",
    "The sample is a phase 2 trial for the drug gw679769 in patients with major depressive disorder, with inclusion and exclusion criteria listed, and the disease is defined by DSM-IV criteria and ICD-10 codes.",
    "This phase 2 trial is testing the drug ispinesib on patients with metastatic renal cell carcinoma who have discontinued prior therapy, with eligibility criteria including measurable disease, ECOG performance status of 0-2, and various laboratory values within normal limits.",
    "This phase 2 trial is testing the efficacy of gwp42003 : gwp42004 (40:1) and placebo in treating weight gain caused by olanzapine in patients with schizophrenia who have been receiving olanzapine treatment for no more than 3 months and have evidence of weight gain in the last 3 months attributable to olanzapine.",
    "The sample is a phase 2 trial for patients with unresectable liver metastases secondary to colorectal adenocarcinoma, testing the efficacy of folfox regimen, fluorouracil, leucovorin calcium, and oxaliplatin, with eligibility criteria including age, performance status, hematopoietic, hepatic, renal, cardiovascular, and other factors.",
    "The sample is a phase 2 trial for hepatitis C, testing the efficacy of peg-intron, rebetol, and hcv 796, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with liver cancer, testing the efficacy of doxorubicin hydrochloride, with eligibility criteria including specific disease characteristics, patient characteristics, and prior concurrent therapy.",
    "The sample is a phase 2 trial for acute coronary syndrome, testing the drugs e5555 and placebo, with eligibility criteria including age, confirmed diagnosis, and exclusion criteria including bleeding disorders and heart failure.",
    "This phase 2 trial is testing the drug zk219477 on patients with metastatic breast cancer and measurable CNS disease, who have received prior CNS-directed therapy, and aims to evaluate systemic chemotherapy in place of additional brain radiotherapy as an acceptable option.",
    "This phase 2 trial is testing the drug pf-00489791 on patients with Raynaud's disease and peripheral vascular disease, with inclusion criteria including active Raynaud's Phenomenon and stable disease and medication requirements, and exclusion criteria including uncontrolled hypertension, diabetes mellitus, and smoking within 3 months.",
    "This phase 2 trial is testing the drug indantadol for the treatment of chronic cough with specific inclusion and exclusion criteria, including normal chest X-ray and lung function, and exclusion of current smokers or ex-smokers with <6 months abstinence or cumulative history of >10 pack years, and current treatment with ACE inhibitors.",
    "This phase 2 trial is testing the drug bosutinib on patients with chronic myeloid leukemia who are refractory to imatinib, have disease progression/relapse while on imatinib, or are intolerant of any dose of imatinib, and have certain inclusion criteria, while excluding those with certain conditions.",
    "This phase 2 trial is testing the efficacy of gleevec/paclitaxel in treating ovarian cancer patients who have received initial cytoreductive surgery and chemotherapy with at least one platinum-based chemotherapy regimen, and meet other eligibility criteria.",
    "This is a phase 2 trial for the treatment of hyperphosphatemia in end-stage renal disease patients using ferric citrate as a phosphate binder, with inclusion criteria including age >18, thrice weekly hemodialysis for at least 3 months, and phosphorous levels \u22653.5mg/dL, and exclusion criteria including serum phosphorus levels >10.0 mg/dL, previous intolerance to oral ferric citrate, and any other medical condition that would interfere with optimal participation in the study or produce significant risk to the patient.",
    "The sample is a phase 2 trial for macular degeneration, testing the effectiveness of three different treatments including verteporfin photodynamic therapy and bevacizumab, with eligibility criteria including new wet AMD.",
    "The sample is a phase 2 trial for asthma, testing the drugs mk0633 and placebo, with inclusion criteria including documented clinical history of chronic asthma symptoms and exclusion criteria including history of kidney or chronic liver disease and evidence of another clinically significant, active lung disorder.",
    "The sample is a phase 2 trial for patients with metastatic colorectal cancer, testing the efficacy of capecitabine as a treatment option, with eligibility criteria including age, performance status, and various medical conditions.",
    "This phase 2 trial is testing the efficacy of placebo in treating rheumatoid arthritis patients who have been taking MTX for at least 3 months, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for previously treated chronic lymphocytic leukemia (CLL) patients with specific disease characteristics and patient characteristics, using a combination of cyclophosphamide, doxorubicin hydrochloride, prednisone, and vincristine sulfate as drugs, and allowing up to 4 prior chemotherapy regimens.",
    "This trial is testing the effectiveness of zoledronic acid in treating metastatic breast cancer with bone metastases, and includes eligibility criteria such as confirmed invasive breast cancer, ECOG Performance Status of 0 to 2, and adequate organ function.",
    "This phase 2 trial is testing the efficacy of sorafenib tosylate and gemcitabine hydrochloride in treating locally advanced or metastatic adenocarcinoma of the pancreas, with a list of eligibility criteria including performance status, blood counts, and absence of other active malignancy.",
    "The sample is a phase 2 trial for head and neck cancer patients with the drug thalidomide, and the eligibility criteria includes age, performance status, disease characteristics, and prior concurrent therapy.",
    "The sample is a phase 2 trial for mild to moderate Alzheimer's disease, testing the drugs azd1446 and placebo, with inclusion criteria including a history of progressive cognitive decline and treatment with donepezil, and exclusion criteria including allergy/hypersensitivity reactions and significant neurological disease or dementia other than Alzheimer's disease.",
    "This is a phase 2 trial for patients with prostate cancer, testing the effect of metformin on patients who meet certain eligibility criteria, while excluding patients with certain medical conditions or taking certain medications.",
    "This phase 2 trial is testing the efficacy of capecitabine, fluorouracil, leucovorin calcium, and oxaliplatin in treating locally advanced or metastatic colorectal cancer with resectable metastases, and eligible patients must meet certain criteria including having an ECOG performance status of 0-2 and not having contraindications to therapy with the drugs being tested.",
    "This phase 2 trial is testing the efficacy of iressa, arimidex, and faslodex in postmenopausal women with estrogen receptor and/or progesterone receptor positive invasive breast cancer, with a primary tumor of 3 cm or more in greatest dimension, who have not received any prior treatment for current or newly diagnosed breast cancer and meet other eligibility criteria.",
    "The sample is a phase 2 trial for patients with metastatic renal cell cancer, testing the drug AG-013736, with inclusion criteria including clear cell cancer and refractory to cytokine therapy, and exclusion criteria including gastrointestinal abnormalities and active seizure disorder.",
    "This phase 2 trial is testing the efficacy of qaw039 and placebo in treating asthma patients who meet specific inclusion criteria, including reversible airway obstruction and a sputum eosinophil count \u2265 2%, while excluding patients with certain medical conditions or who are pregnant or nursing.",
    "This phase 2 trial is testing the drug 7-hydroxystaurosporine on patients with recurrent or stage IV melanoma who have received limited prior chemotherapy or biological therapies and meet specific eligibility criteria.",
    "The sample is a phase 2/phase 3 trial for rheumatoid arthritis, testing the efficacy of rosuvastatin and placebo in patients with a high risk profile, with specific inclusion and exclusion criteria based on disease duration, seropositivity, joint counts, and cholesterol levels.",
    "This phase 2 trial is testing the efficacy of LY2409021 and placebo in treating type 2 diabetes mellitus patients who meet specific eligibility criteria, including stable metformin therapy, HbA1c values between 7.0% to 10.5%, and BMI between 25 to 45 kg/m^2.",
    "The sample is a phase 2 trial for patients with locally advanced or metastatic breast cancer who have received at least two prior chemotherapeutic regimens, and will test the drug E7389 as a treatment option.",
    "This phase 2 trial is testing the efficacy of carboplatin, paclitaxel, and temozolomide in treating metastatic melanoma with specific eligibility criteria, including measurable disease and ECOG performance status 0-2.",
    "This is a phase 2 trial for idiopathic restless legs syndrome using the drug SPM 962, with eligibility criteria including completion of a preceding trial, absence of certain adverse events, and specific medical conditions.",
    "The sample is a phase 2 trial for patients with uterine carcinosarcoma, testing the efficacy of carboplatin and paclitaxel, with eligibility criteria including stage III or IV disease, documented disease progression, and specific patient characteristics such as platelet count and creatinine levels.",
    "The sample is a phase 2 trial for advanced non-small cell lung cancer, testing the efficacy of gefitinib, gemcitabine, and carboplatin, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of docetaxel, cisplatin and 5-fu treatment followed by concomitant cisplatin, 5-fu and radiotherapy and concomitant cisplatin, 5-fu and radiotherapy in treating squamous cell carcinoma of the head and neck, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of td-4208 and ipratropium in treating moderate stable chronic obstructive pulmonary disease (COPD) in participants with a smoking history of over 10 pack-years, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of thalidomide in treating newly diagnosed multiple myeloma patients with measurable lesions, while excluding patients with certain medical conditions or taking certain medications.",
    "The sample is a phase 2 clinical trial for children with autism, Asperger's disorder, or pervasive developmental disorder, testing the effectiveness of the drug DMSA in reducing blood lead and/or mercury levels, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing lenalidomide and prednisone in patients with myelofibrosis with myeloid metaplasia who have discontinued chemotherapy and have certain eligibility criteria.",
    "This phase 2 trial is testing the drug enzastaurin on participants with various types of cancer, who have completed previous enzastaurin studies and have no other treatment options available, with specific inclusion and exclusion criteria.",
    "This is a phase 2 trial for newly diagnosed primary invasive ductal breast adenocarcinoma patients with T2-T4 tumors, not expressing estrogen receptor, progesterone receptor, or Her2/neu, using cisplatin as the drug, and with specific eligibility and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of lovastatin in combination with radiotherapy for patients with breast cancer and radiation toxicity, with specific eligibility criteria including prior surgical resection, negative surgical margins, and no evidence of distant metastases.",
    "This phase 2 trial is testing the efficacy of various drugs, including tenofovir disoproxil fumarate and entecavir, in treating chronic hepatitis B in patients with specific eligibility criteria, such as HBV DNA \u2265 1000 copies/mL and a CPT score of 7-12.",
    "This phase 2 trial is testing the effectiveness of vinorelbine oral formulation in treating metastatic/locally advanced refractory breast, non-small cell lung, or prostate cancer patients who have been previously treated with no more than two chemotherapeutic regimens and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of capecitabine, fluorouracil, leucovorin calcium, and oxaliplatin in treating advanced and/or metastatic colorectal adenocarcinoma, with eligibility criteria including unidimensionally measurable disease by RECIST criteria, no confirmed K-ras mutation of tumor after screening, and WHO performance status 0-2.",
    "This phase 2 trial aims to test the effectiveness of baclofen and placebo in helping smokers who smoke at least 10 cigarettes per day for at least 6 months and considering quitting smoking in the next 6 months, with a list of diseases and icd-10 codes related to nicotine use disorder, nicotine dependence, smoking, and tobacco use disorder, and a set of eligibility and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of saquinavir and ritonavir in treating confirmed HIV-1 infection in infants and children aged 4 months to <6 years, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of gemcitabine and oxaliplatin in treating squamous cell carcinoma of the head and neck region, with specific eligibility criteria for patients including prior treatment history and disease status.",
    "The sample is a phase 2 trial for patients with stage IV breast cancer, testing the efficacy of paclitaxel and carboplatin, with eligibility criteria including prior therapy restrictions and specific disease characteristics.",
    "The sample is a phase 2 trial for patients with stage IIIB or IV breast cancer, testing the drug abt-751, with eligibility criteria including recurrent tumor after or while on taxane therapy, and exclusion criteria including pregnancy or no anti-tumor therapy within 4 weeks of the start of ABT-751 administration.",
    "This phase 2 trial is testing the efficacy of S-1 and LV in treating metastatic or recurrent gastric cancer, with specific inclusion and exclusion criteria, and a list of relevant icd-10 codes.",
    "This phase 2 trial is testing the efficacy of irinotecan hydrochloride in patients with high-grade gliomas who have evidence of tumor progression by MRI scan and have not received any form of treatment for their progressive tumor between their last bevacizumab treatment and enrollment of this companion trial.",
    "This phase 2 trial is testing the efficacy of lapatinib and everolimus in treating locally advanced or metastatic breast cancer with specific eligibility criteria, including confirmed ER(-), PR(-), HER2(-) status and disease progression following prior first line cytotoxic chemotherapy, and exclusion criteria such as active CNS metastases and concurrent investigational therapy.",
    "The sample is a phase 2 trial for locally advanced or metastatic hereditary medullary thyroid carcinoma using the drug zd6474 (vandetanib) with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the combination of bevacizumab and erlotinib in patients with hepatocellular carcinoma or liver cancer who have not had curative resection, with eligibility criteria including measurable disease, ECOG performance status of </= 2, and Childs-Pugh status of A or B.",
    "This phase 2 trial is testing the efficacy of cenersen, idarubicin, and cytarabine in treating refractory or relapsed acute myelogenous leukemia patients who meet specific eligibility criteria, including age, performance status, and organ function.",
    "This phase 2 trial is testing the effectiveness of sirolimus and tacrolimus in stem cell transplantation for various diseases including acute myelogenous leukemia, graft versus host disease, and non-hodgkin's lymphoma, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of sorafenib tosylate in treating relapsed or progressed esophageal and gastric adenocarcinoma, with eligibility criteria including specific disease characteristics and patient characteristics, and excluding prior use of certain drugs and concurrent use of certain medications.",
    "This phase 2 trial is testing the efficacy of lenalidomide and cyclosporine a in treating myelodysplastic syndrome patients with low or intermediate-1 risk IPSS, who have not received prior lenalidomide treatment, and meet certain eligibility criteria.",
    "The sample is a phase 2 trial for hepatitis C, testing the efficacy of telaprevir, ribavirin, and pegylated interferon alfa 2a, with inclusion criteria requiring enrollment in specific control arms of previous studies.",
    "This phase 2 trial is testing the efficacy of ast-120 and celphere\u00ae cp-305 in treating irritable bowel syndrome in patients who meet specific inclusion criteria, while excluding those with certain medical histories or conditions.",
    "The sample is a phase 2 trial for atopic dermatitis, testing the efficacy of placebo and dupilumab drugs, with inclusion criteria including chronic AD and inadequate response to topical corticosteroids or calcineurin inhibitors.",
    "This is a phase 2 trial for postmenopausal women with newly diagnosed DCIS, testing the efficacy of tamoxifen and fulvestrant in treating breast carcinoma, with eligibility criteria including age, biopsy technique, and laboratory values.",
    "The sample is a phase 2 trial for metastatic renal cell carcinoma testing the efficacy of sunitinib and bevacizumab, with eligibility criteria including clear cell histology, measurable disease, and resolution of prior toxic effects, while exclusion criteria include prior treatment with bevacizumab and uncontrolled high blood pressure.",
    "This phase 2 trial is testing the efficacy of panitumumab and cpt-11 in treating metastatic colorectal cancer, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 trial is testing the effectiveness of bevacizumab, gemcitabine, and carboplatin in treating ovarian, fallopian tube, and peritoneal cancer that has returned after platinum-based chemotherapy, with specific inclusion and exclusion criteria for participants.",
    "This phase 2 trial is testing the efficacy of cidofovir in treating perianal high-grade squamous intraepithelial lesions in HIV-positive patients, with specific eligibility criteria including stable HAART therapy or CD4 count > 200/mm\u00b3, and various patient characteristics such as Karnofsky performance status and platelet count.",
    "This phase 2 trial is testing the efficacy of pegylated interferon alfa-2a and ribavirin in treating chronic hepatitis C in Caucasians aged 18-70 with proven HCV genotype 1 and histological infection activity within the liver, while excluding those with certain medical conditions or previous anti-HCV therapy.",
    "This phase 2 trial is testing the drug gw685698x in patients with asthma who meet specific eligibility criteria, including a best FEV1 of 40%-85% of the predicted normal value and a history of using inhaled corticosteroids for at least 8 weeks prior to Visit 1.",
    "This phase 2 trial is testing the efficacy of a combination of drugs including enzastaurin, leucovorin, 5-fluorouracil, and bevacizumab in treating locally advanced or metastatic colorectal cancer patients who have received first-line therapy with FOLFOX or FOLFIRI plus bevacizumab, and have shown evidence of tumor response.",
    "The sample is a phase 2 trial for the treatment of osteoporosis postmenopausal using odanacatib and placebo, with inclusion criteria including low bone mineral density and exclusion criteria including prior use of osteoporosis medications or participation in another drug study.",
    "This is a phase 2 trial for locally advanced, nonmetastatic pancreatic cancer patients with measurable disease, who have not received prior therapy for pancreatic cancer, and are eligible based on specific patient characteristics. The trial will test the efficacy of capecitabine, oxaliplatin, and gemcitabine as drugs.",
    "The sample is a phase 2 trial for rheumatoid arthritis testing the efficacy of itacitinib and itacitinib placebo, with inclusion and exclusion criteria related to age, joint assessment, laboratory values, pregnancy, biologic agent treatment, inflammatory disease history, and hematological disorders.",
    "This phase 2 trial is testing the efficacy of paclitaxel, carboplatin, bevacizumab, and erlotinib in treating metastatic carcinoma of unknown primary site with specific histologies, and patients must meet certain eligibility criteria.",
    "The sample is a phase 2/3 trial testing the efficacy of nitazoxanide and placebo in treating influenza in patients aged 12-65 with confirmed Influenza A or B infection, with specific inclusion and exclusion criteria, and a list of diseases and icd-10 codes.",
    "This phase 2 trial is testing the efficacy of qaw039 and montelukast, along with a placebo, in treating patients with asthma who meet specific inclusion criteria and do not meet any of the exclusion criteria.",
    "This phase 2 trial is testing the drug AEGR-733 and its combinations with other drugs for the treatment of hyperlipidemia, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of inhaled loxapine in treating agitation in patients with schizophrenia, with inclusion criteria including meeting DSM-IV criteria for schizophrenia and having a total score of \u226514 on the PANSS Excited Component, and exclusion criteria including a history of allergic reactions to loxapine or amoxapine and having a history of acute or chronic pulmonary disease that precludes administration of Staccato Loxapine.",
    "This phase 2 trial is testing the efficacy of perifosine and imatinib mesylate in treating gastrointestinal stromal tumors that have progressed on imatinib mesylate, with eligibility criteria including confirmed diagnosis of Kit expressing advanced GIST, measurable disease by CT scan, and a performance status of 0 to 2.",
    "This phase 2 trial will test the efficacy of gsk233705, an inhaled anticholinergic drug, in treating chronic obstructive pulmonary disease (COPD) in adults who are current or previous cigarette smokers with a history of cigarette smoking of \u2265 10 pack-years.",
    "This phase 2 trial is testing the efficacy of temozolomide and sorafenib in treating glioblastoma multiforme, with eligibility criteria including confirmed diagnosis, no previous treatment, and adequate bone marrow and liver function.",
    "This phase 2 trial aims to test the efficacy of tc-5214 + citalopram and placebo + citalopram in treating major depressive disorder and depression, respectively, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for multiple myeloma testing the efficacy of bortezomib, placebo, and dexamethasone, with specific eligibility criteria including measurable secretory disease and documented disease progression after prior therapy.",
    "This phase 2 trial is testing the efficacy of mitoxantrone and prednisone in treating metastatic prostate cancer that is unresponsive to hormone therapy, with eligibility criteria including radiographic evidence of metastasis, disease progression while receiving docetaxel, and adequate hematologic, hepatic, and renal function.",
    "This trial is testing the use of atorvastatin in patients with advanced cancers who are undergoing lobectomy or pneumonectomy, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of sorafenib, a VEGFR inhibitor, in treating extensive stage small cell lung cancer patients who have achieved a complete or partial response after platinum-based induction chemotherapy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for congestive heart failure using the drug ditpa, with inclusion criteria including NYHA class II, III or IV and ejection fraction greater than 40%.",
    "This phase 2 trial is testing the efficacy of ixabepilone, bevacizumab, and paclitaxel in treating metastatic breast cancer, with strict eligibility criteria including no previous cytotoxic chemotherapy and a Karnofsky performance status of 80 to 100 or Eastern Cooperative Oncology Group performance status of 0 to 1.",
    "This phase 2 trial is testing the efficacy of xelox, xeliri, and bevacizumab in treating metastatic adenocarcinoma of the colon and/or rectum with confirmed liver metastases, with eligibility criteria including no prior treatment with irinotecan or oxaliplatin, adequate renal and hepatic function, and negative pregnancy test.",
    "This phase 2 trial is testing the efficacy of vicriviroc and emtricitabine/tenofovir in treating CCR5-tropic HIV infections in adults with specific eligibility criteria, including a CD4 count of at least 100 cells/(cubic mm) and a platelet count of at least 50,000/microL.",
    "This phase 2 trial is testing the efficacy of fg-4592 and epoetin alfa in treating anemia in patients with end stage renal disease on maintenance hemodialysis, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of various drugs, including lercanidipine and enalapril, on patients with essential hypertension, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for relapsed or refractory diffuse large b cell lymphoma, testing the efficacy of panobinostat with rituximab, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug ataluren in patients with cystic fibrosis who have a nonsense mutation in one allele of the CFTR gene, and the eligibility criteria includes various medical conditions and laboratory abnormalities.",
    "This phase 2 trial is testing the efficacy of gemcitabine and erlotinib in treating potentially resectable pancreatic cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for painful bladder syndrome and interstitial cystitis, testing the drugs urg101 and placebo, with eligibility criteria including age, symptom severity, and recent medical history.",
    "This phase 2 trial is testing the efficacy of capecitabine and cyclophosphamide in treating stage IV breast cancer patients with measurable or non-measurable disease, who have received at least 1 prior hormonal therapy for metastatic disease, and meet other eligibility criteria.",
    "This phase 2 trial is testing the drug triapine on patients with various stages of pancreatic cancer who meet specific eligibility criteria, including having no prior chemotherapy and a performance status of ECOG 0-2.",
    "This phase 2 trial is testing the drug MKC-1 for patients with pancreatic cancer who have failed at least one prior chemotherapy regimen, and the eligibility criteria includes measurable disease according to RECIST and specific laboratory results.",
    "This phase 2 trial is testing the efficacy of paclitaxel in treating patients with various types of non-small cell lung cancer, with specific eligibility criteria including no prior chemotherapy or biologic therapy, no brain metastases, and a Zubrod performance status of 0-1.",
    "This phase 2 trial is testing the drug lbh589 on patients with relapsed or refractory non-hodgkin's lymphoma, with specific eligibility criteria including laboratory values, cardiac function, and medical history.",
    "The sample is a phase 2 trial for patients with malignant mesothelioma, testing the efficacy of valproate plus doxorubicin as a treatment option, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the effectiveness of obinutuzumab, cyclophosphamide, doxorubicin, prednisone, and vincristine in treating previously untreated CD20-positive diffuse large B-cell lymphoma patients with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of paclitaxel, carboplatin and irinotecan in treating non-small cell lung cancer patients with malignant pleural effusion who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for obsessive compulsive disorder using minocycline as the drug, with inclusion criteria based on DSM-IV criteria and CY-BOCS score, and exclusion criteria including patients planning to commence cognitive behaviour therapy and severe renal insufficiency.",
    "This phase 2 trial is testing the drugs gsk573719 and tiotropium on Caucasian male and female subjects aged 40-75 years with an established clinical history of chronic obstructive pulmonary disease (COPD) and a smoking history of at least 10 pack years, to determine their efficacy in treating COPD.",
    "The sample is a phase 2 clinical trial for patients with locally recurrent or Stage IV breast cancer, testing the efficacy of eribulin, a chemotherapy drug, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of velcade and temsirolimus in treating relapsed or refractory B-cell non-Hodgkin lymphoma, with specific eligibility criteria including measurable tumor mass and certain laboratory values, while excluding patients with certain medical conditions or prior therapies.",
    "This phase 2 trial is testing the drug PLX3397 on patients with recurrent glioblastoma who have previously undergone radiation and temozolomide chemotherapy, and have specific eligibility criteria, including a Karnofsky performance status of \u226560 and adequate hematologic, hepatic, and renal function.",
    "This trial is testing the drug lbh589 on patients with cutaneous t-cell lymphoma who have had disease progression on or following treatment with an HDAC inhibitor, and have met certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of navarixin 10 mg in treating psoriasis vulgaris in participants who meet specific eligibility criteria, including having a PASI >8 and a target lesion of at least 10 cm^2 in size with a severity score for desquamation of at least 2.",
    "The sample is a phase 2 trial for contraception using three different types of levonorgestrel intrauterine systems, with inclusion criteria of women in need of contraception and exclusion criteria including pregnancy, abnormal bleeding, and liver diseases.",
    "This phase 2 trial is testing the efficacy of the drugs placebo and biap in treating sepsis and bacterial infections in patients between the ages of 18 and 80 with proven or suspected infection and acute renal failure, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for dry eye, testing the efficacy of de-089 ophthalmic solution and placebo, with inclusion criteria of keratoconjunctival disorder and abnormal Schirmer score results, and exclusion criteria of needing therapy for other eye diseases or wearing contact lenses during the study.",
    "The sample is a phase 2 trial for advanced and metastatic breast cancer patients, testing the efficacy of fulvestrant, with eligibility criteria including previous anti-estrogen hormonal treatment and postmenopausal status. The trial also lists exclusion criteria and disease codes.",
    "This phase 2 trial aims to test the effectiveness of the drug nb32 in helping smokers with nicotine dependence, overweight, and obesity quit smoking without gaining weight, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the drug perifosine on patients with metastatic kidney cancer who have failed prior therapy with sunitinib or sorafenib, and have normal organ and marrow function, with a list of inclusion and exclusion criteria.",
    "The sample is a phase 2/3 clinical trial for patients with recurrent follicular lymphoma, testing the efficacy of cyclophosphamide and rituximab, filgrastim, non-myeloablative conditioning regimen, rituximab maintenance therapy, and gvhd prophylaxis, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of firategrast 150 mg and 300 mg in treating relapsing-remitting multiple sclerosis, with eligibility criteria including a diagnosis of MS, occurrence of at least two relapses in previous 24 months, and a minimum of five T2 lesions on brain MRI.",
    "The sample is a phase 2 trial for breast cancer patients with locally advanced or metastatic disease, testing the efficacy of amg 479 or placebo administered with either exemestane or fulvestrant, and the inclusion and exclusion criteria are specified.",
    "This phase 2 trial is testing the efficacy of doxorubicin, gemcitabine, g-csf, and neulasta in treating metastatic renal cell carcinoma with sarcomatoid features, with eligibility criteria including confirmed diagnosis, measurable disease, and various health parameters.",
    "This phase 2 trial is testing the efficacy of lapatinib and letrozole in treating ER and/or PgR positive breast cancer in postmenopausal women with HER2 negative tumors, with specific eligibility criteria and exclusion criteria listed.",
    "The sample is a phase 2 trial for patients with non-small cell lung cancer brain metastases, testing the drug sunitinib, with specific inclusion and exclusion criteria listed.",
    "The sample is a phase 2/phase 3 trial for depression, testing the efficacy of trazodone and placebo, with inclusion criteria including age, DSM-IV criteria for depression, and HAM-D scores, and exclusion criteria including serious suicide attempts, bipolar disorder, and significant physical disorders.",
    "This phase 2 trial is testing the efficacy of empagliflozin in treating type 2 diabetes mellitus, with inclusion criteria including confirmed diagnosis of T2DM, HbA1c between 7.0% and 10.0%, and metformin therapy, and exclusion criteria including eCCr <60 ml/min and glucose level >240 mg/dl after an overnight fast during placebo run-in.",
    "This phase 2 trial is testing the efficacy of abatacept, placebo, and prednisone in treating systemic lupus erythematosus patients with active lupus flare in at least one of three organ systems, while excluding those with active lupus flare in the kidney or central nervous systems, and those with prior treatment with rituximab.",
    "The sample is a phase 2 trial for patients with poor prognosis acute myeloid leukemia or myelodysplastic syndrome, testing the drug ag-013736 (axitinib) with eligibility criteria including confirmation of diagnosis, adequate hepatic and renal function, and not being a suitable candidate for chemotherapy.",
    "The sample is a phase 2/phase 3 trial for HIV-infected patients with tuberculosis, testing the efficacy of nevirapine and efavirenz-based therapy in combination with rifampicin, ethambutol, isoniazid, and pyrazinamide, with inclusion criteria including CD4 cell count < 250 cell/mm3 and exclusion criteria including ongoing psychiatric pathology.",
    "This phase 2 trial is testing the drug gw856553 for the treatment of rheumatoid arthritis in patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug vemurafenib on patients with melanoma who have a confirmed EBRAFV600E or KBRAFV600K mutation and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for bladder cancer using a combination of methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine, with eligibility criteria including confirmed transitional cell carcinoma, measurable or evaluable disease, and adequate liver, renal, and bone marrow function.",
    "The sample is a phase 2 trial for relapsing-remitting multiple sclerosis, testing the effectiveness of interferon beta-1b and interferon beta-1b/atorvastatin groups, with inclusion criteria of successful completion of the SWABIMS study and written informed consent, and exclusion criteria of any disease other than multiple sclerosis that would better explain the patient's signs and symptoms, secondary progressive MS, uncontrolled severe medical disorder, and participation in any other studies.",
    "This phase 2 trial is testing the efficacy of dasatinib, a drug, in treating relapsed or refractory aggressive diffuse large B-cell lymphoma, with eligibility criteria including measurable disease and prior chemotherapy regimens.",
    "This phase 2 trial is testing the drug zk-epo on patients with unresectable stage III or IV melanoma, with inclusion criteria including confirmed diagnosis, measurable lesion, and adequate organ function, and exclusion criteria including prior treatment with certain drugs and CNS metastases.",
    "This phase 2 trial is testing the efficacy of oltipraz and placebo in treating non-alcoholic fatty liver disease, with inclusion and exclusion criteria including age, liver function, medication history, and immune disorders.",
    "This phase 2 trial is testing the efficacy of letrozole in combination with bevacizumab for the treatment of breast cancer in postmenopausal women with measurable disease, and includes eligibility criteria such as controlled hypertension, adequate organ function, and no prior chemotherapy.",
    "This phase 2 trial is testing the efficacy of epratuzumab, fludarabine, cyclophosphamide, mesna, and interleukin-2 in treating CD22+ acute lymphoblastic leukemia that is refractory to therapy or in second or greater relapse, with eligibility criteria including adequate renal and liver function, negative serology for HIV, and related donor predicted to be alloreactive based upon the presence of relevant KIR genes and incompatibility with the recipient for HLA C or Bw antigens.",
    "This phase 2 trial is testing the efficacy of capecitabine, a chemotherapy drug, in treating stage IV pancreatic cancer patients who have progressed after gemcitabine-based treatment, and who carry the double tandem repeat variant of the thymidylate synthase gene enhancer region, while meeting a set of eligibility criteria.",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus, testing the efficacy of taspoglutide compared to placebo, with inclusion and exclusion criteria related to diabetes treatment and weight management.",
    "This phase 2 trial is testing the efficacy of biricodar dicitrate, doxorubicin hydrochloride, and vincristine sulfate in treating patients with histologically confirmed oat cell or intermediate type small cell lung cancer who have received prior therapy and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for benign prostatic hyperplasia, using normal saline as the drug, with inclusion criteria of lower urinary tract symptoms and enlarged prostate volume, and exclusion criteria of previous prostate surgery, prostate cancer, use of other medications for prostatic hyperplasia, and urinary tract infection.",
    "The sample is a phase 2/phase 3 trial for major depressive disorder, testing the efficacy of tasimelteon and placebo, with inclusion and exclusion criteria including diagnosis, episode duration, and history of certain disorders or substance abuse.",
    "This is a phase 2 trial for patients with advanced non-small cell lung cancer, testing the efficacy of carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, with eligibility criteria including specific disease characteristics and patient characteristics.",
    "This phase 2 trial is testing the efficacy of mdco drugs and tranexamic acid in preventing bleeding during CABG surgery in patients who meet specific eligibility criteria and do not have any exclusion criteria.",
    "The sample is a phase 2 trial for hepatocellular carcinoma using irinotecan plus capecitabine as the drug combination, with specific inclusion and exclusion criteria listed.",
    "The sample is a phase 2/phase 3 trial for chronic hepatitis C, testing the efficacy of nitazoxanide and ribavirin in patients with specific inclusion and exclusion criteria, including HCV genotype 4 and no history of failed peginterferon-ribavirin therapy.",
    "This trial is a phase 2/phase 3 study for patients with house dust mite-related allergic rhinitis, testing the efficacy of 300 ir and 500 ir house dust mites allergen extract tablets and placebo tablets, with eligibility criteria including sensitization to D. pteronyssinus or D. farinae and a baseline ARTSS > 5.",
    "The sample is a phase 2 trial for metastatic pancreatic adenocarcinoma, testing the efficacy of imexon in combination with gemcitabine and placebo, with eligibility criteria including age, performance status, and laboratory values.",
    "The sample is a phase 2 trial for postmenopausal women with newly diagnosed metastatic breast cancer, testing the efficacy of gefitinib and anastrozole, with specific inclusion and exclusion criteria, and requiring a paraffin embedded tumor tissue block or slides from either the metastatic or primary tumor site.",
    "The sample is a phase 2 trial for hepatitis C infection, testing the efficacy of daclatasvir, peginterferon alfa-2a, and ribavirin, with specific eligibility criteria including HCV genotype 1 and viral load \u2265 10*5* IU/mL, and exclusion criteria including cirrhosis and co-infection with HBV, HIV-1 or HIV-2.",
    "This is a phase 2 trial for neuropathic pain, testing the efficacy of the drug gs856553 compared to placebo, with eligibility criteria including a diagnosis of neuropathic pain due to lumbosacral radiculopathy and a baseline average daily pain score of at least 4 on the PI-NRS.",
    "The sample is a phase 2 trial for the drug GSK2118436 in treating BRAF mutation-positive cutaneous metastatic melanoma, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of sir-spheres agent administration, cetuximab, and irinotecan in treating colon and colorectal cancer patients with measurable disease progression within 6 months of their most recent dose of chemotherapeutic regimens, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of vicriviroc maleate and placebo in treating HIV infections in patients with specific eligibility criteria, including prior therapy with antiretroviral agents and documented resistance mutations to reverse transcriptase inhibitors and primary resistance mutations to protease inhibitors.",
    "The sample is a phase 2 trial for patients with progressive prostate cancer after androgen deprivation, testing the efficacy of ketoconazole, lenalidomide, and therapeutic hydrocortisone, with eligibility criteria including confirmed adenocarcinoma of the prostate and testosterone less than 50 ng/dL.",
    "This phase 2 trial is testing the efficacy of azd8931 and anastrozole compared to placebo in hormone therapy-naive patients with locally advanced or metastatic breast cancer, with inclusion criteria including an estimated life expectancy of more than 12 weeks and exclusion criteria including any eye injury or corneal surgery within 3 months prior to receiving first dose of study drug.",
    "This is a phase 2 trial for sepsis patients, testing the effectiveness of simvastatin and placebo, with eligibility criteria including age, suspected or confirmed infection, and hospitalization, while exclusion criteria include pregnancy, allergy to statins, and poor prognosis.",
    "This phase 2 trial is testing the efficacy of bevacizumab, gemcitabine, and oxaliplatin in treating metastatic pancreatic cancer, with eligibility criteria including age, performance status, disease stage, and adequate organ function.",
    "This phase 2 trial will test the efficacy of cetuximab, a drug that targets the epidermal growth factor receptor pathway, in treating unresectable or metastatic esophageal or gastric adenocarcinoma with measurable disease and prior chemotherapy regimens, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with Major Depressive Disorder, testing the efficacy of the drugs gw597599b and paroxetine, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for type 2 diabetes mellitus, testing the efficacy of ttp054 and placebo drugs in patients on a stable regimen of metformin or metformin with an additional oral antidiabetic agent, with specific HbA1c ranges and exclusion criteria, and the trial includes a list of icd-10 codes for the disease.",
    "This phase 2 trial is testing the combination of rapamycin and trastuzumab in patients with HER2 overexpressing metastatic breast cancer who have progressed following standard doses of Herceptin or a Herceptin containing regimen, and have measurable disease, with eligibility criteria including adequate bone marrow, liver, and renal function, and adequate birth control, while exclusion criteria include prior therapy with rapamycin, rapamycin analogs, or experimental agents targeting mTOR, and uncontrolled intercurrent illness.",
    "This phase 2 trial is testing the drugs placebo and bms-562086 on female subjects with irritable bowel syndrome, who meet the inclusion criteria based on Rome II criteria and the Bowel Disease Questionnaire, and do not have clinically significant prolonged diarrhea with dehydration requiring IV fluid within 60 days prior to baseline visit.",
    "The sample is a phase 2 trial for lymphoma patients who have failed at least one prior systemic therapy, using temozolomide as the drug, and with eligibility criteria including specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions.",
    "This phase 2 trial is testing the efficacy of at-101 and rituximab in treating previously untreated Grade I-II follicular B-cell non-Hodgkin's lymphoma patients with measurable disease and adequate hematological, hepatic, and renal function, while excluding patients with severe lymphoma-related symptoms, CNS lymphoma, and HIV-related lymphoma.",
    "The sample is a phase 2 trial testing the drug MKC-1 on patients with ovarian or endometrial cancer who have failed prior chemotherapy regimens, with specific inclusion and exclusion criteria outlined.",
    "This phase 2 trial is testing a combination of drugs including cyclophosphamide, cytarabine, and imatinib mesylate for patients with acute lymphoblastic leukemia who meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of s-1 and gemcitabine hydrochloride in treating locally advanced or metastatic pancreatic cancer, with specific inclusion and exclusion criteria for patients.",
    "This phase 2 trial will test the efficacy of thalidomide and cpt-11 in treating patients with supratentorial malignant primary gliomas, including glioblastoma multiforme and glioma, who have shown evidence of tumor recurrence or progression after radiation therapy, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of cisplatin and docetaxel in treating stage IIIB non-small cell lung cancer with specific eligibility criteria, including no prior chemotherapy or surgical resection, and a Zubrod performance status of 0-2.",
    "This phase 2 trial is testing the efficacy of various doses of nva237, an anticholinergic medication, in treating moderate to severe chronic obstructive pulmonary disease (COPD) in patients with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients aged 50 or older with subfoveal choroidal neovascularization (CNV) secondary to age-related maculopathy, testing the efficacy of dexamethasone, with inclusion and exclusion criteria listed.",
    "This is a phase 2 trial for non-small-cell lung carcinoma testing cetuximab as a treatment option for patients who are not eligible for radiochemotherapy or refuse chemotherapy, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of decitabine, arsenic trioxide, and ascorbic acid in treating myelodysplastic syndrome, with eligibility criteria including a diagnosis of MDS, ECOG or WHO performance status of 0-2, and being off prior treatment for MDS and investigational agents for at least 4 weeks from entry.",
    "This phase 2 trial is testing the drug pixantrone dimaleate on patients with metastatic breast cancer who have previously been treated with anthracycline and/or taxane, and meet a set of eligibility criteria.",
    "This phase 2 trial is testing the efficacy of busulfan, cytarabine, daunorubicin hydrochloride, decitabine, and etoposide in treating untreated adult acute myeloid leukemia patients with various genetic mutations and excluding those with prior 5-azacitidine or decitabine therapy, with specific inclusion criteria.",
    "This phase 2 trial is testing the efficacy of gemcitabine in treating metastatic pancreatic cancer, with eligibility criteria including histologically or cytologically documented stage IV ductal adenocarcinoma of the pancreas, Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2, and adequate hematologic, renal, and hepatic function.",
    "This phase 2 trial is testing the efficacy of everolimus 10mg daily in treating metastatic and/or recurrent squamous cell carcinoma of the head and neck, with specific eligibility criteria and exclusion criteria listed.",
    "The sample is a phase 2 trial for patients with dermatofibrosarcoma protuberans or transformed fibrosarcomatous DFSP, testing the drug imatinib mesylate, with eligibility criteria including measurable disease, Zubrod performance status of =< 2, and various blood and serum level requirements.",
    "The sample is a phase 2 trial for major depressive disorder, testing the drug rx-10100, with inclusion criteria of moderate to severe MDD and exclusion criteria including pregnancy, psychotic disorders, anxiety disorders, and significant suicidality.",
    "This is a phase 2 trial for female patients with HER2 gene amplified breast cancer, testing the effectiveness of nab-paclitaxel, bevacizumab, and trastuzumab, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 clinical trial is testing the drug dasatinib on subjects with chronic phase or advanced disease chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia who are resistant or intolerant to imatinib, and the eligibility criteria includes adequate hepatic and renal function, and normal levels of certain electrolytes.",
    "This phase 2 trial is testing the effectiveness of iloprost inhalation solution (Ventavis) in treating pulmonary arterial hypertension in children aged 3-18 years with confirmed diagnosis and specific inclusion criteria.",
    "This phase 2 trial is testing the efficacy of eribulin mesylate and erlotinib in treating non-small cell lung cancer patients who have had prior platinum-based doublet anti-cancer treatment and have disease progression, with a list of eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of bortezomib, cyclophosphamide, and dexamethasone in treating relapsed or refractory follicular Grades 1 or 2 lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, or lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia/WM) with specific eligibility criteria.",
    "This phase 2 trial is testing the use of lovastatin in women with an increased inherited risk of breast cancer, with specific inclusion and exclusion criteria outlined in the eligibility criteria section.",
    "This phase 2 trial is testing the efficacy of lt-02 and placebo in treating ulcerative colitis with symptoms of bloody diarrhea and inadequate response to mesalazine, with inclusion criteria of patients 18 years or older with proven ulcerative colitis and exclusion criteria of infectious colitis, Crohn's disease, and treatment with other investigational medicinal product within 3 months prior to study entry.",
    "This is a phase 2 trial for non-metastatic breast cancer patients with clinical tumor diameter \u22652cm, HR negative and HER 2 negative, testing the efficacy of cetuximab and docetaxel, with eligibility criteria including age \u226518 years, performance status \u22641, and adequate hematological, renal and hepatic functions.",
    "The sample is a phase 2 trial for kidney transplantation patients, testing the efficacy of AEB071 and mycophenolic acid or tacrolimus and mycophenolic acid, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug ro5185426 on patients with metastatic melanoma and a BRAF V600E mutation, with eligibility criteria including adequate organ function and contraception use, and exclusion criteria including pregnancy and concurrent anti-tumor therapy.",
    "This is a phase 2 trial for patients with unresectable metastatic cutaneous melanoma, testing the drug 852a, with eligibility criteria including advanced melanoma not responding to 1st line chemotherapy, measurable disease, and normal organ and bone marrow function.",
    "This phase 2 trial aims to test the efficacy of reparixin continuous and intermittent infusion in reducing the risk of delayed graft function in kidney transplant recipients at risk, who are planned to receive induction with steroids and mycophenolate mofetil or mycophenolic acid plus biological induction, and who meet the inclusion criteria. The trial excludes patients with certain medical conditions, including those with hepatic dysfunction, hypersensitivity to NSAIDs, and those who are pregnant or breastfeeding.",
    "This phase 2 trial is testing the efficacy of docetaxel, doxorubicin hydrochloride, fluorouracil, and hydroxyurea in treating gastric cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of du125530 and placebo in treating unipolar major depression, with inclusion and exclusion criteria outlined in the eligibility criteria section.",
    "The sample is a phase 2 trial for venous thrombosis, testing the efficacy of pd 0348292 and enoxaparin in patients undergoing total knee replacement surgery, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of pemetrexed, a drug, in treating non-small cell lung cancer patients with specific eligibility criteria, including measurable disease and weight loss, while excluding patients with prior chemotherapy or active infections.",
    "This phase 2 trial will test the efficacy of sitagliptin, metformin, and placebo in treating type 2 diabetes mellitus patients who meet specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of carboplatin, paclitaxel, and cdp791 in treating non-squamous non-small-cell lung cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for patients with various hematological malignancies, testing the efficacy of cyclophosphamide, cyclosporine, and methylprednisolone in combination with bone marrow transplant from related or unrelated donors, with specific eligibility criteria based on disease and patient characteristics.",
    "The sample is a phase 2 trial for patients with chronic lymphocytic leukemia, testing the drug mgcd0103, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of tivozanib and placebo comparator in treating recurrent or metastatic renal cell carcinoma, with eligibility criteria including no more than one prior systemic treatment for RCC and Karnofsky performance status \u2265 70%.",
    "This phase 2 trial will test the efficacy of pioglitazone, a drug used to treat diabetes, in treating major depressive disorder and metabolic syndrome in patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the effectiveness of immediate-release quetiapine fumarate in treating acute schizophrenia, with inclusion criteria of men and women aged 18 to 65 years and exclusion criteria of substance dependence and pregnancy/lactation risk.",
    "The sample is a phase 2 trial for overactive bladder, testing the efficacy of fesoterodine fumarate and placebo, with inclusion criteria of micturitions >= 8 per day and urgency urinary incontinence >= 1 per day, and exclusion criteria including known hypersensitivity to the active substance and neurological disease influencing bladder function.",
    "This phase 2 trial is testing the efficacy of gw685698x and placebo in treating persistent asthma, with eligibility criteria including age, lung function, and clinical history, and exclusion criteria including respiratory tract infection, life-threatening asthma, and sensitivity to corticosteroids.",
    "This phase 2 trial is testing the drugs ast-120 and celphere cp-305 for the treatment of gastroesophageal reflux disease (GERD) in patients who have not responded to proton pump inhibitors (PPIs) and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of enzastaurin in treating newly diagnosed glioblastoma multiforme patients with unmethylated MGMT-promotor, with inclusion criteria including age over 18, estimated life expectancy of at least 12 weeks, and adequate organ function, while exclusion criteria including prior chemotherapy or radiotherapy of the head, serious concomitant systemic disorder, and pregnancy.",
    "This phase 2 trial is testing the drug topotecan on patients with newly diagnosed, limited stage small cell lung cancer, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for previously untreated indolent nonfollicular non-Hodgkin's lymphoma using rituximab as the drug, with inclusion criteria of adult patients 18-65 years of age with active disease and >=3 involved sites, and exclusion criteria of typical chronic lymphocytic leukemia, other malignancies within 3 years before study, systemic corticosteroid use for >1 month, significant cardiovascular disease, central nervous system involvement, and hepatitis B or C virus infection, or HIV infection.",
    "This phase 2 trial is testing the efficacy of cofactor, 5-fu, and leucovorin in treating surgically incurable, confirmed metastatic colon or rectal adenocarcinoma, with eligibility criteria including adequate renal, bone marrow, and liver function, and exclusion criteria including vomiting, diarrhea, or nausea of grade greater than 1.",
    "This phase 2 trial is testing the drug sorafenib tosylate on patients with refractory chronic lymphocytic leukemia or stage I-IV CLL who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of RO4917523 in treating major depressive disorder, with inclusion criteria including inadequate response to ongoing antidepressant treatment and a BMI of 18 to 38 kg/m2, and exclusion criteria including previous use of RO4917523 and current or past history of bipolar disorder, with drugs being placebo, ro4917523 0.5 mg, and ro4917523 1.5 mg.",
    "The sample is a phase 2 trial for metastatic adenocarcinoma of the colon or rectum, testing the efficacy of fluorouracil, irinotecan hydrochloride, and leucovorin calcium, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of a combination of drugs including imatinib mesylate, methotrexate, vincristine sulfate, leucovorin calcium, tacrolimus, etoposide, cyclophosphamide, and cytarabine in treating adult acute lymphoblastic leukemia in remission patients with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of pazopanib eye drops in preventing macular degeneration progression in subjects who participated in a previous study, with inclusion criteria including visual acuity and QTc levels, and exclusion criteria including ocular abnormalities and use of certain medications.",
    "This phase 2 trial is testing the drug gsk573719 in patients with chronic obstructive pulmonary disease (COPD) who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of grt6005 and matching placebo in treating painful osteoarthritis of the knee, with inclusion criteria including a pain intensity score of 4 or greater and exclusion criteria including substance abuse and significant cardiac disease.",
    "This phase 2 trial is testing the drug dio-902 in patients with type 2 diabetes who are only taking metformin, and have specific eligibility criteria including HbA1C levels between 7.0 to 10.0% and a BMI of 27 to 42 kg/m2.",
    "The sample is a phase 2 trial for hepatitis C with the drugs Sofosbuvir, Peginterferon, and Ribavirin, and the eligibility criteria includes genotype 2 or 3 HCV infection, cirrhosis determination, and treatment-experienced individuals.",
    "This phase 2 trial is testing the efficacy of ofatumumab and bendamustine in previously untreated patients with chronic lymphocytic leukemia (CLL) who require chemotherapy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial testing the efficacy of interferon-alpha lozenges versus placebo lozenges in treating chronic cough in patients with pulmonary disease, chronic obstructive and pulmonary fibrosis, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of Avastin and doxorubicin in treating intermediate or high grade locally advanced or metastatic soft tissue sarcoma, with specific eligibility criteria including normal renal and hepatic function, performance status 0-1, and no prior use of mesna, adriamycin, ifosfamide or Avastin\u00ae.",
    "The sample is a phase 2 trial for small cell lung cancer and carcinoma, small cell, using topotecan as the drug, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for narcolepsy, testing the efficacy of adx-n05 and placebo drugs, with inclusion and exclusion criteria listed, and icd-10 codes provided for the disease.",
    "This phase 2 trial is testing the efficacy of the drugs e2007 and placebo in treating epilepsy patients who have uncontrolled partial seizures despite having been treated with at least three different AEDs for at least 2 years, and meet other eligibility criteria.",
    "The sample is a phase 2 trial for metastatic colorectal cancer, testing the efficacy of a combination of drugs including iressa, irinotecan, 5fluorouracil, and leucovorin, with specific inclusion and exclusion criteria.",
    "This phase 2 clinical trial is testing the efficacy of aflibercept in treating platinum-resistant ovarian epithelial adenocarcinoma, with eligibility criteria including prior treatment with at least 2 regimens and evidence of at least one measurable tumor lesion, while exclusion criteria include prior treatment with a VEGF or VEGF receptor inhibitor and uncontrolled hypertension.",
    "This phase 2 trial is testing the efficacy of various doses of latanoprost in treating primary open angle glaucoma and ocular hypertension, with inclusion criteria including IOP levels between 24-36 mmHg and exclusion criteria including recent ocular surgery or use of medications known to affect IOP.",
    "The sample is a phase 2 trial for unresectable Stage III or IV malignant melanoma, testing ipilimumab+ placebo and ipilimumab+ budesonide, with inclusion criteria requiring a histologic or cytologic diagnosis of the disease and flexible sigmoidoscopy and colonic biopsy, and exclusion criteria including active, untreated central nervous system metastasis and autoimmune disease.",
    "This phase 2 trial is testing the efficacy of e6005 and e6005 ointment in treating atopic dermatitis in adults, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for head and neck cancer using cetuximab, 5-fu, hydroxyurea, and cisplatin, with eligibility criteria including age, cancer stage, and no prior chemotherapy or radiotherapy.",
    "The sample is a phase 2 trial for gastroesophageal reflux disease (GERD) with xp19986 sr3 and placebo as drugs, and the eligibility criteria includes a history and documentation of GERD diagnosed by a gastroenterologist with symptoms of heartburn and/or regurgitation on \u2265 3 days during the week prior to screening and prior to randomization.",
    "The sample is a phase 2 trial for severe, persistent asthma, testing the efficacy of tiotropium and placebo drugs, with inclusion and exclusion criteria specified, and icd-10 codes provided for the disease.",
    "This is a phase 2 clinical trial for ulcerative colitis, testing the efficacy of tralokinumab and placebo drugs on patients who meet specific inclusion criteria, such as being diagnosed with ulcerative colitis at least 90 days prior to randomization and being non-hospitalized with moderate-severe ulcerative colitis treated with stable background UC therapy.",
    "The sample is a phase 2 trial for seasonal allergic rhinitis, testing the efficacy of budesonide and placebo, with inclusion and exclusion criteria based on medical history and symptoms.",
    "This is a phase 2 trial for patients with small cell carcinoma of the lung, testing the efficacy of filgrastim, pegfilgrastim, etoposide, and cisplatin, with specific eligibility criteria for patients' disease and patient characteristics.",
    "This phase 2 trial is testing the efficacy of folfox-4+cetuximab and folfox-4 drugs in treating metastatic colorectal carcinoma with non-resectable hepatic metastases, with specific eligibility criteria including proper liver, kidney, and hematological function, and exclusion criteria such as prior administration of monoclonal antibodies or EGFR-targeted treatment.",
    "This phase 2 trial is testing the efficacy of bevacizumab and doxorubicin hydrochloride liposome in treating unresectable, locally recurrent or metastatic breast cancer patients with measurable disease, who are ErbB2-negative, have no known CNS metastases, and meet a range of patient characteristics and prior concurrent therapy criteria.",
    "The sample is a phase 2 trial for postoperative pain in patients undergoing unilateral inguinal or laparoscopic umbilical herniorrhaphy, using 5x5cm bupivacaine collagen sponges as the drug, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the effectiveness of bevacizumab, erlotinib, paclitaxel, and 5-fu in treating head and neck cancer with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with recurrent or refractory Hodgkin's lymphoma, testing the efficacy of bortezomib and gemcitabine hydrochloride, with eligibility criteria including specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions.",
    "This phase 2 trial is testing the efficacy of capecitabine and paclitaxel poliglumex in treating metastatic breast cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of pemetrexed disodium and sorafenib tosylate in treating non-squamous cell non-small cell lung cancer patients who have previously been treated with 1 chemotherapy regimen, including adjuvant treatment, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug panzem\u00ae ncd for patients with metastatic prostate cancer who have had prior treatment with a taxane-based regimen and evidence of disease progression, and meet other eligibility criteria.",
    "The sample is a phase 2 clinical trial for patients with various types of melanoma, testing the effectiveness of carboplatin, paclitaxel, and bortezomib as treatment options, with eligibility criteria including prior therapy limitations and specific medical conditions.",
    "This phase 2 trial is testing the efficacy of oncaspar, doxil, and decadron in treating various lymphoid malignancies, with eligibility criteria including prior chemotherapy failure, ECOG performance status of \u2264 2, and LVEF > 40%.",
    "This phase 2 trial is testing the efficacy of tesetaxel in treating stage IV breast cancer patients who are HER2 negative and have measurable disease, with eligibility criteria including being female, at least 18 years old, and having adequate bone marrow, hepatic, and renal function.",
    "This phase 2 trial is testing the efficacy of panitumumab, an anti-EGFR antibody, in treating untreated, locally advanced squamous cell carcinoma of the head and neck, with eligibility criteria including measurable or evaluable disease, ECOG 0-1, and adequate organ function.",
    "The sample is a phase 2 trial for chronic hepatitis C with the drugs placebo and pf-04136309, and the inclusion criteria being chronic HCV infection and ALT >1.5 but <10 times upper limit of normal.",
    "This phase 2 trial is testing the efficacy of ofatumumab, a drug used to treat multiple sclerosis, in patients with relapsing-remitting course of disease who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for patients with myelodysplastic syndrome, using decitabine as the drug, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for coronary heart disease, testing the drugs placebo and dalcetrapib, with inclusion criteria including age, CHD or CHD risk equivalent, and appropriate treatment for accepted LDL-C level, and exclusion criteria including treatment with drugs raising HDL-C, uncontrolled hypertension, recent clinically significant coronary events, transient ischemic attacks or cerebrovascular accident, severe anemia, and poorly controlled diabetes.",
    "This phase 2 trial is testing the effectiveness of cinaciguat and placebo in treating heart failure and heart decompensation, with specific inclusion and exclusion criteria for subjects.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide in treating stage IV or unresectable stage III malignant melanoma patients expressing NY-ESO-1 or LAGE-1, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of docetaxel and cisplatin in treating non-small cell lung cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for locally advanced bladder cancer patients who are candidates for cystectomy following chemotherapy, and the trial will test the efficacy of abi-007, carboplatin, and gemcitabine as treatment options.",
    "This phase 2 trial is testing the efficacy of cts-1027, pegylated interferon, ribavirin, and placebo in treating hepatitis C in null responders to prior therapy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for non-small cell lung cancer testing the efficacy of pemetrexed, cisplatin, and carboplatin, with specific eligibility criteria for patients who have undergone complete tumor resection and are N2 negative.",
    "This phase 2 trial is testing the efficacy of via-2291 and placebo in reducing carotid stenosis in patients with atherosclerosis, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of lonidamine in treating benign prostatic hyperplasia in men aged 65-80 with lower urinary tract symptoms, with inclusion criteria including prostate volume >30cc, Qmax <15mL/sec, and PSA >1.0ng/mL, and exclusion criteria including prior treatment with alpha blockers or herbal supplements for BPH in the past 2 weeks, active urinary tract infections, and uncontrolled diabetes mellitus.",
    "This phase 2 trial is testing the efficacy of various HIV medications, including mk0518 monotherapy and combination therapy, efavirenz, tenofovir, and lamivudine, on patients who have received less than 7 days of antiretroviral therapy and have HIV infections or acquired immunodeficiency syndrome, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cc-10004 and placebo in treating moderate-to-severe plaque-type psoriasis with specific inclusion and exclusion criteria, including a history of treatment failure to certain biologic therapies and restrictions on topical and systemic therapy use prior to randomization.",
    "This phase 2 trial is testing the efficacy of bibw 2992 and cetuximab in treating metastatic or recurrent squamous cell carcinoma of the head and neck, with specific eligibility criteria and exclusion criteria listed.",
    "The sample is a phase 2 trial for patients with Dengue Haemorrhagic Fever, testing the efficacy of activated recombinant human factor VII and placebo, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of a placebo drug on adult participants with moderate-to-severe chronic plaque psoriasis, with inclusion criteria based on body surface area involvement, Physician's Global Assessment scale, and PASI score, and exclusion criteria including nonplaque forms of psoriasis, corticosteroid use, and previous exposure to certain agents.",
    "This phase 2 trial is testing the drug bortezomib for previously untreated or minimally treated mantle cell lymphoma patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of siltuximab, placebo, and best supportive care in treating myelodysplastic syndrome patients who have received at least 2 units of RBC transfusion and have an International Prognostic Scoring System score of 0, 0.5, or 1.0, with inclusion and exclusion criteria specified.",
    "This is a phase 2 trial for heart failure patients with a history of LVEF \u2264 40% and elevated BNP or NT-proBNP, testing the efficacy of omecamtiv mecarbil compared to placebo, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of bevacizumab, carboplatin, paclitaxel, and placebo in treating metastatic melanoma with measurable or non-measurable disease, and has strict inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of multiple doses of GW642444 in treating chronic obstructive pulmonary disease (COPD) in subjects who meet specific inclusion criteria, including a history of COPD, tobacco use, and specific lung function measurements, while excluding subjects with certain medical conditions or medication use.",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus, testing the efficacy of he3286 and placebo drugs, with inclusion criteria including stable metformin use or drug-naive status, fasting blood glucose levels, HbA1c levels, and BMI range, and exclusion criteria including cardiovascular disease, unstable diabetic complications, long term insulin therapy, and abnormal laboratory results.",
    "This is a phase 2 trial for patients with various types of lymphoma, testing the effectiveness of velcade\u00ae, rituximab, cyclophosphamide, and decadron, with specific eligibility criteria including adequate bone marrow, renal, and hepatic function, and exclusion criteria such as known HIV positive status and prior therapy for lymphoma.",
    "This phase 2 trial is testing the drug clofarabine on patients with leukemia who meet specific eligibility criteria related to liver and kidney function, age, performance status, and other health factors.",
    "This is a phase 2 trial for patients with prostate cancer, testing the drug revlimid, with eligibility criteria including documented prostate cancer, hormone refractory and androgen independent, and adequate liver and bone marrow function.",
    "This phase 2 trial is testing the efficacy of gsk716155 and placebo in treating chronic dilated cardiomyopathy of ischemic or non-ischemic origin in patients with NYHA Class II/III heart failure, with eligibility criteria including left ventricular ejection fraction greater than or equal to 40%, stable on optimal therapies for at least 3 months prior to screening/baseline visit, and confirmed QTcB or QTcF < 480 msec.",
    "This phase 2 trial is testing the effectiveness of tipranavir and ritonavir in treating HIV infections in treatment-na\u00efve patients with specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of azd5423, budesonide, and placebo in patients with chronic obstructive pulmonary disease (COPD) who meet specific inclusion criteria, including a clinical diagnosis of COPD for more than 1 year, current maintenance therapy with LABA and/or LAMA, ICS/LABA or ICS plus LAMA combination, and post-bronchodilator FEV1 \u226540 and \u2264 80% of the predicted normal value.",
    "This phase 2 trial is testing the efficacy of ladr treatment for hepatitis C in liver transplant candidates, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of enzastaurin and sunitinib, along with a placebo, in treating metastatic renal cell carcinoma in participants who have not received prior systemic therapy for RCC, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for lung cancer patients with the drug docetaxel, and the eligibility criteria includes specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions.",
    "This is a phase 2 trial for metastatic breast cancer patients with HER2/neu overexpressing and/or amplified disease, testing the efficacy of lapatinib and vinorelbine as treatment, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for psoriasis vulgaris, testing the efficacy of bt061 and placebo treatment, with inclusion criteria including BSA involvement > 10% for more than 6 months and PASI \u226510.",
    "The sample is a phase 2 trial for atherosclerosis testing the drugs sb-480848 and sb-480848 matching placebo, with inclusion criteria including successful PCI and antiplatelet therapy, and exclusion criteria including clinical instability and previous CABG surgery.",
    "The sample is a phase 2 trial for cystic fibrosis patients with the G551D-CFTR mutation, testing the efficacy of vx-770 and placebo drugs, with inclusion and exclusion criteria listed.",
    "This phase 2 trial will test the efficacy of capecitabine in treating stage I-III operable breast cancer with primary tumor greater than or equal to 2cm, and the eligibility criteria includes ECOG performance status 0-1, WBC > 4000/mm3, and calculated creatinine clearance > 50ml/min.",
    "This phase 2 trial is testing the drug fostamatinib on patients with relapsed or refractory diffuse large B-cell lymphoma who have previously received R-CHOP chemo-immunotherapy and high dose chemotherapy with stem cell rescue, or who are ineligible for high dose therapy with stem cell rescue, and have measurable disease as defined by Cheson et al 2007 criteria.",
    "The sample is a phase 2/phase 3 trial for chronic kidney disease using the drug zemplar, with inclusion criteria of eGFR 15-59 ml/m2 and exclusion criteria of current vitamin D treatment.",
    "This phase 2 trial is testing the drug Remeron (mirtazapine) on patients with advanced cancer who have lost 10% of their body weight in the last 6 months, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of gleevec and taxotere in treating patients with non-small cell lung cancer who have had one prior chemotherapy treatment and meet specific eligibility criteria.",
    "The sample is a phase 2 trial for non-Hodgkin's lymphoma using rituximab and bortezomib as drugs, with specific eligibility criteria including no prior therapy for non-Hodgkins lymphoma and negative pregnancy test.",
    "The sample is a phase 2 trial for rheumatoid arthritis testing the efficacy of ph-797804 and placebo drugs on patients who have failed at least 1 DMARD therapy, with inclusion and exclusion criteria provided.",
    "The sample is a phase 2 trial for type 2 diabetes mellitus, testing the efficacy of cjc-1134-pc and placebo drugs, with inclusion criteria including stable diabetes and metformin use, and a HbA1c level between 7.1% and 11%.",
    "This phase 2 trial is testing the efficacy of lapatinib, paclitaxel, fluorouracil, epidoxorubicin, and cyclophosphamide in treating HER2 positive infiltrating primary breast cancer of > 2.0 cm in largest clinical diameter, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of aflibercept, a drug used to treat metastatic colorectal cancer, in patients who have already received prior systemic therapy for their disease. The trial includes eligibility criteria such as measurable disease, prior surgery, and specific laboratory values.",
    "The sample is a phase 2 clinical trial for patients with relapsed or refractory multiple myeloma, testing the efficacy of bortezomib, dexamethasone, and thalidomide, with eligibility criteria including measurable disease, no evidence of POEMS syndrome, and various medical and psychiatric exclusions.",
    "This phase 2 trial is testing the efficacy of GSK1265744, efavirenz, rilpivirine, and placebo in HIV-1 infected subjects who are ART-naive, with inclusion criteria including a screening plasma HIV-1 RNA >=1000 c/mL and CD4+ cell count >=200 cells/millimeter (mm)^3.",
    "The sample is a phase 2 trial for chronic idiopathic constipation, testing the efficacy of sp-304 at various doses and a placebo, with inclusion and exclusion criteria based on BMI, Rome III Diagnostic Criteria, and pre-treatment bowel movement diary accuracy.",
    "The sample is a phase 2/phase 3 trial for type 2 diabetes mellitus, testing the efficacy of alogliptin and pioglitazone in patients who have been taking stable doses of pioglitazone for at least 16 weeks, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of apricoxib/erlotinib and erlotinib/placebo in treating recurrent non small cell lung cancer patients who have failed at least one prior platinum-based chemotherapy, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with metastatic kidney cancer, testing the drug tanespimycin, with eligibility criteria including confirmed renal cell carcinoma, measurable disease, and specific patient characteristics and prior therapy requirements.",
    "The sample is a phase 2 trial for non-small-cell lung cancer patients who failed one prior chemotherapy regimen and are eligible for further chemotherapy, testing the efficacy of pemetrexed and erlotinib, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of peficitinib and placebo in treating rheumatoid arthritis patients who meet specific inclusion criteria, while excluding those with certain medical histories or taking certain medications.",
    "This phase 2 trial is testing the efficacy of carboplatin and pemetrexed disodium in treating previously untreated extensive-stage small cell lung cancer patients with measurable disease, while meeting specific eligibility criteria.",
    "The sample is a phase 2 trial for renal transplant patients receiving cyclosporine or tacrolimus, testing the efficacy of belatacept in combination with the current treatment, with eligibility criteria including age, GFR, and completion of a previous study, and exclusion criteria including infection, rejection, and pregnancy.",
    "The sample is a phase 2 trial for patients with myelodysplastic syndromes, testing the drug obatoclax mesylate (gx15-070ms), with inclusion criteria including pathological confirmation of MDS and no prior systemic therapy.",
    "This is a phase 2 trial for depression, testing the efficacy of evt 101 and placebo drugs on patients who have not benefited from previous treatments, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for heart failure patients with NYHA Classification III or IV, using the drugs clp and placebo, and with inclusion criteria including recent hospitalization for heart failure decompensation and chronic kidney disease.",
    "The sample is a phase 2 trial for rheumatoid arthritis, testing the drugs cp-690,550 and atorvastatin, with inclusion criteria of active rheumatoid arthritis and exclusion criteria of recent serious infection or positive TB test.",
    "This phase 2 trial is testing the efficacy of ep-101 via nebulizer and other drugs in treating moderate to severe chronic obstructive pulmonary disease (COPD) in patients aged 40-75 with a smoking history of at least 10 pack-years, and with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of the drugs nnc0114-0006 and placebo in treating inflammation and rheumatoid arthritis, with eligibility criteria including a diagnosis of RA meeting ACR classification criteria, active RA characterized by DAS28-CRP, and concomitant treatment with MTX.",
    "This phase 2 trial is testing the drug amrubicin on patients with refractory small cell lung cancer, with eligibility criteria including measurable disease, adequate organ function, and no history of interstitial lung disease or pulmonary fibrosis.",
    "This phase 2 trial is testing the drug ataluren for the treatment of Duchenne muscular dystrophy, with inclusion and exclusion criteria for eligible participants.",
    "This phase 2 trial is testing the drug fk778 for kidney transplantation in patients with end stage kidney disease or needing retransplantation, with specific inclusion and exclusion criteria, and the diseases being studied include kidney transplantation, renal transplantation, transplantation, renal, transplantation, kidney, and grafting, kidney.",
    "The sample is a phase 2 trial for bronchiolitis, testing the efficacy of mk-0476 and montelukast sodium, with inclusion criteria of active bronchiolitis or a history of bronchiolitis and asthma-like symptoms, and exclusion criteria of any significant illness that poses additional risk to the patient.",
    "This phase 2 trial is testing the effectiveness of gefitinib, an EGFR inhibitor, in treating squamous cell carcinoma of the head and neck, with specific inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial involves patients with various hematological malignancies and disorders, who will receive a combination of drugs including busulfan, cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, and methylprednisolone, and must meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of GSK561679, a drug, in treating major depressive disorder in female outpatients aged 25-64 years, inclusive, who meet specific inclusion criteria and do not have any exclusion criteria.",
    "This phase 2 trial is testing the drug everolimus on patients with relapsed or chemotherapy-resistant mantle cell lymphoma, with specific eligibility criteria for disease characteristics and patient characteristics.",
    "This phase 2 trial is testing the drug romidepsin on patients with recurrent small cell lung cancer who meet specific eligibility criteria, including having measurable disease, an ECOG performance status of 0-1, and no significant cardiac disease.",
    "The sample is a phase 2 trial testing the efficacy of dexamethasone implant in diabetic patients with cystoid macular edema after cataract surgery, with inclusion and exclusion criteria listed, and the diseases and icd-10 codes are pseudophakic cystoid macular edema and diabetic macular edema.",
    "The sample is a phase 2 trial for patients with bronchial asthma, testing the efficacy of ono-6950, placebo, and montelukast, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for metastatic renal cell cancer, testing the efficacy of bevacizumab, interferon alfa-2a, and vinblastine, with inclusion criteria of adult patients with measurable lesions and exclusion criteria of prior treatment with certain therapies or significant cardiovascular disease.",
    "The sample is a phase 2 trial for patients with adenocarcinoma of the lung, testing the efficacy of farletuzumab in combination with chemotherapy drugs carboplatin, paclitaxel, pemetrexed, and cisplatin, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of ixabepilone in treating metastatic breast cancer in patients who meet specific eligibility criteria, including having measurable or nonmeasurable disease with serum CA27.29 or CA15.3 \u2265 50, HER2 negative breast cancer, and an ECOG PS of 0-2.",
    "The sample is a phase 2 trial testing the efficacy of doripenem, an antibiotic, in treating nosocomial pneumonia and ventilator-associated pneumonia caused by various bacterial infections, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of voclosporin and tacrolimus in preventing kidney transplant rejection in patients who meet specific eligibility criteria, including being between 18-65 years old, receiving their first cadaveric or living donor renal transplant, and able to receive oral medication at the time of randomization.",
    "This phase 2 trial is testing the drug temozolomide for confirmed diagnosis of acute myeloid leukemia or high risk MDS with blasts between 10 and 20% in the bone marrow, with confirmed low MGMT expression, and with certain exclusion criteria.",
    "This is a phase 2 clinical trial for patients with multiple myeloma, testing the effectiveness of bortezomib as a treatment option, with specific inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial is testing the efficacy of bevacizumab and everolimus in treating colorectal adenocarcinoma that has progressed on previous chemotherapy, with specific eligibility criteria including normal organ function and adequate contraception use.",
    "This phase 2 trial is testing the efficacy of sunitinib in treating patients with glioblastoma multiforme, with eligibility criteria including evidence of first tumor progression and recovery from surgery, and exclusion criteria including recent chemotherapy or radiation therapy and significant co-morbidities.",
    "This phase 2 trial is testing the efficacy of RAD001 and erlotinib in treating neuroendocrine tumors, with specific inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial is testing the drug rosiglitazone maleate in patients with inoperable differentiated thyroid cancer who have failed prior conventional therapy, with eligibility criteria including elevated thyroglobulin levels and a negative radioactive iodine scan, among other patient characteristics.",
    "This phase 2 trial is testing the efficacy of fostamatinib disodium and placebo in treating rheumatoid arthritis patients who have been receiving weekly methotrexate doses for at least 3 months, with stable MTX dose for the previous 6 weeks, and meet other inclusion criteria.",
    "This phase 2 trial is testing the efficacy of oxaliplatin, raltitrexed, and other intravenous chemotherapy drugs in treating colorectal cancer with liver metastases, with eligibility criteria including confirmed hepatic metastases, failure or arrest of previous chemotherapy, and certain laboratory values within normal limits.",
    "The sample is a phase 2 trial for schizophrenia with drugs pf-00217830 and aripiprazole, and inclusion criteria of current diagnosis of schizophrenia and increase in symptoms over the past 2-4 weeks, while exclusion criteria include subjects with a current DSM-IV axis I diagnosis other than schizophrenia and females of childbearing potential.",
    "This phase 2 trial is testing the effectiveness of capsaicin patch on patients with Painful Postherpetic Neuralgia, with eligibility criteria including having unbroken skin and the ability to feel capsaicin-mediated sensations, and exclusion criteria including having diffusely distributed neuropathic pain and hypersensitivity to capsaicin.",
    "The sample is a phase 2 trial for the drug tamsulosin hydrochloride in patients with neuropathic bladder secondary to known neurological disorder, with elevated detrusor leak point pressures, and exclusion criteria including clinically significant abnormalities and history of relevant orthostatic hypotension, fainting spells or blackouts.",
    "The sample is a phase 2 trial for atopic dermatitis and eczema, testing the efficacy of mapracorat and a vehicle without active ingredient, with inclusion criteria including a diagnosis of atopic dermatitis and willingness to follow study procedures, and exclusion criteria including pregnancy, immunosuppressive disorder, and relevant drug/food allergies.",
    "The sample is a phase 2 trial for asthma patients, testing the efficacy of inhaled tiotropium bromide versus placebo, with specific inclusion and exclusion criteria, and a list of ICD-10 codes for asthma.",
    "This clinical trial will test the efficacy of sitagliptin, a DPPIV-inhibitor, in improving glucose metabolism in HIV-infected individuals with stable immunologic and virologic status, who are on antiretroviral therapy, and have diabetes or insulin resistance.",
    "The sample is a phase 2 trial for patients with metastatic pancreatic cancer, testing the efficacy of alvocidib and docetaxel, with eligibility criteria including measurable disease, no brain metastases, and certain laboratory values within normal limits.",
    "The sample is a phase 2 trial for melanoma patients previously treated with Stage III or IV, using ipilimumab (mdx-010, bms-734016) as the drug, and the eligibility criteria includes patients with certain stages of melanoma.",
    "The sample is a phase 2 trial testing the drug nvc-422 for the treatment of impetigo, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial for non-small-cell lung cancer using sagopilone as the drug, with inclusion criteria of only one previous chemotherapy with a platinum-containing drug and exclusion criteria of no more than 1 previous chemotherapy for advanced disease, previous participation in another trial within the last 4 weeks, breast feeding, and active infections.",
    "This is a phase 2 trial for patients with heart valve diseases, testing the effectiveness of warfarin and dabigatran etexilate at different doses, with specific eligibility criteria including age range and exclusion criteria such as prior valve surgery and increased risk of bleeding.",
    "This phase 2 trial is testing the efficacy of azathioprine weight-based dose and azathioprine individualised dose in treating Crohn's disease patients who are steroid-dependent, steroid-refractory or steroid naive, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of capecitabine, docetaxel, and gemcitabine hydrochloride in treating carcinoma of unknown primary with specific eligibility criteria for patients.",
    "This phase 2 trial will test the efficacy of SAR292833 and placebo in treating chronic peripheral neuropathic pain associated with diabetic polyneuropathy and post-herpetic neuralgia, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of lenalidomide, dexamethasone, and aspirin in treating relapsed or refractory multiple myeloma patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of sunitinib malate, a tyrosine kinase inhibitor, in treating advanced, relapsed or refractory esophageal or gastroesophageal junction carcinoma that is not amenable to curative surgery or other curative therapy, with a list of eligibility criteria.",
    "This phase 2 trial will test the efficacy of ilaprazole and lansoprazole in treating erosive esophagitis with specific inclusion and exclusion criteria, including a history of certain medical conditions and medications.",
    "This phase 2 trial is testing the efficacy of bevacizumab, gemcitabine, and oxaliplatin in treating locally unresectable or metastatic biliary tract or gallbladder adenocarcinoma, with specific eligibility criteria for patients.",
    "The sample is a phase 2 clinical trial for the drug ataluren in patients with cystic fibrosis who meet specific eligibility criteria, including having a diagnosis of CF based on abnormal sweat test and nasal epithelial TEPD total chloride conductance, and exclusion criteria such as prior exposure to ataluren or ongoing medical conditions that could adversely affect safety.",
    "This phase 2 trial is testing the efficacy of gleevec, a drug, in treating extensive-stage small cell lung cancer patients who are c-kit-positive, with specific eligibility criteria including no prior chemotherapy for SCLC and adequate organ function.",
    "This phase 2 clinical trial is testing the efficacy of oxaliplatine/gemcitabine/vinorelbine in treating non-small cell lung cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of cetuximab, a drug used to treat lung cancer, in patients with inoperable or unresectable non-small cell lung cancer who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug lenalidomide on patients with relapsed or refractory non-Hodgkin's lymphoma who have undergone prior chemotherapy, and have measurable disease on cross-sectional imaging, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for locally advanced or metastatic colorectal cancer, testing the efficacy of bevacizumab, capecitabine, and oxaliplatin, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cisplatin, docetaxel, fluorouracil, and cetuximab in treating stage III or nonmetastatic stage IV squamous cell carcinoma of the oropharynx, with specific eligibility criteria for patients.",
    "The sample is a phase 2 trial for treatment-naive, genotype 1 only, compensated, chronic hepatitis C infected Caucasian or African-American patients using viramidine and peginterferon alfa-2b, with eligibility criteria including body weight, HCV RNA, alanine aminotransferase, hemoglobin, and creatinine clearance, and exclusion criteria including cirrhosis of the liver, severe neuropsychiatric disorders, and other co-morbid chronic viral infections.",
    "This phase 2 trial will test the efficacy of adefovir dipivoxil and tenofovir disoproxil fumarate in treating HIV and hepatitis B co-infection, with specific inclusion and exclusion criteria for different populations.",
    "This phase 2 trial is testing the efficacy of delafloxacin and tigecycline in treating skin structure infections, abscesses, and cellulitis in adults, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation in treating metastatic breast cancer patients with measurable disease, and who have received prior treatment with trastuzumab or have a contraindication for trastuzumab.",
    "This phase 2 trial is testing the drug amuvatinib on patients with small cell lung carcinoma who have progressed or relapsed on platinum-etoposide chemotherapy, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of gemcitabine hydrochloride in treating metastatic breast cancer that has not progressed after multiple forms of chemotherapy, with eligibility criteria including refractory hormone receptor positive breast cancer and frailty characteristics, and excluding patients with known allergies to gemcitabine.",
    "This phase 2 trial will test the efficacy of bay 43-9006, docetaxel, and cisplatin in treating patients with advanced unresectable or metastatic gastric or GEJ adenocarcinoma, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for cardiac surgery patients using GIK and a control drug, with inclusion criteria including age, LVEF, and informed agreement, and exclusion criteria including previous surgery, diabetes, and enrollment in another clinical study.",
    "This phase 2 trial is testing the efficacy of atacicept and placebo in treating rheumatoid arthritis patients who have previously been treated with rituximab and have active disease, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for epilepsy using diazepam as the drug, with inclusion criteria of a diagnosis of epilepsy and exclusion criteria of individuals receiving warfarin or dabigatran, use of any investigational drug within 30 days, blood or plasma donation within 30 days, and not willing or unable to tolerate blood draws.",
    "This phase 2 trial is testing the efficacy of arsenic trioxide in treating metastatic or recurrent endometrial carcinoma, with eligibility criteria including documented progression of the cancer, presence of measurable lesions, and adequate organ function.",
    "This phase 2 trial aims to test the efficacy of tc-5619, a drug for cognitive dysfunction, in patients with stable schizophrenia and negative symptoms, as well as to evaluate its safety and tolerability.",
    "This phase 2 trial is testing the efficacy of prednisolone, dipyridamole, prednisone, and z102 in treating moderate to severe rheumatoid arthritis patients who meet specific eligibility criteria, including having been on a stable dose of conventional DMARD therapy for at least 90 days without dosage adjustment or modification.",
    "This phase 2 trial will test the efficacy of celecoxib, a COX-2 inhibitor, in reducing the risk of breast cancer in premenopausal women with elevated risk factors, including a family history of breast cancer or a known BRCA1 or BRCA2 mutation.",
    "This phase 2 trial is testing the efficacy of irinotecan, oxaliplatin, fluorouracil, and leucovorin in treating locally advanced or metastatic gastric cancer with measurable or evaluable disease, and patients must meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of sunitinib malate in treating patients with various types of recurrent and metastatic squamous cell carcinoma of the head and neck, with specific eligibility criteria including measurable disease, no brain metastases, and normal organ function.",
    "This phase 2 trial will test the efficacy of AllerT low and full dose compared to placebo in treating moderate to severe allergic rhinoconjunctivitis to birch pollen, with inclusion and exclusion criteria based on symptom scores, previous medication use, SPT and specific IgE CAP tests, and other medical conditions.",
    "This phase 2 trial is testing the efficacy of pemetrexed, carboplatin, gemcitabine, and vinorelbine in treating advanced breast cancer in females who have undergone prior chemotherapy containing anthracyclines and taxanes, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug oc000459 and placebo on males and females aged 18 to 50 years with a history of grass pollen related allergic rhinitis, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for advanced or metastatic breast cancer using pemetrexed as the drug, with specific inclusion and exclusion criteria, and a list of diseases and their corresponding icd-10 codes.",
    "This trial is a phase 2/phase 3 study for renal transplantation patients, testing the effect of fluvastatin on LDL-cholesterol levels in combination with immunosuppression drugs, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for dry eye, Sjogren's syndrome, and graft vs. host disease, testing thymosin beta 4 eye drops and vehicle control, with eligibility criteria including Schirmers of <5 mm at 5 minutes and exclusion criteria including acute or inflammatory corneal disease.",
    "This phase 2 trial is testing the efficacy of cellulose sulfate vaginal gel as a contraceptive method for couples in a stable, mutually monogamous relationship, who are willing to use the study product as instructed, and meet a set of eligibility criteria.",
    "The sample is a phase 2 trial for asthma patients, testing the efficacy of budesonide and placebo drugs, with inclusion and exclusion criteria based on clinical diagnosis, FEV1 measurements, and hospitalization history.",
    "The sample is a phase 2 trial for hypercholesterolemia and dyslipidemia, using atorvastatin, rosuvastatin, or simvastatin, with specific lipid criteria for inclusion and exclusion criteria related to cardiovascular events, poorly controlled diabetes, and hypertension.",
    "This phase 2 trial is testing the efficacy of trastuzumab and oxaliplatin in treating HER2/neu positive metastatic breast cancer patients who have progressed on hormonal therapy and have completed all prior therapy, with a list of eligibility and exclusion criteria.",
    "This phase 2 trial is testing the drug lenalidomide on patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma who are 65 or older and have adequate renal and hepatic function, with eligibility criteria including disease-free status for 5 years and negative pregnancy tests for females of childbearing potential.",
    "This phase 2 trial is testing the effectiveness of intensified chemotherapy (folfoxiri/bevacizumab) in treating advanced colorectal carcinoma with liver and/or lung only metastases, with specific eligibility criteria including age, disease stage, and laboratory parameters.",
    "This phase 2 trial is testing the drug sapacitabine on adult patients with advanced cutaneous t-cell lymphoma (CTCL) who have had at least 2 systemic therapies and meet other eligibility criteria.",
    "This phase 2 trial is testing the efficacy of various drugs, including pt005 mdi and formoterol fumarate, in treating chronic obstructive pulmonary disease (COPD) in patients who meet specific inclusion criteria, such as having a post-bronchodilator FEV1/FVC ratio of < or = 0.70 and being current/former smokers with at least a 10 pack-year history of cigarette smoking.",
    "This phase 2 trial is testing the efficacy of ar-13324 ophthalmic solution and latanoprost ophthalmic solution in reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension, with strict inclusion and exclusion criteria.",
    "This phase 2 trial focuses on kidney transplantation and tests the drugs cp-690,550 and tacrolimus, with eligibility criteria including being a first-time kidney transplant recipient between the ages of 18 and 70 years.",
    "This phase 2 trial is testing the efficacy of low, medium, and high doses of bi 1356 bs and placebo in Japanese patients with type 2 diabetes mellitus treated with diet and/or exercise only or with one or two oral hypoglycaemic agents except glitazones, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2/phase 3 trial for patients with Philadelphia chromosome positive accelerated or blast phase chronic myeloid leukemia, testing the drug panobinostat, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the drug sunitinib malate on patients with advanced kidney cancer, with the inclusion criteria being advanced kidney cancer and the exclusion criteria being previous treatment for kidney cancer, except surgical removal of kidney tumor.",
    "This phase 2 trial is testing the efficacy of risperidone and rbp-7000 in treating paranoid, residual, or undifferentiated schizophrenia, with strict inclusion and exclusion criteria including no hospitalizations for acute exacerbations within 3 months of screening and no concurrent medication/over-the-counter products that may interfere with the metabolism or excretion of risperidone and/or 9-hydroxyrisperidone.",
    "The sample is a phase 2/phase 3 trial for hyperlipidemia using simvastatin 20 mg/ezetimibe, with inclusion criteria of moderately obese patients and exclusion criteria of recent unstable heart or lung condition, current use of other lipid modifying drugs, hepatic disease, pregnancy or lactation.",
    "The sample is a phase 2/phase 3 trial for the treatment of migraine with telcagepant and placebo, with inclusion and exclusion criteria related to menstrual cycles, migraine history, medication use, and medical history.",
    "This phase 2 trial is testing the efficacy of ch-4051 and methotrexate in treating rheumatoid arthritis in patients who meet specific inclusion criteria and do not have any exclusion criteria.",
    "This phase 2 trial is testing the efficacy of poly iclc and temozolomide in treating glioblastoma multiforme, with eligibility criteria including confirmed diagnosis, performance status, blood counts, liver and kidney function, and absence of concurrent infections or medical illnesses. Prior radiation therapy, chemotherapy, immunotherapy, or hormonal therapy for the brain tumor are not allowed, and patients must be willing to forego other cytotoxic and non-cytotoxic drug therapy against the tumor while being treated with the study drugs.",
    "This phase 2 clinical trial is testing the efficacy of inx-08189, daclatasvir, and ribavirin in treating chronic genotype 2 or 3 hepatitis C in HCV treatment-na\u00efve patients with non-cirrhotic liver disease, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of pemetrexed and cisplatin in treating small cell lung cancer patients who meet specific eligibility criteria, including having no previous systemic chemotherapy, functional stage 0-2 of the ECOG functional scale, and at least one measurable lesion that complies with the solid tumor response evaluation criteria.",
    "This phase 2 trial is testing the efficacy of LX4211, a drug for type 2 diabetes mellitus, with a placebo control, and has specific inclusion and exclusion criteria for eligible subjects.",
    "This phase 2 trial is testing the drug Velcade for patients with inoperable locally advanced or metastatic colorectal carcinoma who have received no more than 2 prior treatment regimens for metastatic disease, one of which must have contained irinotecan, and have relapsed or progressed while receiving an irinotecan-containing regimen.",
    "The sample is a phase 2 trial for coronary artery disease using the drug ono-1101, with eligibility criteria including age and heart rate, and exclusion criteria including allergies to contrast agent, renal failure, asthma, and concomitant beta-receptor blocking agent.",
    "This phase 2 trial is testing the efficacy of docetaxel and capecitabine in treating metastatic breast cancer patients who meet certain eligibility criteria and do not have any exclusion criteria.",
    "This phase 2 trial aims to evaluate the efficacy of elagolix, placebo, estradiol/norethindrone acetate, estradiol, and progesterone in treating heavy uterine bleeding associated with uterine fibroids in pre-menopausal females aged 20 to 49 years with regular menstrual cycles and a diagnosis of uterine fibroids, while excluding those with certain medical conditions and recent fibroid treatments.",
    "This phase 2 trial is testing the effectiveness of ramosetron, aprepitant, and dexamethasone in preventing nausea and vomiting in chemotherapy-na\u00efve patients with solid tumors who are planned to receive cisplatin-based chemotherapy, and have met the inclusion criteria.",
    "The sample is a phase 2 trial for prostate cancer using trabectedin as a drug, with eligibility criteria including confirmed adenocarcinoma, metastatic disease, and androgen independent disease.",
    "This phase 2 trial is testing the efficacy of gemcitabine hydrochloride in treating mantle cell lymphoma, with eligibility criteria including measurable disease and specific patient characteristics, while excluding those with certain medical conditions or concurrent treatments.",
    "The sample is a phase 2/phase 3 trial for type 2 diabetes mellitus with inadequate glycemic control, testing the efficacy of dapagliflozin and placebo, with inclusion criteria of moderate renal impairment and exclusion criteria of severe uncontrolled diabetes and serious cardiovascular, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases.",
    "This phase 2 trial aims to test the efficacy of asp3652 and placebo in treating chronic abacterial prostatitis and chronic pelvic pain syndrome, with specific inclusion and exclusion criteria for eligible participants.",
    "This is a phase 2 trial for asymptomatic multiple myeloma patients, testing the efficacy of zoledronic acid, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of IL-2 and zoledronic acid in treating kidney cancer patients who have not received prior cytokine, chemotherapy, hormonal, or other immuno-based therapies, and have measurable disease, with specific inclusion and exclusion criteria.",
    "This phase 2 trial aims to test the efficacy of atomoxetine and placebo in treating schizophrenia, memory disorders, and cognition disorders, with eligibility criteria including age range of 18-45 years, normal EKG and blood pressure readings, and exclusion criteria including patients taking certain medications or with a history of cardiovascular disease or serious medical illnesses.",
    "This phase 2 trial is testing the efficacy of chf6001 and placebo in treating mild to moderate allergic asthma in individuals between 18 and 60 years old, with inclusion criteria including atopy to at least one common aeroallergen and positive allergen-induced Early Asthmatic Response and Late Asthmatic Response at screening.",
    "This clinical trial is testing the effectiveness of algeron, pegintron, and ribavirin in treating hepatitis C in patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of colesevelam hydrochloride and placebo in treating type 2 diabetes mellitus with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of cf101 1mg, 2mg, and 4mg, as well as placebo, in treating moderate-to-severe chronic plaque-type psoriasis with body surface area involvement \u226510%, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for atopic dermatitis, testing the efficacy of dupilumab and placebo, with inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the drug rta 402 (bardoxolone methyl) on patients with diabetic nephropathy who meet specific eligibility criteria.",
    "The sample is a phase 2 clinical trial for the treatment of rheumatoid arthritis with peficitinib and placebo, with inclusion and exclusion criteria specified, and the use of certain medications prohibited.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide and all-trans retinoic acid in treating metastatic adenocarcinoma of the lung, with specific eligibility criteria and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of itopride HCI and placebo in treating irritable bowel syndrome with constipation, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of LY3009104, methotrexate, and placebo in treating active rheumatoid arthritis, with strict inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for breast cancer patients with HER2/neu-positive disease, using carboplatin and docetaxel as drugs, and the eligibility criteria includes specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions.",
    "The sample is a phase 2 trial for severe persistent asthma with the drugs cnto148 and placebo, and the eligibility criteria includes a physician diagnosis of asthma for at least 3 years, evidence of reversible airway obstruction, and a score of 2 or more on the asthma control questionnaire.",
    "This phase 2 trial aims to investigate the efficacy of sildenafil and placebo in treating female sexual arousal disorder, with pre-menopausal women aged 18-45 as the target population, and hypoactive sexual desire disorder as one of the exclusion criteria.",
    "This phase 2 trial is testing the effectiveness of sorafenib tosylate in treating hepatocellular carcinoma (HCC) in patients who are eligible for conservative hepatic resection or liver resection with curative intent, and meet a range of patient and disease characteristics.",
    "The sample is a phase 2 trial for heart failure patients with kidney damage, testing the efficacy of bay94-8862 and spironolactone as well as their excipients, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of azacitidine and gemtuzumab ozogamicin in treating various types of acute myeloid leukemia, with specific eligibility criteria including prior treatment history and certain laboratory values.",
    "This phase 2 trial is testing the efficacy of bevacizumab, vinorelbine, and trastuzumab in treating HER2-positive metastatic breast cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of rifaximin, an antibiotic, in HIV-1 infected patients who have been on antiretroviral therapy for at least 96 weeks, with the goal of reducing immune activation.",
    "This phase 2 trial is testing the efficacy of abraxane, leuprolide, and bicalutamide in treating patients with prostatic neoplasms who meet specific eligibility criteria, including having an elevated PSA and belonging to one of four groups based on disease progression.",
    "This phase 2 trial is testing the efficacy of dasatinib, a drug used to treat metastatic colorectal cancer, in patients who have undergone prior chemotherapy treatment and meet specific eligibility criteria.",
    "The sample is a phase 2 clinical trial for malignant mesothelioma, testing the efficacy of cisplatin and pemetrexed disodium as drugs, with eligibility criteria including confirmed diagnosis, specific disease characteristics, and patient characteristics such as age and hematopoietic function.",
    "This phase 2 trial is testing the effectiveness of tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) who are current or ex-smokers, and meet certain eligibility criteria.",
    "This phase 2 trial is testing the effectiveness of vinblastine, cyclophosphamide, and dacarbazine in treating metastatic melanoma, with specific eligibility and exclusion criteria.",
    "The sample is a phase 2 trial for osteoarthritis, testing the efficacy of rn624 (pf-04383119) and placebo, with inclusion criteria of chronic moderate to severe knee pain and exclusion criteria of autoimmune disorders, cancer, and drug abuse.",
    "The sample is a phase 2 trial for prostate cancer patients who have progressed on or are intolerant to docetaxel chemotherapy, and the study will test the drug cytarabine as a treatment option.",
    "This phase 2 trial is testing the efficacy of busulfan, fludarabine phosphate, methotrexate, and tacrolimus in treating various hematopoietic disorders, including anemia, leukemia, lymphoma, and myelodysplastic syndromes, in patients who are not eligible for autologous or mini-allogeneic transplantation and have an HLA-matched unrelated donor available.",
    "The sample is a phase 2 trial for advanced and metastatic breast cancer patients with Her2 positive status, testing the efficacy of larotaxel and trastuzumab, with eligibility criteria including adequate liver and kidney function and no more than one prior treatment for advanced disease.",
    "This phase 2 trial is testing the efficacy of rivaroxaban and enoxaparine in preventing venous thromboembolism in patients undergoing elective total knee replacement, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for lung cancer patients with no prior chemotherapy, using capecitabine and docetaxel, and with specific inclusion and exclusion criteria, including measurable disease and adequate organ function.",
    "The sample is a phase 2 trial for patients with coronary artery disease, testing the efficacy of cangrelor and ticagrelor drugs, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for type 2 diabetes mellitus, testing the efficacy of ipragliflozin and placebo, with specific inclusion and exclusion criteria based on serum creatinine, proteinuria, dysuria, renal, hepatic or cardiovascular diseases, ketosis, hypertension, and severe gastrointestinal diseases.",
    "This phase 2 trial is testing the efficacy of entinostat and azacitidine in treating metastatic colorectal cancer patients who have failed prior chemotherapy regimens and are not candidates for curative resection, with specific eligibility criteria including measurable disease, ECOG performance status 0-1, and various blood count and organ function requirements.",
    "This phase 2 trial is testing the effectiveness of lapatinib and paclitaxel in treating breast neoplasms with specific eligibility criteria, including adequate bone marrow and renal and hepatic function, while excluding pregnant or nursing females and those with major medical conditions or who have received investigational drugs within the past 4 weeks.",
    "This sample is a phase 2 trial for gastrointestinal stromal tumor using dasatinib as the drug, with eligibility criteria including confirmed GIST, measurable disease, and specific patient characteristics.",
    "The sample is a phase 2 trial for major depressive disorder, testing the drug cp-601,927, with inclusion criteria including ongoing antidepressant therapy and exclusion criteria including other psychiatric disorders and substance abuse.",
    "This is a phase 2 trial for patients with locally advanced inoperable or metastatic pancreatic cancer, testing the efficacy of erlotinib hydrochloride as a systemic therapy, with specific eligibility criteria for patients, including ECOG performance status, life expectancy, and prior therapy history.",
    "The sample is a phase 2 trial for the drug bavituximab in treating locally advanced or metastatic breast cancer with specific inclusion and exclusion criteria, and the disease is identified by its icd-10 codes.",
    "The sample is a phase 2 trial for asthma with the drugs bi 671800 and placebo, and the inclusion criteria includes a stable inhaled corticosteroid dose and an ACQ score of at least 1.5.",
    "This phase 2 trial is testing the efficacy of erlotinib and bevacizumab in treating unresectable locally advanced and/or metastatic non-small-cell lung cancer patients who have progressed to first-line therapy, with specific eligibility criteria including bi-dimensionally measurable disease, ECOG performance status of 0-2, and adequate liver, renal, and bone marrow function.",
    "This phase 2 trial is testing the efficacy of gen (xp13512/gsk1838262) and placebo in treating restless legs syndrome, with inclusion criteria including a history of RLS symptoms and a total RLS severity score of 15 or greater on the IRLS Rating Scale.",
    "This phase 2 trial is testing the efficacy of anastrozole and anastrozole plus tegafur-uracil in treating postmenopausal patients with invasive breast cancer that is estrogen receptor positive and HER2 negative, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2/phase 3 trial for the drug cx516 (ampakine) in patients with schizophrenia, with inclusion criteria including stable dose of clozapine, olanzapine or risperidone for at least 6 months, and exclusion criteria including serious medical or neurological illness, current substance abuse, and serious suicidal or homicidal risk within the past six months.",
    "This phase 2 trial is testing the efficacy of cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and sgn-30 in treating systemic anaplastic large cell lymphoma, with eligibility criteria including confirmed ALCL diagnosis, measurable disease, and certain blood count and organ function requirements.",
    "This phase 2 trial is testing the efficacy of fludarabine, velcade, and rituximab in treating patients with follicular non-Hodgkin lymphoma who have received prior therapeutic regimens, with specific eligibility criteria for inclusion and exclusion.",
    "The sample is a phase 2 trial for chronic lymphocytic leukemia using cyclophosphamide, fludarabine phosphate, and mitoxantrone hydrochloride as drugs, with eligibility criteria including previous chemotherapy treatment and certain patient characteristics.",
    "The sample is a phase 2 trial for B-cell chronic lymphocytic leukemia, testing the drug fccam, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of letrozole in treating recurrent or advanced borderline or low-grade epithelial ovarian, fallopian tube or primary peritoneal tumors that are estrogen receptor or progesterone receptor positive, with specific eligibility criteria for patients.",
    "This phase 2 trial is testing the efficacy of carboplatin and paclitaxel in treating stage III or IV ovarian, primary peritoneal cavity, or fallopian tube cancer patients who are HLA-A1, -A2, and/or -A3 positive and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of dasatinib, a drug targeting SRC, KIT, PDGFR, or EPHA2, in treating recurrent adult brain neoplasms, including adult glioblastoma and gliosarcoma, with specific eligibility criteria for patients who have undergone prior treatment with radiotherapy and temozolomide.",
    "The sample is a phase 2 trial for plaque psoriasis, testing the efficacy of itacitinib and placebo, with inclusion criteria for patients who have had insufficient response to topical agents, and exclusion criteria for pregnant or breastfeeding females, and those treated with certain psoriasis therapies within 12 weeks prior to the study.",
    "This is a phase 2 trial for patients with non-metastatic SCC of the oral cavity, oropharynx, hypopharynx or larynx that will be treated with CRT as first-line treatment, and will receive a continuous course of conventional external beam irradiation and a standard cisplatin CT regimen or a standard carboplatin regimen, with the goal of preventing oral mucositis. The only drug used is 0.9% saline.",
    "The sample is a phase 2/phase 3 trial testing the efficacy of pegylated interferon alfa-2a and ribavirin in treating HIV-infected patients with compensated liver cirrhosis caused by HCV genotype 1 or 4, with a list of inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of pazopanib and lapatinib in treating women with incurable stage IIIb, stage IIIc with T4 lesion, or stage IV breast cancer with ErbB2 amplification, who have not received prior chemotherapy, immunotherapy, biologic therapy or anti-ErbB1/ErbB2 therapy for metastatic or recurrent disease.",
    "This phase 2 trial is testing the efficacy of rvx000222 and placebo rvx000222 in patients with coronary artery disease who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug ixabepilone on patients with various subtypes of renal cell carcinoma, with specific eligibility criteria including measurable disease, performance status, and various lab values.",
    "This phase 2 trial is testing the efficacy of imetelstat and bevacizumab in treating non-small cell lung cancer patients who have completed platinum-based chemotherapy doublet and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of carfilzomib in treating refractory multiple myeloma patients who have received prior treatment with bortezomib, thalidomide or lenalidomide, and an alkylating agent, and have measurable disease, with the inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of mitoglitazone and pioglitazone in treating type 2 diabetes in patients who are metformin-na\u00efve or on a stable dose, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of ranibizumab (lucentis) in treating diabetic retinopathy and diabetic macular edema, with specific inclusion and exclusion criteria for eligible subjects.",
    "The sample is a phase 2 trial for patients with metastatic colorectal cancer who have failed first-line chemotherapy, testing the drug CP-4055, with eligibility criteria including measurable disease, performance status, and adequate biological functions, and exclusion criteria including brain metastases, concomitant treatment with non-permitted medication, and pregnancy or breastfeeding.",
    "This phase 2 trial is testing the effectiveness of pasireotide and octreotide in treating active acromegaly due to a pituitary adenoma, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug enmd-2076 on patients with platinum-resistant ovarian, fallopian, or peritoneal cancer, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 clinical trial for common cold symptoms, testing the efficacy of guaifenesin (mucinex) and placebo, with inclusion and exclusion criteria including pregnancy, chronic respiratory conditions, and known malignancy.",
    "This phase 2 trial will test the efficacy of omalizumab and placebo in treating eosinophilic esophagitis in subjects aged 12-60 years with acceptable medical history and physical exam, and with serum IgE level 30-700 IU/mL, while excluding patients with certain medical conditions and those currently or previously treated with omalizumab.",
    "The sample is a phase 2 trial for rheumatoid arthritis with the drugs abatacept and placebo, and the inclusion criteria being patients with active rheumatoid arthritis while on methotrexate having 12 tender and 10 swollen joints at randomization.",
    "This is a phase 2 trial for the treatment of autism and pediatric autism using memantine hcl, with inclusion criteria requiring completion of a lead-in study and a knowledgeable caregiver, and exclusion criteria excluding patients with concurrent medical conditions that may interfere with the study.",
    "The sample is a phase 2 trial for patients with atherosclerosis undergoing primary multi-vessel CABG, testing the efficacy of clopidogrel and water pill daily, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of atacicept and placebo in treating rheumatoid arthritis patients who have failed at least one TNFa antagonist therapy, with inclusion criteria including a disease history of at least one year, active RA, and CRP >=10 mg/L and/or ESR >=28 mm/h, while exclusion criteria include previous treatment with certain biologics and participation in any interventional clinical trial with an unapproved investigational therapy within the 3 months before the start of this study.",
    "This phase 2 trial is testing the efficacy of paclitaxel and lovastatin in treating platinum refractory or resistant epithelial ovarian cancer patients with measurable disease and normal hepatic function, while excluding patients with serious illnesses or active second malignancy.",
    "This phase 2 trial is testing the efficacy of carboplatin and abraxane in treating extensive stage small-cell lung cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of temozolomide and thalidomide in treating patients with metastatic melanoma and brain metastases, with specific eligibility criteria including performance status, blood counts, liver and kidney function, and exclusion of certain medical conditions and medications.",
    "This phase 2 trial is testing the efficacy of mpsk3169a and placebo in reducing cardiovascular events in patients with coronary heart disease and high risk of a CV event, who are either intolerant to statins or on a stable dose of statins, and meet certain inclusion criteria, while excluding patients with certain medical conditions or taking certain medications.",
    "This is a phase 2 trial for patients with refractory chronic lymphocytic leukemia, testing the drug cediranib maleate, with eligibility criteria including confirmation of B-cell CLL, refractory disease, and various health parameters.",
    "This phase 2 trial is testing the efficacy of carboplatin, bevacizumab, and herceptin in treating metastatic breast cancer with measurable CNS disease, while also outlining strict inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for amyotrophic lateral sclerosis (ALS) using the drugs ono-2506po, with inclusion criteria based on WNF EL Escorial diagnostic criteria and exclusion criteria including the presence of tracheotomy or mechanical ventilation.",
    "This phase 2 trial will test the efficacy of epoetin alfa in treating painful HIV-associated sensory neuropathy in patients with HIV-1 infection and stable use or no use of specific dideoxynucleoside reverse transcriptase inhibitors, with inclusion and exclusion criteria specified.",
    "The sample is a phase 2 trial for non-small-cell lung carcinoma, testing the effectiveness of irinotecan and docetaxel, with specific inclusion and exclusion criteria listed.",
    "This is a phase 2 trial for patients with metastatic or unresectable gastrointestinal stromal tumor (GIST) who have failed or are intolerant to Imatinib and sunitinib, and will test the efficacy of pazopanib as a treatment option. The eligibility criteria includes measurable disease criteria by RECIST criteria, adequate organ system function, and a negative serum pregnancy test for childbearing potential females.",
    "The sample is a phase 2 clinical trial for nasopharyngeal neoplasms, testing the efficacy of docetaxel and cisplatin, with inclusion and exclusion criteria listed.",
    "This is a phase 2 trial for patients with stable moderate to severe COPD, testing the efficacy of aclidinium bromide and formoterol compared to a placebo, with eligibility criteria including age, smoking history, and lung function measurements.",
    "This phase 2 trial is testing the drug afatinib (bibw 2992) on patients with stage IIIB/IV adenocarcinoma in non-small cell lung cancer who have had prior chemotherapy and have a known wild-type EGFR status.",
    "This phase 2 trial is testing the efficacy of cetuximab, cisplatin, and capecitabine in treating unresectable recurrent or metastatic gastric cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug bg00012 on patients with relapsing-remitting multiple sclerosis who meet specific inclusion criteria, and excludes those with certain medical histories or conditions.",
    "The sample is a phase 2 trial for patients with active rheumatoid arthritis, testing the efficacy of a p38 inhibitor drug in combination with methotrexate, with specific inclusion and exclusion criteria, and the presence of multiple icd-10 codes for the disease.",
    "This phase 2 trial is testing the efficacy of azd5069 and placebo in patients with bronchiectasis, lung disease, and respiratory diseases who are sputum producers and have a clinical diagnosis of idiopathic or post infective bronchiectasis, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of gemcitabine, capecitabine, and avastin in treating breast cancer patients who have undergone neoadjuvant chemotherapy and have residual invasive carcinoma in the breast and/or regional nodes, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 clinical trial is testing the efficacy of NKTR-181, an opioid analgesic, versus placebo in managing knee pain in patients with osteoarthritis, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of alvocidib and irinotecan hydrochloride in treating advanced hepatocellular carcinoma, with eligibility criteria including Child-Pugh class A or B status, no known brain metastases, and various hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements.",
    "The sample is a phase 2 clinical trial for nasopharyngeal carcinoma using docetaxel, cisplatin, and 5-fluorouracil as drugs, with eligibility criteria including histological diagnosis of WHO type II or III, and exclusion criteria including prior chemotherapy or radiotherapy to the nasopharynx or neck.",
    "This is a phase 2 trial for breast cancer patients at increased risk of recurrence, testing the efficacy of letrozole, with eligibility criteria including mammographic density, prior DCIS or invasive breast cancer, and acceptable bone mass density, among other patient characteristics and prior concurrent therapies.",
    "This phase 2 trial is testing the efficacy of paclitaxel albumin nanoparticle for injectable suspension in treating metastatic breast cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug GSK2118436 on patients with BRAF V600E- or V600K-mutated metastatic melanoma and brain metastases, with specific eligibility criteria for inclusion and exclusion.",
    "This phase 2 trial is testing the drug ezatiostat hydrochloride on patients with myelodysplastic syndrome (MDS) who meet certain eligibility criteria, including documented significant anemia, low or intermediate-1 MDS, and adequate kidney and liver function.",
    "This phase 2 trial is testing the drug vorinostat on patients with relapsed/refractory Hodgkin's lymphoma, who meet specific eligibility criteria, including having completed chemotherapy and radiotherapy, and having a Zubrod performance status of 0-2.",
    "This phase 2 trial is testing the efficacy of sunitinib malate in treating intermediate or high risk, clinically localized prostate cancer patients who are candidates for curative RRP, and have adequate organ function, while excluding patients with prior treatment for prostate cancer, major surgery or radiation therapy within 4 weeks of starting the study treatment, and other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration.",
    "The sample is a phase 2 trial for HIV-positive children at risk for developing pneumonia, testing the effectiveness of azithromycin, atovaquone, and sulfamethoxazole-trimethoprim, with eligibility criteria including CD4 count and exclusion criteria including allergies and serious diarrhea.",
    "This phase 2 trial is testing the drug gefitinib on patients with thyroid cancer that is unresponsive or refractory to radioactive iodine, and the eligibility criteria includes measurable disease, Eastern Cooperative Oncology Group performance status of 0-2, and exclusion criteria such as concurrent chemotherapy or radiation therapy.",
    "This phase 2 trial aims to test the effectiveness of natrecor (nesiritide) in combination with standard care and dobutamine or milrinone in treating congestive heart failure, cardiac transplantation, renal insufficiency, and renal failure patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of bevacizumab, sunitinib, and placebo in treating metastatic renal cell carcinoma, with eligibility criteria including prior nephrectomy and an ECOG performance status of 0 or 1.",
    "This phase 2 trial will test the efficacy of sunitinib malate, paclitaxel, doxorubicin hydrochloride, and cyclophosphamide in treating locally advanced or inflammatory breast cancer patients who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of cyclosporine, fludarabine phosphate, melphalan, and methotrexate in combination with allogeneic stem cell transplantation for metastatic breast cancer patients who have failed previous chemotherapy regimens and meet specific eligibility criteria.",
    "This phase 2 trial will test the efficacy of LY2951742, a therapeutic antibody that targets calcitonin gene-related peptide (CGRP), and placebo in treating moderate frequency migraine headaches in patients who meet specific inclusion criteria and do not have any exclusion criteria.",
    "This phase 2 trial is testing the efficacy of docetaxel, vinorelbine, and trastuzumab in treating metastatic breast cancer with confirmed overexpression of the Her-2 oncogene, with specific eligibility criteria and exclusion criteria.",
    "This is a phase 2 trial for contraception using nomegestrol acetate, etonogestrel, ethinyl estradiol, and estradiol, with eligibility criteria including BMI, regular cycles, and good health, and exclusion criteria including diabetes, severe dyslipoproteinemia, and history of malignancy.",
    "This phase 2 trial is testing the efficacy of sunitinib malate in patients with recurrent anaplastic astrocytoma or glioblastoma who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for asthma, testing the drugs jnj-18054478 and sham comparator, with inclusion criteria including confirmed diagnosis of persistent asthma and reversibility of at least 12% with albuterol inhalation, and exclusion criteria including use of inhaled corticosteroids within 4 weeks and history of life-threatening asthma attack within 3 months.",
    "This phase 2 trial is testing the efficacy of levetiracetam in treating alcohol dependence and comorbid anxiety disorders, with inclusion criteria including DSM-IV diagnosis, clinically significant anxiety, and average alcohol use over past 28 days, while exclusion criteria include current diagnoses of post-traumatic stress disorder or obsessive-compulsive disorder, current cocaine or opioid dependence, and prescribed psychotropic medications.",
    "The sample is a phase 2 trial for patients with type 2 diabetes, testing the efficacy of a combination of aleglitazar and pioglitazone, with inclusion criteria including moderately impaired kidney function and BMI 25-35, and exclusion criteria including previous treatment with thiazolidinedione or insulin.",
    "The sample is a phase 2 trial testing the efficacy of epoetin alfa in treating anemia in patients aged 70 or older with exclusion criteria including a history of serious heart, liver or kidney disease, cancer treated within the last year, problems with the immune system, and having received Epoetin Alfa within the last year. The diseases being studied are anemia and aging, and the drug being tested is epoetin alfa.",
    "This phase 2 trial is testing the combination of itraconazole and pemetrexed for patients with recurrent non-small cell lung cancer who have received at least one previous chemotherapy regimen and have normal organ and marrow function, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the drug vorinostat on patients with transitional cell carcinoma of the bladder or urothelium who have recurred or progressed on platinum-based chemotherapy, with eligibility criteria including measurable disease, ECOG performance status =< 2, and normal institutional limits for total bilirubin and creatinine.",
    "This is a phase 2 trial for sickle cell disease using the drug prasugrel, with eligibility criteria including age, disease genotype, and stable hydroxyurea use, and exclusion criteria including bleeding disorders, recent surgery, and certain medication use.",
    "The sample is a phase 2 trial for individuals with moderate to severe chronic obstructive pulmonary disease (COPD) testing the efficacy of sodium pyruvate in 0.9% sodium chloride solution, with inclusion and exclusion criteria listed.",
    "The sample is a phase 2 trial testing the drug r256918 and placebo on patients with obesity and metabolic diseases, with eligibility criteria including liver fat content and BMI, and exclusion criteria including diabetes and recent weight loss treatments.",
    "This phase 2 trial is testing the efficacy of paclitaxel and carboplatin in treating advanced non-small cell lung cancer, with specific eligibility criteria including measurable disease, adequate hematologic and hepatic function, and exclusion criteria such as untreated CNS metastases and prior bevacizumab therapy.",
    "The sample is a phase 2 trial for persistent asthma, testing the efficacy of indacaterol and placebo to indacaterol in patients receiving daily treatment with inhaled corticosteroid, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of the drug e2007 in treating Parkinson's disease patients with motor fluctuations and dyskinesias during the \"on\" period following each morning dose of their current medication.",
    "The sample is a phase 2 trial for diabetic peripheral neuropathy, testing the efficacy of ds-5565 tablet and pregabalin capsule compared to placebo, with inclusion criteria including age, diabetes diagnosis, and pain score, and exclusion criteria including prior therapeutic failure of pregabalin or gabapentin and major psychiatric disorders.",
    "The sample is a phase 2 trial for tobacco use disorder, testing the efficacy of placebo and 2 mg nicotine polacrilex, with inclusion criteria including gestational age of 26 weeks or less, smoking five or more cigarettes daily for the past seven days, and stable residence, and exclusion criteria including evidence of a fetus with a known congenital abnormality, unstable medical problems, multiple gestation, unstable psychiatric disorder, and current drug or alcohol abuse or dependence.",
    "This phase 2 clinical trial is testing the efficacy of teriflunomide, glatiramer acetate, and placebo in patients with relapsing multiple sclerosis who meet specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for type 2 diabetes, testing the efficacy of teneligliptin at different doses and a placebo, with inclusion criteria including age, HbA1c levels, and previous diabetes management, and exclusion criteria including certain medical conditions and alcohol consumption.",
    "This is a phase 2 trial for metastatic pancreatic adenocarcinoma using gemcitabine, trastuzumab, and erlotinib, with eligibility criteria including confirmed histology, measurable lesion, and certain hematology, renal, and hepatic function levels.",
    "This phase 2 trial is testing the efficacy of GSK573719 and tiotropium in treating chronic obstructive pulmonary disease (COPD) in patients aged 40-80 who have a history of smoking and meet specific inclusion criteria.",
    "The sample is a phase 2 clinical trial for psoriasis vulgaris, testing the efficacy of various topical drugs including leo90100 cutaneous spray, ointment, daivobet\u00ae ointment, and betamethasone dipropionate, with eligibility criteria including age 18 or above, diagnosis of psoriasis vulgaris, and exclusion criteria including use of certain topical drugs and systemic treatments with biological or non-biological therapies.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease (COPD) testing the efficacy of various drugs including tiotropium bromide and formoterol fumarate, with inclusion criteria such as age range, smoking history, and post-bronchodilator FEV1/FVC ratio, and exclusion criteria such as pregnancy, asthma, and abnormal chest X-ray.",
    "The sample is a phase 2 trial for the drug fenretinide in patients with geographic atrophy and dry age-related macular degeneration, with inclusion criteria of males or females aged 50 to 89 with GA from AMD in one or both eyes and exclusion criteria of GA due to any disease other than AMD.",
    "This phase 2 trial is testing the efficacy of pralatrexate injection in treating peripheral T-cell lymphoma patients who have progressed after at least one prior treatment, with eligibility criteria including confirmed PTCL diagnosis, adequate organ function, and use of medically acceptable contraceptive regimen.",
    "This phase 2 trial is testing the drug motesanib diphosphate for patients with recurrent or persistent ovarian, fallopian tube, or primary peritoneal carcinoma who have received prior platinum-based chemotherapy and meet specific eligibility criteria.",
    "This is a phase 2 trial for patients with relapsed or refractory non-small cell lung cancer, testing the efficacy of velcade and alimta as a second-line therapy, with specific eligibility criteria and exclusion criteria.",
    "The sample is a phase 2 trial for sickle cell anemia, hemoglobinopathy, and thalassemia patients, testing the efficacy of drugs such as campath-1h, dilantin, busulfan, and cyclophosphamide, with eligibility criteria including the presence of an HLA genotype identical donor and various medical conditions.",
    "This phase 2 trial is testing the drug tesofensine on obese patients with specific inclusion and exclusion criteria, including stable smoking habits and well-regulated cholesterol and triglyceride levels.",
    "The sample is a phase 2 clinical trial for lung cancer testing the efficacy of enzastaurin and placebo, with inclusion and exclusion criteria including smoking history and ability to undergo bronchoscopy and CT scanning.",
    "The sample is a phase 2 trial for prostate cancer patients with non-castrate level of testosterone, using the drug enzalutamide, and with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of irinotecan, folfiri, and skin treatments in patients with metastatic colorectal cancer and skin toxicities, who have failed first line treatment, and cannot be cured by surgical resection, with exclusion criteria of prior irinotecan use.",
    "The sample is a phase 2 trial for respiratory syncytial virus infections in lung transplant recipients, testing the drugs aln-rsv01 and normal saline, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the drug dasatinib on patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who have received =< 1 prior chemotherapeutic regimen, and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of tmc435, placebo, peginterferon, and ribavirin in treating chronic genotype 1 Hepatitis C infection in participants who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of tg-873870 (nemonoxacin) in treating diabetic foot infections caused by Gram-positive pathogens, with specific inclusion and exclusion criteria for patient eligibility.",
    "This phase 2 trial is testing the efficacy of panitumumab monotherapy in patients with advanced or metastatic colorectal cancer who have non-mutated KRAS and have failed prior chemotherapy regimens, with eligibility criteria including age, performance status, and liver function, and exclusion criteria including prior treatment with EGFR antibody and serious medical conditions or psychiatric illness.",
    "This is a phase 2 trial for patients with rheumatoid arthritis, testing the efficacy of jnj-40346527 and placebo, with specific eligibility criteria including a diagnosis of RA for at least 6 months, positive anti-CCP or RF in serum, and active RA with at least 6 swollen and 6 tender joints.",
    "This phase 2 trial is testing the efficacy of folfox 4 and 5-fu/cisplatin in treating inoperable esophageal carcinoma with specific eligibility criteria, including histologically proven adenocarcinoma or squamous cell carcinoma of the esophagus and no prior treatment for esophageal cancer.",
    "This phase 2 trial is testing the drug sta-9090 in patients with metastatic adenocarcinoma or poorly differentiated carcinoma of the pancreas who have received 1-2 prior chemotherapy regimens for metastatic disease, and meet certain eligibility criteria.",
    "This phase 2 trial is testing the efficacy of lenalidomide in treating previously treated, histologically confirmed follicle center cell lymphoma patients who have been treated with rituximab, with specific eligibility criteria including age, performance status, and laboratory values.",
    "This is a phase 2 clinical trial for mesothelioma patients who have previously undergone chemotherapy, testing the effectiveness of erlotinib and bevacizumab, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2/phase 3 trial for patients with type 2 diabetes, testing the efficacy of sitagliptin and metformin compared to placebo, with inclusion criteria including BMI 25-35 kg/m2 and HbA1c 6.5%-9% without OHA medication or 6%-8.5% with OHA monotherapy with metformin or sulfonylurea.",
    "This phase 2 trial is testing the efficacy of dacarbazine, doxorubicin hydrochloride, ifosfamide, and thalidomide in treating primary soft tissue sarcoma with specific eligibility criteria, including tumor size and location, performance status, and absence of certain medical conditions.",
    "The sample is a phase 2 trial for metastatic melanoma using cyclophosphamide and fludarabine phosphate as drugs, with eligibility criteria including confirmed melanoma, measurable disease, and various health parameters.",
    "The sample is a phase 2/phase 3 trial for patients with primary progressive multiple sclerosis, testing the efficacy of hydroxyurea as a treatment, with inclusion criteria including age, diagnosis, and EDSS score, and exclusion criteria including hypersensitivity to hydroxyurea, recent treatment with immunosuppressive drugs or steroids, infections, malignancy, pregnancy or lactation, and low compliance to therapy.",
    "The sample is a phase 2 trial for overactive bladder, using placebo as the drug, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of fermagate and placebo in treating chronic kidney failure patients on active haemodialysis, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for gastrointestinal stromal tumors, testing the drug amn107, with specific inclusion and exclusion criteria listed.",
    "This phase 2 trial is testing the efficacy of entinostat and exemestane compared to placebo in postmenopausal women with relapsed or progressed estrogen receptor-positive breast cancer who have previously been treated with aromatase inhibitors, and have measurable metastatic disease, with a focus on eligibility criteria for inclusion and exclusion.",
    "This phase 2 trial is testing the effectiveness of abiraterone and prednisone in treating metastatic prostate cancer with specific eligibility criteria, including adenocarcinoma of the prostate and documented metastatic disease.",
    "This phase 2 trial is testing the efficacy of fluorouracil, leucovorin calcium, and oxaliplatin in treating advanced or metastatic adenocarcinoma of the colon or rectum, with eligibility criteria including measurable disease and ECOG performance status 0-1.",
    "The sample is a phase 2 trial for non-squamous non-small cell lung cancer using pemetrexed and best supportive care as drugs, with eligibility criteria including no prior systemic anticancer therapy for lung cancer and exclusion criteria including brain metastasis and allergy to pemetrexed.",
    "This phase 2 trial is testing the efficacy of imatinib mesylate in treating locally advanced or metastatic dermatofibrosarcoma protuberans or giant cell fibroblastoma that are not amenable to surgery, radiotherapy, or combined modality therapy with curative intent, and have documented progressive disease within the past 3 months.",
    "This phase 2 trial is testing eribulin mesylate in patients with metastatic or recurrent squamous cell carcinoma of the head and neck who are not eligible for salvage surgery, and have measurable disease, with eligibility criteria including Zubrod performance status 0-1, adequate blood counts and organ function, and no prior chemotherapy for recurrent or newly diagnosed metastatic disease.",
    "This phase 2 trial is testing the combination of azacitidine and entinostat in patients with stage IA-IB non-small cell lung carcinoma who have undergone complete surgical resection, with eligibility criteria including ECOG performance status =< 2, adequate organ function, and willingness to use contraception.",
    "This phase 2 trial is testing the efficacy of capecitabine and vinorelbine tartrate in treating metastatic HER2/neu-positive breast cancer patients who have received prior anthracycline or taxane as adjuvant therapy or for metastatic disease, and meet specific eligibility criteria.",
    "This phase 2 trial is testing the drug asp3550 on male patients with histologically proven prostate cancer, who require endocrine treatment, and have a serum testosterone level above 1.5 ng/mL, with exclusion criteria including previous or present endocrine treatment for prostate cancer and treatment with a 5\u03b1-reductase inhibitor.",
    "This phase 2 trial is testing the efficacy of idarubicin, cytarabine, bortezomib, and etoposide in treating various types of acute myeloid leukemia in patients who meet specific eligibility criteria.",
    "The sample is a phase 2/phase 3 trial for stroke patients testing the effectiveness of propranolol, with inclusion criteria including symptom onset within 18 hours and imaging evidence of MCA-infarction, and exclusion criteria including patients already receiving beta-blockers and major heart disease.",
    "This phase 2 trial is testing the efficacy of azd9773 and placebo in treating severe sepsis and septic shock in adults with specific inclusion and exclusion criteria related to comorbidities, concomitant diseases, and medication allergies.",
    "This phase 2 trial is testing the drug sunitinib malate on patients with various types of astrocytoma and oligodendroglioma, who meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of GSK239512, a drug, and placebo in treating Alzheimer's disease in male or female subjects aged 50 or above, who have a clinical diagnosis of probable Alzheimer's disease and meet specific eligibility criteria.",
    "This phase 2 trial is testing the efficacy of carboplatin, paclitaxel, and bevacizumab in treating non-small cell lung cancer patients who meet specific eligibility criteria.",
    "The sample is a phase 2 trial for patients with paroxysmal atrial fibrillation, testing the drugs ati-2042 and ati-2042 200 mg, with inclusion criteria of proven paroxysmal atrial fibrillation and a pacemaker with appropriate AF diagnostics and recording capabilities, and exclusion criteria of severe left ventricular dysfunction or CHF with NYHA Class III or above, known allergy to Amiodarone or previous treatment for severe Amiodarone toxicity, and cardioversion within one month of screening.",
    "The sample is a phase 2 trial for rheumatoid arthritis patients who have failed 1-5 DMARDs and have a partial clinical response to methotrexate, testing the efficacy of cyclophosphamide, methotrexate, and rituximab, with specific inclusion and exclusion criteria.",
    "The sample is a phase 2 trial for patients with mycosis fungoides lymphoma, testing the efficacy of pegylated liposomal doxorubicin hydrochloride, with eligibility criteria including prior failed therapies and specific health parameters.",
    "This sample is a phase 2/phase 3 trial for diabetes mellitus type 2, testing the efficacy of ly2189265, sitagliptin, placebo solution, placebo tablet, and metformin, with inclusion criteria including a HbA1c value of \u22657.0% to \u22649.5% and a BMI between 25 and 40 kg/m^2.",
    "The sample is a phase 2 trial for metastatic and locally advanced breast cancer patients who have received taxane therapy, testing the efficacy of gemcitabine and bevacizumab, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of GSK573719 and placebo in treating chronic obstructive pulmonary disease (COPD) in patients aged 40-80 with a smoking history of 10 pack-years or greater, with specific inclusion and exclusion criteria.",
    "This sample is a phase 2 trial for seasonal allergic rhinitis, testing the efficacy of bepotastine besilate nasal spray at different concentrations and a placebo, with inclusion criteria of a history of mountain cedar allergy and exclusion criteria of no active nasal infection or abnormality affecting safety or symptom assessments.",
    "This phase 2 trial is testing the efficacy of verteporfin, ranibizumab, and dexamethasone in treating choroidal neovascularization and macular degeneration, with specific inclusion and exclusion criteria for patients.",
    "The sample is a phase 2 trial for HIV infections testing the efficacy of emtricitabine/tenofovir disoproxil fumarate and lopinavir/ritonavir in reducing viral load and increasing CD4 count, with specific inclusion and exclusion criteria for each step of the trial.",
    "This is a phase 2 clinical trial for breast cancer patients with overexpression of Her2neu, testing the efficacy of liposomal doxorubicin, cyclophosphamide, and trastuzumab, with specific eligibility criteria and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of fludarabine phosphate and cyclophosphamide in treating metastatic melanoma patients who have previously received high dose aldesleukin (IL-2) and have been either non-responders or have recurred, and have met certain eligibility criteria.",
    "The sample is a phase 2 trial for dry eye syndrome, testing the efficacy of ecabet and placebo drugs, with inclusion criteria of being at least 18 years old and having a diagnosis of dry eye, and exclusion criteria of having chronic systemic inflammation or active seasonal ocular allergies.",
    "The sample is a phase 2 clinical trial for multiple myeloma patients, testing the efficacy of velcade subcutaneous melphalan prednisone, velcade cyclophosphamide prednisone, and velcade prednisone, with eligibility criteria including age, disease diagnosis, measurable disease, and laboratory values.",
    "The sample is a phase 2 clinical trial for patients with unresectable or metastatic adenocarcinoma of the biliary ducts, including gallbladder carcinoma, testing the efficacy of Triapine and gemcitabine as treatment options, with specific eligibility criteria and exclusion criteria.",
    "This is a phase 2/phase 3 trial for patients with moderate to severe ankylosing spondylitis, testing the effectiveness of rituximab, with inclusion and exclusion criteria including age, disease severity, medication history, and lab findings.",
    "This phase 2 trial is testing the efficacy of bci-024 (buspirone) and melatonin in treating Major Depressive Disorder, with specific inclusion and exclusion criteria, and the drugs and diseases involved are listed.",
    "This phase 2 trial is testing the efficacy of capecitabine, a chemotherapy drug, in treating high-risk breast cancer patients who have completed surgical excision and are candidates for radiotherapy.",
    "This phase 2 trial is testing the efficacy of DM-1992 and Sinemet IR in treating advanced idiopathic Parkinson's disease with predictable wearing-off motor fluctuations, with specific inclusion and exclusion criteria for patient selection.",
    "The sample is a phase 2 trial for relapsed prostate cancer patients, testing the efficacy of velcade, lh-rh agonist, and androgen receptor antagonists, with eligibility criteria including PSA relapse after definitive local therapy, no evidence of metastatic disease, and ECOG 0-1 performance status.",
    "The sample is a phase 2 trial for patients with metastatic colorectal cancer who have failed both oxaliplatin- and irinotecan-based regimens, testing the efficacy of bibw 2992 and cetuximab, with inclusion and exclusion criteria specified.",
    "This phase 2 trial is testing the efficacy of CK-2017357, a drug, on patients with amyotrophic lateral sclerosis, with specific inclusion and exclusion criteria.",
    "This phase 2 trial is testing the efficacy of ifosfamide in treating various types of recurrent or unresectable malignant meningioma, intracranial hemangiopericytoma, and primary central nervous system sarcoma, including fibrosarcoma, rhabdomyosarcoma, chondrosarcoma, and leiomyosarcoma, with specific eligibility criteria for patients, including age, performance status, and medical history."
]